<SEC-DOCUMENT>0001558370-25-003039.txt : 20250317
<SEC-HEADER>0001558370-25-003039.hdr.sgml : 20250317
<ACCEPTANCE-DATETIME>20250317071830
ACCESSION NUMBER:		0001558370-25-003039
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		106
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250317
DATE AS OF CHANGE:		20250317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		25742338

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>plx-20241231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/17/2025 11:11:40 AM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: 7fddff5b-2b00-4f13-94bc-3ab818c9f5e9 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:plx="http://www.protalix.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>PROTALIX BIOTHERAPEUTICS,&#160;INC._December&#160;31, 2024</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" xs:nil="true" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_3pYSaoLYOUKp8l12A1jLJQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" xs:nil="true" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_v7cgyKJf8UKf_Ak4X-wp6A"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityCentralIndexKey" id="Tc_3h-5lKQmIkWSelMkMtFcJQ_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:CurrentFiscalYearEndDate" id="Tc_pLaZ8mKFZUWi3YG_HB5dfQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:DocumentFiscalYearFocus" id="Tc_-q1SxCHVRkuueIYzVmGqsw_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:DocumentFiscalPeriodFocus" id="Tc_tZZ-n4KwZ0WbY6RlcZcHew_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:AmendmentFlag" id="Tc_cY5Y-PViYUOBGr0N7N4pEQ_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" id="Hidden_j-hLDpbrqk6Soc8k5CS6fw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" id="Hidden_DAQOBjC4YUOk1EvqBtzg8g">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_ZD_LC9yxDUiAkmkArAOCNg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_HsTYEK9eRkCkgOq9_9rEew">P3Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_segment_t--H7-X-rEu1uMJLuZLipw" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="INF" name="us-gaap:NumberOfOperatingSegments" id="Hidden_yJU9lqNC-UmtulHxkqsD_Q">1</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2022_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZT00cGmYjUugrLQ9Ej7B2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_cGsHWgE_gUuxZ-cHUDKhgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zf_c8EYvN0-ChWXNMhtT7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_s7t7THOam0ugmJppb04uiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hOOB-4g72kSTGYF-6-8tow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NcdWC0f2eUqpjFaF4c8VHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d0KQCrBldECa1kWPtwiqWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Bw-Z_-dW70-nqHUT020dcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CuQDsyAkjESynmczRevI1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K7icX2z7sk6vRpP988YnpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZsUy5BXARUihXhlGt1WP2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EW66xBjMwEq-SZFSEjjsxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_c58oJTn8dU-QqeJQC9hc2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69To5.60Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_CZ0iGJrw8kGgZlq0gK2Vkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55To3.73Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_k1pPvAGNuUqJ8-G1h9Wyeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_Ggw7m_bIUEukSBW28yKxbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.03To2.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_D7MJGpt1U0KbxRKh_zdQpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69To5.60Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_i8MSOPNUfk-c4_p410zsvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55To3.73Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_6w7SOn5UPUu_KdKhVUxCsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_ZwQZST8ycESPqOtaPxvgmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.03To2.00Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gk0_QwpkNUi8I2fbbRac5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_V7gvzO9fdE2ntwQ96Fp-5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_tq949hURe0qn3llpv8mqpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GiEgmTjqQECUzJqeHnRG3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qzrqPtv4Nk2sivn3hBJl_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0w_5kQqvoEm_P4OrjYWqWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PjbfOLibbE-CFhp_5N4qIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_EUp6tTdW0UGDY4bhmHe7MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AzD7wSLn2kKSXb3VDmVzTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_gI5UhphCH06Ect3eEtQGMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_yX24jpZNrE2GFNvD-IrRLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AqEdmyQF8UC1svkRrbF5pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_ZD_LC9yxDUiAkmkArAOCNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_ACAfcts15EeexRuNnjxxSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_0jCSqJ2VNUGntWiwLim66g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_07Y7_KkIgE2gCqBzVKzHGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_HeexSHIpsECzwXPmjXRSIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_vAdZZrKJB0GA0kWl76_O5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_yxjzBIAj6UibHOxMuOXLmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_e4DfQC6YoEqi8RVuaPKj1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_HHFZ61393UWe4ugtQPzFMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kRf1Vl0L_E68nTZynfgMNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_gyzvZwhYWUOBEq112uDzLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_QZxZBUTrMkaZV4V80woRlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_cq0BPynITUyIX0XEGY5DFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_aKTCTOwnPkytYKKR5g2_wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_n_xrcTEwnEeMZJ4ZcUw8eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_E_xaP5k14k6Q6Z72Y_IfPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xaYAPIOiqEOStP3Kpoa1Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_nzjGNNa5BUaHDbbP-O186A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_PQ5mf5BQdkWUxiMCts1pFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_w4HPugC1VEGsdplZft_5fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_2OeigBROdEaDOLaH-ucKEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mW8C4Y6b6kywMvvRfs9dNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_vn410UpKkkGalJIGaHTUEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_eCpUQmCcSESODwHxlLzo5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_y8QfLO6YXkKf-_LOLQOaZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_oNp3Hf3CWECKBYdKr9AjAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_h6xjOEjkiUm3MR0Og5Jvhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_S7h6B8zov0uIXGD5I22dew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_EF4dwmnF_kWBNzMVSjLHhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_ur7u-fiQ5k-UQkYO2y0uwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_PjfN7L5Bbk2NLvVOBqJ8Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_iDlflgLsKkiQFmx1cSBg5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_vxkDkBSQz068hELrseMSzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_KFKHQh7CBUC1lg8cpMFN3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_tIPYYN_ZtU-qDljU2Ir6gA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_nxW7H0bxUUC9vT-aI9jhyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_pvpGc5YOlE--wrnCQNPHeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_LO7FCaAqo0anOZnr8urSlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_aERhFlXodEOqRgwjEGZTtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_F6fA0kenUkmkxMJFS7dV_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EoGEj4NR3k60cggFbmTsmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_pglWe4H_g0q1VCrHkTEK2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_k_HBgOQfk0GnMVqO03JGnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_7Kls7CQ7NUqv6IHxTOTP0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_hbAAdy1AFUuwPTqCDJatww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_IFWTaYE7TEGUIFQbsRvpcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_CJv_84vfq0aMskjfjX9YfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_jt7xO17tI0q-J4gtN5A1ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_MVIrjw2PD0mL89oHKVh0jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_JlcwElfBZkmmA58XlgqPmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fg1EWGDGnkyt0zoxUAK0Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DsGA_yFdAkGbxa6Ly0IBzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kNcYnNqxkGT0wOZlcwh9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_pqIJYP9qBkuWs3kgYe1bCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qjP7y_S0VUuKi14nuJCCzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_SDy9pRI4jka-vazM2Ar37Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_2uwOm7rxyEOlHzvvqCFFJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_vDFNTndzl0OM84fywfGerA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_Rre_qLcyTEWy4BikH0eDPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_LmlSAoEiIUGYRz9pAOa8jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_PrcXvhjZKk2qgA6qvhDFGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_QXqL2IzWNEGo_hK_uR7-8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_81bs3kgDHU6NRu_L1eP3yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_wUeqT_M4AEqDZuDuEQf3xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementLifeInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_Mp-0M08qeUKO7h9uqA1McQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">plx:ContributionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EYL9IKHmnkqnNQvhCDuZ0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-25</xbrli:startDate><xbrli:endDate>2021-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_rldSNFnujkmNBG6adoOOkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_PqNi2C8w-UiBnkc4Uh5lLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lgph02zA8EqaEK0ln7pqLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cPolotLkAUmM_tlTQRrk2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LNkKeGiGJ0aS5KHtRlDVsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XM4auoMc-kObwGUUo2NaKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_RWonuWiPxEq0TdRkIcpNIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_12_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_PIfW3nBp4kCRd_d9eGzbYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_MOfdfIKjcUiCrIPtQO8BWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_cq9GoAKDi0yCbmzEVhRxUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_iQmr4uFt5kqfTe94aSywZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_0rzuJ4XtCE6Cs1WYUEVqEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_wHXsbG_dxEq9ZOpZb9KkbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_nUbBkLnYekaez7e1Ka3ENg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kOxCb2VXAkiXIt-mPT3RhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_UuhJLwHi6Em0GrZfesGVyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6ZtY09PpU0m9d_EG_ZwvkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_A7nWnFTiPkOdLlt5xxqpEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_REAyJtvAFU2ys4pnWOJcXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0aTAUQn5Gkm5jNYX11QpwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_GkNNnx-5s06WAA30ohh8Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_L8FMbjn4ykuUigKlaKNOwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XRg9HSXWv0C3QWfvvFGWxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9RS1hcr690mkdTePbZl2Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CoqAPYNvE0GJxaaTTSDOFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_Wf4l6EemkUiStX1y_Xvkzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_VUjg-GUWqkaM24vUWwpyKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_l6LgZROctkqAN5Bg47FtoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_eMpI1Y46mEm3V5aABb_sXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_7kWtOAR1_USec_YP09u_Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_VubLEAIky0aQAmEbs4Z7EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xZcFCwrL3kSsF04JdIujqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KwnYvQGzMUeyVPAkAtMuPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vWRZ9XKCTka09Mlcs7e8PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V2vZho8vMUyXxBTZzlyMew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_wXBT2eXbL0O3AsKeYlYxOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_Yo6i5FE6pU22Md7ma24KKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_qm_86HOq70OOencxym3GVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember__u8SZ_kTp0GNsmMYnwI58Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_2dRWMsEJ6EiuDNv182Eeiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_uwDD5nTakUC2KmTkoR6W8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_NYbG0_upI0OqrbiUEof-HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_W3yUCAONf0SfAzEtMt6Mbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_XGzd5dVqLk6U007ZQL4UiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VM8wfhoeo0Cfc2e6wRsqqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_S5aqBYd2ZEqjmaTVHLVYcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_rPFgBIuGN0iZ81CflTcjcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_B46HhSBVz0yrsK0DY71Erw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3WAGON0zpU6ERbyAHqCRzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_iREdhYdsg0S_5qYZGs1pFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_NW-Pj9G-fkyAiLj-xYz3Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_jaZy5wcLxkiCdAwjd5oXfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2024_To_11_30_2024_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_7SbCZK859Uiaib6y5h0qfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_HhtwKHGlsEOO6RfMSrfRww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_CtbP6sYsCUSsa4BOxiiwkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_OUM-7GtNokqwYO6vx-ub9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_7_J4-MrHIkS9N0JY0GZlRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_E4Yge5ZBuUiAoIRfgSeqmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_t_yYq1YsV0acGDoyhAPn0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_YOGpnjsFYUmoeJZPBCVsFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_H8x2H6ab8UuZgH1Ve9noLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_14_2025_rb1SYpJMiE6v_QmbhlZTGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_segment_t--H7-X-rEu1uMJLuZLipw"><xbrli:measure>plx:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_0mlCI0gGfUK1x1wJKqfHQQ"><xbrli:measure>plx:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_iTLnFIhgHUOHLxUiOlWFJw"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_ZOMDUvl2U0qDBOvYPFWWmQ"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_ocaisUO_C0WWcRJExAkgCA"><xbrli:measure>plx:employee</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_KD5G_ppkGEKfu9q5lyCQiQ"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;">F</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_213cef06_60c8_4b81_9571_d1c3b922b4dd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:DocumentType" id="Narr_UMrrJux9J0OpgowH_5WF5w"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Mark One)</b></p><a id="_d3cfb9af_6096_4d8c_be73_3670c88bd207"></a><a id="Tc_bguPwzcYiEilOe0lBQDsEg_1_2"></a><a id="Tc_X7OpuGie2EugA965YBaoKA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:DocumentAnnualReport" id="Tc_i0HVNA4urE-Jjj_rywLrkA_1_1"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:DocumentPeriodEndDate" id="Narr_-Cr08KcPx0GWFDY1393Okw"><b style="font-size:7pt;font-weight:bold;">December&#160;31, 2024</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_363c4b72_8c99_4fe4_8cf1_fef7ba3a7dcb"></a><a id="Tc_R-pRWmn_mEG15X0xLzHNDQ_1_2"></a><a id="Tc_aZU0EbqrWUmLF5kU0vztuw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:DocumentTransitionReport" id="Tc_Y2zmY6J-1kiFJ8DXo1Qzxw_1_1"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;"> </b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityFileNumber" id="Narr_1X-zBPYrykmVZ109IxGILw"><b style="font-size:7pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityRegistrantName" id="Narr_pqtEIgWV1EOzuWByNAkokg"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a6c241f7_1ec8_4187_a30c_8be39e61aefa"></a><a id="Tc_fdoCiIucuUyTKgPTpwekog_2_0"></a><a id="Tc_V2hNVAAB1kGlIm3-I4hiLg_2_1"></a><a id="Tc_rj72Ol60iESSQAR_Yb6yDg_4_0"></a><a id="Tc__Z4qhpO1I0Wb4wUZpJIhFQ_6_0"></a><a id="Tc_5Mru3_6APUyiBoQyJ7Ei1g_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.51%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityIncorporationStateCountryCode" id="Tc_51-ZsM4iqEWVF2bkD8KLrA_1_0"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityTaxIdentificationNumber" id="Tc_4mIhJOR7jUSRJDl4M7hRJQ_1_1"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization</b></p></td><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:middle;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityAddressAddressLine1" id="Narr_oDITMJMFFEelcrSAW0JtsQ"><b style="font-size:7pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityAddressAddressLine2" id="Narr_4uXnJXc1IU-ITdATOdlzxA"><b style="font-size:7pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityAddressCityOrTown" id="Narr_GQWrJBA1SkOCxzXiqOKz-g"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityAddressStateOrProvince" id="Narr_RhhtRRzp8kKtPDfv737m3w"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityAddressPostalZipCode" id="Tc_RVx8iucAEUqQh08zL01ZKQ_4_1"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:50.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:49.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:CityAreaCode" id="Narr_bjaN6S9IbEi4mUdquuD0dw"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">) </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:LocalPhoneNumber" id="Narr_6xvIRzqRnECRuTy-PcNABQ"><b style="font-size:7pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><a id="_6ead232e_1582_40d9_b92c_15f6a55d95c5"></a><a id="Tc_v0YxKZI5akiDWB8NVJ9FUQ_0_0"></a><a id="Tc_BGHgciv2LEuKfYzl2ZucgA_0_2"></a><a id="Tc_4-GchqZWZ0-CH1Gu0JSj6w_0_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:29.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:top;width:2.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:36.34%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:top;width:1.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:29.49%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:29.59%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:Security12bTitle" id="Tc_xDZLVBW-g06e4z3mLiWY_g_1_0"><span style="font-size:7pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.34%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:TradingSymbol" id="Tc_sRUkVy6wDkaSA9Uurs4QtQ_1_2"><span style="font-size:7pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.49%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:SecurityExchangeName" id="Tc_9cgd33N7bkWcTSVhPWJlfA_1_4"><span style="font-size:7pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_Y9_hd990bEy42D2X5yHiBg"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span><span style="font-size:7pt;">&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityVoluntaryFilers" id="Narr_LkSkwC9PqkGBMTHjWV1jPA"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityCurrentReportingStatus" id="Narr_b8p_dF6OaketzK6Aidg0BQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span><span style="font-size:7pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityInteractiveDataCurrent" id="Narr_8z2pApa2RUijDHDbAMDfeQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span><span style="font-size:7pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_69b1fb3e_fd77_4713_8a3b_720977774d44"></a><a id="Tc_wHv61VaCDEankAwth7JzSw_1_0"></a><a id="Tc_xy5ucMzBqUybfG0297roUQ_1_1"></a><a id="Tc_ulrQcXL40kGJExfxXBw1xg_1_2"></a><a id="Tc__vJzhaOZ1E2b3_Dph-crXQ_1_3"></a><a id="Tc_FbNzzvLMzEGnfaf2HtvVdA_2_1"></a><a id="Tc_bTdkr7a7IUGD4eedZayEjQ_2_2"></a><a id="Tc_2WvvoAE3xEej238l_ko7JA_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityFilerCategory" id="Tc_YnKVjYjoyECcblw7Jkrdcw_2_0"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntitySmallBusiness" id="Tc_iWSzQBQKUUOTS9Ea0l4xfg_2_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:23.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityEmergingGrowthCompany" id="Tc_vxETjOqDQESziNz_Obb9wQ_3_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:IcfrAuditorAttestationFlag" id="Narr_Wvh1Vw_ryUW3WXxTvGZFug"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_1ZtcAShQ0ka7AvikrzSowQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="white-space:pre-wrap;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  </span><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:EntityShellCompany" id="Narr_2FN2xsXlQ02eXxmjah7ohg"><span style="font-family:Times New Roman;font-size:7pt;">&#9723;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Times New Roman;font-size:7pt;">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">The aggregate market value of the voting common stock held by non-affiliates of the Registrant as of June&#160;30, 2024 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" format="ixt:num-dot-decimal" scale="6" contextRef="As_Of_6_30_2024_H8x2H6ab8UuZgH1Ve9noLg" decimals="-5" name="dei:EntityPublicFloat" id="Narr_3DyDW1f_GEKKn_7uu9Q2WQ">82.0</ix:nonFraction>&#160;million, based on the closing price for shares of the Registrant&#8217;s common stock reported by the NYSE American for such date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt;">On March&#160;14, 2025, approximately <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_3_14_2025_rb1SYpJMiE6v_QmbhlZTGw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_mbpCTVp8YEyuBVFlmqtBag">78,032,585</ix:nonFraction> shares of the Registrant&#8217;s common stock, par value $0.001 per share, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;text-indent:36pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_dzdBy1vD1UaqQCcyLxPj3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 2pt 0pt;">Portions of the registrant&#8217;s proxy statement related to its 2025 Annual Stockholders&#8217; Meeting to be filed subsequently are incorporated by reference into Part III of this Annual Report on Form 10-K. Except as expressly incorporated by reference, the registrant&#8217;s proxy statement shall not be deemed to be part of this report.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-indent:36pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fbdeefe0_279c_4abc_9d52_e606801fd680"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">2024 FORM&#160;10-K ANNUAL REPORT</p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTI_803173"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:95.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CAUTIONARY_STATEMENT_REGARDING_FORWARD"><span style="font-style:normal;font-weight:normal;">Cautionary Statement Regarding Forward-Looking Statements</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_89253"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_89253"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_626044"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_626044"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Item&#160;1C.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1CCybersecurity"><span style="font-style:normal;font-weight:normal;">Cybersecurity</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_907582"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_907582"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_932888"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_932888"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_147620"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_147620"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTII_453527"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">63</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Reserved"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">63</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_730194"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_730194"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">73</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_882944"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_882944"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Item&#160;9C.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">74</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIII_463758"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_376320"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_376320"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIV_377623"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:8.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_450405"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:87.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_450405"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:top;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:top;width:8.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_579077"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:87.04%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cbb0c6c5_c89b_47c2_8a3a_31d8f9b1ce32"></a><a id="PARTI_803173"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">PART&#160;I</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Except where the context otherwise requires, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or &#8220;the Company,&#8221; refer to the business of Protalix BioTherapeutics,&#160;Inc. and its consolidated subsidiaries, and &#8220;Protalix&#8221; or &#8220;Protalix&#160;Ltd.&#8221; refers to the business of Protalix&#160;Ltd., our wholly-owned subsidiary and sole operating unit.</i></p><a id="S1_002"></a><a id="CAUTIONARY_STATEMENT_REGARDING_FORWARD"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The statements set forth under the sections entitled &#8220;<a href="#Item1Business_89253"><span style="font-style:normal;font-weight:normal;">Business</span></a>,&#8221; &#8220;<a href="#_Item_7._"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a>&#8221; and &#8220;<a href="#_Item_1A._"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a>,&#8221; and other statements included elsewhere in this Annual Report on Form&#160;10-K, particularly with respect to our plans and strategy for our business and related financing, include forward-looking statements within the meanings of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words or phrases of similar import, as they relate to our company, our subsidiaries or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the commercialization of Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa-iwxj), our approved product for the treatment of adult patients with Fabry disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to Elfabrio&#8217;s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the U.S.&#160;Food and Drug Administration, or FDA, approval received for the product;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possible disruption of our operations due to the war declared by Israel&#8217;s security cabinet against the Hamas terrorist organization located in the Gaza Strip, the military campaign against the Hezbollah and other terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers, and the risk that the current hostilities will result in a greater regional conflict; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the regulatory approval and commercial success of our other product and product candidates, if approved;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the projected market of our products and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in the approval or potential rejection of any applications we file with the FDA, European Medicines Agency, or EMA, or other health regulatory authorities for our other product candidates, and other risks relating to the review process;</div></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with global conditions and developments such as <span style="background:#ffffff;">new or increased tariffs, new trade restrictions, </span>supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity or debt markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic partnerships;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer Inc., or Pfizer, and Chiesi Farmaceutici S.p.A., or Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents and short-term bank deposits;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, top-line or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Funda&#231;&#227;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health, or the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug products to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These and other risks and uncertainties are detailed under the &#8220;<a href="#Item1ARiskFactors_654735"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a>&#8221; section of this Annual Report and are described from time to time in the reports we file with the U.S.&#160;Securities and Exchange Commission, or the Commission.</p><a id="_cca746f4_f460_460b_aa65_e23d51b81947"></a><a id="Item1Business_89253"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;1.</b></span>Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a commercial stage biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced via our proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> plant cell-based protein expression system. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. Our unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have successfully developed two commercial products, both of which are enzyme replacement therapies (ERTs): Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which we referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. We have partnered with Chiesi for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer, and in Brazil to Fiocruz. Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are committed to leveraging our track record of success as we progress with the development of treatments for rare and orphan diseases. In addition, we continuously work on the further development and enhancement of our ProCellEx technology. Accordingly, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. We are also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elfabrio was the subject of a phase&#160;III clinical program. The phase&#160;III clinical program included three separate studies, which are referred to as the BALANCE study, the BRIDGE study and the BRIGHT study. The phase&#160;III clinical program analyzed two potential dosing regimens: 1&#160;mg/kg every two weeks and 2&#160;mg/kg every four weeks. In addition, the phase&#160;III clinical program included two extension studies in which subjects that participated in our phase&#160;I/II clinical trials and phase&#160;III clinical trials had the opportunity to enroll and continue to be treated with PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Biologics License Application, or BLA, for Elfabrio for the treatment of adult patients with Fabry disease was resubmitted to the FDA on November&#160;9, 2022. An initial BLA for Elfabrio was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, but resulted in a Complete Response Letter, or CRL. A Marketing Authorization Application, or MAA, was submitted to the EMA on February&#160;7, 2022, after the October&#160;8, 2021 meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;5, 2023, the European Commission, or EC, announced that it had approved the MAA for Elfabrio and on May&#160;9, 2023, the FDA announced that it had approved the Biologics License Application, or BLA, for Elfabrio (pegunigalsidase alfa-iwxj) injection BLA 761161, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with Enzyme Replacement Therapy (ERT) class labeling, and Warnings/Precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The Warnings/Precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease. According to the EMA, overall, the benefit/risk balance of Elfabrio is positive in the claimed indication (Fabry disease).</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:150pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA publicly released the internal review documents for Elfabrio. These documents provide previously unavailable additional information regarding the basis for the FDA&#8217;s May 2023 approval decision. In particular, the FDA determined that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study (our phase&#160;I\II clinical trial of Fabry Disease, Study PB-102-F01/02) with confirmatory evidence provided by our phase III BALANCE clinical trial of PRX-102 for the treatment of Fabry disease, or the <i style="font-style:italic;">BALANCE</i> study (also referred to as Study PB-102-F20). The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support a non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In December 2024, the EMA validated Chiesi&#8217;s Variation Submission for pegunigalsidase alfa to label a less frequent dosing regimen at a dose of 2&#160;mg/kg body weight administered every four weeks in adult patients with Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our first product, Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, an ERT for the treatment of patients with Gaucher disease, was first approved by the FDA in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we are developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I, or PRX-119, for the treatment of NETs-related diseases, and a number of other technologies and preclinical assets. We have completed a phase&#160;I First-in-Human clinical trial of PRX-115 and we expect to commence a phase&#160;II clinical trial of PRX-115 in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our proprietary ProCellEx platform is being used to manufacture both of our approved and marketed products as well as PRX-115 and PRX-119.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our strategy moving forward is to develop proprietary recombinant proteins designed to address high, unmet needs in the genetic and non-genetic rare disease space that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. Consistent with this strategy, we have a number of product candidates in varying stages of the clinical development process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20241231x10k001.jpg" alt="Graphic" style="display:inline-block;height:149.7pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expression in suspension. We are the first and only company to receive FDA approval of a protein produced through plant cell-based expression, and with the approval of Elfabrio, we now produce two commercial proteins through our platform.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:147.1pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins. The system plays an important role in the execution of our corporate strategy as its allows us to develop and produce tailored complex recombinant therapeutic proteins and to genetically engineer and/or chemically modify such proteins pre- and/or post-production. The engineering and modification of the therapeutic proteins have the potential to provide added clinical benefits by improving the biological characteristics (e.g., glycosylation, half-life, immunogenicity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We developed ProCellEx based on our plant cell culture technology for the development, expression and manufacture of recombinant proteins that are the essential foundation of modern biotechnology. We develop new, recombinant therapeutic proteins by using the natural capability of agrobacterium to transfer a DNA fragment into the plant chromosome, allowing the genome of the plant cell to code for specific proteins of interest. The agrobacterium-mediated transformed cells are then able to produce specific proteins, which are extracted and purified and can be used as therapies to treat a variety of diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20241231x10k002.jpg" alt="Graphic" style="display:inline-block;height:147.1pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.47pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology can be utilized to express complex therapeutic proteins belonging to different drug classes, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines. The entire protein expression process, from initial nucleotide cloning to large-scale production of the protein product, occurs under Current Good Manufacturing Practice-, or cGMP-, compliant, controlled processes. Our plant cell culture technology uses cells, such as carrot and tobacco (BY-2) cells, which undergo advanced genetic engineering and/or chemical modifications, and are grown on an industrial scale in a disposable, flexible bioreactor system. Our system does not involve mammalian or animal-derived components or transgenic field-grown or whole plants at any point in the production process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cell growth, from initiating scale-up steps from a cell-bank through large-scale production takes place in a clean-room environment in flexible, sterile, custom-designed polyethylene bioreactors, and does not require the use of large stainless-steel bioreactors commonly used in mammalian-based systems for recombinant protein production. The ProCellEx reactors are easy to use and maintain, allow for rapid horizontal scale-up and do not involve the risk of mammalian viral contamination. Our bioreactors are well-suited for plant cell growth using a simple, inexpensive, chemically defined growth medium. The reactors, which are custom-designed and optimized for plant cell cultures, require low initial capital investment and are rapidly scalable at a low cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we continuously work on the further development and enhancement of our ProCellEx technology.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:205.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20241231x10k003.jpg" alt="Graphic" style="display:inline-block;height:199.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx</b><sup style="font-size:7.5pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><b style="font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20241231x10k004.jpg" alt="Graphic" style="display:inline-block;height:204.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Business Highlights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have two commercial products, each of which is an ERT; Elelyso and Elfabrio. Our pipeline of product candidates includes PEGylated uricase for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I for the treatment of NETs and other technologies and preclinical assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174; </sup><span style="font-style:italic;font-weight:bold;">(taliglucerase alfa) for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Elelyso for the treatment of Gaucher disease is currently approved and marketed in 23 countries including the United States, Australia, Canada, Israel, Brazil, Russia and Turkey. In June&#160;2012, the EMA&#8217;s Committee for Medicinal Products for Human Use, or the CHMP, issued a positive opinion regarding the benefit of Elelyso but did not immediately grant marketing authorization because of the ten-year market exclusivity granted to Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (Takeda Shire) in August&#160;2010 for </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the same condition, which was extended for an additional two&#160;years, and expired in August 2022. We have granted the marketing rights to Elelyso globally, excluding Brazil, to Pfizer through an exclusive licensing agreement. We maintain the distribution rights to Elelyso in Brazil, where it is currently marketed as BioManguinhos alfataliglicerase, through the Supply and Technology Transfer Agreement, or the Brazil Agreement, we entered into on June&#160;18, 2013, with Fiocruz, an arm of the Brazilian MoH. In 2024, we generated $12.6&#160;million from sales of Elelyso to Pfizer and $11.0&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> (pegunigalsidase alfa or PRX</span><b style="font-weight:bold;">-</b><span style="font-style:italic;font-weight:bold;">102) for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elfabrio for the treatment of adult patients with Fabry disease, is our proprietary, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a lysosomal enzyme. Elfabrio has been approved by the FDA for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. In 2024, we generated $29.3&#160;million from sales of Elfabrio to Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#160;Ltd., our wholly-owned subsidiary, has entered into two exclusive licensing and supply agreements with Chiesi for Elfabrio, one global excluding the United States and the second for the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PEGylated </span><span style="font-style:italic;font-weight:bold;">Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated Uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of uncontrolled gout. Gout is the most common inflammatory arthritis, affecting a projected 14.9&#160;million adults in the United States alone. Based on market research we have commissioned, we estimate that approximately 25% of the gout population in the US and Western Europe does not have their gout controlled. Some of those patients cannot be treated with existing therapies; others stop treatment with existing therapies due to adverse events. In addition, such research presents that there are gout patients treated with existing therapies that continue to suffer from tophi despite having reached urate target levels. The risk of gout increases with age, and is more common in males. Gout results from sustained elevation of serum urate levels (hyperuricaemia). Urate levels may increase due to diet, genetic predisposition and environmental factors leading to the deposition of monosodium urate crystals and\or tophi in joints, tendons and other tissues, which triggers recurrent episodes of pronounced acute inflammation, known as gout flares. Gout leads to substantial morbidity, severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with a number of comorbidities, including hypertension, cardiovascular disease, renal impairment, diabetes, obesity, hyperlipidaemia and frequently in a combination known as the metabolic syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate which we are designing to have an elongated half-life in the circulation for the potential treatment of NETs-related diseases. NETs, or Neutrophil extracellular traps, are web-like structures released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduce NETs toxicity. Our proprietary modified DNase&#160;I, which we have designed for long and customized systemic circulation in the bloodstream, may potentially enable effective treatment for these conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">2024 Company Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">2024 Developments</i></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>In May 2024, we announced our decision to expand our phase&#160;I First-in-Human clinical trial of PRX-115 by adding an eighth cohort with eight new patients and to commence preparations for a phase&#160;II clinical trial of PRX-115.</div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On June&#160;27, 2024, we held our Annual Meeting of Stockholders at which our stockholders: (1)&#160;elected the seven persons nominated by our Board of Directors to serve as directors of the Company; (2)&#160;approved, on a non-binding, advisory basis, the compensation of our named executive officers; (3)&#160;adopted amendments to the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended, to increase the number of shares of the Company&#8217;s common stock available under such plan from 12,475,171 shares to 17,475,171 shares and adopted certain other terms of said plan and (4)&#160;ratified the appointment of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2024.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>In September 2024, we repaid in full all of the outstanding principal and interest payable under our 2024 Notes. The repayment of the convertible notes at maturity was financed entirely with available cash.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.3pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;background:#ffffff;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On December&#160;9, 2024, we announced, together with Chiesi, that the EMA had validated the Variation Submission for pegunigalsidase alfa to label a less frequent dosing regimen at a dose of 2&#160;mg/kg body weight administered every four weeks in adult patients with Fabry disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>In December&#160;2024, our Board of Directors unanimously approved and adopted an amendment and restatement of our company Bylaws.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 4.3pt 10pt 36pt;"><b style="font-weight:bold;">Our Marketed Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in 23&#160;markets including the United States, Brazil, Israel and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen, liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; Recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1&#160;in 400 to 1&#160;in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $1.7&#160;billion in 2024, is forecasted to be approximately $1.7&#160;billion in 2025 and is forecasted to grow at a compound annual growth rate (CAGR) of approximately -0.46% from 2024-2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">The current standard of care for Gaucher disease is ERT, which is a medical treatment where recombinant enzymes are injected into patients to replace the lacking or dysfunctional enzyme. In Gaucher disease, recombinant GCD is infused to replace the mutated or deficient natural GCD enzyme. Elelyso is the only alternative ERT treatment of Gaucher disease to Cerezyme and Vpriv.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Elfabrio, our second commercial product, was approved by the EC for marketing in the EU and by the FDA for marketing in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. According to the EMA, overall, the benefit/risk balance of Elfabrio is positive in the claimed </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">indication (Fabry disease). Similarly, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease. The FDA noted its determination that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study, our phase&#160;I\II clinical trial of Fabry disease, with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study. The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support the non-inferiority margin. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Since the approvals by the FDA and the EMA, Elfabrio has been approved for marketing in Great Britain, Switzerland, Peru, Israel, Russia and Singapore for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack or have low levels of &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">, in blood vessel walls throughout their body. The ultimate consequences of Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">&#160;deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The standard of care for Fabry disease is ERT. Currently, the ERTs for Fabry disease are agalsidase alfa, agalsidase beta, and now Elfabrio. Through an ERT, the missing &#945;-galactosidase-A is replaced with a recombinant form of the protein via intravenous, or IV, infusion once every two weeks. Fabry disease, if left untreated, will progress from a less severe condition to a more serious one. It can have a significant impact on quality of life due to presence of serious, chronic and debilitating complications, including cardiovascular and renal complications, and comorbid conditions such as pain can have a significant impact on the psychological well-being of Fabry patients and their social functioning. Fabry disease involves substantial reduction in life expectancy. Causes of death are most often cardiovascular disease and, to a lesser extent, cerebrovascular disease and renal disease. The life expectancy of Fabry patients is significantly shorter compared to the general population. Untreated male Fabry patients may experience shortened lifespans to approximately 50&#160;years, and 70&#160;years for untreated female patients with Fabry disease. This represents a 20- and 10-year reduction of their respective lifespans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The global market for Fabry disease, that includes agalsidase beta, Sanofi&#8217;s Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, agalsidase alfa, Shire&#8217;s Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Amicus Therapeutics&#8217; Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, is forecasted to be approximately $2.3&#160;billion in 2025 and is forecasted to grow at a CAGR of 6.6% from 2024-2030 reaching approximately $3.1&#160;billion in annual sales in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Regulatory Background</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On November&#160;9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA in May 2020. However, in April 2021, the FDA issued a CRL in response thereto. No concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package were raised in the CRL. The FDA noted in the CRL that an inspection of our manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, was required before the FDA can approve a new drug. Due to travel restrictions during the COVID-19 pandemic, the FDA was unable to conduct the required pre-approval inspection during the review cycle. In addition to the foregoing, the FDA noted that agalsidase beta had recently been converted to full approval, a change in regulatory circumstances which had to be addressed in the resubmitted BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The PRX-102 MAA was submitted to the EMA in February 2022 after a meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. In February 2023, we, together with Chiesi, announced that the CHMP had adopted a positive opinion, recommending marketing authorization for PRX-102. As disclosed above, Elfabrio was subsequently approved by the EC for marketing in the EU and in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio was approved by </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:186.55pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with ERT class labeling, and warnings/precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The warnings/precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">In December 2024, the EMA validated Chiesi&#8217;s Variation Submission for PRX-102. The Variation Submission seeks to add an additional dose and dosing regimen, 2&#160;mg/kg body weight administered every four weeks in adult patients with Fabry disease, to the current Elfabrio label.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our PRX-102 clinical development program was designed to show that PRX-102 has a potential clinical benefit in all adult Fabry patient populations when compared to the then marketed Fabry disease enzymes, agalsidase beta and agalsidase alfa. In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;III clinical program included three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. In the phase&#160;III clinical program overall, two potential dosing regimens for PRX-102 were analyzed; 1&#160;mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2&#160;mg/kg every four weeks. The phase&#160;III program was preceded by the phase&#160;I/II clinical trial, a dose range finding study in ERT-na&#239;ve adult patients with Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;"><img src="plx-20241231x10k005.jpg" alt="Graphic" style="display:inline-block;height:186.55pt;width:388.5pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Phase&#160;III BALANCE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BALANCE</i> study (PB-102-F20, NCT02795676) was a pivotal 24-month, randomized, double blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta. The Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study, completed in July 2022, demonstrated a favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta for at least one year with an eGFR slope at screening worse than -2&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77&#160;patients were treated; 52 with PRX-102 and 25 with agalsidase beta. Approximately 40% of the enrolled patients were female.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta arm. The number of events adjusted to 100&#160;years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">TEAEs were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21&#160;(40.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11&#160;(21.2%)&#160;patients in the PRX-102 arm experienced a total of 13&#160;events compared to six (24.0%) patients experiencing a total of 51&#160;events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients that received PRX-102 were ADA positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Considering that in the trial patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in-line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of the direct, blinded comparison of PRX-102 to agalsidase beta, for the primary efficacy renal endpoints (i.e., eGFR change, eGFR slope) and for the main secondary endpoints (e.g., urine protein to creatinine ratio [UPCR] LVMI, MSSI, BPI) strongly suggest comparability in treatment effects between the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the same time, a potentially favorable safety profile was identified based on lower rates of IRR, lower ADA positivity, and less premedication use in the PRX-102 arm compared to agalsidase beta. Overall, a positive benefit-risk balance was confirmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Phase&#160;III BRIDGE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIDGE</i> study (PB-102-F30, NCT03018730) was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of PRX-102, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa for at least two years and on a stable dose for at least six months. In the study, patients were screened and evaluated over three months while continuing agalsidase alfa treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE</i> study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22&#160;patients completed the 12-month treatment duration. In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, et. al., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. The majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea. An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Phase&#160;III BRIGHT Study</i><i style="direction:rtl;font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study (PB-102-F50, NCT03180840) was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14&#160;infusions). The 2&#160;mg/kg every four weeks dosage has not been approved by the EMA, FDA or any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Enrollment in the study included 30 adult patients (24 males and 6 females) with mean (SD) age of 40.5 (11.3) years, ranging from 19 to 58 years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa) for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12 months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and for lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>levels as a Fabry biomarker, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The final results from the <i style="font-style:italic;">BRIGHT</i> study indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30 patients received at least one dose of PRX-102, and 29 patients completed the one-year study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg PRX-102 every two weeks per protocol at the 11th infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Overall, 33 of 183 total TEAEs reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs led to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36 nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60&#160;nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>&#160;(1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every two weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every four weeks as an effective and tolerable alternative treatment option.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week 52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Phase I/II Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;I/II clinical trial of PRX-102 (NCT01678898) was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. It was completed in 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the phase&#160;I/II study, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Results show that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Extension Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Two long-term open-label extension studies were available for patients who completed the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase I/II study. Overall, 126 patients who participated in our PRX-102 clinical program initially opted, with the advice of the treating physician, to enroll in one of the extension studies: 97 patients in the 1&#160;mg/kg every two weeks extension study (PB-102-F60, NCT03566017) (10 patients who completed an extension study from the phase&#160;I/II study, 18 patients who completed the <i style="font-style:italic;">BRIDGE</i> study; 69 patients who completed the <i style="font-style:italic;">BALANCE</i> study), and 29 patients who completed the <i style="font-style:italic;">BRIGHT</i> study in the 2&#160;mg/kg every four weeks extension study (PB-102-F51, NCT03614234). Two of the patients in the 2&#160;mg/kg every four weeks extension study were treated with 1&#160;mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">After the approval of Elfabrio in the US and the EU, sponsorship and administration of the extension studies was transferred to Chiesi. Over time, and as Elfabrio is approved for marketing in different jurisdictions, patients switch-out of the open-label extension studies. Most of them have transferred to a commercial setting; others withdraw for other </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">reasons. Accordingly, the 1&#160;mg/kg every two weeks dosage extension study is now closed as most patients have transferred to commercial or expanded access programs. In addition, most of the patients that enrolled in the 2&#160;mg/kg every four weeks dosage extension study are now being treated with Elfabrio on a commercial basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Pediatric FLY Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is sponsoring, with our collaborative efforts, a clinical trial entitled &#8220;Multi-Centre, Open-label Trial to Assess the Safety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigalsidase alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed Fabry Disease&#8221; (NCT06328608). Recruitment has commenced. The design of the study is based on the Initial Pediatric Study Plan (iPSP) agreed to with the FDA and the paediatric investigation plan (PIP) for Elfabrio, which has been accepted, as amended, by the Paediatric Committee (PDCO) of the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Japanese RISE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is currently enrolling patients in its clinical trial entitled &#8220;A Multicenter Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Pegunigalsidase Alfa (PRX-102) in Japanese Patients With Fabry Disease,&#8221; or the <i style="font-style:italic;">RISE</i> study (NCT05710692). The aim of the <i style="font-style:italic;">RISE</i> study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned that a total of approximately 18-20 male and female Fabry disease patients between the ages of 13 and 60 years will be enrolled in the study which is being conducted in Japan. The study involves both the 1&#160;mg/kg every two weeks and the 2&#160;mg/kg every four weeks dosages.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Development Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our corporate strategy includes development of treatments for rare and orphan diseases. To execute on the strategy, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. Our current pipeline of product candidates includes PEGylated uricase for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I for the treatment of NETs and other technologies and preclinical assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">PEGylated Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of patients with uncontrolled gout. The uricase enzyme, which does not exist naturally in humans, converts urate to allantoin, which is easily eliminated through urine. This recombinant enzyme, expressed via our ProCellEx system, is designed to lower urate levels and improve clinical manifestation of the disease while having low immunogenicity and increased half-life of the drug in the blood. Pre-clinical data demonstrates long half-life, reduced immunogenic risk and high specific activity supports the potential of PRX-115 to be a safe and effective treatment for patients with gout. One-month multiple dosing toxicity studies in two animal species and a 6-month multiple dosing toxicity study in one animal species were conducted to support single- and multiple-dose studies in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In March 2023, we initiated our phase&#160;I clinical trial of PRX-115 for the potential treatment of uncontrolled gout entitled &#8220;A Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels&#8221; (NCT05745727), or the <i style="font-style:italic;">FIH</i> study. The study was conducted at New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines. The study was initially designed to include seven sequential dosing cohorts, each composed of eight subjects (six active and two placebo), a 3:1 ratio. Subjects in each cohort, males and females aged 18 through 65, received a single dose of PRX-115 and were analyzed for safety, pharmacokinetics (PK) and pharmacodynamics (PD) (concentrations of plasma urate) for 85 days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">After a review of initial positive top-line results from the initial seven cohorts, and following the review and acceptance of the safety data from such seven cohorts by the safety and monitoring committee for dose escalation for the <i style="font-style:italic;">FIH</i> study, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:258pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">we decided to expand the study by adding an eighth cohort of eight new subjects to analyze a higher dose and its potential to result in increased exposure time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Overall, 64 randomized subjects were enrolled across the eight cohorts; 48 subjects were treated with PRX&#8211;115 and 16 subjects were treated with placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Key results from the full <i style="font-style:italic;">FIH</i> study are as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Exposure to PRX-115 increased in a dose-dependent manner. Detectable PRX-115 levels were observed in plasma for up to 12&#160;weeks from subjects in cohorts 6, 7, and 8. See Figure&#160;1.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20241231x10k006.jpg" alt="Graphic" style="display:inline-block;height:258pt;width:414.6pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>In all tested doses, a single dose of PRX-115 rapidly reduced plasma urate levels. The effect and duration of response were found to be dose dependent. Following a single dose, mean plasma urate levels remained below 6.0&#160;mg/dL for up to 12&#160;weeks at the highest doses. See Figure&#160;2.</div><div style="margin-top:10pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:277.8pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="plx-20241231x10k007.jpg" alt="Graphic" style="display:inline-block;height:277.8pt;width:415.8pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>All randomized participants completed the study. PRX-115 was found to be well-tolerated. See Figure&#160;3.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;3. Overall Summary of Adverse Events*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="plx-20241231x10k008.jpg" alt="Graphic" style="display:inline-block;height:135pt;width:415.8pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">*Number of subjects reporting at least one adverse event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Only 25% of the subjects treated with PRX-115 in the study (12/48) having reported study drug-related adverse events. The majority of such adverse events were mild to moderate and transient in nature. One subject experienced an anaphylactic reaction in cohort&#160;2 immediately following the commencement of the infusion (6 minutes) and, accordingly, was exposed to approximately 5% of the applicable PRX-115 dose. The reaction resolved completely and the subject continued in the study for follow-up safety assessments. Premedication with anti-histamines and steroids were administered to all subjects following the anaphylaxis event. No other subjects experienced a similar reaction and no other serious adverse events were reported in the study. No related adverse events were reported for subjects treated in cohorts 6 and 7, and only for one patient per cohort in cohorts 4, 5 and 8.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These results suggest that PRX-115 has the potential to be a promising treatment option for patients with gout. The results demonstrate that PRX-115 may offer an effective urate-lowering treatment with an added benefit of a potentially wide dosing interval, which may enhance patient compliance and treatment flexibility. Further studies are needed to confirm the long-term safety and efficacy of PRX-115 in the gout patient population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have initiated preparations for a phase&#160;II clinical trial of PRX-115, and we expect to commence the study in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gout is the most common inflammatory arthritis, affecting a projected 14.9&#160;million adults in the United States alone. Based on market research we have commissioned, we estimate that approximately 25% of the gout population in the US and Western Europe do not have their gout controlled. Some of those patients cannot be treated with existing therapies; others stop treatment with existing therapies due to adverse events. In addition, such research shows that there are gout patients treated with existing therapies that continue to suffer from tophi despite having reached urate target levels. The risk of gout increases with age, and is more common in males. Gout results from sustained elevation of serum urate levels (hyperuricaemia). Urate levels may increase due to diet, genetic predisposition and environmental factors leading to the deposition of monosodium urate crystals and\or tophi in joints, tendons and other tissues, which triggers recurrent episodes of pronounced acute inflammation, known as gout flares. Gout leads to substantial morbidity, severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with a number of comorbidities, including hypertension, cardiovascular disease, renal impairment, diabetes, obesity, hyperlipidaemia and frequently occurs in a combination known as the metabolic syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Uncontrolled gout is when serum urate (sUA) levels are above the maximum medically appropriate level (6.8 mg/dL), as well as tophi formation and/or flares that cannot be treated with available urate lowering therapies. Currently available ULTs can be effective in treating gout. However, factors such as low adherence, under dosing, disease progression that cause high patient burden or patients that are not suitable for available therapy, require new, effective and safe therapies to treat these underserved uncontrolled gout patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients who have contraindication/failure of other lowering urate treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis and other major side-effects. The FDA label of Krystexxa was amended in 2022 to include co-treatment of methotrexate to prolong efficacy and increases tolerability in patients with refractory gout. Krystexxa is no longer marketed in the European Union. The EC withdrew the marketing authorization for Krystexxa in 2016 at the request of the marketing authorization holder which notified the EC of its decision not to market the product in the European Union for commercial reasons. We believe that new effective, safe therapies are needed to treat severe gout, chronic refractory and uncontrolled<b style="font-weight:bold;"> </b>gout, regardless of treatment history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate which we are designing to have an elongated half-life in the circulation for the potential treatment of NETs-related diseases. NETs, or Neutrophil extracellular traps, are web-like structures released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduce NETs toxicity. Our proprietary modified DNase&#160;I, which we have designed for long and customized systemic circulation in the bloodstream, may potentially enable effective treatment for these conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The administration of PRX-119 resulted in a decrease in circulating of DNA levels and significantly enhanced the survival of mice in both a CLP-induced sepsis model and an ARDS model.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have a robust patent portfolio, which is a key element of our overall strategy. We work to continually enhance, strengthen, and protect our intellectual property and now hold a broad portfolio of approximately&#160;75 patents globally, including in Europe, the United States, Israel and additional countries worldwide. Our patents are designed to protect our proprietary technology, proprietary products and product candidates, and their methods of use. Additionally, we have approximately&#160;50 pending patent applications. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the year ended December&#160;31, 2024, we received the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New patents in each of USA, Australia, Chile and Mexico for the patent family named &#8220;Therapeutic Regimen For the Treatment of Fabry Using Stabilized Alpha-galactosidase, adding to the single previously granted patent in such family.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A new patent in Japan for the patent family named &#8220;Removal of Constructs from Transformed Cells.&#8221;</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our competitive position and future success depend, in part, on our ability, and that of our licensees, to obtain and leverage the intellectual property rights covering our product candidates, know-how, methods, processes and other technologies, to protect our trade secrets, to prevent others from using our intellectual property and to operate without infringing on the intellectual property rights of third parties. We seek to protect our competitive position by filing United States, European Union, Israeli and other foreign patent applications covering our technology, including both new technology and improvements to existing technology. Our patent strategy includes obtaining patents on methods of production, compositions of matter and methods of use. We also rely on know-how, continuing technological innovation, licensing and partnership opportunities to develop and maintain our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2024, our patent portfolio consisted of several patent families (consisting of patents and/or patent applications) covering our technology, protein expression methodologies and system and product candidates, as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:22.7pt;"><td style="vertical-align:bottom;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:22.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Name/Int. App. No.</b></p></div></div></td><td style="vertical-align:bottom;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:22.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Global Pending Jurisdictions</b></p></div></div></td><td style="vertical-align:bottom;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:22.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Granted Jurisdictions</b></p></div></div></td><td style="vertical-align:bottom;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:22.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nominal Expiry</b></p></div></div></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Production of High Mannose Proteins in Plant Culture/PCT/ Il2004 000181</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Russian Federation, Australia, USA</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2025(1)<br/>(3)</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plant Cell/Tissue Culturing Device, System and Method/PCT/Il2005/000228</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2025</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Large Scale Disposable Bioreactor/PCT/Il2008/000614</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A </p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Australia, Canada, China, Europe, Hong Kong, India, Israel, Republic of Korea, Russian Federation, Singapore, South Africa, USA, Brazil</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2028(2)</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stabilized Alpha-galactosidase and uses thereof/PCT/Il2011/ 000209</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Brazil</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Canada, South Africa, Russian Federation, Singapore, Israel, India, New Zealand, <br/>Republic of Korea, Australia, China, Japan, USA, Europe,<br/>Hong Kong, India, Brazil</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2031(3)</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nucleic Acid Construct for Expression of Alpha-galactosidase in Plants and Plant Cells/PCT/ Il2011/000719</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">India, China, Republic of Korea, Japan, Israel, Europe, Hong Kong, USA, Brazil</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2031(2)</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Therapeutic Regimen For The Treatment of Fabry Using Stabilized Alpha-galactosidase/ PCT/Il2018/050018</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Europe, Brazil, Japan, Canada, Israel, Republic of Korea, China, Hong Kong</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">South Africa, New Zealand, Russian Federation, USA, Chile, Mexico, Australia</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2038</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:middle;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dry Powder Formulations of DNase&#160;1/PCT/Il2013/050094</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel, USA</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2033</p></td></tr><tr><td style="vertical-align:middle;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DNase I Polypeptides, Polynucleotides Encoding Same, Methods of Producing DNase&#160;I and uses thereof in Therapy/PCT/ Il2013/050097</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Europe, Israel, Brazil</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2033</p></td></tr><tr><td style="vertical-align:middle;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inhalable Liquid Formulations of DNase I/PCT/Il2013/050096</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel, USA</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2033</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Modified DNase and uses thereof/ PCT/Il2016/050003</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Europe, Canada, China, <br/>Hong Kong</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">USA, Australia, Mexico, Israel,<br/>New Zealand, South Africa</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2036</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Removal of Constructs from Transformed Cells/PCT/IL2019/ 051266</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">USA, Israel, New Zealand, Australia</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Japan,</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2040</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-Acting DNase/PCT/IL2021/051207</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Canada, Israel, USA, Japan, Europe, Hong Kong, Republic of Korea, China</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dicer-Like Knock-Out Plant Cells/ PCT/IL2021/051194</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Israel, USA, Japan, Europe, Hong Kong, Republic of Korea, China</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:30.85%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Modified Uricase and Uses Thereof/PCT/IL2021/051305</p></td><td style="vertical-align:top;width:27.3%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Japan, Canada, Brazil, USA, Israel, Mexico, Europe, Republic of Korea, China</p></td><td style="vertical-align:top;width:31.74%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;background:#cceeff;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2041</p></td></tr><tr><td style="vertical-align:top;width:30.85%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Methods of treating diseases associated with elevated uric acid</p></td><td style="vertical-align:top;width:27.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">USA</p></td><td style="vertical-align:top;width:31.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td><td style="vertical-align:top;width:10.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">N/A</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent granted in Australia expires in 2029.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent granted in the United States expires in 2032.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PTE/SPC applications were submitted for some of the patents.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are aware of U.S. patents, and corresponding international counterparts of such patents, owned by third parties that contain claims covering methods of producing glucocerebrosidase. We do not believe that, if any claim of infringement were to be asserted against us based upon such patents, taliglucerase alfa would be found to infringe any valid claim under such patents. However, there can be no assurance that a court would find in our favor or that, if we choose or are required to seek a license to any one or more of such patents, a license would be available to us on acceptable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In April&#160;2005, Protalix&#160;Ltd. entered into a license agreement with Icon Genetics AG, or Icon, pursuant to which we received an exclusive worldwide license to develop, test, use and commercialize Icon&#8217;s technology to express certain proteins in our ProCellEx protein expression system. We are also entitled to a non-exclusive worldwide license to make and have made other proteins expressed by using Icon&#8217;s technology. As consideration for the license, we are obligated to make royalty payments equal to varying low, single-digit&#160;percentages of net sales of products by us, our affiliates, or any sublicensees under the agreement. In addition, we are obligated to make milestone payments equal to $350,000, in the aggregate, for each product developed under the license, upon the achievement of certain milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our license agreement with Icon remains in effect until the earlier of the expiration of the last patent under the agreement or, if all of the patents under the agreement expire, 20&#160;years after the first commercial sale of any product under the agreement. Icon may terminate the agreement upon written notice to us that we are in material breach of our obligations under the agreement and we are unable to remedy such material breach within 30&#160;days after we receive such notice. Further, Icon may terminate the agreement in connection with certain events relating to a wind up or bankruptcy, if we make a general assignment for the benefit of our creditors, or if we cease to conduct operations for a certain period. Icon may also terminate the exclusivity granted to us by written notice if we fail to reach certain milestones within a designated period of time. Notwithstanding the termination date of the agreement, our obligation to pay royalties to Icon under the agreement may expire prior to the termination of the agreement, subject to certain conditions.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Competition"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The biotechnology and pharmaceutical industries are characterized by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the fields in which we operate is intense and expected to increase. Most of these companies have substantially greater research and development, manufacturing, marketing, financial, technological personnel and managerial resources than we do. In addition, many specialized biotechnology companies have formed collaborations with large, established companies to support research, development and commercialization of products that may be competitive with our current and future product candidates and technologies. Acquisitions of competing companies by large pharmaceutical or biotechnology companies could further enhance such competitors&#8217; financial, marketing and other resources. Academic institutions, governmental agencies and other public and private research organizations are also conducting research activities and seeking patent protection and may commercialize competitive products or technologies on their own through collaborations with pharmaceutical and biotechnology companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">With respect to Gaucher disease, we face competition primarily from two ERTs, Sanofi Genzyme&#8217;s Cerezyme and Takeda&#8217;s (Shire) Vpriv. In addition, Actelion markets a small molecule drug for the treatment of mild to moderate Type&#160;1 Gaucher disease (Zavesca or miglustat), an oral treatment approved by the FDA only for patients for whom ERT is not a therapeutic option. In addition, Sanofi Genzyme markets a small molecule oral drug, Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, approved for Gaucher patients with certain CYP2D6 metabolizer status. We are aware of other treatments and gene therapies in early clinical development and later stage clinical development for the treatment of Gaucher disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">With respect to Fabry disease, we face competition primarily from Sanofi Genzyme (Fabrazyme), Takeda (Replagal) and Amicus (Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>). In addition, we are aware of other late clinical stage, early clinical stage and experimental drugs that are being developed by other companies for the treatment of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">With respect to uncontrolled gout, we face competition from Horizon Therapeutics Public Limited Company (Krsytexxa), which is indicated for treatment of chronic gout in adult patients refractory to conventional therapy. In addition, we are aware of other clinical stage, early clinical stage and experimental refractory or chronic gout treatments. For example, we are aware of a product candidate for chronic refractory gout that recently completed a phase&#160;III clinical trial and has met the primary endpoints of the trial, and of another product candidate that is the subject of a phase&#160;II clinical trial for hyperuricemia in gout patients with advanced CKD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also face potential competition to our ProCellEx system from companies that are developing other platforms for the expression of recombinant therapeutic pharmaceuticals. We are aware of companies that are developing alternative technologies to develop and produce therapeutic proteins in anticipation of the expiration of certain patent claims covering marketed proteins. A number of companies have developed or are developing alternative expression technologies. Examples include Crucell N.V.&#8217;s (acquired by Johnson&#160;&amp;&#160;Johnson) expression system based on human-cell technology, Dyadic International Inc.&#8217;s expression system based on a fungus, Pfenex Inc.&#8217;s (acquired by Ligand Pharmaceuticals Incorporated) bacteria-based expression system, and others. Companies developing alternate plant-based technologies include iBio,&#160;Inc., Medicago,&#160;Inc., and eleva. Unlike ProCellEx, these alternate technologies are not cell-based. These companies base their product development on transgenic plants or whole plants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Agreements and Partnerships</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Elelyso &#8211; Pfizer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets, excluding Brazil, pursuant to an Amended and Restated Exclusive License and Supply Agreement, or the Amended Pfizer Agreement, which we entered into with Pfizer in October&#160;2015 to amend and restate our initial Exclusive License and Supply Agreement with Pfizer, or the Pfizer Agreement. Pursuant to the Amended Pfizer Agreement, Pfizer retains 100% of revenue and reimburses 100% of direct costs. For the first 10-year period after the execution of the Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, subject to certain terms and conditions, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods, subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period. Any failure to comply with our supply commitments may subject us to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">substantial financial penalties. The Amended Pfizer Agreement includes customary provisions regarding cooperation for regulatory matters, patent enforcement, termination, indemnification and insurance requirements. We retain distribution rights to taliglucerase alfa in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Elelyso &#8211; Funda&#231;&#227;o Oswaldo Cruz (Fiocruz)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso, marketed as BioManguinhos alfataliglicerase in Brazil, is commercialized in Brazil through the Brazil Agreement with Fiocruz, which became effective in January&#160;2014. Gaucher patients in Brazil are entitled to receive ERT paid for by the Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicerase is currently estimated to be used by approximately 25% of Gaucher patients in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Brazil Agreement provides for a staged technology transfer which is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of BioManguinhos alfataliglicerase. Fiocruz has not satisfied certain purchase commitments under the Brazil Agreement. Accordingly, we and Fiocruz discuss on a continuous basis, potential steps to maximize sales of BioManguinhos alfataliglicerase sales to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><i style="white-space:pre-wrap;">Elfabrio (pegunigalsidase alfa\PRX-102)  &#8211; Chiesi Farmaceutici</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi; the Exclusive License and Supply Agreement dated as of October&#160;17, 2017, made by and between Protalix&#160;Ltd. and Chiesi, or the Chiesi Ex-US Agreement, and the <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418013053/tv486893_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License and Supply Agreement dated as of </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">July&#160;23, 2018</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, made by and between Protalix&#160;Ltd. and </span></a>Chiesi, or the Chiesi US Agreement. The Chiesi Ex-US Agreement and the Chiesi US Agreement are referred to herein collectively as the Chiesi Agreements. Under the agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and development cost reimbursements of $45&#160;million, and is entitled to more than $1.0&#160;billion in potential milestone payments tiered payments for drug product purchased from Protalix Ltd. equal to 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US), depending on the amount of annual net sales in the applicable territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Chiesi Ex-US Agreement, we granted to Chiesi an exclusive license for all markets outside of the United States to commercialize PRX-102. Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The exclusive license to develop and commercialize PRX-102 in the United States were granted to Chiesi under the Chiesi US Agreement. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, capped at $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi agreed to make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix&#160;Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi amending the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;29, 2022, we entered into the F/F Agreement and the Letter Agreement. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The Letter Agreement changed the obligations of both us and Chiesi under the Chiesi Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amended certain provisions of the Chiesi Agreements to reflect the appointment of Chiesi as a supplier to our company of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services. Subsequently, in November 2024, we amended the agreement to provide that a different Chiesi facility may act as a secondary supplier of such services and that the F/F&#160;Agreement shall have an initial term of 10&#160;years, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement. Prior to expiration of the initial term, the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We use our current manufacturing facility in Carmiel, Israel, which has approximately 14,700&#160;sq/ft of clean rooms built according to industry standards, to manufacture drug substance for Elfabrio and Elelyso for commercial purposes and, with respect to Elfabrio, in connection with clinical trials. We maintain an approximately 3,400&#160;sq/ft pilot plant for protein development and to manufacture supplies for clinical trials (phase&#160;I and phase&#160;II). Elelyso, Elfabrio and our drug product candidates must be manufactured in a clean environment and in compliance with cGMPs set by the FDA and other relevant foreign regulatory authorities. We intend to use our manufacturing space to produce all of the drug substance needed in connection with the clinical trials for our other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since 2017, our manufacturing facility has been approved by the FDA as a multi-product facility. Our facility&#8217;s current capacity can serve all of our current and expected commercial and clinical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our manufacturing facilities are subject to inspections by various regulatory authorities from time to time. We have undergone successful inspections by the FDA, the Irish Medicines Board (under the EMA&#8217;s centralized marketing authorization procedure), the Brazilian National Health Surveillance Agency (ANVISA), the Israeli Ministry of Health, the Turkish Ministry of Health, the Australian Therapeutic Goods Administration (TGA) and Health Canada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Raw Materials and Suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that the raw materials that we require throughout the manufacturing process of Elfabrio and Elelyso, and our current and potential drug product candidates, are widely available from numerous suppliers and are generally considered to be generic industrial biological supplies. We rely on a single, approved supplier for certain materials relating to the current expression of our proprietary biotherapeutic proteins through ProCellEx. We have identified additional suppliers for most of the materials required for the production of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Development and regulatory approval of our pharmaceutical products are dependent upon our ability to procure active ingredients (DS) and certain packaging materials from sources approved by the FDA and other regulatory authorities. The FDA and other regulatory approval processes require manufacturers to specify their proposed suppliers of active ingredients (which is not relevant to our company), intermediate material and certain packaging materials in their applications. From time to time, we intend to continue to identify alternative approved suppliers to ensure the uninterrupted supply of necessary raw materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Government Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">U.S. Drug Development Process</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The FDA regulates drugs under the U.S.&#160;Federal Food, Drug, and Cosmetic Act, or the FFDCA, and the implementing regulations thereto. Drugs are also subject to other federal, state and local statutes and regulations. Biologics are subject to regulation by the FDA under the FFDCA, the Public Health Service Act, and related regulations and other federal, state and local laws and regulations. Biological products include a wide variety of products including vaccines, blood and blood components, gene therapies, tissue and proteins. Unlike most prescription products made through chemical processes, biological products generally are made from human and/or animal materials. To be lawfully marketed in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">interstate commerce, a biologic product must be the subject of a BLA issued by the FDA on the basis of a demonstration that the product is safe, pure and potent, and that the facility in which the product is manufactured meets standards to assure that the product continues to be safe, pure and potent. The FDA has developed, and is continuously updating, the requirements with respect to cell and gene therapy products and has issued documents concerning the regulation of cellular and tissue-based products. Manufacturers of cell and tissue-based products must comply with the FDA&#8217;s current good tissue practices, or cGTP, which are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of such products. The primary intent of the cGTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The process of obtaining regulatory approvals and ensuring compliance with appropriate federal, state and local statutes and regulations in the United States, and foreign statutes and regulations, requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, product detention, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. The process required by the FDA before a biological product or drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of preclinical laboratory tests, animal studies and formulation studies </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">, with certain studies conducted in accordance with Good Laboratory Practice regulations, or GLPs, and other applicable regulations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and well-controlled clinical trials according to Good Clinical Practices, or GCPs, to establish the safety and efficacy </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">of a proposed drug candidate, and the safety, purity and potency of a proposed biological product candidate, for its intended use</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of a BLA for a new biological product or a new drug application, or NDA, for a new drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s or biologic&#8217;s identity, strength, quality and purity; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">satisfactory completion of potential inspection of selected clinical investigation sites to assess compliance with GCPs; </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA or NDA.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Once a product candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit, among other things, the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans. An IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the trial includes an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the&#160;30-day&#160;time period, places the IND on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">concerns or&#160;non-compliance&#160;with FDA requirements, in which case clinical trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. FDA may also place a trial on a partial clinical hold. A partial clinical hold is a delay or suspension of only part of the clinical work requested or ongoing under the IND. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation (or full investigation in the case of a partial clinical hold) may only begin or resume after the FDA has notified the sponsor that the investigation may proceed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. These regulations include the requirement that all subjects participating in the clinical trial provide their informed consent regarding the trial. Further, an IRB must review and approve the plan for any clinical trial before it commences at any institution. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the information regarding the clinical trial and the consent form that must be provided to each clinical trial subject, or his or her legal representative, and must monitor the clinical trial until completed. Once an IND is in effect, each new clinical protocol and any amendments to the protocol must be submitted to the FDA for review, and to the IRBs for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase&#160;I.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The product is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing may be conducted in patients having the specific disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase&#160;II. </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;II clinical trials involve investigations in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and the optimal dosage and schedule.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Phase&#160;III.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Phase&#160;III clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for regulatory approval and product labeling.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Post-approval studies, also called Phase&#160;IV trials, may be conducted after initial marketing approvals. These studies are used to obtain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected side effects. Phase&#160;I, Phase&#160;II and Phase&#160;III testing may not be completed successfully within any specified period, if at all. The FDA or the trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the study subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the applicable product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the product candidate, proposed labeling and other relevant information, are </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">submitted to the FDA as part of an NDA or BLA, requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of substantial user fees which may be waived under certain limited circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The testing and approval processes require substantial time and effort, and may not result in an approval on a timely basis, if at all. The FDA may refuse to approve a BLA or NDA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Generally, it takes one to three&#160;years to obtain approval. If questions arise during the FDA review process, approval may take a significantly longer period of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require Phase&#160;IV testing which involves clinical trials designed to further assess a drug&#8217;s or biologic&#8217;s safety and effectiveness after BLA or NDA approval and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The <span style="background:#ffffff;">FDA impose other conditions, including distribution restrictions or other risk management mechanisms, including a risk evaluation and mitigation strategy, or REMS, which can materially affect the potential market and profitability of the product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">In addition, the Pediatric Research Equity Act, or the PREA, requires a sponsor to conduct pediatric clinical trials for most biologics and drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under the PREA, original NDAs and BLAs and certain supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness, or safety, purity, and potency, of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is deemed safe and effective, or safe, pure and potent. The sponsor may request or the FDA may grant a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for approval for use in adults before pediatric clinical trials are complete or that additional data need to be collected before the pediatric clinical trials begin.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Orphan Drug Act of 1983, the FDA may grant orphan drug designation to drugs and biological products intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 persons in the United States but that sales in the United States are not expected to recover the costs of developing and marketing a treatment drug. Orphan product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Among the benefits of orphan drug designation are possible funding and tax savings to support clinical trials, other financial incentives and a waiver of the marketing application user fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same treatment for the same indication for seven&#160;years, except in limited circumstances, such as (i)&#160;the drug&#8217;s orphan designation is revoked; (ii)&#160;its marketing approval is withdrawn; (iii)&#160;the orphan exclusivity holder consents to the approval of another applicant&#8217;s product; (iv)&#160;the orphan exclusivity holder is unable to assure the availability of a sufficient quantity of drug; or (v)&#160;a showing of clinical superiority to the product with orphan exclusivity by a competitor product. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan drug status in the European Union has similar but not identical benefits in the European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Patent Term Restoration and Marketing Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five&#160;years as compensation for patent term lost during product development and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between (a)&#160;the effective date of an IND and the submission date of a BLA or an NDA plus (b)&#160;the time between the submission date of a BLA or an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the extension must be requested prior to expiration of the patent. The U.S. Patent and Trademark Office, or USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. We anticipate that we will apply for restorations of the patent term for certain of patents covering our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Fast Track Designation; Breakthrough Therapy Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA has a fast track program that is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need, the purpose being to make important new drugs available to patients earlier. A drug candidate that receives Fast Track designation from the FDA is eligible for some or all of the following: more frequent meetings with the FDA to discuss the drug&#8217;s development plan and ensure collection of appropriate data needed to support drug approval; more frequent written communication from the FDA about such things as the design of the proposed clinical trials; eligibility for the FDA&#8217;s Accelerated Approval and Priority Review, if relevant criteria are met; and eligibility for Rolling Review, which allows a drug company to submit completed sections of its BLA or NDA for review by the FDA, rather than waiting until every section of the BLA or NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. We used the Rolling Review option for our taliglucerase alfa NDA, which we completed in April&#160;2010.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as phase&#160;I and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Accelerated Approval; Breakthrough Therapy Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Section&#160;901 of the U.S.&#160;Food and Drug Administration Safety Innovations Act amends the FFDCA to allow the FDA to base Accelerated Approval for drugs for serious conditions that fill an unmet medical need on whether the drug has an effect on a surrogate or an intermediate clinical endpoint. A surrogate endpoint used for Accelerated Approval is a marker; that is, a laboratory measurement, radiographic image, physical sign or other measure, that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a measure of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on irreversible morbidity and mortality. The FDA bases its decision on whether to accept the proposed surrogate or intermediate clinical endpoint on the scientific support for that endpoint. Studies that demonstrate a drug&#8217;s effect on a surrogate or intermediate clinical endpoint must be &#8220;adequate and well controlled&#8221; as required by the FFDCA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Accelerated Approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Under subpart H of the Accelerated Approval pathway, the FDA may grant marketing approval for a new drug product on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. The Accelerated Approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of phase&#160;IV or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA<span style="background:#ffffff;">, which could adversely impact the timing of the commercial launch of the product</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any drugs for which we receive FDA approval are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse effects with the product, reporting of changes in distributed products which would require field alert reports (FARs), drugs and biological product deviation reports (BPDRs) providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements. In September&#160;2007, the Food and Drug Administration Amendments Act of 2007 was enacted, giving the FDA enhanced post-marketing authority, including the authority to require post marketing studies and clinical trials (PMRs and PMCs), labeling changes based on new safety information, and compliance with risk evaluations and mitigation strategies (REMS), approved by the FDA. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. Further, manufacturers of drugs and biologics must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Drug and biologic manufacturers and other entities involved in the manufacturing and distribution of approved drugs and biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, GTP applicable to biologics, and other laws. The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, sterilization, packaging, labeling, storage and shipment of the drug. Manufacturers must establish validated systems to ensure that products meet specifications and regulatory standards, and test each product batch or lot prior to its release.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA may withdraw a product approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Discovery of previously unknown problems with a product subsequent to its approval<span style="background:#ffffff;">, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, </span>may result in restrictions on the product or even complete withdrawal of the product from the market. Further, the failure to maintain compliance with regulatory requirements may result in administrative or judicial actions, such as fines, warning letters, holds on clinical trials, product recalls or seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing, injunctions or civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, the FDA regulations and policies are often revised or reinterpreted by the agency in ways that may significantly affect our business and our development efforts. It is impossible to predict whether further legislative or FDA regulation or policy changes will be enacted or implemented and what the impact of such changes, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Foreign Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are subject to regulations and product registration requirements in many foreign countries in which we may sell our products, including in the areas of product standards, packaging requirements, labeling requirements, import and export restrictions and tariff regulations, duties and tax requirements. The time required to obtain clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements for licensing a product in a foreign country may differ significantly from FDA requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pharmaceutical products may not be imported into, or manufactured or marketed in, the State of Israel absent drug registration. The three basic criteria for the registration of pharmaceuticals in Israel is quality, safety and efficacy of the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">pharmaceutical product and the Israeli Ministry of Health requires pharmaceutical companies to conform to international developments and standards. Regulatory requirements are constantly changing in accordance with scientific advances as well as social and ethical values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The relevant legislation of the European Union requires that medicinal products, including generic versions of previously approved products, and new strengths, dosage forms and formulations, of previously approved products, shall have a marketing authorization before they are placed on the market in the European Union. Authorizations are granted after the assessment of quality, safety and efficacy by the respective health authorities. In order to obtain an authorization, an application must be made to the competent authority of the member state concerned or in a centralized procedure to the EMA. Besides various formal requirements, the application must contain the results of pharmaceutical (physico-chemical, biological or microbiological) tests, of preclinical (toxicological and pharmacological) tests as well as of clinical trials. All of these tests must have been conducted in accordance with relevant EU regulations and must allow the reviewer to evaluate the quality, safety and efficacy of the medicinal product. Orphan drug designation in the European Union is granted to medicinal products intended for the diagnosis, prevention and treatment of life-threatening diseases and very serious conditions that affect not more than five in 10,000 people in the European Union. Orphan drug designation is generally given to medicinal products that treat conditions for which no current therapy exists or are expected to bring a significant benefit to patients over existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Third Party Payor Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Coverage and reimbursement status of any approved therapy carries uncertainty and risk. In both the United States and foreign markets, our ability to commercialize our product and product candidates successfully, and to attract commercialization partners, depends in significant part on the availability of adequate financial coverage and reimbursement from third party payors, including, in the United States, governmental payors such as Medicare, Medicaid and the Veterans Affairs Health programs, and private health insurers. Medicare is a federally funded program managed by the Centers for Medicare and Medicaid Services, or CMS, through local fiscal intermediaries and carriers that administer coverage and reimbursement for certain healthcare items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients whose income and assets fall below state defined levels and who are otherwise uninsured that is both federally and state funded and managed by each state. The federal government sets general guidelines for Medicaid and each state creates specific regulations that govern its individual program. Each payor has its own process and standards for determining whether it will cover and reimburse a procedure or particular product. Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually a significant gating issue for successful introduction of a new product. The competitive position of some of our products will depend, in part, upon the extent of coverage and adequate reimbursement for such products and for the procedures in which such products are used. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by the government and other payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Possible legislation at the federal and state levels in the United States focused on cost containment and price transparency may impact our ability to sell our product and product candidates for maximum profitably. It appears likely that the pressure on pharmaceutical pricing will continue, especially under the Medicare program, which may also increase our regulatory burdens and operating costs. Moreover, additional changes could be made to governmental healthcare programs that could significantly impact the success of our product and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Some third party payors also require pre-approval of coverage for new or innovative devices, biologics or drug therapies before they will reimburse healthcare providers that use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on our ability to obtain adequate prices for our product candidates and operate profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Different pricing and reimbursement schemes exist in other countries. In the European Union, governments influence the price of pharmaceutical products through their pricing and reimbursement rules&#160;and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs and biologics, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Other Healthcare Laws and Compliance Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S.&#160;Department of Health and Human Services (e.g., the Office of Inspector General), the U.S.&#160;Department of Justice and individual U.S.&#160;Attorney General offices within the Department of Justice, and state and local governments. These regulations include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal transparency requirements under the Health Care Reform Law requires manufacturers of drugs, devices, biologics, and medical supplies to report to the Department of Health and Human Services information related to physician payments and other transfers of value and physician ownership and investment interests;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FFDCA, which among other things, strictly regulates drug and biologic product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 36pt;">Compliance with Environmental, Health and Safety Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to FDA regulations, we are also subject to evolving federal, state and local environmental, health and safety laws and regulations. In the past, compliance with environmental, health and safety laws and regulations has not had a material effect on our capital expenditures. Compliance with environmental, health and safety laws and regulations in the future may require additional capital expenditures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Israeli Government Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following is a brief summary of the current principal Israeli tax laws applicable to us and Protalix&#160;Ltd., and of the Israeli Government programs from which Protalix&#160;Ltd. benefits. Some parts of this discussion are based on new tax legislation that has not been subject to judicial or administrative interpretation. Therefore, the views expressed in the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">discussion may not be accepted by the tax authorities in question. This summary is based on laws and regulations in effect as of the date hereof, and should not be construed as legal or professional tax advice and does not cover all possible tax considerations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">General Corporate Tax Structure in Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The income of Protalix&#160;Ltd., other than income from &#8220;Approved Enterprises,&#8221; is taxed in Israel at regular rates. Pursuant to the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget&#160;Year), 2016, the corporate tax rate in 2018 and thereafter is 23%. Capital gains on the sale of assets are subject to capital gains tax according to the corporate tax rate in effect in the&#160;year which the assets are sold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Law for the Encouragement of Capital Investments, 1959</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Law for the Encouragement of Capital Investments, 1959, as amended, or the Investment Law, provides certain incentives for capital investments in a production facility (or other eligible assets). Generally, an investment program that is implemented in accordance with the provisions of the Investment Law, referred to as an &#8220;Approved Enterprise,&#8221; is entitled to benefits. These benefits may include cash grants from the Israeli government and tax benefits, based upon, among other things, the location within Israel of the facility in which the investment is made and specific elections made by the grantee. In order to qualify for these incentives, an Approved Enterprise is required to comply with the requirements of the Investment Law, and Letter of approval received by Protalix&#160;Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#160;Ltd. will continue to enjoy the tax benefits under the pre-revision provisions of the Investment Law. If any new benefits are granted to Protalix&#160;Ltd. in the future, Protalix&#160;Ltd. will be subject to the provisions of the amended Investment Law with respect to these new benefits. Therefore, the following discussion is a summary of the Investment Law prior to its amendment as well as the relevant changes contained in the new legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Investment Law prior to its amendment, a company that wished to receive benefits had to receive approval from the Authority for the Investment and Development of the Industry and Economy, or the Investment Center. Each certificate of approval for an Approved Enterprise relates to a specific investment program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical characteristics of the facility or the asset, e.g., the equipment to be purchased and utilized pursuant to the program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">An Approved Enterprise may elect to forego any entitlement to the grants otherwise available under the Investment Law and, instead, participate in an alternative benefits program under which the undistributed income (after deductions and offsets) from the Approved Enterprise is exempt from corporate tax for a defined period of time. Under the alternative package of benefits, a company&#8217;s undistributed income derived from an Approved Enterprise will be exempt from corporate tax for a period of between two and 10&#160;years from the first&#160;year of taxable income, depending upon the geographic location within Israel of the Approved Enterprise. Upon expiration of the exemption period, the Approved Enterprise is eligible for the reduced tax rates otherwise applicable under the Investment Law for any remainder of the otherwise applicable benefits period (up to an aggregate benefits period of either seven or 10&#160;years, depending on the location of the company or its definition as a foreign investors&#8217; company). If a company has more than one Approved Enterprise program or if only a portion of its capital investments are approved, its effective tax rate is the result of a weighted combination of the applicable rates. The tax benefits from any certificate of approval relate only to taxable profits attributable to the specific Approved Enterprise and are contingent upon meeting the criteria set out in the certificate of approval. Income derived from activity that is not integral to the activity of the Approved Enterprises (including capital gain) does not enjoy these tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A company that has an Approved Enterprise program is eligible for further tax benefits, as an alternative to exemption, if it qualifies as a foreign investors&#8217; company. A foreign investors&#8217; company eligible for benefits is essentially a company in which more than 25% of the share capital (in terms of shares, rights to profit, voting and appointment of directors) is owned (measured by both share capital and combined share and loan capital) by non-Israeli residents. A company that qualifies as a foreign investors&#8217; company and has an Approved Enterprise program is eligible for tax benefits for a 10-year benefit period and may enjoy a reduced corporate tax rate of 10% to 23%, depending on the amount of the company&#8217;s shares held by non-Israeli shareholders.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If a company that has an Approved Enterprise program is a wholly-owned subsidiary of another company, the&#160;percentage of foreign investments is determined based on the&#160;percentage of foreign investment in the parent company. The tax rates and related levels of foreign investments with respect to a foreign investor&#8217;s company that has an Approved Enterprise program are set forth in the following table:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent of Foreign Ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Rate&#160;of&#160;Reduced&#160;Tax</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Over 25% but less than 49%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">23%</p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">49% or more but less than 74%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">20%</p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">74% or more but less than 90%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15%</p></td></tr><tr><td style="vertical-align:bottom;width:81.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">90% or more</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our original facility in Israel has been granted &#8220;Approved Enterprise&#8221; status, and it has elected to participate in the alternative benefits program. Under the terms of its Approved Enterprise program, the facility is located in a Zone A area and, therefore, the undistributed income from that Approved Enterprise will be tax exempt in Israel for a period of 10&#160;years, commencing with the&#160;year in which taxable income is first generated from the relevant Approved Enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A company that has elected to participate in the alternative benefits program and that subsequently pays a dividend out of the income derived from the portion of its facilities that have been granted Approved Enterprise status during the tax exemption period will be subject to corporate tax in respect of the amount of dividend distributed at the rate that would have been applicable had the company not elected the alternative benefits program (generally 10% to 23%, depending on the extent to which non-Israeli shareholders hold such company&#8217;s shares). If the dividend is distributed within 12&#160;years after the end of the benefits period (or, in the case of a foreign investor&#8217;s company, without time limitation), the dividend recipient is taxed at the reduced withholding tax rate of 20% applicable to dividends from approved enterprises, or at the lower rate under an applicable tax treaty. After this period, the withholding tax rate is 25% to 30%, or at the lower rate under an applicable tax treaty. In the case of a company with a foreign investment level (as defined by the Investment Law) of 25% or more, the 12-year limitation on reduced withholding tax on dividends does not apply. The company must withhold this tax at its source, regardless of whether the dividend is converted into foreign currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Investment Law also provides that an Approved Enterprise is entitled to accelerated depreciation on its property and equipment that are included in an approved investment program. This benefit is an incentive granted by the Israeli government regardless of whether the alternative benefits program is elected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The benefits available to an Approved Enterprise are conditioned upon terms stipulated in the Investment Law and its regulations and the criteria set forth in the applicable certificate of approval. If Protalix&#160;Ltd. does not fulfill these conditions in whole or in part, the benefits can be canceled and Protalix&#160;Ltd. may be required to refund the benefits received, linked to the Israeli consumer price index with interest. In addition, if we increase our activities outside of Israel, for example, by future acquisitions, such increased activities generally may not be eligible for inclusion in Israeli tax benefit programs. We believe that Protalix&#160;Ltd. currently operates in compliance with all applicable conditions and criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Amendment No.&#160;60 to the Investment Law introduced a tax benefits regime referred to as &#8220;Benefitted Enterprises.&#8221; Under the Investment Law, the approval of the Investment Center is required only for Benefitted Enterprises that receive cash grants. Benefitted Enterprises that do not receive benefits in the form of governmental cash grants, but only tax benefits, are no longer required to obtain this approval. Instead, these Benefitted Enterprises are required to make certain investments as specified in the Investment Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The amended Investment Law specifies certain conditions for a Benefitted Enterprise to be entitled to benefits. These conditions include, inter alia, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Benefitted Enterprise&#8217;s revenues from any single country or a separate customs territory may not exceed 75% of the Benefitted Enterprise&#8217;s total revenues; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least 25% of the Benefitted Enterprise&#8217;s revenues during the benefits period must be derived from sales into a single country or a separate customs territory with a population of at least 14 million people (starting from January 1, 2012, 1.4% must be added for each year).</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that Protalix&#160;Ltd. will comply with the above conditions in the future or that Protalix&#160;Ltd. will be entitled to any additional benefits under the Investment Law. In addition, it is possible that Protalix&#160;Ltd. may not be able to operate in a manner that maximizes utilization of the potential benefits available under the Investment Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the future there may be changes in the law, subject to the preservation of benefits, which may affect the benefits available to companies under the Investment Law. The termination or substantial reduction of any of the benefits available under the Investment Law could impact our tax expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Amendment of the Law for the Encouragement of Capital Investments, 1959</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In recent&#160;years, several amendments have been made to the Investments Law which have enabled new alternative benefit tracks, subject to certain conditions. The Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Investments Law. On December&#160;29, 2016, Amendment 73 to the Investments Law, or the Investments Law Amendment, was published. This amendment sets new benefit tracks, inter alia, &#8220;Preferred Technological Enterprise&#8221; and &#8220;Special Preferred Technological Enterprise.&#8221; To date, we have elected not to have the Investments Law Amendment apply to our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Encouragement of Industrial Research, Development and Technology Innovation Law, 1984</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, Protalix&#160;Ltd. has received grants from the Office of the Chief Scientist of the Israeli Department of Labor, or the OCS, under the Israeli Law for the Encouragement of Industrial Research, Development and Technology Innovation, 1984, and related regulations, or the Research Law. On January&#160;1, 2016, the Israeli government established the National Authority for Technological Innovation, or NATI, which replaced many of the functions of the OCS. For purposes of clarity, references to NATI will include the OCS. NATI grants may be made available, from time to time, to finance a portion of Protalix&#160;Ltd.&#8217;s research and development expenditures in Israel. As of December&#160;31, 2024, NATI approved grants in respect of Protalix&#160;Ltd.&#8217;s continuing operations totaling approximately $53.2&#160;million (before interest, as described below), measured from inception. Protalix&#160;Ltd. is required to repay up to 100% of grants actually received (plus interest at the LIBOR rate applied to the grants received on or after January&#160;1, 1999) to NATI through payments of royalties at a rate of 3% to 6% of the revenues generated from NATI-funded project, depending on the period in which revenues were generated. As of December&#160;31, 2024, Protalix Ltd. either paid or accrued royalties payable of $19.3&#160;million, and Protalix&#160;Ltd.&#8217;s contingent liability to NATI with respect to grants received was approximately $33.9&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Research Law, recipients of grants from NATI are prohibited from manufacturing products developed using these grants outside of the State of Israel without special approvals, although the Research Law does enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased royalties. If Protalix Ltd. receives approval to manufacture the products developed with government grants outside of Israel, it will be required to pay an increased total amount of royalties (possibly up to 150% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside of Israel, as well as at a possibly increased royalty rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Additionally, under the Research Law, Protalix&#160;Ltd. is prohibited from transferring NATI-financed technologies and related intellectual property rights outside of the State of Israel, except under limited circumstances and only with the approval of NATI Council or the Research Committee. Protalix&#160;Ltd. may not receive the required approvals for any proposed transfer and, if received, Protalix&#160;Ltd. may be required to pay NATI a portion of the consideration that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that Protalix&#160;Ltd. has already paid to NATI, the amount of time that has elapsed between the date on which the know-how was transferred and the date on which NATI grants were received and the sale price and the form of transaction will be taken into account in order to calculate the amount of the payment to NATI. The payments to NATI may result in up to 600% of the grant amounts plus interest. Approval of the transfer of technology to residents of the State of Israel is required, and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer, if requested, will be granted.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Research Law and the regulations promulgated thereunder, the NATI Council may allow the transfer outside of Israel of know-how derived from an approved program and the related manufacturing rights in limited circumstances which are currently as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of a sale of know-how itself to a non-affiliated third party, provided that upon such sale the owner of the know-how pays to NATI an amount, in cash, as set forth in the Research Law (and the regulations promulgated thereunder). In addition, the amendment provides that if the purchaser of the know-how gives the selling Israeli company the right to exploit the know-how by way of an exclusive, irrevocable and unlimited license, the research committee may approve such transfer in special cases without requiring a cash payment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of a sale of a company which is the owner of know-how, pursuant to which the company ceases to be an Israeli company, provided that upon such sale, the owner of the know-how makes a cash payment to NATI as set forth in the Research Law (and the regulations promulgated thereunder).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the event of an exchange of know-how such that in exchange for the transfer of know-how outside of Israel, the recipient of the know-how transfers other know-how to the company in Israel in a manner in which NATI is convinced that the Israeli economy realizes a greater, overall benefit from the exchange of know-how.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Research Committee may, in special cases, approve the transfer of manufacture or of manufacturing rights of a product developed within the framework of the approved program or which results therefrom, outside of Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The State of Israel does not own intellectual property rights in technology developed with NATI funding and there is no restriction on the export of products manufactured using technology developed with NATI funding. The technology is, however, subject to transfer of technology and manufacturing rights restrictions as described above. For a description of such restrictions, please see &#8220;<a href="#Risks_Operations_Israel"><span style="font-style:normal;font-weight:normal;">Risk Factors&#8212;Risks Relating to Our Operations in Israel.</span></a>&#8221; NATI approval is not required for the export of any products resulting from the research or development or for the licensing of any technology in the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Law for the Encouragement of Industry (Taxes), 1969</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that Protalix&#160;Ltd. currently qualifies as an &#8220;Industrial Company&#8221; within the meaning of the Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law. The Industry Encouragement Law defines &#8220;Industrial Company&#8221; as a company resident in Israel and incorporated in Israel, that derives 90% or more of its income in any tax&#160;year (other than specified kinds of passive income such as capital gains, interest and dividends) from an &#8220;Industrial Enterprise&#8221; operating in Israel (including Judea&#160;&amp; Samaria territories and the Gaza strip), that it owns. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose major activity in a given tax&#160;year is industrial production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following corporate tax benefits, among others, are available to Industrial Companies:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amortization of the cost of purchased know-how and patents over an eight-year period for tax purposes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accelerated depreciation rates on equipment and buildings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">under specified conditions, an election to file consolidated tax returns with other related Israeli Industrial Companies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses related to a public offering are deductible in equal amounts over three&#160;years.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Eligibility for the benefits under the Industry Encouragement Law is not subject to receipt of prior approval from any governmental authority. It is possible that Protalix&#160;Ltd. may fail to qualify or may not continue to qualify as an &#8220;Industrial Company&#8221; or that the benefits described above will not be available in the future.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Tax Benefits for Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under specified conditions, Israeli tax laws allow a tax deduction by a company for research and development expenditures, including capital expenditures, for the&#160;year in which such expenditures are incurred. These expenditures must relate to scientific research and development projects and must be approved by NATI. Furthermore, the research and development projects must be for the promotion of the company and carried out by or on behalf of the company seeking such tax deduction. However, the amount of such deductible expenditures is reduced by the sum of any funds received through government grants for the finance of such scientific research and development projects. Research and development expenses which were not approved shall be deductible over a period of three&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2024, we had <span style="direction:rtl;">2</span>13 employees of whom <span style="direction:rtl;">20</span>7 are full time employees and <span style="direction:rtl;">1</span>9 have a Ph.D. in their respective scientific fields. We believe that our relations with our employees are good. We believe that our success will greatly depend on our ability to identify, attract and retain capable employees. The Israeli Ministry of Labor and Welfare is authorized to make certain industry-wide collective bargaining agreements, or Expansion Orders, that apply to types of industries or employees including ours. These agreements affect matters such as cost of living adjustments to salaries, length of working hours and week, recuperation, travel expenses, and pension rights. Otherwise, our employees are not represented by a labor union or represented under a collective bargaining agreement. See &#8220;<a href="#Risks_Depend_key_employees"><span style="font-style:normal;font-weight:normal;">Risk Factors&#8212;We depend upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop and market our products.</span></a>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Company Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We were originally incorporated in the State of Florida in April&#160;1992, and reincorporated in the State of Delaware in March&#160;2016. Protalix&#160;Ltd., our wholly-owned subsidiary and sole operating unit, is an Israeli company and was incorporated in Israel in 1993.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> is our registered trademark. Each of the other trademarks, trade names or service marks appearing in this Annual Report on Form&#160;10-K belongs to its respective holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Available Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Our main corporate website address is </span><span style="background:#ffffff;">http://www.protalix.com</span><span style="background:#ffffff;">. </span>We make available on our website, free of charge, our Commission filings, including our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and any amendments to these reports, as soon as reasonably practicable after we electronically file these documents with, or furnish them to, the Commission. <span style="background:#ffffff;">The </span>Commission<span style="background:#ffffff;"> maintains an Internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the </span>Commission<span style="background:#ffffff;"> at </span><span style="background:#ffffff;">www.sec.gov</span><span style="background:#ffffff;">. </span>Additionally, from time to time, we provide notifications of material news including press releases and conferences on our website. Webcasts of presentations made by our company at certain conferences may also be available from time to time on our website, to the extent the webcasts are available. The content of our website is not intended to be incorporated by reference into this report or in any other report or document we file and any references to these websites are intended to be inactive textual references only. Interested persons may sign up on our website to automatically receive e-mail alerts when we post financial information and issue press releases, and to receive information about upcoming events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our website also includes printable versions of our Code of Business Conduct and Ethics and the charters for each of the Audit, Compensation and Nominating Committees of our Board of Directors. Each of these documents is also available in print, free of charge, to any stockholder who requests a copy by addressing a request to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Protalix BioTherapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2&#160;University Plaza, Suite&#160;100</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">Hackensack, NJ  07601</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Attn: Mr.&#160;Eyal Rubin, Sr.&#160;Vice President and Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Item_1A._"></a><a id="_2c0bd24f_a224_4b97_92de_d2e9b4346150"></a><a id="Item1ARiskFactors_654735"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should carefully consider the risks described below together with the other information included in this Annual Report on Form&#160;10-K. Our business, financial condition and results of operations could be adversely affected by any of these risks. The risks described below include forward-looking statements, and actual events and our actual results may differ materially from these forward-looking statements. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also impair our business, results of operations and financial condition. Furthermore, additional risks and uncertainties are described under other captions in this Annual Report on Form&#160;10-K. If any of these risks occur, the value of our common stock could decline. A summary of the risk factors included in this Item&#160;1A are set forth below followed by a full set of risk factors described in greater detail. For further details on our forward-looking statements, see &#8220;</i><a href="#S1_002"><i style="font-style:italic;font-weight:normal;">Cautionary Statement Regarding Forward-Looking Statements</i></a><i style="font-style:italic;">&#8221; on </i><a href="#CAUTIONARY_STATEMENT_REGARDING_FORWARD"><i style="font-style:italic;font-weight:normal;">page&#160;1</i></a><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Summary of Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Commercialization and Continued Approval of our Products</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We currently depend heavily on the generation of revenues from the sales of our products.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Any current products or future product candidates may cause serious adverse events or undesirable side effects.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">There may be safety issues regarding our products that were not known at the time of approval are discovered.</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Physicians, patients, third party payors and others in the medical community might not accept and use our current or future products.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Coverage and reimbursement may not be available for our current or future products in all territories.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We have a limited commercial operating history.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may fail to supply drug substance to Chiesi or Pfizer.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may be unable to enhance our portfolio of product candidates.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We or our providers may experience manufacturing problems.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Reliance on third parties for final processing of our products and product candidates exposes us to a number of risks.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Developments by competitors may render our products or technologies obsolete or non-competitive.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Our internal computer systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches and expose our company to liabilities. </span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may face product liability claims.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Our ability to utilize net operating loss carryforwards may be limited.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Clinical Trials and Regulatory Matters</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all.</span></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may experience delays in obtaining regulatory approvals with respect to any drug candidate.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Preclinical and clinical trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">If the results of our clinical trials do not support our claims relating to a drug candidate, or if serious side effects are identified, the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may find it difficult to enroll patients in our clinical trials or patients may discontinue their participation in our clinical trials.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Dependence upon third-party service providers in connection with our clinical trials expose us to risks.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to our Financial Condition and Capital Requirements</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may need to raise additional capital to operate our business, which may not be available on favorable terms, or at all.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Intellectual Property Matters</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">We may fail to adequately protect or enforce our intellectual property rights or secure rights to third party patents.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Relating to our Operations in Israel</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Our results may be adversely affected by political, economic and military conditions in Israel.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">The Israeli government grants we have received for certain research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel and require us to satisfy specified conditions.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Investing in our Common Stock</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">The market price of our common stock may fluctuate significantly; future sales of our common stock could reduce our stock price.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses or divert management&#8217;s attention.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Delaware law and our organizational documents contain certain anti-takeover provisions.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;font-weight:normal;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;font-weight:normal;">Our Amended and Restated Bylaws provide for limits on our stockholders</span><span style="font-size:10pt;font-weight:normal;">&#8217;</span><span style="font-size:10pt;font-weight:normal;"> ability to obtain a favorable judicial forum.</span></div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span><span style="font-weight:normal;">*</span><span style="display:inline-block;width:31pt;"></span><span style="font-weight:normal;">*</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to the Commercialization and Continued Approval of our Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We currently depend heavily on the generation of revenues from the sales of Elfabrio and Elelyso. Any failure to successfully commercialize Elfabrio will have a material adverse effect on our business, results of operations and financial condition. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have invested a significant portion of our efforts and financial resources in the development of Elfabrio, and in the past, on the development of Elelyso. Our ability to generate significant product revenues in the future from sales of Elfabrio depends on Chiesi&#8217;s successful commercialization of Elfabrio, which we do not control and may not be able to effectively influence, and on the actions and decisions of foreign regulatory authorities. Chiesi may experience delays in, or be unable to achieve, the commercial introduction of Elfabrio globally. Similarly, we generate revenues from sales of Elelyso which are depend on Pfizer&#8217;s efforts (except in Brazil), which we do not control. Sales of BioManguinhos alfataliglicerase in Brazil are controlled by Fiocruz. The successful worldwide commercialization of Elfabrio and Elelyso depends on several factors, including the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Chiesi&#8217;s efforts under the Chiesi Agreements and the effectiveness of Chiesi&#8217;s commercial strategy and its execution of that strategy, including its pricing strategy, its development and maintenance of successful sales and marketing organizations and the effectiveness of its efforts to obtain adequate third-party reimbursements and, to a lesser extent, Pfizer&#8217;s and Fiocruz&#8217;s efforts;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>expanding the scope of the countries in which our products are approved for marketing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>maintaining the cGMP compliance of our manufacturing facility or establishing manufacturing arrangements with third parties;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the willingness of patients with Fabry disease and Gaucher disease to switch from other treatments to Elfabrio or Elelyso, as the case may be;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>competition from other approved treatments of Fabry disease and Gaucher disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the continued acceptable safety and efficacy profile of Elfabrio and Elelyso; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>other risks described in these Risk Factors.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure to commercialize Elfabrio or Elelyso globally or the experience of significant delays in doing so will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any current products or future product candidates may cause serious adverse events, or SAEs, undesirable side effects or have other properties that could halt their clinical development, prevent, delay, or cause the withdrawal of their regulatory approval, limit their commercial potential, or result in material negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As with most infused products, use of our products or any current or future product candidates could be associated with undesirable side effects or adverse events which can vary in severity and frequency. From time to time, we have observed serious adverse events in clinical studies of our products and product candidates. For example, while conducting clinical trials of Elfabrio, we have observed treatable anaphylactic reactions. Specifically with respect to Elfabrio, as indicated in the boxed warning with which it was approved by the FDA, patients treated with Elfabrio have experienced hypersensitivity reactions, including anaphylaxis. There are postmarketing requirements under the FFDCA included with the approval of Elfabrio by the FDA. For example, the FDA requires that a worldwide descriptive study be conducted that collects prospective and retrospective data in women and their offspring exposed to Elfabrio during pregnancy and/or lactation to assess risk of pregnancy and material complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant. Furthermore, the approval of pharmaceutical products generally includes requirements related to the preparation of a Risk Evaluation and Mitigation Strategy, or REMS, or a risk management plan as required by the EMA, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use. For example, Chiesi must follow a risk management plan agreed upon with the EMA with respect to Elfabrio, which </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">includes risk minimization measures in connection with risks associated with hypersensitivity reactions and possible medication errors in the home infusion setting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our product candidates, if approved, may also be subject to certain post-authorization reporting requirements. As an example, the EMA has required that Chiesi submit pharmacovigilance documents intended to provide post-authorization evaluation of Elfabrio&#8217;s risk-benefit balance at defined time points after authorization, beginning within six months of authorization, and that an educational program about home administration be agreed upon with the National Competent Authority prior to the use of Elfabrio in the home setting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any of the foregoing, including the boxed warning, could prevent us or our commercialization partners from achieving or maintaining market acceptance of a product or a particular product candidate and could materially harm our business, results of operations, and prospects, and could adversely impact our financial condition, results of operations, ability to raise additional financing or the market price of our common stock.</p><a id="page_ci46701_1_33"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">If safety issues regarding our products that were not known at the time of approval are discovered, or if we or the applicable marketing authorization holder fails to comply with continuing U.S. and applicable foreign regulations, commercialization efforts for our products could be adversely affected and the products could lose their approval or their sales could be suspended.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times';">Drug products remain subject to continuing regulatory oversight after they are approved for marketing, including the review of additional safety information. Drugs are more widely used by patients once approved for sale and, therefore, side-effects and other problems may be observed after approval that were not seen or anticipated, or were not as prevalent or severe, during clinical trials or nonclinical studies. The subsequent discovery of previously unknown problems with a product could negatively affect commercial sales of the product, result in restrictions on the product or lead to the withdrawal of the product from the market. The reporting of adverse safety events involving our products or public speculation about such events could cause our stock price to decline or experience periods of volatility and may have a material adverse effect on our business, results of operations and financial condition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times';">If we or the marketing authorization holder, or MAH, of any of our products fail to comply with applicable continuing regulatory requirements, we or such MAH may be subject to fines and/or criminal prosecutions, and the product may become subject to suspension or withdrawal of regulatory approval, product recalls and seizures and operating restrictions. In addition, the manufacturers we or an MAH engage to produce a product and the manufacturing facilities in which the product is made are subject to periodic review and inspection by the FDA and foreign regulatory authorities. If problems are identified during the review or inspection of these manufacturers or manufacturing facilities, it could result in the facility becoming unable to manufacture the product or a determination that inventories are not safe for commercial sale, which may have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If physicians, patients, third party payors and others in the medical community do not accept and use Elfabrio, Elelyso or any other future products, our ability to generate revenue from product sales will be materially impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Physicians and patients, and other healthcare providers, may not accept and use Elfabrio, Elelyso or any other products we may develop in the future. Future acceptance and use of any of our products will depend upon a number of factors including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceptions by physicians, patients, third party payors and others in the medical community about the safety and effectiveness of Elfabrio or Elelyso, or any future product, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects, including any limitations or warnings contained in our products&#8217; approved labeling, including the boxed warning associated with Elfabrio in the United States;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pharmacological benefits of Elfabrio or Elelyso, or any future product, if any relative to competing products and products under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages relative to competing products and products under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of education, marketing and distribution efforts by Chiesi, Pfizer and any other relevant licensees and distributors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity concerning Elfabrio or Elelyso, or any future product, if any, or concerning competing products and treatments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the price for our products and competing products.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If the market opportunities for Elfabrio, Elelyso or any other future products are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, our development efforts have focused mainly on relatively rare disorders with relatively small patient populations, in particular Gaucher disease and Fabry disease. Estimation of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas and are often inexact and prone to error. As new studies are performed, the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Gaucher disease or Fabry disease in the study populations, particularly in these newer studies, accurately reflect the prevalence of these diseases in the broader world population. If the market opportunities for our products or product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Coverage and reimbursement may not be available for Elfabrio, Elelyso or any other future products in all territories, which could diminish sales of our products or adversely affect the profitably of such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Market acceptance and sales of Elfabrio, Elelyso or any other future products, if any, will depend on coverage and reimbursement policies in the countries in which they are approved for sale. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. Obtaining reimbursement approval for an approved product from individual governments and other third party payors is a time consuming (six to 12 months or longer) and costly process that requires our collaborators or us, as the case may be, to provide supporting scientific, clinical and cost-effectiveness data for the use of our products, if and when approved, to every payor. Data sufficient to gain acceptance with respect to coverage and reimbursement might not be available, or post-marketing studies may be required in order to demonstrate the cost-effectiveness of approved products, if any, to such payors&#8217; satisfaction. Such studies might require our collaborators or us to commit a significant amount of management time and financial and other resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if a payor determines that an approved product is eligible for reimbursement, the payor may impose coverage limitations that preclude payment for some uses that are approved by the FDA or other regulatory authorities. For example, the U.S.&#160;Inflation Reduction Act allows Medicare to negotiate the prices of the prescription drugs. Such initiatives and legislation may cause added pricing pressure on our products. Proposals that could impact coverage and reimbursement of our products, including giving states more flexibility to manage drugs covered under the Medicaid program and permitting the re-importation of prescription medications from other countries, could have a material adverse effect by limiting our products&#8217; use and coverage. To the extent that private insurers or managed care programs in the United States or elsewhere follow Medicaid coverage and payment developments, they could use the enactment of these increased rebates to exert pricing pressure on our products, and the adverse effects may be magnified by their adoption of lower payment schedules. In addition, full reimbursement may not be available for high priced products. Moreover, eligibility for coverage does not imply that any approved product will be reimbursed in all cases or at a rate that allows us to make a profit or even cover our costs. Limited reimbursement amounts may reduce the demand for, or the price of, Elfabrio, Elelyso or any other future products. If coverage and reimbursement are not available or are </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">available only to limited levels, the sales of Elfabrio, Elelyso or other future products, if any, may be diminished or we may not be able to sell such products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The pricing of our products in different countries may vary widely, thus creating the potential for third-party trade in our products in an attempt to exploit price differences between countries. This third-party trade of our products could undermine our sales in markets with higher prices which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Fiocruz is not complying, and we expect they will continue to not comply, with the terms and conditions of the Brazil Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We do not control and may not be able to effectively influence Fiocruz&#8217;s ability to distribute BioManguinhos alfataliglicerase in Brazil. Fiocruz has not complied with the purchase requirements of the Brazil Agreement in the past, and we expect Fiocruz will continue to not comply and may otherwise materially breach the agreement. Continued non-compliance may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We face the risk of lower than anticipated purchases of BioManguinhos alfataliglicerase by the Brazilian MoH. In addition, we may fail to supply the intended amounts on time, if at all. We also cannot accurately predict the amount of revenues we will generate under the Brazil Agreement in future periods, if any. Any failure by the Brazilian MoH to purchase BioManguinhos alfataliglicerase, by us to supply BioManguinhos alfataliglicerase for purchase or by Fiocruz to distribute BioManguinhos alfataliglicerase in Brazil, or the experience of significant delays in any of the foregoing, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We and our collaborating partners may be subject, directly or indirectly, to federal and state healthcare fraud and abuse and false claims laws and regulations. If we or our collaborating partners are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All marketing activities associated with products that are approved for sale in the United States, if any, will be, directly or indirectly through our customers, subject to numerous federal and state laws governing the marketing and promotion of pharmaceutical products in the United States, including, without limitation, the federal Anti-Kickback Law, the federal False Claims Act and HIPAA. These laws may adversely impact, among other things, our proposed sales, marketing and education programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The federal Anti-Kickback Law prohibits persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of co-payments and deductibles, ownership interests and providing anything at less than its fair market value. Despite a series of narrow safe harbors, the federal Anti-Kickback Law prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal Anti-Kickback Law include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other state or federal healthcare programs. Many states have also adopted laws similar to the federal Anti-Kickback Law, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs, and do not contain identical safe harbors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The federal False Claims Act imposes liability on any person who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payer and not merely a federal healthcare program. Violations of the federal False Claims Act and the analogous state laws may result in substantial financial penalties, some as much as three times the actual damages sustained by the government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HIPAA created several new federal crimes, including health care fraud, and false statements relating to health care matters. The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">benefit program, including private third-party payers. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are unable to predict whether we could be subject to actions under any of these or other fraud and abuse laws, or the impact of such actions. Moreover, to the extent that Elfabrio, Elelyso or any other future products, if any, are sold in a foreign country, we and our collaborators may be subject to similar foreign laws and regulations. If we or any of our collaborators are found to be in violation of any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment or restructuring or our operations, any of which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have a limited commercial operating history which may limit the ability of investors to make an informed investment decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elfabrio and Elelyso are our only commercial products both of which are marketed by our commercialization partners. Our operations to date have been limited to acquiring, developing and securing our proprietary technology and undertaking, through third parties, preclinical and clinical trials of our drug candidates and advancing our drug candidates through the regulatory approval processes. These operations provide a limited basis for investors to assess our ability to commercialize our drug candidates and whether to invest in our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Any failure by us to supply drug substance to Chiesi or Pfizer may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have agreed to sell drug substance to Pfizer and Chiesi for the production of Elelyso and Elfabrio, respectively. With respect to Elelyso, our drug substance supply commitment is for a 15-year period after the execution of the Amended Pfizer Agreement, subject to certain terms and conditions. As part of that obligation, we agreed to substantial financial penalties if we fail to comply with the supply commitments, or are delayed in doing so. The amounts of the penalties depend on when any such failure occurs and for how long it persists, if at all, and other considerations. Any failure to comply with the supply commitments to Pfizer and/or Chiesi may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our strategy, in certain cases, is to enter into collaboration agreements with third parties to leverage our ProCellEx system to develop product candidates. Failure to enter into such agreements, or non-compliance by us or our collaborators with such agreements, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our strategy, in certain cases, is to enter into arrangements with pharmaceutical companies to leverage our ProCellEx system to develop additional product candidates. Our future revenues may depend, in part, on our ability to enter into and maintain arrangements with our existing partners and other companies having sales, marketing and distribution capabilities and the ability of such companies to successfully market and pharmaceutical products on a global scale. Under these arrangements, we may grant to our partners rights to license and commercialize pharmaceutical products developed under the applicable agreements, as we have done with Elfabrio and Elelyso. Commercialization, marketing, distribution and other similar alliances with respect to our products and product candidates will subject us to a number of risks. We may be required to relinquish important rights to our products or product candidates, and the rights of our partners may limit our flexibility in considering alternatives for the commercialization of our products and product candidates. Our partners may control key decisions relating to the development of the products and we may depend on our partners&#8217; expertise and dedication of sufficient time and resources to develop and commercialize our products and product candidates. Our partners may experience financial difficulties which adversely affect their efforts with respect to our product and product candidates. If we or any of our current or future partners breach or terminate the agreements that make up such arrangements, our partners otherwise fail to conduct their obligations under such arrangements in a timely manner, there is a dispute about their obligations or if either party terminates the applicable agreement or elects not to continue the arrangement, we may not enjoy the benefits of the agreements or receive a sufficient amount of royalty or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">milestone payments from them, if any, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we are unable to enhance our portfolio of product candidates, our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our business strategy is to establish a portfolio of product candidates as targets for development and eventual commercialization. We seek to do so through our internal research programs and strategic collaborations. Research programs to identify new product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. A research program may initially show promise in identifying a potential product candidate, yet fail to immediately yield the product candidate for clinical development for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate is not capable of being produced in commercial quantities at an acceptable cost, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the research methodology used may not be successful in identifying potential product candidates; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate may, after further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory approval.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure or delay in the establishment of a portfolio of product candidates as targets for development and eventual commercialization may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The manufacture of our products is an exacting and complex process, and any manufacturing problems encountered by us or certain of our providers may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The FDA and foreign regulators require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance with cGMP or similar requirements that the FDA or foreign regulators establish. We or certain of our services and materials providers, including our fill and finish service providers, may face manufacturing or quality control problems causing product production and shipment delays or a situation where we or the provider may not be able to maintain compliance with the FDA&#8217;s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing. We or any such third-party manufacturer might be unable to formulate and manufacture our products in the volume and of the quality required to meet our preclinical, clinical and commercial needs. If we engage any contract manufacturers, such manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our preclinical, clinical or commercial needs. In addition, we and contract manufacturers are subject to the rules and regulations of the FDA and comparable foreign regulatory authorities and face the risk that any of those authorities may find that they are not in compliance with applicable regulations. To date, our current facility has passed audits by the FDA and a number of other regulatory authorities but remains subject to audit by other foreign regulatory authorities. There can be no assurance that we or our contract manufacturers will be able to comply, or continue to comply, with FDA or foreign regulatory manufacturing requirements, and the failure to so comply, or continue to comply, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on third parties for final processing of Elfabrio, Elelyso and our other product candidates, which exposes us to a number of risks that may delay development, regulatory approval and commercialization of Elfabrio, Elelyso or our other product candidates or result in higher product costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have no experience in the final filling and freeze drying steps of the drug manufacturing process. We rely on third-party service providers in the United States and Europe to perform fill and finish activities for Elelyso and Elfabrio, and have engaged other parties for our other product candidates. The number of potential fill and finish services providers is limited and we face the risk of being unable to identify manufacturers and/or replacement manufacturers on acceptable terms or at all. In addition, the FDA and other regulatory authorities, as applicable, must approve any manufacturer and/or replacement manufacturer, including us.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure to identify and maintain fill and finish service providers could delay our preclinical and clinical trials, the approval, if any, of our potential drug candidates by the FDA and other regulatory authorities, or the commercialization of our drug candidates, or could result in higher product costs or otherwise deprive us of potential product revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have limited experience in selling, marketing or distributing products and limited internal capability to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We currently have very limited sales, marketing or distribution capabilities and no experience in building a sales force and distribution capabilities. Under our arrangements with Pfizer and Chiesi, we have out-licensed the marketing rights to Elfabrio and Elelyso, except that we retained the marketing rights to BioManguinhos alfataliglicerase in Brazil. The commercialization of a product requires the commitment of significant financial and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution capabilities. If we elect to commercialize our products directly and without strategic partners we may be unable to recruit and retain adequate numbers of effective sales and marketing personnel. In addition, such sales personnel might not access an adequate number of physicians or persuade them to prescribe our products, or may lack complementary products to offer to such physicians. Commercialization by such sales personnel may expose our company to unforeseen costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Developments by competitors may render our products or technologies obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies and other public and private research organizations. Our products compete, and our products candidates will have to compete, with existing therapies and therapies under development by our competitors. Our commercial opportunities may be reduced or eliminated if our competitors develop and market products that are less expensive, more effective or safer than our products. Other companies have drug candidates in various stages of preclinical or clinical development to treat diseases for which we are also seeking to develop products. Some of these potential competing drugs are further advanced in development than our drug candidates and may be commercialized earlier. See &#8220;<a href="#_Competition"><span style="font-style:normal;font-weight:normal;">Business&#160;&#8211; Competition</span></a>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Most of our competitors, either alone or together with their collaborative partners, operate larger research and development programs, staff and facilities and have substantially greater financial resources than we do, as well as significantly greater experience in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">undertaking preclinical testing and human clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining marketing approvals from the FDA and other regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">formulating and manufacturing drugs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching, marketing and selling drugs.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These organizations also compete with us to attract qualified personnel, acquisitions and joint ventures candidates and for other collaborations. Activities of our competitors may impose unanticipated costs on our business or adversely affect the market for our products which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we in-license drug candidates, we may delay or otherwise adversely affect the development of our existing drug candidates, which may negatively impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition to our own internally developed drug candidates, we proactively seek opportunities to in-license and advance other drug candidates that are strategic and have value-creating potential to take advantage of our development know-how and technology. In-licensing additional drug candidates may significantly increase our capital requirements, and place a strain on the time of our existing personnel, which may delay or otherwise adversely affect the development of our existing drug candidates or cause us to re-prioritize our drug pipeline if we do not have the necessary capital </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">resources to develop all of our drug candidates, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we acquire companies, products or technologies, we may face integration risks and costs associated with those acquisitions that could potentially negatively impact our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If we are presented with appropriate opportunities, we may acquire or make investments in complementary companies, products or technologies. If we acquire companies or technologies, we will face risks, uncertainties and disruptions associated with the integration process, including difficulties in the integration of the operations of an acquired company, integration of acquired technology with our products, diversion of our management&#8217;s attention from other business concerns, the potential loss of key employees or customers of the acquired business and impairment charges if future acquisitions are not as successful as we originally anticipate. In addition, our operating results may suffer because of acquisition-related costs or amortization expenses or charges relating to acquired intangible assets. Any failure to successfully integrate other companies, products or technologies that we may acquire may have a material adverse effect on our business, results of operations and financial condition.</p><a id="Risks_Depend_key_employees"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We depend upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop and market our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are highly dependent upon the principal members of our management team, especially our President and Chief Executive Officer, Dror Bashan, as well as the Chairman of our Board of Directors, Eliot R. Forster, Ph.D., our other directors, consultants and collaborating scientists. Many of these people have been involved with us for many years and have played integral roles in our progress, and we believe that they will continue to provide value to us. A loss of any of these personnel may have a material adverse effect on aspects of our business, clinical development and regulatory programs. We have employment agreements with Mr.&#160;Bashan and our other executive officers that may be terminated by us or the applicable officer at any time with varying notice periods of 30 to 180&#160;days. The loss of any of these persons&#8217; services may adversely affect our ability to develop and market our products and obtain necessary regulatory approvals. Further, we do not maintain key-man life insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also depend in part on the continued service of our key scientific personnel and our ability to identify, hire and retain additional personnel. We experience intense competition for qualified personnel, and the existence of non-competition agreements between prospective employees and their former employers may prevent us from hiring those individuals or subject us to suit from their former employers. While we attempt to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely to have greater resources and more experience than we have, making it difficult for us to compete successfully for key personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Under current U.S. and Israeli laws, we may not be able to enforce employees&#8217; covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into non-competition agreements with substantially all of our employees. These agreements prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors for a limited period. Under current U.S. and Israeli laws, we may be unable to enforce these agreements against most of our employees and it may be difficult for us to restrict our competitors from gaining the expertise our former employees acquired while working for us. If we cannot enforce our employees&#8217; non-compete agreements, we may be unable to prevent our competitors from benefiting from the expertise of our former employees, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. While our assessment of our internal control over financial reporting resulted in our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">conclusion that as of December&#160;31, 2024, our internal control over financial reporting was effective, we cannot predict the outcome of our testing or any subsequent testing by our auditor in future periods. Any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information and affect our reputation, which could have an adverse effect on the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management is required to assess the effectiveness of our internal controls and procedures and disclose changes in these controls on an annual basis. However, for as long as we are a non-accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal control could identify deficiencies in internal control over financial reporting that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</p><a id="Risks_Internal_Computer_Systems"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our internal computer systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches, resulting in liability and harm to our reputation, which could negatively affect our business, results of operation and financial condition. We may face liability if we breach our obligations related to the protection, security, nondisclosure of confidential information or disclosure of sensitive data or fail or are perceived to fail to comply with applicable data protection laws and regulations, or consumer protection laws, regulations and standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Despite the implementation of security measures, our internal computer systems and those of our present and future contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. Although to our knowledge we have not experienced any material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. We have a cybersecurity insurance policy to protect us from such risks. However, to the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability despite our insurance policy, and the further development and commercialization of our product candidates could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Further, the global data protection landscape is rapidly evolving, and we are or may become subject to numerous local and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect about individuals worldwide. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with local or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our failure to adhere to or successfully implement processes in response to changing regulatory requirements in this area could result in legal liability or impairment to our reputation in the marketplace, which could have a material adverse effect on our business, financial condition and results of operations.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We could be subject to securities class action litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, results of operation and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If product liability claims are brought against us, it may result in reduced demand for our products and product candidates or damages that exceed our insurance coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The use and marketing of our products and product candidates, including in connection with clinical trials, exposes us to product liability or similar claims if the use or misuse of those products or product candidates cause injury or disease, or results in adverse effects. We presently carry product liability and clinical trial liability insurance with coverages of up to $10.0&#160;million per occurrence and $10.0&#160;million in the aggregate, an amount we consider reasonable and customary. However, this insurance coverage includes various deductibles, limitations and exclusions from coverage, and in any event might not fully cover any potential claims. In the future, we may need to obtain additional product liability and clinical trial liability coverage; however, such insurance is expensive and insurance companies may not issue this type of insurance when we need it. We may not be able to obtain adequate insurance in the future at an acceptable cost. Any product liability claim, even one that was not in excess of our insurance coverage or one that is meritless and/or unsuccessful, may adversely affect the availability of funds for other purposes, such as research and development, which may have a material adverse effect on our business, results of operations and financial condition. Product liability claims, even if without merit, may result in reduced demand for our products, if approved, or result in adverse market reactions, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our ability to utilize net operating loss carryforwards may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our NOL carryforwards as of December&#160;31, 2024, are equal to approximately $227.2&#160;million, of which approximately $22.2&#160;million may be restricted under Section&#160;382 of the Internal Revenue Code, or the IRC. IRC Section&#160;382 applies whenever a corporation with NOLs experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post-change year that may be offset by a pre-change NOL may not exceed the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate. Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, we considered all available evidence, including past operating results, the most recent projections for taxable income and prudent and feasible tax planning strategies. We reassess our valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly. Any ownership change (including as a result of conversion of our outstanding convertible notes into shares of our common stock), or any other limitation on our utilization of NOLs, could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our corporate structure may create U.S. federal income tax inefficiencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#160;Ltd. is our wholly-owned subsidiary and thus a controlled foreign corporation of our company for U.S. federal income tax purposes. This organizational structure may create inefficiencies, as certain types of income and investments of Protalix&#160;Ltd. that otherwise would not be currently taxable under general U.S. federal income tax principles may become taxable. These inefficiencies may require us to use more of our NOLs than we otherwise might and may result in a tax liability without a corresponding distribution from our subsidiaries which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, on December&#160;22, 2017, the U.S.&#160;Tax Cuts and Jobs Act, or the TCJA, that significantly reforms the IRC was enacted. The TCJA, among other things, includes changes to U.S.&#160;federal tax rates, imposes significant additional limitations on the deductibility of certain expenses and adds certain limitations to the use of net operating loss carryforwards arising after December&#160;31, 2017. Effective in 2022, the TCJA requires all U.S. companies to capitalize and subsequently amortize R&amp;D expenses that fall within the scope of Section 174&#160;over five years for research activities conducted in the United States and over 15 years for research activities conducted outside of the United States rather </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">than deducting such costs in the year incurred for tax purposes. As a result of the TCJA, we expect to incur an increase in our tax expenses and a decrease in our cash flows provided by operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We are a holding company with no operations of our own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We are a holding company with no operations of our own. Accordingly, our ability to conduct our operations, service any current or future debt and pay dividends, if any, is dependent upon the earnings from the business conducted by Protalix&#160;Ltd. The distribution of those earnings or advances or other distributions of funds by our subsidiaries to us, as well as our receipt of such funds, are contingent upon the earnings of Protalix&#160;Ltd. and are subject to various business considerations and U.S. and Israeli laws. If Protalix&#160;Ltd. is unable to make sufficient distributions or advances to us, or if there are limitations on our ability to receive such distributions or advances, we may not have the cash resources necessary to conduct our corporate operations or service our debt which would have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Outbreaks of contagious disease or similar public health threats could materially and adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Outbreaks of contagious disease or other adverse public health developments worldwide could have a material adverse effect on our business, financial condition and results of operations. Outbreaks of contagious disease or other adverse public health developments could affect our business in a number of ways, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disruptions or restrictions on our employees&#8217; ability to work effectively due to illness;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Temporary closures or disruptions at our facilities or the facilities of our contract manufacturers or suppliers could  adversely affect our ability to timely meet our customer&#8217;s orders and negatively impact our supply chain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Outbreaks of contagious disease could cause delays or disruptions in our supply chain; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The failure of third parties on which we rely to meet their respective obligations to us, or significant disruptions in their ability to do so, which may be caused by their own financial or operational difficulties, could have an adverse impact on our business, financial condition or results of operations; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The impact of contagious disease or other adverse public health developments could also exacerbate other risks discussed elsewhere in these Risk Factors, any of which could have a material adverse effect on us.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our operating costs and business operations could be adversely affected by climate-related events and increasing regulatory requirements and security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The effects of climate change (such as drought, flooding, heat waves, wildfires, increased storm severity, and sea level rise, etc.) could affect our ability to continue our operations and cause delays in the development of our existing drug candidates, manufacturing and shipment, all of which could cause reputational harm or otherwise have an adverse effect on our business, results of operation and financial condition. In addition, the impacts of climate change on the global economy and our industry are rapidly evolving. Changing market dynamics, global policy developments and the increasing frequency and impact of extreme weather events on critical infrastructure across different countries could have the potential to disrupt our business, the business of our third-party suppliers and the business of our customers, and may cause us to experience higher attrition, losses and additional costs to maintain or resume operations. We also expect to face increasing regulatory requirements and regulatory scrutiny related to climate matters, resulting in higher associated compliance costs. Failure to uphold, meet or make timely forward progress against our public commitments and goals related to climate action could adversely affect our reputation with suppliers and customers, financial performance or the ability to recruit and retain talent.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Clinical Trials and Regulatory Matters</p><a id="Risks_Obtain_Necessary_US_EMA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To commercialize our drug candidates worldwide, we need FDA approval, EMA approval and approvals from other countries&#8217; regulators to commercialize our drug candidates elsewhere, as applicable. Approvals of BLAs, NDAs, MAAs and comparable marketing authorization applications worldwide requires that we demonstrate that the subject drug candidate is safe and effective for its intended use which requires significant research, animal or preclinical trials and human or clinical tests trials. Satisfaction of the regulatory requirements of the FDA, EMA and other countries&#8217; regulatory authorities typically takes many years, depends upon the type, complexity and novelty of the drug candidate and requires substantial resources for research, development and testing. The results of preclinical and clinical trials of our product candidates may fail to demonstrate that the candidates are safe and effective for their intended uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary findings or other comparable authorities for such clinical trials. Further, even if favorable testing data is generated by the clinical trials of a drug candidate, the applicable regulatory authority may not accept or approve a marketing application we file for the drug candidate or may require us to conduct additional clinical testing or perform post-marketing studies which would cause us to incur additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Failure to obtain approval of the FDA, EMA or comparable foreign authorities of any of our product candidates in a timely manner, if at all, will severely undermine our business, results of operations and financial condition by decreasing our ability to generate product revenues from the sales of such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">We are subject to extensive governmental regulation including the requirements of the FDA and other comparable regulatory authorities before our drug candidates may be marketed.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Both before and after marketing approval of our drug candidates, if at all, we, our drug candidates, our suppliers, our contract manufacturers and our contract testing laboratories are subject to extensive regulation by the FDA and comparable foreign regulatory authorities. Failure to comply with applicable requirements of the FDA or comparable foreign regulatory authorities could result in, among other things, any of the following actions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines and other monetary penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in the FDA&#8217;s or other foreign regulatory authorities&#8217; approving, or the refusal of any regulatory authority to approve, any drug candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recall or seizure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of manufacturing or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operating restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">criminal prosecutions.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to the approval requirements, other numerous and pervasive regulatory requirements apply, both before and after approval, to us, our drug candidates, our suppliers, contract manufacturers, and contract testing laboratories. These include requirements related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quality control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advertising;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">promotion;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">export;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting to the FDA certain adverse experiences associated with use of the drug candidate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining additional approvals for certain modifications to the drug candidate or its labeling or claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We also are subject to inspection by the FDA and comparable foreign regulatory authorities, to determine our compliance with regulatory requirements, as are our suppliers, contract manufacturers, and contract testing laboratories, and there can be no assurance that the FDA, or any other comparable foreign regulatory authority, will not identify compliance issues that may disrupt production or distribution, or require substantial resources to correct. We may be required to make modifications to our manufacturing operations in response to these inspections which may require significant resources and may have a material adverse effect upon our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The approval process for any drug candidate may also be delayed by changes in government regulation, future legislation or administrative action or changes in policy of the FDA and comparable foreign authorities that occur prior to or during their respective regulatory reviews of such drug candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Delays in obtaining regulatory approvals with respect to any drug candidate will materially and adversely affect our prospects, business, results of operations and financial condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Delays in obtaining regulatory approvals with respect to any drug candidate may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay commercialization of, and our ability to derive product revenues from, such drug candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay any regulatory-related milestone payments payable under outstanding collaboration agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require us to perform costly procedures with respect to such drug candidate; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise diminish any competitive advantages that we may have with respect to such drug candidate.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Delays in the approval process for any drug candidate may have a material adverse effect upon our prospects, business, results of operations and financial condition.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Risks_Preclinical_Clinical_Trials_Expen"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Preclinical and clinical trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs, which may have a material adverse effect on our business, results of operations and financial condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Preclinical and clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Preliminary and initial results from a clinical trial do not necessarily predict final results, and failure can occur at any stage of the trial. We may encounter problems that could cause us to abandon or repeat preclinical studies or clinical trials. The clinical trial process is also time-consuming. Failure or delay in the commencement or completion of our clinical trials may be caused by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower than expected rates of patient recruitment, particularly with respect to trials of rare diseases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination of dosing issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen safety issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of effectiveness during clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreement by applicable regulatory bodies over our trial protocols, the interpretation of data from preclinical studies or clinical trials or conduct and control of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination that the patient population participating in a clinical trial may not be sufficiently broad or representative to assess efficacy and safety for our target population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to monitor patients adequately during or after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of sufficient funding to finance the clinical trials.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">PRX-115 and PRX-119 are still in clinical development and their risk of failure is high. Failure or delay can occur at any time during the preclinical or clinical trial process. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the safety and effectiveness of a product candidate. Preclinical tests and phase I and phase II clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and regimens. Success in preclinical studies and early clinical trials does not ensure that later large-scale efficacy trials will be successful nor does it predict final results. Our product candidates may fail to show the required safety and effectiveness through clinical trials despite positive results in preclinical studies or having successfully advanced through initial clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any failure or delay in commencement or completion of any clinical trials of our product candidates will have a material adverse effect on our business, results of operations and financial condition. In addition, we, the FDA or other regulatory authorities may suspend any clinical trial at any time if it appears that we are exposing participants in the trial to unacceptable safety or health risks or if the FDA or such other regulatory authorities, as applicable, find deficiencies in our IND submissions or the conduct of the trial. Any suspension of a clinical trial may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">If the results of our clinical trials do not support our claims relating to a drug candidate, or if serious side effects are identified, the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether, which will significantly impair our ability to generate product revenues.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The results of our clinical trials with respect to any drug candidate might not support our claims of safety or efficacy, the results of our clinical trials may fail to conclusively show superiority over other commercially available treatments for the same or similar indications, the effects of our drug candidates may not be the desired effects or may include </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">undesirable side effects or the drug candidates may have other unexpected characteristics. Data obtained from tests are susceptible to varying interpretations which may delay, limit or prevent regulatory approval. The clinical trial process may fail to demonstrate that our drug candidates are safe for humans and effective for indicated uses. In addition, our clinical trials, may involve specific and small patient populations. Results of early clinical trials conducted on a small patient population may not be indicative of future results. Adverse or inconclusive results may cause us to abandon a drug candidate and may delay development of other drug candidates. Any delay in, or termination of, our clinical trials will delay the filing of BLAs and NDAs with the FDA, or other filings with other foreign regulatory authorities, and, ultimately, significantly impair our ability to commercialize our drug candidates and generate product revenues which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interim, top-line or preliminary data from clinical trials that we announce or publish may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data. The results and related findings and conclusions are subject to change following a full analysis of all data related to the particular trial. We also may make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, any interim, top-line or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different than the preliminary data we previously published. As a result, any top-line data should be viewed with caution until final data are available. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more data becomes available. Further, regulatory agencies may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses, or may interpret or ascribe different weight to the data, which may impact the value of the clinical trial and may affect the particular clinical program and the approvability or commercialization of the particular product candidate and our business in general. If regulatory authorities disagree with the conclusions we reach, we may not be able to obtain approval for and commercialize our product candidates, which will have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may find it difficult to enroll patients in our clinical trials, or patients may discontinue their participation in our clinical trials, which could cause significant delays in the completion of such trials or may negatively impact the results of these studies and extend the timeline for completion of our development programs or cause us to abandon one or more clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Some of the diseases or disorders that our drug candidates under evaluation are intended to treat are relatively rare and we expect only a subset of the patients with these diseases to be eligible for our clinical trials. Our clinical trials generally mandate that a patient cannot be involved in another clinical trial for the same indication. Therefore, subjects that participate in ongoing clinical trials for products that are competitive with our drug candidates are not available for our clinical trials. An inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, patients who enroll in our clinical trials may discontinue their participation at any time during the study as a result of a number of factors, related to the trials or not, including withdrawing their consent, experiencing adverse clinical events, which may or may not be judged related to our drug candidates, or due to personal reasons, such as planned or actual pregnancies. The discontinuation of patients in any one of our studies may delay the completion of the study or cause the results from the study not to be positive or to not support a filing for regulatory approval of the applicable drug candidate. Any failure to enroll a sufficient number of patients in our clinical trials in a timely manner, if at all, may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the regulatory submission, preclinical studies, clinical trials, manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our drugs is also subject to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our drugs in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed, which may have a material adverse effect on our prospects, business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our clinical trials depend upon third-party service providers and, accordingly, the results of our clinical trials and such research activities are subject to delays and other risks which are, to a certain extent, beyond our control, which could impair our clinical development programs and our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We depend upon independent investigators and collaborators, such as universities and medical institutions, to conduct our preclinical and clinical trials. These collaborators are not our employees, and we cannot control the amount or timing of resources that they devote to our clinical development programs. The investigators may not prioritize to our clinical development programs or pursue them as diligently as we would if we were undertaking such programs directly. If outside collaborators fail to devote sufficient time and resources to our clinical development programs, or if their performance is substandard, the approval of anticipated NDAs, BLAs and other marketing applications, and our introduction of new drugs, if any, may be delayed which could impair our clinical development programs and would have a material adverse effect on our business, results of operations and financial condition. Our collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators also assist our competitors, our competitive position could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We have only limited experience in regulatory affairs, and some of our drug candidates may be based on new technologies. These factors may affect our ability or the time we require to obtain necessary regulatory approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have only limited experience in filing and prosecuting the applications necessary to gain regulatory approvals for medical devices and drug candidates. Moreover, some of the drug candidates that are likely to result from our development programs may be based on new technologies that have not been extensively tested in humans. The regulatory requirements governing these types of drug candidates may not be well defined or more rigorous than for conventional products. As a result, we may experience a longer regulatory process in obtaining regulatory approvals of any products that we develop, which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">We may seek orphan drug or other comparable designations for our product candidates in specific indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States or other applicable jurisdictions may be limited if we seek approval for an indication broader than the orphan designated indication, and may be lost if the FDA, or other applicable regulatory authorities later determine that the request for designation was materially defective, if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, more than one drug can have orphan </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">designation for the same indication. Although we may seek orphan drug designation for other product candidates, we might not receive such designations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to our Financial Condition and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may fail to meet the continued market capitalization-based listing requirement or other continued listing requirements of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The stock market in general, and the market for pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that may have been unrelated or disproportionate to the operating performance of the listed companies. The trading price of our common stock has been volatile and has been subject to wide price fluctuations in response to various factors, many of which are beyond our control. The volatility of our stock price has from time to time in recent periods affected our market capitalization. Adverse fluctuations in the price per share of our common stock or our market capitalization may result in our failure to meet the continued listing requirements of the NYSE American, which would require us to take steps to gain compliance with alternate listing standards or take remedial steps to bring us into compliance. A failure to maintain or regain compliance with applicable listing standards could adversely affect the liquidity of our common stock and could result in an event of default under the 2024 Indenture, which would have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We may need to raise additional capital to operate our business, which may not be available on favorable terms, or at all, and which will have a dilutive effect on our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the years ended December&#160;31, 2023 and 2024, we had net incomes of $8.3&#160;million and $2.9&#160;million, respectively. However, prior to such periods, as we were focused on the development of Elelyso and then Elfabrio, we generally have completed our fiscal years with a net loss. For example, we had a net loss of $14.9&#160;million for the year ended December&#160;31, 2022. Our net losses were primarily the result of expenses incurred through a combination of research and development activities and expenses supporting those activities, which includes share-based compensation expense. We may incur losses in future fiscal years as we continue to execute on our strategic goals as drug development and commercialization is very capital intensive. We expect to continue to incur significant operating expenditures, and we anticipate that our expenses will increase in the foreseeable future as we seek to in-license additional technologies, continue to undertake preclinical development and clinical trials for our current and new drug candidates and seek regulatory approvals for our drug candidates. In addition, changes may occur that could consume our existing capital at a faster rate than projected, including, among others, the cost and timing of regulatory approvals, changes in the progress of our research and development efforts and the costs of protecting our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently, our sources of potential revenues are royalties and commercial milestone payments generated from Pfizer, Fiocruz and Chiesi. We have also generated revenues from research and development services and milestone and other payments we received in connection with our agreements with our commercialization partners, and generated capital from equity and debt offerings and other sources. The revenues we generate from royalties and commercial milestone payments and other sources may not be sufficient to fund our planned operations and capital expenditures. Accordingly, we may need to finance our future cash needs through corporate collaboration, licensing or similar arrangements, public or private equity offerings or debt financings. If we are unable to secure additional financing in the future on acceptable terms, or at all, we may be unable to expand our portfolio of product candidates, commence or complete planned preclinical and clinical trials or obtain approval of our drug candidates from the FDA and other regulatory authorities. In addition, we may be forced to reduce or discontinue product development or product licensing, reduce or forego sales and marketing efforts and other commercialization activities or forego attractive business opportunities in order to improve our liquidity and to enable us to continue operations which would have a material adverse effect on our business and results of operations. Furthermore, any additional source of financing will likely involve the issuance of our equity securities, which will have a dilutive effect on our stockholders.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Intellectual Property Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we fail to adequately protect or enforce our intellectual property rights or secure rights to third party patents, the value of our intellectual property rights would diminish and our business, competitive position and results of operations would suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2024, we had approximately 50 pending patent applications. However, the filing of a patent application does not mean that we will be issued a patent, or that any patent eventually issued will be as broad as requested in the patent application or sufficient to protect our technology. Any modification required to a current patent application may delay the approval of such patent application which may have a material adverse effect on our business, results of operations and financial condition. In addition, there are a number of factors that could cause our patents, if granted, to become invalid or unenforceable or that could cause our patent applications to not be granted, including known or unknown prior art, deficiencies in the patent application or the lack of originality of the technology. Our competitive position and future revenues will depend in part on our ability and the ability of our licensors and collaborators to obtain and maintain patent protection for our products, methods, processes and other technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to operate without infringing the proprietary rights of third parties. We have filed U.S. and international patent applications for process patents, as well as composition of matter patents, for Elfabrio, Elelyso and our product candidates. However, we cannot predict:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and range of protection any patents will afford us against competitors and those who infringe upon our patents, including whether third parties will find ways to invalidate or otherwise circumvent our licensed patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if and when patents will issue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether or not others will obtain patents claiming aspects similar to those covered by our licensed patents and patent applications; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we will need to initiate litigation or administrative proceedings, which may be costly, whether we win or lose.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2024, we held, or had license rights to, approximately 75 patents. If patent rights covering our products or technologies are not sufficiently broad, they may not provide us with sufficient proprietary protection or competitive advantages against competitors with similar products and technologies. Furthermore, if the USPTO or foreign patent offices issue patents to us or our licensors, others may challenge the patents or circumvent the patents, or the patent office or the courts may invalidate the patents. Thus, any patents we own or license from or to third parties may not provide any protection against our competitors and those who infringe upon our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Furthermore, the life of our patents is limited. The patents we hold, and the patents that may be issued in the future based on patent applications from the patent families, relating to our ProCellEx protein expression system are expected to expire by 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">We rely on confidentiality agreements that could be breached and may be difficult to enforce which could have a material adverse effect on our business and competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our policy is to enter agreements relating to the non-disclosure of confidential information with third parties, including our contractors, consultants, advisors and research collaborators, as well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants while we employ them. However, these agreements can be difficult and costly to enforce. Moreover, to the extent that our contractors, consultants, advisors and research collaborators apply or independently develop intellectual property in connection with any of our projects, disputes may arise as to the proprietary rights to the intellectual property. If a dispute arises, a court may determine that the right belongs to a third party, and enforcement of our rights can be costly and unpredictable. In addition, we rely on trade secrets and proprietary know-how that we seek </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">to protect in part by confidentiality agreements with our employees, contractors, consultants, advisors and others. Despite the protective measures we employ, we still face the risk that:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">these agreements may be breached;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">these agreements may not provide adequate remedies for the applicable type of breach; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our trade secrets or proprietary know-how will otherwise become known.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any breach of our confidentiality agreements or our failure to effectively enforce such agreements may have a material adverse effect on our business and competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we infringe the rights of third parties we could be prevented from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs and may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have not received to date any claims of infringement by any third parties. However, as our drug candidates progress into clinical trials and commercialization, if at all, our public profile and that of our drug candidates may be raised and generate such claims. Defending against such claims, and occurrence of a judgment adverse to us, could result in unanticipated costs and may have a material adverse effect on our business and competitive position. If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we may incur substantial costs and we may have to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain licenses, which may not be available on commercially reasonable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">redesign our products or processes to avoid infringement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stop using the subject matter claimed in the patents held by others, which could cause us to lose the use of one or more of our drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial diversion of management resources; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pay damages.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any costs incurred in connection with such events or the inability to sell our products may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If we cannot meet requirements under our license agreements, we could lose the rights to our products, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We depend on licensing agreements with third parties to maintain the intellectual property rights to certain of our product candidates. Our license agreements require us to make payments and satisfy performance obligations in order to maintain our rights under these agreements. All of these agreements last either throughout the life of the patents that are the subject of the agreements, or with respect to other licensed technology, for a number of&#160;years after the first commercial sale of the relevant product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our license agreements in a timely manner, we could lose the rights to our proprietary technology which could have a material adverse effect on our business, results of operations and financial condition.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Risks_Operations_Israel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Relating to our Operations in Israel</p><a id="Risks_Significant_Operations_Israel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Significant parts of our operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military conditions in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our executive office and operations are located in the State of Israel. Accordingly, economic, geopolitical and military conditions in Israel and the surrounding region could directly affect our business. Any armed conflicts, political instability, terrorism, cyberattacks or any other hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could adversely affect our operations. Since the establishment of Israel in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors, Hamas and Hezbollah. In October 2023, terrorists from the Hamas&#160;organization infiltrated Israel&#8217;s southern border from the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. During January 2025, a ceasefire with Hamas was declared. As of the date of this Annual Report on Form&#160;10-K, the war is ongoing and continues to evolve. The attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, as well as actions that could be taken in the future by NATO, the United States, the United Kingdom the European Union or Israel&#8217;s neighboring states and other countries have created global security concerns that may result in a greater or lasting regional conflict. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and financial conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Our facilities are in range of certain of the rockets that are being fired from Lebanon and elsewhere. We suffered minimal damages during a rocket attack in 2006. As of the issuance of this Annual Report on Form&#160;10-K, the impact of the war has not had an adverse effect on our operations. To mitigate the risk of loss due to the military operations, we have elected to store manufactured drug substance in multiple locations, both within and outside of Israel. Our insurance policies do not cover damages incurred in connection with these conflicts or for any resulting disruption in our operations. The Israeli government, as a matter of law, provides coverage for the reinstatement value of direct damages that are caused by terrorist attacks or acts of war; however, the government may cease providing such coverage or the coverage might not be enough to cover potential damages. Any damage to our facilities as a result of war or other hostile action may have a material adverse effect on our business, results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Ongoing and revived hostilities or other Israeli political or economic factors, could prevent or delay shipments of our products, harm our operations and product development and cause any future sales to decrease. If hostilities disrupt the ongoing operation of our facilities or the airports and seaports on which we depend to import and export our supplies, materials, drug substance and other products, our business, results of operations and financial condition may be materially and adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Parties with whom we do business may sometimes decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary to meet our business partners face to face. Further, shifting economic and political conditions in the United States and in other countries may result in changes in how the United States and other countries conduct business and other relations with Israel, which may have an adverse impact on our Israeli operations and a material adverse impact on our business. In addition, several countries, principally in the Middle East, restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result of hostilities in the region or otherwise. Moreover, there have been increased efforts by organizations and movements to cause companies and consumers to boycott Israeli goods.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Our operations may be disrupted by the obligations of our personnel to perform military service which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Many of our male employees in Israel, including members of senior management, are obligated to perform up to one&#160;month (in some cases more) of annual military reserve duty until they reach the age of 45 and, in the event of a military conflict, could be called to active duty. To date, we have not suffered any disruptions to our operations from the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">absence of employees in connection with the current military action. However, we continue to face the risk that our operations could be disrupted by the absence of a significant number of our employees related to military service or the absence for extended periods of military service of one or more of our key employees. Any such disruption may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">A certain portion of our expenses is incurred in New Israeli Shekels and, accordingly, our results of operations may be seriously harmed by currency fluctuations and inflation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We report our financial statements in U.S.&#160;dollars, our functional currency. Although most of our expenses are incurred in U.S.&#160;dollars, we pay a portion of our expenses in New Israeli Shekels, or NIS, and as a result, we are exposed to risk to the extent that the inflation rate in Israel exceeds the rate of devaluation of the NIS in relation to the U.S.&#160;dollar or if the timing of these devaluations lags behind inflation in Israel. In that event, the U.S.&#160;dollar cost of our operations in Israel will increase and our U.S.&#160;dollar-measured results of operations will be adversely affected. To the extent that the value of the NIS increases against the U.S.&#160;dollar, our expenses on a dollar cost basis increase. Our operations also could be adversely affected if we are unable to guard against currency fluctuations in the future. To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The tax benefits available to us require that we meet several conditions and may be terminated or reduced in the future, which would increase our taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are able to take advantage of tax exemptions and reductions resulting from the &#8220;Approved Enterprise&#8221; status of our facilities in Israel. To remain eligible for these tax benefits, we must continue to meet certain conditions, including making specified investments in property and equipment, and financing at least 30% of such investments with share capital. If we fail to meet these conditions in the future, the tax benefits would be canceled and we may be required to refund any tax benefits we already have enjoyed. These tax benefits are subject to investment policy by the Investment Center and may not be continued in the future at their current levels or at any level. In recent&#160;years the Israeli government has reduced the benefits available and has indicated that it may further reduce or eliminate some of these benefits in the future. The termination or reduction of these tax benefits or our inability to qualify for additional &#8220;Approved Enterprise&#8221; approvals may increase our tax expenses in the future, which would reduce our expected profits and adversely affect our business and results of operations. Additionally, if we increase our activities outside of Israel, for example, by future acquisitions, such increased activities generally may not be eligible for inclusion in Israeli tax benefit programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The Israeli government grants we have received for certain research and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel and require us to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received together with interest and penalties which could have a material adverse effect on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the past, our research and development efforts have been financed, in part, through grants that we have received from NATI. We, therefore, must comply with the requirements of the Research Law. Under the Research Law we are prohibited from manufacturing products developed using these grants outside of the State of Israel without special approvals, although the Research Law does enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased royalties. We may not receive the required approvals for any proposed transfer of manufacturing activities. Even if we do receive approval to manufacture products developed with government grants outside of Israel, we may be required to pay an increased total amount of royalties (possibly up to 600% of the grant amounts plus interest), depending on the manufacturing volume that is performed outside of Israel, as well as a possibly increased royalty rate. This restriction may impair our ability to outsource manufacturing or engage in similar arrangements for those products or technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additionally, under the Research Law, Protalix&#160;Ltd. is prohibited from transferring NATI-financed technologies and related intellectual property rights outside of the State of Israel, except under limited circumstances and only with the approval of NATI Council or the Research Committee. Protalix&#160;Ltd. may not receive the required approvals for any proposed transfer and, if received, Protalix&#160;Ltd. may be required to pay NATI a portion of the consideration that it </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that Protalix&#160;Ltd. has already paid to NATI, the amount of time that has elapsed between the date on which the know-how was transferred and the date on which NATI grants were received and the sale price and the form of transaction will be taken into account in order to calculate the amount of the payment to NATI. Approval of the transfer of technology to residents of the State of Israel is required, and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including the restrictions on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any such transfer, if requested, will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These restrictions may impair our ability to sell our technology assets or to outsource manufacturing outside of Israel. The restrictions will continue to apply for a certain period of time even after we have repaid the full amount of royalties payable for the grants. If we fail to satisfy the conditions of the Research Law, we may be required to refund certain grants previously received together with interest and penalties, and may become subject to criminal charges, any of which could have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Investors may have difficulties enforcing a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal securities laws against us, our executive officers and most of our directors or asserting U.S. securities laws claims in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A majority of our directors and all of our executive officers are residents of Israel, and accordingly, most of their assets and our assets are located outside the United States. Service of process upon us or our non-U.S. resident directors and officers and enforcement of judgments obtained in the United States against us or our non-U.S. resident directors and executive officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel that it may be difficult to assert claims under U.S.&#160;securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability provisions of U.S.&#160;federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S.&#160;securities laws against us or our non-U.S. resident officers and directors because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or our non-U.S. resident officers and directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Moreover, among other reasons, including but not limited to, fraud or absence of due process, or the existence of a judgment which is at variance with another judgment that was given in the same matter if a suit in the same matter between the same parties was pending before a court or tribunal in Israel, an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Risks Related to Investing in our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The market price of our common stock may fluctuate significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The market price of our common stock has experienced significant volatility. The securities of life sciences companies often experience significant volatility in connection with clinical trial and regulatory announcements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We anticipate that the market price of our common stock is likely to continue to fluctuate significantly in response to numerous factors, some of which are beyond our control, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of Elfabrio by Chiesi;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">purchases of BioManguinhos alfataliglicerase in Brazil; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress and results of the studies of our product candidates under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the announcement of new products or product enhancements by us or our competitors;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning intellectual property rights and regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our and our competitors&#8217; results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in earnings estimates or recommendations by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments in the biotechnology industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general market conditions and other factors, including factors unrelated to our operating performance, such as the Israel-Hamas war.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Price volatility of our common stock may be worse when the trading volume of our common stock is low. We have not paid, and do not expect to pay, any cash dividends on our common stock as any earnings generated from future operations will be used to finance our operations. As a result, investors will not realize any income from an investment in our common stock until and unless their shares are sold at a profit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Future sales of our common stock could reduce our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If our stockholders sell substantial amounts of our common stock or if we sell a substantial amount of our common stock in any public or private offering, the market price of our common stock could decrease significantly. The perception in the public market that our existing stockholders might sell shares of common stock may also depress the trading price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A substantial majority of our outstanding shares of our common stock are freely tradable without restriction or further registration under the federal securities laws. In addition, we may sell additional shares of our common stock in the future to raise capital. At December&#160;31, 2024, there were outstanding options to purchase common stock issued covering approximately 7.4&#160;million shares of our common stock with a weighted average exercise price of $1.98 per share. Also at December&#160;31, 2024, there were 4,139,412 shares of common stock available for future for issuance in connection with future grants of incentives under our <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended</span></a>. The issuance and sale of substantial amounts of common stock, or the perception that such issuances and sales may occur, could adversely affect the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">If securities analysts stop publishing research or reports about us or our business or if they downgrade our common stock, the market price of our common stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. We do not control these analysts. If any analyst who covers us downgrades our stock or lowers its future stock price targets or estimates of our operating results, the market price for our common stock could decline rapidly. Furthermore, if any analyst ceases to cover us, we could lose visibility in the market, which in turn could cause the market price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses, divert management&#8217;s attention from operating our business which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The laws, rules, regulations and standards including the rules&#160;promulgated by the national securities exchanges, including the NYSE American, to which we are subject are changed and/or amended from time to time. New or changed laws, rules, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving laws, rules, regulations and standards are likely to continue to result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. Members of our Board of Directors and our executive officers, could face an increased risk of personal liability in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">connection with the performance of their duties. As a result, we may have difficulty attracting and retaining qualified directors and executive officers, which could have a material adverse effect on our business. If our efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies, we may incur additional expenses to comply with standards set by regulatory authorities or governing bodies which may have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Delaware law and our organizational documents contain certain provisions, including anti-takeover provisions that limit the ability of our stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our organizational documents and Delaware General Corporation Law, or the DGCL, contain provisions that could have the effect of rendering more difficult, delaying, or preventing an acquisition that our stockholders may consider favorable. Among other things, our organizational documents include the following provisions or features: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of our Board of Directors to</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, at any time without any further action on the part of our stockholders, authorize the issuance of a series of preferred stock</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, including &#8220;blank check&#8221; preferred stock, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Any series of such preferred stock, could, for example, grant to holders, among other terms, the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of our common stock and the right to the redemption of the preferred shares, together with a premium, before the redemption of our common stock, which may have a material adverse effect on the rights of the holders of our common stock. In addition, our Board of Directors, without further stockholder approval, may, at any time, issue large blocks of preferred stock. The issuance of preferred stock may impede a takeover of our company and may prevent a transaction that is favorable to our stockholders.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the right of our Board of Directors to elect a director to fill a vacancy created by the expansion of our Board of Directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our Board of Directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of our Board of Directors to amend the Bylaws, which may allow our Board of Directors to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the Bylaws to facilitate an unsolicited takeover attempt; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our Bylaws contain advance notice procedures with which stockholders must comply to nominate candidates to our Board of Directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in our Board of Directors and also may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any provision of our organizational documents or the DGCL that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a related premium for their common stock and could also affect the price that some investors are willing to pay for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Amended and Restated Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our Amended and Restated Bylaws, or our Bylaws, provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any of our directors, stockholders, officers or other employees to us or to our stockholders, (iii)&#160;any action </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">asserting a claim arising pursuant to the DGCL or our Certificate of Incorporation, as amended, or our Bylaws, or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the Exchange Act against any person in connection with any offering of the corporation&#8217;s securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The choice of forum provisions above may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees or could result in increased costs for a stockholder to bring a claim, both of which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our Bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which may have a material adverse effect on our business, results of operations and financial condition.</p><a id="_9873979e_40c5_4ca5_80f7_2c4bd1508ac1"></a><a id="Item1BUnresolvedStaffComments_626044"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B.&#160;&#160;&#160;Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_b3b23865_6968_4bcc_8696_0500349d5017"></a><a id="Item1CCybersecurity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item&#160;1C.&#160;&#160;&#160;Cybersecurity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Risk Management and Strategy</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb_YOrqbxYcfU6XzLVoNWcfLg" continuedAt="Tb_YOrqbxYcfU6XzLVoNWcfLg_cont1" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_1-dHyixZDEKokvSkQvbD2w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our operations include the creation, collection and maintenance of sensitive information, including proprietary and confidential business information, intellectual property, third-party information and employee information. To protect this information, we use external and internal services to managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats on a constant basis. In addition, we use multi-factor authentication (MFA) for external use, perform penetration testing and <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_J8qGdgZ4EUK4DbUAHLqU1w">engage third parties to assess the effectiveness of our cybersecurity practices</ix:nonNumeric>. We conduct a thorough risk assessment by identifying critical assets, recognizing potential threats and vulnerabilities, and implement strategies to mitigate these risks and their possible impacts. We establish incident response plans and provide cybersecurity training to our employees and monitor their activity to ensure adherence to our security protocols. A material cyber-attack on our systems, or any other third-party partners or vendors and their key operating systems, may interrupt our ability to operate our business, damage our reputation, or result in monetary damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_gOIfwsfli0ytHQkE7UsOzg">We have implemented a Data Protection Policy</ix:nonNumeric>, or the DPP, in order to establish the high-level direction for properly managing the use, privacy, security, retention, and disposal of our information, data and assets, and to manage identified material cybersecurity risks. The DPP was prepared using relevant guidance issued and technology standards that are used across various industries. It applies to all entities who are using our equipment and resources, including but not limited to, employees and temporary workers. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Tb_Vi3BFJpE-U-Lb-XX2wvLwg" escape="true">Our Senior Director, Information Technology, is a certified information security officer (CISO). He is primarily responsible for implementing and overseeing the DPP and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our DPP includes an incident response process that includes reporting thresholds and follows standardized identification and authentication practices. If an incident is identified, it is documented by our Senior Director, Information Technology, who is required to report the incident to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr_czrXSncaEU6melNkj873hA">We work with third-party service providers from time to time that assist us to identify, assess and manage cybersecurity risks</ix:nonNumeric>, including professional SEIM SOC and other services firms, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and penetration testing.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_IQKvtKIFGkSnAA9iG3-hNA">No risks from cybersecurity threats have occurred that have materially affected or are reasonably likely to materially affect our business</ix:nonNumeric>, results of operations or financial condition.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_YOrqbxYcfU6XzLVoNWcfLg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Governance</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Tb_qSQQ7TyV6kKsL7nbb53yzw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of our management, including our <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_h22gbO-HFUKVhUOLfwm7PQ" escape="true">Senior Director, Information Technology</ix:nonNumeric>, who reports to our Sr. Vice President, Operations. Management is also <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_6kn1SoyQiUGx4vg3ltVTAg">responsible</ix:nonNumeric> for hiring appropriate personnel, integrating cybersecurity considerations into our overall risk management strategy, and for communicating key priorities to employees, as well as for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our incident response process involves management, who participates in our disclosure controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our incident response process is designed to escalate certain cybersecurity incidents and vulnerabilities to members of management depending on the circumstances, including work with our incident response team to help the company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the company&#8217;s incident response processes include <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_Yc4pIhTWcEqqr0QjNhsT1Q">reporting to our Board of Directors</ix:nonNumeric> for certain cybersecurity incidents.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Tb_a3gPoT8X2UqcEdmnekmK_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Management is involved with our efforts to prevent, detect, and mitigate cybersecurity incidents by overseeing preparation of cybersecurity policies and procedures, testing incident response plans and engaging vendors to conduct penetration tests. Management participates in cybersecurity incident response efforts by being a member of the incident response team and helping direct our response to cybersecurity incidents.</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_of8WTzHZl0aydX4J6yfNdA" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_rf5Tdes_VE-f1V4JAZ_yOw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Our <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_xkR1KQ9fp0KqSvX7nkrNOw" escape="true">Board of Directors</ix:nonNumeric> addresses our cybersecurity risk management as part of its general oversight function. Our Chief Financial Officer and IT consultant provide periodic briefings to the Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, if any, cybersecurity systems testing, activities of third parties, and the like.</p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">See &#8220;<a href="#Risks_Internal_Computer_Systems"><span style="font-style:normal;font-weight:normal;">Risk Factors &#8211; Our internal computer systems, or those used by our third-party contractors or consultants, may fail or suffer security breaches, resulting in liability and harm to our reputation, which could negatively affect our business, results of operation and financial condition. We may face liability if we breach our obligations related to the protection, security, nondisclosure of confidential information or disclosure of sensitive data or fail or are perceived to fail to comply with applicable data protection laws and regulations, or consumer protection laws, regulations and standards.</span></a>&#8221;</p><a id="_988bf69d_e54e_4c78_a2d6_ff4953c06beb"></a><a id="Item2Properties_907582"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;Properties </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We maintain a U.S. corporate office in Hackensack, New Jersey. Our headquarters, including a manufacturing facility, executive offices and other facilities, are located in Carmiel, Israel. Our facilities in Israel currently contain approximately 14,700&#160;sq/ft of manufacturing space and 3,400&#160;sq/ft for a pilot plant, 11,700&#160;sq/ft for offsite warehouse space and approximately 43,100&#160;sq/ft of laboratories, front warehouse and office space, and are leased at a rate of approximately $85,000 per&#160;month. In addition, we are entitled to use an additional 14,500&#160;sq/ft in the same facility, which we may utilize in connection with any future expansion of our manufacturing facilities. Our facilities are equipped with the requisite laboratory services required to conduct our business, and we believe that the existing facilities are adequate to meet our needs for the foreseeable future. Our original lease for the facility was in effect until 2016 and we have exercised two of three options to extend the term, each for an additional five-year period. The lease is currently in effect until 2026 and we retain an additional option to extend the term for another five-year period thereafter. Upon the exercise of each option to extend the term of the lease includes a 10% increase to the then current base rent.</p><a id="_7d907f0c_a864_4705_99b3_25a9932ce47f"></a><a id="Item3LegalProceedings_932888"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are not involved in any material legal proceedings.</p><a id="_e5d0ec77_db33_47f0_82e8_740bc93d7dde"></a><a id="Item4MineSafetyDisclosures_147620"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_81e65689_3477_44c5_93b8_d15f9365df9f"></a><a id="PARTII_453527"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our common stock is traded on the NYSE American under the symbol &#8220;PLX.&#8221; In 2023, we decided to voluntarily delist our common stock from the Tel Aviv Stock Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of March&#160;1, 2025, there were approximately 60 holders of record of our common stock. A substantially greater number of holders of our common stock are &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not declared or paid any cash dividends on our common stock. We do not anticipate paying any dividends on our common stock in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance under Equity Compensation Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following table provides information as of December&#160;31, 2024 with respect to the shares of our common stock that may be issued under our existing equity compensation plan.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">A</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">C</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Securities&#160;Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Available&#160;for&#160;Future&#160;Issuance</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">to&#160;be&#160;Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Under&#160;Equity&#160;Compensation&#160;Plans</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Upon&#160;Exercise&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Excluding&#160;Securities&#160;Reflected&#160;in</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Plan Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding&#160;Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding&#160;Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Column&#160;A)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity Compensation Plans Approved by Stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,402,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,139,412</p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity Compensation Plans Not Approved by Stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,402,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,139,412</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_05eb6191_b9ad_44ba_8983_abcef36f7c80"></a><a id="Item6Reserved"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">[Reserved]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Item_7._"></a><a id="_53bcdc57_906f_4e90_8840_54633fcd3c95"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) is intended to help the reader understand our results of operations and financial condition. The MD&amp;A is provided as a supplement to, and should be together with our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form&#160;10-K. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, include forward-looking statements that involve risks and uncertainties. You should read &#8220;</i><a href="#_Item_1A._"><i style="font-style:italic;font-weight:normal;">Risk Factors</i></a><i style="font-style:italic;">&#8221; in Item&#160;1A of this Annual Report on Form&#160;10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins primarily based on our proprietary ProCellEx protein expression system. To date, we have successfully developed two commercial products, both of which are ERTs; Elfabrio (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which we referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. Chiesi is our commercialization partner for Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are committed to leveraging our track record of success as we progress with the development of treatments for rare and orphan diseases. In addition, we continuously work on the further development and enhancement of our ProCellEx technology. Accordingly, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. We are also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our first product, Elelyso, an ERT for the treatment of patients with Gaucher disease, was first approved by the FDA in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In June&#160;2012, the CHMP issued a positive opinion regarding the benefit of Elelyso but did not immediately grant marketing authorization because of the ten-year market exclusivity granted to Vpriv in August&#160;2010 for the same condition, which was extended for an additional two&#160;years, and expired in August 2022. We have granted the marketing rights to Elelyso globally, excluding Brazil, to Pfizer through an exclusive licensing agreement. We maintain the distribution rights to Elelyso in Brazil, where it is currently marketed as BioManguinhos alfataliglicerase, through the Brazil Agreement. In 2024, we generated $12.6&#160;million from sales of Elelyso to Pfizer and $11.0&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Elfabrio, our second commercial product, an ERT for the treatment of Fabry disease, was approved by the EC for marketing in the EU and by the FDA for marketing in the United States in May 2023 for adult patients. Both approvals cover the 1&#160;mg/kg every two weeks dosage. </span>We have entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. In October 2017 and July 2018, Protalix Ltd., our wholly-owned subsidiary, entered into the Chiesi Agreements pursuant to which Chiesi was granted an exclusive license for all markets, both within and outside of the United States to commercialize Elfabrio. In 2024, we generated $29.3&#160;million from sales of Elfabrio to Chiesi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, we hold the worldwide commercialization rights to our other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate which we have designed </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for long and customized systemic circulation in the bloodstream</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on our ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. We cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In March 2023, we initiated a phase&#160;I First-in-Human clinical trial of PRX-115. This study included 64 adult male and female subjects in a dose escalation design with eight sequential dosing cohorts, each composed of eight subjects (six active and two placebo) which is now complete. The results were announced in a poster presentation at the American College of Rheumatology (ACR) Convergence&#160;2024, held&#160;November 14-19, 2024 and are summarized in Item&#160;1 of this annual report on Form&#160;10-K. We are currently preparing for a phase&#160;II clinical trial of PRX-115 which we expect will commence in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July 2, 2021, we entered into an At The Market Offering Agreement, or the 2021 Sales Agreement, with H.C.&#160;Wainwright &amp; Co., LLC, as our sales agent, or the Agent, which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, we were able to sell from time to time through the Agent shares of our common stock having an aggregate offering price of up to $20.0&#160;million, or the ATM Shares. During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, we sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On February&#160;27, 2023, we entered into an At The Market Offering Agreement, or the 2023 Sales Agreement, with the Agent. Pursuant to the terms of the 2023 Sales Agreement, we may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to $20.0&#160;million. As of December&#160;31, 2024, shares of common stock for total gross proceeds of approximately $2.5&#160;million were available to be sold under the 2023 Sales Agreement. Since December&#160;31, 2024, we sold the remaining shares of common stock available for sale under the 2023 Sales Agreement thereby completing the ATM program thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under each of the Chiesi Agreements, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. was entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, and is entitled to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements. In addition, following the approval of Elfabrio by the FDA, we received a milestone payment equal to $20.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we and Chiesi amended the Chiesi Agreements in order to provide us with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi Ex-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. is required to manufacture all of the Elfabrio drug substance needed under the agreements, subject to certain exceptions, and Chiesi will purchase Elfabrio drug product from Protalix, subject to certain terms and conditions. The consideration for Protalix Ltd. is based on the drug product supplied to Chiesi and the average selling price of the drug product in the relevant territory multiplied by tiered payments as described in the relevant agreement. Under the Chiesi Ex-US Agreement, the price payable to us for drug product supplied is based on a range of 15% to 35% of the average selling price of the drug product in the applicable territory, and, under the Chiesi US Agreement, such price is based on a range of 15% to 40% of the average selling price of the drug product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On August&#160;29, 2022, we entered into a Fill/Finish Agreement, or the F/F&#160;Agreement, and a Letter Agreement, or the Letter Agreement, in each case with Chiesi. We agreed to supply Chiesi with drug substance for Elfabrio and, following </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for Elfabrio, including to support the anticipated global launch of Elfabrio. Subsequently, we and Chiesi agreed that the F/F&#160;Agreement shall have an initial term of 10&#160;years, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement and the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement prior to expiration of the initial term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into the Amended Pfizer Agreement, pursuant to which we sold to Pfizer our share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, we agreed to transfer our rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where we are responsible for all expenses and retain all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On June&#160;18, 2013, we entered into the Brazil Agreement. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, we have the right to terminate the Brazil Agreement. Notwithstanding the termination right, we are, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Because our operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. During January 2025, a ceasefire with Hamas was declared. As of the date of this Annual Report on Form&#160;10-K, the war is ongoing and continues to evolve. The attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, as well as actions that could be taken in the future by NATO, the United States, the United Kingdom the European Union or Israel&#8217;s neighboring states and other countries have created global security concerns that may result in a greater or lasting regional conflict. We have elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and financial conditions. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on our operations. See &#8220;<a href="#Risks_Significant_Operations_Israel"><span style="font-style:normal;font-weight:normal;">Risk Factors&#8212;Significant parts of our operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military conditions in Israel.</span></a>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and short-term bank deposits as of December&#160;31, 2024 are sufficient to satisfy our capital needs for at least 12 months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Critical Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing at the end of this Annual Report on Form&#160;10-K. We believe that the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our primary sources of revenues include our sales of drug product to Chiesi under the Chiesi Agreements, of BioManguinhos alfataliglicerase to Brazil and of drug substance to Pfizer under our Amended Pfizer Agreement. For a discussion of our accounting treatment for revenue recognition, see <a href="#kRevenueRecognition_574688"><span style="font-style:normal;font-weight:normal;">Note 1(k)</span></a> <span style="background:#ffffff;">to our consolidated financial statements</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We estimate the degree to which deferred tax assets will result in a benefit, after consideration of all positive and negative evidence, and provide a valuation allowance for deferred tax assets that we believe more likely than not will not be realized. In situations in which we are able to determine that our deferred tax assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, we considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. We reassess our valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, we reverse the related valuation allowance. The tax valuation allowance totaled approximately $50.7&#160;million at December&#160;31, 2024 (see <a href="#_NOTE_13_-"><span style="font-style:normal;font-weight:normal;">Note&#160;12</span></a> to our consolidated financial statements for additional information). Should our actual future taxable income by tax jurisdiction vary from estimates, additional allowances or reversals thereof may be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Significant judgment is required in evaluating our uncertain tax positions. In evaluating the exposure associated with our various tax filing positions, we record reserves for uncertain tax positions in accordance with U.S. GAAP based on the technical support for the positions and our past audit experience with similar positions. For those tax positions where it is more likely than not that a tax benefit will be sustained, we record the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. We believe our tax positions comply with applicable tax laws and we intend to defend our positions, no assurance can be given that the final tax outcome of these matters will not be different from that which is reflected in our historical income tax reserves and accruals. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the provision for income taxes in the period in which such determination is made. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate. <span style="background:#ffffff;">Uncertain tax position totaled approximately $0.8</span>&#160;<span style="background:#ffffff;">million at December&#160;31, 2024 (see </span><a href="#_NOTE_12_-"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Note&#160;12</span></a><span style="background:#ffffff;"> to our consolidated financial statements for additional information).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Research and Development Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect our research and development expense to remain our primary expense in the near future as we continue to develop our product candidates. Research and development expense consists of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">internal costs associated with research and development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments made to third party contract research organizations, investigative/clinical sites and consultants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing development costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, including salaries, benefits, travel and related costs for the personnel involved in research and development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activities relating to the advancement of product candidates through preclinical studies and clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, as well as laboratory and other supplies.</span></td></tr></table><div style="margin-top:10pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table identifies our current major research and development projects:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.21%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Project</b></p></td><td style="vertical-align:bottom;width:2.18%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Status</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expected Near Term Milestones</b></p></td></tr><tr><td style="vertical-align:top;width:33.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PRX-115&#160;&#8211; PEGylated Uricase</p></td><td style="vertical-align:top;width:2.18%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Phase&#160;I (completed)</p></td><td style="vertical-align:top;width:2.16%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Phase&#160;II clinical trial expected to launch in the second half of 2025.</p></td></tr><tr><td style="vertical-align:top;width:33.21%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.18%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PRX-119&#160;&#8211; Long Acting DNase&#160;I</p></td><td style="vertical-align:top;width:2.18%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Preclinical</p></td><td style="vertical-align:top;width:2.16%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.21%;background:#cceeff;margin:0pt;padding:0pt 0pt 1pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We anticipate incurring increasing costs in connection with the continued development of PRX-115 and PRX-119 and in the expansion of our pipeline. Our internal resources, employees and infrastructure are not tied to any individual research project and are typically deployed across all of our projects. We currently do not record and maintain research and development costs per project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At this time, due to the inherently unpredictable nature of preclinical and clinical development processes and given the early stage of our preclinical product development programs, we are unable to estimate with any certainty the costs we will incur in the continued development of the product candidates in our pipeline for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially from expectations. Our future research and development expenses for our product candidates will depend on the preclinical and clinical success of each product candidate, as well as ongoing assessments of each product candidate&#8217;s commercial potential. In addition, we cannot forecast with any degree of certainty which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. See &#8220;<a href="#Risks_Obtain_Necessary_US_EMA"><span style="font-style:normal;font-weight:normal;">Risk Factors&#8212;We may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would have a material adverse effect on our business, results of operations and financial condition.</span></a>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect our research and development expenses to continue to be our primary expense in the future as we continue the advancement of our clinical trials and preclinical product development programs for our product candidates. The lengthy process of completing clinical trials and seeking regulatory approvals for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expense to increase and, in turn, have a material adverse effect on our operations. Due to the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects. See &#8220;<a href="#Risks_Preclinical_Clinical_Trials_Expen"><span style="font-style:normal;font-weight:normal;">Risk Factors&#8212;Preclinical and clinical trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs, which may have a material adverse effect on our business, results of operations and financial condition.</span></a>&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Year ended December&#160;31, 2024 Compared to the&#160;Year Ended December&#160;31, 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Revenues from Selling Goods</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $53.0&#160;million for the year ended December&#160;31, 2024, an increase of $12.6&#160;million, or 31%, compared to revenues of $40.4&#160;million for the year ended December&#160;31, 2023. The increase resulted <span style="color:#212529;background:#ffffff;">primarily from an increase of $11.8&#160;million in sales to Chiesi, an increase of $0.6&#160;million in sales to Brazil and an increase of $0.1&#160;million in sales to Pfizer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Revenues from License and R&amp;D services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We recorded revenues from license and R&amp;D services of $0.4&#160;million for the year ended December&#160;31, 2024, a decrease of $24.7&#160;million, or 98%, compared to revenues of $25.1&#160;million for the year ended December&#160;31, 2023. <span style="color:#212529;background:#ffffff;">Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The revenues from license and R&amp;D services for the </span>year ended December&#160;31, 2023<span style="color:#212529;background:#ffffff;"> included&#160;the $20.0&#160;million regulatory milestone payment from Chiesi in connection with the FDA approval of Elfabrio granted during that period.&#160;The remaining decrease resulted from the completion of our revenue-generating research and development </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">obligations with respect to Elfabrio and, as Elfabrio was approved in the United States and the European Union in May 2023, from the completion of the regulatory processes related to the review of the BLA and the MAA for Elfabrio by the FDA and EMA, respectively.&#160;As a result of the completion of the&#160;Fabry clinical program in 2023, we expect to generate minimal revenues from license and R&amp;D services other than potential regulatory milestone payments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cost of Goods Sold</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $24.3&#160;million for the year ended December&#160;31, 2024, an increase of $1.3&#160;million, or 6%, compared to cost of goods sold of $23.0&#160;million for the year ended December&#160;31, 2023. <span style="color:#212529;background:#ffffff;">The increase in cost of goods sold was primarily the result of the increase in sales to Chiesi.&#160;In addition, during the </span>year ended December&#160;31, 2023,<span style="color:#212529;background:#ffffff;"> a portion of the costs for certain drug substance sold were recognized as research and development expenses, not cost of goods sold, as such drug substance was produced as part of our research and development activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the year ended December&#160;31, 2024, our total research and development expenses were approximately $13.0&#160;million comprised of approximately $7.1&#160;million of salary and related expenses, approximately $2.4&#160;million in subcontractor-related expenses, approximately $0.9&#160;million of materials-related expenses and approximately $2.6&#160;million of other expenses. For the year ended December&#160;31, 2023, our total research and development expenses were approximately $17.1&#160;million comprised of approximately $7.8&#160;million of salary and related expenses, approximately $6.3&#160;million in subcontractor-related expenses, approximately $0.6&#160;million of materials-related expenses and approximately $2.4&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total decrease in research and developments expenses was $4.1&#160;million, or 24%, for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023. The decrease in research and development expenses resulted primarily from <span style="color:#212529;background:#ffffff;">the completion of our Fabry clinical program and the regulatory processes related to the BLA and MAA review of Elfabrio by the applicable regulatory agencies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">We expect to continue to incur significant, increasing research and development expenses as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Selling, General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $12.2&#160;million for the year ended December&#160;31, 2024, a decrease of $2.8&#160;million, or 19%, from $15.0&#160;million for the year ended December&#160;31, 2023. The decrease resulted primarily from <span style="color:#212529;background:#ffffff;">a decrease of $1.8&#160;million in professional fees and of $1.0&#160;million in salaries and related expenses</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Financial Expenses and Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Financial income, net was $0.2&#160;million for the year ended December&#160;31, 2024, compared to financial expenses, net of $1.9&#160;million for the year ended December&#160;31, 2023. </span><span style="color:#212529;font-style:normal;background:#ffffff;">The difference resulted primarily from a decrease of approximately $1.4&#160;million in lower interest and related expenses due to the note conversions executed in 2023 and the September 2024 repayment in full of all the outstanding principal and interest payable under the 2024 Notes, as well as an increase in interest income, net of $0.7&#160;million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the year ended December&#160;31, 2024, we recorded income taxes of approximately $1.2&#160;million, an increase of $0.9&#160;million, or 300%, compared to income taxes of $0.3&#160;million for the year ended December&#160;31,<i style="font-style:italic;"> </i>2023. The income taxes resulted primarily from the provision for current taxes on income mainly derived from GILTI income mainly in respect of Section&#160;174 of the TCJA. Effective in 2022, Section&#160;174 of the TCJA requires all U.S. companies, for tax purposes, to capitalize and subsequently amortize R&amp;D expenses that fall within the scope of Section 174 over five years for research activities conducted in the United States and over 15 years for research activities conducted outside of the United States rather than deducting such costs in the current year.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;">Year ended December&#160;31, 2023 Compared to the&#160;Year Ended December&#160;31, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">For a discussion of the year ended December&#160;31, 2023 compared to the year ended December&#160;31, 2022, see Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash balances and bank deposits. At December 31, 2024, we had $34.8&#160;million in cash and cash equivalents and short term bank deposits. <span style="color:#212529;background:#ffffff;">In September 2024, we satisfied the outstanding principal and accrued interest under the 2024 Notes with a cash payment of approximately $21.2&#160;million which was available primarily from the withdrawal of short term deposits. </span>We have primarily financed our operations through sales proceeds, equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the year ended December&#160;31, 2024, we raised gross proceeds equal to approximately $3.8&#160;million from the sale, in the aggregate, of 2,216,692 shares of our common stock under our ATM program. All such sales were completed during the quarter ended December&#160;31, 2024. Subsequent to December&#160;31, 2024, we sold, in the aggregate, an additional 1,223,935 shares of common stock under program generating gross proceeds equal to approximately $2.5&#160;million. Such sales completed the ATM program. In addition, since December&#160;31, 2024, we issued 908,000 shares of our common stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately $2.1&#160;million. The warrants expired on March&#160;11, 2025. Accordingly, no warrants remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the year ended December&#160;31, 2023, we raised gross proceeds equal to approximately $24.9&#160;million from the sale of 12,560,150 shares of our common stock under our ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;padding-bottom:10pt;margin:0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">Net cash provided by operations was $8.7&#160;million for the </span>year ended December&#160;31, 2024<span style="color:#212529;">. The net income for the </span>year ended December&#160;31, 2024<span style="color:#212529;"> of $2.9&#160;million was increased by a $0.7&#160;million increase in accounts payable and accruals, a $2.3&#160;million decrease in accounts receivable-trade and other assets, $3.3&#160;million in share-based compensation and $1.3&#160;million in depreciation, partially offset by a $2.2&#160;million increase in inventories.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">Net cash provided by investing activities for the </span>year ended December&#160;31, 2024<span style="color:#212529;"> was $4.2&#160;million and consisted primarily of $20.4&#160;million in proceeds from the sale of deposits partially offset by $15.0&#160;million in bank deposits and a $1.3&#160;million purchase of property and equipment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="color:#212529;">Net cash used in financing activities for the </span>year ended December&#160;31, 2024<span style="color:#212529;"> was $16.8&#160;million representing the $20.4&#160;million payment of the outstanding principal under our 2024 Notes which matured in September 2024, partially offset by $3.6 million </span>from the sale of common stock under our ATM program<span style="color:#212529;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Net cash used in operations was $1.3&#160;million for the year ended December&#160;31, 2023. The net income for the year ended December&#160;31, 2023 of $8.3&#160;million was decreased by a $13.2&#160;million decrease in contracts liability, a $3.1&#160;million increase in deferred tax assets, a $2.2&#160;million increase in inventories, a $0.4&#160;million increase in accounts receivable-trade and other assets and a $0.4&#160;million financial income-net. The net income was increased by a $5.3&#160;million increase in accounts payable and accruals, $3.4&#160;million in share-based compensation and $1.2&#160;million in depreciation. Net cash used in investing activities for the year ended December&#160;31, 2023 was $16.7&#160;million and consisted primarily of net investment in bank deposits. Net cash provided by financing activities was $24.7&#160;million resulting primarily from the sale of common stock under our ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">At </span>December&#160;31, 2024<span style="color:#212529;">, there were warrants to purchase 13,439,712 shares outstanding at an exercise price equal to $2.36 per share. As of March&#160;12, 2025, no warrants remain outstanding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Since our inception, we have incurred significant research and development expenditures which have not been offset by revenues. We have not generated significant revenues from sales of Elelyso, and commercial sales of Elfabrio only </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">commenced in the middle of 2023. W<span style="background:#ffffff;">e have generated operating losses from our continuing operations since our inception although the revenues generated in the years ended December&#160;31, 2023</span><span style="font-family:'28mugxoulnobhnx';"> and 2024 exceeded our expenditures for the same period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">As the 2024 Notes were paid in full during the </span>year ended December&#160;31, <span style="color:#212529;">2024, we are no longer subject to the financial limitations related to such notes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As we increase our research and developments efforts with respect to our current and future product candidates, we expect to continue to incur significant expenditures. We cannot anticipate the costs or the timing of the occurrence of such costs. Although we expect the revenues generated from the sales of Elfabrio and Elelyso will increase, such revenues may not be sufficient to fund the expenditures. To the extent we need to obtain additional financing in excess of such anticipated revenues, it may be difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts and (v) tax payments. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months <span style="color:#212529;">from the date that these financial statements are issued</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s progress in commercializing Elfabrio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through sales of Elfabrio and Elelyso, corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the milestone payments that may become payable under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Contractual obligations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our contractual obligations include operating lease obligations, purchase obligations, certain clinical contracts and the liability for employee rights upon retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We lease certain assets under operating leases, which expire through 2026, with an option to extend the lease on our main facility to 2031. The leases relate primarily to office, laboratory and manufacturing space and vehicles used by our employees. Our aggregate future minimum commitments under these facility and vehicles leases over the next five fiscal years is approximately $2.8&#160;million as of December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2024, we are subject to open purchase orders issued to certain suppliers and other vendors mainly in connection with our research and development and manufacturing activities that were outstanding as of December&#160;31, 2024 for approximately $9.2&#160;million over the next five fiscal years.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have a contractual obligation of approximately $1.5&#160;million as of December&#160;31, 2024 payable over the fiscal year ending December&#160;31, 2025 in connection with contractual arrangements we enter into in the normal course of business with CROs, CMOs and other clinical providers and consultants for clinical trials, preclinical and other research studies and manufacturing services in connection with our primary product development process. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of December&#160;31, 2024, we have a contractual obligation of approximately $0.6&#160;million for employee rights upon retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are also party to certain research and license agreements. If all of the contingencies with respect to milestone payments under our research and license agreements are met, as of December&#160;31, 2024, the aggregate milestone payments payable would be approximately $8.4&#160;million, and would be payable, if at all, as our projects progress over the course of a number of years. The royalty payments payable by our company in connection with sales of each of our product candidates, if any, shall not exceed low, single-digit percentages of net sales of the relevant product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Effects of Currency Fluctuations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services. <span style="background:#ffffff;">Currency fluctuations during the year ended December&#160;31, 2022, resulted in $1.0&#160;million being recognized as financial income.</span> We do not believe currency fluctuations have had a material effect on our results of operations during the years ended December&#160;31, 2023 or 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain recently issued and recently adopted accounting pronouncements are discussed in Note 1(r) of the financial statements included in Item&#160;8 of this Annual Report on Form&#160;10-K.</p><a id="_ff1ef81b_5df4_4436_85eb_78ef4046603c"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Currency Exchange Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and above 50% of our expenses and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Approximately 37% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Average rate for period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.360</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.687</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.519</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.627</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.647</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Interest Rate Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><a id="_679f28d1_ff09_402b_b80b_ae61b15424ba"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">See the <a href="#CONSOLIDATEDFINANCIALSTATEMENTS_TOC"><span style="font-style:normal;font-weight:normal;">Index to Consolidated Financial Statements</span></a> on <a href="#FinancialStatementsTOC"><span style="font-style:normal;font-weight:normal;">Page&#160;F-1</span></a> attached hereto.</p><a id="_79a4a917_a7ef_4d6b_9dc2_43c7e3c57bee"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_7502cbc4_8704_4bd9_af63_0b2ae7c2791f"></a><a id="Item9AControlsandProcedures_730194"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form&#160;10-K. The controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Form&#160;10-K, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The evaluation of our disclosure controls and procedures included a review of the controls&#8217; objectives and design, our implementation of the controls and their effect on the information generated for use in this Annual Report on Form&#160;10-K. This type of evaluation will be performed on a quarterly basis so that the conclusions of management, including the Chief Executive Officer and Chief Financial Officer, concerning the effectiveness of the disclosure controls and procedures can be reported in our periodic reports on Form&#160;10-Q and Form&#160;10-K. The overall goals of these various evaluation activities are to monitor our disclosure controls and procedures, and to modify them as necessary. Our intent is to maintain the disclosure controls and procedures as dynamic systems that change as conditions warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Form&#160;10-K, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information related to our company and our consolidated subsidiaries are made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Management&#8217;s Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S.&#160;generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that: (i)&#160;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">U.S. generally accepted accounting principles, and that receipts and expenditures of our company are being made only in accordance with authorizations of management and our directors; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Management assessed our internal control over financial reporting as of December&#160;31, 2024, the end of our fiscal&#160;year. Management based its assessment on criteria established in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Management&#8217;s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies and our overall control environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on our assessment, management has concluded that our internal control over financial reporting was effective as of the end of the fiscal&#160;year to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles. We reviewed the results of management&#8217;s assessment with the Audit Committee of our Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Inherent Limitations on Effectiveness of Controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Attestation Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Changes in internal controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended December&#160;31, 2024 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_099b58bd_bdc4_4dcf_89de_1068879d55f3"></a><a id="Item9BOtherInformation_882944"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Rule 10b5-1&#160;Trading Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">During the quarter ended December&#160;31, 2024, none of our directors or officers </span><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_3EGI1xrZ2UG4cUPXSCJqAg"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_373Ui9QjbUinLEDlk4zWhA"><span style="background:#ffffff;">adopted</span></ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;"> or </span><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_R-vAV1XYSUGr5xl1C87WqA"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_yWow6AUIuEylao8MmbwkCA"><span style="background:#ffffff;">terminated</span></ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;"> a Rule&#160;</span>10b5-1 <span style="background:#ffffff;">trading arrangement or&#160;</span>non-Rule<span style="background:#ffffff;">&#160;</span>10b5-1<span style="background:#ffffff;">&#160;trading arrangement (as such terms are defined in Item 408 of Regulation&#160;</span>S-K).</p><a id="_4df04f31_e6ec_409f_9ba0_ce17c4717e4c"></a><a id="Item9C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1ac7e1aa_bc2b_4bcd_a993_813d37edf5e6"></a><a id="PARTIII_463758"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information in our 2025 Proxy Statement regarding directors and executive officers appearing under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management &#8212; Section&#160;16(a)&#160;Beneficial Ownership Reporting Compliance&#8221; and &#8220;Election of Directors&#8221; is incorporated by reference in this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">We have&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Narr_2MqWGYIfHEu2wnmG0oCL4g">adopted</ix:nonNumeric><span style="background:#ffffff;">&#160;an insider trading policy governing the purchase, sale, and other disposition of our securities by our directors, officers, and employees, and by our company. We believe this policy is reasonably designed to promote compliance with insider trading laws, rules, and regulations and listing standards applicable to our company. A copy of our insider trading policy is filed as Exhibit&#160;19 to this Annual Report on Form 10-K.</span></p><a id="_b2c4f332_334b_41cf_9547_4b86d5e13d82"></a><a id="Item11ExecutiveCompensation_376320"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information appearing in our&#160;2025 Proxy Statement under the headings &#8220;Director Compensation,&#8221; &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Report of the Compensation Committee,&#8221; and &#8220;Executive Compensation&#8221; is incorporated by reference in this section.</p><a id="_ecbaaf74_0922_438e_a5ae_adf07d6a59aa"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information appearing in our 2025 Proxy Statement under the heading &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; is incorporated by reference in this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_0dcdfe19_a2cf_4e4d_82e2_dc76b5a81e21"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The information appearing in our 2025 Proxy Statement under the headings &#8220;Election of Directors&#8212;Corporate Governance&#8221; and &#8220;&#8212;Certain Relationships and Related Transactions&#8221; is incorporated by reference in this section.</p><a id="_aab3ae2b_defe_4048_81e3_9596f40fb047"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Our independent registered public accounting firm is</span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20241231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> Kesselman&#160;&amp; Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, </span></a>Tel Aviv, Israel, PCAOB ID. No. 1309.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information appearing in our 2025 Proxy Statement under the heading &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; is incorporated by reference in this section.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_7cf576a2_9fc7_45c9_b04d_2b766a67d47d"></a><a id="PARTIV_377623"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">The following documents are filed as part of this Annual Report on Form&#160;10-K:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">1.<i style="font-style:italic;"> Financial Statements.</i> The following Consolidated Financial Statements of Protalix BioTherapeutics,&#160;Inc. are included in Item&#160;8 of this Annual Report on Form&#160;10-K:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:92.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:27.05pt;"><td style="vertical-align:bottom;width:92.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB name: Kesselman &amp; Kesselman C.P.A.s and PCAOB ID: 1309)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_216383"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December&#160;31, 2023 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:92.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the&#160;years ended December&#160;31, 2022, 2023 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCHANGESINCAPITAL"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Stockholders&#8217; Equity (Capital Deficiency) for the&#160;years ended December&#160;31, 2022, 2023 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:92.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_110294"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the&#160;years ended December&#160;31, 2022, 2023 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:92.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:5.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">2. <i style="font-style:italic;">Financial Statement Schedule.</i> Financial statement schedules have been omitted since they are either not required, are not applicable or the required information is shown in the consolidated financial statements or related notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">3. <i style="font-style:italic;">Exhibits.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:7.59%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:32.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;width:47.49%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:7.59%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td colspan="2" style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:32.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.59%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:16.4%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Herewith</b></p></td></tr><tr style="height:23.05pt;"><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1.1</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023002104/plx-20230227xex1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">At the Market Offering Agreement, dated February&#160;27, 2023, between the Company and H.C.&#160;Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">February&#160;27, 2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.59%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:32.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.06%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.59%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.4%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.47%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Def 14A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Appen. A</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Def 14A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Appen. A</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;20, 2019</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.6</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:8.2pt;"><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.7</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837024016505/plx-20241227xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the Company</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31, 2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1&#8224;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2&#8224;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.8</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.9</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.4</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20241231xex4d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000095014407000141/g04822exv10w9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement between Protalix&#160;Ltd. and Angel Science Park (99)&#160;Ltd., dated as of October&#160;28, 2003 as amended on April&#160;18, 2005</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">January&#160;8, 2007</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000095013608001374/file2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Unprotected Lease Agreement</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2008</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Agreement between Protalix&#160;Ltd. and Comercio e Servi&#231;os Ltda. dated June&#160;17, 2013</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;14, 2021</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Technology Transfer and Supply Agreement made as of June&#160;18, 2013 by and between Protalix&#160;Ltd. and Funda&#231;&#227;o Oswaldo Cruz</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;14, 2021</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021007157/plx-20210331xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Binding Term Sheet between Protalix Ltd. and Chiesi Farmaceutici S.p.A.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;14, 2021</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:42.4pt;"><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420415070554/v426600_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Exclusive License and Supply Agreement by and between Pfizer&#160;Inc. and Protalix&#160;Ltd., dated October&#160;12, 2015</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q/A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;11, 2015</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7&#8224;&#8224;</p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418013053/tv486893_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License and Supply Agreement dated as of October&#160;17, 2017, made by and between Protalix&#160;Ltd. and Chiesi Farmaceutici S.p.A.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;6, 2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418057990/tv505296_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive U.S. License and Supply Agreement dated as of July&#160;23, 2018, made by and between Protalix&#160;Ltd. and Chiesi Farmaceutici S.p.A.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">November&#160;7, 2018</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9&#8224;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420419027423/tv522023_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement made effective as of May&#160;20, 2019, by and between Protalix&#160;Ltd. and Mr.&#160;Dror Bashan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">May&#160;21, 2019</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10&#8224;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420419036350/tv526084_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement made effective as of July&#160;28, 2019, by and between Protalix&#160;Ltd. and Mr.&#160;Eyal Rubin</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">July&#160;29, 2019</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11&#8224;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837024009567/plx-20240627xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Pro BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June&#160;28, 2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022017554/plx-20220930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fill/Finish Agreement effective on August 29, 2022 made by and between Chiesi Farmaceutici S.p.A and Protalix Ltd.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">November&#160;14, 2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022017554/plx-20220930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement dated August 29, 2022 from Chiesi Farmaceutici S.p.A to Protalix Ltd.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">November&#160;14, 2022</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20241231xex19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Insider Trading and Blackout Policy</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20241231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20241231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Kesselman&#160;&amp; Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24.1</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#POWER_OF_ATTORNEY"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on the signature page to this Annual Report on Form 10-K)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20241231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rule&#160;13a-14(a)&#160;as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20241231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rule&#160;13a-14(a)&#160;as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20241231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20241231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">97.1</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837024003161/plx-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Policy Relating to Recovery of Erroneously Awarded Compensation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-33357</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">97.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;14, 2024</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL INSTANCE DOCUMENT - the instance document does not appear </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"/></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL SHEMA FILE</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL CALCULATION FILE</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL DEFINITION FILE</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL LABEL FILE</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL PRESENTATION FILE</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 0pt;">&#8224;&#8224;&#160;&#160;&#160;Portions of this exhibit were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment under Rule&#160;24b-2 of the Exchange Act.</p><a id="_b9e04601_ec87_4a97_a056_b4780ec4c9d0"></a><a id="Item16Form10KSummary_450405"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;16.&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_aaba2f64_d49a_400f_8af8_636554089781"></a><a id="SIGNATURES_579077"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, as of March&#160;17, 2025.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:middle;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="POWER_OF_ATTORNEY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dror Bashan and Eyal Rubin, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:44.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:21.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Dror Bashan</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President, Chief Executive Officer</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2025</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Executive Officer) and Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer, Treasurer and</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2025</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Secretary (Principal Financial</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">and Accounting Officer)</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Eliot Richard Forster</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chairman of the Board</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2025</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Eliot Richard Forster, Ph.D.</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Amos Bar Shalev</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2025</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Amos Bar Shalev</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Shmuel Ben Zvi</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2025</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Shmuel Ben Zvi, Ph.D.</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:middle;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Pol F. Boudes</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2025</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pol F. Boudes, M.D.</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Gwen A. Melincoff</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2025</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Gwen A. Melincoff</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;border-bottom:1px solid #000000;margin:0pt;">/s/ Aharon Schwartz</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;17, 2025</p></td></tr><tr><td style="vertical-align:top;width:29.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aharon Schwartz, Ph.D.</p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:44.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f787addb_8400_4e31_8e75_b64fdc69cbf5"></a><a id="FinancialStatementsTOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED FINANCIAL STATEMENTS</p><a id="CONSOLIDATEDFINANCIALSTATEMENTS_TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">TABLE OF CONTENTS</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:7.39%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><b style="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></a><b style="font-weight:bold;"> (PCAOB name: </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:AuditorName" id="Narr_mQcKOPOzX0iXJEvEqbmQgg"><b style="font-weight:bold;">Kesselman &amp; Kesselman C.P.A.s</b></ix:nonNumeric><b style="font-weight:bold;"> and PCAOB ID: </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:AuditorFirmId" id="Narr_rv0QUe_yP0Gw5ji4EBIY6Q"><b style="font-weight:bold;">1309</b></ix:nonNumeric><b style="font-weight:bold;">)</b></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</b></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_216383"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December&#160;31, 2023 and 2024</span></a></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the&#160;years ended December&#160;31, 2022, 2023 and 2024</span></a></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCHANGESINCAPITAL"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Stockholders&#8217; Equity (Capital Deficiency) for the&#160;years ended December&#160;31, 2022, 2023 and 2024</span></a></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:89.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_110294"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the&#160;years ended December&#160;31, 2022, 2023 and 2024</span></a></p></td><td style="vertical-align:top;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:89.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">F-9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:61.8pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_107d5ee7_c7ec_473d_82cf_1eb0598beec1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;"><img src="plx-20241231x10k010.jpg" alt="Graphic" style="display:inline-block;height:61.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:86.4pt;"/></span></p><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">To the Board of Directors and Stockholders of Protalix BioTherapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;">Opinion on the Financial Statements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">We have audited the accompanying consolidated balance sheets of Protalix BioTherapeutics, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders&#8217; equity (capital deficiency) and cash flows for each of the three years in the period ended December&#160;31, 2024, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2024 in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;">Basis for Opinion</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:61.8pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;"><img src="plx-20241231x10k010.jpg" alt="Graphic" style="display:inline-block;height:61.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:86.4pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';font-style:italic;font-weight:bold;">Critical Audit Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-family:'Georgia';">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. We determined there are no critical audit matters.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Kesselman &amp; Kesselman</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Certified Public Accountants (Isr.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">A member of PricewaterhouseCoopers International Limited</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="dei:AuditorLocation" id="Narr_fSayNPTDH0qqeCowewBXRg">Tel Aviv, Israel</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">March&#160;17, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2000.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d60a69a4_bcad_4aaf_92da_1b40ae64a8d8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDBALANCESHEETS_216383"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><a id="_bce056b9_e47a_4043_bece_09f9fd587143"></a><a id="Tc_MEZvZ5o-NU6CA1rUOhvOrw_1_2"></a><a id="Tc_TAbQKVxz00aCTZ9Naq3jyg_2_2"></a><a id="Tc_SdEgXJqsmEeqTRMgdnsKiA_2_5"></a><a id="Tc_lRGbH5Ompkqq--asQn1NSA_3_0"></a><a id="Tc_YZWwqg_yyEmLyYQ3XdvBfg_5_0"></a><a id="Tc_SB1P92ySKEq6vFIMnrMVFQ_6_0"></a><a id="Tc_G3PvT-bDxkSqbOtknUtFPw_6_2"></a><a id="Tc_0ccPn_4lekq1O14GmSciTQ_6_5"></a><a id="Tc_6SAAurmcb0uEV8dTCOmsyQ_7_0"></a><a id="Tc_E7g9-U5zGUqHsjEW1ZcqwA_8_0"></a><a id="Tc_GUPLqLuCiU-ve9j8P5RDww_9_0"></a><a id="Tc_GPvd95UbE0Oas3ZGlU3sbQ_10_0"></a><a id="Tc_TwbQxmoph0uQilV72zqw0w_11_0"></a><a id="Tc_f6Wvniz2SE252AkI5bPjCA_11_2"></a><a id="Tc_jeHtwWxh1Uyblb6b18g0ig_11_5"></a><a id="Tc_YShCwQXM706g74Jzk8zZ1w_13_0"></a><a id="Tc_AqwCUt0sWki7O4AQL0n5xA_14_0"></a><a id="Tc_KS7K9sq4RU-IdLWH4OvxOQ_14_2"></a><a id="Tc_h5v4mptpGkOaJxHNfCMNgQ_14_5"></a><a id="Tc_1kOeLgJPJEe45-mfSkh8KQ_15_0"></a><a id="Tc_pHjQfXugk0uzkNN31BR3wQ_16_0"></a><a id="Tc_JKmbxg8wfUysu_exsrb4sg_17_0"></a><a id="Tc_J-F6cNjOpUOZY2buLXm16w_18_0"></a><a id="Tc_cjU6aIuczU6_0Hk057nZAA_18_2"></a><a id="Tc_TF8eF9McN0-6mOb99im3cQ_18_5"></a><a id="Tc_M-HgVOy5kEqu874N0A-w2A_20_0"></a><a id="Tc_IHQOsuspGk26w_EhVtDlzA_22_0"></a><a id="Tc_lUITrHF9P0ao-NIihm-JGQ_23_0"></a><a id="Tc_T06WdOcexkGxZbCSC9IWlg_24_0"></a><a id="Tc_VfNr-X2XtUm-eURw8XXnMA_24_2"></a><a id="Tc_uHBh2H_qfU6fT41N-gPtbw_24_5"></a><a id="Tc_K2BSabaPSEa5oQM0BZ5PPA_25_0"></a><a id="Tc_VvEWjajO-EK4LCH3BuIkkA_26_0"></a><a id="Tc_kRv2Nu9mCUC0j5T17dRqzw_27_0"></a><a id="Tc_ZtlUHfMRkU6IMJD-T2c_QA_28_0"></a><a id="Tc_rdfZUdb1OECrMuEAe1h3YA_28_2"></a><a id="Tc_qW-_Q89O60mZwCNGiYemwg_28_5"></a><a id="Tc_es-8tGgS4EqbYuX3mED-8A_30_0"></a><a id="Tc_Zqda6IgsvUy8ygClB1FVvQ_31_0"></a><a id="Tc_Me7eW8FK-0m-GcIc45ULZg_31_5"></a><a id="Tc_rKWbQL8L8ECsGFOfI4uP7Q_32_0"></a><a id="Tc_RlwZamR_9Uq0VaiswIwbTw_33_0"></a><a id="Tc_ncjA3vOhZkuWcNrufJE9RQ_33_2"></a><a id="Tc_KOwReid8I066MeuoZpEpcA_33_5"></a><a id="Tc_rdV4i4O_Ck6kyiF6QfhXNA_34_0"></a><a id="Tc_IMTzT0NN3kCHsZUB85qWlA_34_2"></a><a id="Tc_iYqtwqJr0EOI-pNKkd6UOg_34_5"></a><a id="Tc_jpGzdEuI6kWKtnSfOnRY9Q_36_0"></a><a id="Tc_CnSjHggNSUusx6XSDS1SXg_38_0"></a><a id="Tc_AhN0_ZaZOkqkCe2Ujan4Ug_39_0"></a><a id="Tc_H3_vCMhXskS7lxBnM16v8A_40_0"></a><a id="Tc_ukkB4qMp0kKYSv2tGFHo9Q_41_0"></a><a id="Tc_5o44hS4Po0S6KTLjaQLyLg_42_0"></a><a id="Tc_j6Gx48tDZ0KeOjCRTyhu1Q_43_0"></a><a id="Tc_8Hi4yCMio06-PoS6wfZV5A_43_2"></a><a id="Tc_iDPU0-dW5k6ewBDCbdAW0Q_43_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_k6dJ6SyIZkaWZH9qlEgrWQ_6_3">23,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_JXtU0vL2SU2HTcGu9QBZjA_6_6">19,760</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_W8yrBETvqUSSyuGAPHay1g_7_3">20,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_2iK9esA4rEKimi5UciuUZg_7_6">15,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_5tAGbsJRMkuoD69H-9NOtg_8_3">5,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_dCAOjvwXY0e48fApjtUvSA_8_6">2,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_3h5A_WXLUUusL7GqxI8Enw_9_3">1,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_jvq2nFoKDUKO_qeB_0SBng_9_6">1,096</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_gNlwsa222EyOiU4HCwEahA_10_3">19,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_cGUNCxpN_kGichsPS4RzMg_10_6">21,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_HlhXdeOhdUa6wkIB3vlXMw_11_3">69,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_zaGUABYQpkaariU5vajqQw_11_6">60,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_L29TGwyp502M9D3epeMDKQ_14_3">528</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_AqlWb6NtG06vvwyRISFYXA_14_6">462</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_AXphAETmsU-dCT7mI4PBmg_15_3">4,973</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_QVFKApTZ0Ua4-PrOIGJyQA_15_6">4,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_gUf2TTyfz02wabYKYVi19w_16_3">3,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_UHJDBzqpS0CUvlyVEhkMjw_16_6">2,856</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_L-NMsJS_m0SFmu5Xi-qeJw_17_3">5,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_7c_eHjsYfkKpI5BbOVbVrA_17_6">5,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_G7iyqK4S8Uq2hEQbemmIfg_18_3">84,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_AdNvhRmNIEivDArNS8Rwww_18_6">73,417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_LPUbRi1APUOco22bWL31GA_24_3">4,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_k6SYDaM_bk-jmgXLW4e9Dg_24_6">4,533</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_h9MNui-Q-E2RkA88JsIdsQ_25_3">19,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_aZhAF8S7bUSsejhhJkpwxw_25_6">19,588</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_ojjW2D7Q8EaQbl5-G7JwCA_26_3">1,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_g4YDGQVJLEWztpsbVOBAoA_26_6">1,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_22ICVPzHHk-FaaIFUb4SYQ_27_3">20,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_dMBya9PwBESfKGZBPCP-3A_27_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_XYJFg7y-UEGMYBPxnsx0qw_28_3">45,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_aJRrDETbb0GrgvHhoBDUwg_28_6">25,621</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_agU4gqeONEePedfUD9f-vA_31_3">714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_prQJmKAMlEioKGR9RFYxqw_31_6">559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_87o_G_L-9UGOJlpRSRg6XQ_32_3">4,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_K1ctYNOYfkurWrPpKzuvsg_32_6">4,026</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_OGKE205inEOdN2t3_DMNSw_33_3">5,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_Od1ev8rg6Em-9GJiMwnu0A_33_6">4,585</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_S2RnceSVf0eVwcG2iRbWmA_34_3">50,865</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_GdD_gDM4Xki7JSDHT41Yhg_34_6">30,206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Common Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_wq_Jrj4AK02VRSqOJClqXQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_XJZpGPfIhEi9e2jy5gp2ng">0.001</ix:nonFraction></ix:nonFraction> par value: Authorized - as of December 31, 2023 and 2024, <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_wisXODDAiECAuezWPnvVyg"><ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_QQWNFdlgXUGwCEOsvD5Gqw">185,000,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding - as of December 31, 2023 and 2024, <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_bBjE4Xvp50a2NY2cNtSa-A"><ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_eY_bXPk87kaX871Lspzoww">72,952,124</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_zHAYrecgRk-oKpTcV9ehpA"><ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_xHyQWTxs0Uaq9PA1jvxKYQ">75,850,275</ix:nonFraction></ix:nonFraction> shares, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_4ivP4vOoTE6ptCV_OxYHaA_39_3">73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_Zo6M2jOb8UOiS7-Nj9P_yQ_39_6">76</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_7kaOvTxYokq-kC4ibjbWqA_40_3">415,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_5BAYmqBhS0-cHIzZFGMrDg_40_6">421,528</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_wqMQdkCexEOXV_5auXZVHQ_41_3">381,549</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_RyO0tUhed0-WtYaB06qrRA_41_6">378,393</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pNm5Gfr1N0qoQ0T7uCVlow_42_3">33,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pjfvDl5W_0OuGy3WsDL1OA_42_6">43,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities and stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_prWhLcUy2U-rHeoKGTGVpA_43_3">84,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_fKAb-WVkqESEaSaUpfJCJA_43_6">73,417</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2a69915c_b9ea_4ae8_9f1a_5232617ed884"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONS_58886"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(U.S. dollars in thousands, except share and per share amounts)</p><a id="_d91fdb32_c624_4904_87bf_07693d72df8d"></a><a id="Tc_gkqyHsw3EE6lrS15gvh-2Q_2_2"></a><a id="Tc_coWgXJWrWUen1KIqmTYdYA_3_2"></a><a id="Tc_N8m-4Qwtl029mcVYJMIjXg_3_5"></a><a id="Tc_w1VxgNkzJE6JeXLVG2lf4w_3_8"></a><a id="Tc_ik1w6xQxnEeL1xaEjpRB4Q_4_0"></a><a id="Tc_Yx6gqZUCf0et_c0WC1z9tg_4_2"></a><a id="Tc_2qax40nAvk-CHslE2grN7A_4_5"></a><a id="Tc_Nn3q0PQJikmtI_NpiweJyQ_4_8"></a><a id="Tc_oF0JV-22bUC-etIJmCitNQ_5_0"></a><a id="Tc_COe0UCcuB0Ck1hxkoOTUkQ_6_0"></a><a id="Tc_9gXB5geHGESsNhw-O4xsCA_7_0"></a><a id="Tc_td-BiQCnYE2fklrX2S-xJA_8_0"></a><a id="Tc_1DRL5bzAlUCKq0BtQe1a7w_9_0"></a><a id="Tc_iIJ5VnmbR0OfOW0cGil1vw_10_0"></a><a id="Tc_Fgax-DjVpEWBfz5BSiklEg_11_0"></a><a id="Tc_Hu5FcH31c0u_TET9cnjhUg_12_0"></a><a id="Tc_BtaHUL1KDUmZ2-wH0irgPA_13_0"></a><a id="Tc_ixW_8p0BQkK0J-Hu7qLoqQ_14_0"></a><a id="Tc_fd0skDkD9UqxWW1OQtYv_g_15_0"></a><a id="Tc_EoQBhh8BeEC0_oxzygF-1Q_16_0"></a><a id="Tc_oC2joiQ9q0e37Sq6E8jYSw_16_2"></a><a id="Tc_P56Gm6CPQESyTFdXrdF_AQ_16_5"></a><a id="Tc_k_3ZbSl1bEu0sxL5n1TBqw_16_8"></a><a id="Tc_uLmYFUwKBEWRQ3hHQLBjvw_17_0"></a><a id="Tc_gDCeflDxBkui_a2MoT10KQ_18_0"></a><a id="Tc_7Y_CfHRGWE6t_Pb_f0OStA_18_2"></a><a id="Tc_JLYG2AoLC0Omm2FRbLPa8g_18_5"></a><a id="Tc_jULUoC2JwEytns27ptlPLA_18_8"></a><a id="Tc_TzRDbqUfvEmX4NvJmFyUcw_19_0"></a><a id="Tc_mxHL-ENHXE2sPPFKbsO4Ow_19_2"></a><a id="Tc_A7MF3vMygkuX_PDGNCpzVg_19_5"></a><a id="Tc_eEbLFzeu40Cf_vDB6T8wLA_19_8"></a><a id="Tc_vHITcSXaf0qtq1xaidZl7A_20_0"></a><a id="Tc_XSW-aqpt10C9dj06wAc5kw_21_0"></a><a id="Tc_Mc37CS14sECBZBfVCrMGzw_22_0"></a><a id="Tc_Dk7CR4AEv0ycSEGXYy_Kpg_23_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_PQ5mf5BQdkWUxiMCts1pFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_yuNYm6Ey8k69BKNuWYBy2A_4_3">25,292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_aKTCTOwnPkytYKKR5g2_wA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_nOT8YAMMt0GTZ7lJd6IMOA_4_6">40,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_HHFZ61393UWe4ugtQPzFMg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_3Ed7cVFKvkigWjt3oEGZtw_4_9">52,981</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_w4HPugC1VEGsdplZft_5fQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_OTLRAJhfgE6Jj4Mm2C3w4w_5_3">22,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_n_xrcTEwnEeMZJ4ZcUw8eA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_360hnqnojES769Iq0njwTg_5_6">25,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kRf1Vl0L_E68nTZynfgMNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_x7NISuqc40O1FnVNWbEC3g_5_9">418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_dDn3psVOHEebdVEd2foJ6g_6_3">47,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_GhBbruk_M0-VyMYadZAQBw_6_6">65,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_F-YshA_p9k-pOZH-sKOilA_6_9">53,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_qWi6pqgt2kqtEUnOHlNRFg_7_3">19,592</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_pGP6wrCU-0-w8FWiuGbtdQ_7_6">22,982</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_XltKa-9EYk2llYyAymVtPg_7_9">24,319</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_1c2YCLgxR0qq3F0vDMaWCA_8_3">29,349</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_SO0xp7KGOECRg55Zc01r7g_8_6">17,093</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_8VujawQNKUquO_4v0Ncc_g_8_9">12,970</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_6hrXMKTPXkKkeVqMEljvZA_9_3">11,711</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_FVjU67L7aEOe9bLL-p23jw_9_6">14,959</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_-8b0nTLdbUGwQiJfsLVVfQ_9_9">12,193</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_vhIuUyoaWUOJ3_15DKRn7A_10_3">13,014</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_JiXHJwkBNU2sad6CmCXzNA_10_6">10,460</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_h7HHI4BFoEKaSfa8IxjuAg_10_9">3,917</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_PHfaR9WKF0uGnSs45rA4hQ_11_3">2,529</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_qG2UHihHaU2EyURj0GqrQQ_11_6">3,180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_HgMxIAQPuE2jzYEFoLOUjg_11_9">1,062</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_S1vv_UdvE0G02DHCuBda0w_12_3">1,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_Hgi8_PANWUyoIWE0j-4rNg_12_6">1,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_t1bIKUX4VkS2jv0FxHMabA_12_9">1,299</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME (EXPENSES), NET</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_7-hHtGKaJUKxVWCwh9DdGQ_13_3">1,383</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_v9C9Xkyd3EG16Z5HhilFZg_13_6">1,894</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_kHbWiwhbS0qVjN-XoKuBKg_13_9">237</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INCOME (LOSS) BEFORE TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_-opybQeaCEaV8sPzZvJx6Q_14_3">14,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_kUs-bUzDfkCKjE0QKnMDcQ_14_6">8,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_JWSkOKf7lkKYdyH4BDHKpQ_14_9">4,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_pSusXthfCkOB5b4b8rooPA_15_3">530</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_aq4uc_EFtUqnxk5Dg91ltQ_15_6">254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_rrIzWHVEb0qiLGiGkuQc2Q_15_9">1,222</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FovWBzWf70W-LF41jvMCfA_16_3">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_UQ7kVcqLekq_NvGmW7Bxcg_16_6">8,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_YoD0ci6LTEaydhWCEWm6DA_16_9">2,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EARNINGS (LOSS) PER SHARE OF COMMON STOCK:</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BASIC</b></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_hQXgxfzKwEWL-dqt_CGidg_18_3">0.31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_sj7rOuGnB0akKO327uOUhQ_18_6">0.12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_2IomFPku3k29LiYX0wFyOw_18_9">0.04</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DILUTED</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_uIzGGifFsUGi1vVU9S7Q0g_19_3">0.31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_TqukFEwPWEWVLdPIax7_0A_19_6">0.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_YEqiWQehv0KTcLa811rI-A_19_9">0.04</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING EARNINGS (LOSS) PER SHARE:</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BASIC</b></p></td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_hz59tYKX-Euf7N3Ks_v51A_22_3">48,472,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_WLx5PaGbR0mXC4wdQawiLw_22_6">67,512,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_I99KPELNgUCx0wEvwE_wgg_22_9">72,530,698</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">DILUTED</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_AVVOY9wbIES3Nh5Jnxs7dw_23_3">48,472,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_kmz2GqGad0i2TXDk6FolqQ_23_6">82,424,016</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_fBhu69xggkCghE2FgjLmng_23_9">81,057,176</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e665b73f_e19a_4d09_a551_f20537516b8f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCHANGESINCAPITAL"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY<br/>(CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(U.S. dollars in thousands)</p><a id="_8855922c_9f36_478f_8bf1_33e13ceb6cc0"></a><a id="Tc_DfInGr4-5U6jW17bktFK4g_1_7"></a><a id="Tc_BHvBi8RxYECfFHKgh0kAbg_2_2"></a><a id="Tc_Bwhh6pn0nkm7k4TP_uqKMg_2_4"></a><a id="Tc_QaPjaDlRpEeN6IEUzAHPqA_2_7"></a><a id="Tc_rW3RLg89UUmGsRX79TY91g_2_10"></a><a id="Tc_wvX0LyuSdkabYePX2x2DaQ_3_2"></a><a id="Tc_6mXZQEJEkk-ZmjlHF5RTOA_3_4"></a><a id="Tc_e398QgaJY0KZEZ4onnA_cA_3_7"></a><a id="Tc_RVpW4sxX2EGWtOB7F8kIJw_3_10"></a><a id="Tc_QJePqi77PU2DCVksjMvmCg_3_13"></a><a id="Tc_eyx6qffHfU2dS3lwWX7hFA_4_2"></a><a id="Tc_ZkYRb98mbUm-Zaqbtn5tBA_5_2"></a><a id="Tc_OyOf-H7YIkWLeEWQy-Ox4w_5_4"></a><a id="Tc_rvRmbvM3qUSSTY8mKI-KKg_6_0"></a><a id="Tc_c9w4Ui_rYE-ur3VDSozmJg_6_4"></a><a id="Tc_pbsI4ZTtFEeWaPiYK5MNOQ_6_7"></a><a id="Tc_xwDJmc9Y7022GPEcPXXR0g_6_10"></a><a id="Tc_Z0Nxzx6dXkC7vXuDPfCg8g_6_13"></a><a id="Tc_Vg6N7kuoME6zomm6vYJjuA_7_0"></a><a id="Tc_AI9jjiBN0kKt8XjCcufvVw_8_0"></a><a id="Tc_nXmINy1_xEStYMB_BhIfIA_9_0"></a><a id="Tc_22rxh3RflECgx0kU2zfKkA_10_0"></a><a id="Tc_GJepdx9qwEKkTS20RsTS3w_11_0"></a><a id="Tc__A7Wl6mOakO7PSRFFPZYXA_11_5"></a><a id="Tc_a1etagFLFEy5zQ4XMlix0A_12_0"></a><a id="Tc_se2VlVFt8kq2pjYbAgCYPA_13_0"></a><a id="Tc_wb6Rfl5OlkunDcfK5R-81A_13_4"></a><a id="Tc_bEQi57WRhEOktEFFtKUtQw_13_7"></a><a id="Tc_r8ORVSlWJkW8ktQkQxFK7A_13_10"></a><a id="Tc_aK1Ox6ijj0COgFe4RlSdoQ_13_13"></a><a id="Tc_0E7IB5-L9UalnIQK6wzaCg_14_0"></a><a id="Tc_q_bQZ-9Bw0aIVNBoaQ7CnQ_15_0"></a><a id="Tc_EkCSQZ0w-kG_0ZdH9PPngg_16_0"></a><a id="Tc_ALGW1IqNNUa13-j9iOdptw_17_0"></a><a id="Tc_3Z9gBGeYj0esL0NWVRYC0A_18_0"></a><a id="Tc_9F0HlPrbtUipuChR2KOYQw_19_0"></a><a id="Tc_5bBEmU2LcUOfM3Ym370Lhg_19_5"></a><a id="Tc_-2dhFWJQV0qk-t-h_qM7KA_20_0"></a><a id="Tc_1h74UQJJaU-dV50WYJwo0Q_21_0"></a><a id="Tc__1Pmjl0_gEGF-bBmdGFZ8A_21_4"></a><a id="Tc_Cl0mx9M4gUafALDDPGdsJA_21_7"></a><a id="Tc_8l2y-hiV50-jVNwoJeqDXA_21_10"></a><a id="Tc_wa_GYOBBA02fh5lHBd9DCA_21_13"></a><a id="Tc_H3mB0bqBG0i3OcW84xUGIw_22_0"></a><a id="Tc_gPMmX2B5x0OAcjdO2DU6XA_23_0"></a><a id="Tc_Y0fS1eSav0OL_nPu2S9dSw_24_0"></a><a id="Tc_lggo2TpHOU-oArFHwiM1aA_25_0"></a><a id="Tc_-t_-YOmIY0Sl5JiKEg6pAQ_26_0"></a><a id="Tc_iF_MHO-WC0-3A8ChlzMf9Q_27_0"></a><a id="Tc_ylFmFpp9Pkmt121wHUxj0A_28_0"></a><a id="Tc_zY3Ha4r1s06ZLT60h5z2og_28_4"></a><a id="Tc_W97fb2PVPE20nTRm7hLfJg_28_7"></a><a id="Tc_G0TgLIRGOUqt6JkbGWVwcg_28_10"></a><a id="Tc_ZypOGZVtlEOLggGklWg2UQ_28_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid&#8211;In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XM4auoMc-kObwGUUo2NaKA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_IaWeMujPfE2Sw-6sNdmVBw_6_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XM4auoMc-kObwGUUo2NaKA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VmfTpKrE5UCAcc78kaDDXA_6_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EW66xBjMwEq-SZFSEjjsxQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dtj1FkYdsUGPvOL4cGDKlg_6_8">368,852</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZsUy5BXARUihXhlGt1WP2A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_wTWeFcsPzEygFLuvH26d4A_6_11">374,934</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2021_cq9GoAKDi0yCbmzEVhRxUA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ZfjEiXoYyki63y0Bci6DLQ_6_14">6,036</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during 2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_AudZYNBsAU6Hs1BvEjvLNg_8_2">7,473,038</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_N6GyK8oYMUmowuz8kfvIlQ_8_5">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V2vZho8vMUyXxBTZzlyMew" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_IjuzLIa7sEGKoNG098_lVQ_8_8">8,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_aM4SuAJJ70Kl3VqL73IpoA_8_14">8,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V2vZho8vMUyXxBTZzlyMew" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_L3xqLScWPk2iIm7Ga3dnbw_9_8">1,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_RLBD192p6EGK5MpTVTp9Ag_9_14">1,124</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock award</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_d8qP4ARUA0GDJ1Ftxjouqg_10_2">759,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_6T7c1NkasEuauS2aoVFBjA_10_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V2vZho8vMUyXxBTZzlyMew" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_BiDKLsS9gE6f9luclFMnWQ_10_8">960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_7FBSlHY7tkiw2sCNYw1cgw_10_14">961</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_GgCK3i0ALUqfaXahtKIKzw_11_2">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V2vZho8vMUyXxBTZzlyMew" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_yVQIUVGAJkyWZ-az2Z-p_w_11_8">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_E7RoCRWbtkmY_pLLNyIlSQ_11_14">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kNcYnNqxkGT0wOZlcwh9g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_eWgsktxEE0W_iql5TZm0eA_12_11">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VFSI79Rc8U-uQpIquHG97Q_12_14">14,927</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LNkKeGiGJ0aS5KHtRlDVsQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_PzrsW4H5rk66xUgZ-vTkOw_13_2">53,790,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LNkKeGiGJ0aS5KHtRlDVsQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_rywY86a0w0mKj4McLz6pBQ_13_5">54</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K7icX2z7sk6vRpP988YnpQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wCgH3aFWQ0GBbSLqFuO61Q_13_8">379,167</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CuQDsyAkjESynmczRevI1w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_RWEWKwQxHkOYj-T7eiZGXA_13_11">389,861</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_KgXHs9dqs0iX6Sm-LHJfzw_13_14">10,640</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during 2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_RaxKwwP44EGhWY9zgnVt5w_15_2">12,560,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_2sbJtUzWNUGqInOftPwzDw_15_5">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_HctF7tnFxUaf0BuKsZAsjg_15_8">23,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_I25AzgMj0EqaYpax7lVU0A_15_14">23,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_Qt9P5a1hwUCP0kq0ohFFuw_16_2">4,691,623</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_jDm-SVmY8kKxlNaptZ1jTg_16_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_7yFVthNarEaQ6J5gNTvg3Q_16_8">7,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_lR29W7cfaUWr3CqoJrIr5w_16_14">7,783</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_tnjvDQzGjkGm6NmGuY1ZUw_17_8">1,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ctZRsSKrzkG_r0fh9h7LWg_17_14">1,928</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock award</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_gTVJD3YijEq3kJLePZySRA_18_2">1,371,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_GPJxCLrDMUCzJmiRw6L5hw_18_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_zB6Z2HYT8k2pT62AN_YVDg_18_8">1,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_5qg9l6XSpkyjq6zy9axHoQ_18_14">1,520</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_VVFY4k7Z3UyQPEM8uVixIA_19_2">538,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_rHl2ge-rBUaAxSeKpYO5IQ_19_8">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_733kZL_vN0q5eAY-m1nR0g_19_14">712</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DsGA_yFdAkGbxa6Ly0IBzQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_MWjoWNjC_kiWhXuS6TN4ZQ_20_11">8,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_P3PPswOACEi2lGvC-x4yQQ_20_14">8,312</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cPolotLkAUmM_tlTQRrk2Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc__LKvqMY1ikWXB_lChoFnPQ_21_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cPolotLkAUmM_tlTQRrk2Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bdOur1ixsEiAWfmyCHcC6A_21_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Bw-Z_-dW70-nqHUT020dcA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__koTryl_BkWpWnde84llMw_21_8">415,045</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d0KQCrBldECa1kWPtwiqWA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_P0DxYTcdZE2-90xFRAxFAg_21_11">381,549</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_S2_BEx0LtEu044f3KReUSA_21_14">33,569</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during 2024:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Initial adoption of ASU 2020-06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NcdWC0f2eUqpjFaF4c8VHg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_HywJyLadB0uFz7_D4sHNCg_23_8">393</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hOOB-4g72kSTGYF-6-8tow" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Yio4Zo4sw06W33geLwRewQ_23_11">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CoqAPYNvE0GJxaaTTSDOFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_IwiOVs6cN0-54SkeECIAFA_23_14">169</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KwnYvQGzMUeyVPAkAtMuPg" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_T__AfSlGSkyjQgL7FvXLgw_24_2">2,216,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KwnYvQGzMUeyVPAkAtMuPg" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_7fFArYrpNUSsQH9PgrMOWw_24_5">2</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vWRZ9XKCTka09Mlcs7e8PQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_BjJykerJ1Um8emUUpsVREg_24_8">3,624</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_0UfR15sDXEOOc4Uzl8ch6Q_24_14">3,626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vWRZ9XKCTka09Mlcs7e8PQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_is0DsEKGQESuioEEo1Pf6A_25_8">1,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_MlSpsOuixkO1BMFdYb0Q_w_25_14">1,593</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock award</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KwnYvQGzMUeyVPAkAtMuPg" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_Igq2CQvO0UOipmBrSMA7eA_26_2">681,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KwnYvQGzMUeyVPAkAtMuPg" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_r2IT87G4U0CHmqIqsMspGQ_26_5">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vWRZ9XKCTka09Mlcs7e8PQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_JWVibX_m80WGx8rmQD-HpA_26_8">1,659</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_Mu7d_7i3KU69khxI8tXM_Q_26_14">1,660</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fg1EWGDGnkyt0zoxUAK0Gw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_dgaPvpd4TEib3XeL-DQLXQ_27_11">2,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_A5D0xCMnn0euMSz9geXFPQ_27_14">2,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lgph02zA8EqaEK0ln7pqLw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_2drl4s5kn0uueohhx-67Iw_28_2">75,850,275</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lgph02zA8EqaEK0ln7pqLw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jGyUXffCNU2izwca765xYg_28_5">76</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_s7t7THOam0ugmJppb04uiA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KZo56igth0me6HgMfYfrRA_28_8">421,528</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zf_c8EYvN0-ChWXNMhtT7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ANXYqsYmdUCzPt36KGGw_g_28_11">378,393</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_JdNbP0Bz-Ei0n95IpIN5oA_28_14">43,211</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a430c62c_46d2_4eb1_8351_16509f57979b"></a><a id="_f039d4ba_6379_4a08_90ba_4461bd382d48"></a><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Represents an amount less than $1.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5100223d_bdc8_4518_a2ae_a7472011b136"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_110294"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(U.S. dollars in thousands)</p><a id="_15df2cb2_a76a_406b_bdeb_65c569f49b2b"></a><a id="Tc_yzb9_E2SOkWVvDq9YOZgig_1_2"></a><a id="Tc_fWvWcRP2YUyw6L6uK9m4qg_2_2"></a><a id="Tc_KsZyHDg2lkemFsEuUIQ5lw_2_5"></a><a id="Tc_TqG0avbS9UadF3cGpydztQ_2_8"></a><a id="Tc_JMbd0udoWEiNX0wLJpJDPA_3_0"></a><a id="Tc_VaXPJCNAmUaPz7JzZniMQA_4_0"></a><a id="Tc_mMaLKoq1FkK8gAdXWGG63w_4_2"></a><a id="Tc_-9ozxkDnq0KFRn8yNCL_zQ_4_5"></a><a id="Tc_L-Z3EPXjJU2-ZavzeAEAOw_4_8"></a><a id="Tc_1IoEQomAWkOMAcw8YLqKCw_5_0"></a><a id="Tc_oB3aWTUos0qH2CXe9f-BNw_6_0"></a><a id="Tc_Q6QgJN_IlEWRpmb51pMY0g_7_0"></a><a id="Tc_qIrknNWetk2zw37EJl3h5w_8_0"></a><a id="Tc_6q4flSKnmkOJeV_S2vBp3g_9_0"></a><a id="Tc_gIqKvIkM00yhiW4rDbJoqQ_10_0"></a><a id="Tc_uJNfMDDiv0-I35R9yNZTKg_11_0"></a><a id="Tc_a4afJsW85UKrdMCFPeEHsA_12_0"></a><a id="Tc_gnU4kgjSxEya0mx-cpoF0Q_13_0"></a><a id="Tc_aO-P5C6KS0WQpGL0dHB8mw_14_0"></a><a id="Tc_ARDyAwcRNU66qahw0t5bkQ_15_0"></a><a id="Tc_l1UPh1bbDEKkif74TfYysA_16_0"></a><a id="Tc_taqUZ8_WJEiEsvA9-qu_Yg_17_0"></a><a id="Tc_wdV7xWDLp0mdFApKjZ8n3A_18_0"></a><a id="Tc_G9Tbk7ephUixRKgfUMX_sQ_19_0"></a><a id="Tc_heySanue00udbLbYm0SoOQ_20_0"></a><a id="Tc_hW_V05YqFE6lZTTWfxr0kg_21_0"></a><a id="Tc_r7Cecmlc3kicQhdQs_FdXw_21_2"></a><a id="Tc_pl48UbG6NkaoyZY-zfRmgg_21_5"></a><a id="Tc_B468_rQZp0uC9snRhbKaiQ_21_8"></a><a id="Tc_LbwpwHw0O0STPt10gscBAA_23_0"></a><a id="Tc_RlmTO2U8cEKaBkVywOurJg_24_0"></a><a id="Tc_pbWOUInqTk6y5WUSkEjCIw_24_2"></a><a id="Tc_zu2Mg4mE3EW6dNyjB9O9LA_24_5"></a><a id="Tc_yJVLCOREl0mP7DSTvKP8VA_24_8"></a><a id="Tc_rnCXd_GkPE6T2gq3TpSZYA_25_0"></a><a id="Tc_0KqBvTzi3kihMXCb_7buQw_26_0"></a><a id="Tc_XHeSLiYk3kap6OUiyXGbRQ_27_0"></a><a id="Tc_k7xk0Z7mf0SOzOIceiT1gg_28_0"></a><a id="Tc_9MHKWWCiQ0G3kNcLvb4OIA_29_0"></a><a id="Tc_Z5EwGwPjqUmKnwwhD1Y4kg_29_2"></a><a id="Tc_v2FYY32Y1kWrraPCjGqjgw_29_5"></a><a id="Tc_0IvbG0KAhECCtK2To0_8BQ_29_8"></a><a id="Tc_t3UrVzO36UC9FSHhKR-gAw_31_0"></a><a id="Tc_-4IYidQc10mBKvmSQdEyrg_32_0"></a><a id="Tc_wWSn31Ed2U-_JRz3C6UMLw_32_2"></a><a id="Tc_b1jZ8o40cEKFuKdsy5nPlA_32_5"></a><a id="Tc_Ipoy69EkEkyV6FPpg4eY0g_32_8"></a><a id="Tc_SZoQ4x9mDkee6n1QHMr-Ag_33_0"></a><a id="Tc_VMcg4wdfRkqgFioqVq2e-Q_34_0"></a><a id="Tc_O3Iro2n2qEOOpGzfL7BkVQ_35_0"></a><a id="Tc_QhmM1s8Zd0qVP9qSj0RoCQ_35_2"></a><a id="Tc_ZYhsHKbTqUWxQ3oJPfRAyg_35_5"></a><a id="Tc_si9Vd15bdUigR6kI-M9Vvg_35_8"></a><a id="Tc_eWQuwTFXYEaUMOmgPUFI5Q_36_0"></a><a id="Tc_FgCZskpXsEq95XzfMUmbkA_36_2"></a><a id="Tc_P1T6kc0ngk-L_yXmquF74g_36_5"></a><a id="Tc_DG79wukcQUq2QnwYEy1zgg_36_8"></a><a id="Tc_-2GDyyRSl0ihq_X1OO7U6Q_37_0"></a><a id="Tc_Are4IavP9UWWXHbZaL-gtw_38_0"></a><a id="Tc_IrsikGQ9502cFtf0CMEdHg_39_0"></a><a id="Tc_VEcHlribs0ubTDu6sMNzNw_39_2"></a><a id="Tc_5TiTEvpHGEqtCBLLEZns3A_39_5"></a><a id="Tc_qmknWMOgL0C5OcU-Of86Mg_39_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Yf-QvjJoBECQ_JfeeaGq6w_4_3">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_6f-7Rlcm7kOPC-8qVjQEFg_4_6">8,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_XhC3W2mzq0uVWig3d8AHNA_4_9">2,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net income (loss) to net cash provided by (used in) operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_nopp3CScrka6_FHSAIYoJg_6_3">2,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_6LndqmL6cUKSryFCZZrW1Q_6_6">3,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_STBROjtoRkCgHT1hXUoC9Q_6_9">3,253</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_RBEjEqYy30KWHv5Fecfv3A_7_3">1,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_sZzcA8UtO0yJ7aRr9tqyag_7_6">1,191</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_-S8gCznnukaRgAIQCIZWJw_7_9">1,304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_zF_u3zLTkU2G9bMz9QkLDg_8_3">989</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_HDnI0jtDEEO6ekqJmngLjQ_8_6">446</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_285inWS9CE-0wTCAAmas4Q_8_9">310</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_gtSQF2dwi0KMT9YsQmUJGA_9_3">543</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_ePiOppWMNkOdg5zFUSVBAw_9_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_LpdCf89zBkqcvmba2cy01g_9_9">151</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_PiOrFN9ppESiGNKpHKhqbQ_10_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_GwZvcdaEk068cLJJZF4TEQ_10_6">3,092</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_Mj6CzYsuH02cmHFu88rF0g_10_9">236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc_otPTPydIQEO3fSerkFVBdg_11_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_Rw1z4py9UkGEMi9fYPt6Gw_11_6">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_YNp95NYto0qFzjklW_kpyA_11_9">18</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_yQ9MqSsraUSW__eBMvF_mA_12_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_mJsJQyIEA0mBa_hZVY4jeA_12_6">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_oILfBfU_8Uy2YO_g6W_XFA_12_9">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on conversions of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:fixed-zero" name="plx:GainLossOnDebtConversion" scale="3" id="Tc_hPEd1uBNJ0GiFQDmFV926w_13_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:GainLossOnDebtConversion" scale="3" id="Tc_a3e0ziqKokS1SVw9aMlL9g_13_6">421</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:fixed-zero" name="plx:GainLossOnDebtConversion" scale="3" id="Tc_W8N_QWCnfUu_-NqNC84kIA_13_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_XnGV6bL54ECWtoH5GwVwgQ_14_3">300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_GyGO6UZpB0qG5U2X86iVTw_14_6">267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_zFgy6BWYoEWPJy62iXunWA_14_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_cg43MBdSWkSCNEiC-syZuQ_16_3">7,162</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_NA4kU7Bv9EG1nh_bOUm4_g_16_6">13,178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_x1HQZG6lNEuhKT6BlkaUMQ_16_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in accounts receivable-trade and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_BeC0KYG4EkaSyS7eIHDUtQ_17_3">1,194</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_Z2w6mvfDnEqlgu2OLvV18Q_17_6">428</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_F0lQ1N9v_0OmzWT8rQNeaA_17_9">2,317</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating lease right of use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_SPHHBuPDe0q17z3yYVsaeA_18_3">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc__ZgkjLRlQUikYjR4-Y_dBw_18_6">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_B1qqfccjk0K9MP8pky5siw_18_9">4</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_6-nUCWdsoUiMxGhW-Z-MKQ_19_3">1,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_szvE47ExCUO_QP9vo3gz6Q_19_6">2,241</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_abOTaC-W5066nkhENoT7SQ_19_9">2,198</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_ItE4fasg6kSaDE_4uTphQQ_20_3">4,804</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_llnCCHqBJkaBAC-uQRBLmg_20_6">5,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_BIpBAmmQkEG4MJlFrXaL3A_20_9">696</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_-XMsmSpozEy7AFODEEk36A_21_3">25,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_5akfTGsaxkaT5LZgj8CF1g_21_6">1,318</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_-jn8SrhFKUGhk0TSl34RtQ_21_9">8,674</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Investment in bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_LW3FW08ikUG6DyzX3luy9w_24_3">16,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_NKqryKyq306sR__aA5DrDw_24_6">20,420</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_ve3ogmbcxkmHHI6Ls7a54g_24_9">15,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term deposit withdrawal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ProceedsFromWithdrawalOfShortTermDeposits" scale="3" id="Tc_INS_1eo2nES6JIEEK3MPEg_25_3">11,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ProceedsFromWithdrawalOfShortTermDeposits" scale="3" id="Tc_WBrHNEvD3kGD90WPkIB3Dw_25_6">5,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ProceedsFromWithdrawalOfShortTermDeposits" scale="3" id="Tc_-_d6gWKHw0Gas-Pttr5kKA_25_9">20,420</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_fwapVL5tW0ux7nBEsUX9cw_26_3">628</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_6XA5JDw4T0q06KpHL3MvXA_26_6">1,149</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_V4bhnsYrK0KUeuZKoZlFYQ_26_9">1,282</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_dbPjgjLF0UOTJBOqyyD6ww_27_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_fI-LOgErYEq_HIrctldLMw_27_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_rK4nkAHOuEywK4IzwHevgw_27_9">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts paid (funded) in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_FsfCIIGOUE6cXkpqz-w4og_28_3">593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_W-Y29NQNZkCciRV-VHvh6A_28_6">142</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_YiYlfpYp0k-WbMDr_027MA_28_9">80</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_T39tvwtjt02dvZwrXwymGA_29_3">5,035</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_15EVq2048k68hKjfFYqORw_29_6">16,711</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_BrOtUd3I7EKrMxNqxIQ5EA_29_9">4,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Payment for convertible notes redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_q4JITGjdtkez5cZ6HqP93Q_32_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_C_TCCKpkhUawHpjDysg4Zw_32_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_ghW3tW7xXEm3FO9ROybVdw_32_9">20,420</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_qIA5DhkwdUeDPO9WFgRNxA_33_3">8,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_ZFpq86V2gE-efZ75dQlqfw_33_6">23,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_ELUCxNWBqkSS76fENpVjRQ_33_9">3,626</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_F_IhESPiUkW4h9IKvXC8_g_34_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_b5zq48s0e0eN5WelMxLZqA_34_6">712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_SFQueqICy0O1Yp6RZHsJmQ_34_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Z1GRKLCdkk-qC3QKTEgAPQ_35_3">8,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_tBpTzEcHT02v7R5Fr171lg_35_6">24,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_OGBiwkzbNECytn6IW8V8mw_35_9">16,794</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_uXszRyW5EUGLQnvWxbfJoA_36_3">77</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_m-D6QFkSJ0S28Xd2eDwq2Q_36_6">114</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_k-vk8OOTXkmOApdUM_EdYg_36_9">25</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_I68mnB81KEuzDgCmTr6ZrA_37_3">21,874</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_O1vdKw5IAk2VMtx8nnoWXw_37_6">6,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_2awtuwzjMUKwWZ0gphR1ZA_37_9">3,874</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2021_cq9GoAKDi0yCbmzEVhRxUA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_I1McGp8_FkCNMZpjflyUzg_38_3">38,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ood_CGaphkOsIfAw-7aaMQ_38_6">17,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_3MXhuIuqV0eWnKpeQIMI2A_38_9">23,634</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_9TgdAHXEiEGDIfWnB-UbTQ_39_3">17,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_OOrE7BMC-kiJrOfc68BBJA_39_6">23,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Rq5eaOukQU2ZCz7r0jKYiw_39_9">19,760</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:36.9pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS </b>(CONTINUED)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(U.S. dollars in thousands)</p><a id="_ceb6d648_2733_42c0_a9c0_4f88182ebfa7"></a><a id="Tc_lWXuakK_4kCAcfqTCxhDEg_1_2"></a><a id="Tc_QhCHpZj0u06F_RnsuLXk9g_2_2"></a><a id="Tc_00ZmgiJWrk6AmITHXwYKDA_2_5"></a><a id="Tc_AmpCqwsi50qWMMPPt3QXiw_2_8"></a><a id="Tc_Xc20Cwg6S0-a_Xk6COAh_A_3_0"></a><a id="Tc_qG2OGbsVbUSG4VD5HAuIfg_4_0"></a><a id="Tc_G2tu74Ao9EqjdVsemHNErw_4_2"></a><a id="Tc_m_ViG3W9WkyzXdn_yUNkrA_4_5"></a><a id="Tc_rn3SlX4pJ0SR5riVDp2FiA_4_8"></a><a id="Tc_VXEa2MrZHUudI4_3PBDz1Q_5_0"></a><a id="Tc_BtcWRIe3zEaX3lZb7sBGdA_5_2"></a><a id="Tc_VU03Zz9VIEe0tgGPqaskCw_5_5"></a><a id="Tc_4ZGEChdLQ0u5eZZZNadaMA_5_8"></a><a id="Tc_Pc5SpBYb2UaNSgN8z354NA_6_0"></a><a id="Tc_Yx1mu_TlI0-h2N5TcZvXOw_6_2"></a><a id="Tc_izDQNa0y8k-s-eo3-hI_vQ_6_3"></a><a id="Tc_oV2N4TONnkaE50p2R4GMjg_6_5"></a><a id="Tc_aWhaOdBnoUSJejRTaX-efw_6_8"></a><a id="Tc_NW9xbffgnUiSh4HVG416jw_7_0"></a><a id="Tc_d5gtdzlH1UKBNhr109LxXA_7_2"></a><a id="Tc_5wfqH0MCd0W3afYq67FTwQ_7_3"></a><a id="Tc_3iSj7LcgSE-lolkTrZptcg_7_5"></a><a id="Tc_vNw1ETz2IUqNXFenrEfaZA_7_8"></a><a id="Tc_mFfOCCseE06LPgIZk6ANDg_9_0"></a><a id="Tc_Prl_TsigN02H8img5lQWRA_10_0"></a><a id="Tc_Ssn82I4eAU68pqg5owE7LA_10_2"></a><a id="Tc_SeWveH0DEE2PLl4nAgjx-g_10_3"></a><a id="Tc_NkNSrcf2NUaYkZ5pMRYVLQ_10_5"></a><a id="Tc_YBZ93Y2fzE6v5joxzmbI-g_10_6"></a><a id="Tc__oEGXrYyeEq6weJ0OcTrbQ_10_8"></a><a id="Tc_fHXdWqVvL0KKfTKFE0w-PQ_11_0"></a><a id="Tc_vjDQGXBRSUOWq3pakYPjXg_11_2"></a><a id="Tc_vIPmVYTflUiZng7giYKonA_11_5"></a><a id="Tc_UJGtZDIQ80qZ2svGEG4ibA_11_8"></a><a id="Tc_sRPneJeO0UeSC8QT4DuSzA_12_0"></a><a id="Tc_TS4aFgRjOUe0OpuOPqsyXw_12_2"></a><a id="Tc_RmtnRPMaJUm06Bzqxnghrw_12_5"></a><a id="Tc_4D1_cgxJpEG7bx1hnwvkRA_12_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_fFTpyfjAK0OBU5ygIBdJ7A_4_3">143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_l53MplPmCEC4cBIbRZtp_g_4_6">614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_EozSKGNOa0mcEi8PI111LA_4_9">254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_QT2g8kFczEu7v9FcBz3CWw_5_3">794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_naVBFWhZ90mWqv-aIyhB6A_5_6">1,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_xbsYH0nYPE62H76QohBndA_5_9">376</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes conversions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="Tc_QLpxz-YNl0uqBiKflQmmGQ_6_6">7,783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="Tc_P6XeJG7k4USnnTKVbGhcRw_6_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Partial settlement of liability for employee rights upon retirement through transfer of the related funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" scale="3" id="Tc_xk0DazYmnUKxsIXlQyYBow_7_6">882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:fixed-zero" name="plx:PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" scale="3" id="Tc_becTtTY9ykegzXdchn5E-w_7_9">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Tax paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 21pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 21pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_Cv0hBZBEhEac3foQz6kzHQ_10_9">385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_2paIcFA9ME-amLK3tRDVbg_11_3">2,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_cNwt46n2g0291z8pEgPv5Q_11_6">2,742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_a_n6cEfnaEKKEWovmsFgoQ_11_9">1,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:InterestReceivedNet" scale="3" id="Tc_kbIgOGBuQEC9ghrFw8AUxw_12_3">93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:InterestReceivedNet" scale="3" id="Tc_jy3vCI10uky23NtdqtqU9g_12_6">355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="plx:InterestReceivedNet" scale="3" id="Tc_VhDlKnLBrEq4C-7JS6qPwQ_12_9">1,487</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of the consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_30336"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_HmJjFwifJUaYvLe3P6FFQw" continuedAt="Tb_HmJjFwifJUaYvLe3P6FFQw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_ccdDjEK3aEqPXWgrUalnCA" continuedAt="Tb_ccdDjEK3aEqPXWgrUalnCA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix BV (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio (pegunigalsidase alfa), each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has entered into <ix:nonFraction unitRef="Unit_Standard_agreement_KD5G_ppkGEKfu9q5lyCQiQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfGlobalLicensingAndSupplyAgreements" scale="0" id="Narr_xAlGiaRfBk6pNPDaMGzZtA">two</ix:nonFraction> exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_HmJjFwifJUaYvLe3P6FFQw_cont1" continuedAt="Tb_HmJjFwifJUaYvLe3P6FFQw_cont2"><ix:continuation id="Tb_ccdDjEK3aEqPXWgrUalnCA_cont1" continuedAt="Tb_ccdDjEK3aEqPXWgrUalnCA_cont2"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_E4Yge5ZBuUiAoIRfgSeqmw" decimals="2" format="ixt:num-dot-decimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_qIxGXiai8EaJ9qbqdHksmA">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The situation could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of December&#160;31, 2024, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p></ix:continuation></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c0d799ef_f83d_4b0f_88c7_0a3dec71527e"></a><a id="_c0d799ef_f83d_4b0f_88c7_0a3dec71527e_2"></a><a id="_c0d799ef_f83d_4b0f_88c7_0a3dec71527e_3"></a><ix:continuation id="Tb_HmJjFwifJUaYvLe3P6FFQw_cont2" continuedAt="Tb_HmJjFwifJUaYvLe3P6FFQw_cont3"><ix:continuation id="Tb_ccdDjEK3aEqPXWgrUalnCA_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_EOLdRGNRr0a6F3aI4sObcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:UseOfEstimates" id="Tb_RL4Pf9idlk-nCj0W4v9vBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_DgvsbXCqh0ikk3T1NFdzLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Functional currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#8211;&#160;exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#8211;&#160;historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_93LAkdlf4UicpY0hNoTcgQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_GfYAOyPA9kCBQsROBHtDMg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Accounts Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. As of December&#160;31, 2024 and 2023, the allowance was negligible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="0" id="Narr_o7XKKk_SxE2ji_k7_T6hVA"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="0" id="Narr_w8kLDkUoHEyzAUOUX-1wGA">No</ix:nonFraction></ix:nonFraction> write-off activity and recoveries for the periods presented were recognized.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:InventoryPolicyTextBlock" id="Tb_xKA4DAB5yUC79eh0GY3HUA" continuedAt="Tb_xKA4DAB5yUC79eh0GY3HUA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_8XlXjq2R9USCb_4yEKThaA_1_2"></a><a id="Tc_BsDTRoXdvUyI-JCVCR73NA_2_0"></a><a id="Tc_nFVFfqhjo0eiNie-X0jDtw_3_0"></a><a id="Tc__HRAUErEu0GKD1FSMjFTDw_3_2"></a><a id="Tc__XGtfQbRO06LsNt0gBHqMw_4_0"></a><a id="_k.__"></a><a id="kRevenueRecognition_574688"></a><ix:continuation id="Tb_HmJjFwifJUaYvLe3P6FFQw_cont3" continuedAt="Tb_HmJjFwifJUaYvLe3P6FFQw_cont4"><ix:continuation id="Tb_xKA4DAB5yUC79eh0GY3HUA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_-RZPs5sCtk-eRQbURcSkRg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="plx:ScheduleOfUsefulLifeTableTextBlock" id="Group_MFncE5vAE0iogOf_T014IA" continuedAt="Group_MFncE5vAE0iogOf_T014IA_2" escape="true">The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</ix:nonNumeric></p><ix:continuation id="Group_MFncE5vAE0iogOf_T014IA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_h6xjOEjkiUm3MR0Og5Jvhg" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_0SzxdVNZC0CZfxZTnZCtsQ_2_2"> 5</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_vn410UpKkkGalJIGaHTUEg" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_zsn2zvKzykKkaCU8BNM6WQ">10</ix:nonNumeric>-<ix:nonNumeric contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_eCpUQmCcSESODwHxlLzo5w" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_mdIBmYHRf0687eZDaHF0pg">15</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_y8QfLO6YXkKf-_LOLQOaZQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_DsvrFyzlNkaPzQzF7qTKrQ_4_2"> 3</ix:nonNumeric></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leasehold improvements are amortized by the straight-line method over the shorter of (i)&#160;the expected lease term and (ii)&#160;the estimated useful life of the improvements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_u8vbHMwcEE6iVSk_fzaZGg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_P8aorFV4iE-OT2_gfWoyJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">j.&#160;&#160;&#160;&#160;Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Deferred income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Uncertainty in income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained. Liabilities relating to uncertain tax positions are classified as current in the consolidated balance sheets to the extent the Company anticipates making payments within one year.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_y1mXLGj0qEOPzzS6UPaY0Q" continuedAt="Tb_y1mXLGj0qEOPzzS6UPaY0Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">k.&#160;&#160;&#160;&#160;Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_HmJjFwifJUaYvLe3P6FFQw_cont4" continuedAt="Tb_HmJjFwifJUaYvLe3P6FFQw_cont5"><ix:continuation id="Tb_y1mXLGj0qEOPzzS6UPaY0Q_cont1" continuedAt="Tb_y1mXLGj0qEOPzzS6UPaY0Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with a Company&#8217;s customer is based on either fixed amounts or variable amounts. Variable amounts are based on the average net selling price of the drug product in the applicable territory. The Company estimates the variable consideration and recognizes revenue only to the extent the variable consideration is probable and that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_item_ZOMDUvl2U0qDBOvYPFWWmQ" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_2dRWMsEJ6EiuDNv182Eeiw" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_gp9luNrf10WNKnMgIULUOA">two</ix:nonFraction> performance obligations in each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;) as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing. See also <a href="#_k.__"><span style="font-style:normal;font-weight:normal;">revenue from selling products</span></a> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC&#160;606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely amount method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA in 2023, the Company received a milestone payment equal to $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_jaZy5wcLxkiCdAwjd5oXfQ" decimals="-5" format="ixt:num-dot-decimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_ugHIYdw_GEKomj85UDjOKw">20.0</ix:nonFraction>&#160;million which was recognized as revenue from license and R&amp;D services.</p></ix:continuation></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e6f2c364_d4fe_4070_9ab7_9f8d8a5f393f"></a><ix:continuation id="Tb_HmJjFwifJUaYvLe3P6FFQw_cont5" continuedAt="Tb_HmJjFwifJUaYvLe3P6FFQw_cont6"><ix:continuation id="Tb_y1mXLGj0qEOPzzS6UPaY0Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">3.    Revenue from R&amp;D services</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_To-3M30_sUekn8gA-hBSnQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">l.&#160;&#160;&#160;&#160;Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_Y_m4ycuS6E6j-JCZXzLzGw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company&#8217;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, the accounts receivables balance was composed of $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_VubLEAIky0aQAmEbs4Z7EA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_YYvMcJUSj0enPwO3QnvU3w">0.7</ix:nonFraction>&#160;million from Chiesi and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_7kWtOAR1_USec_YP09u_Zg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_Ru_dfd3VU0uQslDjfowf4g">4.6</ix:nonFraction>&#160;million from Pfizer and as of December&#160;31, 2024, the accounts receivables balance was composed of $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_eMpI1Y46mEm3V5aABb_sXg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_upT5k1Y8TUyuzAbG6PMp7A">1.7</ix:nonFraction>&#160;million from Fiocruz and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_l6LgZROctkqAN5Bg47FtoA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_fQloYZQX3UKFpApYSz3SsA">1.2</ix:nonFraction>&#160;million from Pfizer.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_BtQzpxkQHkKV0xFEW6DIDQ" continuedAt="Tb_BtQzpxkQHkKV0xFEW6DIDQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">n.&#160;&#160;&#160;&#160;Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. <span style="background:#ffffff;">This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The Company measures compensation expense for </span>restricted stock <span style="background:#ffffff;">based on the market value of the underlying stock at the date of grant</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected to recognize compensation cost for awards to employees with only service conditions that has a graded vesting schedule using the accelerated method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elects to account for forfeitures as they occur.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_HmJjFwifJUaYvLe3P6FFQw_cont6" continuedAt="Tb_HmJjFwifJUaYvLe3P6FFQw_cont7"><ix:continuation id="Tb_BtQzpxkQHkKV0xFEW6DIDQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_TehcF3LbukSwyfq_3MRnhg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">o.&#160;&#160;&#160;&#160;Net earnings (loss) per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_Zi7csbEQyESybyDv-RKYqw">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing (a)&#160;the net income that includes addition of financial expenses related to convertible notes by (b)&#160;the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options and non-vested restricted stock granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:DebtPolicyTextBlock" id="Tb_Fu81K0QBwEWbaP31GJGdlA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">p.&#160;&#160;&#160;&#160;Convertible notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_rldSNFnujkmNBG6adoOOkw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_rq9d5Iy06UKZCOQPmjbNKw">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate.&#160;The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January 1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost. See <a href="#rNewaccountingpronouncements_158576"><span style="font-style:normal;font-weight:normal;">Note 1(r)</span></a>.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_ZuMTJoji2k2hdLos7TjVWA" continuedAt="Tb_ZuMTJoji2k2hdLos7TjVWA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">q.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="rNewaccountingpronouncements_158576"></a><a id="Tc_nXhPy8_U7U-qjYdPAAn_hw_1_2"></a><a id="Tc_t-7MUSXTB0y2GwLcJKkqYg_1_5"></a><a id="Tc_iKTVKEOhMkOPtaNyXsSWvQ_2_2"></a><a id="Tc_sicDieYP3keXWhbHKTanmw_2_5"></a><a id="Tc_-UaSU5n2EEKWET87nsQBhw_2_8"></a><a id="Tc_Yhjh9kaOM0u70K8p5UC7IA_3_0"></a><a id="Tc_5zlSdPCGfEiyiDX-KmQ6XQ_3_2"></a><a id="Tc_SF7A_B4thkqjkVwalZQI0A_3_5"></a><a id="Tc_RRyKkqq-aE6AX9YQ-54cPg_3_8"></a><a id="Tc_qHgIoTJqxEObm7ZTqAxolg_4_0"></a><a id="Tc_FoqsQDNTg0OkH2PFP62rzQ_4_2"></a><a id="Tc_omcRsxhHaUOLz1jZOPDoOA_4_5"></a><a id="Tc_0nw_k1vrcU2G2z3idgiL5g_4_8"></a><a id="Tc_d-ugrAv0EUiiNfUjv3V-Mw_5_0"></a><a id="Tc_L-X4zaA5Q0a3C5i4UQbWvA_6_0"></a><ix:continuation id="Tb_HmJjFwifJUaYvLe3P6FFQw_cont7" continuedAt="Tb_HmJjFwifJUaYvLe3P6FFQw_cont8"><ix:continuation id="Tb_ZuMTJoji2k2hdLos7TjVWA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12&#160;months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_1QWk71hQPkmPDXcBFXrenA" continuedAt="Tb_1QWk71hQPkmPDXcBFXrenA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">r.&#160;&#160;&#160;&#160;New accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently adopted accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued&#160;ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)&#8221; (&#8220;ASU 2020-06&#8221;).&#160;ASU&#160;2020-06&#160;simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#8212;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06&#160;using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital.&#160;The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods.&#160;Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability.&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="Group_R1qrGHQXVkGXQOTJy5X44w" continuedAt="Group_R1qrGHQXVkGXQOTJy5X44w_2" escape="true"><span style="background:#ffffff;">The impact to the Company&#8217;s consolidated balance sheet as of January&#160;1, 2024 resulting from its adoption of ASU 2020-06 is as follows:</span></ix:nonNumeric></p><ix:continuation id="Group_R1qrGHQXVkGXQOTJy5X44w_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_MPMo01U1DE2eTRxBhtkynA_4_3">20,251</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_Wf4l6EemkUiStX1y_Xvkzg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_G5_SPbkUX0--VLizuNEQeg_4_6">20,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CoqAPYNvE0GJxaaTTSDOFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_ZsynfivCkkmPJYofBraJNQ_4_9">169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_dQAzSMhus0mxSmrOhKnz4w_5_3">415,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_Wf4l6EemkUiStX1y_Xvkzg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_j3lBfEOELEu1qoWE7RrzMw_5_6">414,652</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CoqAPYNvE0GJxaaTTSDOFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" sign="-" scale="3" id="Tc_0YhPvcJGokmujfA2AtJfeg_5_9">393</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_1dsKGwbXGkSrNUZcegdFHg_6_3">381,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_Wf4l6EemkUiStX1y_Xvkzg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_ORO-krb7zEOTSN5LoosOkA_6_6">381,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CoqAPYNvE0GJxaaTTSDOFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_kzagx2DzWUyGzHtiat8hGQ_6_9">224</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;) and included within each reported measure of segment profit or loss and an amount and description of its composition for other segment items. The Company adopted this standard in the current period retrospectively to all prior periods presented in its consolidated financial statements. See </span><a href="#_NOTE_13_"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Note&#160;13</span></a><span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_HmJjFwifJUaYvLe3P6FFQw_cont8"><ix:continuation id="Tb_1QWk71hQPkmPDXcBFXrenA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';">.</span></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_znK-7iER70abBadA2TsRiA" continuedAt="Tb_znK-7iER70abBadA2TsRiA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- COMMERCIALIZATION AGREEMENTS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In October&#160;2015, the Company entered into the Amended Pfizer Agreement with Pfizer that amended and restated the Pfizer Agreement of November&#160;30, 2009. Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Protalix Ltd. also agreed to provide Pfizer with:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">1.</span>Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">2.</span>Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">b.</b>&#160;&#160;&#160;&#160;In October&#160;2017, Protalix&#160;Ltd. entered into the Chiesi Ex-U.S. Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter&#160;&#8211;<span style="direction:rtl;">&#160;</span>the drug) for the treatment of Fabry disease. Under the terms of the Chiesi Ex-U.S. Agreement, Protalix&#160;Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. At the effective date, Protalix&#160;Ltd. had maintained the exclusive commercialization rights to the drug in the United States, which rights were subsequently granted to Chiesi in July&#160;2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix&#160;Ltd. is mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted and (ii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_YOGpnjsFYUmoeJZPBCVsFQ" decimals="-5" format="ixt:num-dot-decimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_Q5TmOfcpZUycl8GXPbXRBQ">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_YOGpnjsFYUmoeJZPBCVsFQ" decimals="-5" format="ixt:num-dot-decimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_xn67yzgz-EaqFhF4sMmSkg">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_YOGpnjsFYUmoeJZPBCVsFQ" decimals="-5" format="ixt:num-dot-decimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_bA40dRdewkCs7rgY1ZgCPQ">10.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_YOGpnjsFYUmoeJZPBCVsFQ" decimals="-5" format="ixt:num-dot-decimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr__XUpFHVCq0e7Oiidj2ew2A">320.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Ex-U.S.Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_B46HhSBVz0yrsK0DY71Erw" decimals="2" format="ixt:num-dot-decimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_CIWYor9Usk6Yx6bcRRxuVQ">15</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3WAGON0zpU6ERbyAHqCRzA" decimals="2" format="ixt:num-dot-decimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_j45Y3q6wi02mXvF2Snc8Jg">35</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_znK-7iER70abBadA2TsRiA_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix Ltd. will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Chiesi does not have sublicensing rights (except for certain territories).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In July 2018, Protalix Ltd. entered into the Chiesi US Agreement with respect to the commercialization of the drug for the treatment of Fabry disease. Under the terms of the Chiesi US Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets in the United States. Protalix Ltd. is mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted, (ii)&#160;continuing certain clinical development efforts in relation to the drug after a regulatory approval is granted and (iii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA" decimals="-5" format="ixt:num-dot-decimal" name="plx:UpfrontNonrefundableNoncreditablePaymentReceivable" scale="6" id="Narr_Rgk_rtDCSkSxCvEGA5-xfQ">25.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA" decimals="-5" format="ixt:num-dot-decimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_QQAkk7mVmEG-8WcYuwXXgQ">20.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA" decimals="-5" format="ixt:num-dot-decimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_nvBCtDXQokWX2kbSRnOqhQ">7.5</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA" decimals="-5" format="ixt:num-dot-decimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_MfcYNAYKDkKeekFkDMxKFA">760.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi US Agreement, which has been reduced to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_t_yYq1YsV0acGDoyhAPn0w" decimals="-5" format="ixt:num-dot-decimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_niiKtmPgpUKlz2fGC0-1Rg">735.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_S5aqBYd2ZEqjmaTVHLVYcA" decimals="2" format="ixt:num-dot-decimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_olIWjFpvX0ynTbhfIAx7eA">15</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_rPFgBIuGN0iZ81CflTcjcA" decimals="2" format="ixt:num-dot-decimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_5s0ne9b60kqTa4MR5aGH3w">40</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Chiesi does not have sublicensing rights.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;">c.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">On June&#160;18, 2013, Protalix Ltd. entered into the Brazil Agreement with Fiocruz for BioManguinhos. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p></td></tr></table></ix:continuation><a id="Tc_qbBT2sudh0CH87Jo83TQXw_1_2"></a><a id="Tc_yQOW2bEKEUmwC6VdUFYOzw_2_0"></a><a id="Tc_ED8Copk3ckKGh3ptboh9Vw_2_2"></a><a id="Tc_dc1wnhBuDUOHLtgqF4-oFQ_2_5"></a><a id="Tc_GxwxGydenkSUdDPHoxWalA_3_0"></a><a id="Tc_N3KGb6f1PkiJXYshDZpLZA_3_2"></a><a id="Tc_NzuTAkmlZEOQfeF9cSW7fQ_3_5"></a><a id="Tc_ErZVCGQ2hke5IWaAU3gNAg_4_0"></a><a id="Tc_fUW0gWB1YkSJETnrPnFpfw_5_0"></a><a id="Tc_I9LDkAZ1a0WJoposfd8_aQ_6_2"></a><a id="Tc_HgCYhhd4NUCk9FAl1lRPHg_6_5"></a><a id="Tc_YievyyUI90q8BSFGX302FA_7_0"></a><a id="Tc_wFlus6xD_EmxN3UjPTumTQ_8_2"></a><a id="Tc_OIcQbuUMiEKBeLJxZWmc3g_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_1yhOn8UZL0-dzpDBL0ZUBw" continuedAt="Tb_1yhOn8UZL0-dzpDBL0ZUBw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3 - PROPERTY AND EQUIPMENT</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Group_jYu1UV6NlEyRLtS4sXbpiA" continuedAt="Group_jYu1UV6NlEyRLtS4sXbpiA_2" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Composition of property and equipment grouped by major classifications is as follows:</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><ix:continuation id="Group_jYu1UV6NlEyRLtS4sXbpiA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_ur7u-fiQ5k-UQkYO2y0uwQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_s_jydl1iMECMuBD2e0zhnQ_3_3">18,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_h6xjOEjkiUm3MR0Og5Jvhg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_OnecnT6630SrbkQa9Bh0fg_3_6">19,043</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_PjfN7L5Bbk2NLvVOBqJ8Lw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_fZiwQ_ZIA0WwYLUnU5RpUw_4_3">3,084</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_S7h6B8zov0uIXGD5I22dew" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_s991rNTfD0S0rKFxwxoYEw_4_6">3,374</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_EF4dwmnF_kWBNzMVSjLHhQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_xzRQWWSmjkuk00XlTAaeag_5_3">17,644</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_oNp3Hf3CWECKBYdKr9AjAg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_nlngp4BUD0e-mFIJdwXNXA_5_6">17,913</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ClXaIc16vES0jGvejYwskw_6_3">39,661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_PtpYqOF2WkWDAyj0iBF2sw_6_6">40,330</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less &#8211; accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_y9Z198VhkUSV7WH_pDKQDw_7_3">34,688</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_8AspLsP-gECHiV1HdxnRFw_7_6">35,739</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ErEgeq9jVUq6WTyYTWdiJA_8_3">4,973</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_-zp8wYU0fk2zyRKaVUFSTw_8_6">4,591</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>Depreciation in respect of property and equipment totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="Narr_xdAL_xkm-EG1tAF0Wo7Orw">1.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="Narr_7L4cJmOUIkiwNTybKGymBA">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="6" id="Narr_89-WfwbwXkO3HYM_IXMKow">1.3</ix:nonFraction>&#160;million for the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_1yhOn8UZL0-dzpDBL0ZUBw_cont1"></ix:continuation><a id="Tc_0z0cHL2hLEa4i3qMEZBFkA_1_2"></a><a id="Tc_Sh0fDXYRJkOCLbKOWmE9VA_2_0"></a><a id="Tc_jqITj44310GFUyMCRxuvtQ_2_2"></a><a id="Tc_sVuWbu_pZkGXFIPEr80fsw_2_5"></a><a id="Tc__-gP864zsUCZi8YQ9orj4w_3_0"></a><a id="Tc_7RswlXj2mUKtc5i_7RRDNQ_3_2"></a><a id="Tc_hGiZlVBM30GPNC3k9iUhgw_3_5"></a><a id="Tc_U2ZdGQmFFEC1BwqPoppzcg_4_0"></a><a id="Tc_zd_Q8CJMbU-2iJXaA-AAtg_5_0"></a><a id="Tc_RmXYZ5BoaE-o5itl_cvzdA_6_0"></a><a id="Tc_wtq8UC4md0uTEfsd04cqZg_6_2"></a><a id="Tc_y2jjPCvr40e3q7VoXnXiKQ_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_8mXBP0KLBkmVzF7yyvSySQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Group_UPWnbWl5nUK3d5zYjdpwOw" continuedAt="Group_UPWnbWl5nUK3d5zYjdpwOw_2" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inventories at December&#160;31, 2023 and 2024 consisted of the following:</span></td></tr></table><div style="margin-top:10pt;"></div></ix:nonNumeric><ix:continuation id="Group_UPWnbWl5nUK3d5zYjdpwOw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_T9i6OxkGekexpv3culC6cg_3_3">4,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_OcAfHTiJ5EaIo8bxtOOjDg_3_6">4,549</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_U8Q04UusAU-1T8tsPs8-6A_4_3">9,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_wtiXJ2SO3U2PD6BDnRs94A_4_6">11,245</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_cJ8DJU4Pq0GhmYKS85OSew_5_3">5,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_zhGUFCndLUuyWoIYTiREtQ_5_6">5,449</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_W6Wm3wQfq0qz-SU2tnN7Ow_6_3">19,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_krGRdbS7VkOZSmbX-QxVWw_6_6">21,243</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>During the&#160;years ended December&#160;31, 2022, 2023 and 2024, the Company recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_IUMy0x3zCkCsjJSZtROnNA">0.04</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_JyhvshVZPUqt0vdvaBX4vA">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="6" id="Narr_C5Sodu1TEk6mapDr7EiY4g">0.09</ix:nonFraction>&#160;million, respectively, for write-down of inventory under cost of goods sold.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_qm4OPaXkaUOPXfgDht-rkQ" continuedAt="Tb_qm4OPaXkaUOPXfgDht-rkQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;5&#160;- LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest&#160;monthly salary&#160;- one&#160;month&#8217;s salary for each&#160;year employed) is recorded on the Company&#8217;s balance sheets under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#8217;s balance sheets under &#8220;Funds in respect of employee rights upon retirement.&#8221; These policies are the Company&#8217;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December&#160;31, 2022, 2023 and 2024, the Company deposited approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="0" format="ixt:num-dot-decimal" name="plx:EmployeeSeveranceObligationPayment" scale="0" id="Narr_3Fzebx2YKU-LeC7_9DID7A">96,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="0" format="ixt:num-dot-decimal" name="plx:EmployeeSeveranceObligationPayment" scale="0" id="Narr_5l1EtSMv3EyVXUHHvgl-2w">142,000</ix:nonFraction> and $<span style="direction:rtl;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="0" format="ixt:num-dot-decimal" name="plx:EmployeeSeveranceObligationPayment" scale="0" id="Narr_fgf__r05OUmebgfY46Ye7A">32,000</ix:nonFraction></span>, respectively, with insurance companies in connection with its severance payment obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#8217;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plans&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The amounts of severance pay expenses were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PostemploymentBenefitsPeriodExpense" scale="0" id="Narr_u4J8simrSUazBvwqJmHiTw">945,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PostemploymentBenefitsPeriodExpense" scale="0" id="Narr_xKeITlOtCES8BMY0cb-NaQ">801,000</ix:nonFraction> and $<span style="direction:rtl;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PostemploymentBenefitsPeriodExpense" scale="0" id="Narr_v84AgIjSAUupvNOGCQm7Jg">820,000</ix:nonFraction></span> for each of the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively, of which approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_cZySKQnDM02_vBpnL21OHQ">800,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_QjVoEmRezkulTq_umk3Wiw">798,000</ix:nonFraction> and $<span style="direction:rtl;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" id="Narr_-YgMJ2sZbEG0njOxWj2N8g">859,000</ix:nonFraction></span> in the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively, were in respect of the Contribution Plans. Gain (loss) on amounts funded in respect of employee rights upon retirement totaled approximately $(<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" sign="-" scale="0" id="Narr_zR57-cKTqEOGWphdkbafIA">3,000</ix:nonFraction>), $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="0" id="Narr_Hillohs8xE6Nyts2owvKCA">50,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" scale="0" id="Narr_YTU8n_4NKUCfa_r0Eco-UQ">18,000</ix:nonFraction> for the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company expects to contribute approximately $<span style="direction:rtl;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_wUeqT_M4AEqDZuDuEQf3xw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="Narr_tx4n4ZUGC0qp3vjy86h0pA">956,000</ix:nonFraction> </span>in the<span style="direction:rtl;"> </span>year ending December&#160;31, 2025 to insurance companies in connection with its severance liabilities, approximately $<span style="direction:rtl;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_Mp-0M08qeUKO7h9uqA1McQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="Narr_lmqdv4YhGUOZqUOG-W5zpQ">931,000</ix:nonFraction> </span>of which will be contributed to one or more Contribution Plans.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_qm4OPaXkaUOPXfgDht-rkQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">During the five-year period following December&#160;31, 2024, the Company expects that up to <ix:nonFraction unitRef="Unit_Standard_employee_ocaisUO_C0WWcRJExAkgCA" contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_iREdhYdsg0S_5qYZGs1pFw" decimals="INF" format="ixt:num-dot-decimal" name="plx:NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" scale="0" id="Narr_t--bRf6jDUiriL_ktEsyFA">10</ix:nonFraction> employees may retire upon normal retirement age.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:CommitmentsDisclosureTextBlock" id="Tb_-o1La22ml0Sm7SP5Jp3zKw" continuedAt="Tb_-o1La22ml0Sm7SP5Jp3zKw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;6&#160;- COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Royalty Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is obligated to pay royalties to the National Authority for Technological Innovation (&#8220;NATI&#8221;) on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Israeli Innovation Authority (IIA). At the time the grants were received, successful development of the related projects was not assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the IIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of the applicable funding arrangements, royalties of <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_qm_86HOq70OOencxym3GVg" decimals="2" format="ixt:num-dot-decimal" name="plx:RoyaltiesOnSaleOfProducts" scale="-2" id="Narr_i80oo-7dGkWyIL01lbD6rw">3</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember__u8SZ_kTp0GNsmMYnwI58Q" decimals="2" format="ixt:num-dot-decimal" name="plx:RoyaltiesOnSaleOfProducts" scale="-2" id="Narr_QP0p-xdbWUucjJgpHQLRJQ">6</ix:nonFraction>% are payable on the sale of products developed from projects funded by NATI or the IIA, which payments shall not exceed, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_uwDD5nTakUC2KmTkoR6W8g" decimals="2" format="ixt:num-dot-decimal" name="plx:PercentageOfRoyaltiesToGrantReceived" scale="-2" id="Narr_sr_LCsZ_J0mtliHwTB1P_Q">100</ix:nonFraction>% of the amount of the grant received (dollar linked), plus, commencing upon January&#160;1, 2001, interest at an annual rate based on SOFR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will, subject to certain exceptions, be required to pay an increased total amount of royalties, depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Royalty expenses to NATI or the IIA are included in the statement of operations as a component of the cost of revenues and were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_HeexSHIpsECzwXPmjXRSIg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_enXT7c3OPk-rkQ-rGqrlwQ">1.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_07Y7_KkIgE2gCqBzVKzHGA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_0KvkrO79FkiZDPgkXZa4Ew">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_0jCSqJ2VNUGntWiwLim66g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="6" id="Narr_xa2qY-M9CUuQkY_t-xjQuQ">1.6</ix:nonFraction>&#160;million during the years ended December&#160;31, 2022, 2023 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">At December&#160;31, 2023 and 2024, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_VUjg-GUWqkaM24vUWwpyKQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="Narr_hFLFfQZN5UuIpRnTDhXVAw">35.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_uwDD5nTakUC2KmTkoR6W8g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="6" id="Narr_Bdb8Ap6lfki8nNdpqrLP3A">33.9</ix:nonFraction>&#160;million, respectively (without interest, assuming 100% of the funds are payable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Subcontracting Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December&#160;31, 2024, total commitments under said agreements were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_7_J4-MrHIkS9N0JY0GZlRw" decimals="-5" format="ixt:num-dot-decimal" name="plx:CommitmentAmount" scale="6" id="Narr_lnP6hG5Qck6quVybigTICg">1.5</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Fill/Finish Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:10pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F&#160;Agreement&#8221;) and a Letter Agreement, in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the global launch of pegunigalsidase alfa. The F/F&#160;Agreement did not change the terms and conditions of the Chiesi Agreements. Subsequently, in November 2024, the Company and Chiesi amended the F/F&#160;Agreement to provide that a different Chiesi facility may act as a secondary supplier of such services and that the F/F&#160;Agreement shall have an initial term of </span><ix:nonNumeric contextRef="Duration_11_1_2024_To_11_30_2024_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_7SbCZK859Uiaib6y5h0qfQ" format="ixt-sec:durwordsen" name="plx:InitialTermOfArrangement" id="Narr_fbNfXuWBIUGjYwcKSEvvNQ"><span style="font-size:10pt;">10&#160;years</span></ix:nonNumeric><span style="font-size:10pt;">, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement. Prior to expiration of the initial term, the term may be extended by mutual agreement for an additional period of </span><ix:nonNumeric contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_HhtwKHGlsEOO6RfMSrfRww" format="ixt-sec:durwordsen" name="plx:ExtendedTermOfAgreement" id="Narr_e-TgyKLd_0evJOLD0r8F7g"><span style="font-size:10pt;">seven years</span></ix:nonNumeric><span style="font-size:10pt;"> upon mutual written agreement prior to expiration of the initial term. Under the F/F&#160;Agreement, the Company is obligated to pay to Chiesi an amount equal to </span>&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_iTLnFIhgHUOHLxUiOlWFJw" contextRef="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_CtbP6sYsCUSsa4BOxiiwkw" decimals="-5" format="ixt:num-dot-decimal" name="plx:ContractAmountUnderAgreementPayable" scale="6" id="Narr_a_E8xAbbWUiA_Wuu0vER7g">2.5</ix:nonFraction>&#160;million in connection with the necessary technology </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_-o1La22ml0Sm7SP5Jp3zKw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;margin:0pt 0pt 0pt 54pt;">transfer, QA tests and capital expenditures. <span style="font-size:10pt;">Such amount is to be paid over the term of the F/F agreement based on the actual vials produced by Chiesi thereunder. Under the amendment, the Company and Chiesi agreed to share equally the costs of establishing the new facility as an alternative source for Fill/Finish. The Company&#8217;s share of such costs amounting to </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_OUM-7GtNokqwYO6vx-ub9A" decimals="0" format="ixt:num-dot-decimal" name="plx:ContractAmountUnderAgreementFacilityPayable" scale="0" id="Narr_OHgZxFL9TEudOo8N9T9tnA">400,000</ix:nonFraction></span><span style="font-size:10pt;"> shall be due and payable upon Chiesi&#8217;s completion of the manufacture of the requisite validation batches and issuance of the process validation report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_8946ca28_4ca3_40ce_8e86_26661032a679"></a><a id="Tc_lsQ1qdPqJUm2UN2ubxaNRA_1_2"></a><a id="Tc_SeO5AVK6tEW-Bv_ZFc8bvA_2_0"></a><a id="Tc_mXPWgVllpEmx8gECAIQGFA_2_2"></a><a id="Tc_MAmyHwTSKk6SPnrdsysn7g_2_5"></a><a id="Tc_xSmVXdhQnkmkpO1NVpM-hQ_2_8"></a><a id="Tc_Gm3mMvJa1EiXnMs0p4y6pQ_3_0"></a><a id="Tc_aEacXnh1dk-x468OFjLIqg_3_2"></a><a id="Tc_esqpi7jyhEOgCZRBEFS9xA_3_5"></a><a id="Tc_MK1OBECKy0qu4ar5DOrgjg_3_8"></a><a id="Tc_NBKqQg-qckSSa7XDpnfyFA_4_0"></a><a id="Tc_TRbJI96Vw0eKu04Ip05LCA_5_0"></a><a id="Tc_IauWmcuD0kKVZCF_-YsK0Q_6_0"></a><a id="Tc_1-4FFjO10Ee6vIMSrwTFyg_6_4"></a><a id="Tc_nxKI9WMtZU2unLzO8tN6WQ_6_7"></a><a id="Tc_2UUcSM6idEGpYH_k7TlxTw_6_10"></a><a id="_b58a8809_660d_4181_8b1f_66ae75a25a5e"></a><a id="Tc_telp6etafEuOF1ZPw5OeMA_1_0"></a><a id="Tc_2tzFZeGa6ku4DwhA32qQgw_1_2"></a><a id="Tc_WlZhTJiw8EWc3_hM_Wi7Iw_2_0"></a><a id="Tc_A23k5PKp10yA7ZkOMqJMCA_2_2"></a><a id="Tc_I3nYO6qKc06RUvGYrJZZlA_3_0"></a><a id="Tc_Ena-BWGfok29-CE_YIHZZg_3_2"></a><a id="Tc_KGY8oL1aEEmJxW0SQxkTfA_4_0"></a><a id="Tc_iRt_LO6DpUu2XjkGZp-BYw_4_2"></a><a id="Tc_si-BIfcLNU-tbk3w8u5FUA_5_0"></a><a id="Tc_ImXQpVG-zEma6uT9c2f0Kw_5_2"></a><a id="Tc_u-UJD5SL-EmpEBC4LBHozg_6_0"></a><a id="Tc_qqfTPQw6bk6KwYl-qFFYGQ_6_2"></a><a id="Tc_fsKjYLKOqEeKN1XUNFPCeg_7_0"></a><a id="Tc_IdNFJgkzpUav9SHGKmN19A_7_2"></a><a id="Tc_SetqN6v70U-Yj8O9iFzF-Q_8_0"></a><a id="Tc_OWEZtfw-oEuyHGnq69U4aA_8_2"></a><a id="Tc_HbJEM0NgeUaO45Pmha7I4w_9_0"></a><a id="Tc_rphgm8QbPkuS7C1-htWsRg_9_2"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_gqGhGvyjdkGl7WCRNh9dtQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 7 - OPERATING LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is a party to several lease agreements for its facilities, the latest of which has been extended until 2026. The Company has the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" format="ixt:fixed-true" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="Narr_K6MzxDGN10m12r_1KkFvgA">option to extend</ix:nonNumeric> certain of such agreements on <ix:nonFraction unitRef="Unit_Standard_item_ZOMDUvl2U0qDBOvYPFWWmQ" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="INF" format="ixt-sec:numwordsen" name="plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions" scale="0" id="Narr_zjA88L_6D0aMJDdRMgqmdw">one</ix:nonFraction> additional occasion for an additional <ix:nonNumeric contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_iQYqoQX9_kSsmEojUwu9kA">five-year</ix:nonNumeric> period. During the extended lease period, the aggregate&#160;monthly rental payments will increase by <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_W3yUCAONf0SfAzEtMt6Mbw" decimals="3" format="ixt:num-dot-decimal" name="plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" scale="-2" id="Narr_52Xa8G1zq06KE-2ABApH-g">7.5</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_XGzd5dVqLk6U007ZQL4UiQ" decimals="2" format="ixt:num-dot-decimal" name="plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" scale="-2" id="Narr_MU-txTH8OEK1RvIxrpsB3Q">10</ix:nonFraction>% for the option. The Company expects to exercise the final option in future periods. As of December&#160;31, 2024, the Company provided bank guarantees of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_CiLNrRPdjUC03GXq3GTCxA">513,000</ix:nonFraction>, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company entered into several <ix:nonNumeric contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_pqIJYP9qBkuWs3kgYe1bCA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_s2cGuVkrjEibEj76qwXlsg">three-year</ix:nonNumeric> leases for vehicles which are regularly amended as new vehicles are leased.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:LeaseCostTableTextBlock" id="Tb_WXyvaKUzo065fg3Whjv5Aw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the years ended December&#160;31, 2022, 2023 and 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.89%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_jZ9WWCBugkqfxKS87irfOA_3_3">1,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_hQf_3964m0q0TDkpVo_9JQ_3_6">1,471</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_Z0Y4nFH8dE-iIcZztSG6Pg_3_9">1,639</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_qms7_W8_C0W7k1Cxk4iVUg_4_3">1,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_s-Jjj-eSekenNUimSGyzvQ_4_6">1,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_tLnOyzulz02xMwmYMMBaZw_4_9">1,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_pJvHd3US6Ua3Tdxsroa_xg_5_3"> 8.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_ztlgWYPP30Sd6P-sByE0Sw_5_6"> 6.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_zr89N1p1d0WR0nDsGqp3DA_5_9"> 6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc__4qix_r5g0qshlvz3IGUpQ_6_3">12.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_VpuQ9YtMSk698m92OINakA_6_6">12.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_byluLK82QUKUErYoSHFZaA_6_9">12.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_0XhrUjwmyEiBfDrA3cY_qA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of December&#160;31, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_g62jWwenpkahBlwTnZ0KfA_2_3">1,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_IIHuNPzok0eiRWF73WiaxA_3_3">1,241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_eVghGPqv_kK_WeAF_u2khQ_4_3">1,085</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_kNPl5x9RBUGrhX8kzG3bsg_5_3">1,040</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_lGfXkWzHGkKGF4vcVac8Cg_6_3">3,003</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_UExjDXkN2UmltEnB9oxrhA_7_3">7,869</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_BjE1km7rBEOvFhzfTod0Sg_8_3">2,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_NpJGroqSLEW0H7KIUxANBw_9_3">5,526</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_tQhjd1HGh0WhBO71oqsZ3Q" continuedAt="Tb_tQhjd1HGh0WhBO71oqsZ3Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;8&#160;- SHARE CAPITAL</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Authorized Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Under the Company&#8217;s Certificate of Incorporation, as amended, the Company is authorized to issue <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_JGtJnGZ6rU2mjh3fmPpqvQ">185,000,000</ix:nonFraction> shares of Common Stock and <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_Z66lYzA43kuwQVHk-opYTA">100,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_9GKyRUnSHU-EGS8bZy3mZA">0.0001</ix:nonFraction> per share. </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_tQhjd1HGh0WhBO71oqsZ3Q_cont1" continuedAt="Tb_tQhjd1HGh0WhBO71oqsZ3Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">b.</b></span>Rights of the Company&#8217;s Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s Common Stock is listed on the NYSE American. The Company voluntarily delisted its Common Stock from the Tel Aviv Stock Exchange effective March&#160;22, 2023. Each share of Common Stock is entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_0mlCI0gGfUK1x1wJKqfHQQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt-sec:numwordsen" name="plx:CommonStockNumberOfVotingRights" scale="0" id="Narr_zcanYFy2p0aKsj0vaDiO4Q">one</ix:nonFraction> vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Stock based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;14, 2006, the Board of Directors adopted the Protalix BioTherapeutics,&#160;Inc. 2006 Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Plan has since been amended to, among other things, increase the number of shares of Common Stock available under the Plan to <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_tq949hURe0qn3llpv8mqpw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_mpvA1okKskq6xfelZaAamw">17,475,171</ix:nonFraction> shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&#160;102 and 102A of the Israeli Income Tax Ordinance (the &#8220;Ordinance&#8221;). Each option grant made to an Israeli citizen is subject to the track chosen by the Company, either Section&#160;102 or Section&#160;102A of the Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#8217;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section&#160;3(i) of the Ordinance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2024, <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_CICj4_5oDkmUkOYIsMfR-A">4,139,412</ix:nonFraction> shares of Common Stock remain available for grant under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The vesting period of the outstanding options and restricted shares is generally <span style="-sec-ix-hidden:Hidden_HsTYEK9eRkCkgOq9_9rEew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_ACAfcts15EeexRuNnjxxSA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_5tAqo-KkgUKYceqrCpmEuw">four years</ix:nonNumeric> from the date of grant. The rights of common stock obtained from the exercise of options (once vested) and the restricted stock are identical to those of other common stock of the Company. The contractual term of these options is primarily for <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_EUp6tTdW0UGDY4bhmHe7MA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_GChgm0Nst0u-ZMoNk5VHiA">ten years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">For purposes of determining the fair value of restricted stock granted to employees and non-employees, the Company&#8217;s management uses the fair value of the Common Stock. <span style="background:#ffffff;">The fair value of options granted for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model.</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_AB_y80d36E2x6lbLew4mLQ_1_2"></a><a id="Tc_B2DtDxIU10y0LPZYUJfsmg_2_4"></a><a id="Tc_04R_SisCwkqZFgPXvsLGnQ_3_2"></a><a id="Tc_wTjxmFaRJ02WPrGysqkFzw_3_4"></a><a id="Tc_xTUwAAedyk-XbJmp5jn4Vw_4_2"></a><a id="Tc_jHJlSHrcuU-Sh9POgxpGjA_4_4"></a><a id="Tc_UWZM_v2aLEikws8s1_il0g_5_2"></a><a id="Tc_xWTYQXUfu0CwWC4F67qYjA_5_4"></a><a id="Tc_IcP8i6E7fkCkNlu_AhV0NQ_6_0"></a><a id="Tc_Ag4Skh2Bb0apEAHxV5qWeg_6_4"></a><a id="Tc_xOYYW4h7v0mtJRFbDyGZLQ_7_0"></a><a id="Tc_NurQzJmOTkOZz-1CucL5zg_8_0"></a><a id="Tc_aKAEQKoWTECb2SyXMjHfCQ_9_0"></a><a id="Tc_n2Cldghgnkak0e-Ah04FeA_10_0"></a><a id="Tc_VSCjo16msU-xFsg52OLDcg_11_0"></a><a id="Tc_hGLEZeqmCEeKDxNwfllBbg_11_4"></a><a id="Tc_0NUEPi6MfEWA9501gkKFnw_12_0"></a><a id="Tc_v0-WS7-dEkyZcyGip-B5AQ_12_4"></a><a id="Tc_uZOytDtuqEWfrYqjvX8Qzg_1_2"></a><a id="Tc_ZbkMxbDNGUCTzLMFJa8UcA_2_5"></a><a id="Tc_4A0hean4NUukFz4N-xHgzA_3_2"></a><a id="Tc_9n5TjRjLGUKdOME88xqXnw_3_5"></a><a id="Tc_mxjwmjAfMESadY0Pn-V71Q_4_2"></a><a id="Tc_s3aULMrwl0qipj9V_JtijA_4_5"></a><a id="Tc_aGP0ycFD5UGXmkEepI_uLQ_5_2"></a><a id="Tc_a0TN2XhwZkm_7MQTW8odLA_5_5"></a><a id="Tc_yICtMtbR80eOXU09KvY_aw_6_0"></a><a id="Tc_E0I9bDq7bU6MkOGLLxunSQ_6_4"></a><a id="Tc_ts7uscAlmUifqYltxJ-qEg_7_0"></a><a id="Tc_4hyMeJvI30WbWjsYDCSC9Q_8_0"></a><a id="Tc_mkGeAqXhSUCLiCtqkaCWoA_9_0"></a><a id="Tc_VylwS3AHO0OM8dyCSn4g8w_10_0"></a><a id="Tc_mivxoTkjlUeGXZ5OvLB_Ow_10_4"></a><a id="Tc_RYr_2TK8kkWlZwFFyk1nSg_11_0"></a><a id="Tc_6exlGAWf4UOnebkzJ7lcUw_11_4"></a><a id="Tc_3dC3-nHxOk6atLQnDNBnXw_1_2"></a><a id="Tc_st30_xPZIESB0VG2cTvmIA_2_2"></a><a id="Tc_5siPd9yDtECoYJ6OL6lHZw_2_6"></a><a id="Tc_CuU62OpwsE2fUGxd540aKw_3_2"></a><a id="Tc_BamXNCGRbkemIeG6JkmRGg_3_4"></a><a id="Tc_RLBcomBgi0eUdNjp8ZQv5w_3_8"></a><a id="Tc_Cq5dosc_V0GfAcEl8HkSLg_4_2"></a><a id="Tc_UX7OvsyR80uweXVqfoZ1Hw_4_4"></a><a id="Tc_1sfHH8zKSkGU-ShM-64pMA_4_8"></a><a id="Tc_VBUuR-phlkqiYzO166rCJw_5_2"></a><a id="Tc_MyOIAZlAi0WdvJSw6EkNQg_5_4"></a><a id="Tc_C_FVSLxFLkqnHlNl7h5TJw_5_6"></a><a id="Tc_PxCjA7VjwUSdQdUxr9_g8Q_5_8"></a><a id="Tc_Ylr8qZb2_kK_-PZPD0UhkQ_6_0"></a><a id="Tc_VhgRW6qHk0mzwracOWM-tA_6_2"></a><a id="Tc_xppdyhEGCEuSGn62nF_zFQ_6_4"></a><a id="Tc_CDiL5ZCUGUepZ_0dsctQBQ_6_6"></a><a id="Tc_nAmIWJAp5ESFiVhVZaGXOg_6_8"></a><a id="Tc_21LGeoWwtkKXrYbiGJ4kYw_7_0"></a><a id="Tc_i4QMhe6lX0eNUEhc3YvIsg_7_2"></a><a id="Tc_bMzhxM6f-Ei5rNv7p27W_Q_7_4"></a><a id="Tc_dGyQ63zImEm4kF0Iq8SVKA_7_6"></a><a id="Tc_cI-C-Ycw8ECSsSS0-TsYKQ_7_8"></a><a id="Tc_MvkEtTzlmkOnMGAk0mqNHA_8_0"></a><a id="Tc_0Di5OsywG0ueCD_tke3eMg_9_0"></a><a id="Tc_1lXBLb43n0Gy-tmlEHhe9g_10_0"></a><a id="Tc_lVdmCdE4EUqc5BQg4fshIA_11_0"></a><ix:continuation id="Tb_tQhjd1HGh0WhBO71oqsZ3Q_cont2" continuedAt="Tb_tQhjd1HGh0WhBO71oqsZ3Q_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Options and restricted stock granted to employees and directors:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of share option plans, and related information, under all of the Company&#8217;s equity incentive plans for the&#160;year ended December&#160;31, 2024, and the effect of share-based compensation on the statement of operations for the&#160;year ended December&#160;31, 2024, is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Group_JaEe-wVdPkeRXo0eICR-VQ" continuedAt="Group_JaEe-wVdPkeRXo0eICR-VQ_2" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Options granted to employees and directors:</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><ix:continuation id="Group_JaEe-wVdPkeRXo0eICR-VQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gk0_QwpkNUi8I2fbbRac5A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_WIBHsqJvj0eeZbQSQj-JyA_6_2">6,965,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gk0_QwpkNUi8I2fbbRac5A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_z67vqcZS-U2j8Oc3RS9HUw_6_5">2.13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_ygZ_lLYjdkewtRpTD5dgKA_8_2">1,015,725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_1Yym2ACU00OlzYO48hBZJA_8_5">1.10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">Forfeited  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_7YQ_8bX-6EO2t0PO9_tNhQ_9_2">326,969</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_hBzuH4tJDE2VeoIliBMfyw_9_5">1.36</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_3kSMN5eZ4EKF3ZsQEAW-YQ_10_2">252,062</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_pU_A4eF9HkOBfuzvGhhQVg_10_5">3.60</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_V7gvzO9fdE2ntwQ96Fp-5Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_pZYTeIv5FUmENmanrySvBA_11_2">7,402,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_V7gvzO9fdE2ntwQ96Fp-5Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_NtJ_QhmWCUyM3Lt6wVu02Q_11_5">1.98</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_V7gvzO9fdE2ntwQ96Fp-5Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_BdUnDk8bDkmEIaluY_AVTg_12_2">4,247,896</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_V7gvzO9fdE2ntwQ96Fp-5Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_S83D6UoevEyfjSvE2CdBmQ_12_5">2.49</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="Group_9TNZKzPMTE2kEdieYWA-eA" continuedAt="Group_9TNZKzPMTE2kEdieYWA-eA_2" escape="true">Restricted stock granted to employees:</ix:nonNumeric></p></td></tr></table><ix:continuation id="Group_9TNZKzPMTE2kEdieYWA-eA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">  </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restricted</b></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> of fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at grant date</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_gI5UhphCH06Ect3eEtQGMg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_GjoU4GB7F0aTHl5Xgdo0VQ_6_2">1,173,670</ix:nonFraction></p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_gI5UhphCH06Ect3eEtQGMg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_5PwYJEJ6BUShCOSxqnEd3w_6_5">2.16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Granted</span></p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_Z5QnOERk-06-nyPWu58wJw_8_2">704,869</ix:nonFraction></p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_09P-NuZdB0KO1CSHRyzaLg_8_5">1.24</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Forfeited</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_gGD7vQDKd0iJu9SUypAmng_9_2">23,410</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_-CYilF36oU2dSrY2hK5S9A_9_5">1.99</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Vested</span></p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_MutQqKjn2Uujs5O1R5M5LQ_10_2">992,313</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_oGKXSeAl5UODK9MyQkJaRQ_10_5">1.91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non vested at end of year</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AzD7wSLn2kKSXb3VDmVzTQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_trttbJNi9kGVot9_FF2QNQ_11_2">862,816</ix:nonFraction></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AzD7wSLn2kKSXb3VDmVzTQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_MJyjDqJkQ0e3L8Y2ZJX0Jw_11_5">1.70</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Group_OtdCdYXN80m4wQ0maiBgtA" continuedAt="Group_OtdCdYXN80m4wQ0maiBgtA_2" escape="true">The following table summarizes information concerning outstanding and exercisable options as of December&#160;31, 2024:</ix:nonNumeric></p></td></tr></table><ix:continuation id="Group_OtdCdYXN80m4wQ0maiBgtA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:58.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at&#160;end&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_ZwQZST8ycESPqOtaPxvgmg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_8nG2C0LhNkGIYYRVXAMwGg">1.03</ix:nonFraction>-$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_ZwQZST8ycESPqOtaPxvgmg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_N6yG0Hjqs0qHEaLPBqkJtQ">2.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_Ggw7m_bIUEukSBW28yKxbA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_TkuSCz_D5UWmeiN9qEum6A_8_2">5,899,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_ZwQZST8ycESPqOtaPxvgmg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_XDDhHOeKhkuMbmXnMHA-rQ_8_4"> 7.94</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_Ggw7m_bIUEukSBW28yKxbA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_THhTsODyGUyjeSvAcRlP2g_8_6">2,744,767</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_ZwQZST8ycESPqOtaPxvgmg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_U9tmrecbDk2PdfKjcZtyKA_8_8"> 6.95</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_i8MSOPNUfk-c4_p410zsvA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_HULJHnk2jEmHHhx7SToZow">3.55</ix:nonFraction>-$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_i8MSOPNUfk-c4_p410zsvA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_Hlwr1SA6sUqL-3Z8gKK-2A">3.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_CZ0iGJrw8kGgZlq0gK2Vkw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_iFnRMK2wsUa4lrpq-nkZwA_9_2">994,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_i8MSOPNUfk-c4_p410zsvA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_AO9Wkar4l0SOd3gz-AM8Pw_9_4"> 4.61</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_CZ0iGJrw8kGgZlq0gK2Vkw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_1-WYElFqy0OZFEYlC6ubWA_9_6">994,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_i8MSOPNUfk-c4_p410zsvA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_tCUVjih8g0WgkyfxmPhY_w_9_8"> 4.61</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_D7MJGpt1U0KbxRKh_zdQpA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_Y4O6AcSHqkuZX6b6I0LjqQ">4.69</ix:nonFraction>-$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_D7MJGpt1U0KbxRKh_zdQpA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_Zo16E8zKfEWsuiL7UigaUg">5.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_c58oJTn8dU-QqeJQC9hc2g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_3AQX_yHQ502XDl9DVEdAqw_10_2">435,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_D7MJGpt1U0KbxRKh_zdQpA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_z_-szT0C8EOZpLDRj7HqCA_10_4"> 3.88</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_c58oJTn8dU-QqeJQC9hc2g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_-Uu4e-PF6kG4gZWDm4E8Xg_10_6">435,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_D7MJGpt1U0KbxRKh_zdQpA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_0TFOQEBHPEuNlpq_RoyHsA_10_8"> 3.88</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_6w7SOn5UPUu_KdKhVUxCsA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_PWEseGJU5ESkzWVMFOKfFw">17.20</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_k1pPvAGNuUqJ8-G1h9Wyeg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_EkgKeugyzkSZAizyqezMYw_11_2">72,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_6w7SOn5UPUu_KdKhVUxCsA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_q6HgaPnwdkSjRZVGzuI3pw_11_4"> 0.21</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_k1pPvAGNuUqJ8-G1h9Wyeg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_yhJUVfK54ku8JWPjhFf5ig_11_6">72,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_6w7SOn5UPUu_KdKhVUxCsA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_ZmZ_RsmjrUe5uK5Lauj0cA_11_8"> 0.21</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_FiIXqzjykkmpHoyY48xM-A_12_2">7,402,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_ON52nUH9Z02cN4HESjt2YQ_12_6">4,247,896</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_SbyP8vz-H0KyXu1003KBFA_1_2"></a><a id="Tc_M_jmXSurqUWKRa4p9oYm8g_2_2"></a><a id="Tc_2kviCgmCvESk632kJyLUTg_2_4"></a><a id="Tc_UdAqqxv5ZUaFb5mYIOCIuw_2_6"></a><a id="Tc_GnbJmjiU1kCBu9sRo9s5xg_3_0"></a><a id="Tc_lsjQDHnZGkSJalUf3HhBFw_4_0"></a><a id="Tc_HuLwfr_ct0WSOiCCjJ0E3g_5_0"></a><a id="Tc_jZPDbMMJ_kyoFMjQ-RNHVA_5_3"></a><a id="Tc_9sNHc0lwT0avgaeUFV-sVA_5_5"></a><a id="Tc_SPdOOBPmDUa2WnL7x6vKTA_5_7"></a><a id="Tc_PpcUyNL-VkKTcnI1tyW-hQ_6_0"></a><a id="Tc_NjFxPV4zvU26bDZvmq0VYQ_6_3"></a><a id="Tc_-67vF6CeSkSzkSonTPaYXA_6_5"></a><a id="Tc_dvFidfsYtUSTfboF3ty9iw_6_7"></a><a id="Tc_7HDhDU7CRkSOMzJNU-Fc-w_7_0"></a><a id="Tc_tUlLtI5ufUiuHSrSjyTqKw_7_3"></a><a id="Tc_uHA4f9TREkC6H4VmCDRs7g_7_5"></a><a id="Tc_omvZLJhiZUyZtBST93Z4kw_7_7"></a><a id="Tc_PqT7xAN0EkSHecybKh3Phw_8_0"></a><a id="Tc_Naw8jB8gL0a1OOFxtgD-Wg_1_2"></a><a id="Tc_a7Plb_bjBUunvQXOejXOhg_2_0"></a><a id="Tc_IlnTwHvCxkG7XwtwykFu2Q_2_2"></a><a id="Tc_scDdzXMQLEmQYL8TmtargQ_2_5"></a><a id="Tc_VHDEztBye0WgYM8YfD74Zw_2_8"></a><a id="Tc_atxfThRaMU-_901xiSuAGw_3_0"></a><a id="Tc_b-JFb2LQAUW5SqN0_emvRA_3_2"></a><a id="Tc_6rqY4b3LNE2KtavIGjGzsQ_3_5"></a><a id="Tc_2J6UmuykV0G-R5_UvlGnRw_3_8"></a><a id="Tc_wCEAPCsbtU6OqodZBjJcgA_4_0"></a><a id="Tc_gvKfHGQB_UuvvL0rYoMtow_5_0"></a><a id="Tc_hK794JrR8EK8qddkdvN-Xw_6_2"></a><a id="Tc_VTAxT7xSIEmJEL2Rd56aNw_6_5"></a><a id="Tc_shre4veNsEa6X6TSyrWf2w_6_8"></a><ix:continuation id="Tb_tQhjd1HGh0WhBO71oqsZ3Q_cont3" continuedAt="Tb_tQhjd1HGh0WhBO71oqsZ3Q_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"><span style="color:#231f20;">As of December</span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;</span><span style="color:#231f20;">31, 2024, the aggregate intrinsic value of all the outstanding options and exercisable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">options</span><span style="color:#231f20;letter-spacing:0.05pt;"> was approximately </span><span style="color:#231f20;letter-spacing:0.05pt;">$</span><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Narr_oHCd2Kapd06tQKQPdrcd1g">1.0</ix:nonFraction><span style="color:#231f20;letter-spacing:0.05pt;">&#160;million and </span><span style="color:#231f20;letter-spacing:0.05pt;">$</span><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="Narr_1cWRNEnThES9pd0ok4_Jdg">0.5</ix:nonFraction><span style="color:#231f20;letter-spacing:0.05pt;">&#160;million, respectively.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The weighted average grants date fair value of restricted stock granted in 2022, 2023 and 2024 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AqEdmyQF8UC1svkRrbF5pg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_PJsCMR4mLECyhVXTxduLwQ">0.82</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_yX24jpZNrE2GFNvD-IrRLg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_NSQUSpiDh0Ktif5joeqBTw">1.99</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qjP7y_S0VUuKi14nuJCCzA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_iQjxVScGoketlfP7QfViRw">1.24</ix:nonFraction>, respectively.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Group_rE5BDku8q0yA28KOsyIf3w" continuedAt="Group_rE5BDku8q0yA28KOsyIf3w_2" escape="true">The fair value of each option granted during 2022, 2023 and 2024 for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the options&#8217; fair value on their grant date:</ix:nonNumeric></p></td></tr></table><ix:continuation id="Group_rE5BDku8q0yA28KOsyIf3w_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Weighted average grants date fair value (USD)</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PjbfOLibbE-CFhp_5N4qIg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Tc_UTanaOcdG0q9HnBmFHQItQ_3_2">1.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0w_5kQqvoEm_P4OrjYWqWA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Tc_haKMw4Vz7UqK6TsE7blWcQ_3_4">1.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Tc_P__2L4XAmke35m1yV9QyGA_3_6">1.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PjbfOLibbE-CFhp_5N4qIg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_ITkZ0cjObkOiFGTivkQsFQ_4_2">1.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0w_5kQqvoEm_P4OrjYWqWA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_pbJqh9NIrE-o1Y1nSv01IQ_4_4">1.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Tc_glNvgLjcgESqiRCeSZEXmw_4_6">1.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qzrqPtv4Nk2sivn3hBJl_A" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_GW2dDE6vJ0eeC6mxbdmWNw_5_2">3.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GiEgmTjqQECUzJqeHnRG3g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_Kg6gVx2iVkSK64WOHtghOQ_5_4">4.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_wHtrVQrF00Cm11h_98RWsg_5_6">3.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qzrqPtv4Nk2sivn3hBJl_A" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_WRdoiiU6fEyd3HmwEhZfNg_6_2">85.94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GiEgmTjqQECUzJqeHnRG3g" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_Q1Y0W7gDpEqvV1nPCBxNiQ_6_4">79.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_whroeIaIvUyoRFrkwvLafQ_6_6">79.29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qzrqPtv4Nk2sivn3hBJl_A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_lfa418aKvEuHtncbLfKlaw_7_2">0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GiEgmTjqQECUzJqeHnRG3g" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_bH1RJrvuGkymMIjv6CMNYA_7_4">0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_iU5Grp_ZFkyA-_tJqVsKbw_7_6">0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qzrqPtv4Nk2sivn3hBJl_A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_tt5KRIyOpUa7wFYMqwQmlQ_8_2"> 6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GiEgmTjqQECUzJqeHnRG3g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_MdQClQXVz0284HLlkkLMlQ_8_4"> 5.75</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_wfIDam89JkquwEu7Kzkm1Q_8_6"> 5.75</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The total unrecognized compensation cost of employee stock options at December&#160;31, 2024 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_UXUytBKUZ0yAsvW3YDS7UA">1.3</ix:nonFraction>&#160;million. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_Ws0t7weCaUaRtxbP2OiJ7g">0.8</ix:nonNumeric>&#160;years.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;">During the three years ended December&#160;31, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZT00cGmYjUugrLQ9Ej7B2Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_fLlwNGgWrUO5Nv--_R3cLQ">no</ix:nonFraction> exercises of stock options, and the Company did not realize any tax benefit in connection with any exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;"><span style="background:#ffffff;">The total vesting-date value of equity classified restricted stock vested during </span>the year ended December&#160;31, 2024<span style="background:#ffffff;"> was </span><span style="background:#ffffff;">$</span><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qjP7y_S0VUuKi14nuJCCzA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_381-V-Z9e06lEFk05tsjGw">1.2</ix:nonFraction><span style="background:#ffffff;">&#160;million. As of December&#160;31, 2024, the unrecognized compensation cost related to all unvested equity classified restricted stock of </span><span style="background:#ffffff;">$</span><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_SDy9pRI4jka-vazM2Ar37Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_I4rLJUE1WUmSySiUZfci-g">0.6</ix:nonFraction><span style="background:#ffffff;">&#160;million is expected to be recognized as an expense over a weighted-average period of </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qjP7y_S0VUuKi14nuJCCzA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_ygeBQkZGJUuvEIaXep2fnA"><span style="background:#ffffff;">0.7</span></ix:nonNumeric><span style="background:#ffffff;">&#160;years.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">g)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Group_e2uJDec5RUGhD1EbsxbkoQ" continuedAt="Group_e2uJDec5RUGhD1EbsxbkoQ_2" escape="true">The following table illustrates the effect of share-based compensation on the statement of operations:</ix:nonNumeric></p></td></tr></table><ix:continuation id="Group_e2uJDec5RUGhD1EbsxbkoQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9RS1hcr690mkdTePbZl2Pg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4XxF5faTm0OkIW704HBpoQ_3_3">135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_GkNNnx-5s06WAA30ohh8Nw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_E1MEix9yp0Cd-R4f01ekyA_3_6">596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_A7nWnFTiPkOdLlt5xxqpEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_5dKkCsZADky2uFmv5rm58Q_3_9">631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XRg9HSXWv0C3QWfvvFGWxA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_uSTy5cIS7EClT1gyAFWjqw_4_3">518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0aTAUQn5Gkm5jNYX11QpwQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_wLquSK6vGU-xgYYSs0GVWg_4_6">777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6ZtY09PpU0m9d_EG_ZwvkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_NwTrizRvdEenddgWsMsWng_4_9">589</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_L8FMbjn4ykuUigKlaKNOwQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_bbb_OIwF7UqGd8I32el7KQ_5_3">1,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_REAyJtvAFU2ys4pnWOJcXw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_nzm19bA-40m3I1nCsEMl7A_5_6">2,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_UuhJLwHi6Em0GrZfesGVyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_jnPoonOatkOn9GYeyQEx3w_5_9">2,033</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_jlZl4VFTgEeLtyYeYO7s6Q_6_3">2,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_yFFa_3qBTU-K3iZoLkG3Bw_6_6">3,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_3xj5uzlRg0aRccYUBvY-mw_6_9">3,253</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Private and 144A Offerings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2022</span>, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_vxkDkBSQz068hELrseMSzA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_bjoPaNS6GUOaDlhQtEpu6g">1,000</ix:nonFraction> shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_vxkDkBSQz068hELrseMSzA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Narr_N7XgzSDnDUarLvKMDDhRLQ">2,360</ix:nonFraction> from such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2023</span>, the Company issued (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xZcFCwrL3kSsF04JdIujqg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_XjDnf_8cj0GgGfO-gsBg8w">301,810</ix:nonFraction> shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xZcFCwrL3kSsF04JdIujqg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_cATZxbO0jkap8Ygp45jW6Q">0.7</ix:nonFraction>&#160;million from such exercise and (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xZcFCwrL3kSsF04JdIujqg" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Narr_UgxBeHdEdUGdR3_QGTni0A">237,012</ix:nonFraction> shares of Common Stock in connection with the cashless exercise of a </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_tQhjd1HGh0WhBO71oqsZ3Q_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_MOfdfIKjcUiCrIPtQO8BWA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_8Fb-jAhxiUyT_B9Lm8SYMg">845,000</ix:nonFraction> shares of Common Stock issued in 2020. The Company did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2023</span>, the Company issued, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VM8wfhoeo0Cfc2e6wRsqqA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_VkuUgUKBSkOQs0opKIN5kg">4,691,623</ix:nonFraction> shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during <span style="background:#ffffff;">the year ended December&#160;31, 2023</span>, the Company paid to the converting holders $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VM8wfhoeo0Cfc2e6wRsqqA" decimals="-5" format="ixt:num-dot-decimal" name="plx:PaymentsToDebtHoldersOnConversion" scale="6" id="Narr_4WKB1YdZj0-KwMFCtOwanA">0.9</ix:nonFraction>&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;At-the-Market (ATM) Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell from time to time through the Agent<span style="background:#ffffff;">, shares of Common Stock having an aggregate offering price of up to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_Yo6i5FE6pU22Md7ma24KKg" decimals="-5" format="ixt:num-dot-decimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_jGAE_UdRp0iYuGcCkDgf3Q">20.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million </span>(the &#8220;ATM Shares&#8221;)<span style="background:#ffffff;">. </span>During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_7_1_2021_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_pvpGc5YOlE--wrnCQNPHeg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_7yhZLVQ9FE6qaSGkSWCB4w">13,980,060</ix:nonFraction> ATM Shares for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_7_1_2021_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_pvpGc5YOlE--wrnCQNPHeg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_hgkdVSuTQE6svvjrbB-BNA">20.0</ix:nonFraction>&#160;million, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to <span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_wXBT2eXbL0O3AsKeYlYxOA" decimals="-5" format="ixt:num-dot-decimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_lA_gf0RSG0CbiSeTrLonyg">20.0</ix:nonFraction></span><span style="background:#ffffff;">&#160;million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has no obligation to sell any shares of Common Stock under the 2023 Sales Agreement, and may at any time suspend sales under the 2023 Sales Agreement or terminate the 2023 Sales Agreement in accordance with its terms. The Agent is entitled to a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_NYbG0_upI0OqrbiUEof-HQ" decimals="3" format="ixt:num-dot-decimal" name="plx:PercentageOfCommissionOnSaleOfShares" scale="-2" id="Narr_BhDdbc_vXUWtM2zxcI3DDw">3.0</ix:nonFraction>% of the aggregate gross proceeds from the shares of Common Stock sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2022, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_nxW7H0bxUUC9vT-aI9jhyA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_p5zQBpJud0WrA9y9zsvSqA">7,473,038</ix:nonFraction> shares of Common Stock under the 2021 Sales Agreement. The Company generated gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_nxW7H0bxUUC9vT-aI9jhyA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_on0xqM07dEeBnleXZjvB2g">8.7</ix:nonFraction>&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2023, the Company sold, in the aggregate, <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_tIPYYN_ZtU-qDljU2Ir6gA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_8t56ValgEkOZK4T7jdhc_g">12,560,150</ix:nonFraction> shares of Common Stock under the 2021 Sales Agreement and 2023 Sales Agreement. The Company generated gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_tIPYYN_ZtU-qDljU2Ir6gA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr__kUg29eQiEWdiY_0cMC6yQ">24.9</ix:nonFraction>&#160;million in connection with such sales. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_7_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_cGsHWgE_gUuxZ-cHUDKhgw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_94ARtEAiz0WBypBdQvWdBg">No</ix:nonFraction> sales were completed during the six months ended December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2024, the Company sold, in the aggregate <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_F6fA0kenUkmkxMJFS7dV_w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_u_-oxcdAm0KbLLCVJ8p58A">2,216,692</ix:nonFraction> shares of Common Stock under the 2023 Sales Agreement. The Company generated gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_F6fA0kenUkmkxMJFS7dV_w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_KdNPJw8QkEae324JTWR9_g">3.8</ix:nonFraction>&#160;million in connection with such sales (issuance cost was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_F6fA0kenUkmkxMJFS7dV_w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_3EVa5QL5HkunmaqIUV60tA">0.1</ix:nonFraction>&#160;million). All such sales were completed during the quarter ended December&#160;31, 2024. Subsequent to December&#160;31, 2024, the Company sold the remaining amount of shares of Common Stock available for sale under the 2023 Sales Agreement thereby completing the ATM program thereunder.</p></ix:continuation><a id="_NOTE_10_"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_ujyb91I_LEeULuLbTSFcBw" continuedAt="Tb_ujyb91I_LEeULuLbTSFcBw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 9&#160;- CONVERTIBLE NOTES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="color:#212529;">In September 2024, the Company repaid all of the </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_2OeigBROdEaDOLaH-ucKEg" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="Narr_wWIOAs7qekej1tEVxYdEgQ">20.42</ix:nonFraction></span><span style="color:#212529;">&#160;million outstanding principal and interest payable under the 2024 Notes. The repayment of the convertible notes at maturity was financed entirely with available cash.</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_28195651_5b53_456c_b394_edd9614bd437"></a><a id="Tc_kstpf7dus0edHsqHSIa8mw_1_2"></a><a id="Tc_lW7pQymtMkON5OQ_BLk7Vw_2_0"></a><a id="Tc_qD7QKmkav0WIl-aZQCkWqg_2_2"></a><a id="Tc_gnC8rr8V-0WKS-mly3MULg_2_5"></a><a id="Tc_WzW8ZwAcYUWt2q733pkqBg_2_8"></a><a id="Tc_cCivhJCMd0aol5xrLUXPeQ_3_0"></a><a id="Tc_YQZN_JyYNkmB8J1CqA2xpA_3_2"></a><a id="Tc_MuShLCVKIEWsr93uk3kQ0Q_3_5"></a><a id="Tc_TijUWzMm8EqW9CEv6xCVkw_3_8"></a><a id="Tc_2kxqzB5Kw0e9qJlkGAfFyg_4_0"></a><a id="Tc_v7gxIcH07U6J-CtqrMUF-Q_4_9"></a><a id="Tc_aXi7yI9BLkupuM1B3aJWNQ_5_0"></a><a id="Tc_moPmUBjgWkeWm7OLLnI2cA_5_2"></a><a id="Tc_vRo-EobNRkyeox-9k7J31A_5_5"></a><a id="Tc_ZEhw-ZlD4U2LpodBGOWu7w_5_8"></a><ix:continuation id="Tb_ujyb91I_LEeULuLbTSFcBw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The 2024 Notes were issued pursuant to an indenture entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the 2024 Notes was payable semi-annually at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_PqNi2C8w-UiBnkc4Uh5lLw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_W4n31ahFTE67czrZFTCYHg">7.50</ix:nonFraction>% per annum. The outstanding 2024&#160;Notes matured <ix:nonNumeric contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EYL9IKHmnkqnNQvhCDuZ0A" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_Q5t1ugfTV06Mxi8WQs8EKA">three years</ix:nonNumeric> after the issuance thereof and were guaranteed by the Company&#8217;s subsidiaries. The 2024 Notes were secured by perfected liens on all of the assets of the Company and its subsidiaries.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="Tb_EU20KgN2JkiuDXrBA5vhaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2024 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024*</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kOxCb2VXAkiXIt-mPT3RhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_VfXAMwJbZ0i0Fyw-pbjogA_3_3">2,156</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_nUbBkLnYekaez7e1Ka3ENg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_COHg1_ek7UObDtSu3-NoXw_3_6">2,534</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="Tc_SDQe1xxvhUyV0Hc66Nl10Q_3_9">1,022</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kOxCb2VXAkiXIt-mPT3RhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_Cv4y4kQScUGXraoBSiDpcA_4_3">300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_nUbBkLnYekaez7e1Ka3ENg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_VHi4Eqz6M0mStTwGhQrqfQ_4_6">267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kOxCb2VXAkiXIt-mPT3RhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_3x6uhSbso0ePPniWxua_Ag_5_3">2,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_nUbBkLnYekaez7e1Ka3ENg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_QtfB4bl4qkqMXEBQlBjH3g_5_6">2,801</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestCostsIncurred" scale="3" id="Tc_xGhFaeZ140WbXRySWy3czw_5_9">1,022</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>* See also Note&#160;1(r).</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_yGn3uiNfeUabNO3MFP_40w" continuedAt="Tb_yGn3uiNfeUabNO3MFP_40w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;10&#160;- FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_yGn3uiNfeUabNO3MFP_40w_cont1"></ix:continuation><a id="_2870bcd5_9eed_4bd2_a333_a4e1f5703c4b"></a><a id="Tc_hXDSx1KIZkOvJftyDorvwg_1_3"></a><a id="Tc_24MpO-XgN0-1RgtJqoQRwQ_2_0"></a><a id="Tc_iSh1KUJfikiUQJpPMZD1VQ_2_3"></a><a id="Tc_ZQnljqFnYU-WxQXEhi27Kw_2_6"></a><a id="Tc_4aw5hJ1-KUOlZ05pDPQKpA_2_9"></a><a id="Tc_ULUK5P0N-02ZI9x3N3bcDQ_3_0"></a><a id="Tc_Y-1QxF_LeEWcawurTPp9-A_4_0"></a><a id="Tc_IEqvinU1TEWua2PKK-a81g_4_2"></a><a id="Tc_OiwCY53_R0q6q70KD2gEqg_4_5"></a><a id="Tc_9_QKYn3RoU2MQmpuEtOAFw_4_8"></a><a id="Tc_nqC7x-dW3UmLGn6EVNU_gQ_5_0"></a><a id="Tc_S8Mgq6GfdkiLVXKsXUe-bw_6_0"></a><a id="Tc_59oirPwDyU2R00gcR_WQxg_7_0"></a><a id="Tc_xvzR40Yhk0aPu0dJaQx9Lg_7_2"></a><a id="Tc_zWk3mtXjT0-7lnR7V9X2SQ_7_5"></a><a id="Tc_zYRtMS-YCES3qKY1u_Cekw_7_8"></a><a id="Tc_sU8Qf43glEKAkLcYsvEVng_8_0"></a><a id="Tc_7_VOpkNrdUqZQXOcfzeKQA_9_0"></a><a id="Tc_HzKji0K5IkKlI-Frw3SfJA_10_0"></a><a id="Tc_YuAuhQwHXUuldy5mxj6EyQ_11_0"></a><a id="Tc_ixwBaVKI3EmhMqByEC8myA_12_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_3gbxNBhaD0WGOCsLYytYoA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;11&#160;&#8211; NET EARNINGS (LOSS) PER SHARE</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_aFgRrT2IU0CD3L4jXJsadw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:43.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Xk_NzAN9VE-aYdfOl7wCOQ_4_3">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_T3XvFcOj1USeq4soI5yt2g_4_6">8,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_nawaQPq7G0e35F7eLFWKAA_4_9">2,932</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DilutiveSecurities" sign="-" scale="3" id="Tc_xR8Ax3EzOEalOhLPFO4yJw_6_6">1,168</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DilutiveSecurities" scale="3" id="Tc_PV9gq55EmUWO70eMz8ts-Q_6_9">39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_iFBG3BRNy02tnVyk7XuRtA_7_3">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_d8pvx-unQk-pmGuVEhRU1w_7_6">7,144</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_xUZh0jfcCEK_4vJqzXKz9A_7_9">2,971</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_mot7dQNIXUqb_SS1H40Mjw_9_3">48,472,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_JtbiVZcRDUihl3CnMQ4wsA_9_6">67,512,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_g5ioxJhl_0af5946AkoA7Q_9_9">72,530,698</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_EZLBeu8AokCMENJlldTraA_10_6">13,335,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_dRMlr4in2k-IkTG8yl1D4A_10_9">7,667,323</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options and restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_ITIvYBOLQke0HWXvgBrE4g_11_6">1,576,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_bmbpMpYL6UaTYe1HF4i9qA_11_9">859,155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_L7kaX1KkvU6tiXXtwxGY9w_12_3">48,472,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_hg-w098_tkKcfu7tDxx1Ww_12_6">82,424,016</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_6ctgjrxnMUKUjs1cW_OTeA_12_9">81,057,176</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the year and inclusion of make-whole interest payments that will be incurred upon conversion.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted loss per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_wHXsbG_dxEq9ZOpZb9KkbA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_2uibjN107Uy9RiAmPnPABQ">34,097,716</ix:nonFraction> shares of Common Stock underlying outstanding stock options, warrants and convertible notes of the Company for the year ended December&#160;31, 2022 because the effect would be anti-dilutive. In the year ended December&#160;31, 2023, the diluted earnings per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_0rzuJ4XtCE6Cs1WYUEVqEw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_gUXmgDYLvE2bZr_HYkex9g">18,254,264</ix:nonFraction> shares of Common Stock underlying outstanding warrants and stock options because the effect would be anti-dilutive. In the year ended December&#160;31, 2024, the diluted earnings per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_iQmr4uFt5kqfTe94aSywZQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_TQSF7pZEjECdYwWIkGIFDQ">16,661,907</ix:nonFraction> shares of Common Stock underlying outstanding warrants and stock options because the effect would be anti-dilutive.</p></ix:nonNumeric><a id="_NOTE_13_-"></a><a id="_NOTE_12_-"></a><a id="Tc_1ZHjwt7TTEauwFvRUEtyfQ_1_3"></a><a id="Tc_6ktNMFmeAkOTJFBZZx1a3A_2_0"></a><a id="Tc_QOqEdrcZUkinnKz2H9BL8A_2_2"></a><a id="Tc_KEr9oATvL0exxQq-wiyaWg_2_5"></a><a id="Tc_bPFAVZNNgEuBanZn__zurg_2_8"></a><a id="Tc_7XLdzsQau0i4ztp35d-S2g_3_0"></a><a id="Tc_n78y3x6CmUevzs85ZF1UzQ_3_2"></a><a id="Tc_vnBPckxt1EO8Zc0Fr-Ibqg_3_5"></a><a id="Tc_70j9c5m1WEGub7PvDDlujA_3_8"></a><a id="Tc_fjg0t8_WUUqxNecPYifAFA_4_0"></a><a id="Tc_tZaYFJ8KL0WZnTCODEBv_g_5_0"></a><a id="Tc_v5ayF9UwAUW4J7efgaqXoA_5_2"></a><a id="Tc_yj1Pu-Jif0adIBJBB7dSow_5_5"></a><a id="Tc_W_q8BHIcvUmuQSKqz1MoYw_5_8"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_CYyUChrcPEustD0TA50Yqw" continuedAt="Tb_CYyUChrcPEustD0TA50Yqw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;12&#160;- TAXES ON INCOME</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics,&#160;Inc. is taxed according to U.S. tax laws. The Company&#8217;s income is taxed in the United States at a rate of up to <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_XGzd5dVqLk6U007ZQL4UiQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_09cSP1TWO0iJwY2_bTZc6Q">21</ix:nonFraction>%.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Group_EXsRMfXWmES37A1FbFd1gA" continuedAt="Group_EXsRMfXWmES37A1FbFd1gA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p></ix:nonNumeric><ix:continuation id="Group_EXsRMfXWmES37A1FbFd1gA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:37.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_ZGOoWMWzcEqzXOmiIogDUA_3_3">530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_IQK3Z-CSoEW5Q-Yu8wnpnA_3_6">3,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_egCA5VP2Rk2LAx4dlP_7Bg_3_9">986</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_h5zppj4B90KeS1K28pl0NQ_4_6">3,092</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_mYUREfZ3QU6iiIQxlzuCMQ_4_9">236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_PsOOBK8MvE-hWs13omU3pA_5_3">530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_XqiNAVQtSkqKqhy9YrHmEg_5_6">254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_UElFulPKEUOTULCHm1Viww_5_9">1,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Following the regulatory approvals for Elfabrio in May 2023, the receipt of the $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_5_1_2023_To_5_31_2023_NW-Pj9G-fkyAiLj-xYz3Gg" decimals="-5" format="ixt:num-dot-decimal" name="plx:MilestonePaymentReceived" scale="6" id="Narr_NbaGTsfDjUmeFXEC0UGovA">20.0</ix:nonFraction>&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released the valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_5_1_2023_To_5_31_2023_NW-Pj9G-fkyAiLj-xYz3Gg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="6" id="Narr_5XJbcLNVH0GBLp7njevLVA">3.1</ix:nonFraction>&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_CYyUChrcPEustD0TA50Yqw_cont1" continuedAt="Tb_CYyUChrcPEustD0TA50Yqw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted into law in December 2017 (the &#8220;TCJA&#8221;) which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The TCJA represents fundamental and dramatic modifications to the U.S. tax system. It contains several key tax provisions that impacted the Company including the reduction of the maximum U.S. federal corporate income tax rate from 35% to 21%, effective January&#160;1, 2018. Other significant changes under the TCJA includes, among others, a one-time repatriation tax on accumulated foreign earnings, a limitation of NOL deduction to 80% of taxable income, and indefinite carryover of post-2017 NOLs. The TCJA also repealed the corporate alternative minimum tax for tax years beginning after December&#160;31, 2017. Losses generated prior to January&#160;1, 2018 will still be subject to the 20-year carryforward limitation and the alternative minimum tax. Other impacts due to the TCJA included the repeal of the domestic manufacturing deduction, modification of taxation of controlled foreign corporations, a base erosion anti-abuse tax, modification of interest expense limitation rules, modification of limitation on deductibility of excessive executive compensation, and taxation of global intangible low-taxed income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Modification of interest expense limitation rules under the TCJA provides generally that for taxable&#160;years 2019-2022 interest expense deduction shall be limited to 50% of the EBITDA and for taxable years 2022 onwards to 30% of EBIT. Disallowed interest deduction may be carried forward indefinitely. The Company believes that any potential impact (if applicable) of this limitation will be offset by utilization of available NOLs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Section&#160;174 of the TCJA requires taxpayers to capitalize and amortize research and development expenses for tax years beginning after December&#160;31, 2021. This rule became effective for the Company during the year ended December&#160;31, 2022, and resulted in the capitalization of research and development costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="6" id="Narr_BVMjw3fZAkmc4Kv1OsFE4A">28.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="6" id="Narr_nN_0Qg7yg0iZBC4wz1HkYA">14.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="6" id="Narr_o-HbeteBhkCSnvreizXqag">11.9</ix:nonFraction>&#160;million in 2022, 2023 and 2024, respectively. The Company will amortize these costs for tax purposes over <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" format="ixt-sec:durwordsen" name="plx:CapitalizedResearchAndDevelopmentCostAmortizationPeriod" id="Narr_mOQcshjZ_06sDsFMHhwoDA">15&#160;years</ix:nonNumeric> for research and development performed outside the United States and over five years in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company believes that all future profits of its Subsidiaries will be indefinitely reinvested or that there is no expectation to distribute any taxable dividends from these Subsidiaries. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is estimated as an immaterial amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Protalix&#160;Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company as a &#8220;foreign-investment company&#8221; measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986. The Israeli Subsidiary is taxed according to Israeli tax laws:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tax rates</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The income of the Israeli Subsidiary, other than income from &#8220;Approved Enterprises,&#8221; is taxed in Israel at the regular corporate tax rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The corporate tax rate was <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2018_To_12_31_2018_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_81bs3kgDHU6NRu_L1eP3yg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_o66de2LBykuIZaDrUlCDYA"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_QXqL2IzWNEGo_hK_uR7-8Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_WfbCYoAVbUGWjdbKDhOHwQ"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_PrcXvhjZKk2qgA6qvhDFGQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_isOWDobrKUyvxPWte69F7Q"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_LmlSAoEiIUGYRz9pAOa8jA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_pFE_OVEnEkCSpIs2orVaOg"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_Rre_qLcyTEWy4BikH0eDPA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_d32IvPDHHkquxDtgZqwJGQ"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_vDFNTndzl0OM84fywfGerA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_M-SkMUkwikufXnwEcsjxpg"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_2uwOm7rxyEOlHzvvqCFFJg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_JwXpTFXc_0uhKbsELogBrg">23</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% for 2018 and thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Capital gain on a sale of assets is subject to capital gain tax according to the corporate tax rate in effect in the&#160;year during which the assets are sold.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_CYyUChrcPEustD0TA50Yqw_cont2" continuedAt="Tb_CYyUChrcPEustD0TA50Yqw_cont3"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Law for the Encouragement of Capital Investments, 1959 (the &#8220;Encouragement of Capital Investments Law&#8221;)</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Under the Encouragement of Capital Investments Law, including Amendment No.&#160;60 to the Encouragement of Capital Investments Law as published in April&#160;2005, by virtue of the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; status the Israeli Subsidiary is entitled to various tax benefits as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">a.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Reduced tax rates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">Income derived from the Approved Enterprise during a 10-year period commencing upon the&#160;year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary has an &#8220;Approved Enterprise&#8221; plan since 2004 and &#8220;Benefited Enterprise&#8221; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expired in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; during the tax exemption period, it will be subject to tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable if such income not been exempted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">b.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Accelerated depreciation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">c.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Conditions for entitlement to the benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary&#8217;s entitlement to the benefits described above is subject to its fulfillment of conditions stipulated by the law, rules&#160;and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Israeli Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#8220;Approved Enterprise&#8221; from the Investment Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">d.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Amendment of the Law for the Encouragement of Capital Investments, 1959</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">In recent&#160;years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law. On December&#160;29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &#8220;Preferred Technological Enterprise&#8221; and &#8220;Special Preferred Technological Enterprise&#8221; (the &#8220;Capital Investments Law Amendment&#8221;).</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_Yaz0_A-3GUCus9k5rUbl4Q_1_2"></a><a id="Tc_G_69uaiHEkiOM-pmWUAGZw_2_0"></a><a id="Tc_t6ehT1tFQUarVq_JOr2fFw_2_2"></a><a id="Tc_b1jQMOLNF0-O-EOrYp9z-A_2_5"></a><a id="Tc_HyV-3Qe930CJMCENzmbsnQ_3_0"></a><a id="Tc_AwsuSFDQXEazE_1XKv9Dpw_4_0"></a><a id="Tc_R3cm5YaiT0Ow1BngrbUvFw_4_2"></a><a id="Tc_C5c40rUbb0epSuWvvhlOcA_4_5"></a><a id="Tc_IYrXIJ1WMEiyr9KNZKy72g_5_0"></a><a id="Tc_RZOVeNuSPEe1dCRdLHgpoQ_6_0"></a><a id="Tc_T3WEKHogiEGXkK3jypQcBw_7_0"></a><ix:continuation id="Tb_CYyUChrcPEustD0TA50Yqw_cont3" continuedAt="Tb_CYyUChrcPEustD0TA50Yqw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">To date, the Company has elected not to have the Capital Investments Law Amendment apply to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Tax losses carried forward to future&#160;years</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2024 and 2023, the Company had aggregate NOL carry-forwards equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_hNk55GnFoEqpBg5PMMN8oQ">227.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_-wVbzQws1EaH8Vnq1NMgKg">234.8</ix:nonFraction>&#160;million, respectively, that are available to reduce future taxable income as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company&#8217;s carry-forward NOLs, equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_IFWTaYE7TEGUIFQbsRvpcA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_6ZkeAldg20qHg6-l7clFfw">24.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_7Kls7CQ7NUqv6IHxTOTP0g" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_na-Fn4wCakaJsVHFE5WVtQ">22.2</ix:nonFraction>&#160;million as of December&#160;31, 2023 and 2024, respectively, may be restricted under Section&#160;382 of the Internal Revenue Code (&#8220;IRC&#8221;). IRC Section&#160;382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post change&#160;year that may be offset by a pre-change NOL may not exceed the general IRC Section&#160;382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Protalix&#160;Ltd.</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">At December&#160;31, 2023 and 2024, the Israeli Subsidiary had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_hbAAdy1AFUuwPTqCDJatww" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_acl2apoeO06DkNRncRG-5A">210.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_k_HBgOQfk0GnMVqO03JGnQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_NTKOE0KCHEePFizm-U-CFQ">205.0</ix:nonFraction>&#160;million, respectively, of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Deferred income taxes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Group_Pod1Y9IETEemo9P-2pHGGQ" continuedAt="Group_Pod1Y9IETEemo9P-2pHGGQ_2" escape="true">The components of the Company&#8217;s net deferred tax assets at December&#160;31, 2023 and 2024 were as follows:</ix:nonNumeric> </p><ix:continuation id="Group_Pod1Y9IETEemo9P-2pHGGQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In respect of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_kfKnfWS9LEquSWbc1usL4w_4_3">4,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_zEsCoyN5b0ST-2wH_CyIfg_4_6">3,055</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other timing differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:DeferredTaxAssetsOtherTimingDifferences" sign="-" scale="3" id="Tc_35KMSnGfmEmxYB-iE2qxXg_5_3">1,387</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="plx:DeferredTaxAssetsOtherTimingDifferences" scale="3" id="Tc_ifRxxCsYZUegqbGzUvIxDA_5_6">452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_7lyhncnHx0ajb2pV0mxybQ_6_3">51,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_kO4vjh62DUSG9OEPpFz9iQ_6_6">50,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Z5jFzbz8iEWuFH5iw3OPFA_7_3">51,618</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_3ensud_Y-EGIBck7HpRqeQ_7_6">50,665</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_DEd1zlLJhk6UAxDkGKeXhQ_8_3">3,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_5IZUEqlE_0OaXG7bQ3MS-g_8_6">2,856</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_tnfmGsLU50e9kUlEpqHT5Q_1_2"></a><a id="Tc_UyIHPMuyekKfmtcQbXjXYA_2_0"></a><a id="Tc_AqJpZZ1Xh0aq44_3U8sGdw_2_2"></a><a id="Tc_jrMnsIiViUahXMgbXF_5IA_2_5"></a><a id="Tc_cD_yXiEWFkKyYFXqXWSnJA_2_8"></a><a id="Tc_g0_bMUfLt0uQF74wdQof4w_3_0"></a><a id="Tc_f0NyW_2PsUGiO4X8j0dvhA_3_2"></a><a id="Tc_ReTiAsy2p0aTrlokCkLSaQ_3_5"></a><a id="Tc_qko9eeASrUe7E0QLYVVO1Q_3_8"></a><a id="Tc_QmJbttvlvk6NASiOboupEg_4_0"></a><a id="Tc_kASpwn-DN0mKBoED-XuGCA_5_0"></a><a id="Tc_A0SYQPS110aIJyVZOtDgAg_6_0"></a><a id="Tc_oxSpL40W6km5_hcf4PQRSQ_7_0"></a><a id="Tc_o-vlDNEjB0-slamo6ZTZZQ_8_0"></a><a id="Tc_YuFxJU3ZbE-9TaYJ96JAhQ_8_3"></a><a id="Tc_C2nPHEIv7E-jcjUF-BVNWg_8_9"></a><a id="Tc_dsDOYa5V80aVdyaqj5EajA_9_2"></a><a id="Tc_csywUzZg2UWyTSSmlPu-qw_9_5"></a><a id="Tc_LBMQtifKE0G9_u6p1yFZFw_9_8"></a><a id="Tc_XsBiiFMHO0KO08BBifvtrg_1_0"></a><a id="Tc_gkuGT8IrDkOGfNya06DYcA_2_0"></a><a id="Tc_MuMveJiJYUar4vKXV3xCOg_2_2"></a><a id="Tc_6xQ-2AMUzki3wdh42yHu6g_3_0"></a><a id="Tc_GhIk8RoWYE-52oxgsuiqJw_4_0"></a><a id="Tc_IF2JmoadJEqiMsQdTzO7WQ_5_0"></a><a id="Tc_PqtH89ZzqkGXDK4ZuKGQSw_5_2"></a><a id="Tc_j6HeVVnTA02G-OO9tL-9rQ_7_0"></a><a id="Tc_jehRbJi-AkuAeLkpkz1Z0g_7_2"></a><a id="Tc_Vah8obQ4VUSKmwHWA-s27w_8_0"></a><a id="Tc_CDwWZJG2aUi35bWTVlQHgg_8_3"></a><a id="Tc_oqOlRBeM2USn4eXTlM2fjA_9_0"></a><a id="Tc_-hS9oCrpk0K1hyco1yGtZw_10_0"></a><a id="Tc_zNVRZ54dsUmchCg2_xQnig_10_2"></a><a id="Tc_2urK65WNXEayHcgRffaNww_1_0"></a><a id="Tc_YQxLX-DktkWbKLcZF2OcSg_2_0"></a><a id="Tc_k2rzmSRrDkKJvu156rFxnw_2_2"></a><a id="Tc_mnQ7QkCMgEOsvipa_cr04w_3_0"></a><a id="Tc_AQsD5IfhaEK_4xDD6x10HA_4_0"></a><a id="Tc_gL23RvpFbk6jLRIZxquRWA_4_2"></a><a id="Tc_i1mpbM7eHEm70MpQsligDA_6_0"></a><a id="Tc_VUR-4TVfUUqack3zpOW38A_6_2"></a><a id="Tc_rCzncKk8ZkGhAUQ6vJZOtw_7_0"></a><a id="Tc_Cu9qbFNeHEqXmwv9C8P7iA_8_0"></a><a id="Tc_gp0I9zc4-Um-2Pppa6i_Pw_8_2"></a><ix:continuation id="Tb_CYyUChrcPEustD0TA50Yqw_cont4" continuedAt="Tb_CYyUChrcPEustD0TA50Yqw_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Reconciliation of the theoretical tax expense to actual tax expense</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Group_5lB7iSJ4vUmU19P0KKTLsQ" continuedAt="Group_5lB7iSJ4vUmU19P0KKTLsQ_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A reconciliation of the statutory U.S. federal income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_ece485bhc0SMZvtcKCBgBQ"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_RKfFS4gC6kuluQZqwV1FPQ"><ix:nonFraction unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_Kd1wk5KA-0eO7q8FZxL5UQ">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2024, 2023 and 2022 to the effective income tax rate is as follows:</p></ix:nonNumeric><ix:continuation id="Group_5lB7iSJ4vUmU19P0KKTLsQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:31.51%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax computed at the statutory U.S. income tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="3" id="Tc_LcaSuUJjSU2aV4Av5RpDOw_3_3">3,023</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="Tc_bPb7LP0TL0KUcyyam_qxIA_3_6">1,799</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="Tc_XKbJT6dDE0iAap58Lslw0w_3_9">872</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Differences in tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="Tc_UZ2pAunOTESOFbSP8O8RVg_4_3">1,512</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" sign="-" scale="3" id="Tc_6qzOcUr2sU-wllF73vntuw_4_6">899</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" sign="-" scale="3" id="Tc_luUcsu36b06jajLQDIIcUA_4_9">436</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutorily non-deductible expenses </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="Tc_8ZqWKQvv0EiA-SmBdJwjxQ_5_3">2,979</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="Tc_VkBQR1iTCkiTM2viL8AlVw_5_6">1,684</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="Tc_xy9W1RjKMECCa1GoHXMbrA_5_9">506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in Valuation allowances</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="3" id="Tc_ErJZZm91-UOb6MUhgivn1Q_6_3">2,970</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="3" id="Tc_3zM2w5Lq7keuQrE7BKjVnQ_6_6">6,932</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="3" id="Tc_A12EcJQWhEG1WNF_tEYpvA_6_9">953</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Utilization of carry-forward losses and other temporary items without deferred taxes recognition</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" scale="3" id="Tc_toMOic1xKkGBVAiiX8GNFg_7_3">2,032</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" scale="3" id="Tc_ZqNEDqt3wUSSBppdEZSF0Q_7_6">3,602</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" scale="3" id="Tc_R8jY4Kw5wES1VMSn1H1teA_7_9">1,233</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Withholding tax </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:EffectiveIncomeTaxRateReconciliationWithholdingTax" sign="-" scale="3" id="Tc_QHJLuhLu5UCTkT4PD27zlA_8_6">1,000</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:middle;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_j7eFvlZkfUyVPZNT-TX06A_9_3">530</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_m02wndHK70yy2jwMd1izpA_9_6">254</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_Sk_K0X8n0E-o0UE_jXhNUg_9_9">1,222</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-weight:bold;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Valuation allowance roll-forward</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="Group_hBZ6X-QhsE-HhLECKCe1wQ" continuedAt="Group_hBZ6X-QhsE-HhLECKCe1wQ_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table presents the change in the Company&#8217;s valuation allowance during the periods presented:</p></ix:nonNumeric><ix:continuation id="Group_hBZ6X-QhsE-HhLECKCe1wQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Kfgp5ANjvUCihqVVuMQGpQ_2_3">58,550</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" scale="3" id="Tc_9dIJBvSSZ0etE8z_6kDFXw_3_3">728</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" scale="3" id="Tc_ME4fE9twdkqSCQCdTINcvA_4_3">7,660</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_Ir1-qULNA0G8blvA0GbOiA_5_3">51,618</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_ABWpMu6iU02uBxBaMco0Xw_7_3">51,618</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" scale="3" id="Tc_Yt87BPYWnkSPQZcoB8kKdw_9_3">953</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_R02ILVPgpUiDUT_Oq0EZJA_10_3">50,665</ix:nonFraction>)</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Uncertain tax position</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Group_0ewjuPm860CIvmv6LOOT8A" continuedAt="Group_0ewjuPm860CIvmv6LOOT8A_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Provisions of ASC 740-10, Income Taxes, clarify whether to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, is as follows:</p></ix:nonNumeric><ix:continuation id="Group_0ewjuPm860CIvmv6LOOT8A_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_q0mBUAmTvEi75h0ijLs0HQ_2_3">530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_GhyD4cTcSEmf63V7An1rFQ_3_3">275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_rqVmBbjxs0-4MvYjza-VTg_4_3">805</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_WI3blCcRp0mcuaxpK0e53A_6_3">805</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:fixed-zero" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_vmQKNmUd60O6mnhREiOHEg_7_3">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_lmogYZ45lkCoN9_5HiCf9A_8_3">805</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_CYyUChrcPEustD0TA50Yqw_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Tax assessments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In accordance with the Income Tax Ordinance, as of December&#160;31, 2024, all of Protalix&#160;Ltd.&#8217;s tax assessments through tax&#160;year 2019 are considered final.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="plx:ScheduleOfOpenTaxYearsTableTextBlock" id="Tb_zbuBoXHEXkSInJx8tncIAA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of open tax&#160;years by major jurisdiction is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Jurisdiction:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_CJv_84vfq0aMskjfjX9YfA" name="us-gaap:OpenTaxYear" id="Narr_aq-d5RhV0UmchwIcFMB1Uw">2020</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_MVIrjw2PD0mL89oHKVh0jg" name="us-gaap:OpenTaxYear" id="Narr_cvWIhKnqqEKVsC1_g6US9g">2024</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United States (*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_jt7xO17tI0q-J4gtN5A1ag" name="us-gaap:OpenTaxYear" id="Narr_ihVMBg7GjUGMOTzPll4lWQ">2021</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_JlcwElfBZkmmA58XlgqPmw" name="us-gaap:OpenTaxYear" id="Narr_HUqpDuV8lEG-EN5aU4N00A">2024</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p></td></tr></table></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1pt;margin:0pt;"><span style="font-size:1pt;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_NOTE_13_"></a><a id="_116b3c78_eb50_4367_876b_2b4d901ae4d0"></a><a id="Tc_5yuf23jl-UGCVJgY7Oxgrw_1_2"></a><a id="Tc_MjZiO52o_EW_EAZTASnAYw_2_0"></a><a id="Tc_X4vaq_GBRk-UqmNM58VHCw_2_2"></a><a id="Tc_eqdOtrLkZEa00LrrmrrVcQ_2_5"></a><a id="Tc_Kx4rWCR2rkCeH9ofge9cwA_2_8"></a><a id="Tc_wFKyZ0m4rE23_LiHNnupEg_3_0"></a><a id="Tc_AG1N9WuuCE6PPA8h8ppf3g_3_2"></a><a id="Tc_tKWZ6-IjQUKO3DiB7A2aJQ_3_5"></a><a id="Tc_ywPK1PCRzUe_Ns-wWhpxkg_3_8"></a><a id="Tc_O0xOE39YsUOf-7g6hcSLzQ_4_0"></a><a id="Tc_NnbH8Qo-RkiPHVemeETLEA_5_0"></a><a id="Tc_z3MF9xY0wEKfY6gh-0YX9g_6_0"></a><a id="Tc_j0AoHFcs0UKgXvCd_VcBDQ_7_0"></a><a id="Tc_zmrZBsHSo0mXjkJF9-_DEg_8_0"></a><a id="Tc__AdUayefvESytq_4Zgf1qQ_9_0"></a><a id="Tc_REu4qvEX50yeRLFRvLm64w_10_0"></a><a id="Tc_6wfx6pzRm06KyO379U06aQ_11_0"></a><a id="Tc_7Vxtq6bW5U2oCVOFdE7f-Q_12_0"></a><a id="Tc_pT4iAQB9xE2Y2vQ141ByEg_13_0"></a><a id="Tc_LSG3u5grKUiTedhuY9iLig_13_2"></a><a id="Tc__PmlzOsLhUSWrRiSLA_4wg_13_5"></a><a id="Tc_VGKmg_RkwEyPlbULN5aNpQ_13_8"></a><a id="Tc_MP08GjuAF0qs_Px8g2Ocfw_1_3"></a><a id="Tc_geTWXJP5wkWTxy2rQ96AYA_2_0"></a><a id="Tc_uQv9y2dOUkCIpo7qZRWmwQ_2_2"></a><a id="Tc_6NNqmjLbb0-lepVYz5Li2g_2_6"></a><a id="Tc_xU8fzZsgREOgb-DYQAPt7A_2_9"></a><a id="Tc_UXrPjTQM9kWQWGHHfPUkmQ_3_0"></a><a id="Tc_MK73CCKm1Ea0NYAMPqvPdw_4_0"></a><a id="Tc_2nZic-54LEOlCkrsZ8_rZQ_4_2"></a><a id="Tc_WIzoXKDHKE2hvaoNYKdEmA_4_6"></a><a id="Tc_z3EJIr83rEWSh_FgU3ZCCA_4_9"></a><a id="Tc_ebfroxD0hEe8TmPKI-mtHQ_5_0"></a><a id="Tc_pTt3Pit0N02Ji86Qc0fytQ_5_2"></a><a id="Tc_i5GB-RnJYka-Fai9Efa7Bw_5_6"></a><a id="Tc_jf3tmW2j7EGeT-mRKUI2bQ_5_9"></a><a id="Tc_0y2RkWPvwkuLdmF1x055Tg_6_0"></a><a id="Tc_Cz1S6dLZ8kSbmOvPLvLOhQ_7_0"></a><a id="Tc_TirFeRwL-UWHp-NMkTnn_Q_7_2"></a><a id="Tc_gGaBCVLEEkaBOXwwi5iqaw_7_6"></a><a id="Tc_AwuNGCPYukWGZ67KWbWkcw_7_9"></a><a id="Tc_CZDW3EtraUao3rs_PqOq-g_8_0"></a><a id="Tc_8NXwLyDl50yX3ViAlpjQwg_8_2"></a><a id="Tc_oc-xgmWDu0GTwBoNI74weg_8_6"></a><a id="Tc_gIOqJSsrPkWeaEvM3wZs_w_8_9"></a><a id="Tc_RwpR2Tl_BUmJ8OAgpWzaJg_9_0"></a><a id="Tc_Zm96P_MVtUWmc75L8WT5Bg_9_2"></a><a id="Tc_3uvnuQgmXEOfhGIXe7_7-Q_9_6"></a><a id="Tc_4YHAjPV3XUKJoqrJJi3WOQ_9_9"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_zUJfKFBZl0W7USA-zpIC3A" continuedAt="Tb_zUJfKFBZl0W7USA-zpIC3A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;13&#160;&#8211; SEGMENT INFORMATION</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company operates in Israel as a </span><span style="-sec-ix-hidden:Hidden_yJU9lqNC-UmtulHxkqsD_Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> operating segment. The Company&#8217;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.</span></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="Tb_vkXoTUIRaEG1CVpjIMH0Cw" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:34.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_NzCV8iBzcEq4HJwGSislJQ_3_3">47,638</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_jd-9F0YpAkmgKel_PUiOow_3_6">65,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_7LN2Mj2QD0eayPMoyc68Ig_3_9">53,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_dxNuHM6yAUSEWA1F1Yu09w_5_3">19,388</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_GCEroX-N-UmWKTsKuendWQ_5_6">24,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_yU2yvXumEUO1VFYgOmhtxQ_5_9">21,780</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_a61hRjpziE-YfzWgyyHVfw_6_3">24,181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_gtcQ3hY8Bkq6II1wFABYwA_6_6">14,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_ocN7bEEfY0e_xSxl0D-iLg_6_9">8,682</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_ArjxFJOjdUyf1e7LeBJiOQ_7_3">2,529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_ssEuGSIrmEaQqLZw-BHWnA_7_6">3,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_SVMhcpvdzkujhwY5MOiXNw_7_9">1,062</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc__4sQiPmO_k2ssLnKfKWwzw_8_3">1,146</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_WoWsukM_zE22TP8gEeiYlA_8_6">1,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_KbM6WjH4S0aDDQbES8ku8Q_8_9">1,299</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_fKruCLDBHE6Gpgte3mteyQ_9_3">1,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_aWqMiiclc06PdIV3nozVdQ_9_6">1,191</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_Hq3zJ1eitkmKrYVZkqHCKw_9_9">1,304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_lmLqM7Dfi0im9p84qncV_Q_10_3">15,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_4Z43DfiuxEenVCJQ8dZKIA_10_6">15,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_A5UoW_UPNEmT56TDrN0gvQ_10_9">17,716</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income before income taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_ftEwQD42_k6fpDFoXaKM0g_11_3">14,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_D3i8Ti_As0ObZI57k66-Gw_11_6">8,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_j8h2e4kddUayLm3O6UJesQ_11_9">4,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_vd9edD0OJEyDspsxkKBL9A_12_3">530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_tJOldF0A5E6wvBxeNvrExA_12_6">254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_NEzhkrBCjkKiMHuh8tXceg_12_9">1,222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_PP9Etj9pUEuGGSSpYzyz-w_13_3">14,927</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_Sw-e58SMSEm72XmzBp5cXQ_13_6">8,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_oyGKa3g52UCkxjWRLvu-LQ_13_9">2,932</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_v1Rmq85s7EWNb-y8WNRL4g"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_Sc_L_A8v6kmDDbxCu4Q7Dg"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_JI28fZiqDEGaeeYlfIlzeA">Other expenses included in net income includes raw materials, rent and utilities and others.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="Group_L8chZpRBpU2FpPdMdP9EBQ" continuedAt="Group_L8chZpRBpU2FpPdMdP9EBQ_2" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><ix:continuation id="Group_L8chZpRBpU2FpPdMdP9EBQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.17%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_E_xaP5k14k6Q6Z72Y_IfPA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_09bhS96EVEqKaOCYsJIYXQ_4_3">12,403</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_gyzvZwhYWUOBEq112uDzLg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_imly_kP-MkOlDGfOAoKsdQ_4_7">12,522</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_vAdZZrKJB0GA0kWl76_O5g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_dXIIynuJWEOCKuuA9AkxEQ_4_10">12,617</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xaYAPIOiqEOStP3Kpoa1Bg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_1q-CrEUhAUGbhFAMVdxYkA_5_3">9,452</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_QZxZBUTrMkaZV4V80woRlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_xNNSXERQV0Gh_WYohCSpQg_5_7">10,401</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_yxjzBIAj6UibHOxMuOXLmg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_TxjIMAkxbUqbsaXte-ktJA_5_10">11,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_nzjGNNa5BUaHDbbP-O186A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_tXDwzvEsYEeZjNaFoKjRvA_7_3">3,437</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_cq0BPynITUyIX0XEGY5DFg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_9ibmk-ZAXkCUt7J8Zy-pKg_7_7">17,495</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_e4DfQC6YoEqi8RVuaPKj1w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_KbKwG8_OoUa1GJQI39NwXQ_7_10">29,333</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_PQ5mf5BQdkWUxiMCts1pFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_NXP6oDpUhkiTLjWIV8ocNA_8_3">25,292</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_aKTCTOwnPkytYKKR5g2_wA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_YfUj9VvzrE-7hXiXlHa4qw_8_7">40,418</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_HHFZ61393UWe4ugtQPzFMg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_POMG1kHa3UWRU-cc9G9lrQ_8_10">52,981</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_w4HPugC1VEGsdplZft_5fQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_kozVDPQBVUKJYvO77BIrag_9_3">22,346</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_n_xrcTEwnEeMZJ4ZcUw8eA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_S8TJgfBLL0eaeu_C6U5SWw_9_7">25,076</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kRf1Vl0L_E68nTZynfgMNw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_Sr0Z7x_eVkWeKfHgHnK5HA_9_10">418</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.7pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long lived assets are located in Israel.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_zUJfKFBZl0W7USA-zpIC3A_cont1"></ix:continuation><a id="_73f960ad_5752_420d_8783_ad8d2e519d13"></a><a id="Tc_Orgu_usUKUKXBjLV5X8tnw_2_2"></a><a id="Tc_YPdAd0dHjkemhBLYVlaIiQ_3_0"></a><a id="Tc_AxDViSv0dE6xuP18Q1qCSg_3_2"></a><a id="Tc_af5ACEfVKEiHRTky-b2gkA_3_5"></a><a id="Tc_fYAf1PDMDkmfL8WmQIe3wQ_4_0"></a><a id="Tc_DkL01IkZwUK5Z_LQjaBeMw_5_0"></a><a id="Tc_4eroYNYzfEmLFtyfbO9C8w_5_2"></a><a id="Tc_NvuR0iB6c0WNJjDSG_LkFQ_5_5"></a><a id="Tc_Obrtm5VnP0SPdRdI2paI7A_6_0"></a><a id="Tc_W1R9k4pgXkuiYg2RrXTbHQ_7_0"></a><a id="Tc_D7h0eVwfnEiD4MIrWEvn3g_8_2"></a><a id="Tc_S4MtFpNQ5EOBMflgt0rGRg_8_5"></a><a id="_6a48e2ae_f89a_48d3_981e_fd922cca3af8"></a><a id="Tc_HHd9E7iUgE2myru4-0QLqA_1_2"></a><a id="Tc_UOW877jBjkOIYUecERJt5A_2_0"></a><a id="Tc_Uvlx6vSs7029yOVWnA6FSw_2_2"></a><a id="Tc_6b4RsF6DxkKpu_XNVH6BJA_2_5"></a><a id="Tc_JziE1kkMW0OPjU41uXRoSQ_3_0"></a><a id="Tc_NFmo5l6erEWjhkwLxlsxHg_4_0"></a><a id="Tc_aFHNmoAawkqiX4-8jIFY6Q_4_2"></a><a id="Tc_v6NbqPZPVEaVxRTYXwc4gQ_4_5"></a><a id="Tc_GsZJi7PMO02_QW2DD6RuMA_5_0"></a><a id="Tc_fIm8atVNl0WAKrg-cF7wQQ_5_6"></a><a id="Tc_52Zh2vBqbUqGNfE81vhRYA_6_0"></a><a id="Tc_YSrAp1iCb0q-PEIWXAzLoA_7_0"></a><a id="Tc_dgvmWvkV4U6hinAqKqQx0A_8_0"></a><a id="Tc_XUTOJ2EURkKir0p8V5nuPA_9_0"></a><a id="Tc_PRAdLo32oUyyu7GViaMBZQ_10_0"></a><a id="Tc_kr9OYq2FDkKOmVjg4tOgIA_10_3"></a><a id="Tc_NOFInjIxI029qc7jlu8IWw_11_0"></a><a id="Tc_inxryEc9Uk68_kra8hpo8w_11_6"></a><a id="Tc_c6sMymEUX02yQsK-HkWufA_12_0"></a><a id="Tc_NkF4IV4eeUSw-DyL72KYXA_13_2"></a><a id="Tc_9QO44T3cNkGO22fdFAz4Rw_13_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_0z5_AaWnAkS-s1XIpE2n6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;14&#160;- SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 49.5pt;">a.&#160;&#160;&#160;&#160;&#160;Balance sheets:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="plx:SupplementaryBalanceSheetsInformationTableTextBlock" id="Tb_gG-0oArouEO_vfbI5qyVfg" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;&#160;Other assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherAssetsInstitutionsCurrent" scale="3" id="Tc_BFLlVtrMd0el8siBbpCL4Q_5_3">482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherAssetsInstitutionsCurrent" scale="3" id="Tc_5DwpTGx-FEqL8pdFBh2IKQ_5_6">486</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_tYMAMp_5FU-gi0o9-4wMpg_6_3">444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="Tc_QxzxaKQOcEiJUaO9RxHCew_6_6">500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sundry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherAssetsSundryCurrent" scale="3" id="Tc_F-wV-Mr-u0259UrZcP9NGg_7_3">129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherAssetsSundryCurrent" scale="3" id="Tc_ryj2S4gDnE25pJ-ZIr1C-w_7_6">110</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_t7nE-bndYE-ysFapVbV1vg_8_3">1,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_gR-GbgkzQkao5ncn3noAjQ_8_6">1,096</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_3ZWXDTHzXEC4P77CipuX5g_4_3">1,437</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_jZ_wYimxckSRDneJYn3HtQ_4_6">1,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="3" id="Tc_n_QAM4rBuEG3H_QWzYpuhw_5_3">511</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_w1ZxCuUCLkCZag9_5gtIWg_6_3">1,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_VkdGDuFleEqxvWtQzxgP0g_6_6">1,811</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_u_0R-v_f4kCFuqW8txnRFA_7_3">9,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_koTxPi_XnkSqpfeeGZp_cA_7_6">9,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_rTLjjO9Ypk-gRfu_dgQ9Kw_8_3">637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_cxwh9Zd91UOl55dOxrzfzQ_8_6">1,080</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_h5Lf2v5__U6be8HqvfXRdw_9_3">2,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_cILrZsPF7UuPcoPuBNUXWg_9_6">3,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="plx:PayableToCustomerCurrent" scale="3" id="Tc_DVoZlrbetUWDphONoNd5ag_10_6">2,056</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserves (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ReserveForDeductionsFromRevenueCurrent" scale="3" id="Tc_6xZYS55AN0GBJD4jOt3v8g_11_3">2,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_vmGAoPVXKEevv8L8dKQizw_12_3">614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_T9Wd-Wol_0aWnJ6wODsWUA_12_6">254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_JEZd7BDa1U6ambckMDkhPQ_13_3">19,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_SWb_ZDTWy0KnU98DUt41BQ_13_6">19,588</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">(1) The balance as of December&#160;31, 2024 is based on a final reconciliation that was performed with the customer.</p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_dyz4Nole4UWDj5Kli1NV6g_1_2"></a><a id="Tc_Zzrxmt0nZk2Rn22EUuaykQ_2_0"></a><a id="Tc_IjXrAGpwY0CMDIXptGn92w_2_2"></a><a id="Tc_nW_KJM8Xuk23mI_9-VG_SA_2_5"></a><a id="Tc_rHLh7D_mvEqkdyYvq66Zvg_2_8"></a><a id="Tc_GGJ_dIeysUSq-w7TYK8qYw_3_0"></a><a id="Tc_fELcJh6z7kubiIPEuKNKXQ_3_2"></a><a id="Tc_38EXriAvk0qz8IjwmH9YUA_3_5"></a><a id="Tc_RNpGmkEeYEeHkN_SB9cLZg_3_8"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_2JJFW_zkG0yq2EZTsa4q2A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;15&#160;- RELATED PARTY TRANSACTIONS</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Group_iaGdkbJqOESiB8_A4V27uQ" continuedAt="Group_iaGdkbJqOESiB8_A4V27uQ_2" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-Executive Director Compensation</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><ix:continuation id="Group_iaGdkbJqOESiB8_A4V27uQ_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation (including share-based compensation) to the non-executive directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mW8C4Y6b6kywMvvRfs9dNA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="Tc_Td13I-7C1UqdYyw_5eb4eQ_3_3">368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_pglWe4H_g0q1VCrHkTEK2Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="Tc_I2kOIpbxSEKumW6TM7X8PA_3_6">429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EoGEj4NR3k60cggFbmTsmg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" id="Tc_K15vEIFSOkqzUNxPgpF1zg_3_9">555</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In September 2023, with the consent of the Audit Committee of the Board of Directors, the Company engaged one of its non-executive directors to advise the Company regarding business development and licensing efforts on a consultancy basis. For the years ended December&#160;31, 2023 and 2024, we recorded an expense of a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_pglWe4H_g0q1VCrHkTEK2Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" id="Narr_8JDZSjsOw0GpYFZJFiuGUA">35,475</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EoGEj4NR3k60cggFbmTsmg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" id="Narr_IqNpF5YNT0mFWTWmHuPeBg">1,350</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> for such consulting fees, respectively.</span></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_T0DwMebzKEabrAJUTHWRyw" continuedAt="Tb_T0DwMebzKEabrAJUTHWRyw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE&#160;16&#160;- SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since December&#160;31, 2024, the Company has collected approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_aERhFlXodEOqRgwjEGZTtA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_AwHL0URI-Eq8BZCyl25H5w">4.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Pfizer and approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_LO7FCaAqo0anOZnr8urSlg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_i11hYyee_UK-r7_h1XAcdA">2.9</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Brazil.</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since December&#160;31, 2024, the Company sold, in the aggregate </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_KFKHQh7CBUC1lg8cpMFN3Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_AYj__Q37R0uzGSbKRgHZ1Q">1,223,935</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock under the 2023 Sales Agreement. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company generated </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">gross proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_KFKHQh7CBUC1lg8cpMFN3Q" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_pxW6SFU9jEGXj6QvZ1qHPA">2.5</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such sales. As a result of such sales, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_RWonuWiPxEq0TdRkIcpNIQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="Narr_8jsqApboYEWysGmPTvQFIA">no</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares remain available for sale under the 2023&#160;Sales Agreement and the ATM program thereunder is now complete.</span></td></tr></table></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_T0DwMebzKEabrAJUTHWRyw_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since December&#160;31, 2024, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_iDlflgLsKkiQFmx1cSBg5w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_L2eGYh8dt0e9PMRwPfc1Jw">908,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg" contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_iDlflgLsKkiQFmx1cSBg5w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_AbNQxtkuMU-A40X3C9r8Ng">2.1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from such exercises. The warrants expired on March&#160;11, 2025. Accordingly, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of March&#160;12, 2025, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ" contextRef="As_Of_3_12_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_PIfW3nBp4kCRd_d9eGzbYg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_ZaJhz8FjnkyGByoPnjwtyg">no</ix:nonFraction></span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants remain outstanding.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In January 2025, the Company deregistered Protalix BV in the Netherlands thereby ending its corporate existence.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>plx-20241231xex4d4.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/17/2025 11:11:37 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;4.4</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The following summarizes the material terms of the capital stock of Protalix BioTherapeutics, Inc. We are a Delaware corporation. The rights of our stockholders are governed by the Delaware General Corporation Law (the &#8220;DGCL&#8221;) and by our Certificate of Incorporation, as amended (the &#8220;Charter&#8221;), and our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), which are exhibits to our Annual Report on Form 10-K filed with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;) and available at <i style="font-style:italic;">www.sec.gov</i>. The following summary is qualified in its entirety by reference to the applicable provisions of the DGCL, our Charter and our Bylaws, which are subject to future amendment in accordance with the provisions thereof. Our common stock is the only class of our securities registered under Section&#160;12 of the U.S.&#160;Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Authorized Capital Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">General</i>. Our Charter provides that we may issue up to 185,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of preferred stock, par value $0.0001 per share. The number of shares of our common stock issued and outstanding as of a recent date is set forth on the cover page of our most recent Annual Report on Form&#160;10-K or Quarterly Report on Form&#160;10-Q filed with the Commission. We currently have no outstanding shares of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Voting Rights.</i>&#160;Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Accordingly, holders of a majority of the shares of common stock entitled to vote in any election of directors may elect all of the directors standing for election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Dividends.</i>&#160;Subject to the preferential rights, if any, of the holders of any outstanding series of our preferred stock, holders of shares of our common stock are entitled to receive dividends when, as and if declared by our Board of Directors (our &#8220;Board of Directors&#8221;) out of funds legally available therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Dividend Policy</i>.&#160;We have never declared or paid any cash dividends on our capital stock. We currently intend to retain any future earnings to finance the growth and development of our business and therefore do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our Board of Directors and will depend upon our financial condition, operating results, capital requirements, covenants in our debt instruments (if any), and such other factors as our Board of Directors deems relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Liquidation.</i>&#160;In the event of our liquidation, dissolution or winding-up, after payment of all of our debts and liabilities, the holders of our common stock are entitled to share ratably in all remaining assets available for distribution after the payment of debts and liabilities and after provision has been made for each class of stock, if any, having preferences over our common stock. Holders of our common stock, as such, have no preemptive or other rights and there are no redemption provisions applicable to our common stock. All of our outstanding shares of common stock are fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Other Rights.</i>&#160;The holders of our common stock have no preemptive rights and no rights to convert their common stock into any other securities, and our common stock is not subject to any redemption or sinking fund provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our Charter authorizes the issuance of up to 100,000,000 shares of preferred stock with such voting rights, rights of redemption and other relative rights and preferences as may be determined from time to time by our Board of Directors. Accordingly, our Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights which could adversely affect the voting power or other rights of the holders of our common stock. The preferred stock could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of our company.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Provisions of Delaware Law, Our Certificate of Incorporation, as Amended, and Our By-laws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Delaware statutory law, our Charter and our Bylaws contain provisions that could make acquisition of our ompany by means of a tender offer, a proxy contest or otherwise more difficult. These provisions are intended to discourage certain types of coercive takeover practices and takeover bids that our Board of Directors may consider inadequate and to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors. We believe that the benefits of increased protection of our ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because, among other things, negotiation of these proposals could result in an improvement of their terms. The description of our Charter and our Bylaws set forth below is only a summary and is qualified in its entirety by reference to our Charter and our Bylaws which are exhibits to our most recent Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Blank Check Preferred Stock.</i>&#160;Our Charter permits us to issue, without any further vote or action by the stockholders, up to 100,000,000 shares of preferred stock in one or more series and, with respect to each such series, to fix the number of shares constituting the series and the designation of the series, the voting powers (if any) of the shares of the series, and the preferences and relative, participating, optional and other rights, if any, and any qualifications, limitations or restrictions, of the shares of such series. The ability to issue such preferred stock could discourage potential acquisition proposals and could delay or prevent a change in control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Number of Directors; Filling Vacancies; Removal.</i>&#160;Our Bylaws provide that the number of directors which shall constitute the whole of the Board of Directors shall be fixed from time to time by resolution of the Board of Directors. Directors shall be elected by a plurality vote of the shares represented in person or by proxy at the annual meeting of stockholders in each year and entitled to vote on the election of directors. Elected directors shall hold office until the next annual meeting and until their successors shall be duly elected and qualified. Directors need not be stockholders. If, for any cause, the Board of Directors shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of stockholders called for that purpose in the manner provided in our Bylaws. In addition, our Bylaws provide that a Board of Directors vacancy resulting from the death, removal or resignation of a director, as well as a vacancy resulting from an increase in the number of directors or if the stockholders fail at any meeting of stockholders at which directors are to be elected to elect the number of directors then constituting the whole Board of Directors, may be filled solely by the affirmative vote of a majority of the remaining directors then in office even though that may be less than a quorum of the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Special Meetings.</i>&#160;Special Meetings of our stockholders may be called, for any purpose or purposes, by the Chairman of the Board of Directors or the President or the Board of Directors at any time. Upon written request of any stockholder or stockholders holding in the aggregate not less than 25% of all of the votes entitled to be cast on any issue proposed to be considered at the Special Meeting signed, dated and delivered in person or sent by registered mail to the Chairman of the Board of Directors, President or Secretary of our company, in a form that complies with all applicable provisions of our Bylaws, the Secretary shall call a special meeting of stockholders to be held at the principal office of the corporation or at such place and at such time as the Secretary may fix, such meeting to be held not less than 30 nor more than 60 days after the receipt of such request, and if the Secretary shall neglect or refuse to call such meeting within 10 days after the receipt of such request, the stockholder making such request may do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">No Stockholder Action by Written Consent.</i>&#160;Our Bylaws requires that all actions to be taken by stockholders must be taken at a duly called annual or special meeting, and stockholders are not permitted to act by written consent. These provisions will make it more difficult for stockholders to take an action opposed by our Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Section&#160;203 of the Delaware General Corporation Law</i>.&#160;Section&#160;203 of the DGCL provides that, subject to certain specified exceptions, a corporation will not engage in any &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for a three-year period following the time that such stockholder becomes an interested stockholder unless (1)&#160;before that time, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder, (2)&#160;upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced (excluding certain shares) or (3)&#160;on or after such time, both the board of directors of the corporation and at least 66<sup style="font-size:7.5pt;vertical-align:top;">2</sup>/<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>% of the outstanding voting stock which is not owned by the interested stockholder approves the business combination. Section&#160;203 of the DGCL generally defines an &#8220;interested stockholder&#8221; to include (x)&#160;any person that owns 15% or more of the outstanding </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">voting stock of the corporation, or is an affiliate or associate of the corporation and owned 15% or more of the outstanding voting stock of the corporation at any time within three years immediately prior to the relevant date and (y)&#160;the affiliates and associates of any such person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Section&#160;203 of the DGCL generally defines a &#8220;business combination&#8221; to include (1)&#160;any merger or consolidation with an interested stockholder or other entity if the merger or consolidation is caused by the interested stockholder and as a result section (a) of Section 203 is no longer applicable to the surviving entity, (2)&#160;sales or other dispositions of 10% or more of the corporation&#8217;s assets with or to an interested stockholder, (3)&#160;certain transactions resulting in the issuance or transfer to the interested stockholder of any stock of the corporation or its subsidiaries, (4)&#160;certain transactions which would increase the proportionate share of the stock of the corporation or its subsidiaries owned by the interested stockholder and (5)&#160;receipt by the interested stockholder of the benefit (except proportionately as a stockholder) of any loans, advances, guarantees, pledges, or other financial benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We have elected not to be subject to Section&#160;203 of the DGCL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Listing Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our common stock is listed on the NYSE American under the symbol &#8220;PLX.&#8221;</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>3
<FILENAME>plx-20241231xex19.htm
<DESCRIPTION>EX-19
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/17/2025 11:11:38 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBIT&#160;19</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Approved as of February&#160;24, 2025</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b><b style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;">INSIDER TRADING AND BLACKOUT POLICY</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This Insider Trading and Blackout Policy provides guidelines to all personnel (&#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restricted Persons</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), including employees (both domestic and international), directors and officers, of Protalix BioTherapeutics, Inc. (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and its subsidiaries, with respect to transactions in the Company&#8217;s securities and the handling of material non-public information, as explained in more detail below, about the Company and the companies with which it does business. In the discretion of the Company&#8217;s Compliance Officer, this Insider Trading and Blackout Policy may also apply to consultants and to contractors of the Company and its subsidiaries who may come into possession of such material non-public information as a result of their work for or on behalf of the Company. In addition, this Insider Trading and Blackout Policy applies to the Company itself when conducting transactions in its own securities.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Compliance Officer or, in the Compliance Officer&#8217;s absence, the Chief Executive Officer, is responsible for the administration of this Insider Trading and Blackout Policy. For purposes of this Insider Trading and Blackout Policy and all other policies of the Company, the Chief Financial Officer shall be the Compliance Officer.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Company&#8217;s common stock is traded on the NYSE American </font><font style="font-family:'Times New Roman','Times','serif';">S</font><font style="font-family:'Times New Roman','Times','serif';">tock </font><font style="font-family:'Times New Roman','Times','serif';">E</font><font style="font-family:'Times New Roman','Times','serif';">xchange. Restricted Persons are subject to U.S. laws and regulations, but may be subject to various provisions of securities laws of other jurisdictions where the Company conducts its business, such as the Israeli Securities Law 5728-1968 and rules promulgated thereunder.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this Insider Trading and Blackout Policy, the Company&#8217;s securities include common stock, options to purchase common stock and any other securities the Company may issue from time to time, such as preferred stock, warrants, convertible notes or debentures and debt securities. The Company&#8217;s securities also include derivative securities relating to the Company&#8217;s securities, even if not issued by the Company, such as exchange-traded options. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">It is important to stress that this Insider Trading and Blackout Policy applies to all of the Company&#8217;s and its subsidiaries&#8217; employees, directors and officers,</font> <font style="font-family:'Times New Roman','Times','serif';">and their respective Family Members (as defined below).</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">This Insider Trading and Blackout Policy does not purport to be a statement of all applicable laws, rules and regulations, whether of the United States, Israel or any other state or jurisdiction, and should not be considered legal advice. It is each person&#8217;s responsibility and obligation to comply with all applicable laws, rules and regulations when transacting in the Company&#8217;s securities or the securities of any other company.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Company may change the terms of this Insider Trading and Blackout Policy from time to time, and shall take steps to inform all affected persons of any material change to this Insider Trading and Blackout Policy.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">I.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insider Trading Policy</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">It is the Company&#8217;s policy to comply with all insider trading laws, rules and regulations of the United States, as well as, if applicable, those of any other country or jurisdiction such as Israel.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">II.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Responsibility</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Restricted Persons may create, use or have access to material information about the Company that is not generally available to the public (such information is referred to collectively in this Insider Trading and Blackout Policy as &#8220;material non-public information,&#8221; as explained in more detail below). Each Restricted Person has an important disciplinary, ethical and legal obligation to maintain the confidentiality of such information and not to engage in any transactions in the Company&#8217;s securities while in possession of material non-public information of the Company. Each Restricted Person and the Company may be subject to severe civil and criminal penalties as a result of unauthorized disclosure of material nonpublic information of the Company or trading in the Company&#8217;s securities while in possession of material non-public information of the Company. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">III.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Guidelines</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Prohibition. </b><font style="font-family:'Times New Roman','Times','serif';">Every Restricted Person who is aware of material non-public information is prohibited from:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">buying or selling the Company&#8217;s securities;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">communicating such material non-public information, to third parties other than those who need to know such information in connection with doing business with or for the Company, as authorized by the Company;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">recommending the purchase or sale of the Company&#8217;s securities; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">assisting anyone engaged in any of the above activities. </font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This prohibition, as well as the other prohibitions set forth in this Insider Trading and Blackout Policy, also applies to information about, and to the trading of securities of, other companies (e.g., commercialization partners, collaborators, customers or suppliers) with which the Company has a relationship until such information becomes public or is no longer material. If your work regularly involves handling or discussing confidential information of one of our commercialization partners, collaborators, customers or suppliers, you should consult with the Compliance Officer before trading in any of that company&#8217;s securities.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This Insider Trading and Blackout Policy does not usually apply to the exercise of employee stock options (without a subsequent market sale). However, it does apply to the sale of securities of the Company as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option. It similarly applies to the delivery of outstanding Company securities to pay the exercise price of an option or other derivative security (if otherwise permitted). However, it does not apply to sales of the Company securities by the Company upon the vesting of restricted stock or restricted stock units to satisfy tax withholding requirements per the terms of your award agreements, if applicable.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This Insider Trading and Blackout Policy also applies to gifts, donations and other such transfers of the Company&#8217;s securities or other companies as set forth above.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">There are no exceptions to this Insider Trading and Blackout Policy other than those described in Section&#160;III(7) and Section&#160;IV below. Engaging in transactions in the Company&#8217;s securities that are otherwise necessary for personal reasons, such as personal financial commitments, remains prohibited if you possess material non-public information of the Company.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Transactions by Family Members; Entities Controlled by You. </b><font style="font-family:'Times New Roman','Times','serif';">The prohibitions outlined in this Insider Trading and Blackout Policy also apply to any &#8220;family members&#8221; who reside with you, anyone else who lives in your household and any other family member whose transactions in the Company&#8217;s securities are directed by you or subject to your influence or control and any entities under your control. &#8220;Family Members&#8221; includes your spouse, any child, stepchild, grandchild, parent, stepparent, grandparent, sibling, mother or father-in-law, son or daughter-in-law, or brother or sister-in-law (as well as other adoptive relationships) with whom you share a household.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The prohibitions similarly apply to (a)&#160;all trusts, family partnerships and other types of entities formed for your benefit or for the benefit of a member of your family and over which you have the ability to influence or direct investment decisions concerning securities; (b)&#160;all persons who execute trades on your behalf; and (c)&#160;all investment funds, trusts, retirement plans, partnerships, corporations and other types of entities over which you have the ability to influence or direct investment decisions concerning securities; </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Times New Roman','Times','serif';">, </font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Times New Roman','Times','serif';">, that the prohibitions outlined in this Insider Trading and Blackout Policy shall not apply to any such entity that engages in the investment of securities in the ordinary course of its business (e.g., an investment fund or partnership) if such entity has established its own insider trading controls and procedures in compliance with applicable securities laws.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Company will hold you responsible for the conduct of your family members, anyone who lives in your household and any entities under your control, as described above.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Tipping Information to Others. </b><font style="font-family:'Times New Roman','Times','serif';">You may not disclose any material non-public information to others, including your family members, friends or social acquaintances. This prohibition applies whether or not you receive any benefit from the other person&#8217;s use of that information. The U.S.&#160;Securities and Exchange Commission (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) has imposed large civil and criminal penalties on the person providing the tip, the individual receiving the tip (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">tippee</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and all those to whom the tippee, in turn, gives the information, even when the disclosing person did not profit from the trading. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">When dealing with professionals involved in the securities or capital markets (such as stock brokers, analysts, investment advisors, portfolio managers, etc.), you should exercise heightened care not to disclose material non-public information due to the nature of their business.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Material Non-Public Information.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Material Information</i><font style="font-family:'Times New Roman','Times','serif';">. Information is considered &#8220;material&#8221; if a reasonable investor would likely consider it important in making a decision to purchase, hold or sell the Company&#8217;s securities. In addition, any information that could affect the market for the Company&#8217;s securities is material. It is important to keep in mind that material information need not be certain or definitive information. Even information concerning events, actions, results, etc. that may happen can be considered material under certain circumstances. Examples of material changes are listed below.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Non-public Information</i><font style="font-family:'Times New Roman','Times','serif';">. Non-public information is any information that has not been disclosed generally to the public. Disclosure by press release or in the Company&#8217;s periodic reports filed with the SEC is necessary to make the information public. However, even after the Company has released information to the public, you should generally allow at least one full trading day (that is, days on which the NYSE American, the other national stock exchanges and Nasdaq are open for trading) for the investing public to absorb and evaluate the information before you trade in the Company&#8217;s securities.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Although it is not possible to list all types of material information, the following are a few examples of information that is particularly sensitive and should be treated as material:</font></p><p style="display:none;font-size:11pt;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><div style="white-space:nowrap;"><div style="display:inline-block;padding-right:3.85%;vertical-align:top;white-space:normal;width:46.15%;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">&#8226;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">quarterly or annual financial results;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">&#8226;</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">clinical trial results;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant contracts and technology licenses or any amendments or terminations thereof;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant actions by regulatory bodies;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">possible mergers, acquisitions or joint ventures;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">projections of future earnings or losses, or other earnings guidance;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant developments regarding the products, platform, customers, partners, contracts or financing sources (e.g., the acquisition or loss of a contract);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in management;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant increase or decrease in financial results;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial liquidity problems;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">listing on or delisting from a stock exchange;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in auditors;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commencement of major litigation;</font></td></tr></table></div><div style="display:inline-block;padding-left:3.85%;vertical-align:top;white-space:normal;width:46.15%;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the introduction, or obsolescence, of important products or services;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in estimates of earnings or sales;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">major marketing changes;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">offerings of additional securities, borrowings or other financial transactions;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increases or decreases in dividend payments;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unusual gains or losses in major operations;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock splits or securities offerings;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">public or private sales by the Company of a significant amount of securities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discovery of data security breaches or other cybersecurity issues; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">purchase or sale of a significant asset;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant labor disputes; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of a repurchase program for the Company&#8217;s securities.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:11pt;line-height:0pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.37;visibility:hidden;">&#8203;</font></p></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The items set forth in the above are examples only and should not be understood to be a determination that the matter is absolutely material. Rather, such items should be considered on a case-by-case basis giving effect to applicable </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">circumstances. That being said, if it is unclear if any particular information is material, you should assume that it is and confer with the Compliance Officer.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If you have any question as to whether particular information is material or non-public, you should not trade or communicate the information to anyone without prior approval by the Compliance Officer. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:40.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Inadvertent Disclosure. </b><font style="font-family:'Times New Roman','Times','serif';">If material non-public information is inadvertently disclosed by any Restricted Person to a person outside the Company who is not obligated to keep the information confidential, you should immediately report all the facts to the Compliance Officer, or such other individual designated by the Company so that the Company may take appropriate remedial action. As noted in the Company&#8217;s Fair Disclosure Policy, under the SEC&#8217;s rules, the Company generally has only 24 hours after learning of an inadvertent disclosure of material non-public information to publicly disclose such information, if necessary. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Short-term, Speculative Transactions. </b><font style="font-family:'Times New Roman','Times','serif';">The Company has determined that there is a substantial likelihood for the appearance of improper conduct by Restricted Persons when they engage in short-term or speculative securities transactions. Therefore, </font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Restricted Persons are prohibited from engaging in any of the following activities involving the Company&#8217;s securities</b><font style="font-family:'Times New Roman','Times','serif';">, except with the prior written consent of the </font><font style="font-family:'Times New Roman','Times','serif';">C</font><font style="font-family:'Times New Roman','Times','serif';">ompany&#8217;s Compliance Officer:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">purchasing the Company&#8217;s securities on margin or borrow against the Company&#8217;s securities held in a margin account;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pledging Company securities as collateral;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">short sales;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">buying or selling puts or calls in connection with the Company&#8217;s securities;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(e)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engaging in derivative transactions relating to the Company&#8217;s securities (e.g., exchange traded options, etc.); and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(f)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">engaging in any other hedging transactions related to the Company&#8217;s securities.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Further Prohibition. </b><font style="font-family:'Times New Roman','Times','serif';">From time to time, effective immediately upon notice or as otherwise provided by the Company, the Company may determine that other types of transactions, or all transactions, by Company personnel in the Company&#8217;s securities shall be prohibited or shall be permitted only with the prior written consent of the Compliance Officer.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Approved Pre-Planned Trading Programs Pursuant to Rule 10b5-1. </b><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding any other guidelines contained herein, it shall not be a violation of this Insider Trading and Blackout Policy for Restricted Persons to purchase or sell securities of the Company under certain pre-planned trading programs adopted to purchase or sell securities in the future which are in compliance with Rule 10b5-1 under the U.S.&#160;Securities Exchange Act of 1934 (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exchange Act</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). All pre-planned trading programs must be approved in advance, in writing, by the Compliance Officer and must meet all of the following minimum requirements:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trading program is in writing and is adopted outside a Blackout Period;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the individual who wishes to establish the trading program (a) does not, at the time of entering into the trading program, possess any material non-public information about the Company and (b) must enter into the trading program in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5 (directors and officers must include a representation in the trading program certifying these conditions). However, the Company may be aware of material non-public information (that the individual is unaware of) that may make it imprudent for the Compliance Officer to approve the pre-planned trading program at that time; </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trading program must be irrevocable, which means that no modifications or revocations are permitted, except outside a Blackout Period and at a time when the individual adopting the plan does not possess material non-public information about the Company; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trading program must include a &#8220;Cooling Off Period&#8221; under which</font><font style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no trade can commence until: (1)&#160;for the Company&#8217;s officers and directors, the later of (i) 90 days following adoption of the trading program and (ii)&#160;two business days following disclosure of the Company&#8217;s financial results in a Form 10-Q or Form 10-K for the quarter in which the trading program was adopted (up to a maximum of 120 days after adoption of the trading program); and (2)&#160;for non-officer employees, 30 days following adoption of the trading program;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(e)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trading program must specify the amount of securities to be purchased or sold and the price at which and the date on which the securities are to be purchased or sold;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(f)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trading program must not permit the beneficiary of the program to exercise any subsequent influence over how, when, or whether to make purchases or sales (other than through a formal modification of the program in accordance with the terms and conditions hereof);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(g)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unless otherwise approved by the Compliance Officer in situations where having multiple trading programs in place at one time is permissible under the provisions Rule 10b5-1, the individual may have only one trading program in effect at any time; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(h)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any modification or change to the amount, price or timing of the purchase or sale of securities, or any cancellation of a trade, under a trading program will be deemed to be a termination of such trading program and will require compliance with these conditions as if the individual were adopting a new trading program.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Compliance Officer may impose such other conditions on the implementation and operation of the trading programs as he or she deems necessary or advisable.&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Each Restricted Person understands that the approval or adoption of a pre-planned trading program in no way reduces or eliminates such person&#8217;s obligations under Section&#160;16 of the Exchange Act, including such person&#8217;s disclosure and short-swing trading liabilities thereunder. If any questions arise, such person should consult with his or her own counsel in designing a pre-planned trading program.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In addition to the foregoing, Restricted Persons are reminded that SEC rules and regulations require that the Company disclose quarterly the adoption or termination of a 10b5-1 Plan or a non-Rule 10b5-1 trading arrangement by executive officers and directors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Confidentiality Guidelines. </b><font style="font-family:'Times New Roman','Times','serif';">To provide more effective protection against the inadvertent disclosure of material non-public information about the Company or the companies with which it does business, the Company has adopted the following guidelines in addition to the prohibition in paragraph 3 above. These guidelines are not intended to be exhaustive. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Additional measures to secure the confidentiality of information should be undertaken as deemed necessary under the circumstances. If you have any doubt as to your responsibilities with respect to confidential information, please seek clarification and guidance from the Compliance Officer before you act. Do not try to resolve any uncertainties on your own. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following guidelines establish procedures with which every Restricted Person must comply in order to maximize the security of confidential information: </font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Do not discuss any Company matter in public places, such as elevators, hallways, restrooms or eating facilities, where conversations might be overheard.</font></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">When discussing material non-public information on telephone, extra care should be taken that other parties are not able to overhear the discussion.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Particularly when discussing material non-public information on a mobile phone, such discussions should not be held in the presence of other persons that should not be exposed to the information. Calls while traveling in taxicabs or other forms of public transportation, or in areas that are accessible to the general public, should be avoided.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Use passwords to restrict access to the information on computers.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(e)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Do not transmit material non-public information through any social media platforms or through non-company email addresses.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(f)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Limit access to particular physical areas where material non-public information is likely to be documented or discussed.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">(g)</font></p></td><td style="padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Maintain records in accordance with the Company&#8217;s Document Retention Policy.</font></p></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(h) </font></font><font style="display:inline-block;width:18pt;"></font><font style="font-family:'Times New Roman','Times','serif';">Do not input, share, or discuss material non-public information using AI tools or platforms. If AI tools are utilized, ensure that any identifiable information about the Company, its operations or personnel is removed. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Restricted Persons should also refer to their employment or other agreements with the Company or its subsidiaries to understand their confidentiality obligations with respect to material non-public information.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Authorized Disclosure of Material Non-Public Information. </b><font style="font-family:'Times New Roman','Times','serif';">Under certain circumstances, the Compliance Officer may authorize the immediate release of material non-public information. If disclosure is authorized, the form and content of all public disclosures shall be approved by the Compliance Officer pursuant to the terms of the Company&#8217;s Fair Disclosure Policy. In the case of material non-public information that is not disclosed, such information is not to be disclosed or discussed except on a strict &#8220;need-to-know&#8221; basis. All requests for information, comments, or interviews (other than routine product inquiries) made to any Restricted Person of the Company should be directed immediately to the Compliance Officer, who will clear all proposed responses, which must be in compliance with the Company&#8217;s Fair Disclosure Policy. It is anticipated that most questions raised can be answered by the Compliance Officer or another company representative to whom the Compliance Officer refers the request. All Restricted Persons must comply with the Company&#8217;s Fair Disclosure Policy and should not respond to such requests directly, unless expressly instructed otherwise by the Compliance Officer. In particular, great care should be taken not to comment on the Company&#8217;s expected future financial results without the express instruction by the Compliance Officer. If the Company wishes to give some direction to investors or securities professionals, it must do so only in compliance with the Company&#8217;s Fair Disclosure Policy. All communications with representatives of the media and securities analysts shall be directed to the Compliance Officer. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Post-Termination Transactions.</b><font style="font-family:'Times New Roman','Times','serif';"> The restrictions set forth in this Insider Trading and Blackout Policy continue to apply to your transactions in the Company&#8217;s securities even after the termination of your employment or term in office, as applicable, for such period as the Compliance Officer shall determine you are likely to be in possession of material non-public information about the Company. If you are in possession of material non-public information when your employment terminates, you may not trade in the Company&#8217;s securities until that information has become public or is no longer material.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Policy Relating to the Company&#8217;s Trading in its own Securities.</b><font style="font-family:'Times New Roman','Times','serif';"> The Company shall not trade in its own securities while in possession of material nonpublic information related to the Company, unless such trading activity otherwise complies with all applicable securities laws. Any trading by the Company in its own securities must be pre-approved by the Compliance Officer.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">6</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">IV.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PRECLEARANCE AND BLACKOUT POLICY FOR DESIGNATED INSIDERS</b></td></tr></table><div style="margin-top:12pt;"></div><div style="font-family:'Palatino';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">Designated Insiders. </b><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">The following personnel shall be deemed Designated Insiders of the Company for purposes of this </font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Insider Trading and Blackout Policy</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">:</font></div><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">members of the Company&#8217;s Board of Directors;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s Chief Executive Officer and all other executive officers of the Company;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all Chief Medical/Scientific Officers and/or advisors of the Company; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all employees of the Company who report directly to the Chief Executive Officer and/or Chief Financial Officer, and all members of Protalix&#8217;s Finance and Legal Department.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Palatino';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Protalix reserves the right to designate other personnel as Designated Insiders and shall provide appropriate notice to the persons affected.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">Mandatory Pre-clearance of Transactions. </b>To help prevent inadvertent violations of the federal securities laws and avoid even the appearance of trading on material, non-public information, Designated Officers may not engage in any transaction involving the Company&#8217;s securities, without first certifying that all such transactions will be conducted in compliance with provisions of this Policy and obtaining the Compliance Officer&#8217;s pre-clearance of the transaction. A request for pre-clearance should be submitted to the Compliance Officer at least two days in advance of proposed transaction. The Compliance Officer is under no obligation to approve a transaction submitted for pre-clearance and may determine not to permit the transaction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">Blackout Period Trading Prohibition. </b>The release of the Company&#8217;s financial results is a particularly sensitive period of time for transactions in the Company&#8217;s securities, because officers, directors and other employees may possess material non-public information about the expected financial results for the applicable fiscal quarter. Accordingly, no Designated Insider may conduct transactions involving the purchase or sale of the Company&#8217;s securities during a &#8220;blackout period&#8221;. The Company&#8217;s &#8220;blackout period&#8221; with respect to each fiscal quarter begins on the close of business on the <b style="font-weight:bold;">seventh </b>day prior to the end of the third month of the quarter and ends on the opening of the <b style="font-weight:bold;">first </b>business day following the Company&#8217;s filing with the SEC of the Company&#8217;s quarterly or annual financial reports or earlier public release of quarterly or annual financial information. If the Designated Insider&#8217;s employment by the Company, or services as a director of the Company, terminates or expires during a blackout period, the Designated Insider may not trade in the Company&#8217;s securities until that blackout period has ended. The Company will inform Designated Insiders of the anticipated date of public disclosure of the financial results for each fiscal quarter or year upon request. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time, the Company may also determine that Designated Insiders (and selected others) should suspend trading for a period of time to be designated by the Company because of developments known to the Company and not yet disclosed to the public. In such event, such persons may not engage in any transaction involving the purchase or sale of the Company&#8217;s securities during such period of time and should not disclose to others the fact of such suspension of trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A Designated Insider who believes that special circumstances require him or her to trade during a trading blackout period should consult the Compliance Officer. Permission to trade during a trading blackout period will be granted only where the circumstances are extenuating and the Compliance Officer concludes that the Designated Insider is not in fact aware of any material nonpublic information of or relating to the Company or its securities, and there appears to be no significant risk that the trade may subsequently be questioned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Even outside of the blackout period trading prohibition, any person possessing material non-public information concerning the Company should not engage in any transactions in the Company&#8217;s securities until such information has been known publicly for at least one trading day, whether or not the Company has recommended a suspension of trading to that person. If a Designated Insider is aware of material non-public information when his or her employment or services as a director terminates, such person may not trade in the Company&#8217;s securities until that information has </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">7</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">become public or is no longer material. Trading in the Company&#8217;s securities outside of the blackout period should not be considered a &#8220;safe harbor,&#8221; and all Designated Officers should use good judgment at all times to make sure that their trades are not performed while they are in possession of material non-public information about the Company. Even individuals who are not subject to the Preclearance or Blackout Policies are strongly encouraged to consult the Compliance Officer for guidance in any situation where caution may be warranted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">Pension Fund Blackout Periods. </b>To the extent that the Company has any pension funds subject to &#8220;blackout periods&#8221; as defined below, directors and officers are prohibited from purchasing, selling or otherwise acquiring or transferring, during any pension fund &#8220;blackout period,&#8221; any equity security of the Company, if the director or executive officer has received such security in connection with his or her service or employment as a director or executive officer of the Company. A &#8220;blackout period&#8221;, for purposes of this Section IV(4), is a period of more than three consecutive business days during which the ability of 50% or more of the participants in, or beneficiaries of, the 401(k) plans of the Company or its subsidiaries to trade securities of the Company held in such plans is temporarily suspended by the Company or a fiduciary of any such plan. </p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">V.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance Officer</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Role of the Compliance Officer. </b><font style="font-family:'Times New Roman','Times','serif';">The Compliance Officer shall conduct examinations as required, in order to uncover and investigate any potential violations of this Insider Trading and Blackout Policy by Restricted Persons (including review and examination of reports received in accordance with this Insider Trading and Blackout Policy), and will report his or her findings to the Company&#8217;s Board of Directors and/or Audit Committee, if necessary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If the Compliance Officer becomes aware of any violation of this Insider Trading and Blackout Policy, or related applicable law or regulations, by a Restricted Person, the Compliance Officer may perform any of the following actions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ensure that the violating party ceases the violation.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Take actions to mitigate the implications of the violation, as much as legally permissible and possible.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Examine the circumstances which led to the violation and/or allowed the violation to occur, and act to identify the parties involved in the process.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submit an internal report to the Company&#8217;s Chief Executive Officer, the Company&#8217;s Board of Directors and/or Audit Committee regarding the alleged violation(s) which will include his or her findings and conclusions of his examination thereof, and recommendations for preventing similar violations.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(e)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All findings, examinations and actions of the Compliance Officer with respect to alleged violation(s) will be documented and kept at the Company&#8217;s facilities.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(f)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Update or modify this Insider trading Policy if deemed advisable, and redistribute to all Restricted Persons.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">Interacting with the Compliance Officer.</b> The cooperation of all Restricted Persons with the Compliance Officer is an important interest of the Company, and is the personal obligation of each Restricted Person. Accordingly, each Restricted Person should report to the Compliance Officer any circumstance in which a Restricted Person of his or her family members incident, to the Restricted Persons understanding or suspicion, violated this Insider Trading and Blackout Policy or intends to do so in the future. The Company will not sanction a Restricted Person for making any such report in good faith, even if it is later resolved that no violation was made, and will use reasonable efforts to maintain in confidence the identity of the person/s who submitted a violation report, subject to applicable laws and regulations, and related proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Reports may be submitted to the Compliance Officer at any time during ordinary work hours, by appointment, telephone report, or email sent to: eyal.rubin@protalix.com. Reports submitted to the Compliance Officer should </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">8</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">include all available details and information regarding the violation, including a short description of the circumstances and the names of the persons involved. Although the Company is interested in receiving as much information as possible regarding the violation, anonymous reports can also be submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">IF you submitted such a report to the Compliance Officer, and feel that your report has not been properly handled, or not handled at all, please contact the Company&#8217;s Chief Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">VI.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Assistance</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If you have any questions about specific information or proposed transactions, or as to the applicability or interpretation of this Insider Trading and Blackout Policy or the propriety of any desired action, you are encouraged to contact the Compliance Officer.</font></p><p style="font-family:'Palatino';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Company shall have no obligation to provide or fund any legal defense for any of its personnel with respect to any SEC or civil action that arises from violations of the policies set forth herein.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">9</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>plx-20241231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/17/2025 11:11:37 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBIT&#160;21.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Subsidiaries of Protalix BioTherapeutics, Inc.</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Entity Name</b></p></td><td style="vertical-align:top;width:33.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">State or Country of Organization</b></p></td></tr><tr><td style="vertical-align:top;width:33.31%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Protalix Ltd.</font></p></td><td style="vertical-align:top;width:33.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.64%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Israel</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>plx-20241231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/17/2025 11:11:37 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="plx-20241231xex23d1001.jpg" alt="Graphic" style="display:inline-block;height:93.95pt;width:111.05pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 24pt 0pt;"><font style="font-family:'Georgia';">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><sup style="font-family:'Georgia';font-size:7.5pt;font-weight:bold;vertical-align:top;"> </sup></p><p style="font-family:'Georgia';font-size:10pt;line-height:12pt;margin:0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No.&#160;333-237736 and No.&#160;333-264394) and on Form S-8 (No.&#160;333-148983, No.&#160;333-182677, No.&#160;333-203960, No.&#160;333-225526, No.&#160;333-239101, No.&#160;333-266131 and No.&#160;333-273396) of Protalix BioTherapeutics, Inc. of our report dated March&#160;17, 2025 relating to the financial statements, which appears in this Form 10-K.</p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:85.31%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;">X, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:51.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt;"><font style="margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:18.25pt;"><td style="vertical-align:top;width:48.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';">Tel-Aviv, Israel</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt 0pt 6pt 0pt;">March&#160;17, 2025</p></td><td style="vertical-align:top;width:51.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';">/s/ Kesselman&#160;&amp;&#160;Kesselman</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';">Certified Public Accountants (lsr.)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';">A member firm of PricewaterhouseCoopers</font></p><p style="font-family:'Georgia';font-size:10pt;margin:0pt;">International Limited</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:18.25pt;"><td style="vertical-align:top;width:48.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Georgia';font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Georgia';text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>plx-20241231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/17/2025 11:11:48 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">1.&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)<b style="font-weight:bold;">) </b>for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;17, 2025</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:middle;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12pt;text-indent:-12pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>plx-20241231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/17/2025 11:11:48 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">1.&#160;&#160;&#160;&#160;&#160;I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">4.&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;17, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President, Chief Financial Officer, Treasurer &#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>plx-20241231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/17/2025 11:11:48 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt 0pt 0pt -0.05pt;">This Certificate is being furnished to the Securities and Exchange Commission as an exhibit to the Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;17, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan &#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer &#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>plx-20241231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/17/2025 11:11:49 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Sr. Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt 0pt 0pt -0.05pt;">This Certificate is being furnished to the Securities and Exchange Commission as an exhibit to the Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March&#160;17, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>plx-20241231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20241231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #@ M8# 2(  A$! Q$!_\0
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MXP/B,R70O_MD5[M#KY>^.VDMU&-N<;)6.,]<5TW]IP?WF_[YH_M.#^\W_?-
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M'1&M/LB&'>^[J;AF4D#[JGBLG1/VA?$.JZ%91SZGI>G2R:F]E>>(+FT1["T
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M+185O_M[_P"U/TVP?>C!]Z_,&35-3B8+)>7D9(# /*X)!&0>3T(YS3?[8O\
M_G_NO^_S?XT?4W_-_7WDOQ!IIV>&?_@7_P!J?J!@^]&#[U^7_P#;&H?\_P#<
M_P#?]O\ &C^V=0_Y_P"Z_P"_[?XT_J;_ )@_XB#3_P"@9_\ @7_VI^H&#[T8
M/O7Y?_VSJ'_/_=?]_F_QH_MG4/\ G_NO^_S?XTOJ;_F_K[P_XB#3_P"@9_\
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MO^@C=_\ @0_^-'U-_P WX!_Q$&G_ - S_P# O_M3]7LCU%&1ZBORA_MS4O\
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M_P!LZA_S_P!U_P!_F_QH_MG4/^?^Z_[_ #?XT?4W_-_7WA_Q$&G_ - S_P#
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M\1!I_P#0,_\ P+_[4_5[(]11D>HK\H?[<U+_ *"-W_X$/_C1_;FI?]!&[_\
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M !H^IO\ F_ /^(@T_P#H&?\ X%_]J?I_@^]&#[U^8;:CJBJ[-=7JJC;&+2.
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MHW;31Z[&O+; ]BK%58@[=V[..!^7.:U<)O>K^9BITUM1M]Q?T+5'U*)MUO\
M9]A"XR?[H/3 ]<?A7EG[7Q_XL?JGO<6__HP5ZOI.FWEF\LE[J+7TCX 'EB-%
MQZ 5PG[1'A&X\=?#>?1+:XBMIKBXB(EF!*C:VXYQSVITO<DN9W\SS\VA+$X&
MM3I1UE%I+Y'P7X7O;9O#.LZ8UXEA>W,]M*KN_EB>%/,\R'S,$*26C89X.SU
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M/]5\X_Z!W]Z_S/FBBOI?_AA;Q1_T,&E?]\R?_$T?\,+>*/\ H8-*_P"^9/\
MXFCV]+N'^J^<?] [^]?YGS117TO_ ,,+>*/^A@TK_OF3_P")H_X86\4?]#!I
M7_?,G_Q-'MZ7</\ 5?./^@=_>O\ ,^:**^E_^&%O%'_0P:5_WS)_\34$_P"Q
M%XDMW"MXATG)&?NR?_$T>WI]P_U7SC_H'?WK_,^;Z*^C/^&*O$?_ $,.D_\
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MO^^9/_B:/^&%O%'_ $,&E?\ ?,G_ ,31[>EW#_5?./\ H'?WK_,^:**^E_\
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M0 C:3\HB5<CIYSUZC_PPMXH_Z&#2O^^9/_B:JO\ L3>)(Y"I\1:5E3C[LO\
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MYU/[#/([SF4O]H^T((UP& XCW'&,'/.<<>H_\,4^(^_B'23_ ,!E_P#B:/\
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M_NG^\>X_QKH#]:P[K_CXDZ_>- %?S7_YY/\ F/\ &CS7_P">3_F/\:?^!H_
MT#N,\U_^>3_F/\:/-?\ YY/^8_QI_P"!H_ T!<9YK_\ /)_S'^-'FO\ \\G_
M #'^-/\ P-'X&@+C/-?_ )Y/^8_QH\U_^>3_ )C_ !I_X&C\#0%QGFO_ ,\G
M_,?XT>:__/)_S'^-/_ T?@: N,\U_P#GD_YC_&CS7_YY/^8_QI_X&C\#0%QG
MFO\ \\G_ #'^-6-/D8WD>8V'7DD>A]ZB_ U8L/\ CZ3\?Y4PN;0Z44#H** &
ML,]J^:I?A]XE;0?'UA_9NK37.I/J+6D+6UD+8^9<ET*S ^<2R]F..3TP*^EF
M.WFLG3_%&GZB;DQ7"JL%R]J6D(4/(A"L%]<,=OU!K6G-PNTCGJTU4M=GAFL^
M$_B'H,&O/X;&JK=W^K7=TLL=Q;8P(4\C(="2I;(QD<(,]LW;;0?'^E^)M;N-
M-CU.W2^OKBY="UM]D>,V*JK#/[P2^<J =L ]LY]V^VPF=H1*GFHH9DW#<H]2
M.PJ.'5+2X"F*ZAD#' V2 Y.,_P N:U]O)K6)BL.EM)Z'C.H>'O']C!I\MI<Z
MC?WC:/$M[>E;7[6LC7,33QQ$JJAA'YFT'Y>.YP:VO#WP[U3Q'8VU_P"(KN]C
MOXGG@C^UB)IVM3*6B\SR_D$NS )P0.N-PR/2_P"T[5W5%N(GD895%<$L,9X'
M?CFJ>C^*++5].L[M=]I]J3?'!>#RI@,XY4\@YI.K*2T1:HQB]9&M&@C15 P
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M,/\ B_\ Z#>B?]]3?_$4O_#$'B\_\QO1>F/O3?\ Q%?:&]O^>;?F/\:-[?\
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M:.([K[@_LO#=G]Y\7?\ ##_B_P#Z#>B?]]3?_$4?\,/^+_\ H-Z)_P!]3?\
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M !HWM_SS;\Q_C1_:.([K[@_LK#=G]Y\5?\,1>-.^L:%]/-F_^-4?\,1>-/\
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M;Z'-/8ZUXGTK6H=72XA%O#!;_93*)%+B3?\ Z,P 5"#N7GKA*G&Z3?\ 5_\
M(?M)--I?U;_,]WGU.TM;NUMIKJ&&YNBP@A>0!Y2HRP4$Y; Y..@JR3[U\VQ^
M"_BS#IVCZ@E[>7OB(OK#N-2EMGBLB8IDL@F!P&/E$\MS][C(I/%.D_%I_!EM
M:^'1XK2^\ZYD\W4=1TXW",+=/*#[>&C,N\XWY'\0*E5"]GYC]IY'TD&Z<T[\
M<U\X^(=-^-/]M^)I=$FO9(KNP(M'NY+6..VES#Q"F]M[[1/M9O+ )&[=P1ZG
M\&['Q/8>$#%XLN;BYO\ [5*T)O$C69("1L5RDCAB.<'=G&,\YI2I\JO<(U.9
MVLSNQ2T45F;A1110 4444 (>E>=_'%U3PM8EF"C[<G)./X'KT6OD[_@I?S^S
MA'_V&[7_ -!EJX1YY*)G.7)%R.I\/W,091YJ?]]"O1=+NX=BXE3_ +Z%?B?9
MV=P]JUV(9#:I(L33!3L5V#%5)]2%8X]C6O<V%WI=W-:7D$EK=0.8Y8905=&'
M4$'D&O16"O\ :_ \QX^WV/Q/VR2ZAP/WJ?\ ?0IWVF'_ )[)_P!]"OQ, .._
MYTY$:1E559F8X55Y)-5]0?\ -^!/]H_W/Q_X!^V/VF'_ )[)_P!]"C[3#_SV
M3_OH5^)I!''.:NW&A:C::;#J$UE<16,Q417#(1&^XN%PW0Y,4@_X WI1]1Z\
M_P" ?VC_ '/Q_P" ?M+]IA_Y[)_WT*/M,/\ SV3_ +Z%?BG9V-SJ$K1VL,EQ
M(J/*RQ@L0B*6=CCL%4D^P-7]*\)ZUKMNUQINE7E] K%-\$3,"P&2HQ]YL<X&
M3BAX&WV_P!9C?:'X_P# /V=^TP_\]D_[Z%'VF'_GLG_?0K\32#[_ (TOEN8V
M?:VP$ MSC)S@9_ _D:/J#_F_ /[1_N_C_P  _;'[3#_SV3_OH4V6_M8(VDEN
M8HHUZL[@ ?C7XG?G2$;A@\CT/(-'U#^]^ ?VC_=_$_:C_A(M)_Z"EG_W_7_&
MC_A(=*_Z"=G_ -_U_P :_%7R8_[B_P#?(H\I/[B_E5?4%_,3_:+_ )?Q/VK_
M +?TO_H)6G_?]?\ &K>F>(=+2X);4K0#:>3.OM[U^)7E)_=7\A2&)#U13]12
M^H?WA_VB_P"7\3]S!XDTG_H*6?\ W_7_ !I?^$CTD_\ ,3L_^_Z_XU^&8B0?
MP+^5'E)_<7\J/J']X/[1?\OXG[F?\)%I7_02M/\ O^O^-+_PD.EG_F)6G_?]
M?\:_#+RU_NC\J78H_A'Y4OJ'][\ _M%_R_B?N;_;^F?]!&U_[_+_ (T?V[IO
M:_M3_P!ME_QK\,=B_P!T'\*78O\ =7\J/J'][\ _M%_R_B?N=_;FG_\ /];?
M]_E_QH_MJP/_ "^V_P#W]7_&OPQV+_='Y4;1Z#\J/J'][\ _M'^[^)^Y_P#:
M]B?^7VW_ ._H_P :4:K9?\_L'_?U?\:_"_:/0?E2X'I1]0_O?@']H_W?Q/W0
M_M2R[7D!_P"VH_QH_M.T_P"?J'_OX/\ &OPOZ]>11@>@I_4/[WX!_:/]W\3]
MT?[2M2/^/J'_ +^"J.INLDZE6##8.0?<U^'G6OTM_8Z^(G_"8?!328)9O-O=
M&9M-F#'G:F#$?^_;*/\ @)K"KA'2CS7N=%#&*M+EM8^BP*7!]*RI-<MM-MVN
M+RYAM+=<!I9Y%C09( RQ( R2!^-7]+\0V&JJ#9WUK>*03FWF63@'!/RD]P1]
M:XN4[E.Y+M/H:-I]#5]6#=*6CE'S&?M/H:-I]#5B+4K2:Z:U2ZA>Y7=NA612
MXQMSE<YXWIG_ 'E]14D]Q%:JK32)$K.L:EV"@LQPH&>Y)  [DTN4.8I[3Z&C
M:?0UH4R::.WB>6:18HD4L\CL J@<DDGH .:?*',4MI]#1M/H:OJP=0RD%2,@
MCH:9-<16P4S2I$&=8U+L!EF.% SW)('U(HY0YBGM/H:-I]#6A11RAS%ZW(\B
M/G^$?RJ3(]16;1VHY0YC2R/449'J*S,TM+E#F-+(]11D>HK-HI\H<QI9'J*,
MCU%9M%'*',:61ZBC(]16;11RAS&ED>HHR/45FT4<H<QI$C'45A7*YN)<#^(U
M;HHY0YC/VGT-&T^AK0HHY0YC/VGT-&T^AK0HHY0YC/VGT-&T^AK0HHY0YC/V
MGT-&T^AK0HHY0YC/VGT-&T^AK0HHY0YC/VGT-&T^AK0HHY0YC/VGT-6+!<7<
M>1Z_RJQ4EM_KEI<MAJ1?HHHJ2AC&O+/$7[06D:%>1V\.D:GJI=M0P]JUNB[;
M-D6X;,LJ9 9MH'4E6P.F?5&'!KQ/2_V<]+U/4-,;Q-9VFJZ?HM[JLEI8WUM'
M<13K=W"SI(=V=K1\IR,GD\<9N'+]HSGS?9+=I^TQX=OM<AL(=-U)H);JRM5O
M2;<+ONHXY(?W1E\XC$R D1D YSP":Z#PK\8M,\6^+KCPU::;J,6K6/G_ -HQ
M7$:*+#8X1/,(<C][G='MW;E!/&*Q[K]GW36\9WGBRUNHK/7I-6MM2MKQ;-2]
MO'' D$EMG<"T<B*V1Q@L#@E:;HOP"33==U'5KKQ!=7UQKD=Q%KZ@/"M^KMF'
M84D#0&%?D4J2=I(//-:/V73^F8KVM[/^D=1>_%'1[/XCV/@IH[R35KFUEO/-
M6W(MXTC"D@R' +$.#M7)'?&1GG)?VB?#B^%=3\01VFH&TLM831@ETB6;RS,L
M;!QY[H%3;(#ERO )QTKHQ\,;.W\4>$M5M+J6"W\.V5S8PVLA:8R)*(@"TCL6
M)7RAR<DYY-9EW\)KE8=<;3M=%E>:CK@UM)9M/CN(XF\F.+RRC'D?)NW*R,">
MN,@YKDT_KJ:/G_KT_P SH/#7CFV\1ZF^GBUGL[Q;&WU#9,\3AXIMX4J\;LK8
M,; X)'0@D$&NGVBO+OAA\*'^'VO6\<4CRZ7I>A6VCVD\KJ9+AA+)+*[*/NC+
M( .V#@8QGU*B2C?W2H<S7O#,<]*7:...:=16=BQN,=!2@8''%+13&%%%% !1
M110 4444 %?)W_!2T?\ &.$?_8;M?_09:^L:\._:^^&UM\5_A9;Z!=7LNGQ/
MJ4,WG0H&8%4DXP>.]:4VHS39E5BY0:1^3OAJ]TZX\):AH]Y?KIL\E_;7<<LL
M,DD;*B3(ZGRU9@?WH(^7!P<D<5ZIKGQ%\&:[K374NF0RVMS+?S76^P073EIP
MUO\ OMNX-L7'#8&2#QFO7-)_8$T&Y*Y\6:B/I:Q_XUUME_P3H\.R("?&6J#/
M_3I%_C7K+$47NSQOJU=;(^<_^$B\(?8+Y/M6B-J<EZ)+6Z'AS%O#:^<6:(IY
M1W.05(/EG:%*^8=Q(T]$^(W@C2/&-K>VNG6UEIEG):W-J1IB-<12)J(D?,FS
M>Q%MD<L1\H R0#7T2O\ P3?\.$?\CIJG_@)%_C3O^';OAS_H=-4_\!(O\::Q
M%#^87U>OV1\L#Q=X8FT^2T$6DV]XNGPI!J,NBK)']H^TEYRZ^27;='M"EE(
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M)T5]V_\ #MK2O^A^O/\ P5)_\>J6W_X)IZ5<2;1X^O.F>=+3_P"/4?6Z/?\
M,/J=?^7\CX-Q17WT/^"8FF9S_P )]=?^"M?_ ([3O^'8VF?]#_=_^"Q/_CE'
MUNCW#ZG7_E_(^ Z*^_/^'8NE_P#0_7G_ (+4_P#CE+_P[$TK_H?KS_P6I_\
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MHATZYA&H7EM'JDLEW)>SQ['$6J(8?)&> D4<@/ R ,[FQ7LT<K(,9S4HNO\
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MD]26W^O6JGVS_8_6I;2Y\RY0;<=>]#:"QJT445F:$,DDBL0(BP]<BF^;(/\
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M7WG?H[X_U9_,4[>W_/,_]]"N-3XR>#<?\AR'_OW)_P#$TO\ PN3P;_T'8?\
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M^_3_ /Q-'LY_RL/:P_F1N^=+_P \6_,4>=+_ ,\6_,5A?\+#T#_G_'_?I_\
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M_P#"0:>?^7@?]\M_A2]G+L'/'N7M[?\ /,_]]"C>W_/,_P#?0JG_ &]8?\_
M_P"^6_PH_MRQ/_+?_P =;_"CDEV'SQ[ES>W_ #S/_?0HWM_SS/\ WT*J#6[(
M_P#+?_QT_P"%._MBS_Y[?^.G_"CDEV#GCW+.]O\ GF?^^A1O;_GF?^^A5?\
MM:T/_+7_ ,=/^%*-4M3_ ,M?_'3_ (4N278.>/<GWM_SS/\ WT*"[?\ /,_F
M*@&IVQ_Y:?\ CI_PIPO[=O\ EI_XZ:.1]A\R[G002RB&/]RWW1W'I4GG2_\
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M_N?J*/L$_P#<_44 5-[?\\S_ -]"C>W_ #S/_?0JW]@G_N?J*/L$Y_@_\>%
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MREP 92Q;*%3N\T\8Q@8]Z=>?$);BV:&*R>V"B15".C;PZ*C;BR%AD+_"0,$
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M (5HQF8 ?NT_[[/^%;?6*W\S,/JU#^1'!#]G_P '_P#/K=?^!34?\,_^#O\
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MJ_S#^KTOY3$_X5'HO_/6\_[[7_XFE'PDT8?\MKS_ +^+_P#$UU^^X_YY1?\
M?T__ !-&^Y_YY0_]_3_\32^L5?YF'U>E_*<A_P *FT8?\M;O_OM?_B:7_A4^
MC_\ /2[_ ._B_P#Q-==ON?\ GE#_ -_3_P#$T;[G_GE#_P!_3_\ $T?6*O\
M,P^KTOY4<B/A1HX_Y:W?_?Q?_B:7_A5.C_\ /2[_ ._B_P#Q-=;ON?\ GE#_
M -_3_P#$T;[C_GE#_P!_3_\ $T?6*O\ ,P^KTOY4<G_PJO2!_P M;O\ [[7_
M .)I1\+-)'_+6[_[[7_XFNKWW'_/*'_OZ?\ XFC?<?\ /&'_ +^G_P")H]O5
M_F8>PI?RG*CX7:2/^6EU_P!]C_XFG#X8:2/^6ET?^!C_ .)KJ-]S_P \H?\
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M.&C0#^)S]3_]:K6^;_GFG_?9_P *-\W_ #S3_OL_X4O:3[A[.'8K#2(1W?\
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MT_\ Q-+FD/E1$-,B]6_.E&FQCNWYU)YES_SRA_[^G_XFCS+G_GE#_P!_3_\
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MAU_V]Q?UKS,SQ,\'@ZN(I[Q3:N=^ H1Q6*IT)[2=M#-B^,7A!.NJ-_X"R_\
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M10 4444 %%%% !1110 4444 %%%% !5C3_\ C[C_ !_E5>K&G_\ 'W'^/\J
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(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>plx-20241231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20241231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $G \L# 2(  A$! Q$!_\0
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MR/%/_0?U#_O^U<WBC%'LX=D'M:G\S^\Z3_A9'BG_ *#^H?\ ?]J/^%D>*?\
MH/ZA_P!_VKF\48H]G#L@]K4_F?WG2?\ "R/%/_0?U#_O^U'_  LCQ3_T']0_
M[_M7-XHI>SAV0>UG_,_O.D'Q(\4@_P#(?U#_ +_M7Z3_  >_T_X8>&KBY'G3
MR64;/(_+,<=2:_+4=1]:_4OX)_\ ))_"O_7A'_*O$S6,5"+2ZGT632E*I*[Z
M'8?8X/\ GDG_ 'S1]C@_YY)_WS4]%?-GUI!]C@_YY)_WS1]C@_YY)_WS4]%
M$'V.#_GDG_?-'V.#_GDG_?-3T4 0?8X/^>2?]\T?8X/^>2?]\U/10!!]C@_Y
MY)_WS1]C@_YY)_WS4]% $'V.#_GDG_?-'V.#_GDG_?-3T4 0?8X/^>2?]\T?
M8X/^>2?]\U/10!!]C@_YY)_WS1]C@_YY)_WS4]% $'V.#_GDG_?-'V.#_GDG
M_?-3T4 0?8X/^>2?]\T?8X/^>2?]\U/10!!]C@_YY)_WS1]C@_YY)_WS4]%
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M<'_/)/\ OFC['!_SR3_OFILXHS0!#]C@_P">2?\ ?-'V.#_GDG_?-39'K2T
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M*!/#:6>H6ZS1.N&21<@UC>)_@==:->MK'@N]?3[L'<;4-A6]A7L=A9K:0A0
M,"K)3-?H%"I.BK1?R/I)8>$XI2W[GB_A7XYS:=>KI/C*T?3;Q?E^T%<(Q]37
ML-E>P7]ND]M*D\3C*O&V0:R/%G@;1_&=DUOJ=HDW'RR 8=3Z@UXY<^$/&/P<
MN7N_#]P^KZ*#N>T?DJ/I_45U\M*OK'W7VZ&'-6P_QKFCWZGT$#FEKSSP)\9]
M%\8A;=V_L_4AP]M.<<^QKT$,",UR3A*F[25CMIU(58\T'=#J*;NIU0:A12&C
M- 'GOQK_ .1>T[WU"'^9KD/B;,CZEH"9;>J#&.G:NM^-<R)H>DHV=TFI1!0/
M7FO/_'-W]J\1Z8N<[ %KUL'&^I\IG$DDUWL>C_"8_P"A:F/2YQ^@KOJ\]^$T
MRF#6(P076ZR1_P !%>@YKAQ'\5GMX'_=H>@M%%%<R/0"BBBF 4444 %%%% !
M2'J*6FD\]* .5^)G_(HW'_72/_T,5ROC:53I>D1D9( QS73_ !/F$7A20$$E
MYHD 'KN%<1XONO,;3DS]P#BN_#*[1X&9.R:[H[#X?'_2M2'8%/Y5VU<+\/YE
M_M'4XL_/A&Q[8Q7=5AB/XC/1P3O0C8****YSN"BBB@ HHHH **3F@YH 6BBB
M@ KB_B;_ ,@_3?\ K[7^M=GG@\5QGQ+8?8]+4][M<?D:N'Q(PK_PY&#XZD']
MJZ4 V"J 8KI_AVV[3+O/:Y<?RKBO%UR)_$-F.R@"NR^'!']F7OM=/_2O0K1M
M11X.$:EC),ZZBFDTZO,/I0HHHH **** "BBB@ HHHH **** &R?<;Z&JUA_Q
MZ1_3^M69/N-]#5:P_P"/2/Z?UH _,;X^?\E?\4?]?;?TK@*[_P"/G_)7_%'_
M %]M_2N K[RC_#CZ(_-:_P#%EZLGM+^YL&9K:XD@8C!,;E<CT.*<=4O#="X-
MU-]H'24N=P_K7HOP&?P[?>+;;1=>\/IK U"98XYGE*&$=^!UKU#P+X6\(>.O
MB!XJL;3P?;1IH]HXAM)+ME2:0/@$L?NUG4K1I3=X[(UHT)58KEGNSYMN]7O;
MV/R[B[GG3.=LDA(S^-0RWEQ,(_,FD?RQA-S$[?I7T#\5?A/I,>L>$M+LM)AT
M+7M1GV7&FVUSYZ+&3P^[Z5I>.?@_X:C\4^%)]&TV6'2)-0_LR^BD#+O=2!NY
M[-S6<<53LM-[FDL'5O)7VL?.LNO:E+&8WO[ED(P5:5B#2#7M2\KROM]QY>,;
M?-;&/3%?1OB?X(^'=*U/QG>VEOYVB1V)ELGR?]'F5]KI]14LOPP\(WGP^\_2
M-"_M:/\ L_SFU2SNPUS'-C)#0]=M3]9I6O8OZG53LWW/FF+4[R*W,"7,J0MU
MC60[3^%1&YE,/DF1C$#G83QGUQ7T)X<\">'/#]GX;TR?PG<>+==UF W+^7,8
MS#'GHHXR16MX#^$6D27OC99?"@NKBPGC%KI^JW0MS$K=F8' XJY8F"NTMO0A
M82H[*_E^I\S0WD]NFV*:2-<AMJMCGL?_ *]2#4KP$$74V0V\'>>&]?K7TKX>
M^&/AK7?&7BBPUG0;70X[338Y(TM+S[0D4C' ?<./PIN@?!+1+,^%+/5=.\RZ
MN'O4N7+$>8$7*'^7YT/%4]VA_4JB5D]#YPFUW4;A0LE_<2+D$!I21D=ZA&HW
M0:5A<RAI1ASN/S#W]:]RNM(\"_"_1M&_M_P_+KESJX>9YA,4\B/<0 @[FO+=
M(T*Q\6?$.TTK3#)!I][>+%#YWWU0GO[XK2%2,V[1T,)TITVKRU_S.<^T2^1Y
M(E?RL[MF[Y<^N*;#/);2+)$[1R*<AD."*]G^(%Y\.='?6O#-MX=NK?4+!O(@
MU(2DM+(O!+J> #7I'B7X6Z+HOA2SN;#P5IE]$^E1W,E[/J@BE#E,L1&3DX/Y
MUF\3&*3Y=_0UC@Y2;2EMON?*TNI7<\ZSR7,CS+]UV<EA]#4#R-(Y=V+N>K,>
M2:]&^*?A?3- \+^"+RQMA;S:C9/-<').]MY _2D^)?A73M \(^#+RRM_(N+^
MS,MPW/SMG&:VC4CI;J[&$J,];]%<\X]@.:.U>B_!_P +:;XEB\4?VC;^?]DT
MN2>')(VN.AJ?X,^$],\4)XH.I6PN#::<\\.3C:X/!XJI5%&]^GZDPHN?+;K?
M\#S/H?S[T'V_.OJ^_P#@/X8F\1^&)K"UWV?V-#J=H&/#-&61_H:;X6^%.C/X
M"T_4+;PC8:U=S7$Z2M>ZA]FVJK?+C/6N7Z[3M>QU_P!GU.Y\I#GIS17TA\-O
M WA/6H=:>;0[/4=:2^,1TB2_$8AA]8V/#GM7B_Q,T*W\-^-]5T^UM+FQMHI2
M([>['[R,>A]?K6T*ZG/D1A4PTJ<.>^FQR]%%%=1QBCJ/K7ZF?!/_ ))-X5_Z
M\(_Y5^68ZCZU^IGP3_Y)-X5_Z\(_Y5X6:_PX^I])DG\2?H=M1117S)]>%%%%
M !1110 4444 %<MXC^'FF^)M6AU"Z:=9HU5,1OA6"MN&1CUKJ:Y/X@^(M0T"
MUT]=.$7GW=TL&Z5=P4'OBFKWT)>QCWOP0T&_U-KR:>]9RTCA/-^4%QANU6=0
M^$6C7_GAIKJ,3LK2!''.%"CMQTK@;SX[ZC'#8[!;+<LZPSP[>I9RFX$GVSP#
M3=*^,^IZ/H]RNH7-K=721>9&S_*78S[-F/8<UNHU+;F#=.]K'?-\'-$ ?R9;
MRW:0.KO'+@LC ;E/'3BK%O\ "G1+:..*-9TC28S*N_@$IL(^F*\^U3XUZSI?
MAM-2EDM//=)9TMA$>8T;;@MFMC2/B#J%KX*UK63_ *1,+\)&)#E85?;U_P!D
M9_2DU-)NX)P;22.@O/@SHEV8V\V[B9(8X0R2 ?*@(&1C'>JT7P*\.Q010[[I
MH8T2,H9>'"DD9X_VC7/>)_C+>>'UMDBO-/U&5=AE, ^20,^WAL\'V&:JVOQN
MU V_G7#V;).TR!8E):V*.%7>/?/?%-*IW%>GM8[>U^$6BVU_:7K2W5Q<6K P
MO++G8H! 7ITYJY<_#?3)]%L-.CENK>.QD,L$L4F'5CG/./<UY):_&/6M0UB.
M[%Y:VZVUM<A[=S\MT4<8"C^\0:0_%'6+OQ5'L#0K)(L0@+$A27'./;-/EF[7
M8N>"O9'HJ?!#04MK:V,]ZT-NA15,@YSGDG&3UIU_\&]&?29;6$2LQE\]!-(=
MN\)L&<=L"N1\ _%7799=#T34#%?:AJ/[V.Y5<?N@Q$@;W&*O>-OBCJ]A>ZQ9
MVGD0F"4VD<)4F8@IN\X#^Z*EJHG:Y2=-J]C?\$?#>XTBTUY-8NS=/JBI$RHY
M;9&JE0 Q [&K47P>T%;);64W$\0F$W[R3JP0H,\=,&N2US6=<T3X<^$9X-5V
M3W,BBZN)!DR!HV/4GCFL>S^+_B/0].TZPN$@O+FY2%EO'.Q8E?/WRQP3QQ5-
M3E=IDW@K)KS/7?"?@BR\'Q/%:2S2(0% F8':HZ 8 KHZPO!NL7FN>'K6\OHH
MH;F0'>L+AT^H(]:W:YY7OJ=$;6T"BBBD6%%%% !1110 4444 %%%% #&17&"
M,UG7>@V]YPZ _6M/%+4V3W$U<PK3PI:6C%EC&36M!:I  %7%38HHY4MA));"
MT44510F*:R[L@@$'L:?10!YOX\^"FC^+2;NU']F:H.5N(. 3[@5Y_#X^\8_!
MV;[#XDM3JFF?=BNU.3[<_P!#7T/M%<KX]\!6GC[38[&^GFA@1]^(CC)]Z[:5
M?:%76)Y];#-WG0TE^!A?"#XII\0[*Y6<+#?PN28AW3/!KTBO*?"/P(M/!6OP
M:GINJW",GWHV *N/0UZJ#VK*O[/GO2>AMAO:\EJVX4A-*QP*Y?XB>+8O!WAB
MYO7E5)F'E0 \EI&X Q7.[=3><E!.4MD<)XZ\2IXG\;P:+!$6MM+82S3GH9"/
MNCZ"N-O?*U7Q6=\ZPK$?E+<Y]JV?!GEZ;H%]?7,@NKN8,[3OU9SR:\PNM95;
MF6YR28WSP1FO4HXS"4ERRJ+3S/SK,L6JCYF]V>L^"?$(\/>/)(+B58K2_7:&
M/3>.E>X#D9'2OESQ!>1ZUX>MKR)&W1@-N0?,#V->U_"#QY%X[\)Q3@%;FV/V
M>=3_ 'E[_C6&*=.;4X23N?09/BU)/#R>VJ.Z' I:2O-OBA\5;[P!>VD-KHSZ
MDLZ%BZ[OEQ]!7+"#J/ECN?1U*D:4>:1Z517S]_PTKK/_ $*<W_C_ /A1_P -
M*ZS_ -"G-_X__A75]3K=OQ.3Z]0[_@SZ!I"<5\__ /#2NL_]"G-_X_\ X52U
MG]HS6KS2[F!?#<UHSH5$X+#9QUZ4U@JSTL)X^BE>_P"!]&@YI:^:/A=\=O$<
MUU#IUU82ZXAP-\(_>#ZU])V\K30H[(8V8 E&ZCVK&M0G0=I&]#$0Q"O$DII)
MS2GI6;KNK1Z-IDUS*3\HPH'J>E<]TMSHE)17,]D<9XZU6;4=>M=(BAS;0XGF
MD/=NRC^=<IK#P7>NK'++Y<49X-;>AW:I!<ZA._F%]WSR]2:\\U#58Y;N>3<I
MPV1\W7GM793Q>&HKEE-'Q>.Q"G[S>_Y'<6.KCP[XIM;II"MI,!'(<<8[5Z]'
M*LJ*R$,I&01W%>"2WBZYX<0[.5!R,\^]=[\(_%K:[I$MC,FRYL"(CDYW+V-1
M7G2J)3A*YZF6XE-NE?T/0:*04$XKF/HA:*\F^+GQ1USP-JMI;:9IPO(Y8][,
M8V;!S[5P7_#17B__ * (_P"_+_X5V0PM2I'F5C@J8VG2ERRO?T/I:BOFG_AH
MKQ?_ - $?]^7_P */^&BO&'_ $ 1_P!^7_PJ_J57R^\S_M"CY_<?2A.,]O<T
M Y]Z^8-6_:!\6WNG7,#Z1]G$D94RK$X*>^<4_P"%GQI\52WD.GO8RZ[$2%RH
M^=1]>GYTW@:BBY=A+,:3FH)/7R/IZBH;>5Y88W>,Q.R@E#U!]*D;]*\\]3<.
MN:X;QQ>P7^K6%@IW2POYK@?P_6NLU?4X](TZ>[D("QKD GJ>PKSC2F$\-_JE
MV/\ 2)<ME>0/05M223YY.UCS,;6Y(J">K_(QKQ)-1\0YC8$1'DL>V:ZOP!J@
MM-:OM.DR!,?.3TSWKS)]3,=XT^\@*V"1TK=U741;"SU2S?9)'R7'?VKTIRIU
M8\JDCYG#XCV=5U%W/<NII169X=UJ#7])M[VWD#I(O..Q[UI@Y%>/MH?;QDI)
M2746BBB@H**** "BBB@ HHHH **** &R?<;Z&JUA_P >D?T_K5F3[C?0U6L/
M^/2/Z?UH _,;X^?\E?\ %'_7VW]*X"N_^/G_ "5_Q1_U]M_2N K[RC_#CZ(_
M-:_\65N[-OP7XG?P;XHT_6HXA.]G)Y@C8\-[5T&A_%2YT*^\6W4=LN[7X'@<
MAB/)W-NR#3?AA\+I_B5+J>S4;?3(=/A\Z6:YSM"YQVK6M_@;<:IXI;2M*UNP
MU"WA@^TW.H(Q$,">K$U-25/F:EV*IQKJ*E#N:&A_M"76FPZ-/=Z7%?ZQI,+P
M6NH2-\X5AA<^N*FTS]IWQ$;5H=>5=:"7,=S"TN%,3*<\8]:SM2^ .H6UYI L
M=6L=5T[4;D6JWUJVY(Y#V8=JM>*OV>;OP]I&JWMKKVGZM)I7-U;6Y.^,9P>M
M<]L-VW.I/%ZV>B(K;]H/5+?3_%ED;2-[;7I#-L8_ZAB>=M7[+]HTZ?IKF#PU
M80ZXUJ;0ZC$"A*D8)*C@G%<E\,OA7-\1TU29=3MM*M]/C626:YSC!..WX5U4
M'[-&IOXA;3VUFQ2T^PF_2_R3&T8.#3G'#Q;C+<FG/%32E%W3_P RMX5^/\FC
MZ596FJZ';:S-IY)L[IW9)(LG.,@\C/:I],_:)E:[\0S:[HEOJ\6LR(TD)<HJ
M;?N@8K-U_P" 6K6%QHRZ5?VNN0ZK,;>">U8[0XZ@Y]*E\2? "_T72+V]LM9T
M_6); ?Z9;6DF9(?7/KBAK#/Y@GBEIV]".7XS6EI)K8TCP[!I4.IV0M'C20G8
M<YW9-:D'[2NI^5X:^TV$5Q+HL,D(D+8,H==N3[BC_AFN\>SM-GB+36U2YM%N
MXM-9L2NK+N 'OBN*U+X9W^E:'HFHSRHO]IW3VJQ<[HV4X.:(QP\M%N#GBHKF
MZ'5:!\>4L]+MK36?#=CKKV+L]E-<CYHLG.#Z@'M7GMQXINYO%+:["$M+O[1]
MH18%VJC9R !Z5W-K\ =5E\1:MI\^H6EE9:4J-<ZE.VV)2P! ]SSTJS;?L_O+
MXHBT:3Q-I4?VE%>TG\S<D^XX &.A^M:*5&-VB)1Q$TDP\2_'B'Q#I=\!X5TR
MWUC4$"76I!,LQ[D ]":NZK\?-)U_3;:+5/!UM>7EO:):+<O,P.%7 ./6JFJ_
ML]S6&L7NFVWB&PO[JRMY9[A8<DQ[.JGW-)H_[.NI7VF6$UYK6G:5?7Z>9:6%
MS)B653T^F:RMA[?\.:IXI2_X8?%\;]%NO#6EZ5J_@VTU1M.A:"":60@JI.:?
M_P +QT2[\/V&F:IX+L]1^PQM%!*\A!12<CIZ5CM\!O$$?@W5M?8(%TNZ-K<6
MW_+1<=6'J.:YOQQX%NO!.IVEC<2I/+<V\=PIC'9QD#ZU<8T9.T?S,Y3Q$5>7
MY&K\-_B5#X UO5+LZ3%?V=_"T#VCL0H1CG%;J_&K3--EOFT3PI:Z0MY9O:2+
M%(3G)^]S5FU_9NU6>SA636=.M]:GA\^+2'DQ,RD9 ]CCM5/PS\!9M:\-'6=1
MUZQT*+[2]KY=WD'>O6E)X=MML(K$I62\^A>T[]H_5-+\9+KD-E'L.FII\EJ6
M)5U52H;V-&F?'C3T\-VFD:OX5M]62VEDECDDE9<%R21Q7E&LZ<FE:K=6D=RE
MVD,A03Q_=< ]15.M50I-*R,GBJ\7;F/6?#WQNL-%%Q;3>$["[L/M/VFVB.5>
M ^F\<D5Q'Q \;7?Q"\4W>MWJ)%-/@"./HJ@8 KG:*TC1A%\R6IG.O4G'EDPH
MHHK8YQ1U'UK]3/@G_P DF\*_]>$?\J_+,=1]:_4SX)_\DF\*_P#7A'_*O"S7
M^''U/I,D_B3]#MJ***^9/KPHHHH **** "D-+2&D FZHYH8YPOFQI)M.X;U!
MP?6O!_%^C>,QX@O]0M(I]/M@LXDG68E63 V]_KT'%4/"&@ZMXHUN^GL%U"VT
MJ)F\E;BZ9@)/*&#UY&[\*W5--7N<[J-.UCW2]M=%M9X#<VUG'+*XCA+Q+DMU
M !QUZFIWT+39"I?3[5RIR"T*G!Z\<5X5?> O$5Y/8/-IE_-80&)KFV-S^\DG
M&[?(ISP#D5-J_A?Q[(M@D%O<"ZMVB:.Z2<DJFX[E;)Q]W Z'I3Y/,7-_=/;+
MVPTD+ EU:VF"^R(2Q*1N/89'4U:6PM5@>$6\0B;[T80;6^HKQ&\\!:[J&BV(
MET^\?5K6_CN)KB6Y++*P)^=!G'&1^5,T?X?>*I;:VCO;G4V+7$1O(WD"(^&)
M9E(.2,8I.']X:GK\)[-'I&CWD2,EC:2(F53]POR\\XXXY]*IZ+X8T'1(YM.M
M+6VRV998V569@QSEO49]:\?OO"7C6*TL[:WM+GS()B\4ZW!)5?.)P<G^[ZYK
M;\:>"=8N/';:O:6<\]M/:V\=R8)2C2*A.Y.O!.13Y.G,'-_=/4+C2=&LXTDE
ML;*)%8!2T* *Q/&..N:M_P!FV1DWFU@\P'(?RQD'ZUYCK?@W6=7^%ITZZMY+
MF\2[2>*!I#YBQK)D+NSR0OK7,ZQX(\50>$X+>RLKI]0E65VF^TL7BD+?)_%@
M8%2H\W4;E;H>RQ>$]-AUQ-62W5+I(S$FT85 3DX ]:DU"71[;4K=+M;5;VZR
MD.] 9),#D#C->/V7@3Q8(?M$LNH1W<[S+.\=QEA&4&T 9QUS6=<?#KQ7?PV<
MT=K):WEFMPEO<-,=X# 8)4D@'.:KD_O"<]-(GOTME;3PK#+;Q21(05C= 5&/
M05@WFO>%H[U]-N9['[0I6-H)$''H#QBO/O!O@+78O$.CRZA-J,FF0>;(\-S)
ML"/@;>%/(SGJ:N:[X<U>ZN/%>GQ:1)+_ &K/&T%V2OEH !\Q.<C&*7*D[7#F
ME);'HEGXAT?RBEM>VPCBF%L4C8823LF!T-6;37+&^O[JSM[J*:ZM2!/"C9:/
M/3(KPE/A9XF\/W,%]I\'V@S:J)KZW9\;T4Y64>_'2ND\#>"/$WA_Q?;ZY>QV
MSG4O--^(BV]"S;DW9.#CIQ0X1WN"G*]FCV&EI!TI:Q.@**** "BBB@ HHHH
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M^@J0URSPU*I+F:U/,KY=A\0^:<=3Y6'P'UR53O$D9_VX\_R-+%\!O$$1^24
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M=):6\<+OA%ZECDFO3**TC3C!W2'' 4(NZ1A6GA.TM7B8KN\L?*O;-;03:,
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MQ*<8W-[XK4\,^#]-\(P2PZ=$T:2D,P9LY(&*L>%[Z;4O#]A=7$<D4TL2LZ3
M!P??%:E9-O9LWC&.Z0T\5\)?M.>)ET_XJZW;>85.V+&.QVU]VXSFOS5_:JTN
M_?X]^)899OLYE6*>W6;A9$V=C]:^;SVG*I@W&"U/B.,:4Z^6NG#>XOPI\1RW
MOQ?\$VSRB0-J46"/HU?I4#FORA_9I2^U#]HKPI9RV4LYMKDRLT(W+'@'YF(Z
M#GK7ZN@\]*K)(RCA(J6YT<)PG3RR,9[CJ***]\^R"BBB@ HHHH **** "BBB
M@ HHHH 2CGVI:* $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@".4LJ.R#+ ' ]37EFE_#?6M-U6PUXWK3ZDUV\UU;$@)L?@
M@'J<#'Y5ZMBC%--K8F45+<\T\2>#M4O/%M_>16<.H0WD<20RS2E?LA48) '/
MOQ7)P?"?Q%]F:*0EI(HRAD:88G)<'. /0=Z]5/C_ ,/)>W%J=6MQ/ S)*I8X
M1E&2">F1Z9IB?$;PW)%#(NK0&.;[C<X(]>G3WZ5HI22V,Y*+>YS4O@C5'^'L
M6D!(_MBW:S8W\;1)NZ_2N3L?A'KL5AJ_FQQ?;)4C%M(9,E6$A8D'MP:]&T_X
MI>'[]+MS>>0MO<&V.]22S#N !R*L3?$30+68QS:E!'G'ED/N+Y7/  /:GS2U
MTW$XPLE<XOP5\/-<T7Q-#/?2R3)#-+(UT91^]#'@$ 9/7O4>N_#K7;GQAJ%Z
MCO=6]S<1SQ/YH41JHP4]?R]:],?Q'IB:2FIF\C%@X!6?.0P]N]8,OQ0TAM?T
MC2;)C?SZB'96CX5%7KNR.OM1SR;O87)%*USRC4_ &NZ!I]RUUIZ:B+W4+>6.
M))"?)7?S#T^[SG/O6_8_"K6)]>OKV9([2"XM+A+>,.&-K(Q&W&/H3FO0[WX@
MZ#IU[-:WU_!;RQR% A;<S$#)X [56M_BEX?GO]0MOM@1;-8V:8@E'W]-N!R?
M8<T^:;6B%RP6[//M,^%VLP:>PNH)I7CBC0*EPH+NO\>,8/XU<7P/XE1].G%K
M$-00!'EWJ80@;(!7'!P>H[UZ&OC[P\T\,(U6W,LJ&1%R?NCJ3QQ^-*/'_AXV
MLEQ_:D)BC8*QYSD].,9/UQ1SR[!R0[GE&F?"+7HDUE[F*$W$ULD=M)YN2KB5
MF)'IP13O#6E78\;^'+8V8FGT^XN)+K4-QW.&0@9X]:]0TCQ]I6N>)+K1K-VD
MN(+>.X+[2%97SC&1[5T:Q(K%@ &/4@=:3J-;H:@GLQXZ4M)2UB= 4444 %%%
M% #9/N-]#5:P_P"/2/Z?UJS)]QOH:@L%_P!$C^G]: /S&^/PQ\8?% _Z>S_(
M5Y]7WUXU_9.\,>,O$NH:W=W5ZES>2&1PC *#[5SS_L6^$P>+R_\ Q<5]32S&
MC&$4[Z'Q=7*\1.I*2MJ^Y\3X/O\ E1@^_P"5?:G_  Q=X5_Y^[[_ +Z%'_#%
MWA7_ )^[[_OH5K_:5#S,O[(Q/E]Y\5X/O^5&#[_E7VI_PQ=X5_Y^[[_OH4?\
M,7>%?^?N^_[Z%']I4/,/[(Q/E]Y\5X/O^5&#[_E7VI_PQ=X5_P"?N^_[Z%'_
M  Q=X5_Y^[[_ +Z%']I4/,/[(Q/E]Y\5X/O^5&#[_E7VI_PQ=X5_Y^[[_OH4
M?\,7>%?^?N^_[Z%']I4/,/[(Q/E]Y\5X/O\ E1@^_P"5?:G_  Q=X5_Y^[[_
M +Z%'_#%_A7_ )^[[_OH4?VE0\P_LC$^7WGQ7@^_Y4F#Z&OM3_AC#PI_S]WW
M_?0H_P"&,/"O_/W??]]"C^TJ'F']D8GLOO/BO!]#^5+@^AK[2/[&/A0?\OE]
M_P!]"C_AC+PI_P _E]_WT*/[2H>8?V1BNR^\^+<'T-)@^A_*OM/_ (8R\*?\
M_E]_WT*/^&,O"G_/Y??]]"C^TJ'F']D8KLOO/BS!]#2X/H?RK[2_X8R\*?\
M/Y??]]"C_AC+PI_S^7W_ 'T*/[2H>8?V1BNR^\^+<'T-&#Z&OM+_ (8R\*?\
M_E]_WT*/^&,O"G_/Y??]]"C^TJ'F']D8KLOO/BS!]#^5&#Z'\J^T_P#AC+PI
M_P _E]_WT*/^&,O"G_/Y??\ ?0H_M*AYA_9&*[+[SXMP?0_E28/H?RK[3_X8
MR\*?\_E]_P!]"C_AC+PI_P _E]_WT*/[2H>8?V1B>R^\^+1G(X[U^I?P3/\
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MJ4?VQ>_W4H Z#-&:Y_\ MB]_NI1_;%[_ '4H Z#-&:Y_^V+W^ZE']L7O]U*
M.@S1FN?_ +8O?[J4?VQ>_P!U* /.4^&.L:^NOVET8K*SGU2:ZB?'[Q\J .?2
MM:;X57D=NL-M=0E9]/33[CS 3M"G[R>AKK_[7O?[J4?VQ>_W4J_:/8R]G'<\
M_D^"=W#/%);W^3;R2&,>8R[E=0ISCOQ5C0?@O+H_B'3K\7D;P6O6,@DGY"I_
M4UW']KWG]V/\J/[7O/[J4_:2#V43"B^'5Q!X-T_2UND:ZL;G[3&Q!V,=Y8*1
MZ<U%X;^&ESI/BF/7)[F-I6>:66&-<*#(%&%^F*Z/^V+W^['^5']L7H_AC_*E
MSL?LXG*2?"FXE\<7&NFZC,4KS,(BO(WQA!_*L8_ ^]00[=14/"\4R,K%"73(
MQD=L&O1/[8O?[L>/I1_;%[_=2FJDEL)THO<XC3?@L\#:@9[SB^LWMY"A)969
MLD@GFFVGPAO(+:1Y)H[B[6..&)I)7)4)_$&[&NY_MF]_NQ_E2'6+S^['1[20
M>RCN8O@OP+J'AO6I;VZO1>F>U2"1F^\"I)'X8.*[OCUKGO[8O/[L=+_;%[_=
M2H;<MRXQ4=CH!@=Z,US_ /;%[_=2C^V+W^ZE(HZ#-&:Y_P#MB]_NI1_;%[_=
M2@#H,T5S_P#;%[_=2G+K%X>JI^5 &ZX^1OI45D-MK&/:LZ+4[A^&1:GCNY8T
M"A1Q0!/)"&[5&;4'M7QUXT_;0\5>'?%FK:9!IMC)#:7+PHS Y(!P,UC?\-V>
M+O\ H%:?_P!\M7IQRZO))V_$\=YKAHMIMZ'V[]C4=J/LJ_W:^(O^&Z_%W_0*
MT_\ [Y:C_ANOQ=_T"=/_ .^6I_V;B.PO[6PW=_<?;OV5?[M'V5?[M?$7_#=?
MB[_H%:?_ -\M1_PW7XN_Z!.G_P#?+4?V;B.P?VMAN[^X^W?LJ_W:/LJ_W:^(
MO^&Z_%W_ $"=/_[Y:C_ANOQ=_P! G3_^^6H_LW$=@_M;#=W]Q]N_94]*/LJ_
MW:^(O^&Z_%W_ $"M/_[Y:C_ANOQ=_P! K3_^^6H_LW$=@_M;#=W]Q]NFU7TJ
M-X% Z5\2_P##=7BX_P#,*T__ +Y:FO\ MR^+F'_(+L!_P%J?]FXCL+^UL-W9
M]J2(J@U S(#BOBI_VV_%DG_,-L!^#5 _[:'BMO\ F'V(_ T?V;B.P?VMA>[/
MM@NF:-Z5\2']LSQ4?^7"Q_(T?\-E^*?^@?8_D:/[-Q'8?]K87NS[;WI1YB5\
M2?\ #9?BK_H'V/Y&C_ALOQ5_T#['\C1_9M?L+^UL+W9]M^8E'F)7Q)_PV7XI
M_P"@?8_D:/\ ALOQ5_T#['\C1_9N([!_:V%[L^V]Z4;TKXD_X;+\5?\ 0/L?
MR-'_  V7XI_Z!]C^1H_LW$=A_P!K87NS[;\Q*/,2OB3_ (;+\4_] ^Q_(T?\
M-E^*?^@?8_D:/[-Q'87]K87NS[;\Q*-Z5\2?\-E^*O\ H'V/Y&C_ (;+\5?]
M ^Q_(T?V;B.P_P"UL-W9]M[THWI_DU\2?\-E^*B>-/L?R-?9/P]SXM\$Z-K%
MPQCGO+9)G5.@)':N6OA:F'2<UN=>'QM+%-J#V-+>E&]*O_\ ".Q?\]7H_P"$
M=B_YZO7(=Q0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI1O2K_\ PCL7_/5Z/^$=B_YZO0!0WI1O2K__  CL7_/5Z/\
MA'8O^>KT 4-Z4;TJ_P#\([%_SU>C_A'8O^>KT 4-Z4;TJ_\ \([%_P ]7H_X
M1V+_ )ZO0!0WI3U=/:KG_"/1#_EH].&@Q#_EH] $4+KQ5GB@:5'"A8.QP,\T
M6Z(\*MD\T ?EQ\5?^2D^)O\ K_E_]"-<I75_%7_DI/B;_K_E_P#0C7*"OT"G
M\"]#\PJ_'+U844459F%%%% !1110 4444 %&*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@!1U'UK]2_@G_P DF\*_]>$?\J_+0=1]:_4SX)_\DF\*
M_P#7A'_*O"S7^''U/I,D_B3]#MJ***^9/KPHHHH **** "BBJ5[<R0,H3'(H
M NT5E_VA-ZC\J/[0E]1^5 &I167_ &A+ZC\J/[0E]1^5 &I167_:$OJ/RH_M
M"7U'Y4 :E%9?]H2^H_*C^T)?4?E0!J45E_VA+ZC\J/[0E]1^5 &I167_ &A+
MZC\J/[0E]1^5 &I167_:$OJ/RH_M"7U'Y4 :E%9?]H2^H_*C^T)?4?E0!J45
ME'49L=1^59+^.;*.[U"V:X436$0FN%Q]Q#GG]* .KHKG]/\ $T6J6L5S;3))
M%*N]".X^E)/XGAMYX89+F-))F*Q@D?,1V% '0T5C#6N,F2/&<=12G6&R1O3(
M&2..!0!L45C)K!D;:LB,?0$&K-M>22S*IZ&@#0HHHH **** "BBB@ HHHH *
M**3- "T4F:6@ HHHH **** "BBB@ HHHH **** "BBD/0T +163/J<D(=F(V
M)D].U<II_P 7M(U$VICEE2&YE:&*9X2$9P2",_A0!Z#17/Q>)K>8D1WD#L&V
MD*X.#Z4DGBBVBCWO>6ZJ>Y<8H Z&BN:E\76<2*[WUN%9"X.]>5'4CUJ'3?'>
MG:M:07-KJ-M+#/DQD./FP>U '5T5SH\56QBDD%[;F.,X=_,7"GT)SQ39/%EI
M#C??VR$C< 9%''K0!TE%8\&K-<1++$Z21,,JZG(/T-2?VA+ZC\J -2BLO^T)
M?4?E1_:$OJ/RH U**R_[0E]1^5']H2^H_*@#4HK+_M"7U'Y4?VA+ZC\J -,T
M5YWXOU35AXDT--/F"2$2L8V^[)A>AKH-'\4'5H&.!#<1G;+ P^9&JW!I)F2J
M)R:[&U=7HM652I;(S4/]KC_GF?SJG<S-,P+=A7->(_$S:/?:?I]M;BZU"^9A
M%&6VJ%498DU&^AIMJSL?[7'_ #S/YT?VL/\ GF?SKB+3QDD$XL]6A^P7Y225
M8P=ZNB#)93447Q*T6[B=K262Y*PF8;(R1@*3@GL>*KE9/,CO/[6']P_G1_:P
M_N'\Z\YT;XK:/J6EV=W*9;5IXQ(R,A/E G +'M3D^+?AV1\)<3.,N%98&(;8
M<-@]\&CEEV#GCW/1/[7'_/,_G1_:P_YYG\ZX"7XF:1;PWEP[O);6Q7=)#$6
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@!1U'UK]3/@G_R2;PK_P!>$?\
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M*Y^M>2P?!_6;CP]#X?O=7M4TF*=Y]UM$RS,Q)*\G@8S7NWV:/^X*/LT?]P4
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M?]P4 8U%;/V>/^X*/L\?]P4 <!K7_(Z^'_\ =F_]!JYK.C223+?Z>WDW\?\
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MBB@ HHHH *;U-.IHZD4 .HHHH **** "BBB@ HHHH **** "BBB@ HHI,^U
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M,\D7]CSR3(B?QEEV\UYW??LO:?>ZW/J3:E(TLDJ2*KKG9M+'C\Z /;%U&U?
M6XB8G@ ."2?2L71_B)X=UZ\N+6QU>UN)X&*R('P5.<=^O(Q7&> ?@+9>"-4@
MO3?37\D ?9YS$_,QSNZ]:JP?LVZ!"L#LSM=)<R3O<#AG#%CLX[ MF@#U@:A:
MGI<1'G'#CKZ5+%-'.@:-UD4]&4@@UXI9?LVP6,*)'K-SN6=I?,9B201C!Y]^
MM>E> /";>"O#EMI)NWO1#G$KC!()SB@#I**** "BBB@ HHHH **** "BBB@
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M1'3KD2VR[IE,1S&/4CL*=8>&M6U6)9+/3KFZC=]BO%$6#-Z#'>N=X>E?FO\
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M!6A']P5#4T?W!2;OJ-:'YB?%7_DI/B;_ *_Y?_0C7*5U?Q5_Y*3XF_Z_Y?\
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M_+_Z$:Y05U?Q5_Y*3XF_Z_Y?_0C7*"OT"G\$?0_,*O\ $EZL****LS"BBB@
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MVJ_M&IX_BCT[5-.BT-[C;Y[E-HCW=2N<]*G^)M_^T3;Z^J^&M5L&LG?:LSE
MHZ<E3R17T++\+?"UWX?.MRV;-?>27#&5NOTJW:_"OPOX@TZVU2^M&FN408/F
M,!T]JIXMMW<(]MA>S7<UOAFFO1^ ]%'B>Z@O=>%NOVR>V7$;R=RH]*[C3/\
M43?Y[5A:3;0V>G006Z[($4!%SG K=TS_ %,W^>U<#=W<VV-"#_5)]!4E16_^
MI3Z5+2 **** "BBB@ HHHH BN?\ CWE^AK-TS_CQB^A_G6E<_P#'O+]#6;IG
M_'C%]#_.@#\OOBK_ ,E)\3?]?\O_ *$:Y05U?Q5_Y*3XF_Z_Y?\ T(UR@K]
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MVCW8AF^9(S@\CUKAO@;X!\7>*?%/@;7M4T4Z+H'A^WN&B-Q*#+<2RXP0HZ
M=Z^IM3M+#6+5K>\C2>%OO(XR#4UL;:TA6*+:D:#"J!@ 5Y\,+RXJ6([JQQQP
M\8UW7ZM6+0Z52O+-I[JWE!QY3$D>N15C[5%_?%'VJ+^^*]$[#&;07,<:AERD
MK.3CJ#6S:Q&"WBC/)50":/M47]\4OVJ+^^* ):*16#C(.12T %%1-<1J<%J3
M[5%_?% $U%0_:HO[XH^U1?WQ0!-14/VJ+^^*/M47]\4 345#]JB_OBC[5%_?
M% $U%0_:HO[XI1<QDX#<T 2TC4M(6"C).!0!X;XKT;QQ?^*9WT^WN[>W9YD9
MXY?D9"@V$9/K4-]X-\6V[3V\BZA>Z.T1'D1SYE,C1$9SZ;J]T^U1#^*L'QIX
ML'A;0)]1CMVO&C*@1H#W.,G'85JJC22L82IIW=SCX/!FK2Z'X'M09K&6PR;B
M2,@O%\A'?BN:7P7XKTJ74(PM[=0RW-P\#Q2A&\QF&R1\=L5V^F?%O37L5FOF
M0222&.);,F8R8&20!R,>]2:_\8-$T9;B(/(]ZD32QQ/&5$F!G /KS57FG9HF
MT&MSAO\ A%_&&G&2_FBO=3NC=REX8YSAH_+4+M'8;L]*(/#/B>"SAV1ZM*&A
MD^1I2K173$88\_< XKO_  _\6O#OB"]AL8+Y?MKKDI_#N !90?;-6]3^)>@:
M1]I^TWA7[-,(),(3AR,@?D*?-*_PARQ>O,>67/P]\8WNE7$-U)=3S74=TDZF
MX.TC:#'@=N<U4U[POXVU)XK:UT^\AM/),,B/+E67RP!G)ZY%>S>&?'NC^+ Y
MT^:0E%5RLL91MIZ'![&M[[5%_?%+VC6Z'[-2V97T2WDM=(LHI1MDC@1&'H0H
M!J]4/VJ+^^*/M47]\5B]3=*RL345&MQ&YP&R:DI#"BF/*L8^8XIGVJ+^^* )
MJ*A^UQ?WZ/M4?][]* )J*A%U&.KBC[5%_>% $U%0_:HO[XH^U1?WJ )J*A^U
MQ?WQ1]JB_OB@":BD5@PR#D49H 6HKB+SX9(^@92OYBE>>.,X9@*;]JB_OT <
MWX#\%+X-TN:U+QSR2SO,TBQ[<Y/&:N>)O#C:W%:+"Z0-#.LN2F<@=JV/M47]
M\4?:XO[XH D PH]:X;5?AI8^(O&YU75;*VU"T6V$<:3C<5?/)QTZ5VHNHC_'
M1]JB_O?I0!P7B_X2:/J&EI%I6CV%O=)/'('\O;@*V3R*[^%/+B53V&.*3[5%
M_?%'VJ+^^*0'%>-/A;IOC[Q#97.M6L5[86L3*D,F?OD]?RJG:_!C0]"\3:/J
MFBZ;;V36CL9"H()4C&!7H'VJ+^^*7[5%_?%%@)!TI:A^U1?WQ2BYC8X#C-,"
M'4+=[A5"8X/>LZ33+C:VW /;FMRHFN(U)!;!]* .&UGP7J&KM&3-&A0@COR#
MFDUSP5J.M+;1F:-%B</D]\5W N81_%BE^U1?WA0!R=WH&IW"0A7C&S!.?I2:
MKX:U#48##YB*I(.:ZW[1%_>H%U%V:D!P_P#PAFI#0#IHF3[A3=[&I[+PIJ5E
MI(LUEC8A=H8_2NQ-S%G[U'VF(?Q?I0!A:?HUU!9Q1RE"ZC!(/%:MI;/;12AL
M<^E6/M47]ZG,X>)B#D8I@):_\>Z?2I:KV1W6R9]*L4 %%%% !1110 4444 1
M7/\ Q[R_0UFZ9_QXQ?0_SK2N?^/>7Z&LW3/^/&+Z'^= 'Y??%7_DI/B;_K_E
M_P#0C7*"NK^*O_)2?$W_ %_R_P#H1KE!7Z!3^"/H?F%7^)+U844459F%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 HZCZU^
MIGP3_P"23>%?^O"/^5?EF.H^M?J9\$_^23>%?^O"/^5>%FO\./J?29)_$GZ'
M;4445\R?7A1110 4444 %-VC=GOC%.HH SM>URU\.:7-?7C%88P.@R6). ![
MDUE6GC6V(G.I6TVD+%@[KL *V>F#_2KOBWPY'XJT2?3WE,#.5=)0,E&!R#CZ
MBN-\3?#36?&-O&=4U6W:6"1)(K>)&6!MO4MSNR:N*3W(DY+9&P_Q/T?^WXM*
MA+3R3-&J2QC*$N#CG\*@N_BII]GK%S8R6L^VWN4M))QC:';IQG-8FC_!4Z5K
M5E?I=PQK \3F")"%RF[(&3G^*GZS\'Y]6UK4KCS[..&\NX[L7&QOM$17'"]N
MWZU=J=S*]2QVDWC;0;9IEEU6UC:''F!G V\XY_&J:?$/0Y-5ALDO(G$T9D28
M,-A^;&W/KFN N/@+?W^MK>W>L13(K#K&27 D#C=SCMBK4GP()\20ZQ'J:QS6
M]P]Q!&$^4;GW%2.A&.*%&"ZBYJCZ'KJA1R /KBG4Q00@SUQSBGUB=(TJ,YQS
M39'2&-G<A549)/85)6+XSTNXUOPOJ=A:2>7<W$#)&V<<XH GT[Q%IFK3/%9W
ML%S(G++&P) ]:?>ZWI^FSQPW5W#!-(,HCL 6YQQ^->7:YIWB+4M!CM=&T)](
MN;>".*:Z(42. 1N6,9^8$ \DBN>NOAYXCN;W1I_+O;V*%\[[T(LD:^:&VD G
M@#W-:J"[F$JC70]NU+Q%I>CR)'>WL%L[C*K(P!(]:N27<$5JUR\J+ J[S(3\
MH7&<Y]*X'6-,OM,\5ZM?-HSZW;W]K'% % 81NH(*MG[JG.<BN/UW0_&5YY^G
M)IUPD,LLKDQR@P+&T. @.?[W;%)13ZC<VNA[99W]KJ$7F6TT<Z<?,AR*GX]J
M^>]%\(>*O"<$YM-.OG:19-R0R<,S0@*>3QAA5@^"O&3Z<UQ+-?Q3--")5CDW
MN8A$ P52P'WO>K]FNY/M'V/=[R]M]-M9+FYF2"WC4L\CG"J/4TMK>07UM'<6
M\JS0R*&1T.0P/0BO--=\+Z_JOP^TG0(F>YEN) MW/?\ !6($DAPOKP.*Y1/
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MY9AV[M/[P_X8B\=_\]]-_P"_U'_#$7CO_GOIO_?ZBBJ_M&OY"_LO#]G]X?\
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M_E2'6H"?NO\ E110 HUR ?P/^0H.MPG^%_RHHH /[<@Q]Q_R%']MP?W7HHH
M/[<@_N/1_;D/]Q_R%%% !_;</]U_R%']N0_W7_(444 ']N0_W'_(4?VY!_<>
MBB@ _MR'^X_Y"C^W(?[C_D*** #^W(?[K_D*/[;@S]Q_R%%% !_;D/\ <?\
M(4?VY#_<?\A110 '6X#_  O^5!UR$_PO^0HHH 0:U ,_*_Y"E_MR'^Z_Y"BB
M@ _MR'^X_P"0H_MR#/W'_(444 ']N0_W'_(4?VW#_=?\A110 ?VW#_=>C^W(
M?[C_ )"BB@ _MR'^X_Y"C^W(?[C_ )"BB@ _MR'^X_Y"C^W(?[C_ )"BB@ _
EMR'^X].&M0G^!_THHH <=2CF1E4-DC'--MI%BA52"<444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>plx-20241231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20241231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $J M4# 2(  A$! Q$!_\0
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MA&D\#5<VU[U^CT\D+NHW4E%;'SXNZC=244 +NHW4E% "[J-U)10 NZC=244
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M[7';$R'9\O,JL,9XR.#1[6H_M!_8N6_] \/_  %?Y#?^&7_AK_T+W_DU-_\
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M4W_Q=>K8HQ1[6I_,P_L7+?\ H'A_X"O\CRG_ (9?^&O_ $+W_DU-_P#%T?\
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MX9?^&O\ T+W_ )-3?_%UZMBC%'M:G\S#^Q<M_P"@>'_@*_R/*?\ AE_X:_\
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M#&(XY(XP-S'A4FD '^UZ@5?U+P'H^JWEY<7$,K&\7;<Q).Z13'9L#,@(!.W
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MMTQG(:1L%S;FW)Z_\\F*_KUJ&U^%OAZUN9+G[//-<2 AY9[F21FS$8>K,?\
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M'X&QW!N=0OE++ P>(QA6/)V%<#IV;/U%>%_$I[RWU'6%><F7.W"-T/F)@GZ
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MC>C#*G!YZ5Q.N?&&WT.[\36DMI*UUI4T44*I#*Z3!XT;+.J%4^^1R>WO2VU
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M--E\^UNI)(H&68*/*FD4/'$V&)W%2#QD?,,GFBS0'9T4@Z4M !1110 4444
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MU]J^BLE12?;]#PE=U';^M3],?^"7#(WP$UO9G UZ8$GN?*BKZZO?]6:^1?\
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M2!O7(8;AP<4O,;W')\,](3P['HV;AK5;U;\ON57:82B3)VJ% +#D  5/X<\
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M1)#( N4VM(@YQ]X4#ZB6WPCT6UCBACFO!:J\<DMMYH\NX:.0R1L_RYRK'/!
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M=%E>2%K.7S(EC56=G7;E0%=3DCH:$,2P^$^AZ5#!'8FYLTM[J2\A\J0?NW>
MPG&0> AX![^M7?#?@J/PI=.;&[D:WN))+B[25$!GF8(H?Y555PJ8PH&<Y.3S
M523XK^'$0'[5<,QD>/REM)3("D:R,2NW(&QU;)XP:H6'QCT>ZU75+:9XX(+*
M5HTE#L[7"A+=E9%"\Y-RB@9SG& <\ %NW^$>AVRZB%:Z_P!/:,S;I1_!<R7
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M%% !1110 4444 %%%% !1110 4444 %4-9_X]%_WQ5^J&L_\>B_[XH L6/\
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M<YJO\1D6A?ZF;_KH?Y5=O+.#4+66VN88[BWE4I)#*H9'4C!4@\$$=C5+0O\
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ML2#B/ D+ CY=NY<[L8W#U% &!IGP@C\-V:/IFH2O>VUW+?VQN$!3S6M1;A6
M_A  /'-;'B[X?6OCF/2EU.=U-HQ:580 MP"O*-GG;O$;X]8USQFII?B?X5@L
M?M<FMVT<'F-$2V00ZKO(*XSPI#=.G/2I5^(OAI[![Q-9MGMDD$.]&+98KN&
M!E@5^;(R, GH,T=D(Y6P^!ECIOV1X=6NC-;QVD?F2(C&0PF<EF&.K_:9,^A
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MI+" D2#.&0<'GOS73AL/'#0<5U.:O6==IL/AC\*U\*?:+B34;[4);DEF^TL
MH8L22% ')S7K6DZ:$(PH%/T[3-L:+CH.:Z'3[#!QBNI(P+%K!B+ 'Y4R2#<>
M?RK72TV1@=.*;]E!IV)1CBTXZ<4HL@16RMD1QCBI5M..>#2&<W/8 ]JH7>F
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M&R.-LR6Z,4^?Y2/L^1G(^?G.*K67P!2RU>TO8]8)2WNS<K&8,D@W33[<[O\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:S_P >B_[XJ_5#6?\
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M/.;C3I-#9&U)1;0@Y6*21?.G_P!S!PO..3QQ5QKZ'QBL^EW4;RW$*;V1H]A
M[8[9 QR.O%7IM(TN&Y2UUOP_/87**Q\R-L\8R3]!BNDT?P=/H4*WFCQSWRW"
MJ8H+A>$3.2=V.,]!2A14(W2W)E.4GJS+UO1$TOP7\.K=&W"#4IGR_P![OC\>
M35@Z5K7B9;-6TJS6*V0QJ]R3(S?,2&Q]"*W/B-+HXT'PE;:W83B:6[E,,EC+
MEK5\ $YQSUQ7HWPI\-:/<>&(GTJ]NK^U$C*6O"3*C#[R'(&,>E2P/K__ ()Y
M:-<Z+\'-6AN71G;6)& CC" #RHN./I7TQ>_ZLUX[^R58)IWP[OXT& =0<_\
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M8]J[O_A&]/\ ^??_ ,>/^-'_  C>G_\ /#_QX_XT<Z#E9PP7!Z\4[;R*[?\
MX1S3_P#G@?\ OH_XT?\ ".6'_/#_ ,>-3S)BY&</M'&*".*[C_A'-/\ ^>'_
M (\:/^$<T_\ YX'_ +Z/^-',@Y&<$XSGCM526/@\\5Z.?#6G'_EW_P#'C_C3
M6\+::W6W/_?9_P :7,A\C/(KV+(.![UR_B'0AJ%LPQ\W8U[^_@O2)/O6I/\
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MP;U6'6-*UO4A96RQE9)-/"D[,&^X QC_ )>T^FUJ]:_M6?\ Y]U_,T?VK/\
M\^Z_F: /'(/AIKNC2>%]%BM8]0CM+K2Y[G49 <1"V4!O*)[';T.#ECP0<CH=
M3^'^K^(?%?B3=%;6.G3:C;7<5\V?M$GEVJ+M7 ^Z6RI).<;A@YS7H7]JS_\
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MC<* (/LB^E'V1?2I]PHW"@"#[(OI1]D7TJ?<*-PH A%N!VJ18]M.W"EW T
MXHI:* *ES<B)B"0*IOJB+_$/SKS#X^>+]1\/+:6NGSM:M<,2\L9PV !P#VZU
MXG_PF^OGKK5\?K.U 'UO_:J?WA^?_P!>C^U4_O#\_P#Z]?)'_";:_P#]!B]_
M[_-1_P )MKW_ $&+W_O\U 'UO_:J?WA^?_UZ/[53^\/S_P#KU\D?\)MKW_08
MO?\ O\:/^$VU[_H,7O\ W^- 'UO_ &JG]X?G_P#7H_M5/[P_/_Z]?)'_  FV
MO?\ 08O?^_QH_P"$VU[_ *#%[_W^- 'UO_:J?WA^?_UZ/[53^\/S_P#KU\D?
M\)MKW_08O?\ O\:0^-=?/_,8O?\ O\: /KC^U4_O#\__ *]']JI_>'Y__7KY
M(_X3;7A_S&+W_O\ &C_A-M>_Z#%[_P!_C0!];_VJG]X?G_\ 7H_M5/[P_/\
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M[53^\/S_ /KT?VJG]X?G_P#7KY(_X3;7O^@Q>_\ ?XT?\)MKW_08O?\ O\:
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MDC_A-M>_Z#%[_P!_C2?\)MKW_08O?^_QH ^N/[53^\/S_P#KT?VJG]X?G_\
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M +53^\/S_P#KT?VJG]X?G_\ 7KY(_P"$VU[_ *#%[_W^-'_";:]_T&+W_O\
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MJ-Z-0CC>W%HX+2#/EDE5#_AG/X5K2^$8[/PY#IUS;^7JSW\8EE1-TB(WF*%
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** />_V?S_ ,4Y>?\
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MM;'2=USI;:J[RRNL=OB-F^SR,2 K@@ L>!G.!BG8#H_^&=O"G]Z__P"_X_\
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M!YG_ ,,[>%/[U_\ ]_Q_\31_PSMX4_O7_P#W_'_Q->CMJ%NDBQM/&)&^ZA<
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M$G^Z?Y4 0Z7S80_0_P S11I7_(/A^A_F:* &6W_(3O?^ ?R%7JHVW_(3O?\
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MQZ ?[*_ACI706\<R#$KK(WJJ[?ZFIL =J"..*S;-4K!4-Q9PW0 GBCF Z"1
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M>_\  /Y"HM=\06OAZ&W>YWL]S,(((84+R2R$%MJ@>RL?8*3VJ6V_Y"=[_P
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M7KI'M05!'(!HZ6'?6YXU8S>,-$^'>J3:O?7BW_\ HS-).B0>4H9/M 20S/\
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M]]"N:P/048'H* .E,\/_ #U3_OH4>?#_ ,]4_P"^A7-8'H*,#T% '3">$?\
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M/_/5/^^A7,8'H*,#T% '3_:H?^>J?]]"C[5#_P ]4_[Z%<Q@>@HP/04 =/\
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I_OH4V:>,PN ZG(QP<USJ*/05=M@/2@#5LEV6L:^F?YT5)#_JEHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>plx-20241231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20241231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $T MH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4B<4;A2/
M]TUX3+XUUQOAW)=)JDWV\>+A8"4$;A#]N">7TZ;./I6M.FZCLO)??H95*BIJ
M[\_P5SW?<*-PKQN#XU:O+XA-K-H4":.VLW&B)>1W1,IE12ROL*XP0O/-9>G_
M !LUJW\.:7'IVD#5[R/19-9OI=0O-A$0=E 5@GS,2I[ 8%7["=KF7UF&W]=$
M>\9HS7D*?'&X.B:M?'2H@UD-+(3SC\_VME![<;=W'KCM3/#WQYN-?^(\N@1>
M'KHZ4MW+8_VC'%,P61,Y9SL\L*2,<.3SR*/J]7738/K-+37<]AW#UHW UX[X
MVU;4]9\9>(-/'B'4O#VF:'8PW.W1[<2W-P\F[YMNQF91@#:HY.:PKS]HN;1-
M*\.6^F65QXRN[BR:ZN+M+.>)I%24Q-B)8V*L65A\VU>.O-$:$YI./44L3"#?
M-I;^OU/?]PS2%@.]>.ZA\<-6M=7N_*\.Q'1[.\L;:XGFN3'.OVE5QB/;U4L,
M@D5BO^T/J^N3>(K;2_#L\,$%M>_8M2DBF\L20(QS(QCV ':<88\X!ZT+#U&K
MV!XFFG9L]]W"C(KY_P!)^,6KZ%IEOJ>N1-=W"^&;>_-O;W&8II))=JL04&&.
M1DYP.:]1TG6O$-UX8U677-,@TC48(W,9L[D3QN-F0RG (],$#D=Q4SI2AN7"
MO&;21U^X4;A7SA\(_%FN/X?3Q%J-QXROI(M*EO7.IK"NFSL$SA2HW<]JW8?V
M@=6L]/N)=4\-P074NG6E_80V]YO63SY5B19&*C;\[#/7BM)8>:=EJ9QQ4&KO
M0]Q+@=32[A7B5S\5M;NM2&FZCIZZ5>V.NV%C*+"\WK*)5+')*<K[<$^HI^D?
M'S46^SWFK:!#:Z1=0ZA+!-;W)DE8VI;=E"HP"%XY-3]7J6O_ %W']9IWM_6]
MCVK(HW"O +#]IZ\;PSJ&I7OA.\MY5, L0(9_*G,K85<M$"6'!.P,#GC-:^D_
M&W7]>_X1VUM?"WD:GJ=S<6\D5^\MNB") YD7?&&*D$XRH.:;PU5:M?UN)8ND
M[)/?_ACVC<*,BO"])^+?B%+*PM=-TN/6+Z[?4I"U_>[!&MO(1C<$Y&. ,>GU
MI]Y^T)JD^BR:IH_AV&YM;31H-5O?M-WY;1^:"55 %.[&.3Q[4/#U$QK%4VK_
M -?UJ>X[@*-PP/>O,?C&=1N?AG<:_INN:AH5U969NU6Q= LA*J=K[E.0/;'6
ML >/M;\"6\^G6<=QXK&F:?'K&JWNK7BQRK%("0D05 &(",><#MGFI5%R5T]2
MI5U&5FM#VW(H# UX_)\=+F>]EO+/14E\+VU[;Z?<WCW&VX66;9M*QXP5!D7/
M.>N!7.M\:O$'A;3KISIQUB(ZO?QM>W;O'#!%%*0D>Y48*<="V%XY-4L/4?03
MQ--=3Z"S2U1T;4DU?2[.^CV^7<Q+,NUPXPP!X8<'KU%7JYK-:,Z4^9704444
M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLM0M]2@6>TGBNH&Z20N'4_B.*LT#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(\5^)[
M#P?H5UJNHR-':VX&=BEF9B0%50.K$D #U-<WX?\ BSIVK7L]GJ5C?^&;N*W-
MWY6LQK%OA! ,@8,1@9&><C/-7?BCX0NO&GA*6RL9HX-0AGAO+9IP3&98I%D4
M-CG:=N#]:\P^(/ASQ9XDT;7]?U[3;32OL.@W=G;6%E<FZ>9Y%&YRVU<#"\*
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M ,) VE^< JZ>-2^V[U^S^46*YWY]OI5^V\7:)>6]I/!J]E-#=L5MY([A"LI
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M8_'_ ,(:I8VUY;7LJ03M;E6O;6:V)BF#&.50Z E"$;YNG!Y%+?4-M#C?@/\
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M:[B< [ER,$\UW'Q0^,%S\/\ 4HHK:SM-0AB-LUY%OE,\:33")6PD;*HZD%V
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M-;V*0C35>[\F1FW.%<!2#ERJ@]< &HM3^-WQ N+&+6=6\0VVGBX\(7]W:Z;
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M$\TSG"QQJ2S'T %>T_#W]FK4-8\J\\1R-IMF?F%JF#,_U/1?U/TKV[P-\*]
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ME=R6-Y!<1';)$X=3Z$'- 'US2U5TV^34M/M;N/[D\:R#\1FK5 !12$\9I-U
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MHHK<\\**** .Y^!W_)7/"O\ U_)_6OT)U1BFG7!!P0AY_"OSV^!W_)7/"O\
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MT;AEE1'!63:P!V$<C->.:AX5\>7\<(MK/4+:TN+V1Y)[5/L$]PC3VI,L\<;
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MB2S0+'\_!()(9AW89;G_ &C0&YR?@[5=%^S2+#HDPENXT$\"IYGEQ;5PK9.
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MV09R9,MG@;>IJQ=?LFZWJ$FKV,VLZ-;:2JZ@VFW=K9.+^=[J0R%;QB<.B'C
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MF4]5WQLK $<$ \@D'@UKT4K7#8IZ7I=MHVG6MC90):V=K&L,,$8PJ(HPJCV
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 (3BC</6@]*\M\4_%R3P9XPURVOK5[O2[*VLFAAM
M(P9VEGE,?=@".G%7&#F[1,YS5-7D>I;A1N'K7C6J?'BZ,NC1Z;X<OTGEULZ3
M?VET(Q+"0F_ Q)M)(((.2, ]ZCD_:4T/5Y/$&G:0)%U*RM+J:VEF,;1S/"#N
M&U7+#D?Q 9'2M/85;7L9?6:5[7/:=PHR*\2A^/JZ!::O?>(PAM[>/3EMH[95
M1GEN(B[+N=@H&5)R2  *U;+]HG1=9L=/ET;2=5UNZN8Y97L[%(WD@2)@KLWS
M[3@D ;2<]LT.A4702Q--Z7U/6-PHR*\BM_C?<0>(_$T&H:#>0:7ITUI#!.%5
M78S!0-ZE\@DOG&!@ YYK5\1_&W3/#D.M,VG7UT^EWZV$BQ>6H9S$LN[<S!0N
MUNY'(I>QGM;^M/\ ,KV].U[_ -?TCTC<!WHW#UKS+P;\5#XW\;6%O8!1H5[H
M(U2,2)B82>?Y9!()&  >/UKA[KXS>*!XXU/3[.]LKMK76DT^/0TTF9II8"R!
MI/M(;8I 9CR/X?>J5"<I<O7^D3+$PC%2Z-V_"Y]"Y%&:\P'QVL#;ZC,-"U9H
M[6^.F0LJ1G[9<ARGEQ#?[9R< #OQ39?CO8K:V0BT#5[C5;B^ETY]*2.,7$,Z
M)O*ME]N""#D$CFI]C4[%>WI]6>HY%&X"O&=7_:D\)Z+;Z;)/%>"6Z1Y9;9O+
M22U".8V#AG&2&!^5<DXR*7QC\?GL-(\3RZ!X?OM2DT=$+7K",6P9PC+U<,>'
MST[4U0J_R_UL+ZQ2[GLN:-P%>=6_QDLRCP7>EWUEJB7=M9G3Y-AE9YP"K##$
M%0"Q)SQM-9_QO^)>J^"(M-L]!>R&JW"S73K?#*^1"NYP.1\S$@#WI*E-R4;;
MC=>"BY7V/5<B@,#7COC3X^1:=X<FFT'3+O5K\Z*-6\V"-7AM4<'RVERP)!*G
MA<G@UK:1\9[*X@LK6YLKG^UYKRVL#;1JN7>6+S1*OS?ZO:&.>ORGBG["I:]A
M?6*?<],R*,BO)8_VC=":]UVU?3M0AETJSEOBKB/,\49PQ50Y*G/0. 36?XA_
M:$N(-.+:;X:U*/48[RRC>TO4C#-!<-\KKB3&6 ( )X)&:%0J-I6!XBFDVV>U
M9%&:\QF^/6C67C2/PW?6%]93N747$PCV;TC\QEVA]^ ,_-MVDC@FJUG^T/HT
MO[V[TG5=,LWT^?58;JZB0)-;QE1N7#$_-N& <'D9QD4O8U+7L'UBG>USU?(H
MSFO%[;]J7PU>:')?PV5[+,EU':_9$D@+$N"RMYGF>6!A3U8'/'6O4_"GB*#Q
M9X?LM6MXIH(;J,2+'.NUU]B*4J52"O)6*A6A4=HNYK4445D;A1110 4444 %
M%%% !1110 5Q_P 5?A9H/QA\'7GASQ#:B>SG&Y)%XD@D'W9$/9A_];O7844
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M6\JE)(I%#*ZGJ"#U%3T4 ?%GQ_\ ^">.E^)WN=:^'<T6BZDY+OI%PV+64_\
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M=Q;-%%O*LN?E('/?(Z4W2OV@/"VJ>&]3UP_VA9V%BJ.7N[1D\]7.$,74-N/
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MD,T"X212002>20P(.3QBJLO[/VA23+<"^U%+S)D>Y#QEY)_/:<3'*8#!W;@
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-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>plx-20241231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20241231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %V PD# 2(  A$! Q$!_\0
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M3N *DYQ7S#\<?%/B'XA?&3PEX&DU^;1M(%I90)()2BJ7C4L[<\FN>\#^%I/
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M\<^&O%/@3X:^ ?&O_"67\TFL([0PB9Q]G"'Y0#GFCN'8_7K[7!YWE>='YO\
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M//3VKZU2)8XEC50$4;0H["L?_A-O#_\ T&]/_P# E/\ &C_A-O#_ /T&]/\
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M^@V]TQ9[1$#*H/4 Y!Q[&NVT#]AWP;H?PLU?P@+R[GFU0J\^IOCS R\K@=
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M*LAR>:P? '[!EC\._B;;^*=-\67BVT%S]H6Q\H ,,YVDYY'-?37_  E&C_\
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ME&,HQM+?4X<1*$IWAM9?D%%%%;G,%%%% !7?5P-=]6%7H=%+J?:%%%%?%GZ
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M4-U<?9HM^-W.,5-5+5?^/7\10!#_ &Q_TS_6C^V/^F?ZUF44 :?]L?\ 3/\
M6C^V/^F?ZUF44 :?]L?],_UH_MC_ *9_K6910!I_VQ_TS_6C^V/^F?ZUF44
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M],4 <[XI^(,7Q"\?ZSHE_P".8O!>@Z.RP/%!.L=Q<S8RWS'HH/%;'PE^(?\
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M_E0 VBG;&_NG\J-C?W3^5 #:*=L;^Z?RHV-_=/Y4 -HIVQO[I_*C8W]T_E0
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MVK!_</Y5D44 :_\ :L']P_E1_:L']P_E6110!K_VK!_</Y4?VK!_</Y5D44
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M?%_=/Y4OVI/0_E6=4M)Q0U)FM11161J%%%% !1110 F*-HI:* $VBDVBG44
M-V4;13J* &[11L%.HH ;M%&P4ZB@!NT4NT4M% ";11@4M% "8I:** "J6J_\
M>OXBKM4M5_X]?Q% &-1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '10_P"H3_=%<_)]]OJ:Z"'_ %"?[HKGY/OM]30
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M\;_9B+8+&I"HR9R<Y.3F@#I)OCUX7CL+"YB%_=/>/)'';6UJ7F5T +*R@\$
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M2%C=12R^3$L5T[@[<.#NDSD8STH&NQ].ZEXGTS3-$O-6DO(7L;2-I)98Y%8
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M **** $(S2;13J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEJO\
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MS%9'V^?_ )Z&C[?/_P ]#0!K_88/^>8H^PP?\\Q61]OG_P">AH^WS_\ /0T
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M$(+:/.U!VR23^I-7*;U8@HHHI#.B@_U*?[HK-U?_ %J?2M*#_4I_NBLW5_\
M6I]* ,^BBB@ HHHH **** "BBB@ HHHH \V^,?AR/7M.=XE>_P!2MH'>WT\7
MAMU!_P">W')*UYL/*\8:;JVI7][=/=:/HUO+8RF9HRLF#N? (!)( YS7N'BW
MX?:'XW-N=7LS.\!^1TD:-@.X)4C(/I5/5_A-X6URZL)[O2D9[)%CB",R+M'(
M5@#A@/0TD-F]X=N9;S0-.GGSYTENC/GU*C-:%(B+&BJH"JHP .PI:IN[N2M%
M8****0PHHHH **** "BBB@ J:S_X^8_K4-36?_'S']: -\]#6,WWC]:V3T-8
MS?>/UK2!G,2BBBM#,**** "BBB@ HHHH XGP[:)J_CS7M2N/WCV3):0*W1!C
M)(^N:M:QXON?#.OK'J<"IHT^!%>)_P LV[A_3ZUG75X_@CQK<7-S\NC:MMS-
MVBF Q\WH"*[*[L[/6[%X9XX[NUE7E3AE85T2LFFU=6.2";BXQ=I)LXG4=7O?
MB'=R:9HLS6ND1MBYU)/^6GJB?XUO^%9]-L[F]T33[?R!I^T.<?>+#.<]S4M_
MJ&D> ]#R1':6L*XCAC'+'L .Y-9OP\TZY$-_J][&8;C4Y?.$3=43^$'\*;:<
M';1=/444U45W>77R1U]%%%<QV!1110 4444 %%%% !4M15+28T:U%%%8&X44
M44 4-:MGO=-N8(VVO)&5!]":\%O?AYKEBLTLML!%'DF0N,8]:^AVZU\^?M/>
M*=7TT66E6F^&PN$+2R(/OG/W<U\OF^18;-W&5=M./;S-/[2EEM*52*N?,_Q4
MNO[:U7=;6@$<&4:?C+FNR^!'A;4;#[3?SPM'#* $C;@L/7%=/\/O@[/K&DOK
MNK1-'9(P,,+CF4YZ_2O7-!\-?VFLXMP$DB0%5 P"/2OB\RRQ8=PP&%3=U?7?
MN+*74Q,Y9CBM.UA=.\/WVI0"6VAWKTZCBN_\%:-<Z1:2+<\,[9"9Z5QOAV]O
M-+U=(8U;YFVO&17JR]!Q7O\ #^%H/_:(W4XZ.^QZF-JS7N.UF?/'[0=GI\OQ
MI^%-QK")_9R74J[Y1\@EQ\@/XU[UJGV1=*N3=[/LGE-YF_&W;CG/MBL+XD?#
M;1_B?X=DTG6(2T>=\4T9VR0N.C*>Q%>22_LU^+-5A&DZQ\2]4OO#8PK6B1A)
M9$_NLX[5]P>2>!^ [?[9J'PPBD0R:8OC"^^PB09!A )7'MG-?17Q96;_ (7Q
MX4%KQ<?V!J/E_P"]@8KI=7^ VEW5_P"!I-/E_LVT\*SF:"WC0$2Y7;@G]<UT
M.N?#U-6^(FB>+#<LLNEVD]LMMMR)/,(.2>V,4UH5<X#]C\Z4?@W8I9%/MRSS
M#4%_C$_F'=N[YKGOCSJUGIOQ^^%0M)E359)IXIE0_,82AR#[9KDM+T33]5\<
M>(6TWQ#=_"CQ*MTXN[%F4V]VN?EF0-@<CGBLK2/AII^K_'_PHVCZ[=>+]4T^
M62[UG6IGW1Q+M(6-<<#)/04 >N?L=Z?;P?#34)XXE26;5[MI& Y8B0CFN#^/
MMLEG\6?%Q@41FY\&R/-M&-Y#D FO?OA+\-X_A;X9ETB*[:]1[J:Z\QEVGYVW
M8Q[5G^)/@Y9>*/'USXAO;AI(;C27TJ2SV\%&.2V?6D*YI_!HAOA7X4(Y_P")
M;!R/]P5VHZ5YI\(OA=JWPOBGTV3Q'-K&A1J$LK:XC >W7/3=W&.*]+'2JB(6
MBBBK$%4M5_X]?Q%7:I:K_P >OXB@#&HHHH \X^.'C*]\&:%I<UGJ*:5]JOX[
M:6[: S^6ASDA!UJGHOQ%DT3PB=5N-0NO&?G3F.+['8_9V&!R"&(P/<UV7B[P
MDOBJ71V:;RAI]ZEYM*YW[<_+^M8WQ0^&LOCZRT^*TU%=-:TF,FQX?,BD!&,,
MF1G':EJD_7_(>C:_KN<G-\?EN-8T6?3=,OM1TV\LYI9+2WA#3QR1OM;/.,#F
MNC@^->E7^JQV=AI^H:@IM%O9)X(LK%&P.-W.<Y!&/6N8T7]G_4_#-MIXTGQ0
M+6YM8YX3*;0,KK*VX_+GC':MVP^"<&F6VK06NJ30K?:9'IXD48="I)+Y]RQX
MJNG]>?\ P!+?^O(73?CA;ZM'JD=OX>U5M2L468Z>53S9(V. X^;&/J:7P;\=
M=,\6E2^EW^DHQE59+Q0%9HQE@""0>*XM/V:-7MK;4OLGBU+*\OH([>22WL@B
M^6K9((W9.X<'FM/Q'\.]<C\':7X9E==1N6NT^S7FG6@MX[.,??W_ #'JN1[Y
MH UKK]HC1[2ZDC.DZK)%#'%--/%"&2)),[&;GOC]:LS?'O1K/2KRYN]/O[*\
MM[A;8:?.BK-(S#*XR<8(YY-6;SX0PW#ZUY=[Y4>HPVL(0)_JQ#T^N:J>,?@C
M!XKNKZ[-XB7<L\-Q 9H!+&C(FW#*?O BD"./\9_&K4==L].N?#,DMC SE)PZ
M*75Q]Y2<X&/8\UZ7H/C*Y@\ +K6I037<J X6WC^>89P"![U9\#^ X/"F@BPN
M1:WDC2&5VBM5BCW'T0=*G\?>$&\9^%;C2(+PZ<TA4K*BY P<X*\9!]*;T5D"
MU:N<;%^T-I$U@9!I&IG4%O%L6TU8U:82,NY>AQ@CWJ[_ ,+PTZ?2K>:UTG4[
MG4I9)(GTR.$&>$Q_?+#.,#ZUB>#/V?'\+ZH+Z;6$N9#?QWS)%;")-RH5V@9X
M%:DWP<O+34;G4](UW^S]3FNYY_-> 2+Y<N-R;2>O'!I?U^0!9?$34;[X'7OB
MK>L5^EO+*C-'PN&(&5]AVKDO /Q<O[_Q%8P?\)-%XFM6MVFU%%T]K8V*A<AR
MQZ\\8KT73?AK]A^&4OA)[]IS)$\;7;)@DLV2<4W5?A7:WU[I]U;W'V2:*U:Q
MN]B<74)7&UAZ@\@T;-V#<PK/]H_PW=V^HSF"[BCM8&N8BP4FYC4X)0 D_@<4
MW4?C5]MTX"ST^\TF_%S;#R=0BVF2"1P-Z\]"*YW4O@%<^'_"&MP64]M>R&T:
MWLH[>Q2*;!(^^_\ $?RKH[?X-W^J6R7&M:ZUWJ.+=8W2 1B..-@P3 /)SU--
M6$]OO-+_ (7AI$'BG^QKVPOM/#^9Y-Y<(!'*4!+8&<C@'J*BT_XZZ=?7QM6T
M75K9WMI+R RP?\?$2D#<G/.<URLG[-\J^($U:XUG[?%;23R);K;A991(K JT
MA/)YX-8/A[X;^+/&NMO%J=S?Z9IUEITEA;R7-ND;)E@0!M8[Q@<GC-)%,Z_4
M_CL^I:5<#2=.N;'6+2[ABELKU5+%).A&TD<UG?#+X@>)]8\6K;WUP;J":4@P
MF,+L3G+<<C!]:N^%?V>9- OY[R?68YY9Y[:9T@M1$@,1R !D]:]BBL[>"1I(
MX(XY&^\RH 3^--66I+NR:BBBD,Z*#_4I_NBLW5_]:GTK2@_U*?[HK-U?_6I]
M* ,^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *FL_\ CYC^M0U-9_\ 'S']: -\]#6,WWC]:V3T-8S?>/UK2!G,2BBBM#,*
M*** "BBB@ HHHH AO+*#4+=X+F))H7&&1QD&N0D^&,,#M_9NKZCID9.?*AF^
M4?0'I7:T5<9RCLS.5.,_B1RFD_#C3=/O5O+F2?4[I?NR7C[]OT'2NKZ444I2
M<M6QQA&"M%!1114EA1110 4444 %%%% !4M15+28T:U%%%8&X4444 -(S5'4
M=$LM655O;6*Z53D"50V#6A12L)I/1F-K6A_;M':RMPL( &P 8 QVK-\(>&+G
M19)Y+@KN<;0%.:ZNBN">!HU,1'$R7O1T1O&K*--TULRJNGP)-YPB42_W\<U8
MP:=17:H1CLC)MO<;@T8-.HI\J$-P:,&G44<J YCQ5\-?#/C9D;7-%M=1=>%>
M9/F'XCFK?AGP5HG@ZU-OHNF6VFPMR5@0+GZGO6Y11RH!N#1@TZBCE0#<&EI:
M*:5@"BBBF 52U7_CU_$5=JEJO_'K^(H QJ*** "BBB@ HHHH **** "L/QAX
MUTCP)I#ZCK%VEM .%!^\Y[!1W-;E<-\6O#1\3Z)9V<>GB\FDO(4,A0,88]X+
MM[<"@";Q+\5=+\,26T<UM>W+2P"YD%M 7\B(_P ;^@KJH=2MIK&*\$R+;2J'
M21F !!&1UKRSX@:SJ5YXIC\.C0-6_L)HT2YO["TW^>"?]7O_ (5'>MKXD^%#
MXDM?#>AQ64KZ2MVLMR(B0JQQJ2JDCU.!1TN!W,6IV<[HD=W!(SC**L@)8>HY
MYIT5_;3M(L=Q%(T?WPC@E/KZ5\\6_P (]0TS3=/N-(TF:SU=IKVX$FXC[.F"
M(XAD_*#UQ2Z7X4O([6[NM,\(ZKIT2Z8UI?QNWEW%[*V-SKD_,1R0>] 'T/;7
MEO>H7MYXYT!P6B<,,_A4U>1? [3KGPMI<EO-H5U8QW-SY<4CV_E.R!?ORIG"
MGMGO7KM-B3N%%%%(84444 %%%% !1110!T4'^I3_ '16;J_^M3Z5I0?ZE/\
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1)ELMW\52_8_]JBBB["R/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>plx-20241231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20241231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N K0# 2(  A$! Q$!_\0
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M-2_[_FC_ (7'XW_Z&C4O^_YKCJ*[_9P_E1YGMJG\S^\['_A<?C?_ *&C4O\
MO^:/^%Q^-_\ H:-2_P"_YKCJ*?LX?RH/;5/YG]YVZ?%;Q](H9/$.K,IZ%9&(
MILGQ<\=QL%?Q)JB-Z-*P-?:GP2MH[']GW3-0M-!@UC4([<LENT:[I3NZ9(JK
M\??"ND:I\-=*UJ^T:VT?5X[F!EC"*K*S,-R' YKR'BX>UY'36]CW%@:GLO:*
MH]K]?S/CG_A:GC__ *#^L?\ ?;5'_P +;\=B3R_^$CU7S/[OFMG\J_1F]T>2
M#3=,.D^'],O"P43_ &A53:N!R..37@G[6=_HG@'4_"VLZ;;6,7B&WN-\D,<:
MY>''1EQT)]:FEC(U9J"IK4JM@)TJ?M'4=EZ_YGS"_P 6_'<;!7\1ZJK'HK2L
M":)/BUX\AP9/$>JQ@]-TK"ONC2_!'A'XU67A/QF+"*$VR^<(DA"JY(^ZPQS@
MU\O?M)^+9OB5\09/#_AO2B]II99!':6X#.P^\Q &<5M2Q$*L^3DM;?R,*^%G
M1I^T]HW?;?4\T_X7'XW_ .AHU+_O^:D;XN>.TC#MXDU14/1C*V#72?"3X0V.
ML^)Y8/&\\WANPM8A<-]I'E&49Z#=_2OH3]JC0]!TSX$Z<VAVMO'9B:(0R1Q@
M$KCCG&:UJ5J4*D::C>YC2P]>=*564VK=+ZGRJGQ@\<NP5/$VILQZ!9B32M\7
M?'22;&\2ZHK_ -TS$&OH[]E;X6^"H(='US4-0AU'Q#?Q,\.GR%2(P.IV_P"-
M<S\5_#UM?_M8:9IZ00P6[S0[HP@"8')XZ5*KTG5=-0V3=_0OZK55%57/=I6O
MW/'/^%J>/_\ H/ZQ_P!]M4#?%_QPK$-XGU,$=09C7Z*Z[836[M%HNB:%>&.+
M(BG*K(Q], <"OSB^*+7C>/M::^L$TRZ:X8O:I]U#GH/:EA:\,0VN1+[AXO#S
MPL4_:-W]2ZOQ8\?2)O3Q#JS+_>$C$4D?Q:\>3$^7XCU5\==LK&OMK]F?1M+N
MO@EH9NK*VD::-E+R0J6;)(ZXI_P*^%-IX-3Q";ZQ@9[K4I/)\V)6_=Y^7&1T
MKGGC:<.=."O'\3IIY?6FH-3=I*_H?#[_ !@\<Q,5;Q-J:L.H:8@TW_A<?C?_
M *&C4O\ O^:]M\>_ S4/BQ\?_$-AI7DZ=8VQ5IIRN%3(&  .]5?&G[&.H:'X
M<O-3T?7H-8>T4M+ $VM@=<?2NN.(PWN\UDW;IW..6%Q5Y<MVDWU['CG_  N/
MQO\ ]#1J7_?\T?\ "X_&_P#T-&I?]_S7JGP\_9+D\6^&K?5]4\36>DK<?<@!
M#L/0'GK[5#XB_9-U#PYX^T30I=6CFLM4W>7>QH05(Z@KZU?ML+S..EUY&?U?
M%\JGK9^?<\Q_X7'XW_Z&C4O^_P":/^%Q^-_^AHU+_O\ FO?C^PC=&:ZC'BB#
M>BYB0Q_.W'!8=J^9/%'AZX\*:_?:3=,&GM)3$Q3H<'%52J4*S:A9V\C.M3Q-
M!)SNK^9T:_%?Q](H9?$&K,IZ$2,13&^+GCN)MK>)-45_[IE8&OMOX0VR6'P!
MT>_L] M]8U!+8,D'EKND.?4BLOX_^%M(O/!/A_6;K1;;2]76]M_W2HH8$L,H
M2!S7 L7#VG(Z:WMT/3>!J>R]HJCV3/CF3XN>.X0/,\2:I'GINE85'_PN/QO_
M -#1J7_?\U]._M2_#\>+-=\$:-IL=K837:-NE8+&H'&2<=:YO_AATW-O*EGX
MOM;G4(TW&%8\C...1TS71'$T'%2FDK^1SSP>)4W&FVTO/_@G@W_"X_&__0T:
ME_W_ #1_PN/QO_T-&I?]_P UZ/\ #?\ 93U/QI#JMSJ.J1Z3:Z?.UN[!#(Q9
M>N .U,\;?LQ'PEXBT"QB\16M];:K<+ &48EC)[E/2M?;X;F<=+^AS_5\7R\V
MMGYGG?\ PN/QO_T-&I?]_P T?\+C\;_]#1J7_?\ -?0;?L&S"Y:+_A*X1E,H
M#%\Q/T]*S#^PSJL6CWLS^(;4W\"LRV\:94@<C/H36:Q6%?5?<:/"8U=']_\
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M2_[_ )KCJ*?LX?RH/;5/YG]YV/\ PN/QO_T-&I?]_P T?\+C\;_]#1J7_?\
M-<=11[.'\J#VU3^9_>=C_P +C\;_ /0T:E_W_-'_  N/QO\ ]#1J7_?\UQU%
M'LX?RH/;5/YG]YV/_"X_&_\ T-&I?]_S1_PN/QO_ -#1J7_?\UQU%'LX?RH/
M;5/YG]YV2_&3QN"#_P )1J0/;]\:]E^ W[6.O:5XAM-(\5WK:GI5TXB^TSG]
MY"3P#GN.U?-%/@8QSQLO#!@01]:QJX:G4@XN)O1Q52E-24F?K[#(LL*.A!1@
M"".XHK"\ 3-=^"-"EDY=K*(D_P# 117Q,ERMH_0X/FBGW/A']LG_ )*_<?\
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M[PM=K\/ULO$5NZV=Q&UT(I#\B@#.ZJ_C7XH^$-0^.>DZM;^,AIUO%8^6+RU
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MZ_UI*6/_ %J?7^M)[,M;H_5SX<?\B%X?_P"O*+_T$44?#C_D0O#_ /UY1?\
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MPE.%+WI33;7D<F,K3K^[&#23\]3[2;XIP_#K]G[2M4L7LKV]@M8P+:24<GZ
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M-O@5X6O[VZCU*>*6":>(2JTCXZYP:^8-7^%OCO4=1N[B+PIJ=K#-(SB!8SA
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M $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3
M]*,#TI:* $P/2FR*&1E/<&GTAH Q[8[$91V8BBFV_23_ 'S10!9T+_CQ/^\:
MTJS="_X\3_O&M*@ HHHH **** "BBB@ KAO&F@RW7BOPSJ-K:>;/#-())><*
M-GRY]!FNYHH \I\$>'=?TWXEZI?ZG:*5NK1?,NTD+*6#'"CZ#M7H^I//;PF:
M*4*J8RI7.>0.M7ZI:Q_R#IO^ _\ H0HZ6#K<N*<@4M(OW1]*6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-:FZ-25-] G%PDXL6BBBLB HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ^#N;?4/%MH?^66IN0/3=S7IV>:Z<9)SKRD^IK6UFV+1117&8!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:0T 8E
MMTD_WS11;=)/]\T4 6M"_P"/$_[QK2K-T+_CQ/\ O&M*@ HHHH *XOXBVOC:
MXAM?^$/U+3-.=2QN&U*$R CMC'2NTK$\9"+_ (1+6?-E>"+[)+ODC^\HV')'
MO0!\\>*->\=ZYI.H:+J/Q(\$)%<QM;S*(\, >".O6O?OA[I8T3P1HEB+F*\%
MO:I&)X?N/@8R/:OEOX86D<W@VP/_  I=M=&#MU,E ;E<G$AR<Y(KZT\-H$T"
MP46']E@1+_H?_/'C[OX4 :E%%% !5+6/^0=-_P !_P#0A5VJ6L?\@Z;_ (#_
M .A"@#SWX=JUK\2/'5N>CSQ3*/9EKTXBO,M!W6GQOU]/X;BQADQ[C(KTP$UU
M8KXT^Z7Y&U;XD_)#J***Y3$**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !534K^'2K*:[GW^5$"S;%+'
M'T%6Z:RA@0PR#U!&0: /.Y_CKX92%F1KMGQD VS $_6J&G_M Z'=3;9X;F!
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M%N,8KV;1M1.KZ5:WIMY+0SQK)Y,XPZ9'0^] %^F2+YB,N2N1C(ZBGT4 >?\
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M&.4TJT*$I2O*^O+*VGR_(]6&58J<'-15EYK_ #/6,<YJ)[J&.01M,BR'HI8
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MS1!-&XR"1CK7N$,*6\:Q1HL<:C"JHP /05X%IO[./B[2?$&HZW:_$N]BU+4
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M<QM<0JQ0^V15E-+LXYO-6VB638(]P0 [?[OTIEEK-E?V%M>Q7,;6]R@>*0L
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M 4444 %(:6D- &);=)/]\T46W23_ 'S10!:T+_CQ/^\:TJS="_X\3_O&M*@
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MOT-1+#-KFI/F7EO]PG3=KPU1Z-15:._MIC'LGC;S1F/:P.X>HJS7*9!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %,D<(,DX]Z?5'5M+@UFPGL[C=Y,R[6V,5./8CI0K=1JU]1\^HVU
MK"\LLR(B#+$MP!5:V\1:;>3)%#>0R.Z>8JJP.5]:X"Z_9X\+R6TD<3:@CLN
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M@\2>"O"B:K<Z1IFJW+F\DM)/+D=47(7=VKV^N+^(7PG\/_$TV7]MPS.UFS-
M\$S1LI/7D4 >=? BZD\*>.O&G@M]8N-2TS3'BFM)+Z;?(H<<KN)YYKW=6#J"
M#D'N*\:C_9-\ Q3R3)!J"32??D6^D#-CU.>:]9TG2X=&TVVL+;?Y%O&(TWL6
M. ,#)/6@"]1136SM..N.,T !( K@?BOK.H:7I42609$D8B251G;Z?2G^&=1U
M>Z\3R1'4$U*SC5Q=-&N(XI-WRHA[\=:Z;Q T;V+Q20M*K@ G;E>HZUX^;8*M
MF&"J8:C5=.4EI);HZ<+5A0K1J3CS)=#C_A/XFN];MKBWO&:9H""LK=P>QKT,
M#(KB-*FLO"GB>\L6:.WM[H++%V&>A%=PI# $=*\GACVU' +"8FK[2I3;4GUW
MTOUV.K,>65=U*<>6,K-%>]TZVU)%6Y@295.5#C.#ZBLF_P# V@ZE:M;W&E6L
MD3G)S$,Y]<]<UT%!K[",YQ^%V/(E",OB5SP^7X1:YI6NO>^'[RYT\I(5A\R<
M21K$>V#S^%;6LZC\0_".GM-/<:5K$?W5;887R>![5ZK@8Q4<D*RIM=%=?0C(
MKN>-E.WM(IV\M?OW.-811OR2:^?Z'E_@/XOPSA=*\3-_9VL(=N^0?NI/3#=*
M[3Q;X8L_&FBO:3$<_/#.AYC<<JP-6=4\,:5K5F]I>:?;S0/U4QC\P1T-<4W@
MOQ'X'8S^%K\W]@.3I-\V0!Z1OV_&LZL*&*NE[K?1[?)] _>TH\LUS1[K?YKJ
M7? 'BN[6[E\-Z\=FLV8^61N!<1]G7UKO@1S7A_C3QCIWB'3&N9(+C0/%^ECS
M8(9EP[D=54]&4U)\,/VAH->M6C\2H-+N%;:MP5(B?V)[&O$E4>#J+#U].S?5
M>HZ>)A?D<K]G_F>W"EJGI^J6FIPB6TN8KF(]&B<,/TJWFNU-/5'<+1115#"B
MBDS0!PGQ ^"_A+XDQYU?2T6]7F._M3Y-Q&?577G\Z\\'AOXJ_!T[M"U!?B!X
M=C_YAVH$)>Q*.R2=&_&O?1T/-&./6M8UI15GJNS,W!-W6C/*_ _[17A?Q;>C
M2[YI_#.OCY7TS5T\F3=Z*3PWX5ZFKJX!4@J>XKE?''PO\,_$6R-MK^D6]]C[
MDK+B2,^JL.0:\N/PS^(WPF)E\"^(#XET9#G^P==?<ZK_ '8IO\:OEIU/A=GV
M?^9/-./Q*_H>^X%8GB7PKIOBG3Y+;4+"&\0@X65>A]CU%>;>%OVE-$O-131O
M%EG<^"M>)V_9=47;'(W^Q)]TC\:]?@GCN8EDBD62-AE74Y!%9VJ49)[,UA-;
MQ9XK8?"'Q7X+NX[WPUK,4B@$'3]0S)&BY^ZC=16_;_%Z[T"1;;QAH5SH[YQ]
ML@4RV[>^1T'UKTX'@U'/;Q7431S1I*C#!1P"#^!KJEBO:_QHI^:T9T.KS_&K
M_F4M&\1:9X@MEN-.OH;R)AD-$X-:0KSS6/@MHUS<M>Z/+<>'=1Z_:-/?:"?]
MI>AK..H?$+P1Q>6L/BW3E_Y;6W[NY ]UZ&I]A3G_  I?)Z/_ "#DC+X']YZI
M]#2_6N&\.?%[P]K\XM7N#IFH=#:7P\J0'\>M=NC!AN5@RGTKFG3G3=I*S,I1
ME%V:'T445!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4AI:0T 8EMTD_WS11;=)/]\T4 6M"_P"/$_[QK2K-T+_CQ/\ O&M*@ HH
MHH **** "BBB@ ICH)$93T(P:?10!S_A_P $Z5X8=FTZ)X%8L2GF$J23DG![
MYK3UC_D'3?\  ?\ T(5=KB_BAXAN?#7AYKJV596'6(CD@$'/X4 <O\5_"EP9
MAK4,AD10JM'@DK[CVJ]\//B0E\(M-U [;GI&X& 1Z'WK9^'?BV3QUH9N9X8Q
M%]P\@Y/<8]*3_A56C_VE)=XD!8DA%; !/<5^6XSA[,<!F_\ :>335JC_ 'D)
M-V?FM_R/HZ6.H5L)]6Q:=X_"T=F,'!!_&C/H:\[\6^%-7L-*;^Q[^[F4GF M
MD@>QZT[PDWBW3M)07%JEP,D@328<#T->\N(*U/&_4Z^$G'2_,ES1]-#B^HPE
M1]K"K%ZVL]'^)Z#C)YI>@^E>47/Q.U>T\2"UGLA%"K8>)5+-CN<]Z[RV\8:1
M<V[2B]B4*,L&."OU!KJR_B7+LQE4C"?*X.S4O=>G57,J^7XB@HMQNI=M?R-S
M)[4=JS]+UBSUF$S6=PDZ XW(<U? KZ.E5IUH*I3DI1>S6IP2C*#<9*S1S/CG
MPC:^*]#N();*&YN-I\IGX*GU#=J\UT;X6>*/"T4UOI7V*YTMOG.GZF%EWL>N
M& XKW#]*,?6N^%=QCR-)KS5SBJ86%27.]'Y'S[<V>EZ1=9U32=5\$WI.!>:<
M[26Q/KQQCZUE:7J?CF3XCQC1_$%MXAMDAW(9)0J2)Z,!T:OI.:WCN(S'*BR1
MD8*L,@_A7E.H_ N&[U22\MIXM,G>;S/M-GNCD"^F.E<\L'@\1JVZ;6ONO1_(
MXZE"K!KV>JOZ/_+\#6_X63KND\:UX0O80.LUDPG3ZC'-7;#XR^%[U@DEZUC*
M?^6=[$T1_45G?\(QXY\._P#(+U^#68%Z6^I1X8CTWBJ>H>,981Y7B[P5,J=#
M=01"XB_QI?4ZZ_@U%+UW_0V56<?CNO5?JCTBSUBQU- UK>07"GH8I W\C5L>
MQKR*P\/_  U\52;M*N8]/NCU6UF:WD!_W3WK97X>>(=+&[1O&-WL'W8K]!,O
MTSUKGD\12=JE/[G^C-XU7)72NO)GHPXH/->=?VG\1-%'^D:;IVMQ#^.UD,3G
M_@)I4^+ZV)VZUX>U72#_ 'FA\Q/S6H^LP^U=>J?Y[%^UCUT]3T049KE-)^)_
MA?6&"6VKVWF=/+D?8P_ UT\-Q%<(&C=9%/\ $I!%;QJ0FKQ=S12B]F8_BOP5
MH?C?3GL=<TNVU*W<8VSQAB/<'J#]*\:U+X->*_A1#<:C\-O$LOV&)3(WA_6"
M9X& YPC'YEKZ!XI" 1@UTPJRAINNW04H*6O4^4_#'[5OB+2=5MX?&/AO4?+E
M5FE&FVHN$CQW4H2Q'UYKU+2OVI_AOJ;!)-=.F2_\\]2MY+=A]0PKTNST'3]/
MN);BUL;>WGD^_)'& S?7%0:KX2T37$9=0TFRO0W43VZ/G\Q6TJE*;^"WHR5&
M<5O<@TCQYX;UY%?3M=TZ]#=/*ND8_D#6ZKJZY4@CU%>5ZM^S#\-=7D>4^%[6
MQN&Y,UB6@?/U4UB/^R_!IK%_#?CCQ3X>?J%CO3-&/;:_:IY:+VDUZK_(=YK=
M'J7B/P3HGBN!H]4TZ"Y]'*8<?1AS7%-\-/$/A$^9X2\0R^0O(T[4_P![']%;
MJ*Y\_#KXR:!DZ1\1;'5T!XCUFPRQ'IN6E'B[XW^'P1J'@O1/$$:GE],OC&[#
MV5A6\'.&D9IKL]OQ-(UY15FG;[SHHOB[>^'Y%M_&&@W.E-G'VVV4S6[>^1R!
M]:[S1?$FE^(K59]-OH+R(\@Q.#7CTO[1=W8QM#XI^&7B?28S\KR"V%S$?Q7/
M%<O/\0?@UK5[]HL_$,W@?66/#-&]J2W^TI&TUHZ4*F\7%^6J_P T:>THSW?*
MSZ='Y4'BO#=&^)FN:2JFVU;2/'6G#H]E<HEUC_=SS7<>'?C'X<U^86LER=+U
M#H;2^'EOGVSUK">$J17,ES+NOZN-TW:\=5Y'=BEID<BR(&5@0>XI]<9F%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M _"M.:NMXI_/_@%7J=E]_P#P#T#-'4\UYV/AEK-IG[#XSU2(=DG*R ?G2?\
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MF3<>&[!F/<1 ']*5\++HU]S_ ,@_=>9TUOKVG7:@P7]K,#TV2J?ZU>5PZY#
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&XT4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>plx-20241231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20241231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '/ K4# 2(  A$! Q$!_\0
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M?^9CO_\ OZ:3_A;GC'_H8K__ +^FN1HKN]E3_E7W'G>VJ?S/[SKO^%M>,?\
MH8K_ /[^FC_A;7C'_H8K_P#[^FN1HH]E3_E7W![:I_,_O.N_X6UXQ_Z&*_\
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M!N+.1O#4%B+I(_,(/S< ;OK7-_M8?!CPW\-;?P__ ,(S8R02WLCHX,A<M@<
M5S1Q&'G.,%'5Z[(Z9X7%4Z<IREI%VW9XS_PMKQC_ -#%?_\ ?TT?\+:\8_\
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MMKQC_P!#%?\ _?TU]F:_^SQ\'/#%WIEIJ=H]K/J,GE6RO<-\[^E<!XN_9?\
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MN^(XN4@_X1>\+NN\8 QCZYJM8_ #X@ZE<7D,'A>^:2U;;*"@&#Z#/6IYL/\
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M1AO7!]A6EZ%[:7^1C;%6YO>M\S/_ .%M>,?^ABO_ /OZ:/\ A;7C'_H8K_\
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M'9?J?:O8M-_M=OV;=*'PW,?]I>3'M\O&[.?GS[U\3>+OBQXM\=0+!KFN75_
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M %%%% 'WG^QPVWX-P_\ 7Y-_,45'^QW_ ,D=A_Z_)OYBBOB,5_&EZGZ)@_\
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MBSX7T[3K%K73K>X58HW.6(R"S-Z<"M7]MKQE9ZAXCT;PW9NL@TJ',S*<[7/
M7\JTHPG"=*+5FD[^AA7J0G3KRB[Q;5O4^9:***]X^;"BBB@ HHHH **** "B
MBB@ HHHH ^[OV//^2/0_]?DW\Q14_P"Q_;2VWP?M_-5X_,N977(ZJ3P:*^(Q
M7\:7J?HF#_W>'H=9\3_V>/#OQBL+2YO&DL-3B3:MY !N*^C#O7EW_# >E_\
M0UWG_@.E?4VD_P#(/A^E7,BIABZ]./+&6@5,%AZTN><-3Y-_X8#TO_H:[S_P
M'2C_ (8#TO\ Z&N\_P# =*^L<T9-:_7\1_,9?V=A?Y#Y._X8#TO_ *&N\_\
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M_P" Z4?\,!Z7_P!#7>?^ Z5]8Y-&31]?Q'\P?V=A?Y3Y._X8#TO_ *&N\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !24M% "48I:* ,2^_Y"$O^ZO\ 6BB^_P"0A+_NK_6B
M@"_I'_(/A^E7*IZ1_P @^'Z5<H **** "BBB@ HHHH **BFF2WC:21UCC499
MF. *YUOB'HITR"_BN'N8;B5H8A!&6:1E^]@>U '3T5C/XJTQ/#XUDW ^P%=P
MD Y/.,8]<\8J30_$5GXAADDM2X:)MDD4J%71O0CM0!JT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8E]_R$)?]U?ZT47W_(0E_P!U?ZT4 7](_P"0?#]*N53TC_D'P_2KE !1110
M4444 %%%% $4T,=S$T<J*\;<%6&0:\CTKPIJOA^#0+UM/FG_ +/OKQY+6#!;
M9)D*P%>PT4 >3R>$]47X;P:3]FF:_CG%^8UZ8\W=Y>?[V.U=/X&T^\&J^(-6
MN;:6SCU&='A@G&'"JN,D=LUV-%.X&;?^;!<6TB3.%>94:/\ AP<UI50U;_ER
M_P"OE/ZU?I %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 8E]_R$)?]U?ZT47W_ "$)?]U?ZT4 7](_Y!\/
MTJY5/2/^0?#]*N4 %%%% !1110 4444 %5-0U*UTN$2W=Q';QDX#2-@$^E6Z
MX+XF0B&XT+420WV69QLEB:2([EQ\P7]* .T:^MUM#=&:,6VW?YNX;<>N:9IV
MJ6FK0^=9W$=S%G&Z-LC->2MIVIV_P>&FSEWU$2"Z>%4)/D>=DC'^[VKJ?AXR
M77B#Q-?6<9CTF>6'[/\ NS&I(3#$ @=Z=MP.NU;_ )<O^OE/ZU?K)U43_:+,
M[D\C[0GRX.[O6M2 **** "BBB@ HHHH **** "BBB@ HHHH **** &@@]*&K
M,UKQ%IOAVV,^I7D-I$!G,K@$_0=ZX2;XI:IXE=K?P?HDU\,X_M"\!B@'N,\F
MMX4)U-4M.[T7WG/.M"#LWKVZG?ZMK=CHD44E[.L"22"-2W=CTJ\K9Y!!'M7C
M.J?!_P 1>+;I+CQ'KJ7H"Y6UA+11Q,>XQUK4TSX,W^FV,*P>+M6M;E1\VV7S
M(S^#5T2H4%%?O=?1V_KY&$:U=R?[O3U5SU2DQ[5YM_PBGQ T[/V+Q9;7@'1;
MZUS^HI1JWQ+TW_7Z/I>IH/XK><HQ_ U'U=/X)Q?SM^=B_K%OB@U\K_D>D\TF
M37FQ^*&NV&!J7@K48QW>V99%%30?''P_G%Y%J&G-T/VFT=0/QQ4_5*W17]-?
MR*6)I=7;UT_,]$! I.I[5REA\4O"NI-M@URU+_W7?:?UK?MM7LKP!H+R"8'I
MLD!_K6,J4X_%%HUC4A+:29>HI,CUI-PW;<C=UQGFLS4=1110 4444 %%%% !
M1110 44Q75^5(8=.#3Z "BDS1F@!:*3-&: %HI,T9H 6BDR/449'J*!7%HI,
MCU%(751R0* NAU%1M,B]74?4TTW,2\F5 /\ >%.S"Z)<BC(J'[9!_P ]X_\
MOH4S^TK3_GZA_P"_@_QHY9=A<R[EJBJ?]KV/_/Y;_P#?Q?\ &L^?QAI5OJMI
MIQO(FNKG/EHC!NGKCI34)/H2YQ74W****DT"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,2^_Y"$O^ZO\ 6BB^_P"0A+_NK_6B@"_I'_(/
MA^E7*IZ1_P @^'Z5<H **** "BBDW#UH 6BBB@ HHI"0.IQ0 M%%-!##(.:
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M2CX27K1[9/&>N/ZGS%']*]'HJ?K57O\ @O\ (?U:GV_%GFZ?!Z4 A_%FMO\
M]MP*$^"T2MEO$NML/3[617H^?\YHS1]:K?S?@A?5J78\V_X4?I[2;VUW7&.<
MG-\W-.;X'Z2QR=4U<G_K]>O1\^]%/ZU6_F#ZK1_E/.V^"&B/C=>:FV/6\?\
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MF'PTG\2W?PL\10:G%<B :"IC:X=3_P M!SC:*J^(OVEKCPM\-M+\6ZA\.O%
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MY_*IPO%.!QU!8B@I-/M%]/.UOQ(J997IU/9SM?U7Y;_@//A[QM(.?$EJG/\
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M17?T47ZDG$_$'PM?^(M5\*3V2HT>G:B+F?<VW"!2./4UV]%%!04444 %%%%
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MOTWQ:/ >K227=[):'3PI\V,(,[SQT-9_@S]M>]\67M] WP]UBQ%M9RW8>92
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M  UMH[H7^MW,FMZCUW7!_=H?]E>E=G'&L2A44*HX"J, 4^BM!A1110 4444
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M$3Q2+!-$DB0\;R7P%7ZY-3>&_$_]NS7UM-9O8WUDZK-;NX?&X9!!'7BN=N/
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M%4='MA9:590 8$4*)^2@5=Z5Q5)<TY2[L[:<>6$5V05R'Q5UAM%\#ZC)$?\
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M+Q5=YPL>DVC2*3_OXP*Q/ '[*FCZ;JJZKXJBA\1:A''L$MT[S&1R<F0[N![
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MH;F*W^1]/LX1][V!ZU/VM/ZU0_LZ_P!:'T_\&;J.\\%0R1^%)/!B^:X_LN0
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M7 ]*6BI)(XXDBR$14!Y.T8J2BB@ I*6B@ HHHH **** "BBB@ HHHH ****
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M5JB^)]Y-\3?&EE\/M.D86$)6ZUN>,\+&#E8L^K5Z9JFM:/X&T2-KJ:*QLK=
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M0"I<5$ZS:Y(*T>W^?<<**B^:3O+O_D%&*6BL#H"BBB@ HHHH **** "BBB@
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MZ1\O\RE\-OA'X?\ AE9NNFPM<7\WS7.I7)WW$[=RS'^5=R!BJ']JG_GSN_\
MOU_]>C^U3C_CSN_^_7_UZXI2E-WD[LZXQC!<L59&A16?_:Q_Y\[O_OU_]>C^
MUC_SYW?_ 'Z_^O4EFA16?_:Q_P"?.[_[]?\ UZ8^MI&Z(UK=!GX4>5U_6@#3
MHK/_ +6/_/G=_P#?K_Z]']K'_GSN_P#OU_\ 7H T**S_ .UC_P ^=W_WZ_\
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M_?K_ .O0!H45F1:VDV_9:W3;6*G]UT([=:?_ &L?^?.[_P"_7_UZ -"BL_\
MM8_\^=W_ -^O_KT?VL?^?.[_ ._7_P!>@#0HK/\ [6/_ #YW?_?K_P"O1_:Q
M_P"?.[_[]?\ UZ -"BLPZXBRK&;6ZWL,@>5_]>G_ -K'_GSN_P#OU_\ 7H T
M**S_ .UC_P ^=W_WZ_\ KT?VL?\ GSN_^_7_ ->@#0HK/_M8_P#/G=_]^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_(/A^E7*IZ1_P @^'Z5<H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)N [
MB@!:*3</44;AZB@!:*3</44%@.XH 6D(K%\6^)(/"/AN_P!8N1NBM8RY4'&X
M] /Q.*Y3X5?$K4?'LNH1W^GV=O\ 9]K)-I]V+B/G^!B.CCN*%J&QZ-17D=U\
M9-6@\022QZ'"_A*'41I<VHFXQ,),X+!/[H.!6\_QR\"*TZ_\)+9Y@5F<9;@
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M* -.BLS^VO\ IW;_ +Z%']M?].[?]]"@#3HK,_MK_IW;_OH4?VU_T[M_WT*
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0VB+*6/4\FBKL4.%HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>plx-20241231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20241231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #A K4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZP^,?B#6]
M*^*&K066MZA9P>3;N(89L*"4.<#%<?\ \)EXF_Z&75?^_P#_ /6KI/CG_P E
M8U;_ *]K;_T UPU?4X>G!THMI;'QV)J3C6FE)[FK_P )EXF_Z&75?^__ /\
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MO;0BY2D_O/M+X+W%U??#'1;BZNKB[N)!(SS2N79CN/4T4WX'?\DHT'_=D_\
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M_P#9^DVB//$NEN'MY$?# ^Y[T*-7J^W_  0YZ2V11^)%PVGZ:MXVL3:;#&&
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MSH.FW4=Q#:$O&695=RRAFZG'K5C2? ^CZ+??:[6UV3#(3<Q(C!ZA0>E>V?\
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MKVZ'K%>7>/O#NJW7BV2]MXKNYAELEAMU@4-&LH<$^9G^$BH/^$?M/^FW_?\
M?_&C_A'[3_IM_P!_W_QJ?8ZWN/ZQY'J=JKK:PB0 2!%#!>F<<U+7D_\ PC]I
M_P!-O^_[_P"-'_"/VG_3;_O^_P#C3]EYA[?R/0O%G_(MZC_UQ:K>D_\ (*LO
M^N*?^@BO(?$6@VBZ'?$>=GRC_P MW_QJSIOA^T.G6I_??ZI?^6[^@]Z?L=-Q
M>WUV/8*XSXJ:'K'B/PU-8Z683'(C^?$Y(:4;3A5(]37-?\(_:?\ 3;_O^_\
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M4,71,NTD^G'I78^-/$.I0:O:V-C<&R7[!-?/)Y8;<4&0G-'MNM@^KO:Y@_\
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M%'EA?*;?C;QU&*/:^0OJ_F9/_"2Z?_SV?_OR_P#\31_PDNG_ //9_P#OR_\
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MIZ/JVL/OTW4=2\JXL]/6ZN[I8@#O;G '3 %+VOD5]7?<R/\ A)=/_P">S_\
M?E__ (FC_A)=/_Y[/_WY?_XFE;5?$:>!X]3?69/MU]<^78Q^2O*NV$W?AS7<
MZW-JFC^#[B6&:.XU&WMF9II%PI95)+8'N.E#K6Z!]7UM<X7_ (273_\ GL__
M 'Y?_P")J-O%FEQR)&URRR29VJ87R<=<?+73:+XMO'N/"JW3+*NL618[5QME
M5 Q/T(-:VM?\C;X=_P"WC_T"J]KY$NCYG#_\)+I__/9_^_+_ /Q-'_"2Z?\
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M[.'8?M9]S.62U6V:$>$I &<.7^WKOR!@?-UZ<58;4XVL19_\(HZVR@!8UOD
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M[TO_ *&:*\^?Q,]"'PHYW6/"MSK/Q!\12IJTEHH6V 185;_EF?6G?\*]O/\
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M:1T5;A6%N#CY<DY;.#S[T>TG8/9T[E#3X[;4(]XU^^@_?)"RSV2*59QE2>>
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M:M_X#?\ UZ.;S#E?8;_8>G_\^,'_ 'P*/[#T_P#Y\8/^^!3OM5]_T M6_P#
M;_Z]'VJ^_P"@%JW_ (#?_7HYO,.5]AO]AZ?_ ,^,'_? H_L/3_\ GQ@_[X%.
M^U7W_0"U;_P&_P#KT?:K[_H!:M_X#?\ UZ.;S#E?8;_8>G_\^,'_ 'P*/[#T
M_P#Y\8/^^!3OM5]_T M6_P# ;_Z]'VJ^_P"@%JW_ (#?_7HYO,.5]AO]AZ?_
M ,^,'_? H_L/3_\ GQ@_[X%.^U7W_0"U;_P&_P#KT?:K[_H!:M_X#?\ UZ.;
MS#E?8BC\.Z9#OV6%NNYBS80<D]33_P"P]/\ ^?&#_O@57L=:N;_[1Y6AZJ?)
MF:%O]'_B'7O[U:^U7W_0"U;_ ,!O_KT7\PY7V&_V'I__ #XP?]\"C^P]/_Y\
M8/\ O@4[[5??] +5O_ ;_P"O1]JOO^@%JW_@-_\ 7HYO,.5]AO\ 8>G_ //C
M!_WP*/[#T_\ Y\8/^^!3OM5]_P! +5O_  &_^O1]JOO^@%JW_@-_]>CF\PY7
MV(I?#NF3*!)86[ '<,H.HI_]AZ?_ ,^,'_? JO?ZU<Z='&\NAZJ%>18Q_H_<
M].]6OM5]_P! +5O_  &_^O1?S#E?8;_8>G_\^,'_ 'P*/[#T_P#Y\8/^^!3O
MM5]_T M6_P# ;_Z]'VJ^_P"@%JW_ (#?_7HYO,.5]AO]AZ?_ ,^,'_? H_L/
M3_\ GQ@_[X%.^U7W_0"U;_P&_P#KT?:K[_H!:M_X#?\ UZ.;S#E?8;_8>G_\
M^,'_ 'P*8/#NF"8RBPM_,(VEM@Z5+]JOO^@%JW_@-_\ 7JJNM7+ZA)9C0]5\
MY(Q(1]G[$X]:+^8<K[%C^P]/_P"?&#_O@4?V'I__ #XP?]\"G?:K[_H!:M_X
M#?\ UZ/M5]_T M6_\!O_ *]+F\PY7V&_V'I__/C!_P!\"C^P]/\ ^?&#_O@4
M[[5??] +5O\ P&_^O1]JOO\ H!:M_P" W_UZ?-YAROL-_L/3_P#GQ@_[X%-D
MT#39$9&L8"K#!&P<BI/M5]_T M6_\!O_ *]176I7=I;2SOH6K!(T+M_H_8#)
M[T<WF'*^PL>@:;&BHMC %48 V#@4[^P]/_Y\8/\ O@4RUU*[N[:*=-"U8I(@
M=?\ 1^Q&1WJ7[5??] +5O_ ;_P"O1S>8<K[#?[#T_P#Y\8/^^!1_8>G_ //C
M!_WP*=]JOO\ H!:M_P" W_UZ/M5]_P! +5O_  &_^O1S>8<K[#?[#T__ )\8
M/^^!1_8>G_\ /C!_WP*=]JOO^@%JW_@-_P#7H^U7W_0"U;_P&_\ KT<WF'*^
MQ$WAW3'D20V%N73.UM@XSUI_]AZ?_P ^,'_? JO-K5S!?6UJVAZKYLX8H/L_
M]T9/>K7VJ^_Z 6K?^ W_ ->B_F'*^PW^P]/_ .?&#_O@4?V'I_\ SXP?]\"G
M?:K[_H!:M_X#?_7H^U7W_0"U;_P&_P#KT<WF%GV&_P!AZ?\ \^,'_? H_L/3
M_P#GQ@_[X%.^U7W_ $ M6_\  ;_Z]'VJ^_Z 6K?^ W_UZ.;S#E?8;_8>G_\
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M*=]JOO\ H!:M_P" W_UZ/M5]_P! +5O_  &_^O3YO,.5]AO]AZ?_ ,^,'_?
MIC>'=,>1)&L+<NF=K;!QGK4OVJ^_Z 6K?^ W_P!>JL^M7-O>VMJ^AZJ)+C=L
M'V?^Z,GO1?S%R^18_L/3_P#GQ@_[X%']AZ?_ ,^,'_? IWVJ^_Z 6K?^ W_U
MZ/M5]_T M6_\!O\ Z]'-YCY7V&_V'I__ #XP?]\"C^P]/_Y\8/\ O@4[[5??
M] +5O_ ;_P"O1]JOO^@%JW_@-_\ 7HYO,.5]AO\ 8>G_ //C!_WP*/[#T_\
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MM+7//,V=,\XG)D^S?-^=-T9,/K$.QB_ 'XG:_P".VUJVUZ6&>>UVLDEO!L0
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M_P"_)J#4-6\2WUA<VQN[)1-$T>?)/&01_6FJ,KB=:-CN_#O_ " -,_Z]8O\
MT 5HUYGI^K>);&PMK87=DPAB6//DGG  _I4__"0>)O\ GZLO^_)H]C(%6C8[
MZ^:5+&X:$9F$;%!_M8./UKR[X:7,K:[IPBFDE:>PDDU$-(S;9O,(&0>A_I6G
M_P )!XF_Y^K+_OR:BAU77K9G:%]-B:0Y=DM\%CZG'6DJ,KC]O&UCTJBO.O\
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M\)!XF_Y^K+_OR:H:'>>)=&TV.T%Y8N%9CGR3W8G^M/V4K6%[:-[GJE%>=?\
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M_<21R2OILDD?*,]ODK]#VJ?8RN5[>)Z+;,[6\1DXD* M]<<U+7G7_"0>)O\
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MJ/\ A6?AG_H%)_W\?_XJCVT0]A(P**W_ /A6?AG_ *!2?]_'_P#BJQ+?X?\
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MD_[^/_\ %4?\*S\,_P#0*3_OX_\ \51[:(>PD8%%;_\ PK/PS_T"D_[^/_\
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M*?LX[6%[6=[W-/\ X60/^@+?_D/\:/\ A9 _Z M_^0_QK,HI>RAV'[:9I_\
M"R!_T!;_ /(?XT?\+('_ $!;_P#(?XUF44>RAV#VTS3_ .%D#_H"W_Y#_&LG
MQ)XVEU6RABAT6]W+/'(=P X!R:?13]G%=!.K-]33_P"%D#_H"W_Y#_&C_A9
M_P"@+?\ Y#_&LRBE[*'8?MIFG_PL@?\ 0%O_ ,A_C1_PL@?] 6__ "'^-9E%
M'LH=@]M,T_\ A9 _Z M_^0_QH_X60/\ H"W_ .0_QK,HH]E#L'MIC-/\:RVN
MO:O>/HM[Y5T(=F ,_*I!S6M_PL@?] 6__(?XUF44_9Q["]K-=33_ .%D#_H"
MW_Y#_&C_ (60/^@+?_D/\:S**7LH=A^VF:?_  L@?] 6_P#R'^-'_"R!_P!
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M]LT4=P=JL]P)  ?3;WJ/XA?#?4/ >G275MI;:AHW]K6]Q_94#.Z.HCVL7 Y
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M#K+_ *_8?YUT-/VDK+4GV4+['#?\*\U+_H9'_P# */\ QH_X5YJ7_0R/_P"
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M3_PKS4O^AD?_ , H_P#&JNK>!]4LM+O+A/$;EX87D ^Q1]0I/K7H=9WB+_D
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MC?\ /V__ 'XD_P#B:.5]@YEW.6\=^./$NE^--,\/>'-/TVZFNK22[>34)'0
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M'#0?]RX_]!%=#7"ZIXPTF3Q7HDJW+F-$GW-Y$G&5&/X:W?\ A-M&_P"?M_\
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M $,T57^'5_!<>#[216.TRS8W*RG[Y[$45G*]S6.QU\'_ !_7?_ ?Y59]***
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MBB@ HHHH AO/^/67_=-/A_U,?^Z***?074?1112&%%%% !5:?_C]M?\ @?\
A*BB@19HHHH&%%%% !1110!4LO^/5?]YOYT445+-%L?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>plx-20241231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20241231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !G )$# 2(  A$! Q$!_\0
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MX%>__P#!*G]ICP9X \(Q_#/7'O[#Q'J6HR2V;/;L89]W(4-V./7% '->#?\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>plx-20241231xex23d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20241231xex23d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "\ -\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH @FO;>V8++/'$Q&<.P!Q3/[5LO\ G[@_[^"OF;]J3Q!!I7Q T^&6.1V;
M2XWRF,8\V4>OM7CO_"9VG_/&;\A_C7YMF/%U3 XNIAE0ORNU^:U_P/OL#PM+
M&X:&(51KF5]O^"???]JV7_/W!_W\%.BO[:>0)'<1.YZ*K@DU\!?\)G:?\\9O
MR'^-=E\'O'UC8?$;2)W@N&5/.R%"YYA<>OO7/AN-)5Z\*4Z"BI-)OFV3=K[=
M#;$<(3HT9U%4;<4W:V]EZGVG161X9\2V_BFRDNK:.6)$D,9$H .< ]B?6M>O
MTVG4C5BIP=TS\^G"5.3A-6:"BBBM" HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ^+OVTM8BT_P"*6EQNCL3HT397'_/>?_"O O\
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M.EPR_9([N.]U.[CR!:V<;JTCENQ(^5?5F45Z)_P41_:KU;]HGXY:UIUM?O\
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M-C@:XE:W5L\C$)B '88':OH.BB@ HHHH **** "BBB@ HHHH **** "BBB@
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L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>20
<FILENAME>plx-20241231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/17/2025 11:12:00 AM-->
<!--Modified on: 3/17/2025 11:12:00 AM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2024" targetNamespace="http://www.protalix.com/20241231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:plx="http://www.protalix.com/20241231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>99940301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>99940401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" id="DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails">
        <link:definition>99940702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" id="DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails">
        <link:definition>99940901 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails" id="DisclosureNetEarningsLossPerShareDetails">
        <link:definition>99941101 - Disclosure - NET EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" id="DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails">
        <link:definition>99941201 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" id="DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails">
        <link:definition>99941202 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" id="DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails">
        <link:definition>99941203 - Disclosure - TAXES ON INCOME (Reconciliation of Tax Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" id="DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails">
        <link:definition>99941401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
        <link:definition>99941402 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>995200300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" id="DisclosureConvertibleNotesTables">
        <link:definition>99930903 - Disclosure - CONVERTIBLE NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" id="DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails">
        <link:definition>99940102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" id="DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails">
        <link:definition>99940103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails" id="DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails">
        <link:definition>99940104 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (The Impact to the Company's Consolidated Balance Sheet) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" id="DisclosureCommercializationAgreementsDetails">
        <link:definition>99940201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>99940302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" id="DisclosureInventoriesAdditionalInformationDetails">
        <link:definition>99940402 - Disclosure - INVENTORIES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" id="DisclosureLiabilityForEmployeeRightsUponRetirementDetails">
        <link:definition>99940501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" id="DisclosureCommitmentsDetails">
        <link:definition>99940601 - Disclosure - COMMITMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" id="DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails">
        <link:definition>99940701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" id="DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>99940703 - Disclosure - OPERATING LEASES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" id="DisclosureShareCapitalSummaryOfStockOptionActivityDetails">
        <link:definition>99940801 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" id="DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails">
        <link:definition>99940802 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" id="DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails">
        <link:definition>99940803 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" id="DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails">
        <link:definition>99940804 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" id="DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails">
        <link:definition>99940805 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" id="DisclosureShareCapitalAdditionalInformationDetails">
        <link:definition>99940806 - Disclosure - SHARE CAPITAL (Additional information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" id="DisclosureConvertibleNotesAdditionalInformationDetails">
        <link:definition>99940902 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails" id="DisclosureTaxesOnIncomeValuationAllowanceDetails">
        <link:definition>99941204 - Disclosure - TAXES ON INCOME (Valuation Allowance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails" id="DisclosureTaxesOnIncomeUncertainTaxPositionDetails">
        <link:definition>99941205 - Disclosure - TAXES ON INCOME (Uncertain Tax Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" id="DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails">
        <link:definition>99941206 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" id="DisclosureTaxesOnIncomeAdditionalInformationDetails">
        <link:definition>99941207 - Disclosure - TAXES ON INCOME (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" id="DisclosureSegmentInformationScheduleOfSegmentInformationDetails">
        <link:definition>99941301 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" id="DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails">
        <link:definition>99941302 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>99941501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941601 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreements" id="DisclosureCommercializationAgreements">
        <link:definition>995210201 - Disclosure - COMMERCIALIZATION AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipment" id="DisclosurePropertyAndEquipment">
        <link:definition>995210301 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>995210401 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement" id="DisclosureLiabilityForEmployeeRightsUponRetirement">
        <link:definition>995210501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureCommitments" id="DisclosureCommitments">
        <link:definition>995210601 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>995210701 - Disclosure - OPERATING LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapital" id="DisclosureShareCapital">
        <link:definition>995210801 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotes" id="DisclosureConvertibleNotes">
        <link:definition>995210901 - Disclosure - CONVERTIBLE NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>995211001 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureNetEarningsLossPerShare" id="DisclosureNetEarningsLossPerShare">
        <link:definition>995211101 - Disclosure - NET EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" id="DisclosureTaxesOnIncome">
        <link:definition>995211201 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995211301 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" id="DisclosureSupplementaryFinancialStatementInformation">
        <link:definition>995211401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995211501 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211601 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" id="DisclosureSignificantAccountingPoliciesTables">
        <link:definition>99930103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
        <link:definition>99930303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>99930403 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>99930703 - Disclosure - OPERATING LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureShareCapitalTables" id="DisclosureShareCapitalTables">
        <link:definition>99930803 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureNetEarningsLossPerShareTables" id="DisclosureNetEarningsLossPerShareTables">
        <link:definition>99931103 - Disclosure - NET EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" id="DisclosureTaxesOnIncomeTables">
        <link:definition>99931203 - Disclosure - TAXES ON INCOME (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>99931303 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" id="DisclosureSupplementaryFinancialStatementInformationTables">
        <link:definition>99931403 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables" id="DisclosureRelatedPartyTransactionsTables">
        <link:definition>99931503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" name="UpfrontNonrefundableNoncreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element name="DisclosureOfLeasesOperatingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DisclosureOfLeasesOperatingLineItems" substitutionGroup="xbrli:item" />
  <xsd:element name="PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_CommercializationAgreementsAbstract" name="CommercializationAgreementsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementalInformationAbstract" name="SupplementalInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ScheduleOfUsefulLifeTableTextBlock" name="ScheduleOfUsefulLifeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ScheduleOfOpenTaxYearsTableTextBlock" name="ScheduleOfOpenTaxYearsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" name="SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_PfizerAgreementMember" name="PfizerAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_FiocruzMember" name="FiocruzMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_FurnitureAndComputerEquipmentMember" name="FurnitureAndComputerEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ContributionPlansMember" name="ContributionPlansMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeSeveranceObligationPayment" name="EmployeeSeveranceObligationPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_RoyaltiesOnSaleOfProducts" name="RoyaltiesOnSaleOfProducts" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_CommitmentAmount" name="CommitmentAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_PercentageOfRoyaltiesToGrantReceived" name="PercentageOfRoyaltiesToGrantReceived" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_UsIsraelMember" name="UsIsraelMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_OtherAssetsInstitutionsCurrent" name="OtherAssetsInstitutionsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_OtherAssetsSundryCurrent" name="OtherAssetsSundryCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_DeferredTaxAssetsOtherTimingDifferences" name="DeferredTaxAssetsOtherTimingDifferences" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" abstract="false" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_PercentageOfCommissionOnSaleOfShares" name="PercentageOfCommissionOnSaleOfShares" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ExercisePrice17.20Member" name="ExercisePrice17.20Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" name="NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_OfficeOfIsraeliInnovationAuthorityMember" name="OfficeOfIsraeliInnovationAuthorityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" name="LesseeOperatingLeaseNumberOfRenewalTermExtensions" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeMember" name="EmployeeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_CommonStockNumberOfVotingRights" name="CommonStockNumberOfVotingRights" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="SupplyAndTechnologyTransferAgreementWithFiocruzMember" id="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePaymentReceived" id="plx_MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExtendedTermOfAgreement" id="plx_ExtendedTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OptionsAndRestrictedSharesMember" id="plx_OptionsAndRestrictedSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice1.03To2.00Member" id="plx_ExercisePrice1.03To2.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice3.55To3.73Member" id="plx_ExercisePrice3.55To3.73Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePrice4.69To5.60Member" id="plx_ExercisePrice4.69To5.60Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EmployeesAndDirectorsMember" id="plx_EmployeesAndDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GainLossOnDebtConversion" id="plx_GainLossOnDebtConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PaymentsToDebtHoldersOnConversion" id="plx_PaymentsToDebtHoldersOnConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfGlobalLicensingAndSupplyAgreements" id="plx_NumberOfGlobalLicensingAndSupplyAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OutstandingStockOptionsAndWarrantsMember" id="plx_OutstandingStockOptionsAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutstandingStockOptionsWarrantsAnd2024NotesMember" id="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReserveForDeductionsFromRevenueCurrent" id="plx_ReserveForDeductionsFromRevenueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FillFinishAgreementMember" id="plx_FillFinishAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ContractAmountUnderAgreementPayable" id="plx_ContractAmountUnderAgreementPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Notes2024Member" id="plx_Notes2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" id="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" id="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationWithholdingTax" id="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" id="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SalesAgreement2021Member" id="plx_SalesAgreement2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SalesAgreement2023Member" id="plx_SalesAgreement2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" id="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromWithdrawalOfShortTermDeposits" id="plx_ProceedsFromWithdrawalOfShortTermDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CapitalizedResearchAndDevelopmentCostAmortizationPeriod" id="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InitialTermOfArrangement" id="plx_InitialTermOfArrangement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TaxYearThereafterMember" id="plx_TaxYearThereafterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PayableToCustomerCurrent" id="plx_PayableToCustomerCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesOtherCurrent" id="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContractAmountUnderAgreementFacilityPayable" id="plx_ContractAmountUnderAgreementFacilityPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>21
<FILENAME>plx-20241231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/17/2025 11:12:00 AM-->
<!--Modified on: 3/17/2025 11:12:00 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureNetEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638778067165520470" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638778067165520470" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638778067165520470" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638778067165520470" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638778067165520470" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638778067165520470" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638778067165520470" xlink:to="plx_ShortTermBankDeposits_638778067165520470" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638778067165520470" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638778067165520470" xlink:to="us-gaap_AccountsReceivableNetCurrent_638778067165520470" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638778067165520470" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638778067165520470" xlink:to="us-gaap_OtherAssetsCurrent_638778067165520470" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638778067165520470" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638778067165520470" xlink:to="us-gaap_InventoryNet_638778067165520470" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638778067165530444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638778067165530444" order="2" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638778067165530444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638778067165530444" order="3" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638778067165530444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638778067165530444" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638778067165530444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638778067165530444" order="5" use="optional" weight="1" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638778067165530444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638778067165530444" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638778067165540442" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638778067165530444" xlink:to="us-gaap_LiabilitiesNoncurrent_638778067165540442" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638778067165540442" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638778067165540442" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638778067165540442" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638778067165540442" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638778067165540442" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638778067165540442" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638778067165540442" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638778067165530444" xlink:to="us-gaap_LiabilitiesCurrent_638778067165540442" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638778067165540442" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638778067165540442" xlink:to="us-gaap_AccountsPayableTradeCurrent_638778067165540442" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638778067165550542" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638778067165540442" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638778067165550542" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638778067165550542" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638778067165540442" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638778067165550542" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638778067165550542" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638778067165540442" xlink:to="us-gaap_ConvertibleDebtCurrent_638778067165550542" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638778067165550542" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_CommitmentsAndContingencies_638778067165550542" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638778067165550542" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638778067165550542" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638778067165560446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638778067165550542" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638778067165560446" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638778067165560446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638778067165550542" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638778067165560446" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638778067165560446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638778067165550542" xlink:to="us-gaap_CommonStockValue_638778067165560446" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638778067165570452" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638778067165570452" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638778067165570452" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638778067165570452" xlink:to="us-gaap_OperatingIncomeLoss_638778067165570452" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638778067165570452" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638778067165570452" xlink:to="us-gaap_Revenues_638778067165570452" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638778067165570452" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638778067165570452" xlink:to="us-gaap_CostOfRevenue_638778067165570452" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638778067165570452" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638778067165570452" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638778067165570452" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638778067165570452" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638778067165570452" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638778067165570452" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638778067165580446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638778067165570452" xlink:to="us-gaap_NonoperatingIncomeExpense_638778067165580446" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638778067165580446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638778067165580446" xlink:to="us-gaap_OtherNonoperatingExpense_638778067165580446" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638778067165580446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638778067165580446" xlink:to="us-gaap_OtherNonoperatingIncome_638778067165580446" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638778067165580446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638778067165580446" order="2" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638778067165590445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638778067165590445" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638778067165590445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638778067165590445" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638778067165590445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638778067165590445" xlink:to="us-gaap_ProceedsFromWarrantExercises_638778067165590445" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638778067165590445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638778067165590445" xlink:to="us-gaap_RepaymentsOfNotesPayable_638778067165590445" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638778067165590445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638778067165590445" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638778067165590445" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638778067165590445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638778067165590445" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638778067165590445" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638778067165600445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638778067165600445" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638778067165600445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638778067165600445" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638778067165600445" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_638778067165600445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638778067165600445" xlink:to="plx_ProceedsFromWithdrawalOfShortTermDeposits_638778067165600445" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638778067165600445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638778067165600445" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638778067165600445" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638778067165600445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638778067165600445" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638778067165600445" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638778067165600445" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638778067165600445" xlink:to="plx_IncreaseDecreaseInBankDeposits_638778067165600445" order="5" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638778067165610439" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_ProfitLoss_638778067165610439" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638778067165610439" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_ShareBasedCompensation_638778067165610439" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638778067165610439" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_Depreciation_638778067165610439" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638778067165610439" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638778067165610439" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638778067165620444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638778067165620444" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638778067165620444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638778067165620444" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638778067165620444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638778067165620444" order="7" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638778067165620444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638778067165620444" order="8" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion_638778067165620444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="plx_GainLossOnDebtConversion_638778067165620444" order="9" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638778067165630441" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638778067165630441" order="10" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638778067165630441" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638778067165630441" order="11" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638778067165630441" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638778067165630441" order="12" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638778067165630441" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_IncreaseDecreaseInInventories_638778067165630441" order="13" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638778067165630441" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638778067165630441" order="14" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638778067165640440" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067165610439" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638778067165640440" order="15" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637041422968011145" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638778067165640440" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637041422968011145" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638778067165640440" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638778067165640440" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637041422968011145" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638778067165640440" order="2" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638778067165650449" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638778067165650449" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638778067165650449" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638778067165650449" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638778067165650449" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638778067165650449" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638778067165650449" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638778067165650449" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638778067165650449" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638778067165650449" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638778067165660698" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638778067165660698" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638778067165660698" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638778067165660698" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638778067165660698" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638778067165660698" order="5" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638778067165660698" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638778067165660698" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638778067165670450" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638778067165670450" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - NET EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638778067165670450" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xlink:to="us-gaap_DilutiveSecurities_638778067165670450" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638778067165670450" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xlink:to="us-gaap_NetIncomeLoss_638778067165670450" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638778067165670450" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638778067165670450" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638778067165670450" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638778067165670450" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638778067165680444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638778067165680444" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638778067165680444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638778067165680444" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638778067165680444" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638778067165680444" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638778067165690447" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638778067165690447" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_DeferredTaxAssetsOtherTimingDifferences" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_638778067165690447" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="plx_DeferredTaxAssetsOtherTimingDifferences_638778067165690447" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638778067165690447" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638778067165690447" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638778067165690447" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638778067165690447" order="4" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - TAXES ON INCOME (Reconciliation of Tax Expense) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638778067165690447" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638778067165690447" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638778067165700442" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638778067165700442" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638778067165700442" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638778067165700442" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638778067165700442" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638778067165700442" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_638778067165700442" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_638778067165700442" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_638778067165700442" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_2" xlink:to="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_638778067165700442" order="6" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent_638778067165710451" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="plx_OtherAssetsInstitutionsCurrent_638778067165710451" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638778067165710451" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_638778067165710451" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent_638778067165710451" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="plx_OtherAssetsSundryCurrent_638778067165710451" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="99941402 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638778067165710451" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638778067165710451" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638778067165710451" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_InterestPayableCurrent_638778067165710451" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638778067165720446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedVacationCurrent_638778067165720446" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638778067165720446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638778067165720446" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638778067165720446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638778067165720446" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638778067165720446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638778067165720446" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638778067165720446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_TaxesPayableCurrent_638778067165720446" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent_638778067165720446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_PayableToCustomerCurrent_638778067165720446" order="8" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638778067165720446" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638778067165720446" order="9" use="optional" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>22
<FILENAME>plx-20241231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/17/2025 11:12:00 AM-->
<!--Modified on: 3/17/2025 11:12:00 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureConvertibleNotesTables" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureCommercializationAgreementsDetails" roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureLiabilityForEmployeeRightsUponRetirementDetails" roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureCommitmentsDetails" roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalSummaryOfStockOptionActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureConvertibleNotesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureNetEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20241231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="995200300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesTables" xlink:type="extended" xlink:title="99930903 - Disclosure - CONVERTIBLE NOTES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MilestonePaymentReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" xlink:type="extended" xlink:title="99940102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" xlink:type="extended" xlink:title="99940103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_FiocruzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_PfizerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails" xlink:type="extended" xlink:title="99940104 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (The Impact to the Company's Consolidated Balance Sheet) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_LaboratoryEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="plx_FurnitureAndComputerEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ContributionPlansMember" xlink:label="plx_ContributionPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="plx_ContributionPlansMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_EmployeeSeveranceObligationPayment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - COMMITMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_RoyaltyAgreementTermsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="plx_OfficeOfIsraeliInnovationAuthorityMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_FillFinishAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_RoyaltiesOnSaleOfProducts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_PercentageOfRoyaltiesToGrantReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_ExtendedTermOfAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ContractAmountUnderAgreementPayable" xlink:label="plx_ContractAmountUnderAgreementPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_ContractAmountUnderAgreementPayable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ContractAmountUnderAgreementFacilityPayable" xlink:label="plx_ContractAmountUnderAgreementFacilityPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_ContractAmountUnderAgreementFacilityPayable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_InitialTermOfArrangement" xlink:label="plx_InitialTermOfArrangement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_InitialTermOfArrangement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940703 - Disclosure - OPERATING LEASES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeesAndDirectorsMember" xlink:label="plx_EmployeesAndDirectorsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeesAndDirectorsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="plx_EmployeeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" priority="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice17.20Member" xlink:label="plx_ExercisePrice17.20Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice17.20Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice1.03To2.00Member" xlink:label="plx_ExercisePrice1.03To2.00Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice1.03To2.00Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice3.55To3.73Member" xlink:label="plx_ExercisePrice3.55To3.73Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice3.55To3.73Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice4.69To5.60Member" xlink:label="plx_ExercisePrice4.69To5.60Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="plx_ExercisePrice4.69To5.60Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" xlink:type="extended" xlink:title="99940806 - Disclosure - SHARE CAPITAL (Additional information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OptionsAndRestrictedSharesMember" xlink:label="plx_OptionsAndRestrictedSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="plx_OptionsAndRestrictedSharesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_OptionsAndRestrictedSharesMember" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_OptionsAndRestrictedSharesMember" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SalesAgreement2021Member" xlink:label="plx_SalesAgreement2021Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_SalesAgreement2021Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SalesAgreement2023Member" xlink:label="plx_SalesAgreement2023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_SalesAgreement2023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_Notes2024Member" xlink:label="plx_Notes2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_Notes2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommonStockNumberOfVotingRights" xlink:label="plx_CommonStockNumberOfVotingRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_CommonStockNumberOfVotingRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PercentageOfCommissionOnSaleOfShares" xlink:label="plx_PercentageOfCommissionOnSaleOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_PercentageOfCommissionOnSaleOfShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_PaymentsToDebtHoldersOnConversion" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestCostsIncurred" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - NET EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_DilutiveSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" xlink:type="extended" xlink:title="99941206 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_UsIsraelMember" xlink:label="plx_UsIsraelMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_UsIsraelMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_US" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="99941207 - Disclosure - TAXES ON INCOME (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="srt_ConsolidatedEntitiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_SubsidiariesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ParentCompanyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="plx_TaxYearThereafterMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_IncomeTaxDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_MilestonePaymentReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="99941302 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_PfizerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_FiocruzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_DirectorMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SalesAgreement2023Member" xlink:label="plx_SalesAgreement2023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_SalesAgreement2023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromCustomers" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>23
<FILENAME>plx-20241231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/17/2025 11:12:00 AM-->
<!--Modified on: 3/17/2025 11:12:00 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Securities Act File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net, total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals - other:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Other, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Other</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Accounts payable and accruals - other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value: Authorized - as of December 31, 2023 and 2024, 185,000,000 shares; issued and outstanding - as of December 31, 2023 and 2024, 72,952,124 and 75,850,275 shares, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">GOODS</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and Service [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">LICENSE AND R&amp;D SERVICES</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues from customers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Interest income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL INCOME (EXPENSES), NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">INCOME (LOSS) BEFORE TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for basic calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">ASU 2020-06</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Adjustment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Effect of Change</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Convertible notes conversions (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Value of shares issued during period for exercise of warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Changes in deferred income tax asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss (gain) on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss (gain) on sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnDebtConversion" xlink:to="plx_GainLossOnDebtConversion_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">The amount of gain (loss) on conversion of convertible debt.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">Gain (Loss) On Debt Conversion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnDebtConversion_lbl" xml:lang="en-US">Gain on conversions of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in contracts liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable-trade and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Investment in bank deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:to="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" xml:lang="en-US">The amount of cash inflow from the withdrawal of short-term deposits during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds From Withdrawal Of Short-Term Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" xml:lang="en-US">Short-term deposit withdrawal</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts paid (funded) in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment for convertible notes redemption</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment for promissory note</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment for promissory note</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Stock issuance proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Convertible notes conversions</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" xlink:label="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" xlink:to="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_lbl" xml:lang="en-US">The amount of partial settlement of liability for employee rights upon retirement through transfer of related funds in non-cash financing and investing activities.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_lbl" xml:lang="en-US">Partial Settlement Of Liability For Employee Rights Upon Retirement Through Transfer Of the Related Funds</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_lbl" xml:lang="en-US">Partial settlement of liability for employee rights upon retirement through transfer of the related funds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Tax paid</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="plx_CommercializationAgreementsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommercializationAgreementsAbstract" xlink:to="plx_CommercializationAgreementsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommercializationAgreementsAbstract_lbl" xml:lang="en-US">COMMERCIALIZATION AGREEMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">COMMERCIALIZATION AGREEMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LessorDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorDisclosureAbstract_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">SHARE CAPITAL</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHARE CAPITAL</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">CONVERTIBLE NOTES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementalInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates in the preparation of financial statements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment in value of long-lived assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of credit risks and trade receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfUsefulLifeTableTextBlock" xlink:to="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule Of Useful Life Table Text Block</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule Of Useful Life [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Schedule of ASU 2020-06 Impact to the Consolidated Balance Sheet</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturity Analysis of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Restricted Stock Activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Summary of Share Options Outstanding and Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-Based Compensation Expense in Statement of Operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of Interest Expense Recognized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Earnings (Loss) per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Taxes on Income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Tax Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of Company's Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of the Beginning and Ending Amount of Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:to="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Open Tax Years Table Text Block</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Open Tax Years [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_lbl" xml:lang="en-US">Schedule of Open Tax Years</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of Segment Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Schedule of Disaggregation of Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Information of Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">All Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">BRAZIL</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Represents the number of global licensing and supply agreements.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number Of Global Licensing And Supply Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number of global licensing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MilestonePaymentReceived" xlink:to="plx_MilestonePaymentReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received upon achievement of certain milestone.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MilestonePaymentReceived_lbl" xml:lang="en-US">Amount of milestone payment received</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expenses sharing percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Performance obligation number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xml:lang="en-US">Accounts receivables write-off</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xml:lang="en-US">Accounts receivables recoveries</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LaboratoryEquipmentMember" xlink:to="plx_LaboratoryEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FiocruzMember" xlink:to="plx_FiocruzMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FiocruzMember_lbl" xml:lang="en-US">Fiocruz</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex-US Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non creditable Payment Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_lbl" xml:lang="en-US">Non-refundable payment receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional amounts payable to cover development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum entitlement of development costs to cover per year</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional amount payable for achievement of regulatory and commercial milestones</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment on net sales percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FurnitureAndComputerEquipmentMember" xlink:to="plx_FurnitureAndComputerEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">Furniture And Computer Equipment Member</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">Furniture And Computer Equipment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_FurnitureAndComputerEquipmentMember_lbl" xml:lang="en-US">Furniture and computer equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less - accumulated depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory Write-down</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory write-down</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:to="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_lbl" xml:lang="en-US">Postretirement Life Insurance [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_lbl" xml:lang="en-US">Contribution to Insurance Companies</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ContributionPlansMember" xlink:label="plx_ContributionPlansMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ContributionPlansMember" xlink:to="plx_ContributionPlansMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ContributionPlansMember_lbl" xml:lang="en-US">Contribution to Defined Contribution Plans [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ContributionPlansMember_lbl" xml:lang="en-US">Contribution to Defined Contribution Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeSeveranceObligationPayment" xlink:to="plx_EmployeeSeveranceObligationPayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeSeveranceObligationPayment_lbl" xml:lang="en-US">Employee severance obligation payment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeSeveranceObligationPayment_lbl" xml:lang="en-US">Employee Severance Obligation Payment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeeSeveranceObligationPayment_lbl" xml:lang="en-US">Employee severance obligation payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xml:lang="en-US">Postemployment Benefits, Period Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xml:lang="en-US">Severance expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Contributions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_lbl" xml:lang="en-US">Gain for the period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_lbl" xml:lang="en-US">Contribution in connection with severance liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:to="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" xml:lang="en-US">Number Of Employees To Receive Benefits During Next Five Years</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" xml:lang="en-US">Number Of Employees To Receive Benefits During Next Five Years</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_lbl" xml:lang="en-US">Number of benefit eligible employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementTermsMember" xlink:to="us-gaap_RoyaltyAgreementTermsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyAgreementTermsMember_lbl" xml:lang="en-US">Royalty Agreement Terms [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyAgreementTermsMember_lbl" xml:lang="en-US">Royalty Agreement Terms</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:to="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Office of the Israeli Innovation Authority [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Office of the Israeli Innovation Authority [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_lbl" xml:lang="en-US">Office of the Israeli Innovation Authority</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FillFinishAgreementMember" xlink:to="plx_FillFinishAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FillFinishAgreementMember_lbl" xml:lang="en-US">Fill/Finish Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl" xml:lang="en-US">Arrangement Other than Collaborative [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember_lbl" xml:lang="en-US">Arrangement Other than Collaborative</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentsAndContingenciesLineItems" xlink:to="plx_CommitmentsAndContingenciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RoyaltiesOnSaleOfProducts" xlink:to="plx_RoyaltiesOnSaleOfProducts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RoyaltiesOnSaleOfProducts_lbl" xml:lang="en-US">Percentage of royalties based on sale of products developed from projects funded.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RoyaltiesOnSaleOfProducts_lbl" xml:lang="en-US">Royalties On Sale Of Products</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RoyaltiesOnSaleOfProducts_lbl" xml:lang="en-US">Royalties based on sale of products developed from funded projects, percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfRoyaltiesToGrantReceived" xlink:to="plx_PercentageOfRoyaltiesToGrantReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_lbl" xml:lang="en-US">Required royalty payments represented as a percentage to grants received.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_lbl" xml:lang="en-US">Percentage of Royalties to Grant Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_lbl" xml:lang="en-US">Percentage of Royalties to Grant Received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty expense included in cost of revenue</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued Royalties</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued royalties</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommitmentAmount" xlink:to="plx_CommitmentAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommitmentAmount_lbl" xml:lang="en-US">Commitment amount.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommitmentAmount_lbl" xml:lang="en-US">Commitment Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommitmentAmount_lbl" xml:lang="en-US">Subcontracting commitment amount</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExtendedTermOfAgreement" xlink:to="plx_ExtendedTermOfAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term  of agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended Term Of Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExtendedTermOfAgreement_lbl" xml:lang="en-US">Extended term of agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ContractAmountUnderAgreementPayable" xlink:label="plx_ContractAmountUnderAgreementPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ContractAmountUnderAgreementPayable" xlink:to="plx_ContractAmountUnderAgreementPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ContractAmountUnderAgreementPayable_lbl" xml:lang="en-US">Amount agreed to pay under the agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ContractAmountUnderAgreementPayable_lbl" xml:lang="en-US">Contract Amount Under Agreement, Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ContractAmountUnderAgreementPayable_lbl" xml:lang="en-US">Contract amount</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ContractAmountUnderAgreementFacilityPayable" xlink:label="plx_ContractAmountUnderAgreementFacilityPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ContractAmountUnderAgreementFacilityPayable" xlink:to="plx_ContractAmountUnderAgreementFacilityPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ContractAmountUnderAgreementFacilityPayable_lbl" xml:lang="en-US">This represents the share of payment to a contract research organization to cover proportionate share of the costs in setting up a facility.  May include equipment purchases but also other facility customization efforts, etc., none of which will be owned by the Company.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ContractAmountUnderAgreementFacilityPayable_lbl" xml:lang="en-US">Contract Amount Under Agreement, Facility, Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ContractAmountUnderAgreementFacilityPayable_lbl" xml:lang="en-US">Contracted share of facility cost amount</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_InitialTermOfArrangement" xlink:label="plx_InitialTermOfArrangement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InitialTermOfArrangement" xlink:to="plx_InitialTermOfArrangement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InitialTermOfArrangement_lbl" xml:lang="en-US">Initial term of arrangement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InitialTermOfArrangement_lbl" xml:lang="en-US">Initial Term Of Arrangement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InitialTermOfArrangement_lbl" xml:lang="en-US">Initial term of arrangement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_DisclosureOfLeasesOperatingLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">Disclosure of Leases Operating</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">Disclosure of Leases Operating [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">2029 and thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Option to extend</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Lessee Operating Lease, Number Of Renewal Term Extensions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Lessee Operating Lease, Number Of Renewal Term Extensions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Operating lease, Renewable term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating lease, term of agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Cash deposited as bank guarantee</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of change in operating lease monthly rental payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeesAndDirectorsMember" xlink:label="plx_EmployeesAndDirectorsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeesAndDirectorsMember" xlink:to="plx_EmployeesAndDirectorsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Represents information pertaining to employees and directors.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees and directors</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Number of options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at end of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Expired (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at end of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeMember" xlink:to="plx_EmployeeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeMember_lbl" xml:lang="en-US">Employee</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeeMember_lbl" xml:lang="en-US">Employee</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Non vested at end of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Non vested at end of year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice1.03To2.00Member" xlink:label="plx_ExercisePrice1.03To2.00Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice1.03To2.00Member" xlink:to="plx_ExercisePrice1.03To2.00Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice1.03To2.00Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price ranging from $1.03 to $2.00.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice1.03To2.00Member_lbl" xml:lang="en-US">Exercise Price 1.03 to 2.00 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExercisePrice1.03To2.00Member_lbl" xml:lang="en-US">$1.03 - $2.00</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice3.55To3.73Member" xlink:label="plx_ExercisePrice3.55To3.73Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice3.55To3.73Member" xlink:to="plx_ExercisePrice3.55To3.73Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice3.55To3.73Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price ranging from $3.55 to $3.73.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice3.55To3.73Member_lbl" xml:lang="en-US">Exercise Price 3.55 to 3.73 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExercisePrice3.55To3.73Member_lbl" xml:lang="en-US">$3.55 - $3.73</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice4.69To5.60Member" xlink:label="plx_ExercisePrice4.69To5.60Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice4.69To5.60Member" xlink:to="plx_ExercisePrice4.69To5.60Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice4.69To5.60Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price ranging from $4.69 to $5.60.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice4.69To5.60Member_lbl" xml:lang="en-US">Exercise Price 4.69 to 5.60 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExercisePrice4.69To5.60Member_lbl" xml:lang="en-US">$4.69 - $5.60</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice17.20Member" xlink:label="plx_ExercisePrice17.20Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ExercisePrice17.20Member" xlink:to="plx_ExercisePrice17.20Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ExercisePrice17.20Member_lbl" xml:lang="en-US">Represents the information pertaining to exercise price $17.20.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ExercisePrice17.20Member_lbl" xml:lang="en-US">Exercise Price 17.20</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ExercisePrice17.20Member_lbl" xml:lang="en-US">$17.20</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Exercise price, lower range</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Exercise price, upper range</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of options outstanding at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of options exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Weighted average grants date fair value (USD)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (USD)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (Years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of goods sold</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OptionsAndRestrictedSharesMember" xlink:label="plx_OptionsAndRestrictedSharesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsAndRestrictedSharesMember" xlink:to="plx_OptionsAndRestrictedSharesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OptionsAndRestrictedSharesMember_lbl" xml:lang="en-US">Represents information pertaining to stock options and restricted shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OptionsAndRestrictedSharesMember_lbl" xml:lang="en-US">Options and Restricted Shares [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OptionsAndRestrictedSharesMember_lbl" xml:lang="en-US">Options and restricted shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SalesAgreement2021Member" xlink:label="plx_SalesAgreement2021Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SalesAgreement2021Member" xlink:to="plx_SalesAgreement2021Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SalesAgreement2021Member_lbl" xml:lang="en-US">Represents information pertaining to 2021 Sales Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SalesAgreement2021Member_lbl" xml:lang="en-US">Sales Agreement 2021 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SalesAgreement2021Member_lbl" xml:lang="en-US">2021 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SalesAgreement2023Member" xlink:label="plx_SalesAgreement2023Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SalesAgreement2023Member" xlink:to="plx_SalesAgreement2023Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SalesAgreement2023Member_lbl" xml:lang="en-US">Represents information pertaining to 2023 Sales Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SalesAgreement2023Member_lbl" xml:lang="en-US">Sales Agreement 2023 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SalesAgreement2023Member_lbl" xml:lang="en-US">2023 Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_Notes2024Member" xlink:label="plx_Notes2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_Notes2024Member" xlink:to="plx_Notes2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_Notes2024Member_lbl" xml:lang="en-US">Represents the information pertaining to 2024 notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_Notes2024Member_lbl" xml:lang="en-US">Notes 2024 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_Notes2024Member_lbl" xml:lang="en-US">2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommonStockNumberOfVotingRights" xlink:label="plx_CommonStockNumberOfVotingRights" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommonStockNumberOfVotingRights" xlink:to="plx_CommonStockNumberOfVotingRights_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommonStockNumberOfVotingRights_lbl" xml:lang="en-US">Represents the number of votes for each share of common stock is entitled.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommonStockNumberOfVotingRights_lbl" xml:lang="en-US">Common Stock, Number Of Voting Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommonStockNumberOfVotingRights_lbl" xml:lang="en-US">Number of voting rights</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance under share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares of Common Stock remain available for grant under the plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of award</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Vesting-date fair value of stock vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized weighted average period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding options intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Exercisable options intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PercentageOfCommissionOnSaleOfShares" xlink:label="plx_PercentageOfCommissionOnSaleOfShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfCommissionOnSaleOfShares" xlink:to="plx_PercentageOfCommissionOnSaleOfShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_lbl" xml:lang="en-US">Percentage of commission on sale of shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_lbl" xml:lang="en-US">Percentage of Commission on Sale of Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_lbl" xml:lang="en-US">Commission (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Converted instrument, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentsToDebtHoldersOnConversion" xlink:to="plx_PaymentsToDebtHoldersOnConversion_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">Payments To Debt Holders On Conversion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PaymentsToDebtHoldersOnConversion_lbl" xml:lang="en-US">Paid to the converting holders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xml:lang="en-US">Contractual interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestCostsIncurred" xlink:to="us-gaap_InterestCostsIncurred_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestCostsIncurred_lbl" xml:lang="en-US">Interest Costs Incurred</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InterestCostsIncurred_lbl" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Mature term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsAndWarrantsMember" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding stock options and warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding Stock Options And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" xml:lang="en-US">Outstanding stock options and warrants and 2024 notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_lbl" xml:lang="en-US">Outstanding Stock Options Warrants And 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">NET EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Financial expenses of 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net income (loss) for diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Weighted average dilutive effect of 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Weighted average dilutive effect of stock options and restricted stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">In respect of:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_DeferredTaxAssetsOtherTimingDifferences" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredTaxAssetsOtherTimingDifferences" xlink:to="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" xml:lang="en-US">The amount of deferred tax assets other timing differences.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" xml:lang="en-US">Deferred Tax Assets Other Timing Differences</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_lbl" xml:lang="en-US">Other timing differences</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Ending Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Beginning Balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total net deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax computed at the statutory U.S. income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Differences in tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Statutorily non-deductible expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance related to deferred tax assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in Valuation allowances</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" xlink:to="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_lbl" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to utilization of carry-forward losses and other temporary items without deferred taxes recognition.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Utilization Of Carry-Forward Losses And Other Temporary Items Without Deferred Taxes Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_lbl" xml:lang="en-US">Utilization of carry-forward losses and other temporary items without deferred taxes recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" xlink:to="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_lbl" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to withholding tax.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Withholding Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_lbl" xml:lang="en-US">Withholding tax</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureTable" xlink:to="plx_IncomeTaxDisclosureTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US">Income Tax Disclosure Table</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncomeTaxDisclosureTable_lbl" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncomeTaxDisclosureLineItems" xlink:to="plx_IncomeTaxDisclosureLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US">Income Tax Disclosure Line Items</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncomeTaxDisclosureLineItems_lbl" xml:lang="en-US">TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" xlink:label="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" xlink:to="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_lbl" xml:lang="en-US">Amount of additions to the valuation allowance for deferred tax asset.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Additions During The Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_lbl" xml:lang="en-US">Additions to valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" xlink:label="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" xlink:to="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_lbl" xml:lang="en-US">Amount of reductions to the valuation allowance for deferred tax asset.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Reductions During The Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_lbl" xml:lang="en-US">Reductions to valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Ending Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Increase for tax position related to current year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_UsIsraelMember" xlink:label="plx_UsIsraelMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UsIsraelMember" xlink:to="plx_UsIsraelMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UsIsraelMember_lbl" xml:lang="en-US">Israel</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open Tax Year</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open tax year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SubsidiariesMember" xlink:to="srt_SubsidiariesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SubsidiariesMember_lbl" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SubsidiariesMember_lbl" xml:lang="en-US">Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ParentCompanyMember" xlink:to="srt_ParentCompanyMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ParentCompanyMember_lbl" xml:lang="en-US">Parent Company</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TaxYearThereafterMember" xlink:to="plx_TaxYearThereafterMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_TaxYearThereafterMember_lbl" xml:lang="en-US">Represents the tax rate thereafter years.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TaxYearThereafterMember_lbl" xml:lang="en-US">Tax Year Thereafter [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_TaxYearThereafterMember_lbl" xml:lang="en-US">Tax Year Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Deferred tax liability of research and development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" xlink:to="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_lbl" xml:lang="en-US">Amortization period of cost capitalized for research and development cost, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_lbl" xml:lang="en-US">Capitalized Research And Development Cost, Amortization Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_lbl" xml:lang="en-US">Amortization period research and development costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Employee salaries and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Professional and Contract Services Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Sub-contractors expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US">Other segment expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US">Segment Reporting, Other Segment Item, Composition, Description</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US">Segment reporting description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Other assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsInstitutionsCurrent" xlink:to="plx_OtherAssetsInstitutionsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OtherAssetsInstitutionsCurrent_lbl" xml:lang="en-US">Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OtherAssetsInstitutionsCurrent_lbl" xml:lang="en-US">Other Assets, Institutions, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OtherAssetsInstitutionsCurrent_lbl" xml:lang="en-US">Institutions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherAssetsSundryCurrent" xlink:to="plx_OtherAssetsSundryCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OtherAssetsSundryCurrent_lbl" xml:lang="en-US">Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OtherAssetsSundryCurrent_lbl" xml:lang="en-US">Other Assets, Sundry, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OtherAssetsSundryCurrent_lbl" xml:lang="en-US">Sundry</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Provision for vacation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PayableToCustomerCurrent" xlink:to="plx_PayableToCustomerCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Payable To Customer, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Payable to customer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReserveForDeductionsFromRevenueCurrent" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of reserve for deductions from revenue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Reserve For Deductions From Revenue Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_lbl" xml:lang="en-US">Sales reserve</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Property and equipment suppliers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Compensation (including share based compensation) to the non-executive directors</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Consulting fees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerAgreementMember" xlink:to="plx_PfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Represents information pertaining to supply and technology transfer agreement with Fiocruz.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Brazil Agreement with Fiocruz</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomers" xlink:to="us-gaap_ProceedsFromCustomers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Proceeds from Customers</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Total proceeds from sale of products</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares remain for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants and rights outstanding</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>24
<FILENAME>plx-20241231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/17/2025 11:12:00 AM-->
<!--Modified on: 3/17/2025 11:12:00 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureCommercializationAgreements" roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreements" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosurePropertyAndEquipment" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipment" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureLiabilityForEmployeeRightsUponRetirement" roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureCommitments" roleURI="http://www.protalix.com/role/DisclosureCommitments" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureOperatingLeases" roleURI="http://www.protalix.com/role/DisclosureOperatingLeases" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapital" roleURI="http://www.protalix.com/role/DisclosureShareCapital" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureConvertibleNotes" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotes" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureNetEarningsLossPerShare" roleURI="http://www.protalix.com/role/DisclosureNetEarningsLossPerShare" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncome" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncome" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSegmentInformation" roleURI="http://www.protalix.com/role/DisclosureSegmentInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPoliciesTables" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureOperatingLeasesTables" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalTables" roleURI="http://www.protalix.com/role/DisclosureShareCapitalTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureConvertibleNotesTables" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureNetEarningsLossPerShareTables" roleURI="http://www.protalix.com/role/DisclosureNetEarningsLossPerShareTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeTables" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSegmentInformationTables" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureRelatedPartyTransactionsTables" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureCommercializationAgreementsDetails" roleURI="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureInventoriesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureLiabilityForEmployeeRightsUponRetirementDetails" roleURI="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureCommitmentsDetails" roleURI="http://www.protalix.com/role/DisclosureCommitmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalSummaryOfStockOptionActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureShareCapitalAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureConvertibleNotesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureNetEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeValuationAllowanceDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeUncertainTaxPositionDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureTaxesOnIncomeAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSegmentInformationScheduleOfSegmentInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20241231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" />
  <link:presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638778067166890442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638778067166890442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638778067166890442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638778067166890442" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638778067166890442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638778067166890442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638778067166890442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638778067166890442" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638778067166890442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638778067166890442" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638778067166900443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638778067166900443" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638778067166900443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638778067166900443" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638778067166900443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638778067166900443" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638778067166900443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638778067166900443" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638778067166900443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638778067166900443" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638778067166900443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638778067166900443" order="11" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638778067166900443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638778067166900443" order="12" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638778067166900443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638778067166900443" order="13" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638778067166910439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638778067166910439" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638778067166910439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638778067166910439" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638778067166910439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638778067166910439" order="16" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638778067166910439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638778067166910439" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638778067166910439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638778067166910439" order="18" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638778067166910439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638778067166910439" order="19" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638778067166910439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638778067166910439" order="20" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638778067166910439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638778067166910439" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638778067166920441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638778067166920441" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638778067166920441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638778067166920441" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638778067166920441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638778067166920441" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638778067166920441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638778067166920441" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638778067166920441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638778067166920441" order="26" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638778067166920441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638778067166920441" order="27" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638778067166930447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638778067166930447" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638778067166930447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638778067166930447" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638778067166930447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638778067166930447" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638778067166930447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638778067166930447" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638778067166930447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638778067166930447" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638778067166940547" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638778067166940547" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638778067166940547" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638778067166940547" order="34" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638778067166940547" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638778067166940547" order="35" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638778067166940547" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638778067166940547" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638778067166940547" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638778067166940547" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638778067166950437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638778067166950437" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_638778067166950437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_638778067166950437" order="39" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638778067166950437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638778067166950437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638778067166950437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638778067166950437" xlink:to="us-gaap_AssetsCurrentAbstract_638778067166950437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638778067166950437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638778067166950437" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638778067166950437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638778067166960437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638778067166950437" xlink:to="plx_ShortTermBankDeposits_638778067166960437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638778067166960437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638778067166950437" xlink:to="us-gaap_AccountsReceivableNetCurrent_638778067166960437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638778067166960437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638778067166950437" xlink:to="us-gaap_OtherAssetsCurrent_638778067166960437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638778067166960437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638778067166950437" xlink:to="us-gaap_InventoryNet_638778067166960437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638778067166960437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638778067166950437" xlink:to="us-gaap_AssetsCurrent_638778067166960437" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638778067166960437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638778067166950437" xlink:to="us-gaap_AssetsNoncurrentAbstract_638778067166960437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638778067166960437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638778067166960437" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638778067166960437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638778067166960437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638778067166960437" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638778067166960437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638778067166960437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638778067166960437" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638778067166960437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638778067166970439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638778067166960437" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638778067166970439" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638778067166970439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638778067166950437" xlink:to="us-gaap_Assets_638778067166970439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638778067166970439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638778067166970439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638778067166970439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638778067166970439" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638778067166970439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067166970439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638778067166970439" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067166970439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638778067166970439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067166970439" xlink:to="us-gaap_AccountsPayableTradeCurrent_638778067166970439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638778067166980467" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067166970439" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638778067166980467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638778067166980467" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067166970439" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638778067166980467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638778067166980467" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638778067166970439" xlink:to="us-gaap_ConvertibleDebtCurrent_638778067166980467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638778067166980467" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638778067166970439" xlink:to="us-gaap_LiabilitiesCurrent_638778067166980467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638778067166980467" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638778067166970439" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638778067166980467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638778067166980467" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638778067166980467" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638778067166980467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638778067166990452" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638778067166980467" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638778067166990452" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638778067166990452" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638778067166970439" xlink:to="us-gaap_LiabilitiesNoncurrent_638778067166990452" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638778067166990452" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638778067166970439" xlink:to="us-gaap_Liabilities_638778067166990452" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638778067166990452" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638778067166970439" xlink:to="us-gaap_CommitmentsAndContingencies_638778067166990452" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638778067166990452" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638778067166970439" xlink:to="us-gaap_StockholdersEquityAbstract_638778067166990452" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638778067166990452" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638778067166990452" xlink:to="us-gaap_CommonStockValue_638778067166990452" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638778067167000485" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638778067166990452" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638778067167000485" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638778067167000485" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638778067166990452" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638778067167000485" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638778067167000485" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638778067166970439" xlink:to="us-gaap_StockholdersEquity_638778067167000485" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638778067167000485" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638778067166970439" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638778067167000485" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638778067167010442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638778067167010442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638778067167010442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638778067167010442" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638778067167010442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638778067167010442" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638778067167010442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638778067167010442" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638778067167010442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_638778067167010442" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638778067167010442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167010442" xlink:to="srt_ProductOrServiceAxis_638778067167010442" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638778067167010442" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638778067167010442" xlink:to="srt_ProductsAndServicesDomain_638778067167010442" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638778067167020440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638778067167010442" xlink:to="us-gaap_ProductMember_638778067167020440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638778067167020440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638778067167010442" xlink:to="us-gaap_LicenseAndServiceMember_638778067167020440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638778067167020440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167010442" xlink:to="us-gaap_StatementLineItems_638778067167020440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638778067167020440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_Revenues_638778067167020440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638778067167020440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_CostOfRevenue_638778067167020440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638778067167020440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638778067167020440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638778067167020440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638778067167020440" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638778067167020440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_OperatingIncomeLoss_638778067167020440" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638778067167020440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_OtherNonoperatingExpense_638778067167020440" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638778067167030440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_OtherNonoperatingIncome_638778067167030440" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638778067167030440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_NonoperatingIncomeExpense_638778067167030440" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638778067167030440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638778067167030440" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638778067167030440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638778067167030440" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638778067167030440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_NetIncomeLoss_638778067167030440" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638778067167030440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_EarningsPerShareBasic_638778067167030440" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638778067167030440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_EarningsPerShareDiluted_638778067167030440" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638778067167030440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638778067167030440" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638778067167040453" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167020440" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638778067167040453" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="995200300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638778067167040453" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638778067167040453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638778067167040453" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167040453" xlink:to="us-gaap_StatementEquityComponentsAxis_638778067167040453" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638778067167040453" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638778067167040453" xlink:to="us-gaap_CommonStockMember_638778067167040453" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638778067167040453" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638778067167040453" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638778067167040453" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638778067167040453" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638778067167040453" xlink:to="us-gaap_RetainedEarningsMember_638778067167040453" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638778067167050448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638778067167040453" xlink:to="us-gaap_EquityComponentDomain_638778067167050448" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638778067167050448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167040453" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638778067167050448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_638778067167050448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638778067167050448" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_638778067167050448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638778067167050448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638778067167050448" xlink:to="us-gaap_TypeOfAdoptionMember_638778067167050448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_638778067167050448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167040453" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_638778067167050448" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638778067167050448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638778067167050448" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638778067167050448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_638778067167050448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638778067167050448" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_638778067167050448" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638778067167050448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167040453" xlink:to="us-gaap_StatementLineItems_638778067167050448" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638778067167050448" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="us-gaap_StockholdersEquity_638778067167050448" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638778067167060439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="us-gaap_CommonStockSharesIssued_638778067167060439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638778067167060439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638778067167060439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638778067167060439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638778067167060439" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638778067167060439" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_638778067167060439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_638778067167060439" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_638778067167060439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_638778067167060439" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638778067167060439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638778067167060439" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638778067167060439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638778067167060439" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638778067167070436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638778067167070436" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638778067167070436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638778067167070436" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638778067167070436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638778067167070436" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638778067167070436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_638778067167070436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_638778067167070436" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638778067167070436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_638778067167070436" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638778067167070436" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638778067167070436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="us-gaap_NetIncomeLoss_638778067167070436" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638778067167070436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="us-gaap_StockholdersEquity_638778067167070436" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638778067167080572" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167050448" xlink:to="us-gaap_CommonStockSharesIssued_638778067167080572" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638778067167080572" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_ProfitLoss_638778067167080572" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638778067167080572" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_ShareBasedCompensation_638778067167080572" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638778067167090438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_Depreciation_638778067167090438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638778067167090438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638778067167090438" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638778067167090438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638778067167090438" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638778067167090438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638778067167090438" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638778067167090438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638778067167090438" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638778067167090438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638778067167090438" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_GainLossOnDebtConversion" xlink:label="plx_GainLossOnDebtConversion_638778067167090438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="plx_GainLossOnDebtConversion_638778067167090438" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638778067167090438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638778067167090438" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638778067167090438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638778067167090438" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638778067167100440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638778067167090438" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638778067167100440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638778067167100440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638778067167090438" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638778067167100440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638778067167100440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638778067167090438" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638778067167100440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638778067167100440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638778067167090438" xlink:to="us-gaap_IncreaseDecreaseInInventories_638778067167100440" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638778067167100440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638778067167090438" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638778067167100440" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067167100440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638778067167080572" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638778067167100440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638778067167100440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638778067167100440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_638778067167100440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638778067167100440" xlink:to="plx_IncreaseDecreaseInBankDeposits_638778067167100440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_638778067167110436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638778067167100440" xlink:to="plx_ProceedsFromWithdrawalOfShortTermDeposits_638778067167110436" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638778067167110436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638778067167100440" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638778067167110436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638778067167110436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638778067167100440" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638778067167110436" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638778067167110436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638778067167100440" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638778067167110436" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638778067167110436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638778067167100440" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638778067167110436" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638778067167110436" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638778067167110436" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638778067167120438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638778067167110436" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638778067167120438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638778067167120438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638778067167110436" xlink:to="us-gaap_RepaymentsOfNotesPayable_638778067167120438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638778067167120438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638778067167110436" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638778067167120438" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638778067167120438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638778067167110436" xlink:to="us-gaap_ProceedsFromWarrantExercises_638778067167120438" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638778067167120438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638778067167110436" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638778067167120438" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638778067167120438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638778067167120438" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638778067167130438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638778067167130438" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638778067167130438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638778067167130438" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387780671671304381" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387780671671304381" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638778067167130438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638778067167130438" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638778067167130438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638778067167130438" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638778067167130438" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638778067167130438" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638778067167130438" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638778067167130438" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_638778067167140440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638778067167130438" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_638778067167140440" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds" xlink:label="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_638778067167140440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638778067167130438" xlink:to="plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds_638778067167140440" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638778067167140440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638778067167140440" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638778067167140440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638778067167140440" xlink:to="us-gaap_IncomeTaxesPaidNet_638778067167140440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638778067167140440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638778067167140440" xlink:to="us-gaap_InterestPaidNet_638778067167140440" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638778067167150449" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638778067167140440" xlink:to="plx_InterestReceivedNet_638778067167150449" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638778067167150449" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638778067167150449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommercializationAgreements" xlink:type="extended" xlink:title="995210201 - Disclosure - COMMERCIALIZATION AGREEMENTS">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="plx_CommercializationAgreementsAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638778067167161511" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommercializationAgreementsAbstract_637041422967633303" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638778067167161511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipment" xlink:type="extended" xlink:title="995210301 - Disclosure - PROPERTY AND EQUIPMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638778067167161511" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967633303" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638778067167161511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="995210401 - Disclosure - INVENTORIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638778067167161511" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638778067167161511" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement" xlink:type="extended" xlink:title="995210501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638778067167170449" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638778067167170449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommitments" xlink:type="extended" xlink:title="995210601 - Disclosure - COMMITMENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_638778067167170449" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422967633303" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_638778067167170449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeases" xlink:type="extended" xlink:title="995210701 - Disclosure - OPERATING LEASES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638778067167170449" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638778067167170449" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapital" xlink:type="extended" xlink:title="995210801 - Disclosure - SHARE CAPITAL">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638778067167180437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638778067167180437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotes" xlink:type="extended" xlink:title="995210901 - Disclosure - CONVERTIBLE NOTES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638778067167180437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422967633303" xlink:to="us-gaap_DebtDisclosureTextBlock_638778067167180437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="995211001 - Disclosure - FAIR VALUE MEASUREMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638778067167190460" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638778067167190460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureNetEarningsLossPerShare" xlink:type="extended" xlink:title="995211101 - Disclosure - NET EARNINGS (LOSS) PER SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638778067167190460" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638778067167190460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncome" xlink:type="extended" xlink:title="995211201 - Disclosure - TAXES ON INCOME">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638778067167200441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638778067167200441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformation" xlink:type="extended" xlink:title="995211301 - Disclosure - SEGMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638778067167200441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638778067167200441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" xlink:type="extended" xlink:title="995211401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967789587" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638778067167200441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967789587" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638778067167200441" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="995211501 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637041422967789587" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638778067167210440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637041422967789587" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638778067167210440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211601 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638778067167210440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventsTextBlock_638778067167210440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638778067167210440" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638778067167210440" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638778067167220439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638778067167220439" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638778067167220439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638778067167220439" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638778067167220439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638778067167220439" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638778067167220439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638778067167220439" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638778067167220439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638778067167220439" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638778067167220439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638778067167220439" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638778067167220439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638778067167220439" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638778067167220439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638778067167220439" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638778067167220439" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638778067167220439" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638778067167230451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638778067167230451" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638778067167230451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638778067167230451" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638778067167230451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638778067167230451" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638778067167230451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638778067167230451" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638778067167230451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638778067167230451" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638778067167230451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638778067167230451" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638778067167230451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638778067167230451" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638778067167230451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638778067167230451" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="99930103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637041422967804651" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ScheduleOfUsefulLifeTableTextBlock" xlink:label="plx_ScheduleOfUsefulLifeTableTextBlock_638778067167240446" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967804651" xlink:to="plx_ScheduleOfUsefulLifeTableTextBlock_638778067167240446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638778067167240446" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967804651" xlink:to="us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_638778067167240446" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables" xlink:type="extended" xlink:title="99930303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967809657" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638778067167240446" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422967809657" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638778067167240446" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="99930403 - Disclosure - INVENTORIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638778067167250451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638778067167250451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesTables" xlink:type="extended" xlink:title="99930703 - Disclosure - OPERATING LEASES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638778067167250451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638778067167250451" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638778067167250451" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638778067167250451" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalTables" xlink:type="extended" xlink:title="99930803 - Disclosure - SHARE CAPITAL (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638778067167260443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638778067167260443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_638778067167260443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_638778067167260443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638778067167260443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638778067167260443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638778067167260443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638778067167260443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638778067167260443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422967814662" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638778067167260443" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesTables" xlink:type="extended" xlink:title="99930903 - Disclosure - CONVERTIBLE NOTES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422967819664" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638778067167270443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422967819664" xlink:to="us-gaap_StatementTable_638778067167270443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638778067167270443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167270443" xlink:to="us-gaap_DebtInstrumentAxis_638778067167270443" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638778067167270443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638778067167270443" xlink:to="us-gaap_DebtInstrumentNameDomain_638778067167270443" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638778067167270443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638778067167270443" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638778067167270443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638778067167270443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638778067167270443" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638778067167270443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638778067167270443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167270443" xlink:to="us-gaap_StatementLineItems_638778067167270443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_638778067167270443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167270443" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_638778067167270443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureNetEarningsLossPerShareTables" xlink:type="extended" xlink:title="99931103 - Disclosure - NET EARNINGS (LOSS) PER SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638778067167270443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638778067167270443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTables" xlink:type="extended" xlink:title="99931203 - Disclosure - TAXES ON INCOME (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638778067167280841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638778067167280841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638778067167280841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638778067167280841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638778067167280841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638778067167280841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_638778067167280841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_638778067167280841" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638778067167280841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638778067167280841" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ScheduleOfOpenTaxYearsTableTextBlock" xlink:label="plx_ScheduleOfOpenTaxYearsTableTextBlock_638778067167290962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="plx_ScheduleOfOpenTaxYearsTableTextBlock_638778067167290962" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationTables" xlink:type="extended" xlink:title="99931303 - Disclosure - SEGMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638778067167290962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638778067167290962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_638778067167290962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_638778067167290962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" xlink:type="extended" xlink:title="99931403 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638778067167290962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967854703" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638778067167290962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables" xlink:type="extended" xlink:title="99931503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638778067167300822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638778067167300822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638778067167300822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_638778067167300822" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638778067167300822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638778067167300822" xlink:to="us-gaap_TypeOfArrangementAxis_638778067167300822" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167300822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638778067167300822" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167300822" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638778067167300822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167300822" xlink:to="plx_AmendedPfizerAgreementMember_638778067167300822" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638778067167300822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167300822" xlink:to="plx_ChiesiAgreementsMember_638778067167300822" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638778067167310836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638778067167300822" xlink:to="dei_LegalEntityAxis_638778067167310836" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638778067167310836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638778067167310836" xlink:to="dei_EntityDomain_638778067167310836" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638778067167310836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638778067167310836" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638778067167310836" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638778067167310836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638778067167300822" xlink:to="srt_StatementGeographicalAxis_638778067167310836" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638778067167310836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638778067167310836" xlink:to="srt_SegmentGeographicalDomain_638778067167310836" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR_638778067167310836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638778067167310836" xlink:to="country_BR_638778067167310836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638778067167310836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638778067167300822" xlink:to="us-gaap_DebtInstrumentAxis_638778067167310836" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638778067167310836" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638778067167310836" xlink:to="us-gaap_DebtInstrumentNameDomain_638778067167310836" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638778067167320790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638778067167310836" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638778067167320790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638778067167320790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638778067167320790" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638778067167320790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638778067167320790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638778067167300822" xlink:to="plx_SignificantAccountingPoliciesLineItems_638778067167320790" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_638778067167320790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167320790" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_638778067167320790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived_638778067167320790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167320790" xlink:to="plx_MilestonePaymentReceived_638778067167320790" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638778067167320790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167320790" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638778067167320790" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_638778067167320790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167320790" xlink:to="plx_RevenuePerformanceObligationNumber_638778067167320790" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_638778067167320790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167320790" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_638778067167320790" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_638778067167320790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167320790" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_638778067167320790" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638778067167330934" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167320790" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638778067167330934" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638778067167330934" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167320790" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638778067167330934" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails" xlink:type="extended" xlink:title="99940102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638778067167330934" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638778067167330934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638778067167330934" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638778067167330934" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638778067167330934" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167330934" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638778067167330934" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167330934" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember_638778067167340923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167330934" xlink:to="plx_LaboratoryEquipmentMember_638778067167340923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638778067167340923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167330934" xlink:to="us-gaap_FurnitureAndFixturesMember_638778067167340923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638778067167340923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167330934" xlink:to="us-gaap_ComputerEquipmentMember_638778067167340923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638778067167340923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638778067167330934" xlink:to="srt_RangeAxis_638778067167340923" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638778067167340923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638778067167340923" xlink:to="srt_RangeMember_638778067167340923" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638778067167340923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167340923" xlink:to="srt_MinimumMember_638778067167340923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638778067167340923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167340923" xlink:to="srt_MaximumMember_638778067167340923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638778067167340923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638778067167330934" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638778067167340923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638778067167350862" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638778067167340923" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638778067167350862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails" xlink:type="extended" xlink:title="99940103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638778067167350862" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="plx_SignificantAccountingPoliciesTable_638778067167350862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638778067167350862" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638778067167350862" xlink:to="srt_MajorCustomersAxis_638778067167350862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638778067167350862" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638778067167350862" xlink:to="srt_NameOfMajorCustomerDomain_638778067167350862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember_638778067167350862" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638778067167350862" xlink:to="plx_FiocruzMember_638778067167350862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_638778067167350862" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638778067167350862" xlink:to="plx_ChiesiMember_638778067167350862" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638778067167350862" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638778067167350862" xlink:to="plx_PfizerMember_638778067167350862" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638778067167350862" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638778067167350862" xlink:to="plx_SignificantAccountingPoliciesLineItems_638778067167350862" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638778067167360846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167350862" xlink:to="us-gaap_AccountsReceivableNetCurrent_638778067167360846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails" xlink:type="extended" xlink:title="99940104 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (The Impact to the Company's Consolidated Balance Sheet) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638778067167360846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="plx_SignificantAccountingPoliciesTable_638778067167360846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638778067167360846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638778067167360846" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638778067167360846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638778067167360846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638778067167360846" xlink:to="us-gaap_TypeOfAdoptionMember_638778067167360846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_638778067167360846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638778067167360846" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_638778067167360846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_638778067167360846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638778067167360846" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_638778067167360846" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_638778067167360846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638778067167360846" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_638778067167360846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_638778067167360846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain_638778067167360846" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_638778067167360846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638778067167370923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain_638778067167360846" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638778067167370923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638778067167370923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638778067167360846" xlink:to="plx_SignificantAccountingPoliciesLineItems_638778067167370923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_638778067167370923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167370923" xlink:to="us-gaap_ConvertibleDebtCurrent_638778067167370923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638778067167370923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167370923" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638778067167370923" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638778067167370923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638778067167370923" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638778067167370923" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommercializationAgreementsAbstract" xlink:label="plx_CommercializationAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638778067167370923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommercializationAgreementsAbstract" xlink:to="us-gaap_StatementTable_638778067167370923" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638778067167370923" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167370923" xlink:to="us-gaap_TypeOfArrangementAxis_638778067167370923" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167380828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638778067167370923" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167380828" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638778067167380828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167380828" xlink:to="plx_ChiesiAgreementsMember_638778067167380828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_638778067167380828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638778067167380828" xlink:to="plx_ChiesiUSAgreementMember_638778067167380828" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_638778067167380828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_638778067167380828" xlink:to="plx_ChiesiExUSAgreementMember_638778067167380828" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638778067167380828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167370923" xlink:to="srt_RangeAxis_638778067167380828" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638778067167380828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638778067167380828" xlink:to="srt_RangeMember_638778067167380828" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638778067167380828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167380828" xlink:to="srt_MaximumMember_638778067167380828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638778067167380828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167380828" xlink:to="srt_MinimumMember_638778067167380828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638778067167380828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167370923" xlink:to="us-gaap_StatementLineItems_638778067167380828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638778067167380828" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167380828" xlink:to="us-gaap_RepaymentsOfNotesPayable_638778067167380828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_UpfrontNonrefundableNoncreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638778067167390832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167380828" xlink:to="plx_UpfrontNonrefundableNoncreditablePaymentReceivable_638778067167390832" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638778067167390832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167380828" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_638778067167390832" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_638778067167390832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167380828" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_638778067167390832" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638778067167390832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167380828" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_638778067167390832" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_638778067167390832" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167380828" xlink:to="plx_PaymentOnNetSalesPercentage_638778067167390832" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968011145" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638778067167401097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968011145" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638778067167401097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638778067167401097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638778067167401097" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638778067167401097" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167401097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638778067167401097" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167401097" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_LaboratoryEquipmentMember" xlink:label="plx_LaboratoryEquipmentMember_638778067167401097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167401097" xlink:to="plx_LaboratoryEquipmentMember_638778067167401097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FurnitureAndComputerEquipmentMember" xlink:label="plx_FurnitureAndComputerEquipmentMember_638778067167401097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167401097" xlink:to="plx_FurnitureAndComputerEquipmentMember_638778067167401097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638778067167401097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167401097" xlink:to="us-gaap_LeaseholdImprovementsMember_638778067167401097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638778067167401097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638778067167401097" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638778067167401097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638778067167401097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638778067167401097" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638778067167401097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638778067167401097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638778067167401097" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638778067167401097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638778067167401097" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638778067167401097" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638778067167401097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968167243" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638778067167410981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637041422968167243" xlink:to="us-gaap_Depreciation_638778067167410981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638778067167410981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638778067167410981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638778067167410981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638778067167410981" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638778067167410981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638778067167410981" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638778067167410981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638778067167410981" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940402 - Disclosure - INVENTORIES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_353300" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown_638778067167420856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_353300" xlink:to="us-gaap_InventoryWriteDown_638778067167420856" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638778067167420856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_StatementTable_638778067167420856" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_638778067167420856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167420856" xlink:to="us-gaap_RetirementPlanTypeAxis_638778067167420856" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_638778067167420856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis_638778067167420856" xlink:to="us-gaap_RetirementPlanTypeDomain_638778067167420856" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPostretirementLifeInsuranceMember" xlink:label="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_638778067167420856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_638778067167420856" xlink:to="us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_638778067167420856" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ContributionPlansMember" xlink:label="plx_ContributionPlansMember_638778067167420856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain_638778067167420856" xlink:to="plx_ContributionPlansMember_638778067167420856" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638778067167430816" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167420856" xlink:to="srt_RangeAxis_638778067167430816" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638778067167430816" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638778067167430816" xlink:to="srt_RangeMember_638778067167430816" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638778067167430816" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167430816" xlink:to="srt_MaximumMember_638778067167430816" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638778067167430816" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167420856" xlink:to="us-gaap_StatementLineItems_638778067167430816" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeeSeveranceObligationPayment" xlink:label="plx_EmployeeSeveranceObligationPayment_638778067167430816" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167430816" xlink:to="plx_EmployeeSeveranceObligationPayment_638778067167430816" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_638778067167430816" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167430816" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense_638778067167430816" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638778067167430816" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167430816" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638778067167430816" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_638778067167430816" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167430816" xlink:to="us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_638778067167430816" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_638778067167430816" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167430816" xlink:to="us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_638778067167430816" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears" xlink:label="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_638778067167440823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167430816" xlink:to="plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears_638778067167440823" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureCommitmentsDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - COMMITMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422968167243" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638778067167440823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637041422968167243" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638778067167440823" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638778067167440823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638778067167440823" xlink:to="srt_RangeAxis_638778067167440823" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638778067167440823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638778067167440823" xlink:to="srt_RangeMember_638778067167440823" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638778067167440823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167440823" xlink:to="srt_MinimumMember_638778067167440823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638778067167440823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167440823" xlink:to="srt_MaximumMember_638778067167440823" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638778067167440823" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638778067167440823" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638778067167440823" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638778067167450921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_638778067167440823" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638778067167450921" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementTermsMember" xlink:label="us-gaap_RoyaltyAgreementTermsMember_638778067167450921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_638778067167450921" xlink:to="us-gaap_RoyaltyAgreementTermsMember_638778067167450921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638778067167450921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638778067167440823" xlink:to="srt_CounterpartyNameAxis_638778067167450921" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638778067167450921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638778067167450921" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638778067167450921" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OfficeOfIsraeliInnovationAuthorityMember" xlink:label="plx_OfficeOfIsraeliInnovationAuthorityMember_638778067167450921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638778067167450921" xlink:to="plx_OfficeOfIsraeliInnovationAuthorityMember_638778067167450921" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638778067167450921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638778067167440823" xlink:to="us-gaap_TypeOfArrangementAxis_638778067167450921" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167450921" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638778067167450921" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167450921" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638778067167500827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167450921" xlink:to="plx_ChiesiAgreementsMember_638778067167500827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FillFinishAgreementMember" xlink:label="plx_FillFinishAgreementMember_638778067167500827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167450921" xlink:to="plx_FillFinishAgreementMember_638778067167500827" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncollaborativeArrangementTransactionsMember" xlink:label="us-gaap_NoncollaborativeArrangementTransactionsMember_638778067167500827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167450921" xlink:to="us-gaap_NoncollaborativeArrangementTransactionsMember_638778067167500827" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommitmentsAndContingenciesLineItems" xlink:label="plx_CommitmentsAndContingenciesLineItems_638778067167500827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_638778067167440823" xlink:to="plx_CommitmentsAndContingenciesLineItems_638778067167500827" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_RoyaltiesOnSaleOfProducts" xlink:label="plx_RoyaltiesOnSaleOfProducts_638778067167500827" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638778067167500827" xlink:to="plx_RoyaltiesOnSaleOfProducts_638778067167500827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PercentageOfRoyaltiesToGrantReceived" xlink:label="plx_PercentageOfRoyaltiesToGrantReceived_638778067167510826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638778067167500827" xlink:to="plx_PercentageOfRoyaltiesToGrantReceived_638778067167510826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_638778067167510826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638778067167500827" xlink:to="us-gaap_RoyaltyExpense_638778067167510826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_638778067167510826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638778067167500827" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_638778067167510826" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommitmentAmount" xlink:label="plx_CommitmentAmount_638778067167510826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638778067167500827" xlink:to="plx_CommitmentAmount_638778067167510826" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExtendedTermOfAgreement" xlink:label="plx_ExtendedTermOfAgreement_638778067167510826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638778067167500827" xlink:to="plx_ExtendedTermOfAgreement_638778067167510826" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ContractAmountUnderAgreementPayable" xlink:label="plx_ContractAmountUnderAgreementPayable_638778067167510826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638778067167500827" xlink:to="plx_ContractAmountUnderAgreementPayable_638778067167510826" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ContractAmountUnderAgreementFacilityPayable" xlink:label="plx_ContractAmountUnderAgreementFacilityPayable_638778067167510826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638778067167500827" xlink:to="plx_ContractAmountUnderAgreementFacilityPayable_638778067167510826" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_InitialTermOfArrangement" xlink:label="plx_InitialTermOfArrangement_638778067167510826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638778067167500827" xlink:to="plx_InitialTermOfArrangement_638778067167510826" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638778067167520839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_CommitmentsAndContingenciesLineItems_638778067167500827" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638778067167520839" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638778067167520839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost_638778067167520839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638778067167520839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments_638778067167520839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638778067167520839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638778067167520839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638778067167520839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638778067167520839" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638778067167530833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638778067167530833" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638778067167530833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638778067167530833" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638778067167530833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638778067167530833" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638778067167530833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638778067167530833" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638778067167530833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638778067167530833" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638778067167530833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638778067167530833" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638778067167530833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638778067167530833" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638778067167530833" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638778067167530833" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940703 - Disclosure - OPERATING LEASES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638778067167540834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638778067167540834" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638778067167540834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638778067167540834" xlink:to="srt_RangeAxis_638778067167540834" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638778067167540834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638778067167540834" xlink:to="srt_RangeMember_638778067167540834" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638778067167540834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167540834" xlink:to="srt_MinimumMember_638778067167540834" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638778067167540834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167540834" xlink:to="srt_MaximumMember_638778067167540834" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638778067167540834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638778067167540834" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638778067167540834" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167540834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638778067167540834" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167540834" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_638778067167540834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638778067167540834" xlink:to="us-gaap_VehiclesMember_638778067167540834" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_638778067167540834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638778067167540834" xlink:to="plx_DisclosureOfLeasesOperatingLineItems_638778067167540834" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_638778067167551099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638778067167540834" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_638778067167551099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_638778067167551099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638778067167540834" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_638778067167551099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638778067167551099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638778067167540834" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638778067167551099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638778067167551099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638778067167540834" xlink:to="us-gaap_SecurityDeposit_638778067167551099" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_638778067167551099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638778067167540834" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_638778067167551099" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167551099" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167551099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638778067167560814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167551099" xlink:to="us-gaap_AwardTypeAxis_638778067167560814" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167560814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638778067167560814" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167560814" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638778067167560814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167560814" xlink:to="us-gaap_EmployeeStockOptionMember_638778067167560814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638778067167560814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167551099" xlink:to="srt_TitleOfIndividualAxis_638778067167560814" order="2" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638778067167560814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638778067167560814" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638778067167560814" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeesAndDirectorsMember" xlink:label="plx_EmployeesAndDirectorsMember_638778067167560814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638778067167560814" xlink:to="plx_EmployeesAndDirectorsMember_638778067167560814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167560814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167551099" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167560814" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167560814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167560814" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167560814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638778067167560814" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167560814" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638778067167560814" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638778067167570915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167560814" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638778067167570915" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638778067167570915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167560814" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638778067167570915" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638778067167570915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167560814" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638778067167570915" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638778067167570915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167560814" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638778067167570915" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638778067167570915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167560814" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638778067167570915" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638778067167570915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167560814" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638778067167570915" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638778067167570915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638778067167570915" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638778067167570915" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638778067167570915" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638778067167570915" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638778067167570915" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638778067167580845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638778067167570915" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638778067167580845" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638778067167580845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638778067167570915" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638778067167580845" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638778067167580845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638778067167570915" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638778067167580845" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638778067167580845" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638778067167570915" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638778067167580845" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167590539" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167590539" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638778067167590539" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167590539" xlink:to="srt_TitleOfIndividualAxis_638778067167590539" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638778067167590539" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638778067167590539" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638778067167590539" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeeMember" xlink:label="plx_EmployeeMember_638778067167590539" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638778067167590539" xlink:to="plx_EmployeeMember_638778067167590539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638778067167590539" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167590539" xlink:to="us-gaap_AwardTypeAxis_638778067167590539" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167590539" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638778067167590539" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167590539" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638778067167590539" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167590539" xlink:to="us-gaap_RestrictedStockMember_638778067167590539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167590539" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167590539" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167590539" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167590539" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167590539" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167590539" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638778067167600835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167590539" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638778067167600835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638778067167600835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167590539" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638778067167600835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638778067167600835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167590539" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638778067167600835" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638778067167600835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167590539" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638778067167600835" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387780671676008351" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638778067167590539" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6387780671676008351" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638778067167600835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167590539" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638778067167600835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638778067167600835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638778067167600835" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638778067167600835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638778067167600835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638778067167600835" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638778067167600835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638778067167610835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638778067167600835" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638778067167610835" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638778067167610835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638778067167600835" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638778067167610835" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638778067167610835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638778067167600835" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638778067167610835" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638778067167610835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638778067167610835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638778067167610835" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638778067167610835" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638778067167610835" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638778067167610835" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638778067167620883" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice1.03To2.00Member" xlink:label="plx_ExercisePrice1.03To2.00Member_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638778067167620883" xlink:to="plx_ExercisePrice1.03To2.00Member_638778067167620883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice3.55To3.73Member" xlink:label="plx_ExercisePrice3.55To3.73Member_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638778067167620883" xlink:to="plx_ExercisePrice3.55To3.73Member_638778067167620883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice4.69To5.60Member" xlink:label="plx_ExercisePrice4.69To5.60Member_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638778067167620883" xlink:to="plx_ExercisePrice4.69To5.60Member_638778067167620883" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ExercisePrice17.20Member" xlink:label="plx_ExercisePrice17.20Member_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638778067167620883" xlink:to="plx_ExercisePrice17.20Member_638778067167620883" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638778067167610835" xlink:to="us-gaap_AwardTypeAxis_638778067167620883" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638778067167620883" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167620883" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167620883" xlink:to="us-gaap_EmployeeStockOptionMember_638778067167620883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638778067167610835" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638778067167620883" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638778067167620883" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638778067167620883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638778067167620883" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638778067167620883" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638778067167620883" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638778067167620883" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638778067167620883" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638778067167620883" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638778067167620883" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638778067167620883" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_638778067167620883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638778067167620883" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_638778067167620883" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167642410" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968167243_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167642410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638778067167642410" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167642410" xlink:to="us-gaap_AwardTypeAxis_638778067167642410" order="1" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167642410" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638778067167642410" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167642410" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638778067167642410" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167642410" xlink:to="us-gaap_EmployeeStockOptionMember_638778067167642410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167642410" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167642410" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167642410" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638778067167642410" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167642410" xlink:to="us-gaap_SharePrice_638778067167642410" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638778067167642410" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167642410" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638778067167642410" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638778067167650820" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167642410" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638778067167650820" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638778067167650820" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167642410" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638778067167650820" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638778067167650820" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167642410" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638778067167650820" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638778067167650820" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167642410" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638778067167650820" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails" xlink:type="extended" xlink:title="99940805 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638778067167650820" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638778067167650820" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638778067167650820" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638778067167650820" xlink:to="us-gaap_IncomeStatementLocationAxis_638778067167650820" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638778067167660819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638778067167650820" xlink:to="us-gaap_IncomeStatementLocationDomain_638778067167660819" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638778067167660819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638778067167660819" xlink:to="us-gaap_CostOfSalesMember_638778067167660819" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638778067167660819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638778067167660819" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638778067167660819" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638778067167660819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638778067167660819" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_638778067167660819" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638778067167660819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638778067167650820" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638778067167660819" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638778067167660819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638778067167660819" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638778067167660819" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails" xlink:type="extended" xlink:title="99940806 - Disclosure - SHARE CAPITAL (Additional information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167660819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637041422968323658" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167660819" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638778067167670905" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167660819" xlink:to="us-gaap_AwardTypeAxis_638778067167670905" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167670905" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638778067167670905" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167670905" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OptionsAndRestrictedSharesMember" xlink:label="plx_OptionsAndRestrictedSharesMember_638778067167670905" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638778067167670905" xlink:to="plx_OptionsAndRestrictedSharesMember_638778067167670905" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638778067167670905" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_OptionsAndRestrictedSharesMember_638778067167670905" xlink:to="us-gaap_EmployeeStockOptionMember_638778067167670905" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638778067167670905" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_OptionsAndRestrictedSharesMember_638778067167670905" xlink:to="us-gaap_RestrictedStockMember_638778067167670905" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638778067167670905" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167660819" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638778067167670905" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638778067167670905" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638778067167670905" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638778067167670905" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638778067167670905" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638778067167670905" xlink:to="us-gaap_PrivatePlacementMember_638778067167670905" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638778067167670905" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638778067167670905" xlink:to="plx_AtMarketEquityOfferingMember_638778067167670905" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SalesAgreement2021Member" xlink:label="plx_SalesAgreement2021Member_638778067167681121" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_AtMarketEquityOfferingMember_638778067167670905" xlink:to="plx_SalesAgreement2021Member_638778067167681121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SalesAgreement2023Member" xlink:label="plx_SalesAgreement2023Member_638778067167681121" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_AtMarketEquityOfferingMember_638778067167670905" xlink:to="plx_SalesAgreement2023Member_638778067167681121" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638778067167681121" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167660819" xlink:to="us-gaap_PlanNameAxis_638778067167681121" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638778067167681121" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638778067167681121" xlink:to="us-gaap_PlanNameDomain_638778067167681121" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_638778067167681121" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638778067167681121" xlink:to="plx_EmployeeStockIncentivePlan2006Member_638778067167681121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638778067167681121" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167660819" xlink:to="us-gaap_DebtInstrumentAxis_638778067167681121" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638778067167681121" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638778067167681121" xlink:to="us-gaap_DebtInstrumentNameDomain_638778067167681121" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_Notes2024Member" xlink:label="plx_Notes2024Member_638778067167690523" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638778067167681121" xlink:to="plx_Notes2024Member_638778067167690523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638778067167690523" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167660819" xlink:to="srt_RangeAxis_638778067167690523" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638778067167690523" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638778067167690523" xlink:to="srt_RangeMember_638778067167690523" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638778067167690523" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167690523" xlink:to="srt_MinimumMember_638778067167690523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638778067167690523" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167690523" xlink:to="srt_MaximumMember_638778067167690523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638778067167660819" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638778067167690523" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_CommonStockSharesAuthorized_638778067167690523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638778067167700831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_PreferredStockSharesAuthorized_638778067167700831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638778067167700831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638778067167700831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CommonStockNumberOfVotingRights" xlink:label="plx_CommonStockNumberOfVotingRights_638778067167700831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="plx_CommonStockNumberOfVotingRights_638778067167700831" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638778067167700831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638778067167700831" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638778067167700831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638778067167700831" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638778067167700831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638778067167700831" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638778067167700831" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638778067167700831" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638778067167710822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_638778067167710822" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638778067167710822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638778067167710822" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638778067167710822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638778067167710822" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638778067167710822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638778067167710822" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638778067167710822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638778067167710822" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638778067167720895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638778067167720895" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638778067167720895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638778067167720895" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638778067167720895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638778067167720895" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638778067167720895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638778067167720895" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638778067167720895" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_ProceedsFromWarrantExercises_638778067167720895" order="18" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_638778067167730883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="plx_SaleOfStockMaximumOfferingPrice_638778067167730883" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PercentageOfCommissionOnSaleOfShares" xlink:label="plx_PercentageOfCommissionOnSaleOfShares_638778067167730883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="plx_PercentageOfCommissionOnSaleOfShares_638778067167730883" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638778067167730883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638778067167730883" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638778067167730883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638778067167730883" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638778067167730883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638778067167730883" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638778067167740830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_638778067167740830" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PaymentsToDebtHoldersOnConversion" xlink:label="plx_PaymentsToDebtHoldersOnConversion_638778067167740830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638778067167690523" xlink:to="plx_PaymentsToDebtHoldersOnConversion_638778067167740830" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637520135041292011" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638778067167751033" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637520135041292011" xlink:to="us-gaap_StatementTable_638778067167751033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638778067167751033" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167751033" xlink:to="us-gaap_DebtInstrumentAxis_638778067167751033" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638778067167751033" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638778067167751033" xlink:to="us-gaap_DebtInstrumentNameDomain_638778067167751033" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638778067167751033" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638778067167751033" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638778067167751033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638778067167751033" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167751033" xlink:to="us-gaap_StatementLineItems_638778067167751033" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_638778067167751033" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167751033" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_638778067167751033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638778067167751033" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167751033" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638778067167751033" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsIncurred" xlink:label="us-gaap_InterestCostsIncurred_638778067167751033" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167751033" xlink:to="us-gaap_InterestCostsIncurred_638778067167751033" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422968636206" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638778067167760878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422968636206" xlink:to="us-gaap_StatementTable_638778067167760878" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638778067167760878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167760878" xlink:to="us-gaap_DebtInstrumentAxis_638778067167760878" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638778067167760878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638778067167760878" xlink:to="us-gaap_DebtInstrumentNameDomain_638778067167760878" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638778067167760878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638778067167760878" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638778067167760878" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638778067167760878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638778067167760878" xlink:to="us-gaap_StatementLineItems_638778067167760878" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638778067167760878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167760878" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638778067167760878" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638778067167760878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167760878" xlink:to="us-gaap_DebtInstrumentTerm_638778067167760878" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638778067167760878" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638778067167760878" xlink:to="us-gaap_RepaymentsOfNotesPayable_638778067167760878" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - NET EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638778067167771025" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638778067167771025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638778067167771025" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638778067167771025" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638778067167771025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638778067167771025" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638778067167771025" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638778067167771025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_638778067167771025" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638778067167771025" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_638778067167771025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OutstandingStockOptionsWarrantsAnd2024NotesMember" xlink:label="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_638778067167771025" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638778067167771025" xlink:to="plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_638778067167771025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638778067167771025" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638778067167771025" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638778067167771025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638778067167780850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638778067167771025" xlink:to="us-gaap_NetIncomeLossAbstract_638778067167780850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638778067167780850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638778067167780850" xlink:to="us-gaap_NetIncomeLoss_638778067167780850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638778067167780850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638778067167780850" xlink:to="us-gaap_DilutiveSecurities_638778067167780850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638778067167780850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638778067167780850" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638778067167780850" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638778067167780850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638778067167771025" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638778067167780850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638778067167780850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638778067167780850" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638778067167780850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638778067167780850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638778067167780850" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638778067167780850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638778067167790865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638778067167780850" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638778067167790865" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638778067167790865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638778067167780850" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638778067167790865" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638778067167790865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638778067167771025" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638778067167790865" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638778067167790865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638778067167790865" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638778067167790865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638778067167790865" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638778067167790865" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638778067167790865" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638778067167800997" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638778067167800997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638778067167800997" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638778067167800997" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638778067167800997" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_DeferredTaxAssetsOtherTimingDifferences" xlink:label="plx_DeferredTaxAssetsOtherTimingDifferences_638778067167800997" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638778067167800997" xlink:to="plx_DeferredTaxAssetsOtherTimingDifferences_638778067167800997" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638778067167800997" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638778067167800997" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638778067167800997" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638778067167800997" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638778067167800997" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638778067167800997" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638778067167800997" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638778067167800997" xlink:to="us-gaap_DeferredTaxAssetsNet_638778067167800997" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - TAXES ON INCOME (Reconciliation of Tax Expense) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638778067167811142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638778067167811142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638778067167811142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638778067167811142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638778067167811142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638778067167811142" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638778067167811142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638778067167811142" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition" xlink:label="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_638778067167811142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition_638778067167811142" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_EffectiveIncomeTaxRateReconciliationWithholdingTax" xlink:label="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_638778067167811142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="plx_EffectiveIncomeTaxRateReconciliationWithholdingTax_638778067167811142" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638778067167811142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638778067167811142" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails" xlink:type="extended" xlink:title="99941204 - Disclosure - TAXES ON INCOME (Valuation Allowance) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638778067167821113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638778067167821113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod" xlink:label="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_638778067167821113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod_638778067167821113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod" xlink:label="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_638778067167821113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod_638778067167821113" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_6387780671678211131" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_6387780671678211131" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails" xlink:type="extended" xlink:title="99941205 - Disclosure - TAXES ON INCOME (Uncertain Tax Position) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638778067167821113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefits_638778067167821113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638778067167821113" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638778067167821113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638778067167830821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_UnrecognizedTaxBenefits_638778067167830821" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails" xlink:type="extended" xlink:title="99941206 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable_638778067167830821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_IncomeTaxContingencyTable_638778067167830821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638778067167830821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable_638778067167830821" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638778067167830821" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638778067167830821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638778067167830821" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638778067167830821" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_UsIsraelMember" xlink:label="plx_UsIsraelMember_638778067167830821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638778067167830821" xlink:to="plx_UsIsraelMember_638778067167830821" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US_638778067167830821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638778067167830821" xlink:to="country_US_638778067167830821" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638778067167830821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable_638778067167830821" xlink:to="srt_RangeAxis_638778067167830821" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638778067167830821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638778067167830821" xlink:to="srt_RangeMember_638778067167830821" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638778067167840843" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167830821" xlink:to="srt_MinimumMember_638778067167840843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638778067167840843" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167830821" xlink:to="srt_MaximumMember_638778067167840843" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems_638778067167840843" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable_638778067167830821" xlink:to="us-gaap_IncomeTaxContingencyLineItems_638778067167840843" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear_638778067167840843" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems_638778067167840843" xlink:to="us-gaap_OpenTaxYear_638778067167840843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="extended" xlink:title="99941207 - Disclosure - TAXES ON INCOME (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_IncomeTaxDisclosureTable" xlink:label="plx_IncomeTaxDisclosureTable_638778067167840843" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="plx_IncomeTaxDisclosureTable_638778067167840843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638778067167840843" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638778067167840843" xlink:to="us-gaap_TypeOfArrangementAxis_638778067167840843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167850850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638778067167840843" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167850850" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638778067167850850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167850850" xlink:to="plx_ChiesiAgreementsMember_638778067167850850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_638778067167850850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638778067167840843" xlink:to="srt_ConsolidatedEntitiesAxis_638778067167850850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_638778067167850850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis_638778067167850850" xlink:to="srt_ConsolidatedEntitiesDomain_638778067167850850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SubsidiariesMember" xlink:label="srt_SubsidiariesMember_638778067167850850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain_638778067167850850" xlink:to="srt_SubsidiariesMember_638778067167850850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember" xlink:label="srt_ParentCompanyMember_638778067167850850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain_638778067167850850" xlink:to="srt_ParentCompanyMember_638778067167850850" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638778067167850850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638778067167840843" xlink:to="srt_RangeAxis_638778067167850850" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638778067167850850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638778067167850850" xlink:to="srt_RangeMember_638778067167850850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638778067167850850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638778067167850850" xlink:to="srt_MaximumMember_638778067167850850" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638778067167850850" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638778067167840843" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638778067167850850" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638778067167860989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638778067167850850" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638778067167860989" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_TaxYearThereafterMember" xlink:label="plx_TaxYearThereafterMember_638778067167860989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638778067167860989" xlink:to="plx_TaxYearThereafterMember_638778067167860989" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_IncomeTaxDisclosureLineItems" xlink:label="plx_IncomeTaxDisclosureLineItems_638778067167860989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureTable_638778067167840843" xlink:to="plx_IncomeTaxDisclosureLineItems_638778067167860989" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638778067167860989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638778067167860989" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638778067167860989" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_MilestonePaymentReceived" xlink:label="plx_MilestonePaymentReceived_638778067167860989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638778067167860989" xlink:to="plx_MilestonePaymentReceived_638778067167860989" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638778067167860989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638778067167860989" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638778067167860989" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_638778067167860989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638778067167860989" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_638778067167860989" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod" xlink:label="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_638778067167860989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638778067167860989" xlink:to="plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod_638778067167860989" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638778067167870826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IncomeTaxDisclosureLineItems_638778067167860989" xlink:to="us-gaap_OperatingLossCarryforwards_638778067167870826" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638778067167870826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_NumberOfOperatingSegments_638778067167870826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638778067167870826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_Revenues_638778067167870826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638778067167870826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_LaborAndRelatedExpense_638778067167870826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_638778067167870826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_638778067167870826" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638778067167870826" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_OtherNonoperatingExpense_638778067167870826" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638778067167880855" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_OtherNonoperatingIncome_638778067167880855" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638778067167880855" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_Depreciation_638778067167880855" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638778067167880855" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638778067167880855" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638778067167880855" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638778067167880855" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638778067167880855" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638778067167880855" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638778067167880855" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_NetIncomeLoss_638778067167880855" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_638778067167880855" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_638778067167880855" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="99941302 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638778067167890932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_3" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638778067167890932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638778067167890932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638778067167890932" xlink:to="srt_MajorCustomersAxis_638778067167890932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638778067167890932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638778067167890932" xlink:to="srt_NameOfMajorCustomerDomain_638778067167890932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638778067167890932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638778067167890932" xlink:to="plx_PfizerMember_638778067167890932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember_638778067167890932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638778067167890932" xlink:to="plx_FiocruzMember_638778067167890932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_638778067167890932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638778067167890932" xlink:to="plx_ChiesiMember_638778067167890932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638778067167890932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638778067167890932" xlink:to="srt_ProductOrServiceAxis_638778067167890932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638778067167901036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638778067167890932" xlink:to="srt_ProductsAndServicesDomain_638778067167901036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638778067167901036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638778067167901036" xlink:to="us-gaap_ProductMember_638778067167901036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638778067167901036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638778067167901036" xlink:to="us-gaap_LicenseAndServiceMember_638778067167901036" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638778067167901036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638778067167890932" xlink:to="us-gaap_SegmentReportingInformationLineItems_638778067167901036" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638778067167901036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638778067167901036" xlink:to="us-gaap_Revenues_638778067167901036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638778067167901036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422968852328" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638778067167901036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OtherAssetsInstitutionsCurrent" xlink:label="plx_OtherAssetsInstitutionsCurrent_638778067167901036" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638778067167901036" xlink:to="plx_OtherAssetsInstitutionsCurrent_638778067167901036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638778067167910818" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638778067167901036" xlink:to="us-gaap_PrepaidExpenseCurrent_638778067167910818" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_OtherAssetsSundryCurrent" xlink:label="plx_OtherAssetsSundryCurrent_638778067167910818" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638778067167901036" xlink:to="plx_OtherAssetsSundryCurrent_638778067167910818" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638778067167910818" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_638778067167901036" xlink:to="us-gaap_OtherAssetsCurrent_638778067167910818" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="99941402 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422969008821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422969008821" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638778067167910818" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638778067167910818" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638778067167910818" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" xlink:to="us-gaap_InterestPayableCurrent_638778067167910818" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638778067167910818" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" xlink:to="us-gaap_AccruedVacationCurrent_638778067167910818" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638778067167910818" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638778067167910818" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638778067167920824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638778067167920824" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638778067167920824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" xlink:to="us-gaap_TaxesPayableCurrent_638778067167920824" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent_638778067167920824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" xlink:to="plx_PayableToCustomerCurrent_638778067167920824" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_ReserveForDeductionsFromRevenueCurrent" xlink:label="plx_ReserveForDeductionsFromRevenueCurrent_638778067167920824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" xlink:to="plx_ReserveForDeductionsFromRevenueCurrent_638778067167920824" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638778067167920824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638778067167920824" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638778067167920824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638778067167910818" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638778067167920824" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="99941501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637041422969008821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638778067167920824" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637041422969008821" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638778067167920824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638778067167930840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638778067167920824" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638778067167930840" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638778067167930840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638778067167930840" xlink:to="us-gaap_RelatedPartyDomain_638778067167930840" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember_638778067167930840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638778067167930840" xlink:to="us-gaap_RelatedPartyMember_638778067167930840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638778067167930840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638778067167920824" xlink:to="srt_CounterpartyNameAxis_638778067167930840" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638778067167930840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638778067167930840" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638778067167930840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638778067167930840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638778067167930840" xlink:to="srt_DirectorMember_638778067167930840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638778067167930840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638778067167920824" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638778067167930840" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638778067167930840" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638778067167930840" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_638778067167930840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_638778067167940538" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638778067167930840" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_638778067167940538" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638778067167940538" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638778067167940538" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638778067167940538" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638778067167940538" xlink:to="us-gaap_SubsequentEventTypeAxis_638778067167940538" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638778067167940538" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638778067167940538" xlink:to="us-gaap_SubsequentEventTypeDomain_638778067167940538" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638778067167940538" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638778067167940538" xlink:to="us-gaap_SubsequentEventMember_638778067167940538" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638778067167940538" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638778067167940538" xlink:to="us-gaap_TypeOfArrangementAxis_638778067167940538" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167940538" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638778067167940538" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167940538" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember_638778067167950841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167940538" xlink:to="plx_PfizerAgreementMember_638778067167950841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_638778067167950841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638778067167940538" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_638778067167950841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638778067167950841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638778067167940538" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638778067167950841" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638778067167950841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638778067167950841" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638778067167950841" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_638778067167950841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638778067167950841" xlink:to="plx_AtMarketEquityOfferingMember_638778067167950841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_SalesAgreement2023Member" xlink:label="plx_SalesAgreement2023Member_638778067167950841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_AtMarketEquityOfferingMember_638778067167950841" xlink:to="plx_SalesAgreement2023Member_638778067167950841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638778067167950841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638778067167950841" xlink:to="us-gaap_PrivatePlacementMember_638778067167950841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638778067167950841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638778067167940538" xlink:to="us-gaap_SubsequentEventLineItems_638778067167950841" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers_638778067167960860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638778067167950841" xlink:to="us-gaap_ProceedsFromCustomers_638778067167960860" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638778067167960860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638778067167950841" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638778067167960860" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638778067167960860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638778067167950841" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638778067167960860" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638778067167960860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638778067167950841" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638778067167960860" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638778067167960860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638778067167950841" xlink:to="us-gaap_ProceedsFromWarrantExercises_638778067167960860" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20241231.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638778067167960860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638778067167950841" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_638778067167960860" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638778067167960860" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638778067167950841" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638778067167960860" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638778067167970966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638778067167950841" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638778067167970966" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" />
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" />
  <link:presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 14, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,032,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Kesselman & Kesselman C.P.A.s<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel Aviv, Israel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 2pt 0pt;">Portions of the registrant&#8217;s proxy statement related to its 2025 Annual Stockholders&#8217; Meeting to be filed subsequently are incorporated by reference into Part III of this Annual Report on Form 10-K. Except as expressly incorporated by reference, the registrant&#8217;s proxy statement shall not be deemed to be part of this report.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,760<span></span>
</td>
<td class="nump">$ 23,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">15,070<span></span>
</td>
<td class="nump">20,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">5,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">21,243<span></span>
</td>
<td class="nump">19,045<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">60,078<span></span>
</td>
<td class="nump">69,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,591<span></span>
</td>
<td class="nump">4,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">2,856<span></span>
</td>
<td class="nump">3,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,430<span></span>
</td>
<td class="nump">5,909<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">73,417<span></span>
</td>
<td class="nump">84,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">4,533<span></span>
</td>
<td class="nump">4,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent', window );">Other</a></td>
<td class="nump">19,588<span></span>
</td>
<td class="nump">19,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,251<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,621<span></span>
</td>
<td class="nump">45,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,026<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">4,585<span></span>
</td>
<td class="nump">5,335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,206<span></span>
</td>
<td class="nump">50,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value: Authorized - as of December 31, 2023 and 2024, 185,000,000 shares; issued and outstanding - as of December 31, 2023 and 2024, 72,952,124 and 75,850,275 shares, respectively</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">421,528<span></span>
</td>
<td class="nump">415,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(378,393)<span></span>
</td>
<td class="num">(381,549)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">43,211<span></span>
</td>
<td class="nump">33,569<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 73,417<span></span>
</td>
<td class="nump">$ 84,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, issued</a></td>
<td class="nump">75,850,275<span></span>
</td>
<td class="nump">72,952,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, outstanding</a></td>
<td class="nump">75,850,275<span></span>
</td>
<td class="nump">72,952,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 53,399<span></span>
</td>
<td class="nump">$ 65,494<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="num">(24,319)<span></span>
</td>
<td class="num">(22,982)<span></span>
</td>
<td class="num">(19,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="num">(12,970)<span></span>
</td>
<td class="num">(17,093)<span></span>
</td>
<td class="num">(29,349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="num">(12,193)<span></span>
</td>
<td class="num">(14,959)<span></span>
</td>
<td class="num">(11,711)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="nump">3,917<span></span>
</td>
<td class="nump">10,460<span></span>
</td>
<td class="num">(13,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(1,062)<span></span>
</td>
<td class="num">(3,180)<span></span>
</td>
<td class="num">(2,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">1,299<span></span>
</td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES), NET</a></td>
<td class="nump">237<span></span>
</td>
<td class="num">(1,894)<span></span>
</td>
<td class="num">(1,383)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="nump">4,154<span></span>
</td>
<td class="nump">8,566<span></span>
</td>
<td class="num">(14,397)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAXES ON INCOME</a></td>
<td class="num">(1,222)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="num">(530)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 2,932<span></span>
</td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)</a></td>
<td class="nump">72,530,698<span></span>
</td>
<td class="nump">67,512,527<span></span>
</td>
<td class="nump">48,472,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)</a></td>
<td class="nump">81,057,176<span></span>
</td>
<td class="nump">82,424,016<span></span>
</td>
<td class="nump">48,472,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 52,981<span></span>
</td>
<td class="nump">$ 40,418<span></span>
</td>
<td class="nump">$ 25,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">$ 25,076<span></span>
</td>
<td class="nump">$ 22,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 368,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (374,934)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,036)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="nump">7,473,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="nump">759,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,927)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(389,861)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,640)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">53,790,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Convertible notes conversions</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Convertible notes conversions (in shares)</a></td>
<td class="nump">4,691,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="nump">1,371,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">538,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,312<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance (ASU 2020-06) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(381,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,952,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="nump">2,216,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="nump">681,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 421,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (378,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,211<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">75,850,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,850,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 2,932<span></span>
</td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,253<span></span>
</td>
<td class="nump">3,448<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net</a></td>
<td class="nump">310<span></span>
</td>
<td class="num">(446)<span></span>
</td>
<td class="num">(989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="num">(151)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Changes in deferred income tax asset</a></td>
<td class="nump">236<span></span>
</td>
<td class="num">(3,092)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on sale of fixed assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnDebtConversion', window );">Gain on conversions of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(421)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contracts liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,178)<span></span>
</td>
<td class="num">(7,162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable-trade and other assets</a></td>
<td class="nump">2,317<span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="num">(1,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets, net</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(2,198)<span></span>
</td>
<td class="num">(2,241)<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">5,295<span></span>
</td>
<td class="num">(4,804)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">8,674<span></span>
</td>
<td class="num">(1,318)<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Investment in bank deposits</a></td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(20,420)<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromWithdrawalOfShortTermDeposits', window );">Short-term deposit withdrawal</a></td>
<td class="nump">20,420<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,282)<span></span>
</td>
<td class="num">(1,149)<span></span>
</td>
<td class="num">(628)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts paid (funded) in respect of employee rights upon retirement, net</a></td>
<td class="nump">80<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">4,221<span></span>
</td>
<td class="num">(16,711)<span></span>
</td>
<td class="num">(5,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment for convertible notes redemption</a></td>
<td class="num">(20,420)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">3,626<span></span>
</td>
<td class="nump">23,954<span></span>
</td>
<td class="nump">8,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(16,794)<span></span>
</td>
<td class="nump">24,666<span></span>
</td>
<td class="nump">8,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">25<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(3,874)<span></span>
</td>
<td class="nump">6,523<span></span>
</td>
<td class="num">(21,874)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</a></td>
<td class="nump">23,634<span></span>
</td>
<td class="nump">17,111<span></span>
</td>
<td class="nump">38,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</a></td>
<td class="nump">19,760<span></span>
</td>
<td class="nump">23,634<span></span>
</td>
<td class="nump">17,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes conversions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds', window );">Partial settlement of liability for employee rights upon retirement through transfer of the related funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Tax paid</a></td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 1,487<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on conversion of convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of partial settlement of liability for employee rights upon retirement through transfer of related funds in non-cash financing and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromWithdrawalOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from the withdrawal of short-term deposits during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromWithdrawalOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix BV (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio (pegunigalsidase alfa), each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The situation could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of December&#160;31, 2024, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Functional currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#8211;&#160;exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#8211;&#160;historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Accounts Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. As of December&#160;31, 2024 and 2023, the allowance was negligible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">No write-off activity and recoveries for the periods presented were recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10-15</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leasehold improvements are amortized by the straight-line method over the shorter of (i)&#160;the expected lease term and (ii)&#160;the estimated useful life of the improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">j.&#160;&#160;&#160;&#160;Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Deferred income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Uncertainty in income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained. Liabilities relating to uncertain tax positions are classified as current in the consolidated balance sheets to the extent the Company anticipates making payments within one year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">k.&#160;&#160;&#160;&#160;Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with a Company&#8217;s customer is based on either fixed amounts or variable amounts. Variable amounts are based on the average net selling price of the drug product in the applicable territory. The Company estimates the variable consideration and recognizes revenue only to the extent the variable consideration is probable and that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;) as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing. See also <a href="#_k.__"><span style="font-style:normal;font-weight:normal;">revenue from selling products</span></a> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC&#160;606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely amount method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA in 2023, the Company received a milestone payment equal to $20.0&#160;million which was recognized as revenue from license and R&amp;D services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">3.    Revenue from R&amp;D services</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">l.&#160;&#160;&#160;&#160;Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company&#8217;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, the accounts receivables balance was composed of $0.7&#160;million from Chiesi and $4.6&#160;million from Pfizer and as of December&#160;31, 2024, the accounts receivables balance was composed of $1.7&#160;million from Fiocruz and $1.2&#160;million from Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">n.&#160;&#160;&#160;&#160;Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. <span style="background:#ffffff;">This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The Company measures compensation expense for </span>restricted stock <span style="background:#ffffff;">based on the market value of the underlying stock at the date of grant</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected to recognize compensation cost for awards to employees with only service conditions that has a graded vesting schedule using the accelerated method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elects to account for forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">o.&#160;&#160;&#160;&#160;Net earnings (loss) per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing (a)&#160;the net income that includes addition of financial expenses related to convertible notes by (b)&#160;the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options and non-vested restricted stock granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">p.&#160;&#160;&#160;&#160;Convertible notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate.&#160;The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January 1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost. See <a href="#rNewaccountingpronouncements_158576"><span style="font-style:normal;font-weight:normal;">Note 1(r)</span></a>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">q.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12&#160;months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">r.&#160;&#160;&#160;&#160;New accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently adopted accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued&#160;ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)&#8221; (&#8220;ASU 2020-06&#8221;).&#160;ASU&#160;2020-06&#160;simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#8212;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06&#160;using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital.&#160;The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods.&#160;Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability.&#160;</span><span style="background:#ffffff;">The impact to the Company&#8217;s consolidated balance sheet as of January&#160;1, 2024 resulting from its adoption of ASU 2020-06 is as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169</p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 415,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 414,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 224</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;) and included within each reported measure of segment profit or loss and an amount and description of its composition for other segment items. The Company adopted this standard in the current period retrospectively to all prior periods presented in its consolidated financial statements. See </span><a href="#_NOTE_13_"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Note&#160;13</span></a><span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMERCIALIZATION AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommercializationAgreementsAbstract', window );"><strong>COMMERCIALIZATION AGREEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COMMERCIALIZATION AGREEMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- COMMERCIALIZATION AGREEMENTS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In October&#160;2015, the Company entered into the Amended Pfizer Agreement with Pfizer that amended and restated the Pfizer Agreement of November&#160;30, 2009. Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 54pt;">Protalix Ltd. also agreed to provide Pfizer with:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">1.</span>Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">2.</span>Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">b.</b>&#160;&#160;&#160;&#160;In October&#160;2017, Protalix&#160;Ltd. entered into the Chiesi Ex-U.S. Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter&#160;&#8211;<span style="direction:rtl;">&#160;</span>the drug) for the treatment of Fabry disease. Under the terms of the Chiesi Ex-U.S. Agreement, Protalix&#160;Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. At the effective date, Protalix&#160;Ltd. had maintained the exclusive commercialization rights to the drug in the United States, which rights were subsequently granted to Chiesi in July&#160;2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix&#160;Ltd. is mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted and (ii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$10.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$320.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Ex-U.S.Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">35%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix Ltd. will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Chiesi does not have sublicensing rights (except for certain territories).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In July 2018, Protalix Ltd. entered into the Chiesi US Agreement with respect to the commercialization of the drug for the treatment of Fabry disease. Under the terms of the Chiesi US Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets in the United States. Protalix Ltd. is mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted, (ii)&#160;continuing certain clinical development efforts in relation to the drug after a regulatory approval is granted and (iii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#8217;s requests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The consideration consists of the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Upfront, non-refundable payment of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$25.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$20.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in development costs, capped at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$7.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million per&#160;year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payments for additional studies, as may be approved from time to time by Chiesi.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Milestone payments of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$760.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi US Agreement, which has been reduced to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$735.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Additional payments as consideration for the supply of the drug. The payment will vary from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">40%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of Chiesi&#8217;s average selling price of the drug, depending on the amount of annual sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Protalix will be the sole manufacturer of the drug.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Chiesi does not have sublicensing rights.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;">c.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">On June&#160;18, 2013, Protalix Ltd. entered into the Brazil Agreement with Fiocruz for BioManguinhos. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommercializationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommercializationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3 - PROPERTY AND EQUIPMENT</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Composition of property and equipment grouped by major classifications is as follows:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,043</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,374</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,913</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,330</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less &#8211; accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,688)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,739)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,591</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>Depreciation in respect of property and equipment totaled approximately $1.1&#160;million, $1.2&#160;million and $1.3&#160;million for the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;- INVENTORIES</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inventories at December&#160;31, 2023 and 2024 consisted of the following:</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,549</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,245</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,449</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,243</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;</b>During the&#160;years ended December&#160;31, 2022, 2023 and 2024, the Company recorded approximately $0.04&#160;million, $0.8&#160;million and $0.09&#160;million, respectively, for write-down of inventory under cost of goods sold.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;5&#160;- LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest&#160;monthly salary&#160;- one&#160;month&#8217;s salary for each&#160;year employed) is recorded on the Company&#8217;s balance sheets under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#8217;s balance sheets under &#8220;Funds in respect of employee rights upon retirement.&#8221; These policies are the Company&#8217;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December&#160;31, 2022, 2023 and 2024, the Company deposited approximately $96,000, $142,000 and $<span style="direction:rtl;">32,000</span>, respectively, with insurance companies in connection with its severance payment obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#8217;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plans&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The amounts of severance pay expenses were approximately $945,000, $801,000 and $<span style="direction:rtl;">820,000</span> for each of the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively, of which approximately $800,000, $798,000 and $<span style="direction:rtl;">859,000</span> in the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively, were in respect of the Contribution Plans. Gain (loss) on amounts funded in respect of employee rights upon retirement totaled approximately $(3,000), $50,000 and $18,000 for the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company expects to contribute approximately $<span style="direction:rtl;">956,000 </span>in the<span style="direction:rtl;"> </span>year ending December&#160;31, 2025 to insurance companies in connection with its severance liabilities, approximately $<span style="direction:rtl;">931,000 </span>of which will be contributed to one or more Contribution Plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">During the five-year period following December&#160;31, 2024, the Company expects that up to 10 employees may retire upon normal retirement age.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;6&#160;- COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Royalty Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is obligated to pay royalties to the National Authority for Technological Innovation (&#8220;NATI&#8221;) on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Israeli Innovation Authority (IIA). At the time the grants were received, successful development of the related projects was not assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the IIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Under the terms of the applicable funding arrangements, royalties of 3% to 6% are payable on the sale of products developed from projects funded by NATI or the IIA, which payments shall not exceed, in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January&#160;1, 2001, interest at an annual rate based on SOFR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will, subject to certain exceptions, be required to pay an increased total amount of royalties, depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Royalty expenses to NATI or the IIA are included in the statement of operations as a component of the cost of revenues and were approximately $1.2&#160;million, $1.9&#160;million and $1.6&#160;million during the years ended December&#160;31, 2022, 2023 and 2024, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">At December&#160;31, 2023 and 2024, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $35.5&#160;million and $33.9&#160;million, respectively (without interest, assuming 100% of the funds are payable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Subcontracting Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December&#160;31, 2024, total commitments under said agreements were approximately $1.5&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Fill/Finish Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:10pt;">On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#8220;F/F&#160;Agreement&#8221;) and a Letter Agreement, in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the global launch of pegunigalsidase alfa. The F/F&#160;Agreement did not change the terms and conditions of the Chiesi Agreements. Subsequently, in November 2024, the Company and Chiesi amended the F/F&#160;Agreement to provide that a different Chiesi facility may act as a secondary supplier of such services and that the F/F&#160;Agreement shall have an initial term of </span><span style="font-size:10pt;">10&#160;years</span><span style="font-size:10pt;">, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement. Prior to expiration of the initial term, the term may be extended by mutual agreement for an additional period of </span><span style="font-size:10pt;">seven years</span><span style="font-size:10pt;"> upon mutual written agreement prior to expiration of the initial term. Under the F/F&#160;Agreement, the Company is obligated to pay to Chiesi an amount equal to </span>&#8364;2.5&#160;million in connection with the necessary technology </p><p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;margin:0pt 0pt 0pt 54pt;">transfer, QA tests and capital expenditures. <span style="font-size:10pt;">Such amount is to be paid over the term of the F/F agreement based on the actual vials produced by Chiesi thereunder. Under the amendment, the Company and Chiesi agreed to share equally the costs of establishing the new facility as an alternative source for Fill/Finish. The Company&#8217;s share of such costs amounting to </span><span style="font-size:10pt;">$400,000</span><span style="font-size:10pt;"> shall be due and payable upon Chiesi&#8217;s completion of the manufacture of the requisite validation batches and issuance of the process validation report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 7 - OPERATING LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is a party to several lease agreements for its facilities, the latest of which has been extended until 2026. The Company has the option to extend certain of such agreements on one additional occasion for an additional five-year period. During the extended lease period, the aggregate&#160;monthly rental payments will increase by 7.5%-10% for the option. The Company expects to exercise the final option in future periods. As of December&#160;31, 2024, the Company provided bank guarantees of approximately $513,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company entered into several three-year leases for vehicles which are regularly amended as new vehicles are leased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the years ended December&#160;31, 2022, 2023 and 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.89%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of December&#160;31, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,500</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,241</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,085</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,040</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,003</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,869</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,343</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,526</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;8&#160;- SHARE CAPITAL</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;Authorized Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Under the Company&#8217;s Certificate of Incorporation, as amended, the Company is authorized to issue 185,000,000 shares of Common Stock and 100,000,000 shares of preferred stock, par value $0.0001 per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">b.</b></span>Rights of the Company&#8217;s Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s Common Stock is listed on the NYSE American. The Company voluntarily delisted its Common Stock from the Tel Aviv Stock Exchange effective March&#160;22, 2023. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Stock based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On December&#160;14, 2006, the Board of Directors adopted the Protalix BioTherapeutics,&#160;Inc. 2006 Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The Plan has since been amended to, among other things, increase the number of shares of Common Stock available under the Plan to 17,475,171 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&#160;102 and 102A of the Israeli Income Tax Ordinance (the &#8220;Ordinance&#8221;). Each option grant made to an Israeli citizen is subject to the track chosen by the Company, either Section&#160;102 or Section&#160;102A of the Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#8217;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section&#160;3(i) of the Ordinance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2024, 4,139,412 shares of Common Stock remain available for grant under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The vesting period of the outstanding options and restricted shares is generally <span style="-sec-ix-hidden:Hidden_HsTYEK9eRkCkgOq9_9rEew;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or four years from the date of grant. The rights of common stock obtained from the exercise of options (once vested) and the restricted stock are identical to those of other common stock of the Company. The contractual term of these options is primarily for ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">For purposes of determining the fair value of restricted stock granted to employees and non-employees, the Company&#8217;s management uses the fair value of the Common Stock. <span style="background:#ffffff;">The fair value of options granted for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Options and restricted stock granted to employees and directors:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of share option plans, and related information, under all of the Company&#8217;s equity incentive plans for the&#160;year ended December&#160;31, 2024, and the effect of share-based compensation on the statement of operations for the&#160;year ended December&#160;31, 2024, is as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Options granted to employees and directors:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,965,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.13</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,015,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.10</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">Forfeited  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (326,969)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.36</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (252,062)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.60</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,402,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.98</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,247,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.49</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Restricted stock granted to employees:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">  </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restricted</b></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> of fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at grant date</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 1,173,670</p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.16</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Granted</span></p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 704,869</p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.24</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Forfeited</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> (23,410)</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.99</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Vested</span></p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> (992,313)</p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.91</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non vested at end of year</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 862,816</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.70</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The following table summarizes information concerning outstanding and exercisable options as of December&#160;31, 2024:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:58.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at&#160;end&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$1.03-$2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,899,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,744,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.95</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$3.55-$3.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 994,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 994,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.61</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.69-$5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.88</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$17.20 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,402,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,247,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"><span style="color:#231f20;">As of December</span><span style="color:#231f20;letter-spacing:0.05pt;">&#160;</span><span style="color:#231f20;">31, 2024, the aggregate intrinsic value of all the outstanding options and exercisable</span><span style="color:#231f20;letter-spacing:0.1pt;"> </span><span style="color:#231f20;">options</span><span style="color:#231f20;letter-spacing:0.05pt;"> was approximately </span><span style="color:#231f20;letter-spacing:0.05pt;">$</span>1.0<span style="color:#231f20;letter-spacing:0.05pt;">&#160;million and </span><span style="color:#231f20;letter-spacing:0.05pt;">$</span>0.5<span style="color:#231f20;letter-spacing:0.05pt;">&#160;million, respectively.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The weighted average grants date fair value of restricted stock granted in 2022, 2023 and 2024 was $0.82, $1.99 and $1.24, respectively.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The fair value of each option granted during 2022, 2023 and 2024 for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the options&#8217; fair value on their grant date:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Weighted average grants date fair value (USD)</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The total unrecognized compensation cost of employee stock options at December&#160;31, 2024 is approximately $1.3&#160;million. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 0.8&#160;years.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;">During the three years ended December&#160;31, 2024, there were no exercises of stock options, and the Company did not realize any tax benefit in connection with any exercises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;"><span style="background:#ffffff;">The total vesting-date value of equity classified restricted stock vested during </span>the year ended December&#160;31, 2024<span style="background:#ffffff;"> was </span><span style="background:#ffffff;">$</span>1.2<span style="background:#ffffff;">&#160;million. As of December&#160;31, 2024, the unrecognized compensation cost related to all unvested equity classified restricted stock of </span><span style="background:#ffffff;">$</span>0.6<span style="background:#ffffff;">&#160;million is expected to be recognized as an expense over a weighted-average period of </span><span style="background:#ffffff;">0.7</span><span style="background:#ffffff;">&#160;years.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">g)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The following table illustrates the effect of share-based compensation on the statement of operations:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 631</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 589</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,033</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,253</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Private and 144A Offerings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2022</span>, the Company issued 1,000 shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $2,360 from such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2023</span>, the Company issued (i)&#160;301,810 shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $0.7&#160;million from such exercise and (ii)&#160;237,012 shares of Common Stock in connection with the cashless exercise of a </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">warrant to purchase 845,000 shares of Common Stock issued in 2020. The Company did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">During the year ended December&#160;31, 2023</span>, the Company issued, in the aggregate, 4,691,623 shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during <span style="background:#ffffff;">the year ended December&#160;31, 2023</span>, the Company paid to the converting holders $0.9&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;At-the-Market (ATM) Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;2021 Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell from time to time through the Agent<span style="background:#ffffff;">, shares of Common Stock having an aggregate offering price of up to </span><span style="background:#ffffff;">$20.0</span><span style="background:#ffffff;">&#160;million </span>(the &#8220;ATM Shares&#8221;)<span style="background:#ffffff;">. </span>During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million, thereby completing the ATM program under said agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#8220;2023 Sales Agreement&#8221;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to <span style="background:#ffffff;">$20.0</span><span style="background:#ffffff;">&#160;million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has no obligation to sell any shares of Common Stock under the 2023 Sales Agreement, and may at any time suspend sales under the 2023 Sales Agreement or terminate the 2023 Sales Agreement in accordance with its terms. The Agent is entitled to a commission of up to 3.0% of the aggregate gross proceeds from the shares of Common Stock sold under the 2023 Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2022, the Company sold, in the aggregate, 7,473,038 shares of Common Stock under the 2021 Sales Agreement. The Company generated gross proceeds equal to approximately $8.7&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2023, the Company sold, in the aggregate, 12,560,150 shares of Common Stock under the 2021 Sales Agreement and 2023 Sales Agreement. The Company generated gross proceeds equal to approximately $24.9&#160;million in connection with such sales. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. No sales were completed during the six months ended December&#160;31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">During the year ended December&#160;31, 2024, the Company sold, in the aggregate 2,216,692 shares of Common Stock under the 2023 Sales Agreement. The Company generated gross proceeds equal to approximately $3.8&#160;million in connection with such sales (issuance cost was approximately $0.1&#160;million). All such sales were completed during the quarter ended December&#160;31, 2024. Subsequent to December&#160;31, 2024, the Company sold the remaining amount of shares of Common Stock available for sale under the 2023 Sales Agreement thereby completing the ATM program thereunder.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE 9&#160;- CONVERTIBLE NOTES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="color:#212529;">In September 2024, the Company repaid all of the </span><span style="color:#212529;">$20.42</span><span style="color:#212529;">&#160;million outstanding principal and interest payable under the 2024 Notes. The repayment of the convertible notes at maturity was financed entirely with available cash.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The 2024 Notes were issued pursuant to an indenture entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the 2024 Notes was payable semi-annually at a rate of 7.50% per annum. The outstanding 2024&#160;Notes matured three years after the issuance thereof and were guaranteed by the Company&#8217;s subsidiaries. The 2024 Notes were secured by perfected liens on all of the assets of the Company and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2024 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024*</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,022</p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,022</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>* See also Note&#160;1(r).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;10&#160;- FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;11&#160;&#8211; NET EARNINGS (LOSS) PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:43.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,932</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,168)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,971</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,472,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,512,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,530,698</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,335,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,667,323</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options and restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,576,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 859,155</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,472,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,424,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,057,176</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the year and inclusion of make-whole interest payments that will be incurred upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted loss per share do not include 34,097,716 shares of Common Stock underlying outstanding stock options, warrants and convertible notes of the Company for the year ended December&#160;31, 2022 because the effect would be anti-dilutive. In the year ended December&#160;31, 2023, the diluted earnings per share do not include 18,254,264 shares of Common Stock underlying outstanding warrants and stock options because the effect would be anti-dilutive. In the year ended December&#160;31, 2024, the diluted earnings per share do not include 16,661,907 shares of Common Stock underlying outstanding warrants and stock options because the effect would be anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;12&#160;- TAXES ON INCOME</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics,&#160;Inc. is taxed according to U.S. tax laws. The Company&#8217;s income is taxed in the United States at a rate of up to 21%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:37.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,092)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Following the regulatory approvals for Elfabrio in May 2023, the receipt of the $20.0&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released the valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $3.1&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted into law in December 2017 (the &#8220;TCJA&#8221;) which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The TCJA represents fundamental and dramatic modifications to the U.S. tax system. It contains several key tax provisions that impacted the Company including the reduction of the maximum U.S. federal corporate income tax rate from 35% to 21%, effective January&#160;1, 2018. Other significant changes under the TCJA includes, among others, a one-time repatriation tax on accumulated foreign earnings, a limitation of NOL deduction to 80% of taxable income, and indefinite carryover of post-2017 NOLs. The TCJA also repealed the corporate alternative minimum tax for tax years beginning after December&#160;31, 2017. Losses generated prior to January&#160;1, 2018 will still be subject to the 20-year carryforward limitation and the alternative minimum tax. Other impacts due to the TCJA included the repeal of the domestic manufacturing deduction, modification of taxation of controlled foreign corporations, a base erosion anti-abuse tax, modification of interest expense limitation rules, modification of limitation on deductibility of excessive executive compensation, and taxation of global intangible low-taxed income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Modification of interest expense limitation rules under the TCJA provides generally that for taxable&#160;years 2019-2022 interest expense deduction shall be limited to 50% of the EBITDA and for taxable years 2022 onwards to 30% of EBIT. Disallowed interest deduction may be carried forward indefinitely. The Company believes that any potential impact (if applicable) of this limitation will be offset by utilization of available NOLs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Section&#160;174 of the TCJA requires taxpayers to capitalize and amortize research and development expenses for tax years beginning after December&#160;31, 2021. This rule became effective for the Company during the year ended December&#160;31, 2022, and resulted in the capitalization of research and development costs of approximately $28.5&#160;million, $14.4&#160;million and $11.9&#160;million in 2022, 2023 and 2024, respectively. The Company will amortize these costs for tax purposes over 15&#160;years for research and development performed outside the United States and over five years in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company believes that all future profits of its Subsidiaries will be indefinitely reinvested or that there is no expectation to distribute any taxable dividends from these Subsidiaries. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is estimated as an immaterial amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Protalix&#160;Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company as a &#8220;foreign-investment company&#8221; measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986. The Israeli Subsidiary is taxed according to Israeli tax laws:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tax rates</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The income of the Israeli Subsidiary, other than income from &#8220;Approved Enterprises,&#8221; is taxed in Israel at the regular corporate tax rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The corporate tax rate was 23% for 2018 and thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Capital gain on a sale of assets is subject to capital gain tax according to the corporate tax rate in effect in the&#160;year during which the assets are sold.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Law for the Encouragement of Capital Investments, 1959 (the &#8220;Encouragement of Capital Investments Law&#8221;)</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Under the Encouragement of Capital Investments Law, including Amendment No.&#160;60 to the Encouragement of Capital Investments Law as published in April&#160;2005, by virtue of the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; status the Israeli Subsidiary is entitled to various tax benefits as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">a.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Reduced tax rates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">Income derived from the Approved Enterprise during a 10-year period commencing upon the&#160;year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary has an &#8220;Approved Enterprise&#8221; plan since 2004 and &#8220;Benefited Enterprise&#8221; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expired in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#8220;Approved Enterprise&#8221; or &#8220;Benefited Enterprise&#8221; during the tax exemption period, it will be subject to tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable if such income not been exempted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">b.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Accelerated depreciation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">c.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Conditions for entitlement to the benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Israeli Subsidiary&#8217;s entitlement to the benefits described above is subject to its fulfillment of conditions stipulated by the law, rules&#160;and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Israeli Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#8220;Approved Enterprise&#8221; from the Investment Center.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;">d.&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Amendment of the Law for the Encouragement of Capital Investments, 1959</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">In recent&#160;years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law. On December&#160;29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &#8220;Preferred Technological Enterprise&#8221; and &#8220;Special Preferred Technological Enterprise&#8221; (the &#8220;Capital Investments Law Amendment&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;">To date, the Company has elected not to have the Capital Investments Law Amendment apply to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Tax losses carried forward to future&#160;years</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2024 and 2023, the Company had aggregate NOL carry-forwards equal to approximately $227.2&#160;million and $234.8&#160;million, respectively, that are available to reduce future taxable income as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">The Company</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company&#8217;s carry-forward NOLs, equal to approximately $24.4&#160;million and $22.2&#160;million as of December&#160;31, 2023 and 2024, respectively, may be restricted under Section&#160;382 of the Internal Revenue Code (&#8220;IRC&#8221;). IRC Section&#160;382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post change&#160;year that may be offset by a pre-change NOL may not exceed the general IRC Section&#160;382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Protalix&#160;Ltd.</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">At December&#160;31, 2023 and 2024, the Israeli Subsidiary had approximately $210.4&#160;million and $205.0&#160;million, respectively, of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Deferred income taxes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The components of the Company&#8217;s net deferred tax assets at December&#160;31, 2023 and 2024 were as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In respect of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,055</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other timing differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 452</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,014</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,618)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,665)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,856</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Reconciliation of the theoretical tax expense to actual tax expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A reconciliation of the statutory U.S. federal income tax rate of 21% in 2024, 2023 and 2022 to the effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:31.51%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax computed at the statutory U.S. income tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,023)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,799</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 872</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Differences in tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,512</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (899)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (436)</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutorily non-deductible expenses </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,979</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,684</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 506</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in Valuation allowances</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,970)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,932)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (953)</p></td></tr><tr><td style="vertical-align:middle;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Utilization of carry-forward losses and other temporary items without deferred taxes recognition</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,032</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,602</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,233</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Withholding tax </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:middle;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,222</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-weight:bold;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Valuation allowance roll-forward</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table presents the change in the Company&#8217;s valuation allowance during the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,550)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (728)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,660</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,618)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,618)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 953</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,665)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Uncertain tax position</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Provisions of ASC 740-10, Income Taxes, clarify whether to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 275</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 805</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 805</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 805</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Tax assessments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In accordance with the Income Tax Ordinance, as of December&#160;31, 2024, all of Protalix&#160;Ltd.&#8217;s tax assessments through tax&#160;year 2019 are considered final.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of open tax&#160;years by major jurisdiction is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Jurisdiction:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020-2024</p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United States (*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021-2024</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;13&#160;&#8211; SEGMENT INFORMATION</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company operates in Israel as a </span><span style="-sec-ix-hidden:Hidden_yJU9lqNC-UmtulHxkqsD_Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> operating segment. The Company&#8217;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:34.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,399</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,780</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,682</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,062</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,299)</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,304</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,716</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income before income taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,154</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,222</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,932</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* Other expenses included in net income includes raw materials, rent and utilities and others.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.17%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12,403</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12,522</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12,617</p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,452</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10,401</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11,031</p></td></tr><tr><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,437</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">17,495</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">29,333</p></td></tr><tr><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25,292</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">40,418</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">52,981</p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,346</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25,076</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">418</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.7pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long lived assets are located in Israel.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;14&#160;- SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 49.5pt;">a.&#160;&#160;&#160;&#160;&#160;Balance sheets:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;&#160;Other assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sundry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 110</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,096</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,343</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,811</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,568</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,080</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,476</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,056</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserves (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:top;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">(1) The balance as of December&#160;31, 2024 is based on a final reconciliation that was performed with the customer.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;15&#160;- RELATED PARTY TRANSACTIONS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-Executive Director Compensation</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation (including share-based compensation) to the non-executive directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 555</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In September 2023, with the consent of the Audit Committee of the Board of Directors, the Company engaged one of its non-executive directors to advise the Company regarding business development and licensing efforts on a consultancy basis. For the years ended December&#160;31, 2023 and 2024, we recorded an expense of a total of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$35,475</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1,350</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> for such consulting fees, respectively.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE&#160;16&#160;- SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since December&#160;31, 2024, the Company has collected approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$4.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Pfizer and approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.9</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Brazil.</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since December&#160;31, 2024, the Company sold, in the aggregate </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,223,935</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock under the 2023 Sales Agreement. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company generated </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">gross proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such sales. As a result of such sales, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares remain available for sale under the 2023&#160;Sales Agreement and the ATM program thereunder is now complete.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since December&#160;31, 2024, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">908,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from such exercises. The warrants expired on March&#160;11, 2025. Accordingly, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of March&#160;12, 2025, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants remain outstanding.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In January 2025, the Company deregistered Protalix BV in the Netherlands thereby ending its corporate existence.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 2,932<span></span>
</td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our operations include the creation, collection and maintenance of sensitive information, including proprietary and confidential business information, intellectual property, third-party information and employee information. To protect this information, we use external and internal services to managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats on a constant basis. In addition, we use multi-factor authentication (MFA) for external use, perform penetration testing and engage third parties to assess the effectiveness of our cybersecurity practices. We conduct a thorough risk assessment by identifying critical assets, recognizing potential threats and vulnerabilities, and implement strategies to mitigate these risks and their possible impacts. We establish incident response plans and provide cybersecurity training to our employees and monitor their activity to ensure adherence to our security protocols. A material cyber-attack on our systems, or any other third-party partners or vendors and their key operating systems, may interrupt our ability to operate our business, damage our reputation, or result in monetary damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">We have implemented a Data Protection Policy, or the DPP, in order to establish the high-level direction for properly managing the use, privacy, security, retention, and disposal of our information, data and assets, and to manage identified material cybersecurity risks. The DPP was prepared using relevant guidance issued and technology standards that are used across various industries. It applies to all entities who are using our equipment and resources, including but not limited to, employees and temporary workers. Our Senior Director, Information Technology, is a certified information security officer (CISO). He is primarily responsible for implementing and overseeing the DPP and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our DPP includes an incident response process that includes reporting thresholds and follows standardized identification and authentication practices. If an incident is identified, it is documented by our Senior Director, Information Technology, who is required to report the incident to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We work with third-party service providers from time to time that assist us to identify, assess and manage cybersecurity risks, including professional SEIM SOC and other services firms, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and penetration testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">No risks from cybersecurity threats have occurred that have materially affected or are reasonably likely to materially affect our business, results of operations or financial condition.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our operations include the creation, collection and maintenance of sensitive information, including proprietary and confidential business information, intellectual property, third-party information and employee information. To protect this information, we use external and internal services to managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats on a constant basis. In addition, we use multi-factor authentication (MFA) for external use, perform penetration testing and engage third parties to assess the effectiveness of our cybersecurity practices. We conduct a thorough risk assessment by identifying critical assets, recognizing potential threats and vulnerabilities, and implement strategies to mitigate these risks and their possible impacts. We establish incident response plans and provide cybersecurity training to our employees and monitor their activity to ensure adherence to our security protocols. A material cyber-attack on our systems, or any other third-party partners or vendors and their key operating systems, may interrupt our ability to operate our business, damage our reputation, or result in monetary damages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">We have implemented a Data Protection Policy, or the DPP, in order to establish the high-level direction for properly managing the use, privacy, security, retention, and disposal of our information, data and assets, and to manage identified material cybersecurity risks. The DPP was prepared using relevant guidance issued and technology standards that are used across various industries. It applies to all entities who are using our equipment and resources, including but not limited to, employees and temporary workers. Our Senior Director, Information Technology, is a certified information security officer (CISO). He is primarily responsible for implementing and overseeing the DPP and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our DPP includes an incident response process that includes reporting thresholds and follows standardized identification and authentication practices. If an incident is identified, it is documented by our Senior Director, Information Technology, who is required to report the incident to management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">We work with third-party service providers from time to time that assist us to identify, assess and manage cybersecurity risks, including professional SEIM SOC and other services firms, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and penetration testing.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. Our Chief Financial Officer and IT consultant provide periodic briefings to the Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, if any, cybersecurity systems testing, activities of third parties, and the like.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Board of Directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. Our Chief Financial Officer and IT consultant provide periodic briefings to the Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, if any, cybersecurity systems testing, activities of third parties, and the like.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of our management, including our Senior Director, Information Technology, who reports to our Sr. Vice President, Operations. Management is also responsible for hiring appropriate personnel, integrating cybersecurity considerations into our overall risk management strategy, and for communicating key priorities to employees, as well as for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our incident response process involves management, who participates in our disclosure controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Our incident response process is designed to escalate certain cybersecurity incidents and vulnerabilities to members of management depending on the circumstances, including work with our incident response team to help the company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the company&#8217;s incident response processes include reporting to our Board of Directors for certain cybersecurity incidents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Management is involved with our efforts to prevent, detect, and mitigate cybersecurity incidents by overseeing preparation of cybersecurity policies and procedures, testing incident response plans and engaging vendors to conduct penetration tests. Management participates in cybersecurity incident response efforts by being a member of the incident response team and helping direct our response to cybersecurity incidents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Senior Director, Information Technology<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our Senior Director, Information Technology, is a certified information security officer (CISO). He is primarily responsible for implementing and overseeing the DPP and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Management is involved with our efforts to prevent, detect, and mitigate cybersecurity incidents by overseeing preparation of cybersecurity policies and procedures, testing incident response plans and engaging vendors to conduct penetration tests. Management participates in cybersecurity incident response efforts by being a member of the incident response team and helping direct our response to cybersecurity incidents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">a.&#160;&#160;&#160;&#160;General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix BV (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio (pegunigalsidase alfa), each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The situation could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of December&#160;31, 2024, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">b.&#160;&#160;&#160;&#160;Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">d.&#160;&#160;&#160;&#160;Functional currency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#8217;s revenues are derived in dollars. Most of the Company&#8217;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#8217;s financing has been provided in dollars.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#8211;&#160;exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#8211;&#160;historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">e.&#160;&#160;&#160;&#160;Cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">f.&#160;&#160;&#160;&#160;Accounts Receivables</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. As of December&#160;31, 2024 and 2023, the allowance was negligible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">No write-off activity and recoveries for the periods presented were recognized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">g.&#160;&#160;&#160;&#160;Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#8220;moving average&#8221; basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#8220;moving average&#8221; basis; the value of the labor and overhead component is determined on an average basis over the production period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">h.&#160;&#160;&#160;&#160;Property and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10-15</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leasehold improvements are amortized by the straight-line method over the shorter of (i)&#160;the expected lease term and (ii)&#160;the estimated useful life of the improvements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment in value of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">j.&#160;&#160;&#160;&#160;Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Deferred income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Uncertainty in income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Tax benefits recognized in the financial statements are those that the Company&#8217;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#8217;s management deems more likely than not to be sustained. Liabilities relating to uncertain tax positions are classified as current in the consolidated balance sheets to the extent the Company anticipates making payments within one year.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">k.&#160;&#160;&#160;&#160;Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Under Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606, Revenue from Contracts with Customers, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">1.&#160;&#160;&#160;&#160;Revenues from selling products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with a Company&#8217;s customer is based on either fixed amounts or variable amounts. Variable amounts are based on the average net selling price of the drug product in the applicable territory. The Company estimates the variable consideration and recognizes revenue only to the extent the variable consideration is probable and that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;">2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;) as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing. See also <a href="#_k.__"><span style="font-style:normal;font-weight:normal;">revenue from selling products</span></a> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC&#160;606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely amount method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA in 2023, the Company received a milestone payment equal to $20.0&#160;million which was recognized as revenue from license and R&amp;D services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"><span style="white-space:pre-wrap;">3.    Revenue from R&amp;D services</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">l.&#160;&#160;&#160;&#160;Research and development costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks and trade receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company&#8217;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#8217;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December&#160;31, 2023, the accounts receivables balance was composed of $0.7&#160;million from Chiesi and $4.6&#160;million from Pfizer and as of December&#160;31, 2024, the accounts receivables balance was composed of $1.7&#160;million from Fiocruz and $1.2&#160;million from Pfizer.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">n.&#160;&#160;&#160;&#160;Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. <span style="background:#ffffff;">This option pricing model requires estimates as to the option&#8217;s expected term and the price volatility of the underlying stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The Company measures compensation expense for </span>restricted stock <span style="background:#ffffff;">based on the market value of the underlying stock at the date of grant</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected to recognize compensation cost for awards to employees with only service conditions that has a graded vesting schedule using the accelerated method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elects to account for forfeitures as they occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net earnings (loss) per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">o.&#160;&#160;&#160;&#160;Net earnings (loss) per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), outstanding during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing (a)&#160;the net income that includes addition of financial expenses related to convertible notes by (b)&#160;the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options and non-vested restricted stock granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">p.&#160;&#160;&#160;&#160;Convertible notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate.&#160;The Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January 1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost. See <a href="#rNewaccountingpronouncements_158576"><span style="font-style:normal;font-weight:normal;">Note 1(r)</span></a>.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">q.&#160;&#160;&#160;&#160;Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12&#160;months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">r.&#160;&#160;&#160;&#160;New accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;background:#ffffff;">Recently adopted accounting pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In August 2020, the FASB issued&#160;ASU 2020-06 &#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)&#8221; (&#8220;ASU 2020-06&#8221;).&#160;ASU&#160;2020-06&#160;simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#8212;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06&#160;using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital.&#160;The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods.&#160;Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability.&#160;</span><span style="background:#ffffff;">The impact to the Company&#8217;s consolidated balance sheet as of January&#160;1, 2024 resulting from its adoption of ASU 2020-06 is as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169</p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 415,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 414,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 224</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment Reporting: Improvements to Reportable Segment Disclosures.&#8221; This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;) and included within each reported measure of segment profit or loss and an amount and description of its composition for other segment items. The Company adopted this standard in the current period retrospectively to all prior periods presented in its consolidated financial statements. See </span><a href="#_NOTE_13_"><span style="font-style:normal;font-weight:normal;background:#ffffff;">Note&#160;13</span></a><span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">In December 2023, the FASB issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ScheduleOfUsefulLifeTableTextBlock', window );">Schedule of Useful Life</a></td>
<td class="text">The Company&#8217;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10-15</p></td></tr><tr><td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of ASU 2020-06 Impact to the Consolidated Balance Sheet</a></td>
<td class="text"><span style="background:#ffffff;">The impact to the Company&#8217;s consolidated balance sheet as of January&#160;1, 2024 resulting from its adoption of ASU 2020-06 is as follows:</span><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As Reported</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Updated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Effect of</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,251</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169</p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional paid in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 415,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 414,652</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (393)</p></td></tr><tr><td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 381,325</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 224</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Useful Life Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ScheduleOfUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-12<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Composition of property and equipment grouped by major classifications is as follows:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,043</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,374</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,913</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,661</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,330</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less &#8211; accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,688)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,739)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,591</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inventories at December&#160;31, 2023 and 2024 consisted of the following:</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,549</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,245</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,449</p></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,045</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,243</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the years ended December&#160;31, 2022, 2023 and 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.89%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,471</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity Analysis of Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of December&#160;31, 2024:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,500</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,241</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,085</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,040</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,003</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,869</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,343</p></td></tr><tr><td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,526</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE CAPITAL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Options granted to employees and directors:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">price</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,965,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.13</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,015,725</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.10</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="white-space:pre-wrap;">Forfeited  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (326,969)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.36</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (252,062)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.60</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,402,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.98</p></td></tr><tr><td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,247,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.49</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text">Restricted stock granted to employees:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">  </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restricted</b></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> of fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at grant date</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at beginning of year</p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 1,173,670</p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.16</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes during the year:</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Granted</span></p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 704,869</p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.24</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Forfeited</span></p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> (23,410)</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.99</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">  Vested</span></p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> (992,313)</p></td><td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.91</p></td></tr><tr><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non vested at end of year</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 862,816</p></td><td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.70</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Share Options Outstanding and Exercisable</a></td>
<td class="text">The following table summarizes information concerning outstanding and exercisable options as of December&#160;31, 2024:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:58.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options&#160;exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at&#160;end&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">life</b></p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$1.03-$2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,899,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,744,767</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.95</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$3.55-$3.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 994,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 994,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.61</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.69-$5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.88</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$17.20 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.21</p></td></tr><tr><td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,402,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,247,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Valuation Assumptions</a></td>
<td class="text">The fair value of each option granted during 2022, 2023 and 2024 for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the options&#8217; fair value on their grant date:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Weighted average grants date fair value (USD)</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Exercise price (USD)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Expected life (Years)</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense in Statement of Operations</a></td>
<td class="text">The following table illustrates the effect of share-based compensation on the statement of operations:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 596</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 631</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 589</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,033</p></td></tr><tr><td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,448</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,253</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense Recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table sets forth total interest expense recognized related to the 2024 Notes:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024*</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,156</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,534</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,022</p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,022</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>* See also Note&#160;1(r).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Earnings (Loss) per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:43.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,932</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,168)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 39</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,971</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,472,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 67,512,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,530,698</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,335,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,667,323</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options and restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,576,059</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 859,155</p></td></tr><tr><td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,472,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,424,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,057,176</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the year and inclusion of make-whole interest payments that will be incurred upon conversion.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Taxes on Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:37.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,092)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text">The components of the Company&#8217;s net deferred tax assets at December&#160;31, 2023 and 2024 were as follows:<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In respect of:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,055</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other timing differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,387)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 452</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carry forwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,014</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,618)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,665)</p></td></tr><tr><td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,856</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Tax Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A reconciliation of the statutory U.S. federal income tax rate of 21% in 2024, 2023 and 2022 to the effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:31.51%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax computed at the statutory U.S. income tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,023)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,799</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 872</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Differences in tax rate</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,512</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (899)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (436)</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Statutorily non-deductible expenses </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,979</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,684</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 506</p></td></tr><tr><td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in Valuation allowances</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,970)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,932)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (953)</p></td></tr><tr><td style="vertical-align:middle;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Utilization of carry-forward losses and other temporary items without deferred taxes recognition</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,032</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,602</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,233</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Withholding tax </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:middle;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,222</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Company's Valuation Allowance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The following table presents the change in the Company&#8217;s valuation allowance during the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (58,550)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (728)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,660</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,618)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51,618)</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reductions to valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 953</p></td></tr><tr><td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,665)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of the Beginning and Ending Amount of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Provisions of ASC 740-10, Income Taxes, clarify whether to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 275</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 805</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 805</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase for tax position related to current year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 805</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ScheduleOfOpenTaxYearsTableTextBlock', window );">Schedule of Open Tax Years</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A summary of open tax&#160;years by major jurisdiction is presented below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Jurisdiction:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years:</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Israel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2020-2024</p></td></tr><tr><td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">United States (*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2021-2024</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(*)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Includes federal, state and local (or similar provincial jurisdictions) tax positions.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ScheduleOfOpenTaxYearsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Open Tax Years Table Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ScheduleOfOpenTaxYearsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:middle;white-space:nowrap;width:34.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,638</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 65,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,399</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,780</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,682</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,529</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,062</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,146)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,299)</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,304</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,716</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income before income taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,397)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,154</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:62.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,222</p></td></tr><tr><td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,927)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,932</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* Other expenses included in net income includes raw materials, rent and utilities and others.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Disaggregation of Revenues</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.17%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12,403</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12,522</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12,617</p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,452</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10,401</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11,031</p></td></tr><tr><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,437</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">17,495</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">29,333</p></td></tr><tr><td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25,292</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">40,418</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">52,981</p></td></tr><tr><td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,346</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25,076</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">418</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Schedule of Supplemental Information of Balance Sheets</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">a.&#160;&#160;&#160;&#160;&#160;Other assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 486</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sundry</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 129</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 110</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,096</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,343</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 511</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,605</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,811</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,568</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,080</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,476</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,056</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales reserves (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:top;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;">(1) The balance as of December&#160;31, 2024 is based on a final reconciliation that was performed with the customer.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-Executive Director Compensation</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands</i>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation (including share-based compensation) to the non-executive directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 429</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 555</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>item </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Aug. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfGlobalLicensingAndSupplyAgreements', window );">Number of global licensing and supply agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Accounts receivables write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Accounts receivables recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative arrangement revenues and expenses sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Performance obligation number | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received upon achievement of certain milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfGlobalLicensingAndSupplyAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of global licensing and supply agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfGlobalLicensingAndSupplyAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">$ 2,909<span></span>
</td>
<td class="nump">$ 5,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_FiocruzMember', window );">Fiocruz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_ChiesiMember', window );">Chiesi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_FiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_FiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (The Impact to the Company's Consolidated Balance Sheet) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">421,528<span></span>
</td>
<td class="nump">415,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 378,393<span></span>
</td>
<td class="nump">381,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06 | Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06 | Effect of Change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMERCIALIZATION AGREEMENTS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 23, 2018</div></th>
<th class="th"><div>Oct. 19, 2017</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable payment receivable</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional amounts payable to cover development costs</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="nump">$ 760.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 735.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable', window );">Non-refundable payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional amounts payable to cover development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum entitlement of development costs to cover per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional amount payable for achievement of regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex-US Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment on net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNoncreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNoncreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 40,330<span></span>
</td>
<td class="nump">$ 39,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation and amortization</a></td>
<td class="num">(35,739)<span></span>
</td>
<td class="num">(34,688)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net, total</a></td>
<td class="nump">4,591<span></span>
</td>
<td class="nump">4,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">19,043<span></span>
</td>
<td class="nump">18,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember', window );">Furniture and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">3,374<span></span>
</td>
<td class="nump">3,084<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 17,913<span></span>
</td>
<td class="nump">$ 17,644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=plx_FurnitureAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1,304<span></span>
</td>
<td class="nump">$ 1,191<span></span>
</td>
<td class="nump">$ 1,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 4,549<span></span>
</td>
<td class="nump">$ 4,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">11,245<span></span>
</td>
<td class="nump">9,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,449<span></span>
</td>
<td class="nump">5,814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 21,243<span></span>
</td>
<td class="nump">$ 19,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EmployeeSeveranceObligationPayment', window );">Employee severance obligation payments</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsPeriodExpense', window );">Severance expense</a></td>
<td class="nump">820,000<span></span>
</td>
<td class="nump">801,000<span></span>
</td>
<td class="nump">945,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions</a></td>
<td class="nump">859,000<span></span>
</td>
<td class="nump">798,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Gain for the period</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="num">$ (3,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears', window );">Number of benefit eligible employees | employee</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember', window );">Contribution to Insurance Companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Contribution in connection with severance liabilities</a></td>
<td class="nump">$ 956,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember', window );">Contribution to Defined Contribution Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Contribution in connection with severance liabilities</a></td>
<td class="nump">$ 931,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EmployeeSeveranceObligationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee severance obligation payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EmployeeSeveranceObligationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees To Receive Benefits During Next Five Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period expense related to postemployment benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DefinedBenefitPostretirementLifeInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=plx_ContributionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254,000<span></span>
</td>
<td class="nump">$ 614,000<span></span>
</td>
<td class="nump">$ 143,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ExtendedTermOfAgreement', window );">Extended term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ContractAmountUnderAgreementPayable', window );">Contract amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember', window );">Fill/Finish Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ContractAmountUnderAgreementFacilityPayable', window );">Contracted share of facility cost amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InitialTermOfArrangement', window );">Initial term of arrangement</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember', window );">Arrangement Other than Collaborative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentAmount', window );">Subcontracting commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember', window );">Royalty Agreement Terms | Office of the Israeli Innovation Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense included in cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Royalty Agreement Terms | Office of the Israeli Innovation Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Royalty Agreement Terms | Office of the Israeli Innovation Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_RoyaltiesOnSaleOfProducts', window );">Royalties based on sale of products developed from funded projects, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfRoyaltiesToGrantReceived', window );">Percentage of Royalties to Grant Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,900,000<span></span>
</td>
<td class="nump">$ 35,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ContractAmountUnderAgreementFacilityPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This represents the share of payment to a contract research organization to cover proportionate share of the costs in setting up a facility.  May include equipment purchases but also other facility customization efforts, etc., none of which will be owned by the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ContractAmountUnderAgreementFacilityPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ContractAmountUnderAgreementPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount agreed to pay under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ContractAmountUnderAgreementPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ExtendedTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extended term  of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ExtendedTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InitialTermOfArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial term of arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InitialTermOfArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfRoyaltiesToGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Required royalty payments represented as a percentage to grants received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfRoyaltiesToGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RoyaltiesOnSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties based on sale of products developed from projects funded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RoyaltiesOnSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_RoyaltyAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=plx_OfficeOfIsraeliInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=plx_OfficeOfIsraeliInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Schedule of Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 1,639<span></span>
</td>
<td class="nump">$ 1,471<span></span>
</td>
<td class="nump">$ 1,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 1,634<span></span>
</td>
<td class="nump">$ 1,484<span></span>
</td>
<td class="nump">$ 1,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">12.80%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2029 and thereafter</a></td>
<td class="nump">3,003<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">7,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">2,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 5,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>item</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions', window );">Operating lease, Renewable term | item</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, term of agreement</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Cash deposited as bank guarantee | $</a></td>
<td class="nump">$ 513,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, term of agreement</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of change in operating lease monthly rental payments</a></td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>Disclosure of Leases Operating [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of change in operating lease monthly rental payments</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisclosureOfLeasesOperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Leases Operating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisclosureOfLeasesOperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease, Number Of Renewal Term Extensions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Change in Operating Lease Monthly Rental Payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Stock Option Activity) (Details) - Employee Stock Option - Employees and directors<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of year | shares</a></td>
<td class="nump">6,965,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,015,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(326,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(252,062)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of year | shares</a></td>
<td class="nump">7,402,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year | shares</a></td>
<td class="nump">4,247,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of year | $ / shares</a></td>
<td class="nump">$ 2.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited | $ / shares</a></td>
<td class="nump">1.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired | $ / shares</a></td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of year | $ / shares</a></td>
<td class="nump">1.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year | $ / shares</a></td>
<td class="nump">$ 2.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Restricted Stock Activity) (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=plx_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">1,173,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">704,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(23,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(992,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non vested at end of year</a></td>
<td class="nump">862,816<span></span>
</td>
<td class="nump">1,173,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of year</a></td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="nump">1.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="nump">1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="nump">1.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non vested at end of year</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=plx_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=plx_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">7,402,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">4,247,896<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.03To2.00Member', window );">$1.03 - $2.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range | $ / shares</a></td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range | $ / shares</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">5,899,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">2,744,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 11 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.55To3.73Member', window );">$3.55 - $3.73</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range | $ / shares</a></td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range | $ / shares</a></td>
<td class="nump">$ 3.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">994,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">994,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">4 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69To5.60Member', window );">$4.69 - $5.60</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range | $ / shares</a></td>
<td class="nump">$ 4.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range | $ / shares</a></td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">435,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">3 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">435,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">3 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice17.20Member', window );">$17.20</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range | $ / shares</a></td>
<td class="nump">$ 17.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of options outstanding at end of year</a></td>
<td class="nump">72,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of options exercisable</a></td>
<td class="nump">72,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 months 15 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.03To2.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice1.03To2.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.55To3.73Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice3.55To3.73Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69To5.60Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice4.69To5.60Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice17.20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=plx_ExercisePrice17.20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details) - Employee Stock Option - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average grants date fair value (USD)</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD)</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">4.44%<span></span>
</td>
<td class="nump">3.32%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">79.29%<span></span>
</td>
<td class="nump">79.41%<span></span>
</td>
<td class="nump">85.94%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (Years)</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,253<span></span>
</td>
<td class="nump">$ 3,448<span></span>
</td>
<td class="nump">$ 2,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,033<span></span>
</td>
<td class="nump">$ 2,075<span></span>
</td>
<td class="nump">$ 1,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Additional information) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 27, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommonStockNumberOfVotingRights', window );">Number of voting rights | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares of Common Stock remain available for grant under the plan | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,139,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,139,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 712,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,626,000<span></span>
</td>
<td class="nump">$ 23,954,000<span></span>
</td>
<td class="nump">$ 8,236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member', window );">Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under share-based payment arrangement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,475,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,475,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,810<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 2,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted instrument, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,691,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PaymentsToDebtHoldersOnConversion', window );">Paid to the converting holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreement2021Member', window );">2021 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,473,038<span></span>
</td>
<td class="nump">13,980,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreement2023Member', window );">2023 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,216,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreement2023Member', window );">2023 Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfCommissionOnSaleOfShares', window );">Commission (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedSharesMember', window );">Options and restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedSharesMember', window );">Options and restricted shares | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedSharesMember', window );">Options and restricted shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding options intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable options intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Vesting-date fair value of stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommonStockNumberOfVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes for each share of common stock is entitled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommonStockNumberOfVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentsToDebtHoldersOnConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentsToDebtHoldersOnConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfCommissionOnSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfCommissionOnSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=plx_OptionsAndRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">1,022<span></span>
</td>
<td class="nump">2,534<span></span>
</td>
<td class="nump">2,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsIncurred', window );">Total</a></td>
<td class="nump">$ 1,022<span></span>
</td>
<td class="nump">$ 2,801<span></span>
</td>
<td class="nump">$ 2,456<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total interest costs incurred during the period and either capitalized or charged against earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Additional Information) (Details) - 2024 Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 25, 2021</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Mature term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,420<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 2,932<span></span>
</td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Financial expenses of 2024 Notes</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">(1,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) for diluted calculation</a></td>
<td class="nump">$ 2,971<span></span>
</td>
<td class="nump">$ 7,144<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Common Stock outstanding for basic calculation</a></td>
<td class="nump">72,530,698<span></span>
</td>
<td class="nump">67,512,527<span></span>
</td>
<td class="nump">48,472,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Weighted average dilutive effect of 2024 Notes</a></td>
<td class="nump">7,667,323<span></span>
</td>
<td class="nump">13,335,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average dilutive effect of stock options and restricted stock</a></td>
<td class="nump">859,155<span></span>
</td>
<td class="nump">1,576,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Common Stock outstanding for diluted calculation</a></td>
<td class="nump">81,057,176<span></span>
</td>
<td class="nump">82,424,016<span></span>
</td>
<td class="nump">48,472,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember', window );">Outstanding Stock Options And Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">16,661,907<span></span>
</td>
<td class="nump">18,254,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember', window );">Outstanding Stock Options Warrants And 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,097,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsWarrantsAnd2024NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Summary of Taxes on Income) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current taxes on income</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="nump">$ 3,346<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes on income</a></td>
<td class="nump">236<span></span>
</td>
<td class="num">(3,092)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total taxes on income</a></td>
<td class="nump">$ 1,222<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>In respect of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expenses</a></td>
<td class="nump">$ 3,055<span></span>
</td>
<td class="nump">$ 4,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DeferredTaxAssetsOtherTimingDifferences', window );">Other timing differences</a></td>
<td class="nump">452<span></span>
</td>
<td class="num">(1,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">50,014<span></span>
</td>
<td class="nump">51,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(50,665)<span></span>
</td>
<td class="num">(51,618)<span></span>
</td>
<td class="num">$ (58,550)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets</a></td>
<td class="nump">$ 2,856<span></span>
</td>
<td class="nump">$ 3,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DeferredTaxAssetsOtherTimingDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets other timing differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DeferredTaxAssetsOtherTimingDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Reconciliation of Tax Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax computed at the statutory U.S. income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">$ 1,799<span></span>
</td>
<td class="num">$ (3,023)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Differences in tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(436)<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Statutorily non-deductible expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506<span></span>
</td>
<td class="nump">1,684<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation allowances</a></td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="num">(953)<span></span>
</td>
<td class="num">(6,932)<span></span>
</td>
<td class="num">(2,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition', window );">Utilization of carry-forward losses and other temporary items without deferred taxes recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">3,602<span></span>
</td>
<td class="nump">2,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_EffectiveIncomeTaxRateReconciliationWithholdingTax', window );">Withholding tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,222<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to utilization of carry-forward losses and other temporary items without deferred taxes recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EffectiveIncomeTaxRateReconciliationWithholdingTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to withholding tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EffectiveIncomeTaxRateReconciliationWithholdingTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Valuation Allowance) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning Balance</a></td>
<td class="num">$ (51,618)<span></span>
</td>
<td class="num">$ (58,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod', window );">Additions to valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod', window );">Reductions to valuation allowance</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">7,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Ending Balance</a></td>
<td class="num">$ (50,665)<span></span>
</td>
<td class="num">$ (51,618)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additions to the valuation allowance for deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reductions to the valuation allowance for deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Uncertain Tax Position) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 805<span></span>
</td>
<td class="nump">$ 530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase for tax position related to current year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 805<span></span>
</td>
<td class="nump">$ 805<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Schedule of Open Tax Years) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember', window );">Israel | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember', window );">Israel | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">UNITED STATES | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">UNITED STATES | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_UsIsraelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="7">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance related to deferred tax assets</a></td>
<td class="num">$ (3,100)<span></span>
</td>
<td class="num">$ (953)<span></span>
</td>
<td class="num">$ (6,932)<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Deferred tax liability of research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="nump">14,400<span></span>
</td>
<td class="nump">$ 28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod', window );">Amortization period research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,200<span></span>
</td>
<td class="nump">234,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="nump">$ 210,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember', window );">Subsidiaries | Tax Year Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="nump">$ 24,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_IncomeTaxDisclosureLineItems', window );"><strong>TAXES ON INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_MilestonePaymentReceived', window );">Amount of milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized for research and development cost, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure Line Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received upon achievement of certain milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearThereafterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=plx_TaxYearThereafterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Schedule of Segment Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues from customers</a></td>
<td class="nump">$ 53,399<span></span>
</td>
<td class="nump">$ 65,494<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee salaries and related expenses</a></td>
<td class="nump">21,780<span></span>
</td>
<td class="nump">24,075<span></span>
</td>
<td class="nump">19,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Sub-contractors expense</a></td>
<td class="nump">8,682<span></span>
</td>
<td class="nump">14,008<span></span>
</td>
<td class="nump">24,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">interest expense</a></td>
<td class="nump">1,062<span></span>
</td>
<td class="nump">3,180<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="num">(1,299)<span></span>
</td>
<td class="num">(1,286)<span></span>
</td>
<td class="num">(1,146)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expenses</a></td>
<td class="nump">17,716<span></span>
</td>
<td class="nump">15,760<span></span>
</td>
<td class="nump">15,997<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="nump">4,154<span></span>
</td>
<td class="nump">8,566<span></span>
</td>
<td class="num">(14,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 2,932<span></span>
</td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="num">$ (14,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemCompositionDescription', window );">Segment reporting description</a></td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemCompositionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of composition of other segment item not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemCompositionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 53,399<span></span>
</td>
<td class="nump">$ 65,494<span></span>
</td>
<td class="nump">$ 47,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">52,981<span></span>
</td>
<td class="nump">40,418<span></span>
</td>
<td class="nump">25,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">LICENSE AND R&amp;D SERVICES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">25,076<span></span>
</td>
<td class="nump">22,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_PfizerMember', window );">Pfizer | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">12,617<span></span>
</td>
<td class="nump">12,522<span></span>
</td>
<td class="nump">12,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_FiocruzMember', window );">Fiocruz | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">11,031<span></span>
</td>
<td class="nump">10,401<span></span>
</td>
<td class="nump">9,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_ChiesiMember', window );">Chiesi | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 29,333<span></span>
</td>
<td class="nump">$ 17,495<span></span>
</td>
<td class="nump">$ 3,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_FiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_FiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_OtherAssetsInstitutionsCurrent', window );">Institutions</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_OtherAssetsSundryCurrent', window );">Sundry</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">$ 1,096<span></span>
</td>
<td class="nump">$ 1,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsInstitutionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherAssetsInstitutionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherAssetsSundryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherAssetsSundryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 1,343<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">1,811<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,568<span></span>
</td>
<td class="nump">9,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">3,476<span></span>
</td>
<td class="nump">2,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PayableToCustomerCurrent', window );">Payable to customer</a></td>
<td class="nump">2,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ReserveForDeductionsFromRevenueCurrent', window );">Sales reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent', window );">Accounts payable and accruals - other</a></td>
<td class="nump">$ 19,588<span></span>
</td>
<td class="nump">$ 19,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PayableToCustomerCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PayableToCustomerCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReserveForDeductionsFromRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of reserve for deductions from revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReserveForDeductionsFromRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - Related Party - Director - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Compensation (including share based compensation) to the non-executive directors</a></td>
<td class="nump">$ 555,000<span></span>
</td>
<td class="nump">$ 429,000<span></span>
</td>
<td class="nump">$ 368,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Consulting fees</a></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="nump">$ 35,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,626,000<span></span>
</td>
<td class="nump">$ 23,954,000<span></span>
</td>
<td class="nump">$ 8,236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 712,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreement2023Member', window );">2023 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,216,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,810<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 2,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2023 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">1,223,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares remain for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pfizer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Brazil Agreement with Fiocruz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts from customers during the current period which are usually for sales of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreement2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreement2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $LZ<5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( $LZ<5HN@BF$\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( $LZ<5JGM_]2H0@  /TU   8
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M0+=?/]L)$73I!M)X(+[7]YQ[CBW;T8;Q9Y$#2/12T%*,K5S*ZL*V19I#@<6
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M7;*83^FK'_#O'[*L_'90/=7L\.B^J[\!4$L#!!0    ( $LZ<5J7*PMG]0D
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M.;*.Z<P_DK-:I[B[3G&-(VNZY*DXDREG0:#A(0]G7&8RK 5+3^[>L&#48<H
M0XQLNZ<,,-V(=GH./KRZ.R5=HQ)?0//,P\;:=[7?M%C'5FJ/&%E]2ZD]8M3I
MN7CM>[O:]XRUOPYC#I. 1]L)\+L<]YB,GMZ^5D=1H=N<V;:KJ$",^KT^KJ*_
M4]$WJA@N>?PD,IE<^7R>;F!012%_"*,P?R- =T2LUE'R)@1))<AD9+,NN"N'
M6" # R:XK]?3<I0N&>I&RKCT$3>.S7"Y5J?"CLYG!0.EB30MHE(1P7+^2GB6
MX;VX=5N; 4SIH2%B=,8Z?35:(V:=!EU[.&49==U ]"4G3[R(L-"9JV0CP_;C
M1M*.5 N1: W,2Y+'7^G3[:_7.[6GRD>,G(XJ7C=JZE1:B:>'B,\XI";0^1B^
M@O:B2W%BI$AWJ9ITF[ZJ2#=IZLZ*QBPCG0R^@A8I!1+MLTCE8B>3BLJ/>?@@
M<V^2"UP6,]1GJTHW.;.I&C:-CNK"*BZRS&#DK1*H__^*H"\5+<0#($26;2"8
M"M"7P7@$PB_?+\)L+L<QJM+^6*5N0MVN*E(W8ITFF14Y669TV@LS>[Q3C,1"
MWGN0;6(?ZZCP<U1O_K&\U9NVXA_+#$"P\DD%X(]L6Y@/>0H8F559"VU-'5^T
ML:*;G%G,ZJH@A-EU+9<V#)B*A:R/8&BKZ@2R4?%TNDW*92 '4A+A,X>)?P:*
M%Z(814F^%*DIP.G@0T&3*EVW@F"@"4>L +7L!N$51EEFCD)G2E0T19&>9)"
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M89JL=LNE T0B>T:JP ^1RS>:U)55&$7-&.6MWM-.N" GY>KW]+#E;R-B4)V
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M-(#O'Q-(2-L/\@=VU^H'_P=02P,$%     @ 2SIQ6GYQ7P]X)@  Y'<  !@
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MY'5#;*,X!;F$-45N)(NL:["3F('LHZ2T&6#[/_S:9MXY<"\(BGQ=2E<_Y8F
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M><0'9"2S.U(]<](NE[Z*L]5$,K<Y6/4?#"\8S[C$O=T9-4$4KWP%,E@AXT%
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MF0X/T/?+EGR7_H$)P@_[_OQ_ %!+ P04    " !+.G%:QL-RZB@&  #[$0
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M*#JG\98V95-P0[\E0_KGJ>#MW"/>O)3*B'];Q1[G#4O\X7C\MJ<X]4=L\O8
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M)\EKUD<6"9BN\0(IS%6FO+=NRL;<%(7.V!Q:77HGE=%COP;W7U]>GK^9B?/
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MQVOUH9.D"BNOCH+HP J'-$OX'4M5!S47Y/LMU+FM^#P%T)!+!(DMK*W*Q0H
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M)J>?K[Z>W=Q>3#^=T=7GV[/9J.< ZR=[:0,QK2&27T#T$[K4RJTLG:F,LZ<
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M#?0VB,.2'F/HV("^KRRU03?A /WS;O$W4$L#!!0    ( $LZ<5IK\[5L@P0
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M>G*ALA-H?"(I41<-N\#J$3?X"U!+ P04    " !+.G%:K"]*7 03   Q.@
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M&)VC#*)D97;8-$<C((TRM7'K'E&1:O.@-6*(;%M?PFMD#[$ 2,<%/^L]+E!
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M1&%_H&@?RGS%/PJ<YF69+_GC0DDP2 /P_2S/2_] &]2_$OWPOU!+ P04
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M6]#L1,,*]'^CM3L*[*";QI-_ %!+ P04    " !+.G%:]Q6!T90#  !K"
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MZ?:N=%.B\;PF4+RR+C#G2GN*7>;Z,P'").CS!>=J$Y@"W8<G_@M02P,$%
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M&+H0)O,BC$S*19+$;4-V"$$VCMIXMNHBO.?G6&$XB.O!EL^;M<6@1[/DQD%
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M:9#DCABR Y0%7X#LT1'6< :%DRB%.V5; +)N:W8N5;:(&]6JD3-/MEI5<JP
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M1H1P:X4\.$T-$N"7@L\@IM&DO]PA9\&KP5E/BP);U^@]Y8:9(VJ,$;P#QUD
M6].5Y._8;M<&DR<$'9IIH'![WJH;"6B5K'[1$@&S85M5W:V!F1V*<8'A00PI
MM03D878\O0:\'E8T/ ,%CD5;T.PQ?!-,0@,[U9J--ZT@WK3S)6P%\%W[$$G8
MSK@"PINR:.,0#>>)XQ+YZ%!'48R-A1N<,Y6WB7C1>G'_*72)"0788AB"M_#0
M#J:$I,Q#T);[?%.TP2"JG4TA"Z,[V&$\*]YDUAK(67?XF5]]B)VP(QA"%B1B
MC?41S\2CO8\;"&C)P%C.AVWA*( F9!N&_T"_%!P\FH?<ERU,=8*0)@--^ 6]
MX<:1*TA[\!)<7-+V/J7,"477H7=J-/LI#MCEUK>CW,S5#O:WE(0& > V*T&3
MM-EBF56<_ Y6MV!Q4>W$9A,!*!>@K"<RQA<A8WPQF?A]H22"3-GHNJ6M'\L?
M3P^S D@U-M)HT&ET61'_POL[Q?!^SZO><)(:@52.03:T_#E%,RCV9T$<\;2Z
MT>AB",I33N#7R\L/(:$XP<E'@9./)EGPV=$Q!21N*II-2.#E!*]R;/%C_)Z>
M+ =G\,_/1[MRG^=,30:@ <3?2K(_\,X'>1#CUFHC<2'0>YB9BE01!@!QK79L
M#$B\&06+.XI)*MS'"K>1@:5S6@XHX*N8.Z,S8EP.6A0U"4(P4D4;G#IYDAT0
M.4^B$,?/4ET<),([HQR.\BXKV$SO"/%+)'=@.IL",ZA@RDK!!HS]"[->1V#=
MN(0U4T+W. C=XTDY> UPLA70038_OQT3INE!@/*1<4A("D1&%$V@,(G_2G@*
MYPTKM8(C X[Y5V.;FD0!9"=&<!(TT+?GH2(D+=_H^UWCD>NX/6A38 .^LL9@
MB@GZN?80>.A%(+R.[ADNCBK1@M-A9T%D*O4'PJ8&G'!]:!J1.9"0$#S$ *,I
M!J12J((!'9.T4B7J/& 6>-@P""J\0B./:]7V7B9"1>.B_+:"COV+7J)1/\N8
M\#)FNF5K94\]URF 5<HD&)N0:3I*\8%3#Z IN*8",S$4M 7'&XX$'7DT<S@#
MF#?.2)!_Y/_P:YMYVTZE/)BCM2E=[9 GC)5!G5>@R.D,%QP<.<9(H\ ZT8')
M$8>M2=$AJ0*8H;EA)ZQ'.#( JX&>9D>&T[4]*GPN8O@6*YODT8QK']#:4R&)
M/"G)""-C]Q;D)9@418]YPJ^,:S#Y<5\H '#%:E!JP3V$W0:5Q![4+--M/H\I
ME&3S^BN89U?^8/OMQ_$V')=#)=Q050NRAZM@N-HFJE0X*11>M^%D4:$#Q=-!
M2< D4\KN25!V3R;UU-4 P8UINND1-"QU" ,'&4=$\I;#D1$<SGQU16G@310S
MP)BM@&\)>'.Z[#"B).L9CB58 '2E)9+2;JW6'@YB @D=FSXL1& E ;^9&%'8
M#LYY8$ @EQ*HEK/LA54W, V,U4FDGG=/%::D=8)@MMXI_%(W-W5J^Q KSR3$
M-L3-4SOY4]C)GR;WX9(QF\L^ L"&@8&.T=V<'F7--4O#@>*'-GR8P$M0Z%W.
M 3ATBE 5T/G"(YFC=]R*O/<]"RQ@YD@U11)ZKWF3'DX*(P"*Y_M-A%V71-H!
M8\&Y0I0]#Z)"%FVG;DG6F*(XM]6B^5/SW 9RR.$T:XTQ(?'?8+#>&K-0&6)U
M)2F(&!; '  H#8I[C?#4GQ:*$\C<G!Q+8Y4^2P3'0DD60(-,480,MB/5$;2\
M0#W6*/DXRP&>^2B%% <(T5(B*OR>!<[*TF^ DJU$*1*=B$5_)4M_CT,4O6#7
ME7G8=]/W7$1Z(=8?Q=W"LI!:;TK0 , '#*YG-Z "]$FS7ON$Y*WD1*ABQX@M
M):A%$-,EIOY&BSH&U_O[M#.X.(W%WJ>31^H-Z(4:.3)^'N]X>X/APS! []^H
M?7"3 D8!]MY(&)6 &AA_3?E;3,&AG-#3H*\%QH$^DTQ _H5+,U%(,!#*6^25
M8^%C!(ZSVYRNP#2@\\!=O, *D!A*-IMH<06Q=M>X..T:*\6VAT=%,TAPPCVE
ML8GJD&J;H!E+2L#$U^U@0,;4J*1_A.!G^Y-3)I21$[RP!<U_<$X"#P&KK-B1
M]XI!%DY5,^+G^(VE#!_*<*L1D((-Z6O#9N4:4,@Y1G&E*)HR5XG#F+J&0'#7
MAC 1Z*.:B_;V=,JDK">-#8M):?V ]8O6UQN JJ7XTZC83P^TG6?C8V6+@]]0
M&(E!K&KI",SH *#WF^==U4GQQQ3 FV?+<=_(^\_$1AF +1Z#8ZLP;W="!3^5
M!K<T%*NO?!"'O8BXE8 BUAU6^V%P+15ZG/3T[-F=__TOC6[$[YR>1]&)O+@
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MYQ,F6?[$=Z<%$?HAP<=LO\_!\V:/,*W7.<QI)[9SV.,=$RRA.:A5UC?KC:K
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MWDZS+UNI^C>\%?P[KC:"[E*!:TH-!R.22-6*:&L863OA6DE#,NB6.?UW4-D
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MJ]<=4M/)ZE)2"5H4]B*P%)JN%?8SH7L<2F- ZRLA]%XP >J;X>P?4$L#!!0
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M==;Q0%63KQ*,W+AILY2&9I?;9O2S0&4-Z'PEJ7=JP09H?C^C?U!+ P04
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M/QOT'%!MH]9.C*R:YF@I#;5:S6].O2TJ>X#V,TG>VTRL@JY;GOX+4$L#!!0
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M@;@ WL\Y5]L!'E#>\X[_ 5!+ P04    " !,.G%:&>H]S: $   9#0  &0
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M2,GUD]C\21M[*H*IX*IZHDV]UDLLE)9*B[Q1!@8Y*^HW>6G\T%&(G0\4<*.
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M:T>Q@Z;E_(\4TD1"21)@3(/2U7)C=X<)(,X.,[;#&(/7-(70TWUE.\!)._,
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MYO1F0F4-Z/^UE.9%L ':5]CX/U!+ P04    " !,.G%:(3F0(Y@"  #^!0
M&0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RU5&UOVC 0_BNG=*I::24A
M@8ZV$(FW:976#@'=U(\F.8A5QV:V4^B_G^V$+)4HTC[LB^VS[YY[SO9S_9V0
M+RI#U+#/&5<#+]-Z>^O[*LDP)ZHEMLC-R5K(G&ACRHVOMA))ZH)RYH=!<.WG
MA'(O[KN]F8S[HM",<IQ)4$6>$_DV0B9V Z_M'3;F=)-IN^''_2W9X +UTW8F
MC>77*"G-D2LJ.$A<#[QA^W;4L?[.X2?%G6JLP5:R$N+%&O?IP LL(628:(M
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M-N>Z0@5A%NCYA'.UZ9BBJ:YY_;]02P,$%     @ 3#IQ6K'*W< B P  ;@T
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MEG@;R G;?X7$4$/S^2P0T2_:)W,M _E;(5F8@)6"D-#X'S\F060 =OT%@),
MG-<":@F@%AF-E46V!EABM\O9'G$]6['I@RB;"*W<$*J7<2JYNDH43KK3X<UH
M>#WT^J,9ZGO>W?UH-AS=H/'=[= ;?IFB<X]1'ZCD.$J=+9''84$DFA#Q(!"F
M"S3C> %H CZ0'9X'<('.!R Q"<0%^HCNIP-T?G:!SA"A:+9F6Z$PHFM*)5Y+
M,/U$Z.=8J/."T 'XEZAF?T".Y=0+X-[KX;4\W%21I;DY:6Y.Q%=[*3>RHF1)
M?$PEZOL^VU))Z J-64!\ @+]O%4 -)00BE]%9F/V>C&[WKM78H-]Z!EJ<PK@
M.S#<]^_LIO6IR'I%9+D@:FD0M3)V-S$OU)X^%(!:]:@FBGS'9(V(3#]B=J[3
ML3I=<Y?U<SRIX;2<=%).9SW562_5>4V8S[=/19I*@:>N145D.8^-U&/C38NR
M4640%9'E@FBF032K+,J8K)FI-[ME6?\49>D=_]-/*_73*O7CK=7RD2+II;A3
MEZPBLIS%=FJQ_::UVZXRB(K(<D%TTB Z5=9N*=FIOCM'&R&[#W)V;.NYP[!*
M#8V7Y EXX1N_%'BJ^*K8\C8SC93]I@6<T%<51D5L^3">NR.[M.<XM8@3MNP;
MWW:.GL %L^K-H_HT,\VP_A+YAOF*4($"6"J8==E2>!XW]_% LDW4'\^95-UV
M=+A6'T3 ]01U?<F8/ QTRYU^8KE_ 5!+ P04    " !,.G%:P^#O\Y,#  !Z
M#P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6RM5VMOFS 4_2L6J[96
M:@OFD4>7(*5TCTA;%RWM]MD%)W@SF-E.LDK[\;.!D=!0-#:^)#;X'LZYV(=[
M)SO&OXL88PE^)C054R.6,KLR31'&.$'BDF4X57=6C"=(JBE?FR+C&$5Y4$)-
MV[(&9H)(:OB3_-J"^Q.VD92D>,&!V"0)XH_7F++=U(#&GPN?R3J6^H+I3S*T
MQDLL[[,%5S.S0HE(@E-!6 HX7DV-&;P*H*<#\A5?"-Z)@S'04AX8^ZXG\VAJ
M6)H1ICB4&@*IORT.,*4:2?'X48(:U3-UX.'X#_K;7+P2\X $#AC]2B(93XV1
M 2*\0ALJ/[/=>UP*R@F&C(K\%^S*M98!PHV0+"F#%8.$I,4_^EDFXB  NL\$
MV&6 _;<!3AG@Y$(+9KFL&R21/^%L![A>K=#T(,]-'JW4D%2_QJ7DZBY1<=)?
MSM_=SM_.@]GM'9@%P:?[V[OY[3NP^/1A'LS?+,'I78S!/,E4NH%D0*I9P-0T
M?7PEU"@5C)((21R!:T11&F*PU%S.P.D-EHA0<08NP/WR!IR>G($30%)P%[.-
M0&DD)J94 C0-,RS)7A=D[6?(WN#P$CCP'-B6[3:$!W\?[M3#396V*G=VE3L[
MQW/^+7=-^@I MQE0']DKH5*-IX8ZDP+S+3;\ER_@P'K=I+8GL)IVI]+NM*'[
MZM5O,9?D@6*0,HD;WV8!X>40VD^VOC4QMX<2CE>H=^/!:E6-FUMQ<UNYS:*(
M:(] %&2(1!=JTX4H(Q+1)I(%UN" @FM#SQX]8=JP#'J6ZS53]2JJ7CO5,-PD
M&YH?(&4^)"2RB:-WE"9G.'+&SA..WA%'9P0]=]S,<5!Q'+1S7-[K$V-=6 /P
M"P0%7^6]X,UJI<SX'"PP)RP"; 5F$<MTYL_5Z)LRK[TM-*EJ?6S7P] 36"U#
MPRI#P[Z-8-BG]I[ :MI'E?;1_QM!*T17M:.C76Y;KFTU;_)Q)6/<HV>T8G75
M,VYP%G?@V<V"H+7_LEM]>$L[2E<Q)=H3#W+L9WP2'M0IL(,+%=:C+2>(4;IN
MM)=VP,[">D*KR]^7&K#W6@/V6FSTA5;7OR\W8 _U1CM&9\7.T5:&@V>^I7!?
MF\ ^BY-VL,Z*CHN8B\,JHBYI7\/ 7HJ8=I3.6HYK(ELW!34IYD%CI+O2CXBO
M22H Q2L595T.53@O&KUB(EF6]TH/3*K.*Q_&JCG&7"]0]U=,[;URHMNOJMWV
M?P-02P,$%     @ 3#IQ6DWO&CY=!   T1D  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#,N>&ULO9EM;]LV$,>_"J$50PLLEB@_)9EMP+6\+<6<!$F[ 7O'
M2+1-E!(UDK838!^^I*1(EBTS4<#L16(]W?_(GXZG.VFT8_R[6&,LP6-,$S%V
MUE*FEZXKPC6.D>BP%"?JS)+Q&$FURU>N2#E&46844]?WO($;(Y(XDU%V[)9/
M1FPC*4GP+0=B$\>(/WW&E.W&#G2>#]R1U5KJ ^YDE*(5OL?R6WK+U9Y;JD0D
MQHD@+ $<+\?.%%X&\$(;9%?\1?!.[&T#/94'QK[KG:MH['AZ1)CB4&H)I'ZV
M>(8IU4IJ'/\6HD[I4QON;S^K_Y9-7DWF 0D\8_1O$LGUV#EW0(27:$/E'=O]
M@8L)];5>R*C(_H-=<:WG@' C)(L+8S6"F"3Y+WHL0.P9P-X) [\P\%]KT"T,
MNJ\UZ!4&O8Q,/I6,0X DFHPXVP&NKU9J>B.#F5FKZ9-$W_=[R=59HNSD9':S
M6,SO9E?3/Z_^F7Z]NKD&T]_OYO/%_/KK/?@88(D(%9_ &?AV'X"/'SZ!#X D
M8$$H57=-C%RIQJ"5W+#P]SGWYY_P]V5#.\#O_@)\#YXWF,_,YC>A[ !XD9D/
M&\P#LWF PP[H0FWN]^KFK@)7TO-+>GZFUSM%;TVP((H-F*XXQFH]R"8D1A&]
MLB]%BD(\=M32%9AOL3/Y^2<X\'YM F13++ D5H/7+>%UC?"N67*F%ODFB= #
MQ2!%3YJ?2B8A)EM]J EE+MG/)'5.VT[\_LC=[@,R>FT+R))8#5"O!-0S II&
M$=')$5& 8K9)I-"0,EB2@9!M,5<I;JMR=YJ1"YF0C4LR=S/8A^8=0#..I"TT
M2V(U:/T26M\(;8$>2;R)@0)"),V6)&#+8TX5PE3]/6'$F\CEOB#<0S?L' :<
M<4!MV5D2J[$;E.P&[0*NC#=58*A'M,IVVY(HQZL-19+Q)X"22+&,8\Q#HFQC
M0K%Z<"6X,1@'1RMX.#B,1N,PVQ)M<-BM;F$-U+ $-6R;]\%_H B]IDD;Y=H^
M 6R*!9;$:AC/2XSG1HRW1<I7]5^B2ER!5-SHY1BJ@ZKH; *9"T)O[VYZG=Y!
M^!B]M@5D2:P&Z*($=/&6."/)J3@SRK6-,YMB@26Q&D;H556N9SO2"L6#4(.'
MR=_LN"TE6VIU3'O- 'Q-O,T?SUXJ:<U";2/-JEI@2ZT.L>H)H+DI>%-=:]9L
MS=-_L4P.;'FL4ZJ*?VBN_JT5MV8_K<EUCVOE(W+OT13 JBN YK; ;H5K=M8:
MWW&K ;U#?._1'L"J/X#F!N%_*7+-8VA-M7^TG+N''5Q@RV4=:]4Z0'/OT/SH
M,%?%9LG6E*QV#;;4ZCBK!@.:.XRW%"Q6FXQ"[:#\Z1[EPO?H'V#50$!S!W$Z
MZD[7R&;)UIRL-ANVU.HXJW8#FON-MT2=U9:C4'NAZ YL.<TQN7NOS_7'C@7B
M*Y((0/%2R7N=H<JL//]^D.](EF9OU!^8E"S.-M<819CK"]3Y)6/R>4>_I"^_
MXDQ^ %!+ P04    " !,.G%:2 Z2]H4#  #>#@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6RU5VUOFSH4_BL6FZY:J2L0$Q)ZDTA;TVF5]I+U95=7
M5_O@PDEB#3"U3;+>7W]MH 12%ZV[Y M@..?A>1Z.S?%DR_@/L0:0Z&<2IV)J
MK:7,SFQ;A&M(B#AE&:3JR9+QA$@UY"M;9!Q(5"0EL3UP'-]."$VMV:2XM^"S
M"<ME3%-8<"3R)"'\X1W$;#NU7.OQQA5=K:6^8<\F&5G!-<C;;,'5R*Y1(II
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M0#U?,B8?!WJ+4V]I9_\!4$L#!!0    ( $PZ<5KD5 ^G<P(  )(&   9
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;*U576_:,!3]*U96353:<+[*N@XB
M04,U'MHQVF[:HTDNQ*IC9[:![M_/=D)&J[1B4E^([_4])_=<FY/A3L@'50!H
M]%@RKD9>H75U@;'*"BB)ZHL*N-E9"5D2;4*YQJJ20'('*AD.?7^ 2T*YEPQ=
M;BZ3H=AH1CG,)5*;LB3RSP28V(V\P-LG%G1=:)O R; B:[@%?5_-I8EPRY+3
M$KBB@B,)JY$W#B[2V-:[@A\4=NI@C:R2I1 /-ICE(\^W#0&#3%L&8AY;N 3&
M+)%IXW?#Z;6OM,##]9[]RFDW6I9$P:5@/VFNBY%W[J$<5F3#]$+LOD*CY\SR
M98(I]XMV3:WOH6RCM"@;L.F@I+Q^DL=F#@> 8/ "(&P X7- _ (@:@#1L8"X
M ;A1XUJ*FT-*-$F&4NR0M-6&S2[<,!W:R*?<'ONMEF:7&IQ.YHMO\^GB[A<:
MWZ1H^OU^-K^>WMRAWCC/J3T8PM",U[?+1*>HEX(FE*E3]!'=WZ:H=W**3A#E
MZ*X0&T5XKH98F[XL.\Z:'B9U#^$+/00ANA9<%PI->0[Y4P)L!+6JPKVJ2?@J
M8PI9'T7!!Q3Z8=S1T.7Q\*@#GAX/#U]1$[5G%#F^Z+_.J&O.-4_<S6,=Y$)5
M)(.19RQ"@=R"E[Q_%PS\+UTS>DNR](W(GLPO;N<7O\9NSL.09M3=X*ZIU>@S
MA[8VN4V"R#?79GLXC8ZBX'/PM"CM*/+/!VU1W3T^^+>6(-?.]13*Q(;K^HJW
MV=I8)\98G0$]RQO#'3N?P?]H:K>^)G)-N4(,5H;2[W\R+<G: >M B\IYPE)H
MXS!N69B/!DA;8/970NA]8%_0?H:2OU!+ P04    " !,.G%:I<6":80"  #,
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RM5<ENVS 0_15"#8H$
M:*-=62H+:.P&]:%I8&<Y,]+8)D*1*DE;R=]W*"F"$RMN#KU(7.:]>6]$CM):
MJD>] C#DJ>1"CYR5,=6YZ^I\!275Q[("@3L+J4IJ<*J6KJX4T*(!E=P-/"]Q
M2\J$DZ7-VK7*4KDVG FX5D2ORY*JYPO@LAXYOO.R,&/+E;$+;I96= ES,+?5
MM<*9V[,4K 2AF11$P6+D?/?/QXF-;P+N&-1Z:TRLDP<I'^UD6HP<SPH"#KFQ
M#!1?&Q@#YY8(9?SI.)T^I05NCU_8+QOOZ.6!:AA+?L\*LQHYIPXI8$'7W,QD
M_1,Z/['ERR77S9/4;>P)9LS7VLBR ^.\9*)]TZ>N#EL /WH'$'2 X*. L .$
MC=%666-K0@W-4B5KHFPTLME!4YL&C6Z8L%]Q;A3N,L29;'IU]^/JYO=L^F-.
M#N=X1HHU!R(79"HV((Q4ST?D< *&,JZ/R%=R.Y^0PX,C<D"8(#<KN=94%#IU
M#6JQC&[>Y;UH\P;OY)U ?DQ"_PL)O" :@(\_#@]?PUVL0%^&H"]#T/"%_R[#
MD)<6' V#[44[UQ7-8>3@3=*@-N!DGS_YB?=MR-E_(GOE,^Q]AOO8LQFM\?08
M4(SRP:_6PN,&;CO )HOBZ"QU-]L.!H+\DZ0/>J4LZI5%>Y7=XVVW9ZI2<HF^
M!\6U#,E67M\/HOB-NMVH,R^.A]7%O;IXK[I+)AA>LH(LI1P^[O%.UCC:*=Q
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MVCL1XR7T#'68"N![,/I__&;[UE]59:5)L* AL()@[5RP=JU@C[MH 1RQ-5H
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MIOO6#@MJH5 : _J^$D(_3\P/AJ8L^1=02P,$%     @ 3#IQ6G#DLCO, @
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M2*L2>LN7(/0:;T%(RQ8RRU:7SEE!-]N4FLH#F:R5"IG?@;ITS@H:NLTE7O_
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M2'=?5NU9-=&B, W+B]#4_ICAACI:E"6 GJ^$T.^3<H.F1Y[\!U!+ P04
M" !,.G%:;GMI(M$#  #0$0  &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6S%6-MNVS@0_15"6RQ2((VNENVL;<"V4C1 BS7B=O>AZ ,CC2TADJ@E:3OM
MUY>D9,529"%9$,A+3%)SCF;.S"@D)P="'U@,P-%CEN9L:L2<%]>FR<(8,LRN
M2 &Y>+(A-,-<3.G69 4%'"E0EIJ.9?EFAI/<F$W4VHK.)F3'TR2'%45LEV68
M_EQ 2@Y3PS:."W?)-N9RP9Q-"KR%-?!OQ8J*F5FS1$D&.4M(CBALIL;<O@YL
M5P*4Q3\)'-C)&,E0[@EYD)/;:&I8TB-((>22 HN?/2PA3263\.._BM2HWRF!
MI^,C^T<5O CF'C-8DO3?).+QU!@9*((-WJ7\CAP^01700/*%)&7J+SI4MI:!
MPAWC)*O PH,LR<M?_%@)<0*P_3, IP(X;8!W!N!6 />E *\">$J9,A2E0X Y
MGDTH.2 JK06;'"@Q%5J$G^0R[VM.Q=-$X/AL_6E^=X.6\]7MU_EG=+$6=17M
M4D!D@]:<A \?%D+4""U))BJ-896KFT<Y!I3DP@9S$&7 )>#O JBR8._110 <
M)ZD8?4#?U@&Z>/<>O9.(KS'9,9Q';&)RX;_TP@PK7Q>EK\X97VT'?2$YCQFZ
MR2.(F@2F"+R.WCE&OW!Z&0,(KY!K7R+'<KP.AY8OA[L=\.#E<*<G&K?.I:OX
MW'.YC#&%*F$K_%.E94XISK<J19?'Q$5(Z(^6N$@X3I-?$%VB>49VPOK[9T&)
M;D5*V8^N_)3O][K?+S]1UZS (4P-\0UB0/=@S/[\P_:MO[JTU4D6:")KZ.[5
MNGM][)7N]TKW\+11H-2[2\F2<: 8Y;=Y/W.=@:BA_:E"'4:>-VH:!<^-'&LT
MJ(T:$0WJB :]$2T)4QV])21BB)$TZHJAE^.UU:"3+-!$UM#.K[7SW[@+?9VZ
MZR0+-)$U=!_6N@^U=V')Z)_TCN_:K29\;C,8^ZT>?&YCNV=:<%2',^H-YTX(
MA&D8JRJ)8"]V:(6JI2J<SO^?O92OK0R=9($FLH:4XUK*\1MWY%BG[CK) DUD
M#=UMZVES:6GOR8JRT7"C<:LI.XR&PV&K*[N8[%%W6]HG&V:[/R9Q1DGR[27:
M0B[VNZDJ&AR)O7G"N-S_[J&W1_OI7ULL6MD"76Q-:9TG:9TW;M3* 5WBZV0+
M=+$UQ7\Z/-B]>^3_UZMNQ^;3;6]C.ZV&@W:W/K>R/==IM:MY<M3-@&[5E0$3
M#HOLE^>^>K6\EEC(:PEY5&ZMS^WKN3JDFT\TY5W'%TRW2<Y0"AM!:5T-A4NT
MO#XH)YP4ZD!]3[@XGJMA##@"*@W$\PTA_#B1+Z@O<6:_ 5!+ P04    " !,
M.G%:L*HXQ;X-  !+K@  &0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6S%
MG5MOXS8:AO\*X2T64Z"-K9,/LXF!3"217'3:8-+#Q6(O%)N)A;$EKR0G,XO]
M\4O)BFG:-&.U[R"]Z,0.^7R4\I+ZR%>B+I_SXG.Y$*(B7U;+K+SJ+:IJ_;[?
M+V<+L4K*BWPM,OF;A[Q8)97\6#SVRW4ADGE3:;7LNX/!L+]*TJPWO6R^NRVF
ME_FF6J:9N"U(N5FMDN+K![',GZ]Z3N_EBT_IXZ*JO^A/+]?)H[@3U6_KVT)^
MZN\H\W0ELC+-,U*(AZO>M?.>#[VZ0E/B]U0\EWL_D_I0[O/\<_V!SZ]Z@[I%
M8BEF58U(Y#]/XD8LES5)MN,_+;2WBUE7W/_YA1XW!R\/YCXIQ4V^_".=5XNK
MWKA'YN(AV2RK3_DS$^T!!35OEB_+YO_DN2T[Z)'9IJSR55M9MF"59MM_DR_M
MB=BKX+HG*KAM!?>P@G.B@M=6\ XJ^,&)"GY;P3^L<.H8@K9"<&Z%85MA>'@,
MDQ,51FV%T;G',&XKC,\]K9.VPJ21P_;OU_SQPZ1*II=%_DR*NK2DU3\T"FIJ
MR[]YFM5BOZL*^=M4UJNF=^SZ4T1NKF_YK]<_D7?7\WE:BS!9DC3;=B7YZ7OR
M+A15DB[+[R_[E8Q:U^W/V@@WVPCNB0A#\C'/JD5)HFPNYH;ZH;V^X[X&H':
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MU;5G%CCV 4M>'HU2LE;K+"4D+832(B@MAM(HE,:@-(ZBZ<)UE7#=-U[/;AN
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M:3&41J$T!J5Q%$WO LK-<ZU6R?0FSYY$44EAIUE9%9M:VS\<K"38$EX[OK/
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M,+2#,]+\5IH_*&U1OE[%LI(R>9)2QALQ.BU^;_[ "U!'2A\$'<L*.E+Z*.3
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M$6!U*UZ_"+JIFM-7*N2]LGI<$YP0I@#R^Y)2T;RH"=H?1";_ E!+ P04
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M%8)&Z>6&>#YA28"\OZ)4O ^2!Q3-[<'_4$L#!!0    ( $PZ<5K#7,H@B@(
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M'T5;U67*GH> _#>+V?8AT$",<S$,%'1 P5&@_L<ZA!6\.1[;NC@\PZ$@WS\
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M"T\(C;,B(72!1(HYF.:1H+B1<XHD0S(%1!D]@R>("]VB4%+]]46;\V4%@:E
M=]Q5& 2!XS@]>]7T=#_-=S_LI47[:5[WLIFVY4-0^Q#\PP<J5%?4TN< K3*"
MO8,[7K K8C_)"_R+8$?#T5K^]\;M1J/+@2_,P!#JU@HJRS91[Y8S::AFDNG=
M._MJ5@U,B[;_TI2#[@[S!:$"93!7E,[YA1+ R^%1!I(M33M]9%(U9[-,U;P%
MKA/4^SEC<A/H ^H)'OX!4$L#!!0    ( $PZ<5H*XFXQ.0<  !!+   9
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MXGLNREM^5MU.JI&;+\B;,*GW*+^.:*%=-;.#.<_?MEUD=ZS=G4EMQS#MXU$
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M9\YL P  T!8   T   !X;"]S='EL97,N>&ULW5C=;MHP%'Z5*%VG5IH:0M9
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M?&..%Z(L$LVZE]VV0,?M]O<\;,MR9H[%55B+]7Z[_OZ_&GS]%U!+ P04
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MPP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 2SIQ6IE<G",0!@
MG"<  !,              ( !Y $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !+.G%:I[?_4J$(  #]-0  &               @($E"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 2SIQ6L[N1:E;!@
M/1H  !@              ("!_!   'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( $LZ<5HM6=E9D@(  #L'   8              " @8T7
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !+.G%:H@MH
M^W %  #<%0  &               @(%5&@  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ 2SIQ6AURI2>O"   QD\  !@
M ("!^Q\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( $LZ
M<5J7*PMG]0D  &(O   8              " @> H  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " !+.G%:?G%?#W@F  #D=P  &
M        @($+,P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ 2SIQ6L;#<NHH!@  ^Q$  !@              ("!N5D  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $LZ<5J0X$YC! ,   $'   8
M              " @1=@  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " !+.G%::]W/8Z,"  !+!@  &0              @(%18P  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $LZ<5KJA;%NO04
M !@.   9              " @2MF  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ 2SIQ6O]VJ*9 "   _!,  !D              ("!
M'VP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !+.G%:
MQX*IM-H$  !?#   &0              @(&6=   >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( $LZ<5K%5'21;0T  /0K   9
M      " @:=Y  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ 2SIQ6BSI(W Z!   H@D  !D              ("!2X<  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !+.G%:_Z> 64D$  #J"0
M&0              @(&\BP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( $LZ<5IK\[5L@P0  - -   9              " @3R0  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 2SIQ6JPO2EP$
M$P  ,3H  !D              ("!]I0  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " !+.G%:*;C"23 %  #C#0  &0
M@($QJ   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( $LZ
M<5KZ4#4PJ ,  ,H)   9              " @9BM  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ 2SIQ6H@M4O%& P  F0<  !D
M         ("!=[$  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " !+.G%:]Q6!T90#  !K"   &0              @('TM   >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $LZ<5J+HJU490(  (0&
M   9              " @;^X  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ 2SIQ6BQU:+Y# @  B@8  !D              ("!6[L
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !+.G%:/*4S
M.!$"  #=!   &0              @('5O0  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( $LZ<5H?%$W&^@H  /<Q   9
M  " @1W   !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M2SIQ6L$1X9V_)P  +X$  !D              ("!3LL  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " !+.G%:@)2-": #  #M"   &0
M            @(%$\P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( $LZ<5H^#,[,"P,  -4&   9              " @1OW  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 3#IQ6@_!FO2F @
M* 8  !D              ("!7?H  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " !,.G%:-6B$\;0#   E"@  &0              @($Z
M_0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( $PZ<5IZ
M4TC!G08  ! 5   9              " @24! 0!X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ 3#IQ6NJ7<@K+ @  B@8  !D
M     ("!^0<! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $PZ<5HA.9 CF (  /X%   9              "
M@<8> 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 3#IQ
M6M+P;P#&!0  /"@  !D              ("!E2$! 'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " !,.G%:57/2!L4"  #_"@  &0
M        @(&2)P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( $PZ<5JQRMW (@,  &X-   9              " @8XJ 0!X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 3#IQ6L/@[_.3 P  >@\
M !D              ("!YRT! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " !,.G%:3>\:/ET$  #1&0  &0              @(&Q,0$
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( $PZ<5I(#I+V
MA0,  -X.   9              " @44V 0!X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ 3#IQ6N14#Z=S @  D@8  !D
M ("! 3H! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !,
M.G%:I<6":80"  #,!@  &0              @(&K/ $ >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $PZ<5JSY&DE;0(  '\&   9
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M970U,2YX;6Q02P$"% ,4    " !,.G%:TX5RT&L#  !_#   &0
M    @(%?4P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M $PZ<5H*=*Z3<P,  * +   9              " @0%7 0!X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ 3#IQ6J6*D%X(!   ]10  !D
M             ("!JUH! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    " !,.G%:.[T'#.\$  #U&0  &0              @('J7@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( $PZ<5H%>EPAA ,
M "\+   9              " @1!D 0!X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @ 3#IQ6FY[:2+1 P  T!$  !D              ("!
MRV<! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !,.G%:
ML*HXQ;X-  !+K@  &0              @('3:P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    ( $PZ<5I!N=Y" @,  $@)   9
M      " @<AY 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @ 3#IQ6A]7+FN* @  5 8  !D              ("! 7T! 'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " !,.G%:@<<]O+P$  "1%0
M&0              @('"?P$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M 0(4 Q0    ( $PZ<5KI\3X?N (  !T(   9              " @;6$ 0!X
M;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ 3#IQ6H&F24P3
M P  U0D  !D              ("!I(<! 'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6Q02P$"% ,4    " !,.G%:FU->>@P$  #_#@  &0
M@('NB@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( $PZ
M<5I%D4T]N@(  ,D'   9              " @3&/ 0!X;"]W;W)K<VAE971S
M+W-H965T-C4N>&UL4$L! A0#%     @ 3#IQ6ID?FXNF @  ^ 8  !D
M         ("!(I(! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
M    " !,.G%:2K4]+<P"   ""P  &0              @('_E $ >&PO=V]R
M:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( $PZ<5J4!QM D 8  '!
M   9              " @0*8 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL
M4$L! A0#%     @ 3#IQ6C<D606/!   '!$  !D              ("!R9X!
M 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !,.G%:#[W/
M@R$$  #H%@  &0              @(&/HP$ >&PO=V]R:W-H965T<R]S:&5E
M=#<P+GAM;%!+ 0(4 Q0    ( $PZ<5K#7,H@B@(  -(&   9
M  " @>>G 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @
M3#IQ6@P&$,5U P  APL  !D              ("!J*H! 'AL+W=O<FMS:&5E
M=',O<VAE970W,BYX;6Q02P$"% ,4    " !,.G%: )&@[M$"  #-!P  &0
M            @(%4K@$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4
M Q0    ( $PZ<5H*XFXQ.0<  !!+   9              " @5RQ 0!X;"]W
M;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ 3#IQ6K649\YL P
MT!8   T              ( !S+@! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !,.G%:EXJ[',     3 @  "P              @ %CO $ 7W)E;',O+G)E
M;'-02P$"% ,4    " !,.G%:.C;@3^<%  #N,   #P              @ %,
MO0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 3#IQ6L?7<T]' @  U2L
M !H              ( !8,,! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ 3#IQ6A^=A6\) @  V"H  !,              ( !W\4!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %( 4@!U%@  &<@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>176</ContextCount>
  <ElementCount>360</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - COMMERCIALIZATION AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommercializationAgreements</Role>
      <ShortName>COMMERCIALIZATION AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommitments</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeases</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapital</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotes</Role>
      <ShortName>CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - NET EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureNetEarningsLossPerShare</Role>
      <ShortName>NET EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncome</Role>
      <ShortName>TAXES ON INCOME</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995211501 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995211601 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapital</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - CONVERTIBLE NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesTables</Role>
      <ShortName>CONVERTIBLE NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - NET EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureNetEarningsLossPerShareTables</Role>
      <ShortName>NET EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureNetEarningsLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99931203 - Disclosure - TAXES ON INCOME (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</Role>
      <ShortName>TAXES ON INCOME (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncome</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99931303 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99931403 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99931503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940104 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (The Impact to the Company's Consolidated Balance Sheet) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (The Impact to the Company's Consolidated Balance Sheet) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails</Role>
      <ShortName>COMMERCIALIZATION AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureCommercializationAgreements</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940402 - Disclosure - INVENTORIES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails</Role>
      <ShortName>INVENTORIES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - COMMITMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureCommitmentsDetails</Role>
      <ShortName>COMMITMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureCommitments</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails</Role>
      <ShortName>OPERATING LEASES (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails</Role>
      <ShortName>OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99940703 - Disclosure - OPERATING LEASES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>OPERATING LEASES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99940804 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails</Role>
      <ShortName>SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99940805 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails</Role>
      <ShortName>SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99940806 - Disclosure - SHARE CAPITAL (Additional information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails</Role>
      <ShortName>SHARE CAPITAL (Additional information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureShareCapitalTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - NET EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails</Role>
      <ShortName>NET EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureNetEarningsLossPerShareTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails</Role>
      <ShortName>TAXES ON INCOME (Summary of Taxes on Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>99941202 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>99941203 - Disclosure - TAXES ON INCOME (Reconciliation of Tax Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails</Role>
      <ShortName>TAXES ON INCOME (Reconciliation of Tax Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>99941204 - Disclosure - TAXES ON INCOME (Valuation Allowance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails</Role>
      <ShortName>TAXES ON INCOME (Valuation Allowance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>99941205 - Disclosure - TAXES ON INCOME (Uncertain Tax Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails</Role>
      <ShortName>TAXES ON INCOME (Uncertain Tax Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>99941206 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails</Role>
      <ShortName>TAXES ON INCOME (Schedule of Open Tax Years) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>99941207 - Disclosure - TAXES ON INCOME (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails</Role>
      <ShortName>TAXES ON INCOME (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails</Role>
      <ShortName>SEGMENT INFORMATION (Schedule of Segment Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>99941302 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails</Role>
      <ShortName>SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>99941401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>99941402 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>99941501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="plx-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>99941601 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20241231.xsd</File>
    <File>plx-20241231_cal.xml</File>
    <File>plx-20241231_def.xml</File>
    <File>plx-20241231_lab.xml</File>
    <File>plx-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="plx-20241231x10k.htm">plx-20241231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20241231x10k001.jpg</File>
    <File>plx-20241231x10k002.jpg</File>
    <File>plx-20241231x10k003.jpg</File>
    <File>plx-20241231x10k004.jpg</File>
    <File>plx-20241231x10k005.jpg</File>
    <File>plx-20241231x10k006.jpg</File>
    <File>plx-20241231x10k007.jpg</File>
    <File>plx-20241231x10k008.jpg</File>
    <File>plx-20241231x10k010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="662">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>107
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "plx-20241231x10k.htm": {
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "plx-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "plx-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20241231x10k.htm"
     ]
    }
   },
   "keyStandard": 306,
   "keyCustom": 54,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 32,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2024": 6,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 176,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 649,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 662,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.protalix.com/role/StatementConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "longName": "995200300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XM4auoMc-kObwGUUo2NaKA",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XM4auoMc-kObwGUUo2NaKA",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.protalix.com/role/DisclosureCommercializationAgreements",
     "longName": "995210201 - Disclosure - COMMERCIALIZATION AGREEMENTS",
     "shortName": "COMMERCIALIZATION AGREEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipment",
     "longName": "995210301 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "longName": "995210401 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement",
     "longName": "995210501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT",
     "shortName": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.protalix.com/role/DisclosureCommitments",
     "longName": "995210601 - Disclosure - COMMITMENTS",
     "shortName": "COMMITMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeases",
     "longName": "995210701 - Disclosure - OPERATING LEASES",
     "shortName": "OPERATING LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.protalix.com/role/DisclosureShareCapital",
     "longName": "995210801 - Disclosure - SHARE CAPITAL",
     "shortName": "SHARE CAPITAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotes",
     "longName": "995210901 - Disclosure - CONVERTIBLE NOTES",
     "shortName": "CONVERTIBLE NOTES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "longName": "995211001 - Disclosure - FAIR VALUE MEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.protalix.com/role/DisclosureNetEarningsLossPerShare",
     "longName": "995211101 - Disclosure - NET EARNINGS (LOSS) PER SHARE",
     "shortName": "NET EARNINGS (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncome",
     "longName": "995211201 - Disclosure - TAXES ON INCOME",
     "shortName": "TAXES ON INCOME",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformation",
     "longName": "995211301 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation",
     "longName": "995211401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.protalix.com/role/DisclosureRelatedPartyTransactions",
     "longName": "995211501 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "longName": "995211601 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables",
     "longName": "99930103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "plx:ScheduleOfUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "plx:ScheduleOfUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables",
     "longName": "99930303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "longName": "99930403 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesTables",
     "longName": "99930703 - Disclosure - OPERATING LEASES (Tables)",
     "shortName": "OPERATING LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalTables",
     "longName": "99930803 - Disclosure - SHARE CAPITAL (Tables)",
     "shortName": "SHARE CAPITAL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
     "longName": "99930903 - Disclosure - CONVERTIBLE NOTES (Tables)",
     "shortName": "CONVERTIBLE NOTES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareTables",
     "longName": "99931103 - Disclosure - NET EARNINGS (LOSS) PER SHARE (Tables)",
     "shortName": "NET EARNINGS (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables",
     "longName": "99931203 - Disclosure - TAXES ON INCOME (Tables)",
     "shortName": "TAXES ON INCOME (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationTables",
     "longName": "99931303 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables",
     "longName": "99931403 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables",
     "longName": "99931503 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_KD5G_ppkGEKfu9q5lyCQiQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_KD5G_ppkGEKfu9q5lyCQiQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
     "longName": "99940102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Useful Life) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_h6xjOEjkiUm3MR0Og5Jvhg",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_h6xjOEjkiUm3MR0Og5Jvhg",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails",
     "longName": "99940103 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Concentration of Credit Risks and Trade Receivable) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_eMpI1Y46mEm3V5aABb_sXg",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails",
     "longName": "99940104 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (The Impact to the Company's Consolidated Balance Sheet) (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (The Impact to the Company's Consolidated Balance Sheet) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:ConvertibleDebtCurrent",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_Wf4l6EemkUiStX1y_Xvkzg",
      "name": "us-gaap:ConvertibleDebtCurrent",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
     "longName": "99940201 - Disclosure - COMMERCIALIZATION AGREEMENTS (Details)",
     "shortName": "COMMERCIALIZATION AGREEMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA",
      "name": "plx:UpfrontNonrefundableNoncreditablePaymentReceivable",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA",
      "name": "plx:UpfrontNonrefundableNoncreditablePaymentReceivable",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "longName": "99940301 - Disclosure - PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Schedule of Property and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "longName": "99940302 - Disclosure - PROPERTY AND EQUIPMENT (Additional Information) (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "longName": "99940401 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails",
     "longName": "99940402 - Disclosure - INVENTORIES (Additional Information) (Details)",
     "shortName": "INVENTORIES (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
     "longName": "99940501 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)",
     "shortName": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "plx:EmployeeSeveranceObligationPayment",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "plx:EmployeeSeveranceObligationPayment",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.protalix.com/role/DisclosureCommitmentsDetails",
     "longName": "99940601 - Disclosure - COMMITMENTS (Details)",
     "shortName": "COMMITMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_HhtwKHGlsEOO6RfMSrfRww",
      "name": "plx:ExtendedTermOfAgreement",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails",
     "longName": "99940701 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)",
     "shortName": "OPERATING LEASES (Schedule of Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails",
     "longName": "99940702 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)",
     "shortName": "OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
     "longName": "99940703 - Disclosure - OPERATING LEASES (Additional Information) (Details)",
     "shortName": "OPERATING LEASES (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
     "longName": "99940801 - Disclosure - SHARE CAPITAL (Summary of Stock Option Activity) (Details)",
     "shortName": "SHARE CAPITAL (Summary of Stock Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gk0_QwpkNUi8I2fbbRac5A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gk0_QwpkNUi8I2fbbRac5A",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
     "longName": "99940802 - Disclosure - SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)",
     "shortName": "SHARE CAPITAL (Summary of Restricted Stock Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qjP7y_S0VUuKi14nuJCCzA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
     "longName": "99940803 - Disclosure - SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)",
     "shortName": "SHARE CAPITAL (Summary of Share Options Outstanding and Exercisable) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
     "longName": "99940804 - Disclosure - SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)",
     "shortName": "SHARE CAPITAL (Schedule of Stock Option Valuation Assumptions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A",
      "name": "us-gaap:SharePrice",
      "unitRef": "Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails",
     "longName": "99940805 - Disclosure - SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)",
     "shortName": "SHARE CAPITAL (Schedule of Stock-Based Compensation Expense in Statement of Operations) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
     "longName": "99940806 - Disclosure - SHARE CAPITAL (Additional information) (Details)",
     "shortName": "SHARE CAPITAL (Additional information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VM8wfhoeo0Cfc2e6wRsqqA",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "unitRef": "Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
     "longName": "99940901 - Disclosure - CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)",
     "shortName": "CONVERTIBLE NOTES (Schedule of Interest Expense Recognized) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
     "longName": "99940902 - Disclosure - CONVERTIBLE NOTES (Additional Information) (Details)",
     "shortName": "CONVERTIBLE NOTES (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_PqNi2C8w-UiBnkc4Uh5lLw",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EYL9IKHmnkqnNQvhCDuZ0A",
      "name": "us-gaap:DebtInstrumentTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails",
     "longName": "99941101 - Disclosure - NET EARNINGS (LOSS) PER SHARE (Details)",
     "shortName": "NET EARNINGS (LOSS) PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:DilutiveSecurities",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
     "longName": "99941201 - Disclosure - TAXES ON INCOME (Summary of Taxes on Income) (Details)",
     "shortName": "TAXES ON INCOME (Summary of Taxes on Income) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails",
     "longName": "99941202 - Disclosure - TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)",
     "shortName": "TAXES ON INCOME (Schedule of Deferred Tax Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails",
     "longName": "99941203 - Disclosure - TAXES ON INCOME (Reconciliation of Tax Expense) (Details)",
     "shortName": "TAXES ON INCOME (Reconciliation of Tax Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails",
     "longName": "99941204 - Disclosure - TAXES ON INCOME (Valuation Allowance) (Details)",
     "shortName": "TAXES ON INCOME (Valuation Allowance) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA",
      "name": "plx:DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails",
     "longName": "99941205 - Disclosure - TAXES ON INCOME (Uncertain Tax Position) (Details)",
     "shortName": "TAXES ON INCOME (Uncertain Tax Position) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails",
     "longName": "99941206 - Disclosure - TAXES ON INCOME (Schedule of Open Tax Years) (Details)",
     "shortName": "TAXES ON INCOME (Schedule of Open Tax Years) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_CJv_84vfq0aMskjfjX9YfA",
      "name": "us-gaap:OpenTaxYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfOpenTaxYearsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_CJv_84vfq0aMskjfjX9YfA",
      "name": "us-gaap:OpenTaxYear",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:ScheduleOfOpenTaxYearsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
     "longName": "99941207 - Disclosure - TAXES ON INCOME (Additional Information) (Details)",
     "shortName": "TAXES ON INCOME (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "p",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "p",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
     "longName": "99941301 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)",
     "shortName": "SEGMENT INFORMATION (Schedule of Segment Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
     "longName": "99941302 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)",
     "shortName": "SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_vAdZZrKJB0GA0kWl76_O5g",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails",
     "longName": "99941401 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Other Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "plx:OtherAssetsInstitutionsCurrent",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "plx:OtherAssetsInstitutionsCurrent",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
     "longName": "99941402 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails",
     "longName": "99941501 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EoGEj4NR3k60cggFbmTsmg",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EoGEj4NR3k60cggFbmTsmg",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941601 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_KFKHQh7CBUC1lg8cpMFN3Q",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20241231x10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:",
        "verboseLabel": "Accounts payable and accruals - other:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "AccountsPayableAndAccruedLiabilitiesOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).",
        "label": "Accounts Payable and Accrued Liabilities, Other, Current",
        "terseLabel": "Other",
        "totalLabel": "Accounts payable and accruals - other"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "AccountsPayablePropertyAndEquipmentSuppliersCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Property And Equipment Suppliers, Current",
        "terseLabel": "Property and equipment suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r52"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable - Trade",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r803"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties",
        "terseLabel": "Accrued royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r54"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less - accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r149",
      "r664"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones",
        "terseLabel": "Additional amount payable for achievement of regulatory and commercial milestones"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs",
        "terseLabel": "Additional amounts payable to cover development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r1011",
      "r1012",
      "r1013",
      "r1015",
      "r1087",
      "r1149"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r186",
      "r187",
      "r188",
      "r189",
      "r199",
      "r248",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r270",
      "r271",
      "r279",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r560",
      "r561",
      "r574",
      "r575",
      "r576",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r618",
      "r619",
      "r620",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r414"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r906",
      "r917",
      "r927",
      "r960"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r909",
      "r920",
      "r930",
      "r963"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r955",
      "r964",
      "r968",
      "r976"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Share-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r452"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Accounts receivables recoveries",
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Accounts receivables write-off",
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "plx_AmendedPfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "AmendedPfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r827",
      "r828",
      "r1007",
      "r1095"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "NET EARNINGS (LOSS) PER SHARE",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r118",
      "r150",
      "r175",
      "r223",
      "r229",
      "r237",
      "r240",
      "r251",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r518",
      "r522",
      "r562",
      "r656",
      "r733",
      "r818",
      "r819",
      "r857",
      "r884",
      "r1039",
      "r1040",
      "r1105"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r155",
      "r175",
      "r251",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r518",
      "r522",
      "r562",
      "r857",
      "r1039",
      "r1040",
      "r1105"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AtMarketEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "AtMarketEquityOfferingMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares",
        "terseLabel": "ATM Shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r890",
      "r913"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r890",
      "r913"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r890",
      "r913"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "country_BR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "BR",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "plx_CapitalizedResearchAndDevelopmentCostAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "CapitalizedResearchAndDevelopmentCostAmortizationPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized for research and development cost, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Research And Development Cost, Amortization Period",
        "terseLabel": "Amortization period research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r147",
      "r800"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r84",
      "r172"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r84"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "plx_ChiesiAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ChiesiAgreementsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements",
        "terseLabel": "Chiesi Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiExUSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ChiesiExUSAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex-US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ChiesiMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiUSAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ChiesiUSAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants issued (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants and rights outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COMMERCIALIZATION AGREEMENTS",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r126",
      "r136"
     ]
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative arrangement revenues and expenses sharing percentage"
       }
      }
     },
     "auth_ref": []
    },
    "plx_CommercializationAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "CommercializationAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMERCIALIZATION AGREEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_CommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "CommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment amount.",
        "label": "Commitment Amount",
        "terseLabel": "Subcontracting commitment amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r111",
      "r658",
      "r719"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares remain for sale",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875",
      "r876",
      "r878",
      "r879",
      "r880",
      "r881",
      "r1011",
      "r1012",
      "r1015",
      "r1087",
      "r1145",
      "r1149"
     ]
    },
    "plx_CommonStockNumberOfVotingRights": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "CommonStockNumberOfVotingRights",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes for each share of common stock is entitled.",
        "label": "Common Stock, Number Of Voting Rights",
        "terseLabel": "Number of voting rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r720"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common Stock, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r62",
      "r720",
      "r739",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common Stock, $0.001 par value: Authorized - as of December 31, 2023 and 2024, 185,000,000 shares; issued and outstanding - as of December 31, 2023 and 2024, 72,952,124 and 75,850,275 shares, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r659",
      "r857"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "verboseLabel": "In respect of:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risks and trade receivable",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r128"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r518",
      "r519",
      "r522",
      "r523",
      "r607",
      "r788",
      "r1038",
      "r1041",
      "r1042"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r518",
      "r519",
      "r522",
      "r523",
      "r607",
      "r788",
      "r1038",
      "r1041",
      "r1042"
     ]
    },
    "plx_ContractAmountUnderAgreementFacilityPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ContractAmountUnderAgreementFacilityPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents the share of payment to a contract research organization to cover proportionate share of the costs in setting up a facility.  May include equipment purchases but also other facility customization efforts, etc., none of which will be owned by the Company.",
        "label": "Contract Amount Under Agreement, Facility, Payable",
        "terseLabel": "Contracted share of facility cost amount"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ContractAmountUnderAgreementPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ContractAmountUnderAgreementPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount agreed to pay under the agreement.",
        "label": "Contract Amount Under Agreement, Payable",
        "terseLabel": "Contract amount"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ContributionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ContributionPlansMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution to Defined Contribution Plans [Member]",
        "terseLabel": "Contribution to Defined Contribution Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Current",
        "verboseLabel": "Convertible notes",
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ConvertibleNotesDue2021And2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r175",
      "r251",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r562",
      "r818",
      "r1039"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of goods sold",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r300",
      "r325",
      "r605",
      "r613",
      "r655",
      "r807",
      "r809"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance"
       }
      }
     },
     "auth_ref": [
      "r999",
      "r1000",
      "r1014",
      "r1029",
      "r1030",
      "r1031",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1086",
      "r1087",
      "r1088",
      "r1100"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adjustment",
        "verboseLabel": "Effect of Change"
       }
      }
     },
     "auth_ref": [
      "r139",
      "r185",
      "r192",
      "r199",
      "r255",
      "r261",
      "r271",
      "r488",
      "r489",
      "r502",
      "r504",
      "r527",
      "r529",
      "r530",
      "r532",
      "r533",
      "r534",
      "r539",
      "r542",
      "r544",
      "r545",
      "r596"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r139",
      "r185",
      "r192",
      "r199",
      "r255",
      "r261",
      "r271",
      "r488",
      "r489",
      "r502",
      "r504",
      "r527",
      "r529",
      "r530",
      "r532",
      "r533",
      "r534",
      "r539",
      "r542",
      "r544",
      "r545",
      "r596"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r139",
      "r185",
      "r192",
      "r199",
      "r255",
      "r261",
      "r271",
      "r488",
      "r489",
      "r502",
      "r504",
      "r527",
      "r529",
      "r530",
      "r532",
      "r533",
      "r534",
      "r539",
      "r542",
      "r544",
      "r545",
      "r596"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current taxes on income",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r1010"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r987"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r987"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r989"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r989"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r902",
      "r991"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r900",
      "r989"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893",
      "r982"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r983"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r894",
      "r983"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r981"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r981"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r892",
      "r981"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r895",
      "r984"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r897",
      "r986"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r897",
      "r986"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r898",
      "r987"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r901",
      "r990"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r899",
      "r988"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r896",
      "r985"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "verboseLabel": "Convertible notes conversions",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "verboseLabel": "Converted instrument, shares issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r19"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONVERTIBLE NOTES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "CONVERTIBLE NOTES",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r173",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r285",
      "r286",
      "r296",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r312",
      "r319",
      "r320",
      "r321",
      "r573"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r108",
      "r110",
      "r181",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r855",
      "r1008",
      "r1032",
      "r1033",
      "r1034",
      "r1094",
      "r1096"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "verboseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r298"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r181",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r855",
      "r1008",
      "r1032",
      "r1033",
      "r1034",
      "r1094",
      "r1096"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Term",
        "terseLabel": "Mature term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible notes",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Changes in deferred income tax asset",
        "verboseLabel": "Deferred taxes on income",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r134",
      "r1010"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Research and development expenses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "plx_DeferredTaxAssetsOtherTimingDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "DeferredTaxAssetsOtherTimingDifferences",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred tax assets other timing differences.",
        "label": "Deferred Tax Assets Other Timing Differences",
        "terseLabel": "Other timing differences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfDeferredTaxAssetsDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "negatedPeriodEndLabel": "Ending Balance",
        "negatedPeriodStartLabel": "Beginning Balance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "plx_DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additions to the valuation allowance for deferred tax asset.",
        "label": "Deferred Tax Assets, Valuation Allowance, Additions During The Period",
        "negatedLabel": "Additions to valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "plx_DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reductions to the valuation allowance for deferred tax asset.",
        "label": "Deferred Tax Assets, Valuation Allowance, Reductions During The Period",
        "terseLabel": "Reductions to valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "terseLabel": "Deferred tax liability of research and development costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax",
        "terseLabel": "Gain for the period",
        "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r99"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r339",
      "r340",
      "r361",
      "r732",
      "r833",
      "r1114"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "verboseLabel": "Contribution in connection with severance liabilities",
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r834"
     ]
    },
    "us-gaap_DefinedBenefitPostretirementLifeInsuranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPostretirementLifeInsuranceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postretirement Life Insurance [Member]",
        "terseLabel": "Contribution to Insurance Companies",
        "documentation": "Plan designed to provide postretirement life insurance benefits to retiree or beneficiary. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contributions",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r36"
     ]
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Financial expenses of 2024 Notes",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "verboseLabel": "Director"
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1146"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE CAPITAL"
       }
      }
     },
     "auth_ref": []
    },
    "plx_DisclosureOfLeasesOperatingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "DisclosureOfLeasesOperatingLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Leases Operating",
        "label": "Disclosure of Leases Operating [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r889",
      "r890",
      "r913"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r889",
      "r890",
      "r913",
      "r956"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NET EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r201",
      "r203",
      "r215",
      "r216",
      "r217",
      "r222",
      "r506",
      "r515",
      "r545",
      "r546",
      "r652",
      "r670",
      "r812"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r203",
      "r215",
      "r216",
      "r217",
      "r222",
      "r506",
      "r515",
      "r545",
      "r546",
      "r652",
      "r670",
      "r812"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net earnings (loss) per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r219"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET EARNINGS (LOSS) PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r218",
      "r220",
      "r221"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r465",
      "r493",
      "r846"
     ]
    },
    "plx_EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to utilization of carry-forward losses and other temporary items without deferred taxes recognition.",
        "label": "Effective Income Tax Rate Reconciliation, Utilization Of Carry-Forward Losses And Other Temporary Items Without Deferred Taxes Recognition",
        "terseLabel": "Utilization of carry-forward losses and other temporary items without deferred taxes recognition"
       }
      }
     },
     "auth_ref": []
    },
    "plx_EffectiveIncomeTaxRateReconciliationWithholdingTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTax",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to withholding tax.",
        "label": "Effective Income Tax Rate Reconciliation, Withholding Tax",
        "negatedLabel": "Withholding tax"
       }
      }
     },
     "auth_ref": []
    },
    "plx_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "EmployeeMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee",
        "terseLabel": "Employee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Unrecognized weighted average period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "plx_EmployeeSeveranceObligationPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "EmployeeSeveranceObligationPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee severance obligation payment.",
        "label": "Employee Severance Obligation Payment",
        "terseLabel": "Employee severance obligation payments"
       }
      }
     },
     "auth_ref": []
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "EmployeeStockIncentivePlan2006Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan",
        "terseLabel": "Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "plx_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to employees and directors.",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and directors"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Entities [Member]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r139",
      "r159",
      "r160",
      "r161",
      "r182",
      "r183",
      "r184",
      "r187",
      "r194",
      "r196",
      "r198",
      "r224",
      "r255",
      "r261",
      "r271",
      "r337",
      "r488",
      "r489",
      "r502",
      "r503",
      "r504",
      "r507",
      "r514",
      "r515",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r544",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r575",
      "r578",
      "r598",
      "r669",
      "r685",
      "r686",
      "r687",
      "r705",
      "r764"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r906",
      "r917",
      "r927",
      "r960"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r903",
      "r914",
      "r924",
      "r957"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "plx_ExercisePrice1.03To2.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ExercisePrice1.03To2.00Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price ranging from $1.03 to $2.00.",
        "label": "Exercise Price 1.03 to 2.00 [Member]",
        "terseLabel": "$1.03 - $2.00"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ExercisePrice17.20Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ExercisePrice17.20Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price $17.20.",
        "label": "Exercise Price 17.20",
        "terseLabel": "$17.20"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ExercisePrice3.55To3.73Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ExercisePrice3.55To3.73Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price ranging from $3.55 to $3.73.",
        "label": "Exercise Price 3.55 to 3.73 [Member]",
        "terseLabel": "$3.55 - $3.73"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ExercisePrice4.69To5.60Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ExercisePrice4.69To5.60Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to exercise price ranging from $4.69 to $5.60.",
        "label": "Exercise Price 4.69 to 5.60 [Member]",
        "terseLabel": "$4.69 - $5.60"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ExtendedTermOfAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ExtendedTermOfAgreement",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended term  of agreement.",
        "label": "Extended Term Of Agreement",
        "terseLabel": "Extended term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r651",
      "r849",
      "r852"
     ]
    },
    "plx_FillFinishAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "FillFinishAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fill/Finish Agreement [Member]",
        "label": "Fill/Finish Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_FiocruzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "FiocruzMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiocruz"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Financial income, net",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r741",
      "r882",
      "r1091",
      "r1092",
      "r1148"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Functional currency",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r964"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r964"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r964"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r964"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r964"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "plx_FurnitureAndComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "FurnitureAndComputerEquipmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture And Computer Equipment Member",
        "label": "Furniture And Computer Equipment [Member]",
        "terseLabel": "Furniture and computer equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_GainLossOnDebtConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "GainLossOnDebtConversion",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain (loss) on conversion of convertible debt.",
        "label": "Gain (Loss) On Debt Conversion",
        "negatedLabel": "Gain on conversions of convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss (gain) on sale of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r889",
      "r890",
      "r913"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment in value of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r93"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE TAXES ON INCOME",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r113",
      "r117",
      "r653",
      "r666",
      "r814",
      "r818",
      "r1017",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r278",
      "r280",
      "r548",
      "r550",
      "r554",
      "r680",
      "r682",
      "r749",
      "r796",
      "r850",
      "r1116"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r280",
      "r548",
      "r550",
      "r554",
      "r680",
      "r682",
      "r749",
      "r796",
      "r850",
      "r1116"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r465",
      "r466",
      "r475",
      "r484",
      "r846",
      "r1078"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r465",
      "r466",
      "r475",
      "r484",
      "r846",
      "r1078"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "plx_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure Line Items",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "TAXES ON INCOME"
       }
      }
     },
     "auth_ref": []
    },
    "plx_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure Table",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r457",
      "r465",
      "r472",
      "r473",
      "r474",
      "r478",
      "r482",
      "r494",
      "r496",
      "r497",
      "r498",
      "r700",
      "r846"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "TAXES ON INCOME",
        "terseLabel": "Income tax expenses",
        "totalLabel": "Total taxes on income",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r135",
      "r197",
      "r198",
      "r223",
      "r232",
      "r240",
      "r464",
      "r465",
      "r495",
      "r671",
      "r846"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r460",
      "r461",
      "r478",
      "r479",
      "r481",
      "r486",
      "r697"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance related to deferred tax assets",
        "verboseLabel": "Change in Valuation allowances",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r846",
      "r1074"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Differences in tax rate",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r465",
      "r468",
      "r846"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax computed at the statutory U.S. income tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r846"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeReconciliationOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Statutorily non-deductible expenses",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r471",
      "r1074"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Tax paid",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r171",
      "r483",
      "r484"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable-trade and other assets",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "IncreaseDecreaseInBankDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Investment in bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Decrease in contracts liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r1006"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "calculation": {
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Weighted average dilutive effect of 2024 Notes",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r217"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Weighted average dilutive effect of stock options and restricted stock",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r217",
      "r416"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r955",
      "r964",
      "r968",
      "r976"
     ]
    },
    "plx_InitialTermOfArrangement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "InitialTermOfArrangement",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial term of arrangement.",
        "label": "Initial Term Of Arrangement",
        "terseLabel": "Initial term of arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r980"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r980"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r891",
      "r980"
     ]
    },
    "us-gaap_InterestCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestCostsIncurred",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Costs Incurred",
        "totalLabel": "Total",
        "documentation": "Total interest costs incurred during the period and either capitalized or charged against earnings."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r572"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails": {
       "parentTag": "us-gaap_InterestCostsIncurred",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r317",
      "r827",
      "r828"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Interest Expense Recognized",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r169",
      "r170"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "verboseLabel": "Interest payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "plx_InterestReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "InterestReceivedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r804"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r801",
      "r857"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r146",
      "r151",
      "r264",
      "r265",
      "r267",
      "r616",
      "r810"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r806"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r805"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "Employee salaries and related expenses",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "plx_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Schedule of Operating Leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r591"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r592"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of Maturity Analysis of Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted cash flows",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "2029 and thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "LesseeOperatingLeaseNumberOfRenewalTermExtensions",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease, Number Of Renewal Term Extensions",
        "label": "Lessee Operating Lease, Number Of Renewal Term Extensions",
        "terseLabel": "Operating lease, Renewable term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, term of agreement",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "OPERATING LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LessorDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LessorDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING LEASES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r55",
      "r57",
      "r58",
      "r59",
      "r60",
      "r175",
      "r251",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r519",
      "r522",
      "r523",
      "r562",
      "r718",
      "r813",
      "r884",
      "r1039",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r112",
      "r661",
      "r857",
      "r1009",
      "r1028",
      "r1090"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r145",
      "r175",
      "r251",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r519",
      "r522",
      "r523",
      "r562",
      "r857",
      "r1039",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r57",
      "r58",
      "r59",
      "r60",
      "r175",
      "r251",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r519",
      "r522",
      "r523",
      "r562",
      "r1039",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Service [Member]",
        "terseLabel": "LICENSE AND R&amp;D SERVICES",
        "verboseLabel": "License and R&amp;D Services",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r832",
      "r867",
      "r871",
      "r1044",
      "r1115",
      "r1117",
      "r1118",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year",
        "terseLabel": "Maximum entitlement of development costs to cover per year"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r410",
      "r453",
      "r547",
      "r614",
      "r679",
      "r681",
      "r695",
      "r710",
      "r711",
      "r772",
      "r774",
      "r776",
      "r777",
      "r779",
      "r794",
      "r795",
      "r823",
      "r829",
      "r841",
      "r851",
      "r852",
      "r853",
      "r854",
      "r868",
      "r1043",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "plx_MilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "MilestonePaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment received upon achievement of certain milestone.",
        "label": "Milestone Payment Received",
        "terseLabel": "Amount of milestone payment received"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r410",
      "r453",
      "r547",
      "r614",
      "r679",
      "r681",
      "r695",
      "r710",
      "r711",
      "r772",
      "r774",
      "r776",
      "r777",
      "r779",
      "r794",
      "r795",
      "r823",
      "r829",
      "r841",
      "r851",
      "r852",
      "r853",
      "r868",
      "r1043",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r832",
      "r867",
      "r871",
      "r1044",
      "r1115",
      "r1117",
      "r1118",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "NatureOfOperationsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCOME (LOSS)",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r87",
      "r114",
      "r143",
      "r156",
      "r157",
      "r161",
      "r175",
      "r186",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r213",
      "r251",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r506",
      "r515",
      "r546",
      "r562",
      "r668",
      "r742",
      "r762",
      "r763",
      "r882",
      "r1039"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income (loss) for diluted calculation",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r202",
      "r207",
      "r208",
      "r209",
      "r210",
      "r214",
      "r217"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "New accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r910",
      "r921",
      "r931",
      "r955",
      "r964"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_NoncollaborativeArrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncollaborativeArrangementTransactionsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Other than Collaborative [Member]",
        "terseLabel": "Arrangement Other than Collaborative",
        "documentation": "Arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL INCOME (EXPENSES), NET",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "plx_Notes2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "Notes2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2024 notes.",
        "label": "Notes 2024 [Member]",
        "terseLabel": "2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "plx_NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Employees To Receive Benefits During Next Five Years",
        "label": "Number Of Employees To Receive Benefits During Next Five Years",
        "terseLabel": "Number of benefit eligible employees"
       }
      }
     },
     "auth_ref": []
    },
    "plx_NumberOfGlobalLicensingAndSupplyAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "NumberOfGlobalLicensingAndSupplyAgreements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of global licensing and supply agreements.",
        "label": "Number Of Global Licensing And Supply Agreements",
        "terseLabel": "Number of global licensing and supply agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r1018"
     ]
    },
    "plx_OfficeOfIsraeliInnovationAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "OfficeOfIsraeliInnovationAuthorityMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office of the Israeli Innovation Authority [Member]",
        "label": "Office of the Israeli Innovation Authority [Member]",
        "terseLabel": "Office of the Israeli Innovation Authority"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Tax Year",
        "terseLabel": "Open tax year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r814",
      "r1017",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r856"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r586"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r856"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r856"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "plx_OptionsAndRestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "OptionsAndRestrictedSharesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to stock options and restricted shares.",
        "label": "Options and Restricted Shares [Member]",
        "terseLabel": "Options and restricted shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other assets",
        "totalLabel": "Other assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r857"
     ]
    },
    "plx_OtherAssetsInstitutionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "OtherAssetsInstitutionsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount, as of the balance sheet date, of current assets related to institutions. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).",
        "label": "Other Assets, Institutions, Current",
        "terseLabel": "Institutions"
       }
      }
     },
     "auth_ref": []
    },
    "plx_OtherAssetsSundryCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "OtherAssetsSundryCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of current assets as of the balance sheet date, arising from sundry. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).",
        "label": "Other Assets, Sundry, Current",
        "terseLabel": "Sundry"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other General and Administrative Expense",
        "terseLabel": "Consulting fees",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r1147"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES",
        "verboseLabel": "interest expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "negatedTerseLabel": "Interest income",
        "terseLabel": "FINANCIAL INCOME",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r908",
      "r919",
      "r929",
      "r962"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r965"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r911",
      "r922",
      "r932",
      "r965"
     ]
    },
    "plx_OutstandingStockOptionsAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "OutstandingStockOptionsAndWarrantsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants.",
        "label": "Outstanding Stock Options And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "plx_OutstandingStockOptionsWarrantsAnd2024NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "OutstandingStockOptionsWarrantsAnd2024NotesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants and 2024 notes.",
        "label": "Outstanding Stock Options Warrants And 2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Company [Member]",
        "terseLabel": "Parent Company"
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "plx_PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of partial settlement of liability for employee rights upon retirement through transfer of related funds in non-cash financing and investing activities.",
        "label": "Partial Settlement Of Liability For Employee Rights Upon Retirement Through Transfer Of the Related Funds",
        "terseLabel": "Partial settlement of liability for employee rights upon retirement through transfer of the related funds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "plx_PayableToCustomerCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "PayableToCustomerCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Payable To Customer, Current",
        "terseLabel": "Payable to customer"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PaymentOnNetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "PaymentOnNetSalesPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage",
        "terseLabel": "Payment on net sales percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts paid (funded) in respect of employee rights upon retirement, net",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r998",
      "r1004"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "plx_PaymentsToDebtHoldersOnConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "PaymentsToDebtHoldersOnConversion",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to debt holders on conversion for accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.",
        "label": "Payments To Debt Holders On Conversion",
        "terseLabel": "Paid to the converting holders"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement",
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r58",
      "r98"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r362",
      "r364",
      "r370",
      "r387",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r405",
      "r406",
      "r407",
      "r833"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r937"
     ]
    },
    "plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "PercentageOfChangeInOperatingLeaseMonthlyRentalPayments",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Change in Operating Lease Monthly Rental Payments.",
        "label": "Percentage of Change in Operating Lease Monthly Rental Payments",
        "terseLabel": "Percentage of change in operating lease monthly rental payments"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PercentageOfCommissionOnSaleOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "PercentageOfCommissionOnSaleOfShares",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of commission on sale of shares.",
        "label": "Percentage of Commission on Sale of Shares",
        "terseLabel": "Commission (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PercentageOfRoyaltiesToGrantReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "PercentageOfRoyaltiesToGrantReceived",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Required royalty payments represented as a percentage to grants received.",
        "label": "Percentage of Royalties to Grant Received",
        "terseLabel": "Percentage of Royalties to Grant Received"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "PfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Agreement",
        "label": "Pfizer Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "PfizerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_PostemploymentBenefitsPeriodExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PostemploymentBenefitsPeriodExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits, Period Expense",
        "terseLabel": "Severance expense",
        "documentation": "Period expense related to postemployment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r323"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r720"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Other assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r268",
      "r269",
      "r802"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromCustomers",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Customers",
        "verboseLabel": "Total proceeds from sale of products",
        "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Stock issuance proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "plx_ProceedsFromWithdrawalOfShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ProceedsFromWithdrawalOfShortTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from the withdrawal of short-term deposits during the period.",
        "label": "Proceeds From Withdrawal Of Short-Term Deposits",
        "terseLabel": "Short-term deposit withdrawal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "GOODS",
        "verboseLabel": "Goods",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r617",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r798",
      "r830",
      "r866",
      "r868",
      "r869",
      "r872",
      "r873",
      "r1036",
      "r1037",
      "r1044",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r243",
      "r617",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r798",
      "r830",
      "r866",
      "r868",
      "r869",
      "r872",
      "r873",
      "r1036",
      "r1037",
      "r1044",
      "r1115",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional and Contract Services Expense",
        "terseLabel": "Sub-contractors expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r156",
      "r157",
      "r167",
      "r175",
      "r186",
      "r194",
      "r197",
      "r198",
      "r251",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r506",
      "r515",
      "r517",
      "r520",
      "r521",
      "r546",
      "r562",
      "r653",
      "r667",
      "r704",
      "r742",
      "r762",
      "r763",
      "r847",
      "r848",
      "r883",
      "r1002",
      "r1039"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r591"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r129",
      "r132",
      "r133"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r148",
      "r665"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, plant and equipment, net, total",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r591",
      "r654",
      "r665",
      "r857"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r129",
      "r132",
      "r663"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r591"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r362",
      "r410",
      "r442",
      "r443",
      "r444",
      "r453",
      "r547",
      "r611",
      "r612",
      "r614",
      "r679",
      "r681",
      "r695",
      "r710",
      "r711",
      "r772",
      "r774",
      "r776",
      "r777",
      "r779",
      "r794",
      "r795",
      "r823",
      "r829",
      "r841",
      "r851",
      "r852",
      "r853",
      "r854",
      "r868",
      "r876",
      "r1035",
      "r1043",
      "r1089",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r362",
      "r410",
      "r442",
      "r443",
      "r444",
      "r453",
      "r547",
      "r611",
      "r612",
      "r614",
      "r679",
      "r681",
      "r695",
      "r710",
      "r711",
      "r772",
      "r774",
      "r776",
      "r777",
      "r779",
      "r794",
      "r795",
      "r823",
      "r829",
      "r841",
      "r851",
      "r852",
      "r853",
      "r854",
      "r868",
      "r876",
      "r1035",
      "r1043",
      "r1089",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Segment Information",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r903",
      "r914",
      "r924",
      "r957"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r388",
      "r602",
      "r603",
      "r657",
      "r662",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r738",
      "r740",
      "r771"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r602",
      "r603",
      "r604",
      "r605",
      "r657",
      "r662",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r738",
      "r740",
      "r771"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "verboseLabel": "Compensation (including share based compensation) to the non-executive directors",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r602"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r745",
      "r746",
      "r749"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r388",
      "r602",
      "r603",
      "r657",
      "r662",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r738",
      "r740",
      "r771",
      "r1104"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r600",
      "r601",
      "r603",
      "r606",
      "r701",
      "r702",
      "r703",
      "r747",
      "r748",
      "r749",
      "r768",
      "r770"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Payment for convertible notes redemption",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment for promissory note",
        "verboseLabel": "Payment for promissory note",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r300",
      "r325",
      "r605",
      "r613",
      "r655",
      "r808",
      "r809"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r1073"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r1073"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r796",
      "r818",
      "r1113"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "plx_ReserveForDeductionsFromRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ReserveForDeductionsFromRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of reserve for deductions from revenue.",
        "label": "Reserve For Deductions From Revenue Current",
        "verboseLabel": "Sales reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r904",
      "r915",
      "r925",
      "r958"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r905",
      "r916",
      "r926",
      "r959"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r912",
      "r923",
      "r933",
      "r966"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "verboseLabel": "Restricted Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails",
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r97",
      "r660",
      "r689",
      "r694",
      "r699",
      "r721",
      "r857"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r182",
      "r183",
      "r184",
      "r187",
      "r194",
      "r196",
      "r198",
      "r255",
      "r261",
      "r271",
      "r488",
      "r489",
      "r502",
      "r503",
      "r504",
      "r507",
      "r514",
      "r515",
      "r527",
      "r530",
      "r531",
      "r534",
      "r544",
      "r575",
      "r578",
      "r685",
      "r687",
      "r705",
      "r1149"
     ]
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r391",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r408",
      "r409",
      "r411",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r391",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r407",
      "r408",
      "r409",
      "r411",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840"
     ]
    },
    "plx_RevenuePerformanceObligationNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "RevenuePerformanceObligationNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number",
        "terseLabel": "Performance obligation number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "verboseLabel": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r797",
      "r811"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues from customers",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r162",
      "r175",
      "r223",
      "r230",
      "r231",
      "r236",
      "r240",
      "r243",
      "r245",
      "r247",
      "r251",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r562",
      "r653",
      "r818",
      "r1039"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r856"
     ]
    },
    "plx_RoyaltiesOnSaleOfProducts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "RoyaltiesOnSaleOfProducts",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties based on sale of products developed from projects funded.",
        "label": "Royalties On Sale Of Products",
        "terseLabel": "Royalties based on sale of products developed from funded projects, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyAgreementTermsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreement Terms [Member]",
        "terseLabel": "Royalty Agreement Terms",
        "documentation": "Terms of the royalty agreement under research and development arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense included in cost of revenue",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "SaleOfStockMaximumOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "plx_SalesAgreement2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "SalesAgreement2021Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2021 Sales Agreement.",
        "label": "Sales Agreement 2021 [Member]",
        "terseLabel": "2021 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SalesAgreement2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "SalesAgreement2023Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2023 Sales Agreement.",
        "label": "Sales Agreement 2023 [Member]",
        "terseLabel": "2023 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Taxes on Income",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Earnings (Loss) per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Tax Expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r846",
      "r1074"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense in Statement of Operations",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenues",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r68",
      "r69",
      "r70"
     ]
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Schedule of ASU 2020-06 Impact to the Consolidated Balance Sheet",
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r25",
      "r26",
      "r1085"
     ]
    },
    "plx_ScheduleOfOpenTaxYearsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ScheduleOfOpenTaxYearsTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Open Tax Years Table Text Block",
        "label": "Schedule Of Open Tax Years [Table Text Block]",
        "terseLabel": "Schedule of Open Tax Years"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesScheduleOfUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r591"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r745",
      "r746",
      "r749"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Related Party Transactions",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r1073"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r415",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Share Options Outstanding and Exercisable",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r100"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Valuation Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Beginning and Ending Amount of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r845"
     ]
    },
    "plx_ScheduleOfUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ScheduleOfUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Useful Life Table Text Block",
        "label": "Schedule Of Useful Life [Table Text Block]",
        "terseLabel": "Schedule of Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "terseLabel": "Cash deposited as bank guarantee",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r707",
      "r708",
      "r709",
      "r773",
      "r775",
      "r778",
      "r780",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r799",
      "r831",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r870",
      "r876",
      "r1044",
      "r1115",
      "r1117",
      "r1118",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r233",
      "r234",
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r815",
      "r816",
      "r817",
      "r818",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "SEGMENT INFORMATION",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment expenses",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r234",
      "r235",
      "r240",
      "r818"
     ]
    },
    "us-gaap_SegmentReportingOtherItemCompositionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemCompositionDescription",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Composition, Description",
        "terseLabel": "Segment reporting description",
        "documentation": "Description of composition of other segment item not separately disclosed."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r234",
      "r235",
      "r240",
      "r818"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockBasedCompensationExpenseInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non vested at end of year",
        "periodStartLabel": "Outstanding at beginning of year",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non vested at end of year",
        "periodStartLabel": "Outstanding at beginning of year",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Vesting-date fair value of stock vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Exercise price (USD)",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk free rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r415",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance under share-based payment arrangement",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares of Common Stock remain available for grant under the plan",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of year",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of year",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding options intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of year",
        "periodStartLabel": "Outstanding at beginning of year",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of year",
        "periodStartLabel": "Outstanding at beginning of year",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r420",
      "r439",
      "r440",
      "r441",
      "r442",
      "r445",
      "r448",
      "r449",
      "r450",
      "r451"
     ]
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Exercise price, lower range",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Number of options exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Number of options outstanding at end of year",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise price, upper range",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Weighted average grants date fair value (USD)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "verboseLabel": "Term of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalScheduleOfStockOptionValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life (Years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable options intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfShareOptionsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "plx_ShortTermBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "ShortTermBankDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesConcentrationOfCreditRisksAndTradeReceivableDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r62",
      "r65",
      "r66",
      "r139",
      "r159",
      "r160",
      "r161",
      "r182",
      "r183",
      "r184",
      "r187",
      "r194",
      "r196",
      "r198",
      "r224",
      "r255",
      "r261",
      "r271",
      "r337",
      "r488",
      "r489",
      "r502",
      "r503",
      "r504",
      "r507",
      "r514",
      "r515",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r544",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r575",
      "r578",
      "r598",
      "r669",
      "r685",
      "r686",
      "r687",
      "r705",
      "r764"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r707",
      "r708",
      "r709",
      "r773",
      "r775",
      "r778",
      "r780",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r799",
      "r831",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r870",
      "r876",
      "r1044",
      "r1115",
      "r1117",
      "r1118",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r224",
      "r578",
      "r617",
      "r696",
      "r706",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r720",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r743",
      "r744",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r764",
      "r877"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesScheduleOfInterestExpenseRecognizedDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureLiabilityForEmployeeRightsUponRetirementDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r224",
      "r250",
      "r578",
      "r617",
      "r696",
      "r706",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r720",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r743",
      "r744",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r764",
      "r877"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r907",
      "r918",
      "r928",
      "r961"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Convertible notes conversions (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r38",
      "r62",
      "r65",
      "r97",
      "r313"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r61",
      "r62",
      "r97",
      "r698",
      "r764",
      "r781"
     ]
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r61",
      "r62",
      "r97",
      "r426"
     ]
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercises",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "verboseLabel": "Convertible notes conversions",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r62",
      "r65",
      "r66",
      "r97"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of issuance cost",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r61",
      "r62",
      "r97",
      "r705",
      "r764",
      "r781",
      "r883"
     ]
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "auth_ref": []
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r66",
      "r89",
      "r722",
      "r739",
      "r765",
      "r766",
      "r857",
      "r884",
      "r1009",
      "r1028",
      "r1090",
      "r1149"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "SHARE CAPITAL",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r174",
      "r322",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r535",
      "r767",
      "r769",
      "r782"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r609"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r609"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r609"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r609"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r609"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r610"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [Member]",
        "terseLabel": "Subsidiaries"
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1101",
      "r1102",
      "r1104"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Schedule of Company's Valuation Allowance",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "SupplementalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementaryBalanceSheetsInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "SupplementaryBalanceSheetsInformationTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for supplemental balance sheets information.",
        "label": "Supplementary Balance Sheets Information [Table Text Block]",
        "verboseLabel": "Schedule of Supplemental Information of Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "SupplyAndTechnologyTransferAgreementWithFiocruzMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to supply and technology transfer agreement with Fiocruz.",
        "label": "Brazil Agreement with Fiocruz"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "plx_TaxYearThereafterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "TaxYearThereafterMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the tax rate thereafter years.",
        "label": "Tax Year Thereafter [Member]",
        "terseLabel": "Tax Year Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1023",
      "r1103"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfRestrictedStockActivityDetails",
      "http://www.protalix.com/role/DisclosureShareCapitalSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivables",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r1025",
      "r1026",
      "r1027"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesImpactToCompanySConsolidatedBalanceSheetDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r186",
      "r187",
      "r188",
      "r189",
      "r199",
      "r248",
      "r249",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r270",
      "r271",
      "r279",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r560",
      "r561",
      "r574",
      "r575",
      "r576",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r618",
      "r619",
      "r620",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails",
      "http://www.protalix.com/role/DisclosureCommitmentsDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r476",
      "r845"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeUncertainTaxPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase for tax position related to current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r845"
     ]
    },
    "plx_UpfrontNonrefundableNoncreditablePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "UpfrontNonrefundableNoncreditablePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureCommercializationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non creditable Payment Receivable",
        "terseLabel": "Non-refundable payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "plx_UsIsraelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20241231",
     "localname": "UsIsraelMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeScheduleOfOpenTaxYearsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates in the preparation of financial statements",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r125",
      "r127",
      "r130",
      "r131"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)",
        "totalLabel": "Weighted average shares of Common Stock outstanding for diluted calculation",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r217"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureNetEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)",
        "verboseLabel": "Weighted average shares of Common Stock outstanding for basic calculation",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r217"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-12"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-13"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>108
<FILENAME>0001558370-25-003039-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-003039-xbrl.zip
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MA+_\3=/DBJ<3 G-/S!KQR']X.&"RL=TG\$Q8[3N!TPKFLR9^/"_&V3-8(OJ
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M5?''7#^Y OF?;O1%KU3SZ_I);MR%)[P$$ZWS7>KSM6R>_^=]TEY\!?$%T0=
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M7*]*;;<3E6HX$NZU\.[ENK_\/U!+ P04    " !,.G%:1XV\6HT2  !3]0
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M2ME<6A(TB0YVB(]KN*DC XFY53#8U?URX$FT7RZZB;UDQ?G$PQ3F'IEL[8.
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M=X_,IP3,H)R#/:*&VO),(C+>R2X+<X]G7#%A#G#F RLFHFA!YFDB"/FB<7&
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MN69'FKHLKTC.$R@FCZ_09+PP^!G-;(%,1"W.F5>8+'"YRK62? '(J3[PBE2
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M+PX6"4D<4X0&(*M+_OH%>)%("@#!*Z J14QXJL4$D#<D@$1FXN__\[)QC6>
ML .]7]_=7%Z_,X!G0=OQ5K^^"_SEQ<_O_N<?_^N__OZ_+R[^=3<;&3:T@@WP
M?,-"P/2!;7QW_+6Q@-NMZ1F/ "''=8T[Y-@K8!@WUY>?+J\OWQL7%_\(N[@S
M,6D"/2/LZ_;R)OG0CWN#WB_&^ZN;GZYNKV\_&#<WO]S<_G)];?0>$\!'@MK2
M*81T'>_/7^A_GLB(!J'1P[^^6_O^]I>KJ^_?OU^^/"'W$J(5:7W]_BH!?!=!
M_O*"G0ST]_<)[,W5OQY'<VL--N:%XV'?]*Q#*]H-J]W-IT^?KL*O>U RO.WO
M8=/8?+B*/A)0[/R"PZ%&T#+]4$"%)!A<"/JOBP3L@OYT<7-[\?[F\@7;"5Y'
M%!3PB7QU!/![#OWCOPPCD@F"+IB!I1&RXQ=_MP6_OL/.9NO23L/?U@@L?WVW
M=5\(CK<_WMQ&&/Z?N4\4A&I>'WH8NHY-]67_(YXL)UN 0B[A=P8=Y<MLF$%M
MBZ!ONL[+I04W5Q3@JE275UW0T%^;W@K@H3?WH?7G&KHVF9F#_P2.O^N;6X?@
M?P^6CN60*;IKC,IR@S;!AWL'6R[$ 0($)V)\?.?)!6/H [PPR5_2 BSNIUEL
MY\[*(];',CV_9UDP\'QB)J>$IX0YN&?;#M45TQUZ2X@VH>+< ]]TW H$U1BJ
M0YJI);0#%TR67S!8!N[(68)V2!:.U"'%1-$L,FTBLT#F#@)$%#,'_XE[GKU
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M. ;$D3)Q8%K'/!J.N9SD/S-QS@-4U6PQCR![L,X4E8D=54\65IW[GO?'NL\
MKI"Y73N6Z7(<T%Q8IK-6"-T5=5%@3AH#KBN:"\NF3@1=QQ4MPV0H@4.G_F@!
MTHE36HALYVH_H^:?H^;[;TS!9[YVB2US/Y+[RL>X_OZ!QQK('*53]4NAE:A;
M#AVUCMK@"3NV8Z+=W-P'C(N<M#QXOM=$U$(%Q0<LZ %GLDSMLL2^IL*&?!Y(
M-:WMPY60#2R+5/?.7#X5&6^/%/;*YU8JS+/ O\N!%LXK#KP>M(HG$P^^#+W-
M3ATQ\Z$D)DKF"Q/US&P1H=SY#J=/<[,!VM*X;3IY.9L=%AAS%\$#[&H+!+8!
MLM8F!OL$[#Q&W)V]=%OV]JE,ZSJ;JP)1P KH=+H+8^._WY"5P5O=,7AN <]$
M#BPZ J?AQ,??/&17%,7#?O'P%EAAV2;^T9<'RZ9,!-W(T9?#7"@QOIIC;Q;A
M_9%7A*C:7=,:(G\!T(9>1A3MF5BP@OM;#K0.5!9<<S.AY2EM<*=4P'(HA47W
MNR0VVMG[8RZZ2B?$@^D@FLL.[G;[/W]S "+<6.]&X!FP?*+E&G,52;ZY2L8\
M I-F$H27*,=H"F=6J3Z*V23;2]U96%JLL :RG4]66>K2L[<T54KG= K)H;<-
MBM8Y'CA7(44--"%7."WY#4J1W-R$DY  E,6E\_G$1SX]@\1(:Q0%-0,VB.JY
M3 '9PMK245&LAI+!0[RFVC&C1 05NVE%AK05654@,VZD%1\_Q5%7;(+X45A\
M0I1.R:@X[- [5%H<8-_9D$/GW:Y@-9-IRD\EE&RL%4L*USN9IA58TNP:6%)N
ML#R&G4]-.9(R>9F2I'3N)EQ0(FDY*-MY=NR &RG#A&,ZT[B0JBCZW?'78<T7
M&A"W=K8+* CSJM"#'!>*^ZCC:"P2#ZR,5:?N1PX9B?NQ OI*5[O/R/1\$*;;
M!:(<MB,XKM%F0JJF3+A&,2#EJ&MN!1*Q%Q:.WOGJPD WO91PT%2JZ$GZBT#'
MTR!<!<@#*21%J-22J5_-)VUQN A%8W:NP%DDT[JK69I44@^<HN6GBX(7'D8D
M6O*U0JZM3OPH/(E(M"S/CV;/(>5$!DOCU_TTDR$H,_OD"%&;TVS_.\!13?@'
MB,;@>^I-!@0]\J<5I[T(<I[+],%/9"K;B[H$-SM2.V%^%PNT*+WM"+AVSG%%
MR<!BU+K/*2Y'2WHB\FA0.O,.3T90^U"P_K&!N?K$!]>"4.'2Q@,O06QSBU@A
MWZ$<'IW/%A[BZ6DA0ECIU!A!;^7+Q1:Q0+F:P@/6@$3AE& #2Y/9W'0HX#:4
MP:'SJ<!&.CT1^,@J7B$PH.$09.MX3\,I8+AY3.4B]R%]2(R^ES4%B%8.)POC
MQ%\#A L/5(WT+3#)#?5^6ER76-L:Z+L-KC>]:C:K7+ %&A6LR(TP);N -\0,
MQ:'$K(I X:^X%_AKB.@[*5\\@F+JW2"Z92&,B=]+ E/D6("7D]OB2(+@WE;&
M.BWY'--1H4Y8K9':D(]HK/J!VVVJ:&&ML=KT*P@9;X%AQ07+:C-*;5A05+;Z
M]["*C3]!X4.6HE@@'CP_VD740A>*90JGLUJ4H[K!T!X),1R74N=ATWT8#Q]]
M1DUU'MJ*CV3LMXSN=NDOPG.7; >";7Z9+A0SJ> XE >4(KK)@TH%:< BK!0<
M+>3)R)X?6.AK4-]]8;[$2ZMP,K&!N3K$!]>"4(E:[L?@)8AMNH*[@.]'Q=O9
M>"BJVWZ,^'')=C;""FHP>!BZCDVG:1AJYP#63:P(E!DN*0)62!HW1)0/+$U>
M4R46"KD,97#HN*X"#^DDTE.,K-(5X<XD1RD+S-< R#SWP0/G&DI1 TW(%:X,
M_ :E2&YN=9"0 )3%I?,5@H]\>HT0(]WY*O%H_ANBZ$4V@'CKPS$0TW2RP3HB
M)*H1ED&!NR1P89ED":'K+ A"MD*)P3M="5C8)FN $$NU06ID1;(=-_"=9S '
M5H#"]6GP8KF!#>P'(@OJF@O\^('DY#GOY"GONQV[ U%(6WLC\@/@VAU3&[D5
M1GL7-2O)P8:?\>A$,V YHKH/QFN3"YG*ZQ+4*[5-7P&F(8@"6Y*"X&IN#D8=
M'<*)F8$IHJ6Y*<=F(!2,V/E\R*"8UM\CU'1T7Y?W5U=Q4&OBD98M)"QL4Y;V
MUEW6<CYJ/6H'"TG@^:<[*AQ<Y+0*-@%-?WT&@^426'Y4[.$06\[SS4DT8SNR
M)!MJ0C[??R?5L!(+&O+KE9,0+(M;M_X^*6+VOC]I(KI_9(&LGG&!3,[,RD$P
M-8@!TSW^@MK".9@B&II1>#[CH&#$;A]ER*-XJ 3,0$V/EW3O NQX ./XL1*I
MEW19;?AQ:T6M5% ?H2".[4O#\*G+0S7V8FX!DZ$ !W4OY;*1SD2GY9'-38._
M7^4X-R+_##\P?H\1R]#U_?OWRRV"ONDZ+Y<6W%R%1.TQ3%\<[7_$D^5D"U!4
M)N1=1E#@Q0>>#>P<$SY]^G![?4W^9UP8^V[(W_W)>#X9#>][B\&],5^0_WL<
MC!=S8_)@3*:#66\Q) #O%,[WA?GD@J()'@-UM.A,$;0#RY^@.4#/CL6KV\\&
M*S_?I"?"FK1$5O $+O93(JVNPMF;87.R0K$IR,W6;IE.7P>,L>%?9@M@6V1_
MR@[%@[%Y7Z1".>ZSJ&A)!"7F9XR<,$,[!],FZT.^7&SBD0KYSM>B7)V$-/[J
MF3XB^'H8') 7LI\+W;D@;FL*@DN)>I'L#2A9WL&0_%FX&4T!MB@(TW6E;?\1
MZIG-6FZ%R._5" *V_XL%/9_L/ 9N"$I$'.V:#M]=B(']ZSL?!0VNTZ4<E,_
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MIZ)RY\R)<^;$ZPJ#D">_G1BU\N.?S,*M;^Q:>::_&77/7I)WKNWYX4_>:)^
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M6_:\C2=.,AO6'24\IG(U"%%5*P4PDD)IN5&I$D,B52RT%6OJNFQ2XO1_KKV
M?E+**H7%U!L-\U6=D0 BZ8N2$Y6NI)"3[!\$<,@B0/ U==Z_;2'GM[;IRK>F
MNO*M-;KR;1==6;V$:+IRP?ZYB%;A2] D91G2 CVI,R[5D@(,5T<.^6C4$$"
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M4A)1M*ZJ!&^'OZHQ9.BT2GBVF4=;D4(#44;JX =UQ/D^8]O\EE$)C=G73RM
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ML&C2\=-(\O@WT<>? +$U&,I+!>XB>:+1;<C"9)JP\!>"C7,:4+;?3R,-U9E
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M-.\K$(3!&3]Q**4B!:[T,2I67:QQOT,Z'"G&@P):^8B$#=G4MYRDXY)L8*
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MWN;_5/(X.D_$3SQ&1_.FA\._1U<JG^)Q_&AU['?F1&7"(7I0P<X?PGT:S;P
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M:>SE@J5QM-.Z<3$49XPK71C<2F<WYKR6$.ST=A>^$\>+S<\\#R]91#PC.<^
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M(HN-2&8X2_DB@C%>O#%-/<J_!V>.I-Q5@AH:DQ*#B*E)EGV3^X$U'R=.@+F
MNB[,[-GO';_"(1%[UV:YN&U6U2H%J]=#&:O_=R7+5K*78G: L,4+C]%W-%\R
M2N0 ""T1IU?Q?ZY^S?Z=:<[@I1>OF;+MY8V)]* XCK&)]<S]J>#0G)R>(5EE
MA4SQ"P3",7",NQ?^^V@O9*K1UXK:V,W@UFAV302-=E\/7HNZ@X9?-U1,EFO)
M=5XPVAI5[R:(!:6O.\JSFOYMMB2+&S*_N5A\.:YXM=E[J?H)Y=1U^68BOMQ'
M;"D4^942\;J3LN1%54O1E4^L#.G8\^:J%<.::-_)L+*FV\^2$WU>NK-VE&_+
M>ZSCIL(T47U"<JI$D"7PE$W01@V>^]:-LD9(M '%H=V)"^M>/)J*EK4N32]\
M"Y\F)V2S4]-QK/%J48[VGMQ:J\DP]VL%V=$<6Z<GJ4=.R%U%)_IV;$=GP-P'
MZ2'P[USD--%6]3)5"8V7J](@0#D!10&*DE6BY:5^^E^"YI:5P0]K*#N3)U_M
M)!GEF5>%_<;W7>T$*-YT/=CPIDO!/"^%Z<1PLQ3O?7B-R^O0B?I6PE\QZ-LP
M%C%7NYEI3=PZ[]!Q>@R<24O*-OF>3JR;NRJH9B,&(/D ::''M.R:&(,CY:,@
M9[ -.E7Y?$!$"('@+D4HY[*MT\EYHTYD2;+L!;_A>J3!^DUV"6$ ;T%JJTH(
M:<;J(3!N(JJ<&]T)9PFCEQ/]_G1IND^>PLA+WLHMZE6"'P!;H$52]J4J5('$
MU1\)*SKE^?_8)B=V/;Z)L:*O?5T0;3][-;A-"J3N7Z^"M42)M/WJE6HT6*?Z
M^W@>1P[UE?VS#P%PSM_D;&:':M5?1_W0JN'KGY:#].<)8KK^^!@^LXG;!TGT
M)AQ!^A^%#TC_\'?&097O\@_C?](Z6_ IB[^.^@D/AZW'Z#?SU>R2+%?3U6QI
MB2\OA2C7#3VR&W L\.HZ89H"S&O4%M7_?WE7T]NXS83O[Z_@;;= MD!1]-)#
M@>PF:0-D$R/VVV+10Z'(="Q4D5Q*"M;[Z\OAATQ;)$5]Q$.@EUW$GJ%FY&?(
MX7 X$R!1L*-Y%W"6?A:0/>QHP:7[PK=0#K6/*/  9!'4A(OQ-0HX.L_OEF3D
M% ((7WS;U?/LW0.EA8WW&VVN*U8;\.1_':#)__B+&TM5YMD:MOK7W&Y$3>ON
M-LA/>GZPAH@.J/71G16^_8)82J@?R(FF?[O-SPB@6+<\?<3Q@*6[W?%31@$8
M[U;' 9DY-CJC0+-LGJILG26,BV'=#+F(<$#B%E>#HTMQ=E"X1.A6/C (R9^2
M%"NA<+3@Y\?L(H%8-[2 2(J]$[16*AS4>@36L+60G!VW3ADZO[^D)(HT!NB.
ME7W^T))R)E=;RFBRX4([8TQ.2IQ@4X_@.NKD($-+U/+*8TFTV7$A1-<;R+S2
MM[7@#\4NW'RL>O[#E-%;*'*@Q[;%693 C0.$W/<:5^MSEI'QX@XSOA@S7C'#
ML"AQCMGDGG!/,JR(YX)RM='K_+S=^UJZ+N%&4TG;Z$>F/U5%T3XENZQ.<D@=
ML?="^E16SDS+69\01=WNN5Z4H]SWU.&QJX3/([\_']MXQL6AZD9;==!XD+/=
M&!$/BZ=1R5N_-IAO<O6,O<SQ=W0J2[TO9O2F(TB-RY>2U:H\B/..RNB1<#8M
M$Q77FYJ1PZ!M>B;):[N;TA(2F0\MRL?P,4AJF#MD('J1?0$%YMXMBB_%Y^)J
M5?S&_UN^ [:7A'\'[/1K\K++^33R;O'#EY\^__#CU3NHWJ'W9&TACTTB&G*2
MLJ!B0\:YP1]Z*8MZRZ<E>'B]S3@I+<@ZV6/MU^;]':Q3ZZ5E:A65&P\_&?IU
MF+>'XQM.J',<' ]KW19GI[9AC=DBZ\,VN G9J YK9X'3,MW2=9/3A\V2/@/&
M'\6DR$6]+>14RNWBXUY]Z<NM'C42'@ G*&XB<\0P*) =+6=W_ZM&@@53D9-V
M,&*,=@$%K31%%"G>'M7O>A*\PE@1X3Q M2/\!O#A #98L"Y"?:B,H9[*'#I>
M__KY^GY%;N]O'AX_7ZYN'^YQ;>N^@;#[PZ9=ZI1R+H/RT.-94:\2INDXB5'L
MI4>:;E]400^3^,$YT2RX2.(64S+NT3_*&V?^_B0N8CP,^<4W 62G1$&/3Y0.
M= 2QV!LI<AVO0YY.!REQ_;++RSVEI$IRF1,#"NE;CG'T EFP<D.KBB\'2<[U
M@DQFEJ3UDK+7+*65WS)"F?$L99AZIN6$<:)8TA#1NNDB!K/ HV8GFC\24YND
MY;)Y^I JCI)5VMCBVAN(,MG@@<E:.H$>7(<KGAV!0R'?9N"$)8I]@%6F_BW
MA2KXKK^ $2)I23-.0ZE.I=2)8[UR:@+Y;ZJ0P!6M4I;M+$<-HT>)T,;\"@?9
MG'V(N&S0)^-8FS3&A!/A=M18K734.V!M:&(=H.&9G$VZ2S+M->M&$;+@F"HC
M<OE4B47;Z10,& '3[1RLZ+'O&<R.Y( .E,_BA8H1M*LI'%%IJ;IZGBZ/\Z<>
M"3N2-EUIJ:#LS/;S_#D3ACRW155G=2/*\"C9+*><?0PX&1!A:NA$!S\U6CY#
MB%C=<^+G9R:JS\I&-S!U)\(_N^"@T=U"5/TU4FTIK<E:Y$-";H,R%XDNLY12
M9CS_^]:L%%W"Z*&%""=^@HZ"ZL2^9-#5H^)ZKD7CCJQHLQ?(>ZC=Q*4I()B<
MZY8?7.!TGT(V1+8A>5D\4_8=4B+#J!_@> 8R^=KY"#$I891*)F5,B[]]5NJA
MC65!M\Q%7L((%FD_2DZ68VRT3U%AEFUJW_JZ;(HUVP>MK">DZ&NJ573+:GI$
M%\,Z:A$H? 6U+)'^)35A6=66:JS$H_^3BV?(6S]>-B4']A0R0@U)@WQ72QT9
MJ?,E(\_;OV &\"'>LPI5ZN@651\3SAVI,*F<1X$?M&-^="DACM5VK&Z+9,\?
MD$=XN'E;<*5I57,)(37,;T(N8LS"6C[QCRMJV2B12FFY1;'L3B0Q4=1G,H6@
MQO5CU-A):ES47Z8I:^CZ]R057I4?]2YB/-3[Q3=1;Z=$0;U/E*Z7*HF)IHYE
M 1BDQ(*5KQF<SHMK,*^*)PKD!WM-'GIT_(=Y24YB3"L(]ART(43H#(U5)0['
M1TGS6.Z3/-@,NM3H1N!2P&("IZ28!F"7Q8F9ECPR\ >JT9+%X?ZLDJ^T"O+X
MK91XF/<(;N+=0H:"=:<<MHHX'!SG=?%[,1XN_NVA!L<< +?&EI4@J_)34]7\
M:<P=6W:3XL26^T37L647'5ILV2^0Y3*SBBA#-SOJ#1_K;\JG/'M.9!N\K!#Q
M9[CFS<KF><O_3Q0U!$X4LF3O&RE.]3WY?R4CRQPX.4UK,:@.8XOL'NY^JV?E
M!T^%O%]S 4^CSMQ+5Q^Y8\_XH>>!/XHB)ZN2: ;L"6:"%L://_\4 Q?9V2N]
M*=E5VYP1^C<]TE=:-(ZE<@@CSO0S3"T]&85QH4U-0\2;.E$Q^2S5H+5MVRD.
MOIA\'M)<,.DM*&;"N<F!G0 _40.@!QLG*[E,<EKI7W#^*8/O ^#P5+M)"P;+
M1;V_+-;7_S29J%>Q;':[/.-SH7O^&#4*SF0R06$]LXP8 FV:&2WKU#G'ZAB=
MN$$[)8WXG&IY2*4%^B]Z1_/]8'JDP[9,#R8*]+3#D7:\&/RJ^?1?]* KEI(I
MZC!VD7!95RPIJD0N$1_W1]\$%4T9-%8,95-&*&\OG#)@(.32*8,EM3@^\@A>
M$!)CC#@*I(0IZ.F+.60 /! /5]-$;C@W"ER'BN?$*$R^]V7!#,B^:<>9D3CU
M-MJT$<:!.W=SS2X5.HZ\76;Z\/)V[69&(L;:(\%'& =BNAT2W%3HB.GIBV"N
M@LA-!*9)?_Z&-%<9HU WP=F+YI0 IPV-74S=@>;XV[,WG[$]OEMP61&=":">
M4-1@D>.9:PT/Y*ZGQ%X_6QSSL$^E #_Q#K6L7IA00_8M=[&T5'6H)JMH5 \;
MX[-A+\<^0G1@]"D:@$L;>TP0=<L7CE9=\45$0(W/T3.:I^L,92@HIQ%&^3XK
MTKQ90W"TVL)-J*<$PK&I0?,=!&=E.+7X0+_2M!$]8-9J!<&N<@VW@WZE!71G
MN2S6E^N7K,C@_CX(Z:][%L:*6/EZ@&I'-; #^'"J80<+YKB<IGC%!O*8.Y)J
M9Q,TA!:L32Z.*384._,4.FG2?QI:U->OM*>:MY44,>[L$?THK&RAPXD:.P6Q
M-CB5I$30QA$+/E6 /\H3^'52QP.9$P5\J%&D40#G2)9^[ !]%#%:BQ[>4*V'
M/BH,N0.W3N)8<.0-XSJ0%$7T]D07;P#701L-AMQA7"MA#-CI;<]]O'K%$<^=
MHL,;Y)!OLF^473XS2E]<"/;0(66/^X1N4\=M1'AYXVYINFDF@I:TQ$A)U1,D
M[K>UT8 5J3J0O+.BZ;8H\_)9!B8VAJQ_9/7V)BM3UGQS GKD.#B GZ2T-HA1
M@Z 9S 1I??W.,Z/C"N1R<1\"]L!U*;.X9&I7W3Z2U.J9)&FQ#2E_1#T6*:5O
MSI?SD27?LMRP75._J-RKN[Y>2$[R:)RLC@H>/^L.M\^15Y@ ;^LNEO.7!2M3
M2M<B05Y?K7%!R$&+VHO"+?Q)ZXDN(5:G"9<DMHQ:02MOCK34Z.<>0W18E762
M0^:YH4F5R$9T_%.XGX$<7_U4OKR4Q;(NT[]5D](EG+Y4ZAK)^J9D-TW=,'I;
M50UDWCO>RHAQ\"QGM-*F50T>!,7B1DII.ZOCXQ Q4-OCG,BQB!Y,W/F2PQ$]
M'O*6>B[]E::,0FA)Z EVC&R[>5)5#YL_$L8=O/J!/6;/V_JAJ:N:>ZK<=76]
MDEXV1,L,5.G($'MX<.PN2*BNF0$;K Z*$>X1"=8+8C!CV]0XW12]ZEH&/%Q3
MMU+FW]QA_/N7_^E/^#^0'/#+OU!+ P04    " !,.G%:KRM.UC9?  #2C08
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M( _H.00%*A1%D'^$XIJV'_YM^+%#ZQ9Q5%/J-(L(_*(6M7&J0HP%,&%SFV_
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MK6983.B=BBN)(2,<63AF2"D03:R[Y_EJ][@'L$RG;^FHZ#/8O@+G#"W6:C5
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M;GP.ODH'GPAT2GA3K?S@:]ZI[7.H*7AJ2XZP3QM[W  K86 Q?OUS8%4YL(J
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ML""J-2Z"E[O3=<Q7)G2?J6*(D+_^.5I*'2V<BE?"K"IFX+P*TF!:<V>.@7.
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MRE3YPBF=7T<1W\K*3WDK+NP!3<C?-,<??-&]#,[5AJ^!RV24(#U%K&K2I>S
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M'%K&W>MERE?[/(FB8J>J C@#9OA- H-L*F4-*2, JBH8,L*1A6.&E&4'0%V
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M43T(<A\3>LV*-4L.UVNP0LY&B04_J8P7#_X4Y5?P31Y/@<D#F4  .M\$]C<
M#T&.!O<.R-_I-\-[L_=>3(' #1,#HH8P=DY97:DWD973G*B#J+A9.#?QD?CH
M#9QA;>#?<U(VV<AED(U!YI FMT+-6<HLU\(<46I'D3S"A5RX:Y@K2GJOD,.
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M6_B?:]+&0I''5,<N#FP+37+ 6AUHB6:(Y6LWP-D>1O')*SLRO3@Z]/?>FV]
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M2_IE%"RE;38..FH9*'5I9/'-<275Y;Z22GX<_2;Z?#-NIN1D-TG=-!X[%F/
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M4:],E0B***78/@JGJ.G><SW-TN&PY:%<K%I2@7?M^UL%$L&4P:DLF06%EJK
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MV]9T&ME ]J$>75M@.:E"^8KE7LB>B0>'PZY_/#>.^I0[V>L$RME[LY,$T_Q
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MF]/0_'Y3;ZWC7V/JO96<?]_U[A#*Z0%P>E[9%UX,V97O!XUO/OCF@^CPP8&
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ME=//+QNYL3X>/D$CK7:SFZM5[JA\I8D\H7:NQ?6ZE4+GPA5UE4;A,L($SBV
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MS?=C0SH%$ZOXI*;T!_S0J^DX7(O_XP^NRM3Q75T<7U#_F[ZD:88R@$G-@.K
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MDTU>4D@+68\R/EZEKB&9XR'1/8J<R!'W3'L,EID"YY9W'C">AT1@BN&+7Y\
M)%NV19;+.Q0I=G8'7!]VCZ0YV1! SC_$M^;0U8HV&$-*0[@25']1:"C'(-]#
M$#$A @AZ!XEI2M+Q:R. MTQ3!K+*1'*^.7D8K]%_G$A ?.KV02#@;_BK]>:+
MCV973-&9X$-519PHQ,[I>NUH8O.1(HY<G 4#(<E @*&;X3'Q,[J(,.:>*(DG
MJ:WEA.1]\P*)*?_@2,20F#:"L]]=DP$8!EHE<=%4,+\,CE,X@-4094WP^DVD
MTEQ,.&@:I-Z 4! A5"(M*!$@*4<PCC0?UE>FIX/1&)(B8PL:RRH3(1%1C&SJ
M$Q>R+J[]A[UC+_$)R(0AD=P+#B]^A'?>Q2KC%@!-:'WR[B&@>"H3:0O')M#$
M)V^J2,BX)X]>>(M157V.(X=D[B'/] UF'YQ&&+H4'$@5"C\$P9[PP8=;1H\?
M+U,T$OX2\,&P)&#ANL+DE? 8)"@U0FN-H5%$;"GA$XI(("B;2@=GGKO "YW'
MZKIXDPDT,9\K*Y>%<>\H50:"J>C_6,XFAMTC8R]QM"0<F2/.N;^Z/;%=<@A/
M.H$GXAA_J+\,.$1.SA"H2*(CE8#DK@QBRGSQ\+<KZ\FYU+CE-OJ/Y(AVH.)M
M$P*;\"Z:)9 0_2)+#%% L/^UA.:]1,1O033N[]T R)?#M'>6KH_1P,*?N%TI
M@(B%F"O:L;J%-K'H+]#+RD1P3&M=$8@,-&3O(@M[206%36M+#AM]GDCQF570
M%PB%2'YH[J'V&F97WRJ#5.^R<^F:U"5=E]P:*=,94CD) 8 T1'-G@E!?*N:\
MP\IG1,J)4,'4X5.%1R5?%MT$!CIRU["N0=\P'</G9,Q->N".49(#?<9'>,$'
MJB,KS!7W%<L$4 WHP^\ CI2,@.:*2&"(L&>YZO$*3+#%!DU31Z2&$&X.D1/B
MR0^T*")@/#27P0I0'=M4#%<*3W"P&D<^1"3: =YVM3$R7 GX<,!1R(!<?P?3
MW<PUI/!M8.)CE1%AR:JRZ5?LH<9-N! EOX8+NN*IDPTR=^R1;JZ_%WK* ZV%
M>U0H$._?(&<:"GBK!BY1Q_ZA1JZCJ4'-@CCH)"*L8\F(Q!BVJRR$6'15PK2N
M(,6E>Y6XR/-&!$=>!L0R=?6>J_F)S":VB4V-=.2-J.[\L$'NKQBW!Z"&6%1"
MDQQ6K2/_/8#3;^JK\LE>!1C&MR]A"!8"Q8BPC*2D&]XC_$2HTE=-^%G_;^3O
M223<B$6C'*BQ+RN8=@".P1=V[W?\$$^<8TL8O>$I*0_N'I2M R#_LE"6@:)B
M@QY[60C42U_R$@I&FMVUEUQW6H5AS8 ,_T F6382G9Z@VQ14B)A=[\GS<XC;
M072&A7PA$STF V\36R"!?U$6LK6)#X;6[Z(<O8-C-H2//*L-ZW+348A)]QO9
M]$BC(P<8:L2Q1LI'P8U-K=]H73AL@SQ2?_:2CCW%X+X*Q#&^#)'3@W4$)/$U
M"6DP;'ELKN8WFB5P4Z:8XO V(LM= "(3]*4)HDL27$).A(90@=PH13>]IP/+
MU":Y!P5N#(> [&A8$J//^@F!"?;3T<<5;8:#1T,0R'FL]!3;/8)/)=XOHDU!
M!SA<@EURXJZX@1!_!>CCMHY+0K<6@>:LX-KRP!A&;NW406O *W*A@.YZ7K%O
M0Y,@S4]TW8>>Y>"=AP0O,O)A/=/1#03 S8EXH/RJ+$?XS/(9+= ;& -^U TA
M],$+GF)?15OZ 0%/\"%_5%&]0 P>A-BXG(,/H$#3KV.JP5%B*C=$/+PD9C!7
MSY'_N@IH!(%*A.=>>\4/-F\JJ[""6AM8N^Z"JQ@)01JX$XH5H'KGW^]R@N]R
M@O,M)_ARDLN+H%F6CDQ;K)*) !JJNN"Z"&Y&SU50$E+OJFYX&5$'60#(K]J8
M9+A03R;_ASZH(:CA4*(FFC@*@W0E0"##*1Q\!ZE6B00?D0KQPPC>W(@WA1S#
M$?:PT+^J"G&[,]=O1(K8W6R%?4>HS113UX+8A(TQ3A'_RS,:+P(5ZZM)3U@+
M0".A3 0VY&>9R[!Q Z09/OL*S4%!OJD73??3=1=AAY&XGVO]:P)<'(')S]/F
M03J/^ 'X86L='R:25_,R45X$!K,>#IY_79VZXRQ@G6F']M%AG8FQY!IY/CX-
M1T!:E:A>+]T"W<[WQ!P6;(\>K#6:1&2WV=B&6=LVZY X$FCB:)OZ0X&'"PKI
M8V+T$JR&8E7(Z\=VKF9Y1O1<-PFA>9_[QFM@71 O$-E+#@BJ!PS'M!#6B!7J
M97;%((B"=U=^6?#MAG_,=:7%'IO<C03A_ <6I[A\P3-1_624J )EXF9A72<+
M,0K$AC\0EU[ "=AAASMD-:X')YD\$E>#%A%J+E>27!QY"#F*VUH&Y\70PV06
MEH*T0.@=UQ)UM,!51/+?1&P'<>!/$;\N_O>S3]CW(TEP<M4,[4=V0>ZFT?W(
M)/'1-^*-Q&?T0Y6!]^[FT;9S:"T900_O7Q8OB1OB_G85;6&$9*-"E0"R)452
MD:=0G4OC,N<^ZM[^QF$X\ @F>&^K6R+D.]YN4IP@#5BN&B)_8)6&!&:0G+>0
MGV?'L %![!G$A,30_>:2-9>(7J]<7 J"*Q.5";(C=2.&/^M:"Q 3-S$GD6P#
M;GY\6Y@263C';=XUW2%1$-.U.*S1-ZPWP@4DNJ@0:TI84B4DZ\&__\7&F=_H
M7S;]6Z>:UARHDDX53&?E9O44721_HQDCN>&G9?(F6"EX)*KNVE:$)ZY(M",H
M* L]I%]=N+(.E_P:WA%(H9H4RZO'"/(UGI:#XDC357WH&9FX6B+HIAQV"KR:
M%;^2PG<2?#-4Q[5F9$3B0:B6'DK#^ 5GH<BEZT?Y'_K21.16@@TU!1L?&O;?
MYM@(M#8K!-?]9]2@>,K'CV*1*#>"K =L59&1;4%$*21)3*3EOBR,,<6O>XU@
M2@V5<KDE/HHIQ; !L'3+UR1<U8ZQXC59\+0327)NH 4S'#[<@M@''DJVTYO>
M&%\6_&[4 M<5XT3'P<HEW]'$8)5P 02:"SYQ;K*1Z I*H.RE 8E&,F'HS:\-
M9"]8(V_X[#A;[U:T8"7EIVO\G$<@_O$UQ JN_^%6G"I?F&CWIFP]M8D!3 C4
M)TETVW4"OBRXUND>WUE&1HGGFQ%0NNZ1"U4B6$4W'><GZ"@5DRRYYP-=T2S'
M)"):Q"T_D7/W9<&[KFSR$JPRC@-C !(8AA584+F$JW2U<% !F_\J+NUU7#3A
M$]XQ=H8CSYO"7UE+9=<%$_#?^"/^< 07))&ZIQ0!9\@";4F*160'U]Q"G-$6
M_;<>GTA0!>4OB227T9 G17YT<7_8I4,ZTTU^BE@)8JOQ@C)Q?Y9PG2*Q_/U2
M0TUQ>QFZY0?F>L?/Y;ZD8;!ZQLNMN<^<NMBYC.L6\'PMN&DD7%!+W:'<C1@D
M*H/ +9(:? =' SVO2_???6S#0\%7<$'X?+0.V7A!;4'10\Z1ER?!KQ!/",<J
M( [XA2UW"]HX%>2>3"/-\'Q(.3D6:#'T_2'<K2G!=?1>24*(VY 33C8!4!"8
MN++.,R:#F.>FXRXKI$S!37<3SVKK,Y<4AS^CR)0,9KH;>K1Q'08VMK#7CSP(
M-Z!/-F'M"P'@[/V&WKOP\_5X-K+7._Y &A[[A!AC;I:'%&&X%23$H\2)"2+(
MUI4!I"J %-> ;=R@ES=1X^V/">I@PY.\/-_^!NQWQX+O$H//4V+P#CN7+;A3
MS;/K:;H.(_JI!EN4L-#8OX<YAW?4>AMJ^50RD8Z_LI74@9VY_C9!:UTBM6?C
MK5OD37),HJD(OH2V$:1(V!'_U]-C[A;//755ZVT&H6UX>.!@3RH^;%TAFYV#
M\.+ZTF5H$SXOBB"=2,D)7DZD:![]3^ !2"5YR,:E)"-DF&PBO;%'?_]^\!-N
MR-\F$W9_UYB])MN.C;8VWW;:-QXUX8-4X_5^#+5DNW1[/Q*Z\>%(O<O6L[X;
M8@$;A>#$DD%*>$LSKQ6Q2$IC75,L'(VX\/6RG_#>N^_*A.BR@&L2;"]B0;Y
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M9EG1#:N#<LW*6I@!WS),^;%/-RD=@Y09HIR.,U2X3FDSL5P"04^&8PZ)\KX
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MY(KY>B).)4: ?G#GASG3A$%H3)B"C+X[04@^K8-QF^4?8.4F( JYBJ-\7ER
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M%H&+U]!8A9/ 0PGH/?181?EX14D<MA1Q%Y0-F;BLU+D G$)G93KFL&5MD4N
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M@#-(I%@^$O[":UW?-'BK+O?S:+<OZVB/(332;NLVT&.#U.S.EJ5SMS,-WR*
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MT';/@KD(^V$X$7MK\'^*4FIE5(URMRN$>=9R4HZ!1!FE:C@Z_((4KM]D84B
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M2_:9ZK/&HZ)'[ZD'Z''GJ>\:3[UWL'6P8SWU"8C<Q$"+Y1^VYU_@NR\Y[+>
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M5DE^EN1[.@/?P!EXQ='7Z%2#CO_PNW%][C%0??!T#KZ%<Z!QKB]Z %0]/AV
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M>5)PKLQZ9S]E9:RB@,8-1# $_47X(<M5 "V[T:]%CCH'>\-B=?K=.X/WX%#
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M60^VM0 XL"MC6(X:$T]F1@*(:'$[5H_AX0NRS2T VUPP\'UVD)@.;PZ.'LL
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M[H-*NU@Z+TVA6I=07!<FQUG0RUFC>!I<VIN].S&6N[J#PS)@S5 U)7&G)AQ
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MC._E97@?MR!S7(Z8 "2PHTUD?N:@$/.Y!57.^Y(!^3CY$,&\DS$2X-"A;X2
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MY;-1ED*ZR<="C-W>V/H>MH+9J7\2"X:R5,5PB.,C:Y:'KSUQ*]J" X 7U@U
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MEDR_M=9*_GI0&BN^8 53L@C/N<S)HG+VK[\\N&5!4*[BY&=NIN@Z&UN%3N'
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M06Z(YB#L+P$[NY&>;2+)3MBFB$HEE;91AO<S0[E)H7B_+86]9F!#:IWV#;4
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MK24!JAJUIUFT#N,47$[J<OIQ%,*?;D=\N1C1JY,AV_;GVC5OCE0OI5"ZDA3
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M!FJ%&55PN3&;'3?+8.AQ&.C)[)?R=4'PY(RY<)CE<*A6K9S;T3W,TJZPR^9
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M06$!&3#PD'*YMK F69&"6X&%-G#LNR #V\BJP5VI4DN8K@N0N03&*\\3R(I
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M+3 DL%FVW_&.?:)<4LTW ,-SETLNMH8M16-:NI,]PA6D=$-6$&3B0\J0C%H
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M+AEF0;=FD"R0KI(W)R]?O]"4"$)IR$J4.$3T8_&FM,H+RP9J+>2S/N-$-:9
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M04PJGXEB2+XP:!TK,T%/U)XVN 6)8NIRK6)9LY/,"#?8[,$[W%8.,0J+5#R
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MJQQSE5]/KO)S)Z;B::V=2($:'7#J+;AY)Y+:03,N'9=9'SJ@JW&L1NO=6-[
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M+1DMV5%]B&TU91 \;AO6=P]]WP^J!8%[=[KI)! #*EK-0Q, 6:?(@Q5TV81
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M,L4B5F,0;SKGT2N7&MA-EXC6EUF3<3369(PU&5]/3<:HW_]4^MV[]&L%B^3
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M)G$D!]J6"% EH/$N<0[O\O=M@K\\!VG*E8G37W-R7<ZQODGT J6U+3*FUJ7
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M=PRX* "<,$602LTS7/IUR\7>]]YO9"DNK;CT$8F40(1+GYXJ0P!K+M'VF"'
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M'R6-4D*JZB=SM F\"' 8R(F1,!8&D3D0I<%EC!4W]4 <FX)"\"-&X$!\ZK*
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M@$0FKX.@,=')4#=[,2^U>4JWARP20] B''K\1)O@-=_P4@0P'5-=+P7,:"F
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M5/F[A1V24Q.YH1U,Q:C* TQKTRJ@=_THZ3>"6(Z;%S!N2S%BD.J326? -'O
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M;(71SSP79TE94W5S8!K]9D,U^L; :O71L%[MJP,=X8:I-UK:<)Z4;5I!UW-
M EU +3,+3*E^HZIJ+2,'1%RO:(:8!"5),HU7*FJ4R>).V$)Y^5$N+1*6U+.
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MO)%\8?NIBF+,C$HHG.KUR6U"RGYK5*(B,@>LMX<)J_.2DCFLO@=P-KR'5<A
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MX=(X+Q1HE/0J%A"5]"H67)7.Y6(A6[F_).3-&^3=N+:H1+%Y]R6+<A6:7M7
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M.4;WY=2*<>J7'3P,]_EMXCN?#DI\Z04V'/KN^_2T^ [#TS//I80AC+:ODYT
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M(;F>KA:$E_<K.;4B:PLSJV%*UK. 7#.Q7/.G7)<WZ+DH>2NP#SYLK(M\%'^
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MKT();\$5RF,U-&-D/!;RR=1K85G19IB2GRWIGIU9F&6 BNR^J-3I6C7WY6A
M&)$4?\RUEY\DC+A$X8A?Q C6T,SB-.R/G<J\1&>'<F?8"02($0S$"(J\F_*7
MKR]MGE<?>DA@^T&,22#&(W\):XDF <;.>0_SVNM,$EY=[-;E$6 JL/9V4:$4
M3ET0$ZDY-&>STMC2\+@B)D<!9$+]0I!$_W'AB >7Z(O=FSP6_AW55Y/6K%Z2
M[%5.".H*UUJOUU"B@:K!DFD*9^_72W,MV48.&V23)B 1)F'[@-@!;4,"<D<>
M_E+)TRM.W;>LEH1LJ5IJER0E)=1S*:4MBY6B7,U)+>6_4E)3+;7[Y[R >9,T
MOV%SYY[:5B""/NB:[ZFEPSN+>[M$9(\A>PQIGL@>0^R M@'98X]CCSW7OGEE
MEYVU ,Y-TABIKLC^2@I!'W'-R/ZZ-?OK;3?:N;Z-6]'"2]ZZ801+W0V_(7OK
MGC7+.[_?C<B.MN%QKSY?]!2[;@8I:I)^NXHBJFF6F,3/)\VOL5?\8JEZO]A^
MM:$.6S8N-%39\ EBV*V2>$'0"&I?.H0D3J6IWS"_(AF]63ON'E(Y?TE&'4;I
MY_2:-G0RTYG5JW8ID\]94$;WM3_(^V\)%K=M158KTMMOUFJ]8<UB[F[>(I;@
MC03H3#)'55N/^=4VPUA(WX>Q"5^K+^U,,R,1+4?@N')8&H5-C:"?NI;2] 5U
MC80Q.Y+Y1[#5;UA3.9/,ZX.)D.<4=J@JH3F=3,K.?+U90YEG]C+/W4TOK^/5
M0MSO6X5<&[=I-MU3(/>&M9#C%_&?H6C[/@;YTVF7R+%-3M*;0Y?.%-CR6A0T
M(BY*AJ>I2U;K0+)ZN[**_!QG+IKQ 5FUJ'ZNT.R4JU)W%\W#84?."GXLJU!?
M2-/8^:MF)$8E?M(@1-^+9PV#]IX?G4]O2,Q"$V<"7;MT3L*V"94ANXYF\TKR
M<^8P>A\E":(D=AJ[8M')Y'6]E%>'E-)O:D1<?XS T@1]JAKT?;D0$(PD=9M0
MI;(+*5UC>V..,CLS\'\;04:U[%;G&^NLI(PKA4&V(38RI  1A-FS D[\ZUX<
M,Z_KDSVU T)NF4N4-DH6XEVL5MEC ]8%])Y7[N3W$:O7+^<M=IM1I4*MGVUL
MO'"#+=8:$9<MH^@T?;*@X@V[-)!L?V+5LL>6[0MX@#XDVWJY%>2D]G"(%0)K
M59SXV9RZMJ!LPRKS=)HASM_=YN'-&.030C9M G)F$K8/B!W0-B0@JP1=F)__
M],)\5:X74FVI54-7YN_$U+FG3 M$T ==\SVE(+RSN/N\,O^2G@#MVY0YF[O^
MUGSJ]Q6FEG-@;@=F9 <F[-**#+![5C71782D^XP;IA>"B0K>*,Y ;OAA]%TX
MP;?PB[T(PR^RIF>.[0CV6@Y?>:3JOF>\[Y2R5,I:F')=,AOF:*SF^'%F)< 5
MD5_^8?$+-LE(F# @3#B[S_FQX> 2W=0O#@?SH%F>582:*]E^I=#B6_G^9K&&
M*X+]O.A3.<2W9'>C:PR/&E,[N\Z# FM7N 9Q$L,XUM<*6C7#JP6Y[,Y;2LMB
M>DV-)/;%'DZ'V6[8)$?B_@E7+Y&X7^$FQ4EQK^!&U*_+_;&S#+I!8U[9+5>A
M!<4]KAN!$??<O/UUUI_K T4F,H/9)?28Q"PY<=;:M2'AL[(#D[?R)('A91,&
M3P*@7*A(!$;;GB2/ZD1$:KE:70$V&[GOTTZ2-'+B(%CX/"?/M5>>)%BX;*[A
M:5@8X>:*"RQ&FF7X0MFNK;TE)D!8V-?3XD[!PDTY<WY0@I +Y]YM.G3EX08U
MF", I1 MSS"5SA@S.VNC0-BM87<& "HNRDEC:8ZYH.*"A/HNA1KY:#Y3_S@B
MU(513K-R-:KGV&Q9R17;%-Z?6%"H@=9!8FD"NW]WS _RO1^9<<UQ%$\!W7JX
MOFWV8-N0R.R<)&P,X@^T#0G/6CG?QMR22?_TBI.-!.5:K=2N2?6V@BY#(%L(
MW9I E$=KOHWK%9]\A#V\9H.L0:3F)L :3-@^('9 VY  XR]!!V5B;3VE+8N5
MHES-22WEOU)24RVU^\CH0VHP,OH0Y=&:D=&79*./B5\A^K.9[Z64R#><=.H_
M3@=]<_;*'IEQR#><Z($9:B;='9)D8SZ7,O,JG^E/VP$U;_YQ.D>IGO_%TMUP
M%?$B&GH@!TJD1^:HH[M+LV$&"ISK2T@8VX>$ZWH0:.N%5@ZFE%#!B$Y+6<AE
MT5WTFF#C+[\-'PF ?]8V],J#>:$Q+DTDFS>)Z9:VYH1G??D'< IV[$[2FR]2
M<SU(K>!;OJ6$933Q \!ZHU0FI8<I?YS*F88Y&YI!BL33*<@ *=T;P0]4^J-)
M!D_;3-LK45Y@_8DC5W5FD:_V%^W:5;DMWM/P^Z*/<YD=]N1<3K E45B:NV[#
M6W6VUL^X[ R+OS"/?6CQS6:WGA^Y5D\MK$5)#E<YNK!8?_D'Y^@TAF'POP]P
MV'X/_I6RPW )6 LRD+^,0KA%\);LX[":_'W51[=[F)U*5&\UIS&=J/<)HQXI
M>D;X!%[[E-678O(?7;C9UX:]AL.QCM[C6+P:SG?^&O 92Z1YFDCCQ+&*$6_9
M#'++?4CES_AD5Q3Z@6E8+2?C5^9MH\.;D_EG\,FGK/X$GVR*VV:WO0DQ55_P
M#0&?KC:5/CCR63K-T5B:8(_E=AZ'HW0*_)B;X+N5Z6Z1/QQY_N[#'YZD/-&+
M]/EY08M8-3Z2+$K9JP:UDOVV!*PDL:/)FWY1%S22CXL/G>KWCK@>;<--N_V3
M)/P72!+_@/ /?*9&3.4AI\JVPF;J4[ZA;9M0^!D@_.?/$K]JI2$!O!"N0G>!
M%6^/,K:7,O2Y'>DNBF$@K^[-Q##N0"WY+HD-((@E3]R+X2O .H)5P-J55^U-
MWW<6&4>D[.%TV%T(&H7%)85P.HU1Z*X:$NU;#MC<@=+Q6Z)-9X7^;)&=*%C&
M*)9V@WRA%N0L*-KPFCR!IVF"N^,;:T_JB6$L9TL7AC' ]H]MPT:EGQ^Z0DB2
M_##7WJ=?"G.G_KHYC:AE1KKMF2-)#SRP>>$K,,CML0# )E@]>/ 1_%PO:LV1
M(YH;2>YU-%I?]@:=8E.CX@+2) ?PDSJL&OLW<F$@>$F(I^?:^Y0H>+F 5O9G
M\-+:REBD3LP1ENE&?3V+,8N@)4!X@?4$6"Y-\H=^XK]OTU>T3Q7:US$*H;HZ
M\5W FN%_I<S%$H@'<A7] 4 B-$3ECSY9L5)>R; 42_"QBOOU&5T8!W@=6_A-
MK,TNQ8[KKS4JKE9-DFF:.55T'WE9$!*@FDF)UX$^A@33\2KGTET-DY>%+=D-
M<U5<%B 20$\4F2;P.^X/_5KW>57#,4X5NZ0NE)@-2+C]2 )(&/G+H6LF B@_
ML[#U%9:>)#B\;%U(P1M]#!R#[J1JJ%M"S01%TZ\4VH7.'(!C7.2:H](4B5J5
M(9"X7IGK!P>)R]:9_"A(C"O",-/M. M)D71%5^?CLEB.00*F%)%I"F=_ID']
M;Z0#&IZ?.]^*[?>!U,NX%_4;!N4^*-=G9R7#!$0.WLS\U.7L]L1,Z8;AS\"<
MMO"6B.='4'$+P-=>R@9/LX(X[2F(X-V1" P'C!2;%W&\<6Q[NF?8L<\+? $[
MUX5?7VYW?QX=@,C\ZV!Y'T77D;UZ_@E^/#_<<$T]@! S>4-A$L[D&6"P_[P(
M)OQ(2()Z1L@72,AGJ+>3_[?7L_^.>1G#=_W@VS.PO5K69+]71(QQEID9!J;N
M9/0Q>/,WW5WKV_#9WN!C;3O&S&\OV CW(04@EJ3_,_7J,]R/@\V<Z9O,JRU[
M@M1]8=6G/WO^+H;#ER_],,X*^!:8K@[O$,"G__#<F#*1/_]&X%^A'3(#OSXM
MC&2^\A<BU9N3B_Q.F/_34Y, @NR_MV7Q*+_"SP#% ):Z/_#LTU= *"&*07$3
M(68#B7KA5OTUQY[DU7AG,U!+_HY0^YW]_N6/)#G8Z?T_ I@V_H(C4O^3(N*_
M_/L-#=X0\_N)^4)*^-4[CW\FBQX? QJA,SR/TX8VY$U=HW23T_@QKFLT01(,
MSIHCCJ.^[#?B/(0\ (V?H&FC);>%:JF7RI;D=E%J"0U);9=$);UO5E:JBU]C
M$NW7(\IU1:Z6<D);RBEM\#,N>2CGY0;XRW8)_*M&<QS'7'5)KR>9^C[+E)Q/
M?9_G)YU7L33!(_1)FOY2ORI?@6[FNGH0@O,(G$#^,@3J3IA.F1O#! /C>T:Q
MJV%N!L^_S0#R1>'?KTBAC7A\/!J2A&8P0..A>(S2.'8XUC"6X<D12XS&W.B)
M#OJS3F(YBVTQ7).2Q+B!@M/6:I(AFAJA$6]'&G[7ZI6[05<U/;Q26LS:_5%?
MT,C#D75NEJ&:Z\C%"'YF=/KE6FG:L\!(^NW(-=[96'5G5Y:8LMFK=@J$.Z;6
M8"3W=J3MX&MFT]QXDEG%-[HTG;>R5%.C-.SMR/Z&L18#51QC9J096%?$=WQD
M@9$'\R06^H;"/&'E9,1BZ$J$%=19H(\=SK/ND0NLT2S;SBPJ:?6YO3;+6_CV
M@WGZ>:S<R1#$4!4S9E0JST0[JC<U^G">HFQBJF@LLYCHX).-X\MMU6EJS.%(
MWNIE:<LL%B0EK$_6&9G:A**@L8<CHU$F:S=%KR\18\<->H22V0 -DSL<B>=:
M57JX$UQ5K"RP;-0T<9U=:_SA2+M4ICO>;-C"Y+'<Q8R"[>*KM89CAT/S%D#<
MW+0SE[K9\8[.*K;C2I:&XX=#BTLZ;Q1)W,"66EMJ\X8WG:@6U-@/AF8CO:A6
M\4I.G0V(S+J(V8'5$#2</#+735?CYEBVZ52P<J:X9!=5?]'4\"-L,AYAH9-S
M<KRZV'2[N-R,^BL-3. (I22_F9U,N*PIB9CF;W9;*Y_!P5./D,H7B:EO-_D%
M9I*LLF D;MI7UG#H ?<U:*8P8\1&4U*V[?RH%XSRFA _]8#]'(T<#!47'TI+
M+-Q4:0]O9Q?Q4P_X;UF=]?/JNI*5NJTF.2DVJ]DII-819K%RHCEV<YNLL[0U
MG:CY;1RK@ D<X1:VKXGC8JO0E9A(:PRU,28KD0"''BRK7.T7",&OBI@\FQ'Y
MUK#:T#D+#CU8UE2MJF##RFMI&WDAP<XCMU&-GWJPK/:NE1LNU/%*FO6H^JH\
MRV]5 RSK"+_.-L5J1JH7>Q(1-AKYRC"4*3D>>C!7@:WER55M:SG+GM;( 0MQ
MONM8<.C!7$UI6,WOS"6%B6-ME<LR;6X-Y\H?SG55++4-I:>/L46T %AECP8N
M@!7BB,#TE&Y&7\PC'!/YT11CUH)!.VN-."(P-8-D106G0DG,#K+CCAC4"CLP
M](C Y!Q6;%&"M,*VAB(5>OVM5IE;&O%=8&(K\D61WGL*#'@$S4/SV_.'UZ<:
MU#N?=$ZH51E[M>T'54Q?1OZ/>EC\S0^ZTZ'J=&AI1,'SQ)Y>B.^USM_VD=#$
MUY/W$EXI>J_>Z(.WC%U__6Q8/?^>@4_^MC<DUF#G?JK /]E4/ZB(^A 8F,OH
MK8KXR;ZY5W_W<8O^M2WY,=_54S3C].401(3+$N%]URE!(;HDD"[$5Q()3 ()
M X",1W1)'ET D)W,&$)TN1Z0(8%)(&$0D"63+@C($DH7!&07)<Q3AB R_F^)
M:,CXOP4B(./_QNB"C/]D$@;IS,FD"]*9$TH7I#,GDS (R)))%P1D":4+ K+/
M,/X_:E#^S*J_VAYPO[ 'Y[.?;VFYAN_"+__?%^[+;\HB17_%KWLG&"[[ISF>
M'^\?US?U("5Y(W/TTKIBGVM+XD])MS]VDT/"\NO:3G)WX+<O=;P5*.)W!0HG
MOS+D/0D4@1'$V1HPGE:4S[+TWU[H'AT.?QXL_CQ,<MWR%.=G$A(Q"6*2GS$)
M];N'[^F0U.=>VOXC!FI)':FN2DHJWY)K*46J5DOU0JH@RSGE%P7HU6F<Y$OK
M?WHD_TDT)F'[<I9+ZOMPQJ.UL<@M QT^1\.U^!(ZH;7][U?2"2T,(JT1^*.E
M$<F!8@8KVS"%C1UJ3U?,G_^Q%EL$6J-)S\9TMCERNNK&KHE1B,_S?U;Y<&5Z
M2S,\<E-]NZSW9XRTY1R&SU;JRVX_NR7@S2@20"*=)GCB$M4L]L=HP@3@&M4L
MB.05]3@7#ER'P(G" ?(''"!_%0?T2EMLRVNOX6RC?J72HBU"6PN7P0%/;G-]
MH5:+L$)[P+KE$5.JP9I?<<DO+$WAIVK/(QQ .(!PX'T<H'[  >I7<:!8S \8
MG.1)M6M22RMJ-G;YFG49'""E$6MT\I658UO=:43Z4F$0K0$.\%_^H8DTSYVQ
M]-_%W95GM(6J)5&J*U)*J.=2K?]/G\W_E0/V4:L#OOX#TR@Q,'=5.RC!=5"?
M_2=GLXP>N;SI'YM)5?"%%YJP"M?^7Y\ <DT5&TM+Q#M2(1S-W<$XTNCQGW6B
M>!<@Y7:U)90G8TMBRE.J-B-$<DVM-3HVF(@T29UJ&)A<OV-RM:)'00?^^FM-
M%#K\LO'T'CIXVB8PVM+:D\S:H$P-#'7-F1<RHT@&FW@+SY]*"LOPI07F3==M
M"Z #$[M3L)/M1!$Z('1 Z' AD^H]='!:8[SC8E5-8CBO/=AZ8ZM6OY"S=</6
M2\IR85"8C.>]3KT[E$02H@,/FW>>L;O?S06>VK 27>K)Y$*AICL/-5WAM$"!
MJ6,6ER1T"HM0;,S51;6YU15J6NQ=RG :Y3QR'G;DHF0.1QUI1(S],F-I3-RY
MF$TS)/(P/YB'^3HP@/S1!Z954Z57$;&:!4ZF;+!D4RCZW>R%+*3")#L,EHY6
MPS*=;:VOCP9",[L&,  L)(9.4_Q%VB<@&$ P@&#@)S94>Z@-V'I>MYW,UH]F
MTL;3_=&%8""?Z8<309OS3F8N#XJ9L"+;K@!@ ,:9R#3)GVHV=U=Q)E%6VK ^
M=9QEEU+D:@[%D_[(V+D;G\\G$/2Z/7\_W3P1_3"2QT^P= 25%EV;F2^LB' 6
MD:1Z<M&MM_*6QD(;!>?3])%LN'-T$']<_^W=R.HGT"]9LGIQ&^)GLCHO-)AU
M(*H9++/F\EU[61A&HR:0528.Q/(<DE4DJTA6/T71_YFL]MRHHF=XJ>\0KMO?
M"MM9)VK <Q5H^P25)O%#;?_OWU'W[^@BCB()+;$8YYOEI(Y4E1NPDTU*ZC5@
M'AJZCG/O,9*S9YXER]EQA\9%RPQ-/3 F@C?* 21T_3EL(2AMYC#N? 04<8/H
MBU5KT\(6"S*/K7(UO2O"%CXPDXQ/D]1)4$2NT#MTA9X]9>31A?X3(AV_)O2*
MC&WF;*4@2V++HNF!@>$!:P&A!U8+SJ8QGD1"CX0>"7VBS9U?%7JNLYSJZV:]
MHBZ6LD:ML+IA:%#H@?F#$VF>Q3[#_$FJK?-49B"=*DAUJ2548YM'R-5*]9+2
MABT[.](9S)[$ !VZ:H.NVMRA]:.8K@OVL&!Z9J"[ !F%T<SV[# *XBJ'[X,C
M,PEZM4J[T7,JCME9U"1WNAH(&A_'7/ TBQ_>.$1^7)0S?_LY\W=H#?TV".0[
M4Y5AJZPNR28_K%8S<X*<PB;%T"RBTCQ]25\( @$$ H\# A>WCGX;!#+<$//:
MU=%0+:R;=GD<5CN=<1. P-Y,PD_[1N[]BHS<D* Q5"^D2G51KDFIOZJRHOR-
M D$H$(0"08DRA>2Y"=_H627/\&=FU0]A!BQ8/7C2$=A;34I+=>OK754NDQI.
MYRHMCQ4T'(LM(#*-X8<I\<@GC'S"-^P3OK\;+\=E_JVHE^U>L;QVLG65"/41
M(\[$WJX>BSJT<[ TQ1QZ@I&D(TE'DIX<\^9CDCYAB\42E<W[4D57QCI7VDR7
M@@4E'1@S9)K'V4>YWY(OU86Z6!*J*(B#[K>@^RV7M3RBB1G4?<]_QJCWG2V-
MXEAO\=U*'EL6/"6DZ$"@)DT-Q^/TLS1-((\K2I]'Z?.?8SQ\7&P7!4(MVI.B
MKA+25FU-L<(B:,9BRT"] N=.II(@L45B^S!B>WE+X.-B6[1JFY+0;"PE8KKK
M2WF_*JM3"XHMC&VD,>;D9;5[#VU\-Q'VH0T4T_B$F,:UHZ)7CGE<>_F)<II\
MOF&R=YX<2Y#'5RM-':TDK( 1N:*XS(YT;!U/#B(E?LGZRDE&C^MZ2*\M+5?V
MH%Y[^8D"B\\WA]X%BZ)E<UI#J'?5K5_J2M@T0P5U"TX.QE/2!(?  H$% HN[
M#L=\&"PB?%BJJ#VJXRC$=(7E-\6:/A3@Y&(;C'B<DF-O[:W47\^AF;_3J;K4
M1@$:%*!! 9I+V$&'0/7=9_1N@AB;F12C0D4OJY5-IRNN)WQN5&AJ.+DWB4CN
MDG>&$R/1R.>+?+[7MTU^2X!7O,CWG.V(E HX,Z"+$]O-#RPHP+&9PAVI>8P$
M& GP]07X_LR%4_+[5FR=XK!KKR=#!5MTIO5,SZ\LLY58;&'9,O+L&5PW%+'Y
MX0I**BOEY9:4:@L]24G)=13%>8R;*:B-R]W:*=]S6_.!/Q/!5&QO"3;U*?G5
M]\*L"1YG[L>U]8T92ILHT/T ;+T>;$N1.0L!UL)%!'Y\'[ $EA.8871*4<KX
M\^VP:>JBI'>XL+$;K,H;!E@Z5&SI4&F2/P1==!7FOA/D47N(>XWS7!9D#K0Y
M-<P,U5UN[(B5J80U*UXM9\38 HPP+DTS*%:$D 4ARUU8>9^++.6NXLB5,>LZ
ME?YH6Z2RN6)E'B,+[.N9QNE3+:WN*K!T-@LP,;!P57,OP7'TZ]E^"8ZNWZTA
M"!#RR4V6-3US;!]#P;FR#'O19"PZ<I8>4D,N\/V&H.$TM-UH$MU+>)P"3M=3
MK! X?+X!]Q%PT!?4TM"D?*0NO(U#YRP>=Z,F! ?8K>>(@H3  8$# H?;M\$^
M @Y!4-IUBQUIB"WL:L$N.,NF0<3@L$_,(\YT.>INN@/5I38J G?E"U,DP(^1
MOQRZ9B)0]3\^\;+4%9:>+.R\?)J@&7VL=ES>7W6SN^Z8Q;J9:I["IZN:. 9&
M%_,4,.,)%#"[_A6(.\6*CUQ_2!A6W%\0[2U4O$4(M<DZ'6-1-9V%5E\59ETV
MNS$LB!!QV(O$#Y4KA \('Q ^W$DH[&?XT/=SF&$SU;:D;T>3KBAU9TPNUB!@
MDF.:)T_AP[VW)I*$5KU4+RC/B8X-J952BD)+2LGY%+"_:G(]I;1EL?(-A;I0
MJ.O>0EW)VA3DS45\D"!O;K(V!0D'XH-[%XX'=/1G!:4D(N<^<NXCY_Y'G?LY
M>V6/S-@>#R=Z8(::27>')-F8SZ7,O,IG^M-V0,V;Y_;P$[]DE4MZX(%]#!MF
MH,!99O70-@X=_=CW>O+-GK49[RIKJ5O-C!:1)A;LD:7A''3T8U_)2S;)3#*,
M(#<><N/]N1OO/*#QZ[[^\X#&6ZP(IVP@+PM>%M.=BDP2[%)686EW#KK\L:_(
MXX^@ D'%=:'BU]W^EX$*HN3/\@UG23H$7[7[/6R=W\IK"!4\A KL/#=7;M/Y
MGRM5U;:40Y[],WKV[Q3W#ISU"0.Y![&B<K:[C,S1*3MJ6=H5"O8X'ZH%&U]U
M5%YAFQBPH_A/L*,2@P=7<\_>J?@?>%P3)OZ/80Y]E_ZW0M]>+)V\M&YTI6ZG
M.FJ4] VK80(4^M@@PDX5?D4RCV0>R7Q2[9KW9;XO+>QNTYRLL$K;J.H<C@>E
M3"SSGV?9W%"DJ2N5"D5@[:2$CM02"E*JKM:R4@OF.<4)3\K;C*<4"DNA\FZ/
M6=[M6ND=B#]0%:'D5A%*P,8@,4%B\CAB<N_^=U4!ZFBI#K7.AMHNU0NI=]/Q
M4?K][78LN9J:>1\H@/Q3-]4=X&K'(.)VQ.V/L.9[XO8']$.BC'>4\?ZO*S0
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M@H-"IR/W^?6P)"ED?4*7O4W(CH!.17Z6?988E$"YMA?2EJZ]V*2!PI7,K%\
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MK#7N<*37FY7J6US;2$K4KV6U[*0T+@D:?SB2((+-A&R-74FT-IBC$KMQQ1'
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M:]W)O0N1,GP7[DC<A^%WC3[NI+)TEHWX168YM34"F!U4J73W;/ARVKJZ$4Y
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M^.]Z32GL*W%/S"/,_*47G<-MFK2VO:=6G=5=W3/,E!ZERKJWU(-M"D^G8//
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MEH2M+T')6%=LU'@CF<^(?1(:84M01M&UI>C#V_3#6T2PZF%@@Z<637=EPIV
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M[_!.$AQ.[<4S$)QGK<G+##JY^ ND#0FA)H_/F2=D-'S7CZJ.H,YJ6N2VFZW
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M0(*)+ .)9#XTFAJJOD1L8K3%.88.O]O8> 4(AD.C_Y@MGG$#L/<NK M;?GU
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M>=G?T45R]W5GTT5RM%=0NQ!03B6??2\D2APP;\^.QFQWP7+4B&L#&ZB(%(U
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M\>I555+/H9&J<2B-('@")Z/"+C)LXM[W17W6Y2.&H)"D$ME157\;2S^/\?(
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MIGCLG3_QZ-STKO0G)3%)C*6Z;F5[3[=WFX.U]UYW-N'TV5YMDF[_A -3=K6
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MS\7G.U7"?7P1!G]P80@L>ZK/2?22<2@6P")1/:AEL5PG)@5'A,"1K#SQS^M
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M7>Q]<;IG6W*_)U(&BQ'F=Z4A$/:03/(BG_^/'USL=2[H?-Y,W_/!JI4Q0KA
M<S^3OH>_: P"AJ6\Z/MG\9B 'U088HQV[$T_Z'NKX_L1(_YZQ/ 'GOZVI5>
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MF]K-MK/0\U]5 ZUL+7=6%QT[1Y?T0G-;-GR3D8,W3VG0:/;X03PYV)F;3BJ
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MT3 >N\38W\+GD1=5T9P)?&BJ:7S@]+B]2?3H$B5W5%6></7/A(*WU&X\MBY
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M 1$._$%WC+%# VP&+#-5L_8/@Q_N9G53"70!D\:O&K[.GHXX$T9+@#4(JHG
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M:N.@P<KKPU])7H8YRX'@"03/P[;HB_":$Q41^K*5^@.1$HB4=Y#YM=JP/%0
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M_5F>PNKX3C?P;VG6@3/@:QF(WY0V3Z7<9Y;]-:V^]Y0D#X5VO5P^P8Y/M=+
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M"!&>#/#R>'@A(@&[/"!:DA'RF\[L>FR\!&+L,?$2B+&'1$LB0G[3J:B/C9=
MC#TF7@(Q]I!H =88&>#E:GAY;_W^:S[^W8  8YSV)_B7WY()=L^_&2Q7E>CW
MAXEW2-G?CF9-_NUH5HJ())(//=7-!Z"O3FI])D7M-ZGU[WCLSO!Z$3K2,:UY
M.>['GY]LI!W!!!C)U U8UV#.-,O@5 %>L9$^!<.]"H"7R,,F@?/_GLT%W+,6
M^;>LE8K$XG>GE MRUD4'I 8TXAA0L<<>HOI^&KG<3-6 1EPY0GXQ&HE>1 ??
M<Y34^9DS3F'Q5-,$ R+G/:UI7F:"!SOI%0W:#T0''@Q(_WV!<]G)CD=L<N ]
MZ5OKFO^V./.Y>\%%E=<68MNM9:@XE1I']520*>N3-J>(AE-+E6JUB1FOQU/X
M0A8Z8F,\5,C&42^1,/6N2CFG1D04_$M(&+NV;%_V1NWOB$7[VUQLPG46>%TN
M]A)XM)!>:G \)?7C#T%=J1]P($Z^KSBQDP[?79P\=RG[[\1)7J[5U&TX9N#Q
M'DU3N#:;)6N;>X@3AJ@RTC:U6^(9(=R*3G!"E'?.3,]8RJ>.-A G@3CY>/#_
MNXN3Y^J[_TZ<T FUI^8Z4D.N"Q7%C&VWJR73O(<XB0EE.6,,Z:R\(ZW<8AW3
M%[$DM$Y2/_[$J9?Z#7^^K$5+-$1.YV?H7I@@KD5%6Z+R6.=B@/$9PAGO$XRW
MDWS?Z\BOU:=]00GX$?_,Y3Q:%;('OG.DDB,3^ZUIJM#N]]9XAFKV)NMU+M_;
MTO>0B5:[LXOQQ7:"R2@=8KJC<[WY"LYQ!!Y;C$A>S\3Z7CST#<7&:_5@7U!L
M?,0/>XO8P+D.S3;56%Y>Q.:U09\@FLO-74RI365EM<OQ=9X-;Z>#0=O \]W>
MU![_FD@D K$1B(TKU5]]0;'Q$7_K+6(C/C0'>*JQ9/%%2A@Q^=%PLY;O(C9J
MFXXN/;76 B.J@C#M&56CIT*Q 3RP6/*EF15?(I_6%A4%O#"$3455U#D%.6><
ML)!4"=UZE-;BY?VS!X/!G82H#Q3NF'Y^%4H7:S7Z;+[MWJ=_* G\$7_/8>J\
MS=) #M-'#.T(0S<:5DGFJN.Y&MW)%BM-RPI7KM7O8\*-Q^-1O;C))=A57D@6
M*5)4$F4X'1?FZD+1:\V?#D32=Q=)S^;L[GWZAQ))'_$EWR>26@R]*YEK.L>2
M.R.Z5'OU$M^_2[Y/?5H0J3$=CN(+JDBH&8.I*@G:GB=,AO#$-RT@"$32#:PD
M_[S?O4__4"+I(W[J^T02:\U*E4U!BC,+/*\/)Z*1[^[N$A^?JPU-4^N<*=?5
M5'X@[IK,EMH D91"(HDZ;]WZF;.&MQ<[WS:J=RQ9*"!9!,V"G7H>0;!>L-+S
MWL=\* EZZF<R=#>_,C*-);NJ-'=<.SHO]"=W\0;GRE")=G.=*2-6S-U '-03
M1AS.DZ60G$M>T?0*F/_K,;_CX]W[F _%_*<>79.-K4URO=#E<(E/4$VZH/72
M=S%R=KD<-Z)6Z0X;+E/24*O(>2J]L8=)4Z%H-"@#")C__=[4O8_Y4,S_UMZ>
MMV=^:CN/64]*:XIS+9X?L.GU(+R S)^"S$_&7O5P[C?AYJ3_*FQC^T8VOLS.
MSHJO3S@+-;JGXFCC0N2Y^Y4-75K#=O8P&4A$HS16GTQ$V*;>N'(+_ECT'*2^
M[8<]4R)>:Y=/.E .'0TCD-"8A)M/BS@D<MK6V) $B=-WL#2Y/D&MJ(\"% X6
M&@H09S"*X40BUELY*Z?;S2<\GIPQ%=T0J^WC%OBG8R->[8'_TMP(@%#T)\-W
M5L1XKC6X6CN>9^M<5IDU369IQ:<P70/DZ?FX"!N.\ (GP,,"P!N]VF_R \05
MSQFS_?@'^",.VW"P,[_IH@_\$  51X1J9[!A _*EKO&B*!BP-SVGP'[DEQX@
M] !(QM^%XH8#DIRN+7HV#-TA(/Z(K27ZTZ=V5LVRG%Y9EZO9[*P%AX"0(2KN
M@]@)>"YF6/P!7U><UG$M24&])"E^2K^<X.[51<9SB9:_IJ;MD,]E-GJ%DMM&
M#H^6A*(U7TWO)#+Z\ZPZ&27Y.9Z?YB?U\-1(3Y,;H-EQ(I0DOI'0N .:WSF?
MXDU2PSMB@J<[P^VXCL]E;ID<3)?1V+P7;SJ3!EX:*.8C0!!^?DH!VP$8+Y7M
MRRSG8,=X6:BSTVU:+ B,P.:%%G#W\QU5PFD@U*E$""?.RRO^@O44T3!.V,\V
MSL],<6\C-D^[.5X!4AHZ=+-_CHUI"FJ":_2;>[;K!AGU*!S;V,^%85N-XS9R
M_^>H6]Y>!\&6]IK^V_4M/>=RNO39,RZF8MANQL=-P*M_<\J&VQENS"IU\,Y_
M[]U3RC:7(U3L7YCGWQ @9]"$[?(],#MJA^_\[+@COOOE*TT!'=3 H1(D$8'^
MA&=H0)2()&)70M:)*4 =4/,?#IOID*__JU//^-Y0A?\&] VX33ERE)RO?OSI
MH,$$B-K1A %C[Z!Q5W727AGWVFC5.W2EV,?2Q7JGP+3H!L-VBIFVTVJM6,M<
MTMAZU^YLUXW<(Z%6[S!M>UN=.I:IU]KU2C%+=Y@LEBO6Z%JF2%>P=@=\465J
MG;:'E5X4 8A>PX1W&H5#KX<OCPG]C'[M/P*9R/^$*[#_!XP ^,M?)Y1]PB*'
M4-">09;FLX]W:=UO>$=G/#*;L[E %/(SO#=+UQ.$MC*&5',$ET:OQ2%>O]HU
MA(!QL[1T?L89UYB7>#)KZP**M%J?")-B><ZS4D8O-LQF/9GN?<CES<!Q9?6)
MHS;K>@OBMF;!MX%]B3Q0L*8D&AE.440AO7/5J[/07[LF<^/PG)YM)7;7&:53
ME46R/:@"7S@9C;W/&SXR4^U1JZ<S%%V[%4U(W)NNR(CRU<37GIUX:W<L9'=5
M!.>?3G5Q"B 1ND$LYSD+,2N.S<,D0$31P&(;U313-&!LU2'C#_-!MYK<3&::
MJ.&9"4^*\4W+6*T^Q =PYQDXE$PWT/@Q^"\TM= ]C&U>VF8GX4OV7=EBIVPY
MW9;K30/7EN5B+28#LH^&XBDB%"?/H[7O-2OW^T,_02.B$6@C6/'\%\B'\/PD
MM)^P^2IM_CU1+CD)S;T[;!?.!,5F0'V";=S-DWP<NGRCXPG]'&?(IM'1X/8+
M-@CKZH%*?3W/:*^<)@;"<(Z'RYMJ+F/6-QR<@H='SN_P''N>NK@$Q"BJ"&,H
M>K!T=@ H1T3S+GE>AQ)Y;)D <PC7$K2#1,,,80M.%L,;@&EQ_^7A ="%W7\
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M"I51J\WHQH"3W^(__L03H1A!AF(^";3/'/V^-U=\6VGP  U0[B\0WA_)OJU
MF,8D;5N:*2.<F\12T3@M:W2B"01"ZL<?8!K$*#P43YW7&WZJ2/:9BR0XI588
M($>1-X\O$P2Q[L\1]/@R<;Y['_$F@>R['S(@UJ^G7-]O;1=KN7>IUZ+*Z^)"
M5$U.<5+#:+>T9^ K3!JK %,&V%A]DA7'ID\%[T'A,L-*6K22M"9GJDRMI"A"
M1^?01&58W$^%*"H6BE+XYVV_<F\F^!Z<_DD[L=S4DKX_LPNMJJ)')964PT6Y
MDT_N%"(;1<P.S>M0'+C<%.Q[_\7*]M]B<!MV5F()#VR@6=L U #0//P=^F.0
MD B"#I\C!'GO4P>!]N]U[B#0_BBF/_HNS1FBT.!V<#&MZYPZ1;_S,PB*G>)Z
MD*Y7FK*(%WK]]32M,]'IB"#LJ[VQ1#R$7RT;%\3?O].Y@_C[ WD-[Y43X\5X
M65T.*G&6ZPQ$HI"+2JD5#>4$<!R2L52(B,6^6%#^C75+0?/V(#3ROFXF7^(F
MS>>K4'(NSIQE(GVD724A<WVB+*_9N"GU^^9FFQ^D-FC/MRE2^NH\$3#^=V3\
M.Q4CO8/Q9]/P!D\E1Z9<YB=6PLQNMT0/,3YL0T^&HF0TA!/Q(!GR,>?GWEQQ
M;RCX]3+Z[L+A3H5)[Q .<=Z<SO6M6F7+[-P@^-ZHWA%IN&?H Q$A/)8($8F7
MA -R@_Z-7+#+D[*++HR*G].UO2RLB!,3T= ;Z?PJ>R0\F_P?S*^7JNHI?X)$
M8TB&B3PQP 48C"# ?T].?P@[,UFZ#GPQP=*A>V;.1&PG<CK*YH _*A9,D\'?
M+CA9#&]FF@)_9(HPTX,M;4?8 #_C3&PC*0HV]CS36H*?\OMD6\3&JHUJ-!-6
MXF\ +X=<,=A\"EN*NNVE L&!J9IIGU$0[V##.UPVHE53$LX:AS%;M"\AIVL+
MX$PO+1,]K#YA.%T%F#(:HFY')';^#Z"WDC%:*MN1AT.1.UZW\W4]#H8O3(-6
M!4@YB'"J(N3PT:;0-\;YD;!E5JEA?3D<I\KR^$,!E@^>D5YHEFJ>RI<:.,&(
MM*3QO$;@"7:7:DGTHJ$VZ'3SQQ\*6!VI1"CA8WD\%Z:P5*!;E!UD V_$XBC+
M&<(V#MP0A]C$;4I0!:F(]<!#(0_!XW#J#H4[]CPE@A<(6%;D$9C_[W\1<?P?
MB@A!SB4!X_"<!3@2KG92K!O-4@3(4>!]4MB%7P0KJF]Z)A5"R]QHB^@ ]9X\
M<&K.WID' .V[;."0/JX_6:5HW\PP\8Q!] 8LTUTQF\<D_2G;7TRS@\J:(<=#
M?508R.(V-?WQATB&R%@T1,;/6^"\D_2/:/TXVW]Y<HT^'KF>&E@/1ZY2<Z%'
MK9P9DU>3CIB*<NW=9MA\3'+M--NYQ'+(S)F,,-CTBG*^F,L"24W$0_$X$4KA
MYW=6[D&NOD8*AXXQJM4[S(B@1F%@*OZ;._F://D:F+_$L##?F(E.A^&L36[=
M8AES-VD"VJ).5\9ELU;-+41:KG=*N?1PN"4XBAZ1(_QT9;.^8@2='[*RI*KE
M)[*02E>2<"5YNK+,Z"F-[JPKN+C=-E?AC;3C>E.P,G:Z<MS(T=UAK39EK#2G
M#M71Z,G2X<KDZ<I$OR(\&4W.PJ7HD[FD8D*X34Y'U/D^U41R1VWCF04KKI^,
M9&R8(]BG)EAYML^UFF[P\M8DF'IRR.,Y/5P<K^ SS_:9P.<I/K8@>DS>&B<:
MZVQ6L>8T6'FVS\E\BIO)48]E5]N:R#<&TH3.P:E;9_LTA]P@5TJ6*WAOJ'8R
M]2R37H^FH]CYRG6,V^52[(9F>]%20IQ,N55?H\'*LQ/MYD3#"I>D"<X)Q70I
MG4X(;6T#5IZ=J#=:)=.%(K]F%U:S75X]$55M %>Z)SHBQ(MX@V>I+VTA=KAM
M5C)X8");NM@!;T@K@'L<-VX\R@QV;&:F\PW&,LPLWJ%C^&"UL66GI%K 0S1?
M6#>"RX@?F B$PA*\VM0M\6(.^5F[ #]/P/;((9O:&H<@[?\/8QVZS[2Q>@TK
MUC+U*H.8'SF;[N:<B .O*0JW-,3?[C_^N8"[LN_)C"(+\*UAA=L!B?9[(FU%
MP0U]X+@;^'!C&<=I07N9[>W\V_N'RP+V)&*#(B&FMGPA9I,\B\)PD=,XT$F4
M9GRYO:,'@1T!U:><G^;'G\[!3/_/O\<W"S<@@HQ%T7$;NF8":&ZQM*2![0#0
MB4 )\4;()D_ FQ%, MXUMX5)5IX'1("<= UC(^T(_!Y3N(T1P3QG@2$)(O&/
MX39=WO]>LLTP:!R!3\ \@NX*<-LY#,@1$>I8:PD?_4:S:@DDQ:A#[X99==.4
MY7QA/":GB<487[[3J#)T<]2"B71D_L!/56XK+:R%8^/T\T]"3.BN*G*<Q?'$
ML%F)LM*1C4.^R\)AD/H'JGXO^EK@_"T1[)F7% GME39S(N W3H%@LDQ-WQTM
MWMLW8=)CX. IOMT@.KTZ+I4V W(T[@SY.#!PR/,N<O^RS8QK"_<V/Q,%2Q'K
M$T@<F@IC-?7)_BB,'01*BZHXD<P.*G,XEOUY7;.6(Z9OM*J3?F_!M*D$3>3&
M.8&8TB?B_Z6E0$->1_HC(20!:U U;7'S0ASH*+CGK:F9H/\Y$F$"Y+NV05QF
MJP%K 9X)7FAX_?H]DT'60M$WF]M^'T6\3XQ(\-&!&$+MJP!&=L6%9!!0-C-;
M^N&1E\/YAU^^(^CY#I5I;PJBQ-G0@MN&$>FK>[V(8JX<X#OW"Q1KM[]Q%,8A
M+NM^8:^!W]CJ)PG4)M*5[KZ<]Q&.#GU;64TBDGSQEH8@K7V>KX%G3@ =N4!S
M/X>A>OP]UD5.#F\ F/Y9:H8$B>&W+L)"F+5X\DS'0D O=I=R8T.#/K+7/KA5
MARI[X=L)X]_@+/O_?B@#1+Z2[ L0<2-$$!$RX(B'0 3^2L5;@(F;L40@FQX$
M$8%L>@Q$!++I43 12<0"1#P$(@+9]!B( +(I4-</@8E((E 2%T3$>^\,O1;<
MN-VID^\X]57#"!\^<O+LQ,<YC>,DA!WH/_^OG9&X1/'P TP ?2L!G*><WD<1
MO*; +__W1^+',_!:@*<HXO/PHA(1G+PKP)++U]NEOT10 UAEP_A7V5R8M%Z6
MW9^(=/Y.;-Z92(XA(QV#!:4^)9A;Y,%??Z)LH0##\+IAYP$UR^!4P?CUGW]+
MGT*JWD>.D,_)D5>9@X@D/[<<@36I%Y,4 7%\.>*@+J=&7@Q/?$?BB'YVXH@&
M-L:%;(P[]SS)P(L\JGE:YG QB^'>Y[O+=<X'P.M%IJ#B]^K,]SA#3J\^=MUA
MP&=*MGPFF@[S=:U7[3WQS.JI7U](16V:96&)-/7C3^R:/6GO3=(!*P>L_-!#
MS]_-RL5FF1J&,VV-Z<6:X8&5W*A+%;)R_,<?*D1%K]13 =KC]R;J@)D_G-[Z
MULQ\]>'C[V9F<9JA8]T&V9+)"KV-"DICE$C#2TZI'W]2R6NQ\F?NI?L)DEE9
M<2*B3@?7\H\^!Z:^;'KJ-D!PC*\[0^$%X7TGV@@8(&" AV$ [.=G]S]<9?6\
MS0*.#I[J8[S,8D_+Y3R:3N%EL4V4R>12P6O-4=3V1/ 4>6:^_/H"J8%  IP^
M-@/.--8E\)B"J*Q%>$[X2$XUPN?/?4\ATT4<GL>5'U_-^WE=E)Q*D,6 ;3&3
M(=5DXY)4;&Z5)RM3A1($N#\D=47WYW.(C\^9'>K V^M!;NCZ,:B[M[V\8<3Y
M[F=]'#E^]>S2V^5WPZC7T^5D=<V$9SV#H+0%2RUA[YL@K11(@4 *?&K'\.U2
MH+^2:G2W:;;E57DUVZ4&>F'!P%Y9P \D8^?M!H-\5" %/I*PNOM9'T<*7-VG
M>[L48!DE9RF-,L/6.VPE4U@076D#>]:EX/PSDCR/!@7)K*.^8O\^Z01TJVY(
M^%]W.O=MEW2KYN?XH6%:[M"=:29BNCB%XZ,T?8=QRZ6NK0'=HX[+C#+AQKJD
MP;L.56[G:8:LB[PH+4VW3?-_7XMK8Q[='=NK[EHOW)BG\N&)O*.ERCR\'3Q1
M^>D1T\;>Q+1+9?N[*BFB86JJZ(PC:\&CK45AS[%Q3V^RVIC+=XQ)=LXNQ%R?
MR>!L7EO3L%@W<FZ\V_>$ .X4")*%^QZWW3MJKPJAIW"6RL\@++T /VLR%SKJ
MB*V+B@B'J*$O <:<9E@<1"RG\N MNKB6-,M0X%K8\@ZL!0L$3ZX5XPQ#--%5
M%ETTELXX8@E\4ZM7#/].=V"AI9B0=,"?.4P5454K-K;%'/S]9R6&,PE^W,LN
M,X/-]8JJ&[0#"V@$OJX+?-J%_7D.P$M#L7YIS%=JW0*>3U>6"74NKBM=0$-4
MY+S!W1$)'?4GA""RFPFCJ0$A;(RH <T*@%@#Z ?_A,WW(#$ M-A7<^'@Z;4$
M9!'\$N@.@, I=_RU2Y:PGR\O+3DTF<Z68["OH=O^UX>00H!VL UG8 M-!V0M
MR2(@/K [%?6;]FWFYKU[Z[E2S /BUJ$RFYWT^*2@8+O&G>)G2_7)J$=^VNHK
M%R83IS>'_\_1C>B]G(?MVS3]MVMH><[EW,0FD<*=BF'[PC4W :_^S2D;;F<X
MYTRD(ONTWN^]K08!@0&3CXK]"_/\&P+D#)JP-9P'9D>MWYR?'7=_<[]\Y>*W
M@QI36_XFB0C4B)X&>5'H<EP)62>:C3J@YC\<-M.AU/BO3CWC>PT!W>GS:6?J
M?/7C#VK@:/?*1MWTC+UFYBZIG<^N0;QR6:31JG?H2K&/I8OU3H%IT0V&[10S
M;;?):2T3N=?N[!Z1Y%&'X+:]K4X=R]1K[7JEF*4[3!;+%6MT+5.D*UB[ [ZH
M,K5.V\-*+XH 1*]APMMYT:'7PY?'A'Y&O_8?X<#,GW %]O\P$OWRUPEEG[#(
MP2C>,\C2?/;Q+JW[-:I\M;OS.WI!7["OY0DJ/:8B&DD#Y+WA*_$/W=^!]%*D
M)\0Z@B5"10%4KLAS!E0?P*@$QH%QIL ,H')TQX;9=PS]C?V4?MG4PUL+RP:M
M^PA[$@AX/U)>CJ)#=@X@0&QE<3H@362ZP,7HPJZV%&T#PO@'/-E]-/RI!#9B
MVSQM$>E;IZUU(NH:MO !#B&#=V8LIRE^21L;&,T#K0L<+6"Z09TGJN!9J#\P
M.+O";> >W*OC@,J(!/83/A%:^R1X7*9$HW\2__QR'J*+*TO2CQND0CCRW!)=
M07ZR53,'E*L)/\ #@N6 2\"/X5\$<2TJVA+9EH>)1A!.1 R-C0  @.L $*1?
MF /,$Q3Y&WV3U_T%C_5Z23GT F5"6H)@!/M90CC B043H'(Y>P*Q#1*= V:?
MQ .+1) FP$^VQQ@ J+K81<1D[  ,%A&L:"+^XR2PQA#AN"X%D\4=6@,/*AGV
MSR%/V,3C$*^++GNFQ@%0@F6;P XY+>R.S/:+)W9K9/!&?:FAWM%.JVGX-O1Y
MHFL+#"IXL%^2^%?(&;D V:'$ :FB[QR"A8,_B&0$JX.7Z,CX1(<%=, CJ]6P
M1SV@/2"0.;,_@,4&R F.?X _A)^ BR"&38 2"%7.U&W;U^8X%?;.MCD2'!O2
M#GC1?L (_+$B+21[I 4\,7 B $VZ( !G2 *)"R'!;9&<L(\;<F9D >DB0:(#
M]*[K.T2VMM5JAA'W0)?$%B#H!(#F-+A'('8<'!S@R"E "*BVW  6"0(Y/($K
M.Q O *$%* MN'4-&E^\T%2(1P2J: 1EI"CP<G;-918(/TGR18(_O,DQGB)=A
MC>?0KW(HCL3#:'X+.B/8S@8X0EZH[6UO_Q.X&+9ISW E[2E:!8?Z('!<TA,
MJ W$"6#3$_!K>U#9'C^A(Q9QT>3^&W*%#H2 !^\NN.UQ3ASR/S!1UPS['*84
MYL;(5^"VY\_>CSYS!ZAY8*!;"B3,TY]X:4MU]^VX)>#/XI87#0,Y,EN11S-(
MP!87\.F<?3X$6\^9IHHV!O !6P$L@D9/P>9';I-W2)HW$F35]P+GE)N1:!+V
M-*K87I?ITCMD-IM&;<('9)H*HV%99V\ZL*LQXVP*1B^')*5A,8=_P7N9=+&3
MI1%,/6_!W!> 9VLJ)&XD:RG[=_ W$2PK&2A(8:M*^_6'URZX'7PIY _))C;$
M(@?QH.R.K8BQJ$A 4CM"&7ZSU*#5#J?S.?K]IS2!BDH!( 9[_&4?03*\8'5G
M[FF3"3!KL/$. Q0$[1D7)]R:DQ1T1"2';D,8SUDECM9SS05NN^1VT.IYP5AX
MW5!XOW $/A] !0 D)$HT&F@A>E24.[/-Q=3I:,27QKC9W&K'F@XS%_:'VZ/E
MV6/QFCNW$5HH0.MRD'0N'INBC5%]XJTMZ)=7%JU-C1[>6\=VHV&O4TKK'XE&
M><)-%<D.PTBBX7[K)!DR>ZP++0<BM"ID#_#(0'#X1J/2W>I\0TV&M+S@H^4U
M43=R3!1&-).1V,OAJ-"UH4F-$N/&*&:LEQLYTUUFRFIVS<VRS0>&IEH;X<UI
M8C?%I6$Z$]T\$05Y *!)1"/G:=WC^#"DX"L#-#HJ5O*U3*J0+>+A"?.T*E24
M4;&U>6" :N'"6#3%]$S.M-4UL#R>^BL.#N<C(JE7 "JICBB!I(3 :T_'<T+=
M0$2=ZA*D!?8BTW9Z;4'B"L>E!8R>O5MUA<$C'M"'#9'_#80F[,$(O!MOSN)-
M *7M@Z!M-, &-<$#UT6]R1NS^7"$QXVLD:L69ALM"PDUYK$43J.U" S/BES@
M9L/=PS0#\).!/>(W)P?\!H%N C6$K6K\/,X;NI#/&!* $B86,)(/D0<G-=*V
MQN!P$@?L$\,SJ_=@GP (22IX$#P-4H%V $5',X14#6E<WK$[@,86) .X66,+
M^BWJ;F])"1**QP,#"GF!-C%ZWVV3K@"80P<> N=U,SDT/=#]9*DP_P-<PB<X
MG]@;PU$D-ZZ/(EBVD6?_Y+ KSPA)L'_H0RSLE #$)C"QX"<=6EOV6Z\:A/1#
MI9.)'4>>ZP'I3H>R/U5,X0[$!8'EAGX<!RIL$XECK>S'X9#$/]A"Y.  .<,-
M\0 CR$<$ ;ZQ>]$YJ1^ ?SMUA<%85<L.TJ!XQ<^TILFR*"ZA_=4 5A@O+15[
M'F3.\>:*+L7:.Y9<7IU@&5&' 1&LP>DF\"Z,F;0T]GYJ]I3\P*$E'6X $;&]
MGU\AC$@EXS;!%@V= YQV(.7=,Z.YW(7N=*[?]QDJY_D&YCE0JNB#(^9L^KC<
MB+E+3)0C'FFBG!/_,IZ9)^>?@2*<C=J)A.MQ=X+<<[<3KW/D[#EEA^RXFIT"
M=18C:>Y( AI%3P'A,] 17NH28.N0*P2\ ^?L1V.V(G'BK[HGX.5&#*^N-SV'
M/W\["H-?>>P=D?0:4N 3''27 4(.WE&">@F \C $&/[1JS.=47CN_.%]II^V
MS)FF T6X'QT,OH0M8.$T01%YP,Y/D\38H.1IML#&:RUK5"'$!K6;/N 4/2T>
M%T2RDM[)5G'(9756R62A)W)M_*2.\).Z-7Z:_56%+#[U:DQ>&\W*(ZN5""<?
M<<IA;S+.##2Z.V;SO;DP+F=G]<*F>77\D/B1(X+?&C\-G>^O@=]1ELG5E(ZO
MUK-L+O^(^)&,>B^KC?4RNUMO&SU3C*=RB1O@ASC"#W%K_%062IO6&*G(Y@>M
MI]22KG/).?V ^%GFF%&]RZB,G&DOBP:IZ5VN/KT^?DXO$]T8/RVP[56%WW68
MWBZ:EN0"+F8;CX@?@2*+ZT:V4)!7UC9K3H>K32E_ _XYO>9Q8_RLL[E:1Q6>
M%+Q>348GN\TD+^J/B)]JN"U767DCR=:DKVX8WIAOES?@'[^QQ3?$#VEMZHN$
MOMTQ=:7PM%ZO,KE<Z1'MM]*FO^SD^OP(MV;EL<%4M"E,)/R!'://K@7<XHM_
MH0@$2G$[WK\#V1OY'$[,$YO"8 2,EV,&9]?IN57,AC?;SGN7HX(E;W#!]'=@
MP%([?^4$)0^Q4#=[99?JH"";_59.%V&#!">H='XEX;,6N":# M>@P#4H< T*
M7"]:X$J^J\"5^A$$?*\5\"4?*> +U&F%V^PK1AA@'@&S<2JBY @45(XR+^Y3
M)@;,*<121S6U;_D9?(];=_O(X65V7^'UUE.%/,6G-/A60.MKFI,7B^.NW?/6
M!\*DU=(:*Y(QLZ/0]%*7%/MI)(['0K!,:BWIIK4/@3\?UW:CV@##SB+G8JSO
M*@,:RL8S4764AH1>@F(G+-? -8#UWYYK: ;<NUVT[.2-+H.P8ZFYG_#AW!4-
M^UT6]2*5>S9'^>(DD!:LCG-2MIZ\R%6-[I1-[DY"$= BO!*Y3T5C/AAV+60.
M/, N<EVBH@.8W 0TQ<._N;?3/'8UH*N#32T>GC:1=,-T;A7816Z>FF$G.0)+
M/1=+,^060 K[9/N^TMK9 R 3^RV2"7\+BPYU"55OCW?O8XH99Z#;;")2/%?/
M)3MX>"9S.K.3\*^SW5*!5J($K_<!UHTB#^X-?'C\LY2=P75 "F"TY[;C"Z0V
M_*$O=4"G\[6;#W>AN!--ESX ++V//_.W]B7VQ]SOW0.P&52[9!+;2*;],[_C
MP1(,2;>%&@SBW0B)Q>?RA-!O-<25!<ZE[.#U8%@MX!: P&H:NRK8GQ4O)7,]
MY9D'UH*@M!%BW^WTJ6JW;P; GP&'T##<XA-O <G/XVL1O'NW9?]3PZU9,7Z%
M]EE.E%&TK]>@2T8S;@VK3$754\R+21.P&<C7-G0@3:$E]O8ORY\?E/[/5ZB\
M*/UIGA<5Y^:! &^Z\'94Z79*X/FR#2\C\@HG+6"4Q7>W(61-N&(:"%WW@8IM
MN=A7P)#,]Y2& ;+?W]Y"1?X<K#N#@9?0B<P96Y(BV-=0%F"1I(KP=A+@'E@E
M;=>G6<9!W/OI+[>FQ8])'HB,^+\C(^#K"Y)=#@3-; =S"#".7>A*TGL3%A1(
M1.(?XZ4] MHR>"!>T-5T@,B3X!^ZVV8I$R"N7'W.'\YOF-+2N<3DD ,B0G2U
MPH:D77Q^** ZF,$H[(FN7X3V!".I0-19MHG@5IRO@>G@NC.02.$%#\Q3\06;
M)ZC.4EAB=Z T+,=)"JP[=/;FPWF0VX ,579[-8<*5?<'A)<H[+*Q0^4\4+"*
M<E0EZ,(R9-M@&HP)(7MLR>GFX70^[W<N:3@W$!#WZR*\>N=3?;C'&-JJ>^/C
MV5HPW>F^ 13@1%+M.QPV"3@7I%S@HL>Y L!!^>NJ<*\U#V8=ED' ?R .%_Y2
M4>R=/@?T?^=2W]*Y0.A634_)<6A_[Y)SCV-X-/^"$\1W^[&V$8$>(JK0:A P
M%>S?>\?.;5]BZAPOPTUX$@E._>.!OVYH\[_]C- 36-A7:J"F!2R\OZH%=JXM
M@/AI:,!JVGG)XN16& %O6I+8SSWHL7CRO=#^Y;T3O82Z6CB59&55A"H<VG['
MMW_(%+I#B=O2X; +.]'R++KL+6I0!MKC9)2=)Y-SN"OGN<'K@N:-AXI@]6?V
M&@]Y@BT)ZOVTZ0VR.->I3@X.:?64/I$<!2"1N) K]1JZ6]K=$?F9JBG:%,8(
M?82@Q_EK0]4$%KW]Q]Z VW.'VD/$C;1]M>18*DB.!<FQ(#D6),=>2(YQ;I_'
M ?>$C^@PE6<SEI&28SH[5J)-6 WSPZ:J_<K\*)ZR.*G R%*]&EXN>BR='VY&
MY @_76G&Q5F','--EM.[JU&IKI.3'%QY]LPQ,6]6ZY5:#@_7PTQ='RQ33V$:
MK(R=KBSLNF&J*:8H/%.J9IC:TV)LJ,T1=?YV>F-8[5RVV6>X)V9$],OK5':Y
M&47/5[8H?A$;<%('KV^(M#K5Q^PZ!U>>[3,3XZ,X ,T8%Y=MJ[=>SY0Z3X.5
M9_LL#O1^L43TJHRTTU/EVK"\2Y"P>^[YVX?UKEBSV@U&)(1,2Z@4IDNM.8J?
MK^Q0/:9< $J/R??E,C7?+9M\>C-*[%>^/]5)O2O5&;UJ+Q_7HM0P6&-UW$@0
MAF)%143!<!@^ Q8,,I71FM<4/ K%[5RKQWGDO:Z /1\9@3=*%+N-QVEG =BH
M"-WS.[KW>(O[830R0WWOOT?=ZZK4*:Z =3^=ZK!G'^I$8#<2"3N',6"T"XZ2
MT&Y[[?T*]XKK=MA/G<+N*QE/MQ3_:\*SFAR+Y=6<QJR6Z6FL4:W6DEKSQQ^2
M3$3.^^C>_.+U%6ZROQ- X4UW_-3<& 3#%9)==474JM,R*B>,1I*OW?/WWI@.
M.?=C=='3$P,%@&"2TKTS>Y*N.\W&!D4=W^ 6WT%N/7*AA6>;^\#SD5!%#5]"
M=Y*L;ZA?;W ZNO"/CN!4.1=SO0XW8!(=)L\6<\VQT5HO>?IVTB8^E$5:$:8D
MOBI,XV$EP2NYR09(FP=I@_%70$V4%2.1:29J[&H=+Q:VG7JG@7^DM<L[@:IR
MX9P:W60XF2L9W4*.B?6Z)M)QKZNXYTV-YSICA Y1_GVMA!U*.^I*1"7)_?U7
M%07H%*PEKD5@]0*V$D3LIQ,K*K8R^V@0!CZ</P9E=6%/A9FHPA@PQGE[C-D!
M?VCRP/X)P(13>71''=,VSJUTI]==!*-A^MS)?X"]^;TLY.:YO5H*!D7M!E*&
MVSC/4ZB"U)X#DT.;* [VGPS;B]'NX I4'[+E1:<1F].5R__4AR94;N!4L@N?
M)IRD@Z?I,G@1[.^]KZ'PO!!ER';8 G;DAL [A%K!JQ0-.*SP>KXGGX^RZI%
M!W^3PDJ_UA>/JXII\W41]4Q&$CE&#Z:8?2XNS<8T+>P(.L=:FT9GE<F6.'-S
M0S>)XQ626VIB'8]GY5I+Y5OY< PV^R+P3Z*8?8 JCPKI:;TYD?&\6NVNZCA5
MRJLW=*UJG7*=P<N9 B,V<M+3(LR&,SFHE_'8:T,A3E4NK%,XLSW_QN%"RE+5
M]LT;#S5[UF6+65Y@Y[:G#>W<$J9VW8-Q*!N #6R<_C&H<!2H7K]!%OOI%1R\
MRX6Z19[UH08FA8K^:1ANE9DJVE$>H*)]GGH<5_&THH:-GPYP=H<B>(NKEQS8
M@^;2B-N?QW[@0D-%JSSJAZ5K<UO;[YOWG+6]7>J6X(X"F8B<@=J0HBX_"F>W
M7P3&%V"$Z;[ATV'^AWU<ITN0[P00A'2HSQ2[%DJ:N.1R&/: O'('3C!K#+.!
MX,/$ G!P9HRXAH<O&+FC\1]N@> !9^ZM.^5N8<'GRRG<-G6>QLOB1>O%7XC^
M7:%WW+$4:_,S("$4L3XYFUA"JX*G61_*>'7 R].*QLNV8,OKFK4<-32!&*2*
M3(<1%UJJ$2:7A7R^>1+7?FGIB/R!B4!D+L&^3-T2W<XQBZ6FNN52IH\##J?*
M^'6;YUZU$+ -;+1V%&\ZZ6&'T.L7SG_E(!>CB4.2U)O+>G9H./HE,D[?-B?K
M'7:]O2G()<Z&8 :-M_.>1VDWSC*UXYP;^N8H3W:>)CLDZY-V2LS4W7TY[R,<
MT_Y-TYH3T0B5>FD2M<>(]3P?MAN< %)P@>9^#D,S_K>==X<M%E_-=WO<F/U2
M;@Q,%<L\S?U=9WY7!(\=,MW^=/*>8?&>VHM+S)D.\/)H>+%G7P9X>32\I"+1
M6("7Q\-+(,<>$R^!''M,O 1R[*IX00':XZCWA\SCNP$A^0X@7%6 WQ4"9R&+
M=X($N&[PR__]$?OQM^"A(K'HOTZF@1/++8;"K;<8!KZ_"O-2*>DQ0%^Z\7(6
M"W!NR;@W6#[ 1G<&TDL@^?D?R:>F&<T#X&'G"#A;S&X,[O36URR#4P78S?_/
MK\_ 9:\!X$6:>/;JU!%1>/F)_%M^(O!(XDOQ$XRDG<$I()* 2$Z()'H1";N_
M)?/[OWA>%">3NVKNHO<Z^>^+<<"#G=(E\P^?SO;)'NQT1];732Q.VP6Z Q@\
M#(V"[6_ ^L5P'U!V0-D/3=F?R7.V<]2MU\8S?@:3[ &I^+70X?7/_-\7X\5[
M,AYU>JRWSGFYYH49ZF\G%=I5$$6UH6MP:+#_"+U]K1?UP[TE*$_*ZJ373E68
ME=7NC7G",BI1>)N1^O$G&HJ3YP,S [8-V/8;L>V;+@+>G&V?&".C[6JQ,=[N
MA,E-8939%2=3P+;Q'W^H$!Y[B6T_N6]K6Q?VT'A36J")[]($0!1=G_BJOL"]
M!-:#@>%B+M'G\ 6PGY_&)H$S?,\$&^+2#F+2[(%'@3P#QP=/]A%L5*Q<;:OY
MR8)9; ?IL,20JVT?=D( ]@@1HI*),\%VN?C_@]%ZP/+?@.4_L3GS/HX_971I
MTMIN,\9@R(K3U3C_Q*Z+VRP-&!U8,-'8^>W/SQP*J8G>VQ6P:X=])\;MV!&$
M0CZK3W5AX?2=)-$MXB%ON/9VD$@)93=3>;6PQ;GYF%QV\<5V-X:ME8#I$2-"
MT<1+0BG@VX!OOP??WB(@\BZ^E>O1]7P6)[-L.Y^J,XUE[BDE0;X%ED0,#^'$
M^37@+Q,,L5_1/;_%&#A%5W>*[EC_\@!.T[U/_U7C*,_*Q#V3TRZ/^\C"86R>
M>QH_)26F9^4*,6E#U1LY>I1P;)@X<=X8+8B?!*(B$!4W$Q6W,)_>)"HH434L
M830(,_EBFI<3A65K)3:!J+#-IGC\/(?TZW,&8>XE#KZO:W?,\13@>$&SX!W^
MKRCP[GW61W(.;V$(U42_C'B6$8@GI5*:R7&6WF;E?%GLSYJC)+1\J!">"H(W
M 8<''/XY[!=_#H\5ARRS4I@17N?Z^<2X257;X2G@<&"PD*%D+/Y:F,?M#'@^
MM.4Z)+D\=$;R<NEQ"TDX9>*H,0U\TAL9^>H=G;*>AD6P-:EN=SI"$S"M?5NR
M_1!?5-J+VJJB*::>B46P :HST,A3K(/IL"FJV[WMR\S2H?!@EDXP2^=#9SB[
MI!;,TOFJLW1,=;+(&Q4VAHLIF568Y:K0B?G.TF%WQ4*C:NU$N3Q9F'QSW)_W
M![3?+!UZ55H.AT1_AG.K:'1$L4DC+_C.TIGK5=4H2EV)Y6;]ZG3<SP$]ZSM+
MA\^.=GV)Z>7D\FZ0ZZ_ZO;9:@BN3IRNG^&A<92<5$[>:N41T(S2U273C-W5G
M@M=VO1'9,-B\5(_VDW-<6,]HL/)LGRVQ(]'&CESB7$=7-#DC5]H<G.1SML^5
MK*5$D6[KK)A@\&9ET.W6";CR;)_-16ELFFME+<=K=%NJCS5KR4S]9O[(='NY
M4</9&KXHIS4F&^Y;^0SM-Y^'QMN#9J--$#A7+.VZP[J9G=)3O_D\VK:]K$3Q
M7EQ>Q$8S?A)M-%OMIF<^SV%E>*UD:\P\C8<-A5MH\6%G.(2NS=G*@97;EEAJ
M.&;"J0XW**7B)=IU@DYF$Y%JH\ 4UPDF/.?G;"Z<[M9ZT)A*G:X4C&Q]P,6Z
M29SK"CMN-8\QW)P>I<YQQ!N[#?LTG))L;]=IMQ=*PPJO-F#E&8XJZ6K3E"9E
M!L^G1E9\2>QRPQQ<>8:COI&6I%RU4,?+=3R93DN3M:E/ 7><G7TJ6_E.LJAG
MY7I^4MMQ>#P[X'VYHVI5UV))*@U83H^NR_TNM<W4IW[<$=\VPR1=99]DB=H(
MLRBY*UCQJ1\EYV=%.=G2>@,F'".U[=2PI%7)=WY4,4>6%AHGE)B55#6:0N>I
MGN@U_6BIL3(+R=3P:27G^]ER=&B5\\WV!JP\Y^)X0>QVU0Z-D_EPO9XR*^&4
M[DM+<W'6&I>D,"U;M%B1E_(3,<2G8.79,[O<+*F-F]$NVRXO-H4>'3;(Q,:/
MZC+936]8RI,<*U&Q<:_359J%Z=2/ZK1576FEQ2K)MM6HV.\H57*":.GLF>%9
M.Z5E]*6,EXG9CM>(7=X<;D8$?K[TJ=9M#6-1P6 7_"PS)4?;IBI-X=*S,Y&6
M7O[_[;U7D^I*EC9\/[]"L>?K+\Z9*3BR(';W[ @!PGL0[D8AA  ABPSNU[^9
M$E3ABG)0"$H7?7J72$2:M9Y<?L6H3J7+"JN<.&Z,1D)EL3A%3;WZLM2-I!5'
MZ0R*);&?P:MB<WR*FA3<6FO-!J"[8F'N8E3,RBSUDUBKZ?5X74F5QVS5GLNF
MP(L6>AH7F;J=IO*CB< 6>7*93L>6&)IC3E'3N(03C;F9&2BQ::F1[R]G;J/#
MG.I&)F.:.2C'I1RKQ=&R6;?!=9UF3B%3FVM$R%9[Q'$S(*H2:[/:(6@X\NB=
M5FJMBT6%[BO9"</58_," +S%*;I+N8G9(%,!OS[K:HMY(D77XC)SBIK&)II/
MK$4RPFD1O&::0DSF:Y#NMK_^\;YEY(?ZEE$7DT2/Y*13JM:FI*_T:DG?A@1F
M)0)M<*_5-?B?84F>,6/3#,'+JO3:N8B.N_]T6R#VFZKSLI[2!V2>O%>$&.CU
M#: >[J_C]1*]E)J,R\T".><T#DO4T&*Q5;)/E^@]/?2X1.\W=#[SZD,?'Y/M
M"([K&-8*\8K8C*2AUS?CI3JSISG#T>\TVYBN)?$M9M5/ZXNZHF1S@P$^CFL#
MU*S_.GNH^-ZAXCS+M+,S.U4SN5FIOA*:Y#37'>T9:O$/67'><^B,D_$WH+G=
MEKW!ST:?"+Y3C%X2)9*F!A,1;9;[<T<LII+C9/W7GVMO&+&W801?YZBY@\\U
M2XD4Q#A19W)&)\D$<,,:Q5&F28Y3,<55W7I_MFACF=HW;-A[82-P&U8<8@N%
M*C(15*K&9W2FORQ1'&QW@)TP*;[UX%_0[.5W]M@MXXUO.TI*VU4<@0#LDWW0
M5>Z@TO>9(M^O0F%8Y'O7&/"Q(M];9?UK5;YCL2B)AU4ESQ+*5:I]:N MJA38
MZKC'AP&-I10X"<<2=!LBXV_O7^#;TE_H4P1\]/>//C LBL?# PO0@;WE0*6C
M6%CG.(",%"+?G1U8B'P!.[ 0^8)Y+B'R/=B!A<@7L -["_GBT5#9O64+A2U#
MO<_V</\M%+Z*^%<.$?OHGAPYC3[;5(%^K;[W6QM&8%$*.ZKO'86SO]<*WSW8
M[IS58?O.:W18V'!9@#LLG&^P\->K'1;^ABT6[H$)+TPP%RRG_];6G HROV]N
M@^Z.=S9=".DFI)O/-.L(Z>;3=$-'R?C#T<W7^G=L[^]@);"WA.5+NH7@G(HG
M.7 A7XQQOG<G;L5+7S%(!(Q6+E'<V3=9!JQ XM%*+YZ@__5 J0_FN[U$I.R%
MKCP_9OV@O:2D2R/9>3NBY=5BJB51:+I<8=KD<*%-,G.J8::K,.#4SXF%E^TG
MBH&$"!(BR#TAR-4S9+\>.'AC #G$C4%M$"_5T%8)+7+B:B5H_&R9AVDY,5B$
M.9Y(?":7/H2-$#;.>0Q^.FI\/'HV8*C1+0X*K=@PS:(R(Y@47;+5!0JEC<2O
M/_39XJF?T]9N2?4[M:T]<^FE]:_ ^&N^Q4/SEHOW'M?\U?B0!T2X6RE6J8F@
MCZ6\SNH"+$[Q.H)Q?=QD7!TFJ%<S@V:-KM*-]MAOAH4]4=BG:@B%#!\R?# 8
M_OM-*;?2A%[E^%=-);'9NBIR%FYSD86J9N+$7'?<A=]0BSZA\%S.4/)87!!R
M_H<#HAZ1\6^ES'R<\567$VV7B W0V%28ENKI?%[D8 (]T%I(XKBFV.=KH ;3
MR;15[\"+$;!.L-]#%ZP4YN)M&_4B=VK="2S\/?PVA';B(.M#%4-_X?*-U><$
M,M+]6:=8G\]15F8B32TY+"RFR[K?B@]_2L0?Q@H<XD2($T'&B5MI4>_$B;:2
MK#<PN952Y%89G\LEFE';"[^3'_84H\^UWPEQ(L2)T(%TWSK7.V%BN4ITL,:T
M6&93*0'+&KEN>6#!&HH)V&_BS>+-=^4>\M50Z!DZT9KK/=T^0]-1:#KZJ4;C
M6[N)WM=.YU6#$FL5^GTM@46XZB!6YB9C>:YCFS:B4&U"0UMR" @A(-R!_G,A
M0"#697Q!E69Q17+K%AM/%J=M?=.?-/:4((Z]RB$@A( 0.I<"I^A<" \8#&?%
M0KTS8;-8IY+A';9GSF%Y9: ():BS,?F?2_X/F'F <\"&KI^KY(JPO7-DT]\9
M40T;>IQ@T4S#F4@6XDB::5B"M4(  V@VLI!A;K(##G>O-0VLOCO6O7(/H74I
MM"Z%5NC[4<M,=?FNTKX[N%$=>4WA,SYHE#S,8/1A%2)&:PL8>8@7'1\N=B!;
MLALO6'$"GAVC7)5%;%E4LLDV(\M=.EO)C/T6RO@3>D)<"P$G!)P0<.Y'[0L8
MX/1G%38]<X@%UVPF37/(]IL9=-.(F7B*H2'@A( 3^L_NV'\6,+QIT-,>65Q0
M"[:)M<M-'<MACL0 O$E ?SU.'&N@GW'%O49J ?#.P2V;&.K0ZU\J+"\7WOA8
MH/%.[+Q=S;,  NE&<KOQGGP(5B,A^8?D_W/)_^&UF)W;#GQ^SC!=SQ5*[J3D
M4ERJI;3(6AJ/KU7&;["./8&3"],?0^BXK@IR3\@1>3"_S'%-XB]4(0ZM$E_@
MA5>M$OO\00#^&!HN3-4* F9<M8#4S5<>**'B^T+D]HO"G! :IG$I,U?[RHA;
MM6O]2BO2ZJ(QV-*9^/6'(JXH,H0H$:)$X%8>*)3XOKBY-U%"0_&%/LP5X^AJ
MA4\7Y2$FKTV($D"UP*DP0RA$B>^K*G?SA0<*)+XOF.Y-D&@J?!'MTCK*1@R4
M8_EI=U+AQ@ D?,<$_F8)N7^\'L)_O&&[;9*O1;'F<_OW\[J3_[UGM19_?M5+
M!^)W8L%EUO'*!)\7YC6V)V+>RD;1UZI:GDAM0BQ#5;>Q?-Z$]_I77X00]ZFK
MZ6I@\JOJZ#@&LP5^*:D:HO)KITWV)-F/=2/UB<U&<I,2FRJF)&RQZ6L.R$4:
M,L[YH3S^"Y$ Z9I@$H[E2M>"0VR'NEH3:=,6W'=90; R+<F6=,?VJL*+S_EF
M\*^4H0&"64'RP>+_MI'YB8,:NI;W+C#<!-,QAO;VC=+PHZW'7]VHL/6X_^ S
MK<?I2W0>IZGH+9L=/GHOMD^+)G@TCH7G$KQSP:+QL'=A ,\E$4U0X;E<[5P^
MF&#OWRH!;G;WU_EN=Z\VNX.][MZ3>_=5>+\%D6Q_)066,+!D\-:<I,XEN"SX
M"X)N1XY_YB-$=57@#7?LHY#XL#OV.; *EADP*:B>%B8XS^U($0)[0OS&B1?"
MGX"M^=X8S(>D@&WB)>RB/G($+-K[:*47SR)F;+XZVG6:=HLSES'&=@?MS*D5
MW^^T"DEK_ 5+Y_OR@@^MGL71V*28RG3.I>3)K-UVR_6L6>=QSX%*/U'4V8(A
MGT+#6U(P WX/+L)&'..492H4OT+QZPYV['O$KV#57;AJ*.L[P/,9.M*>\;KF
MV:U/(&IBF"\DY\UF'Y4<EE[S,26=Z6[:'L9Q^N)P&C 9H>$7X_L&B W8PN\-
M0UZ5,&\=!OM(F_RJM'OK30Y4%,"MH?T%L][ ]C)+CMB$LQ@JLV:JGAJV\A5Q
MSO@MFN)/L=BY@,.[DY5/F E\USN!/?G_P+TFOJ'$?"OLOG4HT3?9"FZ]S$!9
M#@@^/JCQE#TW%TJJ;::*>GHN3-)?";?^G.4@;V&1&5>J,&B6'JAS\'^#JLSX
M#1HH["F&/;RH^_WAE*'@^ZBFU7O;Q/LPXWZ:0T-A+136'L>\>3E9+%#<_6-$
M+2;9,<MN3.90W$TNDT)9--#NPB\*^#-$K6_SVP1LW?>)=>$F/IYL];4"! &3
MEK[/21'2_=>L6J'[X=(&M!_N:[AJG<5+^AIZ#AU/UGH=76G6ZGW12-)*<;CP
M2QN<*M3_6 +?N_19,A3[@H$S[_0E/ZZ+(H K#Y0J3?+Y4K:22N32>30R8M>S
M7$GE\XW%MZO2#13/E]JUL<G)::[%5V<HVR\P/(9ZNC3Z%(M1;^K2 4GTON>\
M[O&K>=T<.#?+$6!BC+!$M@E/WY/-+4[ Y:Q*U1&G;SJZK#WZVA0-L!N&JFZ*
M(K<@"9S,\4:EQ=2M:70,3>7GVCQ6JE9;-',RQ_OTT%OD>-<L ](*5(B,$<(T
M4TB<1",8^H3X!100K[+S$R*J GCS"EE,)+\_CH$\[Q0B>&R(&!:BRH)'=C*8
M'V#IO:,$*I>@2##O"=SMFK!"!EX&N:I*^E@:(H,5(GCC!=>9&!8@W2C">#_R
M4E02SA'FC@\DL!X=9I+#CCV2[M54%C2 PPX<XNZ<HO?*P>8<GQ#9!K/=9+7;
M'\TX?_78PHSS6V><QZ($$:9JGJ636Z6<D^&Y!.]<PI3S8)Y+(HHEPG.YVKE\
MU$+B7RL!SCD_GW+^UZLYYW_#I//+6%'.XGMH,@E>5,"][=A;F/BP._9)M J6
M2?/Z2>=DX-9\;QP62._]9:RT$#J"[E&_M.OK^CGGK]C)3MA=9ZB6Y!BM-6?E
M.#5!Y6G)1G/;//.SA;H_AWZWI-B\+@)1VY:.3%^()VY#8Y2!B*YE2;J#K"3!
M"@6P,-K@ 79T@[)AM,$W%D%_!8&W$&0W)-M5';#)&<O04C[F^"$'8'1M:Y(_
M =C9R2I-BBVQR6JC&-&.,SIF9>I^&CL>/W:2/;ZX>K5X^E!P#>,/+B[9WGSE
M01)]KQ#)_W[1UYJUM>1@NK31"%F>]Z9K(=)NC?VD<1J]/)(&!CB^*R4R%'Q#
MR^,#6!Z#F=D82F>!6_V]L4]H5@QEJRO)5IT\,5!38L-$-=$5EF81E2B"X6./
M*%N%9L4[ KO0K/B3S8J!SV$:R4MI&%E+EO%M!L6Y5B]6-&X80ZLQ39\T6+F:
M8\=^$GLD-"=>+ITI%%A#<V)H3KRS;*;WB[RJ9HQ[?9)2E9112?!43DZ-$@Q/
MOU/D?;CDI>.%[(9[[@2UBBJ0B2$'3/Z]_^L$_+5K1+7NT*P(>QM:V]W!R9WM
M\4DV$R&PPV#5_]J+R7UF2IBK85B_MYRWLZY-+##N,>%8BO@AO\((_/1O05T(
M*WO;G381?0YH_?W,O' C$ R-$M2_D)U_PPTYVDV8![*S9WMY'INO[:=Z;!^^
M$7J\.1K','_C6!0FGNQDPY  F:DK'=8!X1(O1_,? 9E8$ ;^NU5-G8Q']L)M
M=<CMZEX:W.;1KS]>NAC,24KYJ3/V,P4+5TW!>Y4"_975&M464\IWD62^VLJQ
M#:;&<JU\JKF12?*55/16L_-3U/#G0ZA46VS3GU:KBJ2JE6:UE$\S+3:-9/(5
MII+*,R6DV0(/RFREU=QAI;,0X-%K!-M-L]K0Z\O#?4(_HE__0P#3XE]P!/*_
M".Y]\^\#RCY@D9>+\IE!3.?5UV]I_516&A#_4[T5EYI88HUU;2>-MA@*[<T6
M/!Q*78Q#/I+@.7DUP;,%<_MLH$G8FL\(%Z.O,_F->1T11!' G2>%+V1GXB40
MOB0W(E4+' 7\] EF!@)./9+38:@J^01KQ,"/:Y8!P^N7_L<E9QA][GCK[*\0
M_!* [?$$/O='0^,,>!N60 1+@H*&+0,<EH;("$Q!C5XUV166J7A)=*V:D@Y6
MWP,3LD^EM()WK0=NTNCFV*[2S.N%)>WH8IYAOC]%E4%LO]LRW'W#E/3]_;1A
MYJ@F3 T+F;J6; ]E7_*3=UH+(P,)9L<\=@XD24>IL%UE '.Z\"A-A^<2O'.!
M#!/VJ0Y,LMT&OVZ<;/>F:+J_:X.]W]R5D7[]*>Q<1^#N&5PFZN4\E@1M#UX3
M!B^T'1L6?AR:\02R V+Y)!_=U#O]CGW(VY8@J1?CB8"9OK=D?C$2#_IQ?D%Q
ML2V';PCZ6&*6LNW]599U67.ULJ>(\1M;*>]K;;#NT[9$C/<%H-GPG.V3T^8;
MJ<*<I\GY:(8*95N9CJ;=1&]T5/=G1PGRM9Z*8%F\,(L,J<:DC7*:.%GDQ4PY
MB7&+7W_ 5-'#8C&1RZY:6'YIU>5VWIHN\%H:U4ITPL@5VQ-T.G[?JL5Y)S\I
MZK,96VS;*8P?Q[AF8NRMFCPJD?-%: H6X4+/ % 1FX[@@%_YZW\NTXK]RM?T
MM^-/L,[L=F CPB)3UHKGFOS4B2^K6-S)H[-(@1P[%8K!A'>RFSQIEY/C>';*
M9<O5UKJFJJ3:J7OLA@4(9'966U#%!:N.DGU%TQB*[JKC64U;O&^U.6YFIMTV
MK;+9"%NA!(ZLH"CS+G#9NJTNS3'O\$M=M*C6L\OEUQN Z3&"8YAGO-3T=0$E
MLJ.8[GAE_%]Z!1]O-1U MZH[A-7F)+"]@OH$?AC@N%<73C7 KB)_&19BRV "
M@H68L-J=+LK@\:ZMT/Y[OU!=](SK=(]2K^1*W7<8/&L8L@YH$/HGZ"M1\I6\
M!:JL2Y$= \I[BMIA!R_:.-0^OS;!0R,>>I-XC.!_^1ZXS5,,BPT(,4[STH!"
M>9*(Q7DZ'AOP^( <)E!,D,@ANO>-ELA3*W>$$U,UPF53[<*X%Z\NQ]8"HO#A
MR/*T+U<IW.#9#L\R_1;3U)G>@L?YHW=VR;DPX[/)AA+A9EJE3-'M7 J./'JG
M-!M6':ND]%D!14N6I5E66X1I]=3AR.*2M#JI!FXI*2F7,$9C*2$N&#"2/ARY
MR!17?50C+18G^)*<J^BNR8YYXGB>3!:K)#JNFV)CM1I#3VC3'!%PY-$\G6*G
M'XODIW6N6"72<C+.X$(!9I,>S7.UJ!6Q6JJQYB2^8D<6G8FY5. [C^9919=5
MEDCT;*XZBL3'L8G8+*WK/'D\SXH^R-%U(])0Y%JN+6D2VRJQL%7=T<@U4<XD
MECUTP19'O=AX$D%[W<28CQV/G**,D<N(-LH5Q]UY:LBWQ62ZSL=/O%.S^DD[
MUS10K3M5"IE$A$^#_:2/1_+,D!-6TFC.-E?.C"?[XQ$VJ_.)XY$-UB5G<[9+
MH2NI4<HTYB4M1BY@&=NCH;'%:!DSUPT-C15752*>X-"84 >T?CPTWEXZL]B@
M0W&XD6I7,T,V/HK4H1QQ--1LD3)33R:6+-[#YW6,Q)(KL"CL!)64FEG"I<96
MD9-;TG#B]A)R2?:&'I$)7]/4==4N3;AFQVK(S1+#DPMOZ!&=M+-%;<PWE 6[
MJJD#K@3$B8I9AT./"*5<0^GLU&4RZ,SF:TMZC%?%$611XG#D6&IUNH4:M5 Z
MK>4*M^J)&--C3K&H6Y\G5OBPRBFIO&G$9_U&1UO43[%HK%*9:=/28( "(#?;
MO355DO$Q&!D['+GDZ-&Z;X\;;'4\B*1[=:;FQ.&O)PY'<EVK-FW5RPFE4^]D
M<[E1C5.T^BD6+1?C1"I5U#  $)4>4Z[-YK7AXA23X'I?%B,466*K:DJQ[#[-
M6WW(3D<KZN371K>8SA59?#(7C$JO.&0UV 7W:$5K@BWD+9JPV$YSPF?&'-%/
MI>#(HQ5)@Y%E+-/HA)7HEE8KYB.:DZN?8E&SY1 UV4$K*%Z0Z5A=1$<K!XX\
MFJ=,99.1AE[H*4(D(\@)=B3$DPLP\FB>TQ'A:!U\&F>S4BNB-8I<'A_ =Q[-
M$UWA#:53FR\4MS34,M@2I:C628!(K;%F;%CJTTISH%7GM=*\5)V<!(B6;&6D
MQJ(4X3HY,U(I*RU=Y^'(HQ6-LT(RU2ZQK"(DJ]W%0J;DF0 ;01VMB%FXE6RJ
MUG.53K8?BQ<[@XXBPI%'*TKUTQV"=2R!$PS" @PRJ\XB)^&)KG07I55:!:#3
M)=HRHYK3^@*./)JG(4:68ZV3=M%L:Y$T*ODXN9#@R*-YCO/56:%I6S6E(PGL
MO$PL^C:_ "./YME8F V\I?))3BO0569L=M9"87P*'/M:(E;CRVV'ZVABG"K1
MG1:5A"./YDFX<]VMC[4N6QU-LOFN%.?C$0BX1_,D>SEF6FL37:Y8,&96H2 3
MG2H<N9WGU8M32V,83="03,."X==IV195PW:M4RY[KC J9I)]%>W$N28369OY
M%'%8@OK5<5[4"'8E!_^[8DA>(GY\\P5&;'T&-(YA_T::;!8&^2#Y2J;:*#.M
M?+7R49_^9701[(0RXDTBH@HKP]W$V>\Z\;;ZW\:COZ<!^L/\ )I_=C^X[(Y?
M0M$4HF]H?J]&?']J^N\(L)M(2,K0P*^N8'"(Y1GQ9!WQ#:,PI$= MGK [MPB
MMB1&Y&7$UQE^Y[S_XU<%+J'.*JD(ISFNFELJ,SO-UV^Q+AOLJ2H]:S#'"_B.
M26QV%%97MWT8BB([&_X<^%2S)!C)I#N>WIV:R-((89>2Z$*O-U(=C611LF!$
M#HR]2E73Y<UKP+\035# U&%T]*8,/4QKLPW7@ED3*M3A(88^;0*KP% P)2^^
M&@9T;>O!NV"[P*?>SVN&+CL&C MRAV/)00#9VR[X2'1<H/=;7AJ+]S."%X$%
M'85>$MU L&6H^F]V_$C[OS;0-_9*W7LA6O[>URQC)#LEP[9AZLWF/K!;1FIG
M]L=WP5SI&BTNWQ#8+)9JF]-\.8>F%D?H_NW0^5.1<Q TY-P0$@!+/UW!CU)X
MC?I/1VICF[G[41^/%%JG@0M!W8;AQ/ H&;]AI-!Q>!#<? HL#8CON@W/[[?W
M+Y@._!?Z% $?_?T((41?<,!1MSRP1P_M^D*&'1[&0@;P7!)1,HP=#N"YA#@6
MS',)<2R8YT)'R;!_2@#/!8^B8:A] ,\EQ+%@GDN(8P%)37GM@-XT"3QFS=7S
MTFBPURP:*GSX?[_H7V\8?5Y;/T'Z79\?*MT$8?6A--QKSO/9_),WF.76I;S.
M1Q3O(XQG/OW61FJW9JW74[5.\1#^&@^]*7&@?J6JA^$AOY'5("2"#YF;XO2#
MT0!Q,1HXKRE=OZ7D1?(Y0QHY02/D1R_64UZH@"4Z-J2YI+LP M\R-$1T;7!.
MDF5?# T#MMR+Y57YFG? 5G>94H+DS=./;]\ "M^+ <%YEFEG9W:J9G*S4GTE
M-,EIKCOZ2JWL+=^=J!186:?:M)Q<B^R,S!46V:9LJX5-"R<R_A0CZ#/% D-V
M_5GLZEN:?CJ[7KU?VQEVG0XCB0S:,QE%&Q<EE:]Q<M58 ':-_?H3HY[(!'D=
M=D5O4U8@9->076]?"/WS[!HO5?#R%*^G44E8U<K&2HS1>9BHEH =;9^(1.)+
M1<T_%GAV?:(M2;;]^R%L&]]O+W_+N_:(:WXKDN@1UQS2]L]8\UM>V4=<\]7M
MD0%<<TC;=[7FA["CLIJI&BM)0FQ!%2Q9\I.9MAV^I*4IZ;;TL&;56_%XP+;A
M8OIO:(3]%B-L21@8%J,/&SZ;LCZ7GE :A\N*FRO'5@S79#L,EL%Z+IJ )0F(
M7W^PQ!-!_QR3;,CJEV7UT"+T+0;<=[-Z-L5:1C=2B7!:I]BRBZZD#SMUO_H(
M3CZA\7.MFA[+G!NR>LCJ=VC\?3>KKSA\->^Z&LM5L7:F-ZYJ$V>Y*1^$8T]Q
M&GTH4W#3'7@YVG ML,#"1BD)#6AW:F2XL+;QHT#HZJH%K/HAV; FBJ "+$IM
M^*XI67-9E.S704F(89/&U%S+;*0W6G?&JU6N/5KXK=&!_('1V/54C9"#[Y2#
MO\?Z%R@.OKK&\&D.'CMBG9CTZ*0RB^7SV"+#)'L+!G PT" PH$&@5S(6A(;^
MD(/OB8.OK@A\FH,-L1(?L.RHATK\LKE4T71$+L%JH4 QH)]B-'YQO2!@*J\,
M8^4EV[FXCA"P=886CM!O<8?*1=692%;%T)_K.[X.98PU768*U>F06XTP*5Z2
MD@6Y"HL40W7BB<+/1;N%O![R>FC-O+$:\@%>MVW6S3;SEL8*]5FIOX@D<QV=
M\<N,$T_867-FZ+D(>3WD]1LK+!_@]6:[/!'-^7"MN-/)HD>5JW*WLFD4@#VA
ML<NK*+<DY/Q6'Y&]1F>AP?-.S26/&L]^#J:.-@'YZ^'T#[__X F8XDF[+M>T
M*J_@MEW2BZ-B9[&&?4)@X-031L:.8.HR_3M#YOX):[Z]T?3[F?O[%8Y7F;MC
M=&Q7*?-K%L=;-7K,2G)/9?QV0=@33E^+N4-'QT]8\T]D[N_7,%YE[N*@'.M,
M<V03%=+I^H!MTHI+U_T.7X"Y3Z3)_OU@3I"T9%I@%[T#"HVB#VTHN95>\M,M
M*E?75'9Y^ 3(C8J6FRJEDSDVEC7'CD1HCK2"[0$]]00](<&$0! "P17$G)\.
M!%?7:MX  J$S*\NRJ(IHK#;,MPG=6+>'FXZBV!.6N%+09>@Z"8$@!()OU8#>
M (+<C%@7,$EV%*UH]=I]999+%1=^PV#LB4#/%?.Z/[^*IPYNFX,^9ZG_3VB"
M#:TT=^-?>3REY;!GN,>E>4?2& U<#,X)U%*UTJP<3X]D5-82)DW.=+'-UWD,
M]109ZBF1B(=9(R&3WZ\I]O$4DH\S.=DG"<#B[I*5]':J4*>'_6*>@4P>\Y@\
M'KMB@-?/(OB0R7\$DU]=V?@XDS,49W1XKE9AM185:Z6M"CJ>>S<Y5$#B3W'L
MG$WR(?PNODL*&4A@HZ5-Q!?B"$OP Z'U-32Z/+X;YFA?[C]BS.?IDF';&<O0
M8":>K+L0$'T_M*';28_=_7$MR.SLTK$$PP);+U@KB)EVQ="]^A6&JGJ>:S\F
M%( HV$4PHU/^'8==U-,DSBNQD9G.&%VA6$;'/(9Y>A'Y1)S0BRX7@/;CN2L$
MF="R^WT:U74QYA!:TH1,MV2>L='JH)^GXDHL%LDN(+3$8)(P%;N2[SAT&87
M$@++MVIQWPLL4WJ"2Z0R''+"JJ01U1A7D.PZ!!:@ 9)/&'49%U2 .R-[.X@
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M@JO(Y$NT..F;C:3)X1FS-BP/@0J5K/LX+8/7#QGG_% >_X6 <Q5,,'/'<B5
M:QX&;K%C<\6)AJH*IBW]WO[CWQ< E2W([3QQ#-/[TYM#1!56ANO\'LE+:;B5
M0E!T:\K<7J7[YB]_F(^S_^Q^\*4)>W\N)'C' G%!'?[[0(3P+F(P^3/B$WTD
M!(C10\'D0$@XNB6^-'WO16!2@ #5O05M'OWZTYI(X#Y656,!)H%LZ,#5P-F
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M>Z>QC.SLV8;0?&S8?&W[S/+;&FX>OM&P<.>4<2P*N4X#?VX61F+1.'6EPSH
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MHWQ=7ZZ70K%>%5FYP G51&.92TD+P-= '*%0].+BR"V)M@GHRUJ%^LY78"C
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MY]!6(>@K1-+'PMA+<?*^(COV:]8(:*P0AH!"I;T76-(8_ (T<PQ<6]8EVP9
M,)=4PZ^? ZOIJ+(HZ38< E#;L,!/> E5< &N"G!17,$\*]F.(AG#\EZ^DJ!G
M0CKMPO$VPGLQ!$*P(Y*7E67!P>!X-NT'X6H$,&='4.$_M^SSW2?X_X6"Z/.U
M@'[H5O"2#K.2+EF""K,2AYJLR[9C>3Y_UC_DY^L ]:^#BF!9/%U(]YM3N[I
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M-BF,['OP*=F$IB]NG8;V+;+_6F!/_T>1_0KLK[A& $),##!YF"0 !#A1?Q_
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M7F;:.7F"!F!Q2(O>UMQ/&16:_;']A&]JPYIP;^PXKC2R/[-<\\*6#YWFIJ2
M'[NC@6*(TD?/K[4'>>TTPDK*EP@NSL\]]*Z1S#V+]9!1Y;IXA^BQ$1I P=;A
M&SNP8"9U6,>)YQS\O'F:J2\,084&++S>/3CN>;8!C4$#H[1^2#0PA@8F]]$
M+:3D"?$A&JA  _ UE!#J QIX#9EA[D,#[TS1@ ]L/VT9A_@3M?3>(>RD,!W6
M=3)T@K+92CXVO8L&$H_SCI&3LXK+-H?PO*K_II1\_^0.#.H":Y !KS_7NM#
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M'DW1*.I0B=E\OFG&?#J:(=<IZK $?E+AB1*G5[WVE2.7;'<ZI]%0!]%VJWH
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M,%9X_80_2;=ZD'E*9U@1E<387+6@'-UA"^C[W,3$FV6C2;#D.Q=B6?5W\V]
M\Y#I  ]Y-'#C7"0:\&A# PW=F6JE#8JMA7GFG1^C^QY]KDCK.63U]W:AG*&3
M<=KON<9:+"J0$J$@+JT!C_6Q%PFK,RQW/J=\K:ZOJ Q)=2G%=T\HSM:7GR5E
M6Y&NR>2BO_C=E$L8M4[,N8#5ES78G\9ZT "A^@SDB-HQ\1OXH>8JA\&P @?P
M"L ')N@B&A!\^I08QY5/4-@[2C6"XTX!">LAMV_XMDCPM)>F_L,@_FM*MJC+
M(DHYG8Z()-]1"X_H[:+PC2^B:R; K)/+W+F&(+)U^&:C-"L:2 J\#:;\$9AR
MLV\@,)T07E4YV>%% V3*PI>;U^B_!(6*-<A'/3A\LM2&,NU\I=63N-EX_U32
M3^%ODE?^+JGK[N;9)7&BU0G[RG"R@NQZ^S4O&82TZE^BU/A[E#8J9;#,PZX3
M3/@GV)N=>(I=4R2_BC\XP@U[X=^R$D'\);"AL'I@ZUS46]/U5E!'[_[N<>!?
M=N*^YH%KX?2+*E70$$X4:*CUAR'NF= CZE,NJYP:4CPUU/S#D"S%+AS)5QH
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M)CP(M)W0$AL/*>NBR3P868]/[<*B<B[9+U1I4.#R43S!2$U?#V1T8#HT9%^
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M)32_U(VZ!_=)P90<0@,)*H>A6\D=L,,Y-/ :C!8V988DPK!+L 3C9P<5]BS
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ME>!Z5G#]+5HS&*"<80_WU:"HY>)/P/42SW2#!' 5>U[M7',>\<P0;<:>VOZ
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MK?8C>KVAI*V?E\7YY+<JQ=K$X6_>YW;EZ?TEWXT*P58K<U(AJE\0JX,HLH[
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MK8V=?8OV_'^ZJ5C(-S7W=,G?:O)Y&465>SF\7?%8M4$D)U?(DG('BCC#1J'
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M#;5D@!4=R4"1,@A+SZ*;X(O0ZUN _;\Q&VAYMM-/N\'PR1N;LPS6*ZX8BEO
M:,#[6T#'GL*_<4:+;#T,?^B_^QAD_;XYRK\%?(U=R;H@V;XS4O&_,F5I/=1Y
M=TJ3@+3.LQ9=LU UDEJW@-?7LC>W@'K&?^-<//,H?$3=7^_9!PA<_HF_H5((
M#]B2*0Y8.LW[E^=*1PKS&!OB?JG_#XS(_A_5L_FKQ-=HIIZGMX#^?UC#],X
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M?>S8V/%V(_3]->_IT K(<_D%:J)FW-\D%B;3J."^6,^#3B<U+,,TBU.OR5N
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MF6WJ3/>I2UZX(/("]$-2R(RX"58XNLUW[TL)-7/Q<CJ0!36$,%HBG=!.<9,
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M_:B$Y8UO?23<5,N;X>$;6VX&N'T)M>-[%4)91#,[$//=4RVCF%2N].6+SS[
MS'G/PGU'BH;6ARHJ'75^.53WX<6S_0!OH L(A:N3W&W0D"6=8V=E5< A]*=
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M6?'\E'.(/1.^_6(^+J>+_;3,0YIM"L+%7)/V/M-0R?I2MM-PW4L&ZK=#,Q,
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M.8MHLXPP,J8=:<M+(8Z,.M,5E0Z6&6OQBJ'#_'P.D!Y=C!5S!:+MGF$P5VU
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MDC]*+WG."&X@FQ0VT6@IE,T4RTO.(O=UF5*Q.+K6:G[IBA%!704ENWKX^3
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M^'Q?UT:,6?,P1*Z)<L\K>[9B(CG^:\,8RVHHW;>49XY'!')U [;[&J<@G(J
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M1:SK$5L4]JMV)2BEV\J$P<,.LP8Z=Y9L(MP8JV,ZR2@W:X/;F?M:GM:'(+X
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M,)F/0CRY+A-4@JRV=!YR05H-D=DHKU-0>,8E+^$4!#:EO7-IZ2*_]LQ-Z@:
M%[-4?($YA1(/0WZ&DD"&A'\]833Y2WQL#NY5:\]H]%3:4@ZF/7[%/'8/6S&Y
MG=9Z$2K7:#L0VC_%YEJVV[ I?EP< (*77GV\K?,EL&OX-W3*'] [LQ*W_O-O
M0B@[PQ%1(]UO%+D_4*YX= (A&T#]<\I?8O+]HQI7;1DN?S!F^D\8WP!^"V?^
M.,,%$JE#]*N:.<E<MZPGIT$$MDL+Z!NP]E;R]?I*J23%5#J'(G6D>JQ=XL2Z
M-I!*AACF,S4R_]U2&GH#P-K1.1K?N %\<6 [WSKI<B3FS:(:*;X!M+PBNSIQ
M <$?!:%<&@ ?_AWU\1U1%_F&VP)>T99 !E4R4(13T/7\H7MXM]+(OP$<A+;?
M (2TPY 2>C> Y&*1_T'^'^3_0?Y_'5E(2RAO_8IVF.#<Y!B>V@9:S1A"_U"+
M4'9*-95O\?4I:1KDTD@79)H6',)<[6S7.6<4?GX#*#Z''--J9ME#2" KF<@$
M%'3U!C 48N,-%<D^8!,]PH%2-ZC*BY$8Z?[EW.0=\7^S>//71/P?\=W_OBGW
M^O_BIERN]FPW&L,[&X:[NR0QUVF\.;>6S%#,F(?2G5PQPQN B<P6B E4_NP$
M& 4PDU>#P(@NPGK"=K'=)59%*+\KZYQ^:<PXS+A\HR-__@$CZQ<"V_\]A._V
M%"5C'A\C4/REH?L?*L&^#U7?/J_6=&_C7S].Q2\*7#^^ 3P4RU-OMS7GD"+.
M;\#:$_X>B4RF<H;[R<2.2,46? H_(ISZ@"DJIH\'#HZC[; >4TC2+14_[J*@
M#;T'^"ROVEU 0676%>Q^!Z-@1EOJ14]V6BK>OTHWLQ_ 0AR7]1_1=O\A,1*(
MBMP7,QC,[<9RT.-Y+O=^O,?T!D!6'O(6%KL:]:0F*BW0^,L78W1O3N0'S-1A
MS2OMYU6QX8]6\)LKOQ7A$V31)3-4!@KM.UODN<:0I^+[!:YE(>P3)8O.)N!J
M]WT:G.7'PM3]91'S2?GJKVW!.3,RN.?LWY;7FG=%'FF1#(21:)!G?M.>B5WF
M<SPBPW'''B2>%E0SQ>==F'E":X4A1NTRA"DEIM^<S]TF\^)]Q-M6IBT;@J&Q
ME-^B]^1F*(#^%K_$;]&GXDDSL_T6O_P?RD-3".S]0X&0W[H#C'*I)"&A2N/^
M 5Q<HVO83XA*0AIW8K7]:O& [9C*7J'HO(1)I4VM:^+Y5J;/#?+HG]=1J:BD
MCT=)1W?UBUX7@=;CKK:2^OHY[\[YVFK3(CA-SF >*>86K!7WUW2)#2MS/E+H
MR8I?4)KGOP+N6M\ ! ?7)4YOI^=DXZ.BIZ,=4NA+@\K^.V2K=%'ZF"ZUC[L-
MN8EUB,HUJI,*GT6L%#S7+>40OQOI[4K#5*,FV+4/JO _(_@%@()?;0_860;"
MA+.RIN=Z#"M,EXDX.!ZNWK6Z3S.V@JR"3P.QK3F#JY55R?VFK*:$#DQ68SZM
MA]D.@RHZKXY 24!8*\HY9: :V^.Y*>G!O.:K^NB)=D<I7#%/= .+SHFLH*7W
M/B\"@+ >_Z:YIP_R)+MPY41#QVQZ?YYGS.Y!*_S_AG'I5_V(=@GO1]V2;A9,
MC+;-O&\)/I;#Q[<L)-'PUN.%DY,T(F!-K_BIP9LV(O]UP%F[L!3+BV<,9T(/
M+Y4@@YSG(X]4@8O<K55MYEC2>1;="@_BWD0$U/U8'C*>+SDA"(JWK_S!LJ3B
M:FTQFA"M0.9WWVM[LH(Z8@??6DON VH">-2'LH. P\[7( *'2?>725-R>YTL
M:2]Q']3E.7ON665;HCWJ+NP-"Z!\E%4J]^*P(]OJ2?HGE4>.=_E^P)\-25N[
MO]^^U/Q5CN$_%+G=5^C!:NHH$+5"4#N/Q8K^U/3US./INL?73,<IQ'98WI;5
M40;.)*2T#RWUYK#(![ >F=KTEF@.[SG> &#+O^09]C<5:W)#V[2(MC2<TI-6
M([0#2XA4$FTW^^V6LV2"-+Q-=TRD\K )OS^A(-^6UY#6]U(*#I_/4QJ^;I;,
M.'JX5'SU/>4A9/(*>D%8]$%%!:&"DI8+@&ZC=*ZQ)AF8CW$@Z.X$?;=#.M'O
M#92RE_]T6>:_2G<DY$^*QP:](8=2]<PW &W"&P#35=F_;JBT]$/\@8J;'')+
M<D.[.>F!YY';?\;F1N=.R0UO$([*D!>4H;W;RI>*:\9LO#,<MDCLG@S:PP%T
MI%=Z# +/[@&-PRZ]/=ES"E/*.J^;)::748M_D")N %;RITXW@&H&-,K Z4M!
MR.S_SJ/DQ\6O$ 1>%0%N$D4ZIK:P<\KV"%A?%6 ON$@<'EK_L-UE_]>#&3NW
MMK;5!\P^F&5S"F%EC2U6/5A(8-XD6(4&S"P=1$.AA ]X7K7;2+0M/S.%S5JX
M!N;/9 ^@",KC"#\KZ\:,/RLND_A5AHS;,A"D['E@FW%LS ,K!#*+)B1[[<)G
MZSU<B23UW'W);@#8]?*0?#G&B:=^XX4K56(A*<^D<[0ZQSX=[>N(N,??5A"O
M7A2)N2I"PPZ'^D[6XM>9>E1E?%;!$-?:L?%[6><L7#^9-TUP''5<2(A+CQ1C
MHC.S2;7>%"$:_FL )<GW#+=#]Q.*#.X>9.^2</BBT1<SF]BKG=T._O;G([,Y
M[?TPIG5%KVV9^,,; -(D#!LRV.N1LJRF?YI]\&F\(X5NDK"N^FUD;T_)A8]"
M-ED9MQU3X=*@87J)(/<R'G/[A>-,>5U%317^AY_H#UIS'D]4?R/\UE+0%!'X
MR7J+<0Q0_I<S<,3^:5GIGOS;U7TE[SP7?S*G%#J_ &*>)(01B,(OY[3'N6*S
MG<\TWO9RLM,5TWL%3];]%H)P_ZV& 6[KP)T;0%Y64E.0EM_(B6XHLVGATB=>
M9N.^R)2XKTM%M_9+&6(TTS#E(UEE^A(CK9_A"]*7-AN0>3U9UQO +VW\J5AO
ML0.>M07%LCCN^Y#G!/Q8#&WG%E)3F"+\N?7<!V+'_C\U$A)40GL&P*J^]<]>
M:@40H Y(]J!&MRTL[)=F18""W0>T2G)X<Z8\M2$A:=6?GB7SS9;G</8:7.];
MRZ2B!BVS8=.=D)SVG&Z+H=65-XY,=RGD)KF/V?Y:B(>+4((JWWJ0^8_R%GWL
MSQS!N$22: ?<=1J@/QC=-F,1\C'EP3]:Y*]F_ &#FZ3LCZ;\NP?<"1'[?/VK
M%PC_Z@$ *\K)J]!&X W P?(:HP@LP!7QKNK"U9GW]M$%CK"]G_O*W!L/G+9;
M?4R:U6X QY1;J$$:N2YF8]:/0-%D1EXVQ<B1BM@3IX05$PO:5X:^_GW^%V$N
M PB@'WZ9HR[$W/I45KPYMIU1J]>/G$G"6DL\ TRL0C7"+6[8^H!?.*K'J;@=
M>A 6:UZX:] X1A\RS_# JR4X0NKXN&"BM%[6W.2R@S7_8/_#V+K?J:Q)969)
M[_VN(>]DS2#OO%?Z$WFP*SI775VRTZ^JA?J$T8&/(T ]XN0^WOQY%[P=O12?
M=V6/78UQO#?#OSN_7_=\R&_94MR/T)O<L;0]=39/DQIYN1J5<*^DQY@9.5$9
M/]3MRINK, A'FU9MB-^";!QU?)LE8# <ENOUF3I2+FA\**IK;HRC7:+AM*>/
MGMI]%(!2RV%KY%;;1,ET9\[%LBKV57XC:<NO,SFC&'1)M@Q6=R^K*)\H%<LM
M* H#T^4DO F.K$ZTHPV$U!/,?8^!X\UEI,.V[Y]"N)]%SZO:E!)K,O#M"(R5
M7E%7UH\9)+M&L6M*/H\C%999!K)]8N26"_+>ZC8>*IA?(ZGV9BPB]RRQ%&(?
M0VQJ\8;52]C#=;"US:*CM^T%GTAW])=3_P1.1*UY#[D2"[(O,AX_4K@?9T]H
MBU=1//TI0 _GC3$M?4U>B=N+0/*TURX0AS.V;TEN"P?YZI"V!->ZKB<1 ZII
M$9:EU]E6C.O+44V@0A4$9MM&.0&1;&80<]"VISXVM:N20=KG:.&6F,:IZUYG
MX@RD</BTS(^0MS< HUGRY#5.8%^?#S5-TY@*"#.S)H E1;D]\0&5JU.;*%-6
MJXWK<?N[!<H7R^52JR-%0[T/XN<YE.)>F_M#R2V83(599R1R.K,K8_@:[XK'
MD]K?)9&/D-IPXE_*7WAS/:U@Z3WT;F8@?>GM"\0W'YS55K3]KDT%\ T I]CM
M#:5,H8D,5WB]9>,#>31'L4?M6CI!I/+U=]<ZEJ99[W;C!K_&H_B,*9RX'.AW
MM,P3;F[[@OE^]=<2&RW%%4RJ,2+.05V9!>!>#\&!-$7&(=V85F$0G:\#H/V+
MKL"%%9X&$!NVK/ISG(V;5F@N,YQXYL''*4_/3)>CB8:[,#CK[G(RQZWM;R^<
M&CP6A6_S+NL]B\FO*&?8\6\E,\:4N8[Z.CX&$?W0<.QI/5QK("338UJIQ.!P
MB5=GY.>W4/<.;5:4.+LG^NOCM<0:_3\Z.ZE%Q?\P4RO\\G4DAJY:BCO9E(D]
M, _3&V3@-X!F54%CN/BDI?VE.^7,[M/QM\-DO2CB]]8_:K)^*F8SE:YZCQW"
M0(3:H^!+7EF:M&+1// IS+SRN_Z<E7R<)FCN\4>JV_%N03&L[<(H03]78UYU
M08.J?,Q9=>3)>((0>V"['J,0JYT@BT'1\,IWE1QDS*)!K4<HMQ"F1CGB4=Y
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M:U[_YN#=2*^Y+4XIW5#B2V5RW6/NL2WHMLJF)ENPH)IK.EA .4'?'/=POJ!
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M>L6[R *6;PB?41Y57]MZ$I)UIA\(N+@;*,UPQR2SG^7WZ&+C<G85YD%] W"
M7&/4EHQ-,A9#NL[@@V?&-X A</XC64W48%HP;TQN3-X-H% NR[J1[H#;/]#>
MG>,461ZD1W<?BPYC%D#WS196Q_+;D/5$# :PE2<I2I64)U.1[WTI?+;;8O$6
MQD%\;2KA?C\J8FPBK#F>4M3V[N;0EVJ<9Q^$3^=3W@B)B0MBIS*)^\A^V:'S
MGJ9/KN%?1Q0#&Y$!A29'VK)@014.P8C2KH]Q'#P$WVEFDYE5U)%1Q2:PQ.B]
M<)U!,!0_G&3NLCY4**"P(;&J)JS<9\.%#^D,'Z1KL\N)Y[ 1);68VI)[1Q.5
M80F?$Q@1BYB??A)EWIY7>Z+J+U;,-^[Q>*O6O/ZE6-[T@I8T[YXW-3$5K_GG
MI(R3? A>O8;K$MF$_2O/OK41;.4'[X>:-?AH5A16HY*FI:UK2WG+;ZU5_*AL
M[O+*?*?!.K>(=7I; T0B02M)H?7B'.D>@C7K9\"Z;+5^HO4H+1_?63'GF ?#
M]H5[8<%P0\-P;=" G6I->9NG;LVZSWR>F<Z#D]PK9>.J&N7R$M<HR:>:!3-Z
MLW?XM^.E.=S?KM\;.A%=-$<_=QY](BQ_;ILL;#YKN]TO^\-)3G)XGV9OH/UQ
MM=OJ]^1K*\Y.N"8>-/3$^7W"9UAAI-#>I*NO/TJHM*[RYP"'W-V2=&324L(-
MH**;.OH4 2O0Q\/8YXKCL< <.KDR/>P%AR5339V\*KZW$:,GRI-"1?&,DQW=
M6],3NXO_$=- #'R.]VV$VHO/RQ7.;_)CCXX +T&%SH8+[00/-+22!#L>+2<;
M@-N^?/+]\&8Q/%36)<SWA/\DY&[/X1H[\9'X_9S-^!@*,3QI%A@LKG:RM8%,
MM:I1IY2.C-=D8[1(2J$5W7> $RF??<4W9'?-0<7VDRZ?_%U=A%I@,%KBBCLF
MR:B\VM$KU=%P[34\J!?7?5487WF7/'G:)\YNQ:C]J3'>&P!^/7\>YJ5R%&["
M=%R-8;<>]H;KHL?'$7FY.'^F'=O<@Z/6+@3TU(RSLTK_51T)S(8]<MM';9X>
MJ:^_A&%[_UE,?-^H>=CS-[,/$R>-Q:C[,9F8-M4_"_#$@?4M<)K-B=H\$P\P
M[IG\N9#W?#]GPO^?U_+^Y>!"U-D8ZMZ&A[X*,FS<U_W>P3J*B!R%T4OO]7&@
MX3K=8];\I04ZW[GU D5Q"EA.%"%<"(^+UZ*7KQY=T?4#.^,8>)!PI^V2A&?A
MY'T_C]_4WV(N-"V'4CH)=+8EJV\+#,2>4I8F6IPCWR#W1XJ=7,;<A) ^BU"
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M]MS\FJ/Y)XK'?WLYYKLA-$,(*P]DSQO<=[P0XC"I\H3>C_QIN)&A-9^>-^?
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M=19RCQKR1^R%R*2J-0+V"Q<_;36">S"P%#L\_,J S1YD/[W!/T9W=4-BUF,
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MJ&H!^OIB7\%/0$D7%O2(1XWD+]KCZU3/=Q1NZ>N=EPEN0^5^T!QU +15E2\
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M.=>RFO'U-\+]XI.J4&J#JQU4>B2XB?\'4$L#!!0    ( $PZ<5J0XN2.+,T
M %/D   7    <&QX+3(P,C0Q,C,Q>#$P:S P,RYJ<&?DN6507-&:-MIHHR&X
M2Y 0/+A[L! T01L)[NX>($!P"R1X@@:"!.O&">ZN:=PM2"-- TUS.:=FOCMG
MZJN9;^Z?6W7OVGM7UZZU]M[O\\KSKJ?Z8?%A'?#TM;*:,@ -'0! >SP #TL
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M:7\H'?0<\<M/=8:>I!;*9>K'"Z:-"X@M&V:Z]<7*)@:\NVW/ZZAW*7?DK1,
MGENE)/Y02R><"+9LH3?O%_C38T$GR@ :9Y73EXKPVSJ[79CH8(4$T1NKMV;E
M;S#?7*N&;F[,<B;]SFNNX:)/S'^>6VXQHRE5C6K)!P/QBG0D3E6\.ML0X>29
M578$>,52JJD!<I_? 9**DC?N"=TE)GI[-M:(S4";*J+X>Q'M@)LZ+9FUDO=.
M$H4'J0Y+BUQ&1O&Q F%_\L)R\,XGDLVXFR:#+82+B:*:IC>)\IM6Y[8M'U/9
MZ>./"I&;W$"X]#)C?1)O-HB-99^'ML\XNK98I*,E5WO)B!^];Y"0Y1G07?PV
MKCMRJQA^??LQ'32HV"IG+*)/K;U7&H A?#'Q\<HR6 4(M<Z8RKY4I*FEZ\?'
M2/8TU&<HV.+Z@M/:-L3:U)Q23YK/+'XO:*;QICJYON1OD6U-R'7+[.5Z^<6<
M'OW,TO3 &@,VK#]O:XW<WQ*^ZE^<:ZXYC<4D@:S WCF4\*LQK&N+?@4+Q5DV
M^AR$+$,Z;3)^E.&907)A5=?3.7Z!+Z9MOB_SBHA[2KI,V-\Z01HZ"<EG@#3S
M<V'-ZG*HO;%NB*$:6'<Z=K"5Z?YL\:)9J!IUQTAO@,:945 ?:+ITT@R_JH\)
MET,]!1YHK](]J^&XS^I@'X.!NFDZRO@EO\VN+CF@Z)A%9&&'5^IK5[;M;<)N
ME;J)(..]'./T(IV9S/V-J]/(51)$?-#]]YH#R]N39]O%T79OF%BW\.0.->S"
M>OB"13!02J?([)P'0'S-J\D'P.S8 \"4Z+Q<>$7MTH4&?BLI?@4$1^V U/56
MN/O>I7R2K-T'MOMRIL5-Y;.9E*&9N9:\)O8,@I %="(%'@ ]YK>4G>>.;BC>
M9(3- R!Z[9(O;'MY#6D:R!CMXP<#QG@?:X+PJSC5FTA\Z]HUTN4,[:QJ;.EQ
M:GA@E$D^\8SD1RE]%6N_YV\SJA*COC5^7&Q5(W,#.[P)^N)A"SBER\!@_>"T
M] YE:W,?G_D F)22/2-'*3T $#:GT9V7O,E(O$<<<=]0(P\ PK!]LP? 4'DG
MHL6V"-;A)*W@9-\@*-&JFIE&G46AK_[UFW.M1M/HMXB2&$PZ&I?3_BQNGYT9
MVYE%\\I$ZTD5,9'=]0DW,KO0L24M*-E> D%B\6:RP]N;KV&6.YV71$1(K+!4
MOO\=XLY_()Y]1*Q1A%2:MSASSHXZ+J;,SG$Z=U!#'R=AQ?[;72!FII#@!6$_
MTIO9<CY?GL"SK]"H=.:5G=:ZA?G.AY-N[[R)>[*5P,%.354$G46]1_6-A.TS
M,"+P'@#/UL[^%9OLQA<4S:,GVA\ Z6_#8#YO^PJH?$!!1"0.4-\\ @:F:>X3
M5[O4O5'B3_,"5;1D-T,7\E"Y_IG\PJH16!>W=X ;K]"\V_-#^%3$*)J5&\/Q
M<I(H@W3+A4IC.7)4MM9S[188@T+O'/Q/G_%^S!RD\ /@>] #X'GI V#SR$L#
M)ONI&!'N5.0HHD^1Z58ZYKVYNE%B><3)F?*:C\JJJS(<%HA2?9XF34+RSI$2
MI_0L<=)HF"4U]L^'T5X7LZ^'2@SS91?X=Y0\#X!O_F'K7,A/G?_=-UFZ"JA7
M'P#]QI_F&X-,97L.>1F '?Q+']%5/\IGU8[3)9#.0VI"^:7S4F=EZS)-);S<
MP9YLXV:*!-]I_9?.(X<P26> U(\>GEFU^@\N9B;ZUS@R_B>/3\[(,!_23/0>
M>%.Y,,5H-*0=K@8P*%BG%L5!E6RH?C,>8%I)UQ\;02$#V#-\5R^4$V:ZW,B7
MEH;9;$B%6PLE3C@@:?=Z.51,Z[!')Y>UW<7 >4$/ +FSQV9@<(/_ "#H/%M
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MQR1"'M>RB98,5)%(2=F$6UFE?77HU%ZUJFD9K=A1]F$'7>@XB@71_P5R"SH
M3W6)="_,?%X-W) #BC&.MZR1(9Q,)B^_>Y6#5E0P-A3'G$E9D[*N*K6 #BV?
MLKGBG6SC)D=5F]8R%'#N>AB_';R59#_E01<UU3!/E,7Q/HV"TK?7/0"LG/Q$
M_X"]03WP3Z5;,L;AD0E[N>Z<1!_,:%$39\?;T\^TYV<2,I<]&1?.*A@I@D&4
ML1WL(94#9-/R="_[:U%_*;9)5F-8:GY5C_SF!^><9:OORN-KT0]7< QB!%D!
M.^7'?)1?>^H+ICDX!N2G31H=D0X(5@#S\#(QM_;VRMY&AIOE5"#*O;&RYX$7
M:5SJA@O<"HF#N,X$7A$2"XG+)I\*9VVM(O#$9+ZR)<ER0N>N8N*X=E(B6^9[
M(WKR70H'+FK8R;ETTE3*/L;!4WVE\\.>TOY,C@E:OB\0;&N#)0N?R9Y6-<;
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M7[7NIHQU&SDV)#XA[:0C1?Q=A;2WQ:8S$_X L/;ARIMRY6G8JQGMW:O6#%S
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M;."VF2Q0BG/J1KE;T246 +E[DZ\M\,HRY>]*0AT)[C5[>7G.ADKTREYJE:V
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M5U?"LX68VM_>HWW XN%!QWM1&!Y%IB.']3^]M.?#MJ;"ULA#?SC)PO8[3^,
MM?]+>!D^BK+*,*TC)4#PT , BSY35=;617X3? =Z #@86S*7A-\D6YCC!@N>
M\9R4G$V\6[AL98_7S:L:6RFI5&))8DTA+7AS,DX8LO#X,$OVR1+<;,ZF/H E
M51A?88+TJ<(IT[FD07\G@,^V _%L$ZL)>_T^*FZPA[?82E;4>#M=TRO^B/2[
MJ8* *?6$@X.4<7MAY3S\"U?%SXHL S_7#Z3IV7.(,BLW!QA%/US2?6K5Q';[
ME#WXIYB!;#)V,Q^^,>OM<3%.D=?AR" ]UYR,Y))#BWYZV8CK"+QX-N$O07CR
M^"&(X4^?/\*P;Z-X$VQ_7+T&CDM?,81-?#HHK3K)$<FPNL^/#GA7Y+5K:=M#
M?,4:@N5HKN%6XC\_Q]Y"6@RUZ:M,R'7ESTV2CGJ/-)U]\P"P 1N.FMN1 G[?
M'T\/_H$?&^;C^J6Y"!A%C@Z>]QN->[(FHJ%LVZT? $'"N\G2)4,4043AQW:M
M'5/HZCNOR(W^:)+#)3;"3G,7($C-I&GXM&3[Z()'/ZFM>V76T17P9B$_F/BL
M1:L"JB%D[3"I$$_#V+Z+/<$.;;_;/*FR<U@'Q9XPB$4T..V^EJ2@LZOR?1O#
M7>.5[[I_P1A>NTR;IW"CSDW P$*E+Y47Y2[AZWROY&_>6]8&F?6)"ACZ(NF>
M.'D3&Q'ZH6!P878-\ZITVD5*A>#0Y0$PLUCX]S<+O0&T X38V%C*H^Q;D(@8
M=GN?N6D4^E[^61->:-; I&UMKRX\V;-\%AZ8J]E<.>!44M^FX& ',4E->R?D
M\>,VI,=L9OWH:TR/-#4/5/D#M Y]"ZMI@.6BID#X%V\=1B*XHK:>#T9.E!!D
M'8XPZ/0WAJK*D._7DI3:0(8X/:5OR!-?B+TS^.LDSJ&XZVGV# SYT@N5,M!6
M\7+S$%AJTXT(K$M(8 R,[ MD9:"=+ZG/8(- 6O*=$&ET+Y72K''$61 LQ@6]
ME$2,"4BI6)PO-M.J:ICA,70%I8*(=VO$PE$PRE[KI$/]N'GR:, PX$66_NG)
MRM%HK^3;@AP56WHS]X4B<;?XI[]EF/T--&9<73OZ[C]_H9AR%G!=R\T$;+B+
M$BZO&X3 ^!OIS?N-.X[4;)>\4Y4M$\ ZI/8'IGR12.&R0]D&I8P6);;5Q&*$
M7#D[(6U:[S-+,9[FQ>3OU< ^:$L!F6/B4XYG;99LT<K*4E=B0E;3[XHF2J#(
M1/?@\9_;"UJS&S[J 5],9FHQOU)F(H89PC6\&>G(766X#Y]LW[B1_T(+S/TQ
M,)VW8>IF$$:^3Q/94>156/T=3YWDQ)K8JUD<T]OB9D'I3ND0$BC:GZ@+'<P!
M&=',I?H^^8H1.<$XW[SQ=P7W]:D!RLXY][[R_?P0*B;+GG>!4K^.+G-H+;_Y
M2<P5X^"<_8GB&W=/VG$6QI-&9WL9MHZVC@;2\?'*.&H]/46;2>MUK]EY.ZCK
M\4D$;DDD^OOA2@.JM8/+:OMSSQ5R7NN_HUKTR#6<J\O4CO$Z1]^C++1+<S?'
MG'XS6GOA.SD(N$-[9L,^83K A9GJG IC<;=>AG5E2+2;7LDFHSA ^&N'G;@4
MTV.WFX&QKME/-?RP51)T^-7X[6M!5M%[UD2M&2^\:_KV"+MTVCM08$%QY]F;
M%PFR&#Z39J*R2],7I#&,AQ8G7$=.:U>V':\> !$F5B@RD::P0UE15&QT1^L_
M958](?)%[E7GI\'_I:>4IJQU*S$XUB/$A//^_3\IW:/ OK*8R_@Q390Y\_ X
M9;Z#NV:OMCK=$RW 974ZR;(.-W^E_7<=9?0?OS&FFWE4-O2C*@[/'0WX1Z^U
M/*]?W7REA6)]3 ATT6-BW-0.TK^."9:WVJS"[C&<8;_3+PA!7P:--23N]W"Z
M!QR8:#;#HM<46V'"Q>"TQOD,(1V%<H+J=& B+?=AU-O3U*'C4W47.9TSEIZ?
MKN!N%SGC&F9B@2T/R)VXI>]V 5^2)MHVFO';8,YIFLW57>I3%]>J>;(X?QO:
M#*O838P,EL^IX5O+[^/"0WD/T.C;6D?"R;JI5U<)*FFKS5;P+_+-1 [RL?W)
M/\A(*7BKXT=/ER5K-[= /H'4NMMTS?!MTT3HW37=Y2;HDQR6OM'""X -&C+#
M4.@\:)&P(46-K%O/3C^.D4UKM)@QG6F;05.94*,4^6):*%['R<$CA/"G<57N
M66PTKY6>C?G+XV55 F5YZM-<O0*$H:^H#,-L(PBGM W$(^V#_O5/DX#@QPG;
M[G-)Z\!YG\Z^=@DG'-8TZ"[U"HL!P;<!\I[?SPVIP^_Z5/^J,-FQD^%_)YSX
M?8]]3F69>:3S\IF*_<=A"C6*Y:48MR_BY^/28D#J73!/!XT]/+LOOXP12CA6
M[*'"8'WC0:=%LFU5D*F,]##9C86=]ES?$I;<S[2W#CGL#;+T?/L,NCE7:-O)
MTN;?1^O:$ZZ2[3LF&=_2B#Z7'*'L7&2F)*Y(,>&74_Z;II!^ODV0D"HWJJX5
M45YR"$4W-)>NCBHVD?<$?\MT6.7RPLL2VUXO7WXB8]Z:[U21OC&?SOO=*W U
M+,_#_WHB5NR"9A&4ZS$S0B\=4.T3*G)P#6X1@OIFA;C[T,:S&N[JQ6;2IO2+
MMUS>T"8]4?(V[NPEE%2=M:U/Y2U^.41',D+P?H"N#F"5D*8R^L?$ES9:=8SK
MX#X@[#>E^='MB458=\S9::H+($<;Y.0>_HR4%Y^G%DR@N9R^0V<E-B%V9/ -
M(;ZQ+]3WJV]FB;MNK+%T3P"4X[='+T**N-"[-(^;'%OG(_)/UVO([&NLBE@=
M%R@)]^&N,/K*M_)VB$4:R(I7[P>S4F^8U4A>;.0HNTA;NO9=3Q9?)ZT,_K5G
M)[[//W3P!1QI?*B;LVX;[IG."C%.2!W9I5042&C+[%]93FD>2KA=9_B@5XH0
MW!AR)AE_U9R&E0_Z4,4'&Z+\O-+*IQ68=+0E$HYWT,J:U=FPJ<9#/\O9[#^:
M6L/NQ\0@Q^3-^HX!&]',&!O\+*3FD*)(*V)2SHC9ZYF;P"J''!U![DC#$P1#
M0T!TW\CI1QK-[Z5:]M<M"9Z:Z4H\LV\YAZ>&X]*8NH_UGE%&Z0Q.F&37UB"Y
MIJ64;!R<A!;<5=PL;^U?JGYK;XTB*,X0&Y_;<0\Y$M5!-#.D;QI>WHTQHZ"3
MBR%U1JO\'41K-^82>[0!0*:"$L,VQ,#&';T":MBV!12O"E6D2J!(U=>+C:OV
M<S\IVL5@VK;6V69YS1A#8T*#757$_>7Y@&[*""<U]KN4[^!<C[SFVW0=1UE\
M;VE]U&Y00[934);Q)NBYQ[;0&&7:M!7ULA6KST"P7?9W']@7!7!C2TI/Z(51
M;/;YO!B&NG/M2P,[VMJ$7_VX$V+[[D?)":LTD#NCH-C@UC A7)'$N@9-EE2#
M7&2EN_I['_'?S\-O*-XC#(K91BD%M8+\?("X4N<1=Y@""C_<L=]Q3R3=B+-F
M3T\%$Y;N,]N +UZ/V6'%QS**Q['9: T\\72D5QR@R&1@:)C;,;* -#5%K^A-
M"MJJH1.UJ!ZJ,*6>OCE+[I46['>F&./]YML0AQ)N2;9(PQ7%](CP'_[5U;55
M K U0E)-.EM&O"AI)U8B<*\+J)":HL&9K,<B4-7&1@.L6]-DFW^\?5D7O2K2
MI(,'_324+B:R/T+AOQ<M?E41#ZM1" )Q*(&+63M>XJL2-I&8X'ZM$(A8[)<'
MLEI%3D8::/6YD#'75RVK<68VVGVR/"7A]H_/U[R6'Q=,"?22,QDZ.^TB%-4Z
MZTBT*E]=/I0HS7-Q(0B,)U\ACL)+YB;_;9ZO226BZ)4]'_;Q5AS<].G_8N4M
M@^(*GH;?)7AP=R= <'<G6 @2W-UA<7<)[DL@P19W=W=WAV1Q#X2%Q1W>_-^G
MGJ?JO56W[KU5]T-_.6=FSISNF>G^57>-DA>I*[##@LD& [YQ9) Z_LQ+D#HQ
MVU1;+N:B4:4KR80T(6<FAP'D5.3SV<F9@0A%]RIA")R=)*-/.CHLR,;[4'/*
M6_DBAW*VUX17P#Q,1[)"!!GNC8@Y07(=L7,BLY7!ZF=[1TSY(?,-X-X$XHTT
M-9ARR&TZ?VJ;F!# Y/H5QFQ %?9*U0A4S*EEWU\R Y%%M?W$[3_DP>LC%IF1
M+RU6M+BP4.@((^%RF^>1)V]%1;W<L:/G&JE1'&,=)'\GA+#'YS\@@>,Q2Z(P
M_[MXBN-6MU;32+YQ*DRZG]P4S!TO],\@:J1!Y+#IWDB@521J:1N/@A5(*1(A
MO8\<\*YL(!$?;JN<_B\8T0W[66GQ#%AM'3;Y-<?9!)@^)O6D.\C_9^;4PC[U
MRB+>+[;\#8"6-/BT(U(3T<B+<@?$I(TI&4LP3$U6)!9U\=M-IIA1+6;SI:R^
M>-Q26>;(-V+>7QLME0VT7\"H]NYF-T0D&2@W<-R_NG)#=/KU;+QX]C4%ZHQQ
M,L( FD )'\?UY9HX#7+$+M#\HRC4AQ11T489*NM['4PF*L3JKE+K?4L,T338
M8N12N!@^;*@58K297B2G=#>RB;JY#Y O^7#3Y3:,!\)7:LUUT4R6;V,(X;/C
M,23H':$@5<K(^^AUN/F5_$H>^6P'P_5#!R']T8^$*,#C==E-;5P+)# GXJ8[
M8@D2.+W;?]M.Y.A,N?IACTZD_@",^6]!J2'G+:QBYQ)<^X?:I]=O&JUO&$AY
M(C:Y/%_2UW?%Q2<+ZO[*!@N[*5O\"29G]<3@GO'/8LGW=77\P;  83L-&;!R
M!,G+:AP?KX2("<YG[CF*,]MVU)26ZO]^J3@4>?B$O2E/="8ZZ.3$3S@C=3GB
MYRGX5X\HEP"\-O18\CU*!;0[J18V[7'>%%RBTD#_Q5+SVH03_'. 4A;@IU!<
M0]<G@0M]MB-H4O^];O?X;:774;?8!*0P^)TU 2PI2![B2U%1M44F*H9Q>NO3
MZ3^V'T&X88ZX?V5UJ1;:&=J;E&5W'O]UI:]9#"F5[\AO=$19?$WA23O'SKO,
M$(MU$OE'4B-2&V?0]5%2CB6YS1GE^O*&_VY@;F27HF_)UIHR/O::P23%0D,*
M;^/G^:+/J.2@;A5DPV1$@#>^#A@K89/*%\)$U]-IN\+PLQ_%%17D':J5>-Y]
M*#<A.2,H)E0N/V*$OO--9YCPHTV;*_*D?<J7N0E+H3W'V+X]T7=RLI2FWDN1
M;2RU"904S3SE_C&?B72?RP8#\XHJ\1X";KV_7EG4R,GS:0SWDGGTHD'L0ZO9
MU]0;F\ [; QH)&D%43.V(RI!YQ< G? PA?S08_SF?J, \[E3WG8.]H5++&:]
M[70Z;-8&&;A,V>WM':E1T<QFHF$QDF8?WM\!3P;E]+%(>F%)S';XHJ[\Q#G#
M"J*6 8.,F:QS%#GXX<5L_W]D0%6?\1V^*HO<ZJ_>Y;N++3>A)0[U:CSHC% U
MUE3>4H61#D(*AB5^6ZI9B822(PG247GSW6(]X_>^*CNKOP'J<G)?(QUV.4+U
MS9;%D>VS&+@FDL?&"HG-1D[W_?", ]:TK)P/1'"-A_VR[\+9]2%G9'5#DP2+
MT]DV9T/3F;F[">N/.2-IONX?+0((%6XMT[2Y7*$S]J51^;9-XV=Z])??5;N7
M/%XFX6*CA@1*SN5AC8(BIB^;JGD@GN<$WS9E3O"=YR.%8%3 YWJ9W6L6S]W1
M5JT^W4*-T0OLH3> <%+_(]],%G ?_]WV1C2=QO)/VGVX>ZVD6,[BT;ASFZT&
MMLX'"1\F<]<3%V&MVBCAV).[7?JT(P.6$*  .W%1<B&2:'#SUJ-.HPKY,B/C
M^I4-A]M'*M5G-MC3[]\# :?Q[P"UJJMLN'LJE\7 $]?^&L:=Y:Z!3=8:3F&/
MFD[#E.?N-KI8J,*!%04_"K#Z""TI)V;8=RNI2\BN:FU=EM>.VDG*;$R\<%W'
MWP;M)SVC(-^L?3H&2XN<K!4O?8#!GBJ6Z@[9,9LE!P>$(8$6N/T0T\7%*IR(
M'WZB4.L$0R\/AC7*IBB^4[ :$0FXK\:*#L:B6ZW.2=^@O*2>=KJTV7<37E9%
MMU._]][93++A9E5?JRPLR Y1NN067CI;9'\D+ZFVX]N*IP$A78+1]"S1A<\D
MF-\ >U/-P[.5T[LF^ ZK1$2<J'1+11&?HJP/M)/(KV?%QFH5#103V[U]L>6X
M#)@&@U<]QI\KQST"F14]JS_3M,BW+:^S8_JRAF=>N#(O&:V<WKC,7&F?!E+
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M%9,P/'F@_LJK+W5W.N'7K&YQU&RY5-'Y"IZ/3#(*?0TWQ'\D^<H%1E0QUGQ
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M],ZK7! :"PD?ZM :NI2B++6]PZ$!*7SZ8X3OR=H^!M^>I\/'5.-SOZ4(.IM
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M7]6Y]7WWUOV#*KJ>7K_5W:O[M[JIAYF%1TON4YHP\D[-3="LQ,L2YM>,C\^
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M$@GXK\!\0NJ/6(D_^FO0566-@:\0]445N;^_SYZR*9L7L2WI^&J4!4!/<<M
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M-Q\S;],0ST/^E=2E'EF(K=4)^Q&;?,/YTY+DRM6P3OTM3DG9]4"O +B7LU.
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MDU\*FI*&[D%58-#CG@'DM[[?[I+I)EHWR?[VIPP VP+T@UOK*<;FNRO%VF=
M=.K)(^S=ZV81-*<@FOH5K +PF!1+.U_H4I--?!7WKU@=^>9"G=PD1X/ (W:D
MD3ZGB)U)FJID>2:VK/I-82QO+6:.@Q*VQ4)+.-.EU($"ZQMR+.%W)J3OJG5I
MZ,P:(X JGX_>VMY5]"E/76AHT08TB1;\UDF5E)#CVZ,UC;3J5]OZ+3UJ)-+;
M6F*Q1X;F(BM[V63F-_*-8F()C_2VAZ']6I6XU+/I3/;'<0O9_KFE5@J6)-N@
M.:\>+]5,<^[OQS[5;V)0SO/34]H01A?D8HZ<YH!110?&^9R210=I\^[S!^S
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M_6GY>[B)*3;-F,3'0JMG:?[#.!4!"QD=^MJNC^4P-HSZ(6[W9R+W\FRVB$!
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MP?$9EJEUD];K&0" ?O@UZRUJM;9KL[SC)3C4@401A-+/^!5W/L.+@<P@^[K
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M_8S1!&_VU?309(G,_"6=ZNM*?3DB/05+)5-7%'LWRA#CC2$3GD6^2"2$QF<
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MQE=]AC=OXI5=I:L)J,7*^'88 =Q6H\.@16#VO'<KYB\#W+:,]J113#M/3U&
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M;>4;]-G\_&"7JK@VNU=[N;JZ8JKA9E=MLXMDPMAI%*:E&O=,WW*H-VK_//O
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MSE-#6 _ZD!OXUV9J[ERJC=<&BT_\4D'4*FV[V79J_W9G/G96NITWNJK/K2(
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MH$F]1).#-9<N5!H-AG"97S\TPJJT' W"/4NEXQ=4H[>H+\A:_':NMCS,N&
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M_MEXK@DRIAY8CX[J%[WS2_+,N>;N112C_?,S^B+C,$D\NJ[RY_*>AF+9W/1
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MZP.E&>:X'>+Z=4P1?KM31=#<E:@"D=3(#X?-U($K,NTGO!DA39I'=[Y+Q8@
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MI+G/=B.;9L")$SR$3LTW4VU-R:B4588WV+0HKV5\[HWK,:D MLEH4G)%![C
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MW7S+-;PB07H=SC O*+F73A/D>$Z/0FMJDRB<N,*NSHHL@.H@TV[I^<#0;:H
MPK+HT@5-N$,^EA2&OMX>L@H>7(MW&1:]+#ZG1Z7CXA>G*8I-C04D'<%M7NY
MY0[QNOR^-""+SMA#@>*XKO_U/0JJ*G6+$IY_DUBQ,)Q(+09+2DUG7$T)H/Q'
MN2>"DL!_1T4H>G,2Q8E6L&D&=&5F(R@>="F>T%;Y%5M0\RL+1C*^36]->!I)
MJ$,* <J-4P],6F=F.GE)WO-;\E[M"+LI6]CK<(%Y02F92)]]N>:8MH'H6@.:
MN]G_/)<OBI-0@19KF#GM"/X):Z>T=\HG_F5 &%+/ $SAKT\\<0,-2HQMQ63C
M3DA^QL.HG^2"4O:<,V"M;VS7#?>;O\13),?;4*EHJ_\'WJ^X@I4RJ6 =C>TA
M/!_N('?MPE#^E\@.DA@,IIKUXI+'%]#L#CO>BQ5F-:'X$*J,>1?;6+HOW*95
M +(#O1IV!5$.4U[U&,#$KGH.C1R_8SY\^<UIHVO\(;6HH)HUBM>#4.YJ4#H6
M$'?TYYACAWG:0WDJ/,A9]H<L (!AK?$_*GYXLQ&CUY#'(MA30"TJPOY?]4]B
MVA(_[) JJ4V]_</#F?E.B>MZQ&XP%=C1T53Q7E+AYUNDA6H(S>O';Y=T,<=6
M!2<[?QN)QK346!BS;SP>6$1.R\Z? 0)[ IRN/"=LG?XQ2B1&4P7<_W.1D?_"
M4<4S@&FM7^;T):T7PKH0B,YG ./D@,S5P=J846]W@W?Q AWU@SA<\9Q1DT%U
MA)_ #_3[LK93FE.):;@_B4"%2# 19/:JB'%A? MV-R9ME74EYARB7S!Y+OU6
MRHG-F&" 0([&\S\1W?L_52VA-BWP+YJK2!()"BCW3BN*LJO(XP:!SO0V9X.E
MII]Z P^R5WX^;)7E%B5LW27!:U,X%&077!Y$JDP/#/F_U50OBR>#I;_?TQ8D
M>'SDA0_(K_C3M)B_J[OHUBI;*\QHK8U^$H+"]Z*JH1*?.'@7!2VVDKU)IQ=&
MU+EQ!T^"<AG+2%F/^F)9*SC_5__DRH:-M!HQW67S6-W%L?(OT]\J6C#@-Y<K
M _WUIB,=D$>'$HY(0Q@F1^2VZHQ_J:66$M%5J7PP0)!ON,;-M\QSCIF&<_^%
M4KEF. Y;Y\=+)0(W7>,*&F[BI,D@S>Y]WN.X:O1W4UBV5G>.>4:'OVYJ/R',
M[JTT'>GKX%^9-PD_6V@M!GO?>)U>4=\;S;31?1&L)=N/"2BUE"M?5!<%?^,O
M^"A!9V-Q64]:E[A4-)8NR?VQM?"89W@W6,T&.?81!=%[3P\&;@(*WD\)@P-,
M/YAYJ3TE<80T190&J>Q8D3\H(U0V0SYGIT 7+A??QC?1M\>[A%L?U(C^;Z2;
M55A4X=?V!VD!D>Y02NGN$)$6$9 N:8:A<V@! >F205H:I&/(H;NE8>ANF"&'
M_OQ_)^_[U=%WL*]][6>=[;6N^[E_SWK6_0M"J.\%G_MA.5VVQ2Z2DKW1YI2C
M8F_SWP\Y$7T6*3Y7>L_RD XS1)KK[09/[_MPRSJH(%7R"*^P=64^21V*)S,I
MNZDM4&L5B==L![=(UN"P-*>^"A.!Z$IHO[3Z=8MV:*KHQ_ 0#3VE\*9.B5R^
M(&!I,P-%+ZM(\8)E3US]2_=7O_\#_\KO;21=B0OP&#E=])WIBFG!U"? 5W?9
MB]V55FSMN;(+6_T3UB]2*4V5Z$2I8KYU[N?2*03)\KXSEV?\?@3_F#:;P+V@
M^J_[O/UK=,(W5(ER!R?>0A,L2R35V@FTL3C80L.ALY*::_7NK8(9P8JG&;Z$
MZ_?>5^7HZWBB#M,& O E-N408KTG #0+NMXD)C&XG"U+V<<!81_8"F#TP_[K
M9\?<U! -%$_%)EDLGM]]J#N]I!0Z-XUYI#A\1,N(4?C;6A&@VN@Z(;*YN <Z
M1%U&C5+U&-2@$XD:-@:]"6A?O@?I3T[IUMDN6_PS\68)WZS,+BH.*(=^NOOD
MC?5\?:M[#8F^?\AM2T.%W GI'619[89M&4OO;<?DAU]S74CIWOAS[&83@2V^
M( KN] _J-1?&BO)#PJZU_L:YF#S0JHD_ ?#FJL^U$5!;&6_@TG!N)$?QUO,W
ME8HH?X2(";(I=L=V++E0F!#.31KF\MAU*:,5I#^6#ZP ME!/%?PG:TV[];-3
M)I_B.TE&!3(X74HX^_^BF4PAKJ_LIH7BV,][7(73K0/,['X)R$Q?F$X_<"S"
M"!"5[Q $S0_!TZI><5DG@6ER%U+A516Y3X#/]9/'!AL'X.-UDTJFK\\1ASLO
M3(ZY),=SNK<3XEH-=><+UMOQ]K.(IA+[5>IB)Y=<W[_0N_WG?&;'0/TP,V1C
M0ZI#CL*[;;6EO"> K.D!J YELU&[D4W0SSS>=H:^_5%=4U'A7MZ;H/YDW(6%
MS-)C6D/^52BIQCO,_X\'Y],;UI!)6%R/A3;R'^'*Y_=OI*_BP?<@56K8\ZDD
MHUZ:?<IXZ$U8@'[T\B\6(\=N8L,))OT5Z$K@RC>S;1PK* ,IS_F'%&U_A@_U
MT^3G$IA3+?Q)01W8MDSTT"QIX<-$\(X_L0/Y9-?$L"S0Q4V@=)@MN56/KH5*
M>0#^XD3<Q: O>J7O$XRIZ6BS7!R&U]E.[@=T68\CU$_G$M!"DCVTSOZ>,C(2
MU/#/>BN<L1YPP_4-&_#"=D;&]MAF(.GS)$P*Z%)H".2UFWN_LYWX.7:;BN0?
MK8A*L;>52\R'1A;._.<RK]8J+GHY%SCTM)?.Y^R, ^].]*)59;Q'N/Y3O<A'
M\T0Q"_XWYKILP6B4?W2>  SWJA;YJ%*M:7<I\5/U24M5"=]R;GT3B?3"KP6D
M-5M_=A.Q33!Y2L=O;P)33?6+'OR> (-95SY:;I>51)/2XN"D'O)FDVSLL-=U
M2,SMT9Z/:2&J#MC)SSEJ*[8)DV  G /<$D%U^D-/F=HH<*QJDG3M=O-#H=L.
MSOR8EK=4%WIV[@2GY&;IF2DX+Z)(Q#9K)MO']:*2%/DINPR,UVGRMJ4!.993
M^LF]L#$2;Y!)H)<U<+9O"$W[.-IBI<0ND$%H'!?8'%I8\+M;&(JW4)#O63/(
M/\#],IDG=$G/WCZ4%AE)AJNZ/BU=35DZ+K<"Q*W$E*G#CN3A$H36(,I>VI'H
MFRP;=1</,K^2'M%B03/NX75$ ^RD%ON!9J%.A ?FIVIJ+/"N_B^UB7U'J9*I
M11_@QPUA6Q<#G;TB8<4-F)&%5U*W:?UD.SYL/<=.ADC6?*Z+=#+$;*;G%<GR
MJ'?-FE(4Q#_?82&++^.Z4FPZ0.90FO6OI)8=I'K?K=.*[#+Y*ILSG"]UAJ_I
M)Y;DP_: Y&0LO>N\$XF:XWB^VZ%J,TQW<S=2*)O 3AJO:1**>\RUF09JF;?P
MX^KA^T=]+S:!%D8-(6T\A\(ICR)SW(ZL,^6.!;7B0M&3QY%"6<#7<=GK6G5\
M0AK=0QH[IK/UKS8LJ%RA#P9/@*"+0J"(;HPZ,MNT'OM#DOS4>!16$7D:D6/Z
MD3YX).CZ>#GF=[2%6(7,>U3X1A$%O=6P=,G.H=7KQ+W69DIGC4_8(Q0H_[><
MDFD.,1N_TY1NOQ"E>?CUKS%$-#\!0NYE6*Z@'AZ5IH.Y"RM]22OD$?F-6?*?
M_@B[-$BY1'M67/>NDONIKXWC=;(\)N17M',-]\3+>Y[UON;T'6;/3<4]CG:9
MSM#@E/Q9%D[[D86F53RKY5!%7'<$/M>G3GKH?-!<T#9,0 9C%9)UPC]*ZGUE
M;3RP&'"U'AL8OM*2@IKZ(UOV$;E//@EV'-<*5VAL\@WFCCZM<_K2]SQXLTV=
M-3RL./-[M2"\71U%(146B720V/3ZP3IC=J<8?C26[.;O7V0(H^#:A=5O(U02
MOE&RBE]>E6=_9R#W(&18MA/V:<MT*%@U[$LJKW,5C6<BYMT[>"&+GA#OULOV
M'BAF:#[[.CTQTB<K1YYQ7]5H5^E_MOCE7XG^?GX;<R'N$-J[W/UC+5@X8?[B
M.99RY6@@'3C7B1K<KC.[PVEPYID@Y_%EKQ0%P%XW!05,K;!+4Z/42I@=:OSE
M(:-BG=VNJZ@](82UFTDLN;@8 T_Z+"Q/V7V:(P=A$W=Y"K!3]<VU(X:+,OE]
MW1'#SN-YSY&5VY*FII\M0R4JT3M_)[+N=&R6B\KH-MOXG,::'Z#ADGT!))Q^
M&.^/\[E:UE69O-?.;RVXA+85%1FQ\0WD*BW1?P^,"3"?R_430!UO.(7QYPLW
M*-RI/'))[T<I8'DO+JM/1:YGT901!A*FR00W-Y\^VA3ZF3Y$$&M(EZPI!_,-
MUR>Y/@'>7L7<^=.<5V8*,@1+"R,I(K;^.OC)@%,0523^N0+4[Z7TXP"!TC/7
MJ]V$<6U4J(R$Q4Z9JX *!8+00;1?U_,^(NOC4!\= $92T-)LU0B'IE&B[F,[
M2?DVREY5^VT+#\^AW*YIR!.@NCW\GFK+3IK-]EZVE)ORO>X#.=-1T6FV6S_4
M'^=L<;^^^T0. _3M-P!P\:SJ4H;BCQ&-E+! H)\B4?\ _9'O\["IKA3J_"B7
MRH]LCKECKS^H7CY>GU5*EP-G_::\I'P$W_Z-XR0+4]Z@.7TY]->V?NL#+H$O
M#U'EU%W_OH&XS/??4P44(OQ"#]>FTHZ>3X!F"9TE#>8W)=3?Y2FU-;YA2E>+
M/%<Q>(-6$?6:S H__VLP/\'7);"KX5NUOB2QH.9T:YEFIZ("=]+/6.39&[Q3
M4:I[!F-'@?B9-'L^U-D]]#13DMI?9],R,W3KC_^*;OF&3%,W!18NVCE3.IKK
M:U5*R5YB5]_JT"S8I:$[UKH5Z[_XJ,FP\OOJ'XQE"BX93_!')M8JAM[+/J0Y
M":YSG899@A9=(,*:V2N5=T6H]DSO_M  <E12;W,&Q+/9O>KFDR;0D;0O@7XM
M:76QW#\S_]"SN8:(Q"'>?V\Q3.N$0_%KI0I5J%[?N.[2F0U$\V=34LV1MTWW
MZ3=JAN]^I:67QJ::E-*6I7=U,D>5ET('BI:@,;(O_@"R47#I!GG"^INA<=ZL
M0P:N.D7.@+9@F%;O*O&E$UE*1+XP1/'1>%T4([#.]PG OI:I/..5WK0_5?!<
M8SNX>O^1!]5=N!=@U9;9H &C==2ZRY?>;5\W$=A@(+,+8&L2,%VJRT-9T+[V
MQ[3<B1R9YFA%_6?4QQ)5XF!<C7EP8TF??EORF!WCK"V4O 01B3?ZX#E($JZU
M)SL*\'=3U79?W)JNNS-L?-Q"EH4@J4J_ #24U*GRE]^]R$UBC9YLQ),7\:#:
M^/4B-TTO4N0S>G'A29ZG[[]W_BC5;\S<]#01:H 'Z5\UP-]_2VRD0<5HTUI>
M&BU2;UX>O&T)I=H(BLV-IYW\^[^/CSRC3QX&5Z['A<$<W.CZ:@O*I_?:3'\E
M*9.(![I$\JZT']4K0CVX.BJ\/J."UI<YOB1]@LW:'U>:OV$.4W[WMO%92ZM
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MY \=FXO=J!M,0%%$>09 D7H\7Y^)98-YN 1$K=/!U-W2KU7=IYVMBX[;V/)
MX>1P3+QXYLK*\R:8A\-)O24VH.Y45DJFO'TM+N7E["X7Z.Z=K-5OH, 2T">K
MULVE@,[ N\PA+T:3S*%L).;58FPCQDQ+-ERURQG</"S+):'L_%7+[5>7PCDC
M>+K$83>,ZI42U=9L9ES',77_)U5!&,QV3C[I _Y(_@UG;Y3_:NOX%#RG#H67
M.P\.GOO2T#[]B@@'?_;/_O:2I,:/B:7C)6EMHV_O1/??@STO2?2^UPDX/ H;
M@5;$$&WI!?NZGK?">=X>CO#0I7>*KM4*NWPO%R@]'E\-[.NUDTIS@T.Z381G
M!<M%OM34W9']%/DG</L"QH.^'%@/\^ EC#$ 1NSEW%X[^L4Q24^:==&+VC^#
M3H5&XVXVA:JO:<#X0YU=,2W5Y\3\X(KFX2[/>FF.&:$MB$[S-&,D%9.Y\)LX
M4:;HW1W!C.+>(C(/I[XGP);0\TG-'4^'RI:*?BJ&OD.0OI HE(M"HTY</M^+
M.KGC"V_'Z<MX!6F'W@@)!6P#^VQZP4.087+KWTM?.A,QQE@I>MO-NP^/GA_D
M>;>=/1MT*#M'W?^)"[Y@YD=P@6.:MP7R9;0QZYJP_;L0,_38U%W)63P_G*D*
M!^Z8G:8R4[NS08R$0Q*5;-N00>8^$AP*=#</;#&Q_$SLYB/ATG*2TW_U7KIF
M&MU /7,T>]N6+94Q)WX!5\NGU]/]SDSO=!I@+M"-'WU5RH5<5?]EP)J=:W?;
M.KTO. ZT(A9,D"?-,E3JJ!K@%$5GOM6@Z/#%<4<2@VZ[5BO^P)L/ BP#P*EY
M9XLHX;42)LI3M?"U%YEFH*]IGNWEP!3/:E7'N=DIQC1P?I(O4V(XJ@D#H%BN
MY4[3Q'&(:WC?DJK+0"VD,"LI;P>WA'MD99?H&<AZ,>.Q(@48V8=WWN)[6=)W
M%[-%[C&A%@KJ8?:!M5"R:A%7(/+@F/HA3?7GV%[_:,N?A,3&@3[@]2J6X.*Q
MPM4V5$K> @89\W88+GT+6?B9MU5BG_F;'ECM1S*9-Q=S?07)GWV&O,2Y@"0'
MC-(-[[J';"]/)T5OLA5P_ 69'LH_ 3" NL8^3X#L>P!"L<^7D.;@2H=HGSHK
M_>I0MZ4NZ_*EHC@3IG^+7A8NW;LQT'=D=I\,"? ?1KY(+UQ=$$RS1RB"<C-9
M@86M*W]ZO ?N/I]Y,T%];,+;*(!M=##$/<)H60G.E3'+B_L\?I^)@WB>3J%S
MBJPZ%_5I3FX6VJI"Q>P-!28"M9%0E=_O*.)DM<95^)MU=1X"!RI4)F/2:]O7
MG<Y%KU&;%GB@0@<:+27!B-#\!K27^0W,O_4L:&KT4BC7"+74DC8+ONL4B@E*
M&4CY'D>9"PHK/4Y:6JXT2EPY+(YYF4,KVDB (LV?VLTXKPV%HIX QVS)E!R=
MHG#M/-%-H#R36%D1BJ)HU&YRL,+NM"*]MY5Z4RD;2,QN;T20+ARZ2>.B)D[H
M\0!\ F C6,K>+UP?[SX!T)%OP7E7<8C3D.R/<5]JIKFXG1CO/M:?Y[LH.]"?
MI7IX48EA?U]2VG(Q()>A$W10[:L!>ZX,/2HHS#L]>Q7GE;+CO[R(4%18C$:F
M17U!$13:3>U?\Q\:]"^6_[X3O';@ETQQN0E%;/_<W+$8<N@0W==:\2.8=()9
M.%2.EMAI^J<Y2=,(L!_%ODN7)6P806?H;J&?GILYOGX"=)#<CEZ<'9\_MFWT
M=P=&^]CTE-Z5@FCP#M5?>96EO!(>:(E\ N )3R5<&V+#6S%TLU%L:SN9:Y4D
M1H<)=KJW,5M5Z1YWAJS$_(O5R9^-ME[H)9E\:^5XGI&QVC*_7W L%NC=6*<A
M;^GXW_MHKZC(MG6? ,^=8.H;E529JI^;ZQ!7%5>_X88W$HX)K[2=1[XTG_%U
MTL\<%!6XSLF0P'AL*D=SU<L-Y4JZ#FFK!E2^6QL?%/R XYJ\8V--T5@90&*A
MF"KT>@6/UWMFK&'4O_A8EI001L/NIP[N(V,"]?R_R889UU[,9'H@1/IT/Q=
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MVW.^(OAQ<I!@N2Z^I\QS*YD[/WHSEKUNM98B]E)-M:O&])">RI".C+.^%^C
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M(#AH:F>Y3^[%"XZ>?RH^3G[8QCQ7"<UTDVL./E>;=E^TB9S]\(NEQXZ)_PF
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M0["S@(977KF'!+!&.4C=K]T;*TG:_3-33:C 4XF;(^&=L,G;S]/NS'<?EE\
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M>=<R'P&WIH'>GM_=SL)N6/J3:]=,)A^69OQ,R(;O=#+S;_<+05,' .0BHGK
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M1MC[M*X(. )BBAP%<YJI.$Q,U#1JG!<L89EM1X,*FQ"*N2N(/K4+,H&.Z\2
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M[5<0,:RKIB41+&EXB,(@<YBHPJJBE)W&3206N1O:>P'HR)$Y[$?JX1?Z37.
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M3++@:'X.EF_M*EMWUV0X416'4<7&0!7GXC8E2W<2.61^>?901UX\A6.VGGW
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MTP93[$= Y2$+>N(N=H;115;%JT9& C_:7 &?V7"(HF6'&2,)(&+#-\$SS5'
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M,7@Q,&LP,#4N:G!G[+IW5%/OLS<:NO3>A8B@@$A1FB 0$&DB(B#204'IO?<
M"DB-@("&$NF=B/3>04! >F]!>DN0$B#EYOM;YYS[_9WWM'O7NG>]?[Q/,DG6
M?O:>>6;FF9G/[!W\+'X5P/!$74L=0$0, ! 17@#\ D 50$),_->;,$@);[)K
M9&2DI&14%!3DUVBH:&BHJ:BI:>F8&&CI&.FHJ1G8&!B965A966GHV3G86#B8
M6%A9_F)"1$*XAI2,DHR,DH66FI;E__' =P 8KQ'YDE"2$-T$$#,2D3 2X7L
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M32B<G,$K]&\EWDIX0:I7([0O L0QN]'C ;_<=/& CD]X !=H3880*5CR$SP
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M)I:T*LI[6D/[\-GGI]_+K=6]$K7.I0^!"U _#!Y@A@>LC!$LX>JP\@?KA@>
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MN/9UW=36)#$MU]$,'!^NY[G_GRY>JE\9/>.F\*A5B?+<16:99Y[J_A56<7A
ME484[JZQ?>5\:E]*Q4Y=U3P>8&_V5<GS:\=B6]LI 2!\(N"/$Q9"M]N^]U=6
MU2-(^J4_BB/TU@3$EC9-YW^N%( 6O:+?AE&WF-!_.%4,/.]I2FA<<JTG<?:H
MM^T+D [JL/K.HD2!7B@)?F3%,.!S:Z?A]H\.@)64S9%=;5 _YA87"$MVE^"(
M2SR   G_2:#G4!!U]D-S)"@26#4,ZW;[H'0#)=!T LTT[9%4$<U[Q'#GAV=
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M"L$5MGK*7. %X,GH:=Z5#>X+KO:+&L#A?RLVWA\6QLPF;:NYC9*,$^(Z*SC
MDX)7N8T72E<A.@!+W&S*59S&60]LT70T-TP*5"> 0XQAJP3/V:JWO]+2'\2
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M&TZ4W@E:Y;E)KS,,C:/G$+Y]1 *_3Z^'*_.TLG(V1;YA_/)<T\A??_'@M+]
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M]X")@VUR%I:=ZD-O(K.K9.<D0U5U7.YQ&C0W0:.[YXUB0A7-'4WWEV^W(_&
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M?GJ-5%;>IZ*'#].1_+B<)' UL59Q.MTNQ'K:C^W;L'VW0\1CLFLG_4^RTTZ
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M=9SH,9@;K$V'Q@V6RTB6!/ 8D4KR@P%6PU(M\AD^I!"E,I6\M(=[^/62S/B
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MX7LLJ% 2&A5VM:IF)JBQ_&#+1N3@JVZ4J;2[*O/2JD@K'7J(-9'+#^_>7[>
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MN@:2N&'8<H_IU=.YV3)&.^X5QK"!QI\.A3_83#/ Z0_^Q.<$3G^M#@$Z__!
MXM_!'V:=EKDONOIL9HW++5[PL?W]\&X>X.L8@VU<;3E=39"4C?#SR04@@L^H
M0);_\:O*A?79<L84VY33E<O!CL'G.V?:L5'V-#7UT)J*FNI:38II:5=;Z%<^
MJH5&=\+$0]:62Y6!3V4_LX8AUEAQRH)&.GDPG7N1DXL\OI;,^Z_DR/AG'VA]
MB*RO]./[&&G?4M#<:.?5'TK:OD BJ+*DFB@9.S*I!$=KD#7=MT@W"0*]\M@=
MD 6P!8_? AZY=&G!-8*N:=^4FKU)=BJ?EV22_ !Z,U1CF97DB>W,>!C0&K1T
MP6F]"^56EMW@_F+XYA9P8#VPB^1*SW3!D!C"_EI>\8P+7->Z%O1V[KQ"IH>6
M?%-TD 7Q+0/505VZM,>L7EEZ_1[!IU KOA(33A"/U'PC:G':<U+\#:[NB:<
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M\E,&F![KGZ;O/\T-Q;$);_@QY80/SZ"$9O]YV$25PI\QY&O2W8W?$F__7L'
MP[T,<Z3@))0Q;%XHBB;KR=Q30^JP$O.)\N6K5*R='8K<>SDAPO<U F\!3#,U
MW@K%)KIZ(KZ"(%M[^Z--6-5L/XS>IZM_\U')[_V!09UR%Y-0@7HMC1A>(P/=
MYQ5F4$?#R,<U-1TPF<K ,4?WA1_.=F8)3/V@+*FIVK$HI+9;AG>(-4+=DWM@
M_?S=Z-[UU]P]'-OS(*P-H7Y9[SPS"O2AHW=.L64E5/YLO12_<%8GK-OZ^5<E
MO OG.PUJQM:.O\N-XR'$KNFKDL@AND*2^..2SJZ.1T!]27P-MJG_ZL E/E>A
M2>.HU:>0JH:(&(RAA$.=A8"$-7 _4]4O20J9\)I.(="FTXZ^L-?H//WXR;!1
MMK:U?^L2INQKW";[<WM]UL1538NY3K49>:&&?A%(=NQ(C'1A*L>U:AT2-NZL
MHXU&1BR5&EQ;TKL(](.2XD(6!C&!6&GW0VJ8A&QU1=H.OE7ND,CNU$'DR"/?
MOFU=B9=WNV&<Y*3$]C8K6IZ]'TG]0!7KGA#C\C%3N<'L6R+5N?'3A9J*.!4\
M/F/>8@%-78&V<UCT/1U3YU+Y3/#!-4'FQRW"2.9!K+WP^*V/U@'6UIR-NJ]"
M=-8M2XD)MGN';%%]%W?)5.3LQYP\O\"NVT]8I=X*-/ZX:P_#)+<7GKLDUUD6
M>),4IUQR >RFZ>K&7=$[+?",<"B,<J[<35%Q38176_$-5C%B+@/;+"F7O0.^
MC#C^D 4FP^6(9ZA9^-E3VC4B9:^X$)5JW\WXN]H;E:_:#)],!!+)?%'8KPP=
M/\>(=*'TV4-.YWF\!;]C-PM:P3PH"WPH]OV>!L5TOR<!W,CX%N '7Q(#=72=
M/<Q<NP4T?@5O.7K[P'114^#7K-$U9#_DL&C=E'E%]%VM;@WM:;\#_T;;V'C3
M:],4)AZFBBVGJ!GFJME P58<F;U@%6T">Y^;L(%H+^RI[ B%:J9C;#'O8(5U
M\IGZ]=J#,'YH2B+\:DD1$J^B%FFV'*]XW?D\X.65<2TSZ[O14WTR%S_(PM.Y
M:SHXPQQO?;FQBK53[86QZ!19J$M1,=523FKAM?=AINGEWF30J9RP%LMILKG)
M')DLQ"_$]E>/T . V\:N<^Y,R^&H8@IO#$VB1KT9$8YFX*/U&I&PJAX3N$E'
MYX-GB:D/NX\MB>8EPA^7>B%D#^=%_)J(XZ3!>Z5*^SEUQ\1.J<G5AA3CJ<L*
MWV+UZ."G@S^LK4BDK3CC1K(J9UJD^)A3M<5K<P]-_1$:2^)\MX! "[*P\P=.
MF=FNN:VL?K#J5D3NZ!<X&:S3C^1[155-,$;UQY.Y64/P2?E(P6M",%WATW]Q
MY1?*WA=<60D(+O4@3C>SU]JFS_8L0 J86<'016(#^%YA:.=F7$M&O3L,'+?B
MPBPEOAC]N7Q%'C8]]<GNT>>W0OU.>BR'D8@"7?($:SJS\WQ72(GSWF#OY01/
M!ZY_!>*R5P$\JJ3+5?R&W<+%HSOKOB%6/'&7N7;6C7>W&W=SR08M3]=:S02G
MULD<^Y72J#73>JRLK(N$ EE$T\0@[Z_U.EYAKBV-RR(G)Q*O]#QZB,XTK2]3
MD5(9[]R ?;B4$.CGL+?)C4(;-\QEQ$.1V<K2, 6/'H)54E&U<K01[%0\@^MK
M8Q8+@Q#690T5G\53I% K!8AG15Z<,[D4;-VXW@)^/5^X/'HAAUBR+@06 *V7
M]M2@C/A:H2EJ@M-4ACXKZYW".7$MS>0.@X0QK-D+6W2=:EJL^ ^,@XU\7H:[
ME#"+&(?HP6:4KVB#E'\?73[:6XV<[WY]83[],F1:(  C811.V=9H)X)AYD4<
M,ZE4"X)<<:TGHWIS9;#GS2V ;;N6XB(-&U0*HP)"ZB(YLK8K)+%LY3CAXL2O
M93C*$U,0-^9]"Q0G("&&H_4#A>:*ANH:'8/< 7"E=!][34_GHXTH=6OAIVTV
MEY-Q[FO O#;0(]'4[78AX=J"%#8$%09XO[2D?YEFMK+-%BT!C<FT.]'FM]?A
MZW"J,'AJ9S%0MW*TQ(.#NNHM1W02/[VC[7DTREJ8.M:+2T/\7L<%L$#SQ;AF
M\W (YT52#)+N831J'8KX+![F^#*Q2!:OAKR*@3&J@86ZAC'>IW;-/[4F1JBO
M2/L>;O6_4J[(6,4B6RPEQAA)'-:Z-UZ89*$/X8[@^AIN1A(_1@BWT)'3',]Y
MSKZO%T!$-5]R"V@]',T=*5Z'CC@*)+_7H@X\Z5YZZ/+!VZ-LX*TP-'!Q<!I^
MS5J N07]7AN^T.710U 6R,-  'OH0I#/T]+;*R>UH3+"M;![(P^JW3C60WM]
M8;=B9TE;2D:B/[F*9@3'4VI"D+LO%^\07.KT,G  6Y=^$.L;P&I9 =<?FYOA
M!,&4AU&2RR#U:C,HOJY0<0C8K]NNJU3P<R.J5X#.*/V5$3(','MJ!5+=BD^1
M_9&V<N->!+ %O:US]7/*+PF,ZN7U4TFZXAJDFF[?NCDMYK[9/QD\"SN<FVO*
MY//=I]O[!/H9].#-.A<O#8 :B8$_!US1F'%89#JYZG]S_7$&EU8QR"SR,1GV
MSJ X8_)8$]I'A'<KR2RARHQ>MR7)_&\!=WRPQ7/A*Y1!=EV868W@\2[0H>F$
MED#G,X,<0T;0B$)YI]Y^0.\95)'35+!N&$&ITZ4LL>747= ,YIZ@2/SJ_,>7
MSWXK/I\B[EZDR,@81?)O34YVCD-TM:?G8;+=6&7>7>WO16>3CI,F&6EW%Q@0
M7[E (29[<!T9P4"KJB6C:.FB)Y#O1ZZ+$[@!3:2(RLZZF8[\V86M!,?89!J_
MACCN+=(WFD\?3@AT8M &CTARE(XA!82SLS]BT\K7ED\PLRR!=1C'E3NH-Z5&
M@%S)A[W+&(&G883%C:<M=;YFTF]_MN[*V\W:O?4T/_#S-HGGQ+PXH)TP3-':
MJ(H?P51ZCOZL&_#EM/0S>&#^,8GT8B@?Z0%[VGTDYWAL5GT%2F^%#_RWEW+^
MDY!3>0L(^XF$8LN9W (HV6Y,T3U.N((77&Y 7_Z*I8G[WM-E0#C^OCW\JJ'B
MFV*U"\MGF71;?R#QP]K'PD1MZ-5G5J5Y6Q%1J0S$34HG&-E.$+5.N]"^ =45
MD4"RG*C#%;G1 _6C=9E3@>RK"CWAFV:QD;JF:*7WRG;CY9W/?"&*2I($-'Y_
M_RLF6255R,_AN\MC'RY)XBNB2_<KC3G(,FNI65M^KE/CNZ>&_4T;7[DL04'*
M$*1-.0-QJJC&? 2P 'S"<BI:>.3R>4,RTI7ER;XMY %?20EX,>5AR(=WMNQZ
M)PY2\$*Z48>)OH(ZC\<\2:^56,_A_9HMN4JZ!<]"NWNJSDF_26'S@SWR)&Q,
M450@ _I/N$:;/A9B.@+:3SBIY+BD]^4B8)FOT(OX4#UP<4?%.F,K%F;!W*/Y
ME,4KM]$*]0NT&LY/HWF9,8!9$FUM^NQ/*+']_-=@_>^A2(3(95+Z\$WX96BY
M4^P0#CYEPT:9TNS$FLT"80.GAT*&UG17;E!/5H,?EA\ZD>$\9G7U/9\W<-8.
M7=:VYSI +NA>KRR@-EQ'5+_[QRV ]/+)=OI8<4XY^/!#D"5#@ RQS_UG$1,-
ME<L/*_/U7')$<$+0U9&MIL,LUKO,/!>+J:?NJ'$$=(,AHI8DEF7UL3=MM=Y?
MOI\KJG[]6KS(-I\A*TSE*U#VZVQ'_O3 9L1<"Q7O;X;NQP;;?.O)!#>0O===
MMO@AE N/%J,O+S4&">^<-K$YY$;W.4/>@(1T<QIKGEM1[6[Y4OWX<IUVVL$2
MMR3;O6>U#QE\M%WG()O#E7UM-:_;L5L<,E KPD86[CZ$,70V&7N>IS?OLB%J
MHTV+Q8%0'5_51X?LI&*:V>GTI^MJ=MG;KW50S5S(=[\X^!W?FC)]H%<O%RB
MZD32?_?MQY#\<_M3W:H4"16.R?[[6S1:ZG_'&4!%ZQ;0U>>M[?_7R(&@-;F1
M=%HW>$$K_HJSL-9I\)6TB?W^G3\;^[.'YXSX[7W@ 6 M#DM^LI*:_)VYGQ "
M?:>_:#T IKO'49S&>Y1XG#?3SE9Z76[=A[+MI>9I X&7 =<=;Q$EKU PA?(8
ME=:S5")QC&OWYIL3^MS.\+ +IRCD)8K\R /TZ!809W9WC/X6\!A">;Q'>W."
M&L3X+K#G(BLPA:M-)10]2^0?]!=(/&GOC3NZ<FEPNB'*6AKQ7A 'TZ&M= Q%
MA57>I;_2P8:'3$=-Y)+X: P(,/<M();Y ASAV&[AM55[C@)F,8[OK%&ES]99
M,TC.0=5!09"B,[,F6+>CFL:U'U_Q@?ZN'PI0!AQE\4M3'@TA55&E3Q88O@7P
M^^T]"25!_0 #J* P4-@K&#BLBN14$B5(58JQOX+< II"-#P_.XIL9XH<4B%1
MM7LJ\H,%3Z0V#'DILJ38#&:)0^HNH[@&$2@IO9MGJ5<)JY2X!7BF'N90$NE^
M1=5EZ!:P8'*-JB:5,%?#+2!5T_N@$HF?>I@P?PL8+*(\G[X%/*%+P_!N!3G?
M H3+_N"FU^B,L[ ]^Y-5213W%O"]]0#IF?Y'1BJ3'7$?.,Y,__KX/#=P7]/^
MOOXYJC9/DKEV_%&R84.E KS+DZFCH)_VNA(E6M0XTP[=!E+: I=-4?1.<GAK
M6&<13;[!W>HZ",C!P+!HPS91>:IN$O,60_X$!=](^]!%F-^-O.>W1,G75S9_
MC.S^RHY:UIA57%K0*8I4^ ;JUDA(.5'8NTPNQN'W[8Y6A*0?F\S004+1$<WJ
M*CZQ"\7XBO?OKDKT]IT\S4OLO/Q]"^@54+AV0[5N0)?VU!9Y+E)(#E6] QU4
M\SAY(T[Q%>^%D>^8(+50<ED9:SY,!GD?#XRBY(A*W0ZQHFU]86*&&@<JDYUU
M@PZH]NG*R_"AT2?:WBC01D+974K5+(R8:R^')0%:8>T)48XZWA/%7<4+/&H!
M=\6#$F8[S;W3+]8.77?:QKNC).NI3%KJ0.99J&BMM>G2L)=70\<EBW$4^B^5
M)#EA>#+AC?6L4@1Z"ESVOA EA?B@&(*LVIH/*T:J42KU*CZO;TPS0HW)\@HN
M][93[D31LRPG9O_]3A1\/VN5=*^U\NF7!;PG,JR)S3_= @JJKOOQE?JZ?O^8
MZ4S(0[63^D)\CG>K;0&J)S!:3X#IU@U^^U%PCTL/QEA>)-C <PJ\UV*JU__,
MPP8>FW\+$-QKUH[QT,U/*9]!0I2 '#BJ"I2!IX3;X5[0S\Q>%_#H@#_RMLN8
MU2Z>37XG<5Q8_G%6F*/BC[2#E!Y_V58OHJGG@3^ARXP/8'BCP[S0H7P3=E-
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MD^N&H)"PB*B,K)S\'05%S7M:VCJZ>OIF#\TM+*VL;1R?.CUS=G%U\_'U\P^
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MKUSJU^FWFE:&%D'73'N\A'/J]2*UU_2H$\L)&$.H+%X 11^W!;TA'UF>U2;
M!UTC!8H##[T&G6W*7 ?-(A0^5H UXM?-_(3,TAQFC9,NS!8R SSF//@?,MK(
M02OI*HPO5+0:2/<X6(R2^7M#\&M"'5JE%[1F3_]:[<E&:0C_(48+)U$ #W[V
M>= M[]*CI_&)T<C2Z0<)]:.&^[7+QA.XVXT%TP8EP2=\4O_*#<OQ9(?J];CA
M5^5^PUL_]X^=_"U?N>#O\_!DV_3C\T^%U\]),W1MJ?$':>-.#-?,V^A@A<U4
M+:P#J08GE"B<&]^8;5"6S[]:H*[KE/E8[D<7#,/-K6)C=52>1W+LUW<R1;]
M!/SR[.03Q144YR!F$<TM'^9;6LR:Z8(<>5U+\,_>CQE?:U*5E#,Z"G6F_5<+
MP/$KA_*MV*-H#]D0H%VTE8&'T^MK9HEXU8F\SZ&=5>M(U8Q094/6I@"OTKI,
M99;>515#G<D734W(D*X0,\Y0>\]U".RO[J8_SP%]D9?-O*ZY<0O^ CN\6>6*
M\HQO>):$IM6GGI733>A4S_#,TL$^:0 FM9+*J 2@Z:*="M;3,Q]F7'./RJ9Q
M]'53BR/-F'Q!6!=QF=AY<EX8L^CC/7F(&'[_SR/5H10PM&=MP9T-?0ABO;N;
M4$I#%V:C+<371/5C!/8D+,09? AGM]&$*7I8\=O/-OB5G'1SS2!M?PRO_S;D
M8>^Y001<PJ)P<=UG:BBA\1@BH&(Y*YM=.4!@ZR+95\S/6EM-C<R3PI[-*G6T
M,OK9@I@&G(MGK0"/$'Y#"T&JM&YX,.JL)OE48X-QM?;$Z5==K:L#Y2.Z-SQG
ML\T)3N+FEY#QGOF#>:\ZO;OZ#<&>QIW'KN<W(<MRUYH,BT7VI;D\_[I_#DUJ
MSA(@=$8GC&5&+Q"<[UJ3<?^K703RW3XULDKUVGF__!SCC]S)_?)G\W9C\A'I
MNCK"E-WJ.S;=+=RZC: ?W9#GIDUI6^N!A7^=5.=O*^# IW2& 9Z%=E*Q5V.Y
M?^NH?<=VY?I3D@V[R)[-C'(=G KT>F9:?<RG4]VF1SK;>\,#&QJ=CVW!ALH1
MV)^]GP^VZI?GL74$3R) 4SN?"( -BD(?XSJ^F/\.)8(I8V37YU3.4IG;'3B;
M)\J5S3Q])]_1TW8^D^CTH\Y"H%7I<%1XX\Y)KE*;\I^(-[J/8 WGW8A"4?,G
MLW<*=V\54^U?SS,U!'V?OW#I8AS9>?A)S]GA^-A%+OD6J7IM(DRM_>GSJ1FU
MRZH":_,L3<Q%&W!4*;=@M7B+:7=Y(YF*EX/>0G;<(8Q=57K5@A8UH"*G)'*#
MXDGQGI+WK2V[6YURBQ]EMW<J5P=H7;I*X'/3L#U5_U0T$9"8^P2.MC?A'EF^
M.O8WRSH9P%!L9LTS$NR+W Z#$ 69]Z[J.//8OU!\HVCYAB![EB+9%%C@EFI<
M+ICM\]C[<)A9IUZ/=\]6DS7J0^#'C-[N GIVK@^Q6[Y3YY1+L+_M&O!O7% G
M["OM<AY&Q#=$"53;\+7FM<KLX7PZ/RR:=UV-][RW=HX7.]A=FPL^1)XUMYXL
MOH9V\'HEWBEGA8JYN@8L.AU [=]/#GS?;?T7^+T9V-E:18DE EX15. P=TH8
MXEF4E%!_]_!-#!QJ/L]RWML0E83>HE#_,C&Y:WA?NAK.-\*4J*=:?5;#=J:Z
MW7F!&8+!1UF6?X_R<1=1/C%RJC.H].IZNX7 'CPH[I K,?BX/!>7T)2B\2Y=
M-DDR8;M^S2$,RXZ:J"6([C"OTM6,&?..3Y8&B!LD=TNOD_L,LT:;>,<:>T2;
M*[,)FII\R)Q#7J0L5?5_7K>,G8N%]F5FO%16H(,[E6J5B?56-GD5S+ I/YJ<
MBSMEM1LNL%&%H^-4I$P;[;J>#:0822?6R]9.WIPIL0$O^IQ9<GY'E4^]0[?^
MJS/QC"("GC:;F> CBR&V#\=-N\H?L3/.Y'HRB]S!C.9CLS>+H/>AIFJU]]1^
MILK<.[;>>U$_*&]+DV%<9T ?YZ]/! 0N=6 H$GD(+4+C0XKG^-%_2^8T)W\D
M\X/:=N K5=8:O&R(TLROX9! FCC)(ES43?^>&C%T-N/:FU7DUD$:HM^AXU(Y
MEYV0'F!;9*14OWJ)E;<IVB$!JNRH8 "3_O2O*KN&YHO*CH</6;BGUK3YSZ,G
MIJAP$T4H4D$8+\,"?_X+^-%CHE,5O?OI<$+MW=F*X[_**KQ:?$/ _O#IA^?.
M1Q^3_FDHLO-C"?Z/BM( E]J]$$X$4&I_IO><YSH$O9Q')#;G0Z+&=''V&VY!
MYF.O6\84SA:O8^F"$R?VM%0OWQKFEJ+A8-"9K"R-*C2EDQ3<]S(7,=33RX9_
MZ?W:GAC!\NB*0%WNER82:7N\@$:ZD7U9[G4BX)L6*^ZV77G>_AU5E\(9O,YA
M'Q&0TNI%!-A9-(DV3_V-;9FF)EP) F8YPN:$UEE,M/P^J&NQ/*! 9EW"3^?@
MU0Z]HN8&0-7AG?Z3A?TU/AGT6;_!/QQ<U$=S(OB8,E<Q-*]Y?E5M?:*QA/;/
M*1K5)^2!S:Q=-#?NZ)O-UOJ,%">4FC)&]8D%9?L1+,X^R\#HD1"CC8Z&1?9!
MVO:X:1=NA==%%&KZW_"+K;3GM]U4^28>XQP^.BM[B\YY>'/F;"1^U-''#\6N
M))+>=.TVE(5UKF8Y*\9TFQ@JN:Z&K)6=CSG0X0.+\8X=R$N'1\B;I&*EKU4W
MJ>/I>^KATO@VS"#U-Q #/VZGX\S6L+6Y63MV^P>TS>H &CS5OV^N269$=W2P
M=R 8F&;=U96_M+0: &)5E=I08T=PVPXZ/=*3&!LP\6C4ELX"SX;>@6ICYQI/
M55RXM*(JW?V*V[_$2&"@7]I?^H"$3>R9.M1W;;78?=+O-"2;+D_T66<UGDI"
MWAMB"[L:>34MFV.[^ZZEW1_C$;[^0JP 7XF!4ZV#JN\'C8_!W%8YM%)L]:B2
MN^5)%= MT-P/7W!IEA9GXHQ=^C)IUZN-5F9M*&+.F2!JG5\AW3W=]W_5,!(!
MSDU;0A[?]C*/F='#\1@<$9!T$.)QA5 DZ20HNU-; WZ36Y47F<"I,%M;TQS7
MZ7C#@8JG6&S>:.5G-OWY+7QP>S:)LIJ;['O?B2U) 6?$3  &I@#4=(A!TR.Y
MVYGPC>V5T^#);$=!/8\E&O^>W9<D1X.AP2-6!E*%(@KRS40 <PGG1RLMK1OY
MK61;(.K0'PZLV*/N85;J<FVIS8^&R;GC9K^UD7$(C2*48;C2#B[V*%F+:MS.
M87Y7>T.'DS.5-P?C*Z\QBG*HA!;PU_AQ:LLD@>*LV&+0&AQZ9MS0PDVXCP?E
M017'FA*>=>@W)YAO6Z#5Y"[B>^?-X)5F&]Q*M]1E,-]-K-99X>NR_!K$.Z3S
M?,++HFX(_-5JWJDJG9'=,!P-1*8IL"A8&G\[A1OC^U!WB  76C,S&)--PK7]
M7K1>?/2 5&/R ?S-N>2Z?\-P9TC08;]O/2)S*5.!/4^JJ$(C=BZ13>;&]VP#
M'@0NI5,G71\Y<VK;/L_C"[H2.I0^>>+1ZLH>(U'NQ5O%.\2M<@NDZ-;*K6R,
MH^@,DL:GFM_^-3TK< SSEP7$UY 'YK.8MHU%Y$M,4]6M(P0X-E-L BH/=SKA
M,?-T?CM\>-'@,XOI!V/N3QZ+:7=^]NR6?]),;8R?QF(,)JVOX8PRWS0Y/M%A
M>/ RJ.4V>.]5[%*Z/>7U^JSHASXVR1YV<69;P*AY)JAT'CZUZW879GSL:7UC
MH, K],W#X:SXPG(K?#$N[EMF!6)AWU!_P'1\"SX*3M"8E?NLK[B(;A',A9^J
M\LS,? ==;%=@H"4Z!%4,=<+&M_+*#*HK&[CY%FUR<IE<V^U8R3DJ:;F"[T'9
M@OCPA\M[G?X#KKX=FV6[O!5R1  ]!D0S8G;VD=KF3)Q:INCCL<71&7U-* -4
M ^^4C[=\L.=GRZMD"8[AL_88"]VLO/H2(L K6K@EA+-M=Y#&J]8$R36#8?Y?
MBW??/G]&UC(W@4M@!9.0FR%]E&8RW@V.^1Z;9U9.$WCQ840 U7 /TK]NI/I+
MY[23^GCQ1E)^B'/YAAK9^35(^D"W37HSZ=RWE^]=>5[J;@XD@E$V8D$_K28S
M%-U5JA6P^/H'T55>II8MS<-P9?E3+0A]1RMGQ<J8+[YZGGY&XRKXYY/I^M:6
MNUOV]A?@-$J-$HV3JR^ ? "S-[2Y:GUVKXL2>$GQ&$1C8C5 1JDR;W#\D?%[
MB<YF1<UN_>%U(#M!S>M4<<::UVUNVC9+.W4SI]<K8TA-=/3"/7ND:%S/6;&&
M@P7%GL7V5@;,=NK,2^/NRRTBN4E%&D>MMDFG^OEE*<B>Z2SY5KP:#F3S%:>=
MC]&N<BDGU%1'622T1),I5, 6HKOA #Q]5]!YG'NPEVO.K-Q&B,;!4<HLG2$T
M6HN:A)6=0G!JT>![X5!!;NK&<D@7CAMC&;4O10VZD9%$5^GG3=4%=J4*"]\(
M&ZTB!.-\.N1;+F$-$86O)9#+<^L4]8D*= _HFXP14%LM_8&%E*DG2^_&T_9M
M3K(="7;X#I0SOGG!_=FPQ:N3[F%^M"XEO_*1;'!/EC ^I AJC9V/+U>V=I<I
M02L\IMW-A4$^6'8]- _1%IU,'6$\RY.;]K)IK3N1/DS '44W6>*2M.N3S+@R
MHG-U.R_"F;<EYW)+Y-CY+:CD"+-^B%IGD%_^UR(34JWZDX#G3N"]AEBAL @,
MQYX**>=;E*G9DJ7S="DNM0WIN<4J67&R5+468 .)L+]V@W5O),$,"X^%DJ.D
MDFRR:CW1I=:;!]S/4O3LOQ1?4_/U K&;&*PSZL\,@UGV1&H#6)N'$5!6W%1;
MZGJH-':RO*3'R;'(3DD]5!532L,7XI8=UR**9T;UM'=B8=&RB*GES/N!X<M7
MJ)^FR^(0+.<YU'/;LTT=IT;YY?WP^=Y3'S1]UPZU/;SCX"N.M;'\8Z>[+_\;
M0BQ@:!V. <6J,HRK*JPI(EKCHSYZLB:E2TG<A0QX+ %E<?8L>2\C_#WA:*;O
M)0:;%1]/@,%03?S40@R4NLQF?>[:F+*>S,A76RU/^AU*@?AX+Q!YKZ9NES9+
M:MB686[#BY\NJ%23@/J^V*X!EK$41%)YZS/@ZW-.++R]V:W#?-*]3$K0^1?-
MX)[\ +(I^Q"*D\M S2<PN 4E+,KYDUIS#[]!:>MU!=*RBM%R#\ZC@9-++F)0
MH=D@^FYC*G5<8Z=-Q-SU&GM)VSNC(C::2^F\D<_P0NBI2)E62OR)B+(ZF'QP
M=F;GN?R;4=(F1A"SB=W\+RSRK)4,?FI40"@ZL3T$X2=R((:RL_2=4^ZNGL4*
M3YN]=<UZV]02 FP*.^>C6RE".==/I*+]=O"Z%3M('=WQQ6*/>I6&J:Y]B]0V
M#;/EQOW;48]-&1[HV?NMATQ\AC[$.V+H(^=X$5.(GUO/QN)-WS_JLM/_>/G6
M*!Q,!+#M-SNCIR*>8<OBT#=TGUJCOBI ?B2V$ 'Z>#Y$TRUT@G$;\CM71:KW
M9,8/GL]Q)TE!74NXQK>@D*'7RRG^IK%K >-G_-C0=Y_H>< GB(2:/+KB (93
MDT:-R@HEFB,X/W:X<YX6#VMK41OSE&T$&VJ#!^"B3(O23Q\]:9*R.*M0Y7=K
M>%KC6:3.U!MIH_N)JM-WPT%>>=1.?[>_:_&9^/>@E*#,[D12H_,+/*D[5^-$
MJY*RLQ@27DQX@CW(WMQ#;5@A@H.;/8;[4@PTCM^D03],F<%P0!2L<WJ>!I]+
M!'11?YYS!3:?,E>:-?*\$D.)BA6>JG(72Z>>&A5:%20A]D%(<'M01H]M7%]%
M9$&\>,)GRZ_8LE]]0M-SC=ST,6K4RDI@=$X!)/WGS+K2<@8T(LK[\V,(?#A(
MQ$"JX-"=E6?TLT7E_1,B8,&X$W99K=TPH#USKIDN67EO./T-1GCE56$S-!]M
M*R8A[]",&-O6VHKPN:UYD5[3XWY.NK-.Z;_*5]!3&>+ZF>' &)_1SALTHL4Z
MZ47.8G+W;R0.VS#;.',5N8#8-MF@#;W- =N\ Q]4#^&U Y (@ NW[C-J >G4
M%C4N:KFS0"TBX%.LV((;]/F98$8;\!Y4ZO0I$= 'JB,"*L0<6!TV_L:"7"//
M+ZG0O[S ZDW&X\*YL1MW7L4*?R+]IY39+Y.YS;'D*2GO9^FY_>J%86@8!+P
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M!SN&=H6D^R3EY6OU']7P8CV[S_EQ'VQP4_MU^WNN(=<9KRQ9?N,XIE/$3+6
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M# \L7UP"0HYV(;)8VJ(O+GSTMMG%!JPU*>;+UBP-,K CTN!]VXD ]OSY>=/
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MR(!W-\)4YC__P=OL9A'?>B/O;^57U)QW42G$-]J1KRA/>IL1W=* R&)NQ:3
M+@%WH.%Y=G'O'<6XQ]"@?:OSSB90^-)]D4M A%ZMLAV,[5Y!/*>A/IBBA**%
M!6FTQ:'VO(_]!AON.Y<DS:1?Y<96Z&[I=#]FY.NS%L.\N2TQH:\/DZS]V9;/
MIQII5R4G"Q =^]0RM1;,RBC_3="X4VIVK<0E("526AH\?K3@B-!](]9 /?3K
MQJ='(_U^3*4328%G?CV[1+62SL4C+]N8!UHFO1;_8(G_G4,Y4>Y%J62_F6KA
M/'_VX]=^;T\U'_:'[<9K'ZE_;>9-A8ID;B.LQX*>)UE<5.>Y"?;\&G)OH\+
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MF8R5/ZGYF:@_P?^C#OJ>$^[M/,/J@Z@(M,,L&65TF]T<%>4MGN+><])6E&<
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ML[H70[""[)F;_6;*STD./@)P5:")HPI]12S?<1X:1*Z*]IXH9P\3JPFV4>(
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M%<43./B&K6-\#K,@WX8'&8"K5'B!6+)I) ,:<^-(+,N1B)7G__BCFD.P=L*
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M&NQ-O>@_7>!%LQ>;:^%$WTO6>^]I<_&OS1L]5,$4VOG,%ZL[;NB^0T(=5EQ
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MOO+(O[!'TX0.Q&$+X3$S9$"DWRTO!]CW%2_CCY95T>?6=VJY X%FDX?7?]=
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M;JG [405OG2H-2*\-_F"0?CG/:&/&AK][*O[2(MAX1Q_H$GX!O8W[!KEP0P
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M83#97<2&->WD98X ;8*AV7ZP1KSQ%SO)]C $E!G55M<HE"[JLFTZG&%U5Z9
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M#^^K]M8&FL-WO+FL)]!]OT5I<P L:=$U:'6JS251.OV*#/ Z:P 2>S?>#\_
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MS!JZ9TA9-,(>%M+ CA?#;17,ZW!W6)BR,%I+_KP6^OQ<L:+FS7J.*AV;F=!
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M/S@"<YN+#4LE+6P&R_T\WZ5O7I8VGC+Y$6/[[,_-00;A$L:C6_7]>C$BIX!
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MA350E:('?@]RA8G&\#BMCWI$N];A_5;&EM9V2-]I_!,.O%X=C3UR?=[]591
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MLB.7G]K@AWR-0:+9,%6A<9Q?EZ3JM$C=.Y9EZ/OB?Q[IX0,,V6V^>".)4YI
M-\5NOY/)HG.LU^4O2OK=)<2*KZ76-!XN=%?%)*H6M/4IAP=WU?IZ("?W.K;9
MN(_$2(W%8N>023\A^6VW4+4QTP]:34<ES7/S,AD/.,E6;<.ZO'U\5SC>?D4P
M[F1<A4OXJ?0BB,JA(\X6F^9. TWIF46SH'PA) \_3E"82>\ZGR[\Z&3)^(KN
M2^4FP9\@S958SBU<*-S-'R=/\P@)@BS)]$EF.\5]MPT>?&+EF; 5]*PZS7+E
MHI_CSJ.'-B\LSZ\UTWL! &JHG75+&+R<-30B E2#^^LC&=/P-]$'N8V_NX^E
ME7L=?"68M4.X7]QZ\=K=Z'7.;@G[CQRT3Z_%<V_=VA+."+'B_]+D='>!C#&^
M8>MS4A*E#DK5%0 0&Q+^;FLCX5%M;8JN^8XBYY$/SRL_&46.J)6V]*K$,+<H
M+T_E7\8;Y9E58;TNLI\TE%!1[/[H)2#!'TBVOIB11Z!X]F(62(>U ['O.23+
M?Q7*75;O#I>#S%S5&^V^%WQ3\)>F8SOA-Z(MR-]9G88(2%;)V]+<'$(74^V'
MH*+R1UX99=;VYP349*A'G/_$ UHHH:1V6B0$0H3(TY0SI@=C,V=Y-V7+6<%X
M=@GFX"C.N,)6TZ^,P]U(*3N# O+M;7-_Y=AX5TK&I/= \B\_->_@/QB$+XDO
MO6#=(.[JT0U2XT]ES4KL#=./R)OHL"OTX>=. >+-G3>/2#7!W(84T.')0E>:
M;96 NB@8DCGT/\6_!Z4E&':P_$-9$&]TZ4,ITVGC"_X\2&M6 <CW_^960<R:
MXS<.--#U]0F;VJN]93XMN.0#$TP&];RC=5_JP4#>@O-H QR<A1@R'SE3X5*4
M4?D6U:'[I.D&9"&/,+-XT*^C<2^JN!##'.TQIRV-3M^<RK\5C++@>X9*CO>2
M<1MT0G?#/6C<)YO4F-4W]TZ6;881/^I4[+-. 4/6@V>_6$[!/22?[_2));@+
ML+97M[-DE39RM'A<NZ=_HT]:X(^222A57(H!,82Q/P7 C8'\,,Z5156^UUNX
MO^L>5CR]Z)B/8>DRTL-I[A>\RE+N-Y]]*;$I]<3@D6.I*L9UBHJU2;#SDU(G
MVP=YP H:R$)G6B6TW^D@VH\WM^+->QFV45]C2>!<KH*7R4-+F*]^Y9#4$N=^
M0T<GO(@[[:[$V),U73F4C0!ED?P.%X]K]WGN\B+>8F+2>]"U/T]C+H;=7K&4
M6TT(-F,XO.M\:>43>,A!"=KA*I_'WIF7KD@0SP)^V>TMZVPI$-X6'E)37%'2
M+2M7*\A9X<W/@)3T0>[G<0XE]=;1<ZM4\*Q;::#)>??V^"CNY:PSJS4I3FHS
MWHY&(CQ\E4%]5Q_=,'E+L44BVFK(KT*NL=:L*'VIE6:5AHK]N=2[]DF\F"+1
M16-/M:X:DI0]/F;^=%CNXB'?A8K+N71V9.08&7%$#P)'@D["H3&KYC4CLLP7
M=VQ22+U28^OS1OI\_*X6644M##"<.1D36EZ&;E:SN/NN)44$+&#A&M)U457)
MV#G4AJD<SD8:K;./@5S:=2A]WMCR(='&3: Y5*Y\JZ0=/QB,E+-2-JH)D*1-
MW=NOO=I7]SN&4&]#O)4>?D):/O#7E)@;(]>$OBVAI-A<%TV3_- 9DL"N37[U
M@\YXT&!@W1J=:ZGCG?=WT(4KP45$?%OS9/S&-: 2N5GS)26V$(9?TL=LC6>4
M+->,V.O60K4,%$?=/2U=3P'6B>ORSK))%>B.=SQ_G\#&:NF=YE27)4,.[IUQ
M2^O_<=D-'7+3A@MF:S(J>PJX!OLERQHL,:=[;V6$K<A2_#!U9^?FX!L?T/BT
M.#DF=K9$K%RN\=_NL98(V^6\/ZW=^7J.AYLT#B>T6FW)"HV'T@?-,W4$,;OM
M^[H)=@[.C>?!0;0&9J@MGG;-:MH:IG;7N>E^"UM:S]\1$+?^R88J!"T@T7<6
MD&7M[9[CUMSC*B[.) S;@ 0T[A*8V^,7TQ#CWDTL\N#V1TD7FZLJ=B[$U6;A
M5]6@8Y/<;?&F3X>E65QWF"9Q$%/KFUO]/M0DM])ML^F_];#[PH!O/;^X59^P
MA[QQ%%1*;R=B(8_;Y0B)7V2"*I35^N,(@HE91 '/HP/#<?>?&J8;3NY+47[9
MLA/\2O,N$Q%F*G3@.Z&O(CY\->/X(ZW@G5KK_6-OT+&1B+F2'R"YMNEQ>V]]
MKD3710Q0,_Q96NF-_B1K(@8Z&,6EQCGJ/D4OF[HZH:/IM=2%:3!@G?JCA(4S
MG.3?/V/O('_A4=8O:*;0X0V%L*\".$%;=VME4"$-IR\,5ZU^%V&Q/APUES)R
MDI;(&NRA_"%:+QGF>DE@E'?1_0'KCRYT#@3?IPL]7/&KW4\RO-+(^JJ,*24[
M,:T>WUPZ'0[V*(AKI<J<5#NKW83][GN60*25YR'_K$U9WKST_<).-]KM*'9]
MV>]MT10^-B1EON]".>=>= 7!-"HVN45B]1LZ@&\^1$XMB_[.!+0ZH[HSXX#>
M]?B*GK@UP9I:F)<Z;XTW%K380,7'HI*BK3?V6QK \_ I,M-^>^.67$N0..RZ
M\2@"?2_X[]6BD]X[?'PQJ#X$@7>!QN&8+I/<>I1[\?>VLEY%3^X+8I=7C!+C
MD8G."R&^+(UNW1YFF%Y7M M5BR1A<WD99J'\[K[<M<_KBDM]B@(OROK5F#C"
MBK%(!T+52/].B;V9Y!65ZWV;MV][K=\N;EZ'@/.3#]/UMPSW"UK&59R+^##G
M5RJG'3=V3FJ>O^5WR>8TXG>?VRL)/8,_C!DCHJT29\$@M$(X!827(]TM(/(C
M2)' L5NQOZTBJ^DUE(PQ%18L_H-7U1KIW8QRHE(/2E9I'-NJO-XM3WCDJS >
M>7;K=CGCFU!GCP,A!;C!2<4&30 6.*,;V^I34UQM]L1KB9 EGJ_^I[W;>-.2
M*P(!\=XK;)(C79^--AXHW?XA6\DC$\(OD:X$^KN-MZCK_YICFY;(L23$ KV)
M:](G14.S3(++_/L $P\JE>;(Y<I<FFP&N>#B!JUUNVQSZEXE[O. C*/1HX7D
MXR'S/KS.=$L2&M6\66#;W\))FTA&L,%?'+U,/S^&RK/0*H,??[OYJG.JNL 0
M6]\G1?BSOVH<.$+CR*\+U$J2DLYY8U>9T6AC$6DJS//"]MG*5?U]B8^G@.XF
ML[T)B<:)=]X&^_@CX=AC"^']ZN1]YP:LEJ^6PUYC,[IY/%VS_TRX(SXV#H:V
M/&@<%MZZ6%Z<2V=J99$E]O<U;&XZO^ZDHFR68@LFS5 >[WU((NVM ZL#,^2>
MG@)XYK+*<].Q4W^LN2?2US*'H&_P7+VZ.13/*&-Q[G0P$))#4"\X_'X*<'S?
M\N<;HOKD'^''L9;ON/DR5*HE=&"&!?-1 B,HX #\O =]>*S46]:=7G#0B0B
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M*0)P]ZY#YKGXLP^Q_*3*,]/N"V0V0U77R;!M=[%*G@+&RQZ2]#I28Z_,=$/
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M*N$X0;7FC]9M='B^GKC):ZN'/POX(]+2T9%$9G^AZS#/=H. 6I&M$J'7+CW
M:/"T)1/DT:*JL(8;Y<KXM<BH2?/1V:AOF;DU*CM$,:X&7)3'/43Y:(KT=):&
M!#;:>Z:UD)'";J4@Z>VEVC4W^3 -E&TR43ZGY3FR,=3-3!4Y7CT(-;_$CC:A
MK:YYQ@^@,_H,"*"B3E>%WV5_.M)^QBUAA2@OU&1R;1>#-*HG_2[$"RU%[*:!
MOE-YXW7U]Z:<'-[;K//5.,S#72,\ ZPSTG6]*5P#NF.T#S-]!;,^BGMK*\7
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M8JKW*XE^SL3FG[@ONWG#LN-Q[1-T05<RB:/'B\WB918KSSVO5389DRR EQQ
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MD%$@?D]X]U%?[]P[N96'JE5./)0&B9D?%2FH8,"(N]7L0$U)$=*#\[R^#_;
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M(5"O=A0)KY34]IGT[EJTL#BLN&CTNE[!<G$U[1A,\Q/[EEJI:ZD].#H'VHB
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M\(\:X_]1V1.6_]2XW']4-D3^_]BMXVM?51U4RGD[7FOLNGVF?<KUMW?_AVX
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M)!%J^J_-TO^-7,04_F?! '\3C,)0E3G2'AX4>F.E=E4!VMQ<VY>4LVZ'%C'
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MD&7.*;T"S0D9#F-J&]S,YE1QPRV#6>5P%?CV+9A0@_6*?T,NG48]!O "JM:
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MV F0Q %PV8>@PKZ]1GL>+1DGQC:<NG0KY[15$.**@A7J(^SW<C,T%#K+*=E
MQ57J8;#UM>@=AX3X'?(KY1]#E[5WG4^T*_H-R[22<!'+#Z;:_=_>K!3MJZFG
MC3QG6-Y)Q-\16/G(J1E4DIJU?*@L@W[O >6$C72\<I'.PG^]WRF3Y=RLYM=
MGD_3'&-NF5F??A;3CN=:-K\[S.<&N>NAUY'^*\WJD9U<R/O;VL7^SH1?R^E0
M1$XU!,.IPQQ60[.7%[I69#0U)7#)1"2GQ5G>U,YIEF+Y(W]&E'D"YM9W(P+;
M^?VV@53HT5F !H,'D_H#F8(4I41FFUJK6&^_>@A:S!>EG[(0  O$LU.D5/EV
M70_SYO6*3W@C@E(ZF!3WT#ED^*W=!*=93F?GI]U:(=L$=6,L7H_>-F\*1$?
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M*MD63!?23:""(W8PIIKAC+J/JNK#__\OZPWKL7":1*VA9\7FFXY/M&']?5C
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MRR\QI%"R8,F\6]&;RXZ#IH2%$-- RX>D]Y<PHOB[.WO-U1:0'T]FP8='A5A
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M.D1PBO=SW-?HQ$@NIE97:%47C<MF,^^SO@.%5UJ1"T3.YETTBS[PV1O8_EE
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M@V=.:TRTE!L6.?M <-#!&S)_+@TRE*-[!(#>I)\NN5-1IBFGGFZIPF0,?/Q
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MH*NM&]J4QQSO<>M%32R@!1)HI"!=Y.%BZH";M&8,2([.3V$D3@ZT]/P,7":
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MQ735W-,EJG_=:GX5=1'10>: 9U8T?A6 UP=V#IZEK'>3J'.VC509U32[*8B
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M90@2B-&'(,CB<3-GKE>9+KYCO>Q'E/[/<KNIC)]K7YGF:5^C1R>P@$]C4EA
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M%"[%)G$_5'RR^V741.U-ZYX@R,I:=Y2T"[NU;@H7>:&0 SB_2N\=@'Y6[-Y
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M_".0H,HMR8?;% PW;[!#]7(SNK@Z_9?G541(S7MXT" _+'GZ#:4C)./Q-[3
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M)>8=1K[<IO$0M]DW(4^-:I>"Y(;RXM'$YI^TW6-#"H8S5L4L1;<Y'"SXXSS
M41-$%HS+N]<"!,:O<?ZL="X)WIJ\>?;G%VK9G)6%!9EK/(Y 9H6!=2(U:M6V
M8 R2HDFD'F51*G9_W'N&P-]K/8[J<>C%NMC;9;1C!$)^2=_6=FY*F+&^!4$)
M\(N"L]-9@V!LS8-'5"VDL.!"\\X&W[1UN$S$Q78_@]-76? #2U-,X:[J,RGW
M+$]I7BQ(D[&$+RQP_$U,&-DM#+\ED3JWFB]K(2J^5[5N;W'G9HISD^29(%,(
MXLBX2MP[*(TYU9U"LQ4(Q?;.I\*]F'R7!S?QF#;%2"]LHOISK&M$_[43Y)U8
M0:*+V)H).W\?.2# )>XG)R<[+[CRLOGYOS@Q/HZ.T6UTJ=2;Y:!I)Z2@M;<-
MF4;0@0++A$:109"PL5NM"D+K^NH"]Y>IK[K"+=Z4HGN@J\IDC4"W(45U:=R;
M)G"_D11]'_F7)UO*OYR%\@B;11.]_Q)DMV1)? /?M8@WH6#6O_-J ^D:1!,W
M#@F@@:E#F%P?S-*HS<5=3K M/))HSN_BD"P8]8/M#6[+SBE(_,@?\%()"^+>
M3_I)&Q?X3(7&C:Y5_--X 'ZOT#>NK488#95H\,2B_I%3[6$@- )0N[3"\E#\
M8\Q+X0>CW1I1BI6_(->,W5PTU]7-A50#%?R=8H'O29,1Q3.3)B,"8,N/Y_!B
MB?P,'AX\E/_L?J:_^S^8"9Y$1M&<9PHCI I_VD.$A;J$*]@C2E0%TAA\#I^!
MU^B^1'ZC^R/5DKAC)E^B$G2NP)$*#UKUH2R?RYD$IUG5Z_CP=KS68;OAU9)>
M[*A=WI<(7&]A0+ 'B "[@Q[.7>!ME,L%^Y9>P-#V8T(T%RF;@ \^!;\T"(#[
MC]#_%\UP#J \CIYP01J#IV9<(8+3<3"%RSKXJ%_+/.L(GG7!,Z4BED3'4I )
ML@['R8Q2 T' <6<2O+$K%D#EUE16S0=/?,',O0Q6RE.@,MJ)@^\&#YV"BL&\
MN?E#U@'V>2/82W#W#:<2S\U8@M-QX[H3^Q6FX^ZR8 B!2G)K&HS1'7[)&1_C
M-O".4DRXB:V32VT:!THZ/Z(+2;(ID%4.?/K]+!"[9BQ _I[;A,"=B(>W?%H/
MZYU=\ U!H4W50M$.-&@7/=)P,!A4@^OAM&B*F4X\HT0;YR^['^L<3%.L$RJ;
MI7R>CT-QF4!='=:JZAYW 8G]X#KG25)\MQ=9N):-+;AIXTY[F.]H(\?XMIOG
M<[L]J=8& ^]/5D%!!T#HUP2$/@S'R(6^+I$PDIQXW&'[2%2$G*'MKLCYP1\2
MKG,^6..24[*D#B=\TPC,]W%V?KJML[-9+'"W.0EB(K"#_H8^7K&!XS$<LJDL
M /=G ?/K9JGKBL ,#((<S2(D7NL5Z:DU&CQ:.FKE%"-2\9\555S #DF<$LU4
MGP]4^J)P2^-CG8HUGL5PB.X8P#6^=4JP6<M=%=KG>X(78"H+Y&IA)_QCDXOL
M6.@D4+7GANL-[@??V\?C-YOC>D-G"(MJ"BR>![V]HE1$ O^\ D):Z)(GI5F,
MQ+.#[<(D%044<36#*^[)',-(%UIOEE*/SLP<WLDYK"!S D]B;J_*9J/HG'8%
MGL< B49,*4PO(&QUH,DXL;(6B>&")5B3ALJ(-_O0:%+^!V<BT8I2U>2#XXMS
MW9!*"Y?/3MQIHIG.B-7"E"">G!TLI$@.DQJ4I^*,(VW6*EW2(3TX8R"[1$$I
M;*Q%FX+$8'U9!@X;?J;+>+S;R&+[=![/E,XHATF9!8K->:M\E45.*E_<EZE2
M2K*8.L73&0X^P!9]@&=;\@%^=0O_'A;^E!<^\ ?N&O>'N<V,TQ2C\IDX?//@
M=5\]-K>S#>.&,V6*D""F5;'J8]A3PME@]HM.\:SN.<)D4(53\PFK8]U],(M>
M5Z)B(:OZ1-$1'T +F;]&?& 07/T5L?P6J2818X9.&8-:<$Q,84*W$Y!#"S[<
M2U=6A%"@+M74)ZT7]$*&*DM5V5^43(!GQ[ZC+576$K?8U&2&0ND-1^R86+Z"
M[P?11=S7T,!*MF,DA:AB2=T8,&H#^R1\4V4MRA\_0#XEN>'$QL;5O' NZ/%G
M-5\(RJ%%\L+YDY3!)9QMO7M[Y09U[GV]NVQ6Z]ZOK(/J%6-T/5F&<"N733 )
M2MH;A>SCZ&U=BCQ!PFP, EJ=:H$0KTB3@7MD\@2&9#7*>1%-3>H:0>#UX$T3
M5,XGQ*E:_)-N>V!^&!Y*0QX9!6<ZF#T95M(^4-6OT_ 0@BK^%,0O@LG![Y>$
MK)M6E&OAF&0"FK C!  C_(U<\AHXV*#Z' 5G)L>'+1Z.(]/CL]![523J3X8(
MH))-Z\KM76]5V"22Q\EKC''>"3A"$[J'OE!IA81=[7D3@!Z^+N5*KLYGWD'U
MNXUB'*6(ESLG[FFA;4!PA!&N!C0\?#9P"9T^D\MK"<XFR =M-92+G,)S=6#9
M.CIF&$AG8H%Y%CHKV$ '-&K(G"NM3E2]/QSVKH)SV,!%U>M"ORNPU5N9XGH8
MW95^^J(- L=KD(65DV*',Y. 8REGM?VGC:J:(.K9 ^OOC[HW/-EF@/7I^,<?
M_MJIXN[4#)#WR3[NL^?C@Q_^^B5U]>VZAGM4KM!7E+]ME#[Y@<^[)57?N&+A
M6TS%GQ48#(W&@H"T6=5 ?XEWMN7BLT%:!VF]9E$GC(F8?TJ[/?$<2$I6KL F
M--6+\UH9WIC0K _UR$>/7A?P/F:*?G3I&W-(IPX=S[(\S<^7X+S%X%%Q4)$*
M%[# D>'KZ#8C M\!L(E;/9_6HCF(Y2"6MQ/+ '(K))0Y'& G<-P-V1D&.1OD
M[.9RYH^H<VTYLX%)75,XI)B-_L@-#.E"N@D,\C;(VZWDS>9_Z-BSZ$XK2G!I
M15%BDK>4*DI&=3F2_R/VS,,X[R"#@PQN:F]-](5.\P7[<K"[*EL35]B<^N^,
M$*]=8L0MJ&8>-2J>G=N(V'8^0R.@.J]L7)>/$T2[MJU.U!G\[FZQ.\CV(-M?
M+MOA^!=6[TD <P/MM[Y,TUSV@7*G")U /1M$?!#Q39EODR'7-F<&$RT_@[2M
MB60.0C<(W<V%KA:HU, >GF"%"3@(,/'S0;8&V;J5;*7"'"55KMK]3N!.U4KE
M#\(V"-N&7#)5@1G+[6"_!I&ZG4@1X6/L^P7.U1]XN(5C+G?F6"-?G5+)M?@*
M*FK[FO"*09R_0W%F9%O)T1]'-99/BCS51<QMUQ&#Y?&T+D[$T%^+/2D'DSK(
MX*9V:41C(EB/22""0#G1N0V"-@C:;02-]VJN+" V!!:\0:P&L;J-6.73*7R=
M#-74U[D@+#UH"@_3:@GE'% /UF&6D!MKD,9!&F\CC2Y*7(1A8MI<J8)9(_&+
M6E(.<!"U0=1N(VI51H3+T3GQ97HX V? <*O-%UI(O@91&T3M5GDPB@L7B]2X
MLV? LRW;[R!C@XS="J[E^PPLB(=<"XEXBRJ<,"P-R.H<NYLW&=\&61QD\3:R
MB+7#N:/93U2I:D9\9%"+9PT.\R62%KF_FZ*H0E[+00('"?PB:]AM9=6R>^#L
M#0"G0<PV!G"B5CI(F["HRG9GM$&Z!NFZN71Y3ER7KD5&'&_9%C8_MVI^#9*9
M\6HYW J90Y-C=A73P/YFR!PV@)B])OG MB@7-C(1]3!ZU^.:KQCR\6ZK1'GM
MC&Q4S39(//%-2$]NJQI(MPDV<-YIT^>[&V)!CV<KR83$7TA(A$V*2)R*,L^I
M ==$$Z=64$=;$Y?/58G4.\@NA"EXV 7394!N]8$Z14@G&QF6ISL)Z*.0C13[
M?NF]R7(/_XTFJH";GC-MI1:6K3SD^!XXO;\1I_?3@=-[X/3>Q#;>8H<[0Z,R
MT52<I4Q"/>68K:G*:&Z((#!;!F1*;8HS9WD:Q%YPZJOF6JB82F9"H[:64^S4
ML;JKY0-CP.*>H]R0!&?QSPJQ*VAY"^;"91;HJR>7B:(=RUQCJHE,E?C%<FY#
MRJW>NWQDW)Z".-BED>7"&J1O6""=,3PC"&&V5N5;<>B&!*C/]L<_++X*O^H!
M/>CK,JS^L"6&U9-,);AAXLFFYA'< +WZR?1*VE[DV*P?#TY*S74X69(^?*@;
M99XRFS,*J6-VQL:AV&@LC*MC^P#ADLOA@>=$WN;X.]L2'_;N;>B,F<]U8A1Y
M3DR/*"35.II2V:I0%G958<3]Q<"UXJAJ0/F=: Q3*&E%UN@HFM?>F_L,J3U+
MI%LD]0--1)7%;D@)\\@S@>@1O6K-YMP^?+Y3QH;\D*[Q,U.""LVCO]I6*<),
MPF'4#(Q(WTB^Z9-GV)+!%D+QF K"3MJQ!BOJUE,(F:_!J\^?!I+0Z>=,.Y#G
MI+P3AN?ATCH_WY+1^3@#C=K#P\LH^KC0N+,1]6+8+G%##1!#\E%W7M*)5S>0
M3/0]J&$S0I.Y7.V33LT,3UHNIH,4N\J2GC.0V2(HP;<TF?18JL)STB^EP1/J
M:.'?G.Q$\.YA6]+&-%##560*K?MO;6XE>H:-A]&@:RF55.F@QZKO(MY@W831
M7K@N54@P[R@!5D?#;KV\(VD_6_N+[*]<6FSN3-:]D( =_O'V\:E'K]]LXB:M
M&>GN(0V"T?L5H4:[M]40==,6MN+$WSQ^O:-V[UCL6L+45ZLCQGMXX:A)*"%-
M(T6@K/*JK\YT2AZ(<G=0<8QHA@>3UOO>Q7IRY\0ZU0EM2-Z%#IH885\#D(H2
M'==!!!^(",9W303)E7M@)47?NY E=TO([AHYT:1:TD&?&[88ZGA02M^H-)4&
ML%G&;'7-,&Z_YS HS@-1''VW%.?1Z_#$"I.*2%P\98=':^EJCYYQ?I6'*XQT
MCE*$ ^I)E"^D-P\U-QNP1@]'H*=W6: I!$/AY9FXP5VYYK#W%P.2&KE5+P5D
MYAYM$)DRQ%O#:-R++<5;WU66I.6T[C2[@?#J.^JD:>;<>Q'^'0DHA-J<!1F4
M:H&=T7*0!,I!8AX!AW-I&#V']83ME,BHDPOQP5N.W;+X^\Y H?Q3"D:E:>M#
M>("['^>/,IU>W7(I*F9XJTDC)HH.D/\81U72IY@<N5XL\NXDMK\/Q?IQ2XIU
M1*EQ#)Z#=WZ:J@QS"V?2DNR4@:%%=%K9HI(^@A\J\ $.]B<_[!UL0 7?YR4*
M'*8NZ)'UQH#,SQJ7AIH\8N,_&!EF$@RFT$J17\&6J>C"Y"EGX4A"31&=2$='
M]S:(S_@Y5?$G! 9P&I'2(ST9A*#%HV_NV"BU:RAWLSLA'G,6,I&NM]O"3:1*
MP.'BC6W= T2IA2F;>\!A5H..)U[Q2%.#Y0ARHKV]L7U?["-N8G_PT]-G]Z1I
M<SCTC;5N'D=',.UKUVL.1H;DRZD)^B[)A2)&(/@9K2-\8;0:64)B1[>9:\U)
M^$[N"38%,Z_FX/;\61E+G%K%D$*YMY[WG4NA!,W"/=B?H"M.?DE(36V>'"Y%
M!0938[/-(=SQ0&3TSN5#&-GDH4:(@@+W&NL[8:_T]2M1GRB#PD5)K@E(-(H$
MA41N/;)G(8:93YURFFQ]?40M.['C+#OJZR$^:H+*$.[^J#HPG6SCZ6DK'X4:
M=TZH#(5;-WX3_1?%G3RY+@>W(G()XIGF@XF^4 (16]2G'W)"W-Z_]T.TD\#&
M$2.S)]TVY\U'-C"3Q6E%ZFPU-M>%40I^+>L=)KHR(.J2<BT(5,]T/L5NT"6W
M?<#!??)270\JM>/A8L&B$RC7W6*W;A!-37NY,;>MT!=OE"JU]EO&\^-N+7.V
M<GMG4<'_@*RL*Q0>"@&^8B' LZ$0X"X4 @S;^7W:SN]<;KEO6W&'*6.MOLBI
MWFHDA]NY5M1'$8QQED?S/*%::-^/C*_G7PG=YT)6'D&WTF.E[1!NJ]@C<)#&
M<-LAK]?ABVC_==Z$=PUN[!8\'-Z)[UVU[EA&?8UJU6Z>Q'/>Y#GEN,$U$FV0
MT(=$BDCW^E+Q[$S2EE"F+[_&2WTS1 "8&ZXMBA4%UXC5'.:G-.EAM'.PRU&T
M5:7QWL]&*^-=<':-";^%OO".V8U^VH\2\ -"P''"N5<7#NHXIWBN,$8&4%[F
MT:0J,!Q:M._4+%+H&V:G-0YC'=_!)( ;M_?_T,:Z7_[IG6MI%TYQ K+2?<.\
M5'788*=:<'D+.!@4T,(@XQ-Y<ZZUN.*M.0,=[3P)YAU-KLQSI,'=SY<::SR>
MWG1&A]C% ['(=PZJL=(B8WD$S#M78/30HTDAO$L%<%XN3]EID1P<6"-P7R0'
M(!\G6$J5AVH9HD>M7G7?004>B K<.7#'2A4@+YK<=9+3B<XTF'*CK*_!<9=C
MJ.NSMC$FU0D074T*_6>EJ>7;-*UH8T8RN&B67X[(DZ=$N:LQAN]3H,A)?4V8
M'^U(LGVFT/FW>74.NA21^YXV3AOM,4DE@$WJA!N]*;R0+_B6R%C$3> ?3C?/
M[UW'SN^:CE59BMY?#3WQ6<G5V4>LV#-E)6?G2ZH7G"DJ;IN#(V@6:4=OR3F$
M8S!O/%A-3R=G4[ >2^_P.M=, )B"[A\DHT?M4S8&<HDF@% F=-MN=%PX6?"\
M#A: X[(#)/&A:-3LKFD492X:YM]&#A^;!U[;2!PQ/!B9N92*D^SWL$.&_0X0
MQP7/B%$GTQJ?HOC,Z:K85?=491B;E6BLE_=\22%;$CX)2\O[SHWT=4$3=! C
M[90.YI_,M*VNEV@I?&1,11G,?>M1]P=\N27RD[-^FXN6#EM%N>)_8:>M)SR7
M$"329<U],H[R=HXI?L49EA9KQN(V8_$H:C(!$K<$C#$N@N!_'A;=S+&"^>QR
M:@BU&,Q@4?-0>-:7O!EV4&MS@@:!GM&E0MJ,I(K9B]2I(;U#-"6N*,,OZR@0
M\W30VK)&?^3P&2_!P7.WFB&,:23Q.F(FZKEI$-41+C4+BW I6&GZ&L@=,<[1
M21*W=GKX.#J9-KAX\$@([L(H?(SC"4%8)_@!;!D0-9<C)-M&^25&PZJL8(@I
M,W^P)5@S>P^-W"CS?6S<?H T!N<Y0;Y6, ]8/4? J# T?#Q^PZ0DM(CPW2I5
M#N/.YKG#F^*90R3^EDK\P(NP;>\#R@$ 3P4\H"AH%D(#W4(I:U$ B0<4O$8X
M<,45P9W[(YD#J'>;H-Z#_2VA>M\$M$#(A?YWCZ7=!"E)[C#OX#LA[Z.'S,/'
MI93.A77W7TZHTT7;2&@ZIE_1[I'AXCB8*3EQY^+D383*+ A4-^&7 =+8=#4^
M -W0P4A9!:9N,8N>,O<E\9N M@9W03. <0^3P3LGWG_3GV<*Y?M"?S/6GRT9
MRJ.ZV]=<*UQ="FV2)ZQEP9H2B20TP4+7_)VTA2%M%%'(B?];>SCUL;/%\]<F
MHDOR:E(*"QW\ 7/(Q0*Y0?V.29*#GPH+:#C$)F$3N&GHXQ=:?XKB%#93?UY
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M!H(B\:\37QL+)XX<MUWY])SSZ-('8XR6AUBU=LG9]_K=G>WSX)%EO<X2FL7
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MVS@0_RJZ,"TP@QW+SL-QTLS0-'"90F @S-V_LJW$NLJ61U8>W*>_]2L$D[;
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M<R("^)WDM8!.!+\3A0C 429?L@JQ(]@1',&P5KAJ0FJO# WH"L\P(I*H<P@
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M;M_(G>0@:"","LBAS3!MJQ,E$>JFYJXV2PO)+ZB(!L+FRZBGFOZ4LCT'^B(
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M3:)MULVH3[7.G^:R%T/_[_O.:& 'G5<>OB8 VR=$E=+2X7#I?K@P?5=[[Q>
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M+;QFV&(I_@0+V8V6O/7F;#8<']V5M8;FNSFJN7H<N9O+/P%02P,$%     @
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M<@88<%I _;78 8J)1C)#>I_8E81C KPD_,>3;#M2JXYEC?U^!4XA/'F0WN_
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M+3,>SU:^6WZD>7;E!:-()ASM55;D2XGGT6U>3NP:=V/Y\K%P&*6+E<Y,U9V
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M^C]02P$"% ,4    " !,.G%:2G#;F^P6  !)ZP  $               @ $
M    <&QX+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( $PZ<5I'C;Q:C1(  %/U
M   4              "  1H7  !P;'@M,C R-#$R,S%?8V%L+GAM;%!+ 0(4
M Q0    ( $PZ<5I1G]3S8#D  /"L P 4              "  =DI  !P;'@M
M,C R-#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( $PZ<5H*M?7$.'\  #\@!P 4
M              "  6MC  !P;'@M,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( $PZ<5JO*T[6-E\  -*-!@ 4              "  =7B  !P;'@M,C R
M-#$R,S%?<')E+GAM;%!+ 0(4 Q0    ( $PZ<5HG!BO4#LX# /1W(P 4
M          "  3U" 0!P;'@M,C R-#$R,S%X,3!K+FAT;5!+ 0(4 Q0    (
M $PZ<5H74A:V5&H  #N!   7              "  7T0!0!P;'@M,C R-#$R
M,S%X,3!K,# Q+FIP9U!+ 0(4 Q0    ( $PZ<5J4ISEHH)T  -RQ   7
M          "  09[!0!P;'@M,C R-#$R,S%X,3!K,# R+FIP9U!+ 0(4 Q0
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M;'@M,C R-#$R,S%X,3!K,# W+FIP9U!+ 0(4 Q0    ( $PZ<5JL@C%+PGD
M !J=   7              "  69["0!P;'@M,C R-#$R,S%X,3!K,# X+FIP
M9U!+ 0(4 Q0    ( $PZ<5KCY1?2R P  )@-   7              "  5WU
M"0!P;'@M,C R-#$R,S%X,3!K,#$P+FIP9U!+ 0(4 Q0    ( $PZ<5JG,B"8
M;#0  ,26 0 5              "  5H""@!P;'@M,C R-#$R,S%X97@Q.2YH
M=&U02P$"% ,4    " !,.G%:^*Q\H&,#  "V$0  %P              @ 'Y
M-@H <&QX+3(P,C0Q,C,Q>&5X,C%D,2YH=&U02P$"% ,4    " !,.G%:A_H]
MWT4%   R'0  %P              @ &1.@H <&QX+3(P,C0Q,C,Q>&5X,C-D
M,2YH=&U02P$"% ,4    " !,.G%:BFD(Y# (  #$*P  %P
M@ $+0 H <&QX+3(P,C0Q,C,Q>&5X,S%D,2YH=&U02P$"% ,4    " !,.G%:
M[X9852$(  !1*@  %P              @ %P2 H <&QX+3(P,C0Q,C,Q>&5X
M,S%D,BYH=&U02P$"% ,4    " !,.G%:PY/.<C$%   Z%0  %P
M    @ '&4 H <&QX+3(P,C0Q,C,Q>&5X,S)D,2YH=&U02P$"% ,4    " !,
M.G%:3(9 4D,%  #=%   %P              @ $L5@H <&QX+3(P,C0Q,C,Q
M>&5X,S)D,BYH=&U02P$"% ,4    " !,.G%:]Z$?F:(2    20  %@
M        @ &D6PH <&QX+3(P,C0Q,C,Q>&5X-&0T+FAT;5!+!08     %P 7
+ !H&  !Z;@H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>plx-20241231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20241231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2022_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZT00cGmYjUugrLQ9Ej7B2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_cGsHWgE_gUuxZ-cHUDKhgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zf_c8EYvN0-ChWXNMhtT7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_s7t7THOam0ugmJppb04uiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hOOB-4g72kSTGYF-6-8tow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NcdWC0f2eUqpjFaF4c8VHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d0KQCrBldECa1kWPtwiqWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Bw-Z_-dW70-nqHUT020dcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CuQDsyAkjESynmczRevI1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K7icX2z7sk6vRpP988YnpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZsUy5BXARUihXhlGt1WP2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EW66xBjMwEq-SZFSEjjsxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_c58oJTn8dU-QqeJQC9hc2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69To5.60Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_CZ0iGJrw8kGgZlq0gK2Vkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55To3.73Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_k1pPvAGNuUqJ8-G1h9Wyeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_Ggw7m_bIUEukSBW28yKxbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.03To2.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_D7MJGpt1U0KbxRKh_zdQpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice4.69To5.60Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_i8MSOPNUfk-c4_p410zsvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice3.55To3.73Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_6w7SOn5UPUu_KdKhVUxCsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice17.20Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_ZwQZST8ycESPqOtaPxvgmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">plx:ExercisePrice1.03To2.00Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gk0_QwpkNUi8I2fbbRac5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_V7gvzO9fdE2ntwQ96Fp-5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_tq949hURe0qn3llpv8mqpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GiEgmTjqQECUzJqeHnRG3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qzrqPtv4Nk2sivn3hBJl_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0w_5kQqvoEm_P4OrjYWqWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PjbfOLibbE-CFhp_5N4qIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_EUp6tTdW0UGDY4bhmHe7MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AzD7wSLn2kKSXb3VDmVzTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_gI5UhphCH06Ect3eEtQGMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_yX24jpZNrE2GFNvD-IrRLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AqEdmyQF8UC1svkRrbF5pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">plx:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_ZD_LC9yxDUiAkmkArAOCNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_ACAfcts15EeexRuNnjxxSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">plx:OptionsAndRestrictedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_0jCSqJ2VNUGntWiwLim66g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_07Y7_KkIgE2gCqBzVKzHGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_HeexSHIpsECzwXPmjXRSIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_vAdZZrKJB0GA0kWl76_O5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_yxjzBIAj6UibHOxMuOXLmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_e4DfQC6YoEqi8RVuaPKj1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_HHFZ61393UWe4ugtQPzFMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kRf1Vl0L_E68nTZynfgMNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_gyzvZwhYWUOBEq112uDzLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_QZxZBUTrMkaZV4V80woRlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_cq0BPynITUyIX0XEGY5DFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_aKTCTOwnPkytYKKR5g2_wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_n_xrcTEwnEeMZJ4ZcUw8eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_E_xaP5k14k6Q6Z72Y_IfPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xaYAPIOiqEOStP3Kpoa1Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_nzjGNNa5BUaHDbbP-O186A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_PQ5mf5BQdkWUxiMCts1pFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_w4HPugC1VEGsdplZft_5fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_2OeigBROdEaDOLaH-ucKEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mW8C4Y6b6kywMvvRfs9dNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_vn410UpKkkGalJIGaHTUEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_eCpUQmCcSESODwHxlLzo5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_y8QfLO6YXkKf-_LOLQOaZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_oNp3Hf3CWECKBYdKr9AjAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_h6xjOEjkiUm3MR0Og5Jvhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_S7h6B8zov0uIXGD5I22dew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_EF4dwmnF_kWBNzMVSjLHhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_ur7u-fiQ5k-UQkYO2y0uwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_PjfN7L5Bbk2NLvVOBqJ8Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">plx:FurnitureAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_iDlflgLsKkiQFmx1cSBg5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_vxkDkBSQz068hELrseMSzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_KFKHQh7CBUC1lg8cpMFN3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_tIPYYN_ZtU-qDljU2Ir6gA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_nxW7H0bxUUC9vT-aI9jhyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_pvpGc5YOlE--wrnCQNPHeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_LO7FCaAqo0anOZnr8urSlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_aERhFlXodEOqRgwjEGZTtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_F6fA0kenUkmkxMJFS7dV_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EoGEj4NR3k60cggFbmTsmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_pglWe4H_g0q1VCrHkTEK2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_k_HBgOQfk0GnMVqO03JGnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_7Kls7CQ7NUqv6IHxTOTP0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_hbAAdy1AFUuwPTqCDJatww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_IFWTaYE7TEGUIFQbsRvpcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_CJv_84vfq0aMskjfjX9YfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_jt7xO17tI0q-J4gtN5A1ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_MVIrjw2PD0mL89oHKVh0jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:UsIsraelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_JlcwElfBZkmmA58XlgqPmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fg1EWGDGnkyt0zoxUAK0Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DsGA_yFdAkGbxa6Ly0IBzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kNcYnNqxkGT0wOZlcwh9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_pqIJYP9qBkuWs3kgYe1bCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qjP7y_S0VUuKi14nuJCCzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_SDy9pRI4jka-vazM2Ar37Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_2uwOm7rxyEOlHzvvqCFFJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_vDFNTndzl0OM84fywfGerA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_Rre_qLcyTEWy4BikH0eDPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_LmlSAoEiIUGYRz9pAOa8jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_PrcXvhjZKk2qgA6qvhDFGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_QXqL2IzWNEGo_hK_uR7-8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_81bs3kgDHU6NRu_L1eP3yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">plx:TaxYearThereafterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_wUeqT_M4AEqDZuDuEQf3xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DefinedBenefitPostretirementLifeInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_Mp-0M08qeUKO7h9uqA1McQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">plx:ContributionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EYL9IKHmnkqnNQvhCDuZ0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-25</startDate>
            <endDate>2021-08-25</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_rldSNFnujkmNBG6adoOOkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_PqNi2C8w-UiBnkc4Uh5lLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lgph02zA8EqaEK0ln7pqLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cPolotLkAUmM_tlTQRrk2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LNkKeGiGJ0aS5KHtRlDVsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XM4auoMc-kObwGUUo2NaKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_RWonuWiPxEq0TdRkIcpNIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-16</instant>
        </period>
    </context>
    <context id="As_Of_3_12_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_PIfW3nBp4kCRd_d9eGzbYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_MOfdfIKjcUiCrIPtQO8BWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_cq9GoAKDi0yCbmzEVhRxUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_iQmr4uFt5kqfTe94aSywZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_0rzuJ4XtCE6Cs1WYUEVqEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_wHXsbG_dxEq9ZOpZb9KkbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsWarrantsAnd2024NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_nUbBkLnYekaez7e1Ka3ENg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kOxCb2VXAkiXIt-mPT3RhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_UuhJLwHi6Em0GrZfesGVyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6ZtY09PpU0m9d_EG_ZwvkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_A7nWnFTiPkOdLlt5xxqpEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_REAyJtvAFU2ys4pnWOJcXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0aTAUQn5Gkm5jNYX11QpwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_GkNNnx-5s06WAA30ohh8Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_L8FMbjn4ykuUigKlaKNOwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XRg9HSXWv0C3QWfvvFGWxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9RS1hcr690mkdTePbZl2Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CoqAPYNvE0GJxaaTTSDOFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_Wf4l6EemkUiStX1y_Xvkzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_VUjg-GUWqkaM24vUWwpyKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_l6LgZROctkqAN5Bg47FtoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_eMpI1Y46mEm3V5aABb_sXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_7kWtOAR1_USec_YP09u_Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_VubLEAIky0aQAmEbs4Z7EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xZcFCwrL3kSsF04JdIujqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KwnYvQGzMUeyVPAkAtMuPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vWRZ9XKCTka09Mlcs7e8PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V2vZho8vMUyXxBTZzlyMew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_wXBT2eXbL0O3AsKeYlYxOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_Yo6i5FE6pU22Md7ma24KKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_qm_86HOq70OOencxym3GVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember__u8SZ_kTp0GNsmMYnwI58Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_2dRWMsEJ6EiuDNv182Eeiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_uwDD5nTakUC2KmTkoR6W8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">plx:OfficeOfIsraeliInnovationAuthorityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:RoyaltyAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_NYbG0_upI0OqrbiUEof-HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreement2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_W3yUCAONf0SfAzEtMt6Mbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_XGzd5dVqLk6U007ZQL4UiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VM8wfhoeo0Cfc2e6wRsqqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_S5aqBYd2ZEqjmaTVHLVYcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_rPFgBIuGN0iZ81CflTcjcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_B46HhSBVz0yrsK0DY71Erw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3WAGON0zpU6ERbyAHqCRzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_iREdhYdsg0S_5qYZGs1pFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_NW-Pj9G-fkyAiLj-xYz3Gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_jaZy5wcLxkiCdAwjd5oXfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2024_To_11_30_2024_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_7SbCZK859Uiaib6y5h0qfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_HhtwKHGlsEOO6RfMSrfRww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_CtbP6sYsCUSsa4BOxiiwkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_OUM-7GtNokqwYO6vx-ub9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:FillFinishAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_7_J4-MrHIkS9N0JY0GZlRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:NoncollaborativeArrangementTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_E4Yge5ZBuUiAoIRfgSeqmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_t_yYq1YsV0acGDoyhAPn0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_YOGpnjsFYUmoeJZPBCVsFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_H8x2H6ab8UuZgH1Ve9noLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_14_2025_rb1SYpJMiE6v_QmbhlZTGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_segment_t--H7-X-rEu1uMJLuZLipw">
        <measure>plx:segment</measure>
    </unit>
    <unit id="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Vote_0mlCI0gGfUK1x1wJKqfHQQ">
        <measure>plx:Vote</measure>
    </unit>
    <unit id="Unit_Standard_EUR_iTLnFIhgHUOHLxUiOlWFJw">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_item_ZOMDUvl2U0qDBOvYPFWWmQ">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Standard_employee_ocaisUO_C0WWcRJExAkgCA">
        <measure>plx:employee</measure>
    </unit>
    <unit id="Unit_Standard_agreement_KD5G_ppkGEKfu9q5lyCQiQ">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      id="Hidden_3pYSaoLYOUKp8l12A1jLJQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      id="Hidden_v7cgyKJf8UKf_Ak4X-wp6A"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_3h-5lKQmIkWSelMkMtFcJQ_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_pLaZ8mKFZUWi3YG_HB5dfQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_-q1SxCHVRkuueIYzVmGqsw_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_tZZ-n4KwZ0WbY6RlcZcHew_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_cY5Y-PViYUOBGr0N7N4pEQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-6"
      id="Hidden_j-hLDpbrqk6Soc8k5CS6fw"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-6"
      id="Hidden_DAQOBjC4YUOk1EvqBtzg8g"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_ZD_LC9yxDUiAkmkArAOCNg"
      id="Hidden_HsTYEK9eRkCkgOq9_9rEew">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="INF"
      id="Hidden_yJU9lqNC-UmtulHxkqsD_Q"
      unitRef="Unit_Standard_segment_t--H7-X-rEu1uMJLuZLipw">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_UMrrJux9J0OpgowH_5WF5w">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_i0HVNA4urE-Jjj_rywLrkA_1_1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_-Cr08KcPx0GWFDY1393Okw">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_Y2zmY6J-1kiFJ8DXo1Qzxw_1_1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_1X-zBPYrykmVZ109IxGILw">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_pqtEIgWV1EOzuWByNAkokg">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_51-ZsM4iqEWVF2bkD8KLrA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_4mIhJOR7jUSRJDl4M7hRJQ_1_1">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_oDITMJMFFEelcrSAW0JtsQ">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_4uXnJXc1IU-ITdATOdlzxA">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_GQWrJBA1SkOCxzXiqOKz-g">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_RhhtRRzp8kKtPDfv737m3w">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_RVx8iucAEUqQh08zL01ZKQ_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_bjaN6S9IbEi4mUdquuD0dw">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_6xvIRzqRnECRuTy-PcNABQ">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_xDZLVBW-g06e4z3mLiWY_g_1_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_sRUkVy6wDkaSA9Uurs4QtQ_1_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_9cgd33N7bkWcTSVhPWJlfA_1_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_Y9_hd990bEy42D2X5yHiBg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_LkSkwC9PqkGBMTHjWV1jPA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_b8p_dF6OaketzK6Aidg0BQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_8z2pApa2RUijDHDbAMDfeQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_YnKVjYjoyECcblw7Jkrdcw_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_iWSzQBQKUUOTS9Ea0l4xfg_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tc_vxETjOqDQESziNz_Obb9wQ_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_Wvh1Vw_ryUW3WXxTvGZFug">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_1ZtcAShQ0ka7AvikrzSowQ">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_2FN2xsXlQ02eXxmjah7ohg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2024_H8x2H6ab8UuZgH1Ve9noLg"
      decimals="-5"
      id="Narr_3DyDW1f_GEKKn_7uu9Q2WQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">82000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_14_2025_rb1SYpJMiE6v_QmbhlZTGw"
      decimals="INF"
      id="Narr_mbpCTVp8YEyuBVFlmqtBag"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">78032585</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_dzdBy1vD1UaqQCcyLxPj3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt 0pt 2pt 0pt;"&gt;Portions of the registrant&#x2019;s proxy statement related to its 2025 Annual Stockholders&#x2019; Meeting to be filed subsequently are incorporated by reference into Part III of this Annual Report on Form 10-K. Except as expressly incorporated by reference, the registrant&#x2019;s proxy statement shall not be deemed to be part of this report.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_YOrqbxYcfU6XzLVoNWcfLg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Our operations include the creation, collection and maintenance of sensitive information, including proprietary and confidential business information, intellectual property, third-party information and employee information. To protect this information, we use external and internal services to managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats on a constant basis. In addition, we use multi-factor authentication (MFA) for external use, perform penetration testing and engage third parties to assess the effectiveness of our cybersecurity practices. We conduct a thorough risk assessment by identifying critical assets, recognizing potential threats and vulnerabilities, and implement strategies to mitigate these risks and their possible impacts. We establish incident response plans and provide cybersecurity training to our employees and monitor their activity to ensure adherence to our security protocols. A material cyber-attack on our systems, or any other third-party partners or vendors and their key operating systems, may interrupt our ability to operate our business, damage our reputation, or result in monetary damages.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"&gt;We have implemented a Data Protection Policy, or the DPP, in order to establish the high-level direction for properly managing the use, privacy, security, retention, and disposal of our information, data and assets, and to manage identified material cybersecurity risks. The DPP was prepared using relevant guidance issued and technology standards that are used across various industries. It applies to all entities who are using our equipment and resources, including but not limited to, employees and temporary workers. Our Senior Director, Information Technology, is a certified information security officer (CISO). He is primarily responsible for implementing and overseeing the DPP and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"&gt;Our DPP includes an incident response process that includes reporting thresholds and follows standardized identification and authentication practices. If an incident is identified, it is documented by our Senior Director, Information Technology, who is required to report the incident to management.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"&gt;We work with third-party service providers from time to time that assist us to identify, assess and manage cybersecurity risks, including professional SEIM SOC and other services firms, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and penetration testing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"&gt;No risks from cybersecurity threats have occurred that have materially affected or are reasonably likely to materially affect our business, results of operations or financial condition.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_1-dHyixZDEKokvSkQvbD2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Our operations include the creation, collection and maintenance of sensitive information, including proprietary and confidential business information, intellectual property, third-party information and employee information. To protect this information, we use external and internal services to managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats on a constant basis. In addition, we use multi-factor authentication (MFA) for external use, perform penetration testing and engage third parties to assess the effectiveness of our cybersecurity practices. We conduct a thorough risk assessment by identifying critical assets, recognizing potential threats and vulnerabilities, and implement strategies to mitigate these risks and their possible impacts. We establish incident response plans and provide cybersecurity training to our employees and monitor their activity to ensure adherence to our security protocols. A material cyber-attack on our systems, or any other third-party partners or vendors and their key operating systems, may interrupt our ability to operate our business, damage our reputation, or result in monetary damages.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"&gt;We have implemented a Data Protection Policy, or the DPP, in order to establish the high-level direction for properly managing the use, privacy, security, retention, and disposal of our information, data and assets, and to manage identified material cybersecurity risks. The DPP was prepared using relevant guidance issued and technology standards that are used across various industries. It applies to all entities who are using our equipment and resources, including but not limited to, employees and temporary workers. Our Senior Director, Information Technology, is a certified information security officer (CISO). He is primarily responsible for implementing and overseeing the DPP and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"&gt;Our DPP includes an incident response process that includes reporting thresholds and follows standardized identification and authentication practices. If an incident is identified, it is documented by our Senior Director, Information Technology, who is required to report the incident to management.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"&gt;We work with third-party service providers from time to time that assist us to identify, assess and manage cybersecurity risks, including professional SEIM SOC and other services firms, threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and penetration testing.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_J8qGdgZ4EUK4DbUAHLqU1w">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_gOIfwsfli0ytHQkE7UsOzg">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_Vi3BFJpE-U-Lb-XX2wvLwg">Our Senior Director, Information Technology, is a certified information security officer (CISO). He is primarily responsible for implementing and overseeing the DPP and identifying, measuring, monitoring, and reporting on key enterprise-wide risks, including cybersecurity risks.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_czrXSncaEU6melNkj873hA">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_IQKvtKIFGkSnAA9iG3-hNA">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_qSQQ7TyV6kKsL7nbb53yzw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of our management, including our Senior Director, Information Technology, who reports to our Sr. Vice President, Operations. Management is also responsible for hiring appropriate personnel, integrating cybersecurity considerations into our overall risk management strategy, and for communicating key priorities to employees, as well as for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports. Our incident response process involves management, who participates in our disclosure controls and procedures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"&gt;Our incident response process is designed to escalate certain cybersecurity incidents and vulnerabilities to members of management depending on the circumstances, including work with our incident response team to help the company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the company&#x2019;s incident response processes include reporting to our Board of Directors for certain cybersecurity incidents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"&gt;Management is involved with our efforts to prevent, detect, and mitigate cybersecurity incidents by overseeing preparation of cybersecurity policies and procedures, testing incident response plans and engaging vendors to conduct penetration tests. Management participates in cybersecurity incident response efforts by being a member of the incident response team and helping direct our response to cybersecurity incidents.&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_h22gbO-HFUKVhUOLfwm7PQ">Senior Director, Information Technology</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_6kn1SoyQiUGx4vg3ltVTAg">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_Yc4pIhTWcEqqr0QjNhsT1Q">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_a3gPoT8X2UqcEdmnekmK_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"&gt;Management is involved with our efforts to prevent, detect, and mitigate cybersecurity incidents by overseeing preparation of cybersecurity policies and procedures, testing incident response plans and engaging vendors to conduct penetration tests. Management participates in cybersecurity incident response efforts by being a member of the incident response team and helping direct our response to cybersecurity incidents.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_of8WTzHZl0aydX4J6yfNdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"&gt;Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. Our Chief Financial Officer and IT consultant provide periodic briefings to the Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, if any, cybersecurity systems testing, activities of third parties, and the like.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_rf5Tdes_VE-f1V4JAZ_yOw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"&gt;Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. Our Chief Financial Officer and IT consultant provide periodic briefings to the Board of Directors regarding our cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, if any, cybersecurity systems testing, activities of third parties, and the like.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_xkR1KQ9fp0KqSvX7nkrNOw">Board of Directors</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg"
      id="Narr_3EGI1xrZ2UG4cUPXSCJqAg">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg"
      id="Narr_373Ui9QjbUinLEDlk4zWhA">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg"
      id="Narr_R-vAV1XYSUGr5xl1C87WqA">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_xF_m3Fzyb0Wv_q_h2qdsZg"
      id="Narr_yWow6AUIuEylao8MmbwkCA">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_2MqWGYIfHEu2wnmG0oCL4g">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorName
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_mQcKOPOzX0iXJEvEqbmQgg">Kesselman &amp; Kesselman C.P.A.s</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_rv0QUe_yP0Gw5ji4EBIY6Q">1309</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_fSayNPTDH0qqeCowewBXRg">Tel Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_k6dJ6SyIZkaWZH9qlEgrWQ_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">23634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_JXtU0vL2SU2HTcGu9QBZjA_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19760000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_W8yrBETvqUSSyuGAPHay1g_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20926000</plx:ShortTermBankDeposits>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_2iK9esA4rEKimi5UciuUZg_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">15070000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_5tAGbsJRMkuoD69H-9NOtg_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5272000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_dCAOjvwXY0e48fApjtUvSA_8_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2909000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_3h5A_WXLUUusL7GqxI8Enw_9_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1055000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_jvq2nFoKDUKO_qeB_0SBng_9_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1096000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_gNlwsa222EyOiU4HCwEahA_10_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19045000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_cGUNCxpN_kGichsPS4RzMg_10_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">21243000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_HlhXdeOhdUa6wkIB3vlXMw_11_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">69932000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_zaGUABYQpkaariU5vajqQw_11_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">60078000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_L29TGwyp502M9D3epeMDKQ_14_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">528000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_AqlWb6NtG06vvwyRISFYXA_14_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">462000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_AXphAETmsU-dCT7mI4PBmg_15_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4973000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_QVFKApTZ0Ua4-PrOIGJyQA_15_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4591000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_gUf2TTyfz02wabYKYVi19w_16_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3092000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_UHJDBzqpS0CUvlyVEhkMjw_16_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2856000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_L-NMsJS_m0SFmu5Xi-qeJw_17_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5909000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_7c_eHjsYfkKpI5BbOVbVrA_17_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_G7iyqK4S8Uq2hEQbemmIfg_18_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">84434000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_AdNvhRmNIEivDArNS8Rwww_18_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">73417000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_LPUbRi1APUOco22bWL31GA_24_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4320000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_k6SYDaM_bk-jmgXLW4e9Dg_24_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4533000</us-gaap:AccountsPayableTradeCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_h9MNui-Q-E2RkA88JsIdsQ_25_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19550000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_aZhAF8S7bUSsejhhJkpwxw_25_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19588000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_ojjW2D7Q8EaQbl5-G7JwCA_26_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1409000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_g4YDGQVJLEWztpsbVOBAoA_26_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_22ICVPzHHk-FaaIFUb4SYQ_27_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20251000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_dMBya9PwBESfKGZBPCP-3A_27_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_XYJFg7y-UEGMYBPxnsx0qw_28_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">45530000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_aJRrDETbb0GrgvHhoBDUwg_28_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">25621000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_agU4gqeONEePedfUD9f-vA_31_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">714000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_prQJmKAMlEioKGR9RFYxqw_31_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">559000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_87o_G_L-9UGOJlpRSRg6XQ_32_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4621000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_K1ctYNOYfkurWrPpKzuvsg_32_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4026000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_OGKE205inEOdN2t3_DMNSw_33_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5335000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_Od1ev8rg6Em-9GJiMwnu0A_33_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4585000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_S2RnceSVf0eVwcG2iRbWmA_34_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">50865000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_GdD_gDM4Xki7JSDHT41Yhg_34_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">30206000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="INF"
      id="Narr_wq_Jrj4AK02VRSqOJClqXQ"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_XJZpGPfIhEi9e2jy5gp2ng"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="INF"
      id="Narr_wisXODDAiECAuezWPnvVyg"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_QQWNFdlgXUGwCEOsvD5Gqw"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="INF"
      id="Narr_bBjE4Xvp50a2NY2cNtSa-A"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">72952124</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="INF"
      id="Narr_eY_bXPk87kaX871Lspzoww"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">72952124</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_zHAYrecgRk-oKpTcV9ehpA"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">75850275</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_xHyQWTxs0Uaq9PA1jvxKYQ"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">75850275</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_4ivP4vOoTE6ptCV_OxYHaA_39_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">73000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_Zo6M2jOb8UOiS7-Nj9P_yQ_39_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">76000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_7kaOvTxYokq-kC4ibjbWqA_40_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">415045000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_5BAYmqBhS0-cHIzZFGMrDg_40_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">421528000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_wqMQdkCexEOXV_5auXZVHQ_41_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-381549000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_RyO0tUhed0-WtYaB06qrRA_41_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-378393000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_pNm5Gfr1N0qoQ0T7uCVlow_42_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">33569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_pjfvDl5W_0OuGy3WsDL1OA_42_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">43211000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_prWhLcUy2U-rHeoKGTGVpA_43_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">84434000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_fKAb-WVkqESEaSaUpfJCJA_43_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">73417000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_PQ5mf5BQdkWUxiMCts1pFw"
      decimals="-3"
      id="Tc_yuNYm6Ey8k69BKNuWYBy2A_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">25292000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_aKTCTOwnPkytYKKR5g2_wA"
      decimals="-3"
      id="Tc_nOT8YAMMt0GTZ7lJd6IMOA_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">40418000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_HHFZ61393UWe4ugtQPzFMg"
      decimals="-3"
      id="Tc_3Ed7cVFKvkigWjt3oEGZtw_4_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">52981000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_w4HPugC1VEGsdplZft_5fQ"
      decimals="-3"
      id="Tc_OTLRAJhfgE6Jj4Mm2C3w4w_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">22346000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_n_xrcTEwnEeMZJ4ZcUw8eA"
      decimals="-3"
      id="Tc_360hnqnojES769Iq0njwTg_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">25076000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kRf1Vl0L_E68nTZynfgMNw"
      decimals="-3"
      id="Tc_x7NISuqc40O1FnVNWbEC3g_5_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">418000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_dDn3psVOHEebdVEd2foJ6g_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">47638000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_GhBbruk_M0-VyMYadZAQBw_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">65494000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_F-YshA_p9k-pOZH-sKOilA_6_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">53399000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_qWi6pqgt2kqtEUnOHlNRFg_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19592000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_pGP6wrCU-0-w8FWiuGbtdQ_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">22982000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_XltKa-9EYk2llYyAymVtPg_7_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">24319000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_1c2YCLgxR0qq3F0vDMaWCA_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">29349000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_SO0xp7KGOECRg55Zc01r7g_8_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">17093000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_8VujawQNKUquO_4v0Ncc_g_8_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">12970000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_6hrXMKTPXkKkeVqMEljvZA_9_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">11711000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_FVjU67L7aEOe9bLL-p23jw_9_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">14959000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_-8b0nTLdbUGwQiJfsLVVfQ_9_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">12193000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_vhIuUyoaWUOJ3_15DKRn7A_10_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-13014000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_JiXHJwkBNU2sad6CmCXzNA_10_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">10460000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_h7HHI4BFoEKaSfa8IxjuAg_10_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3917000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_PHfaR9WKF0uGnSs45rA4hQ_11_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2529000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_qG2UHihHaU2EyURj0GqrQQ_11_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3180000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_HgMxIAQPuE2jzYEFoLOUjg_11_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1062000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_S1vv_UdvE0G02DHCuBda0w_12_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1146000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_Hgi8_PANWUyoIWE0j-4rNg_12_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1286000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_t1bIKUX4VkS2jv0FxHMabA_12_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1299000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_7-hHtGKaJUKxVWCwh9DdGQ_13_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-1383000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_v9C9Xkyd3EG16Z5HhilFZg_13_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-1894000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_kHbWiwhbS0qVjN-XoKuBKg_13_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">237000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_-opybQeaCEaV8sPzZvJx6Q_14_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-14397000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_kUs-bUzDfkCKjE0QKnMDcQ_14_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8566000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_JWSkOKf7lkKYdyH4BDHKpQ_14_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4154000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_pSusXthfCkOB5b4b8rooPA_15_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">530000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_aq4uc_EFtUqnxk5Dg91ltQ_15_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_rrIzWHVEb0qiLGiGkuQc2Q_15_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1222000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_FovWBzWf70W-LF41jvMCfA_16_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-14927000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_UQ7kVcqLekq_NvGmW7Bxcg_16_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8312000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_YoD0ci6LTEaydhWCEWm6DA_16_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2932000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="2"
      id="Tc_hQXgxfzKwEWL-dqt_CGidg_18_3"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">-0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="2"
      id="Tc_sj7rOuGnB0akKO327uOUhQ_18_6"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="2"
      id="Tc_2IomFPku3k29LiYX0wFyOw_18_9"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="2"
      id="Tc_uIzGGifFsUGi1vVU9S7Q0g_19_3"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">-0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="2"
      id="Tc_TqukFEwPWEWVLdPIax7_0A_19_6"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="2"
      id="Tc_YEqiWQehv0KTcLa811rI-A_19_9"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="0"
      id="Tc_hz59tYKX-Euf7N3Ks_v51A_22_3"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">48472159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="0"
      id="Tc_WLx5PaGbR0mXC4wdQawiLw_22_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">67512527</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="0"
      id="Tc_I99KPELNgUCx0wEvwE_wgg_22_9"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">72530698</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="0"
      id="Tc_AVVOY9wbIES3Nh5Jnxs7dw_23_3"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">48472159</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="0"
      id="Tc_kmz2GqGad0i2TXDk6FolqQ_23_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">82424016</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="0"
      id="Tc_fBhu69xggkCghE2FgjLmng_23_9"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">81057176</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XM4auoMc-kObwGUUo2NaKA"
      decimals="INF"
      id="Tc_IaWeMujPfE2Sw-6sNdmVBw_6_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">45556647</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XM4auoMc-kObwGUUo2NaKA"
      decimals="-3"
      id="Tc_VmfTpKrE5UCAcc78kaDDXA_6_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EW66xBjMwEq-SZFSEjjsxQ"
      decimals="-3"
      id="Tc_dtj1FkYdsUGPvOL4cGDKlg_6_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">368852000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZsUy5BXARUihXhlGt1WP2A"
      decimals="-3"
      id="Tc_wTWeFcsPzEygFLuvH26d4A_6_11"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-374934000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_cq9GoAKDi0yCbmzEVhRxUA"
      decimals="-3"
      id="Tc_ZfjEiXoYyki63y0Bci6DLQ_6_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-6036000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q"
      decimals="INF"
      id="Tc_AudZYNBsAU6Hs1BvEjvLNg_8_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">7473038</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q"
      decimals="-3"
      id="Tc_N6GyK8oYMUmowuz8kfvIlQ_8_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">7000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V2vZho8vMUyXxBTZzlyMew"
      decimals="-3"
      id="Tc_IjuzLIa7sEGKoNG098_lVQ_8_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8229000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_aM4SuAJJ70Kl3VqL73IpoA_8_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8236000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V2vZho8vMUyXxBTZzlyMew"
      decimals="-3"
      id="Tc_L3xqLScWPk2iIm7Ga3dnbw_9_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1124000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_RLBD192p6EGK5MpTVTp9Ag_9_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1124000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q"
      decimals="INF"
      id="Tc_d8qP4ARUA0GDJ1Ftxjouqg_10_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">759482</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q"
      decimals="-3"
      id="Tc_6T7c1NkasEuauS2aoVFBjA_10_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V2vZho8vMUyXxBTZzlyMew"
      decimals="-3"
      id="Tc_BiDKLsS9gE6f9luclFMnWQ_10_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">960000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_7FBSlHY7tkiw2sCNYw1cgw_10_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">961000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cx2OvOrHq0aAwB0Pvj393Q"
      decimals="INF"
      id="Tc_GgCK3i0ALUqfaXahtKIKzw_11_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">1000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V2vZho8vMUyXxBTZzlyMew"
      decimals="-3"
      id="Tc_yVQIUVGAJkyWZ-az2Z-p_w_11_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_E7RoCRWbtkmY_pLLNyIlSQ_11_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0kNcYnNqxkGT0wOZlcwh9g"
      decimals="-3"
      id="Tc_eWgsktxEE0W_iql5TZm0eA_12_11"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-14927000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_VFSI79Rc8U-uQpIquHG97Q_12_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-14927000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LNkKeGiGJ0aS5KHtRlDVsQ"
      decimals="INF"
      id="Tc_PzrsW4H5rk66xUgZ-vTkOw_13_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">53790167</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LNkKeGiGJ0aS5KHtRlDVsQ"
      decimals="-3"
      id="Tc_rywY86a0w0mKj4McLz6pBQ_13_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K7icX2z7sk6vRpP988YnpQ"
      decimals="-3"
      id="Tc_wCgH3aFWQ0GBbSLqFuO61Q_13_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">379167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CuQDsyAkjESynmczRevI1w"
      decimals="-3"
      id="Tc_RWEWKwQxHkOYj-T7eiZGXA_13_11"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-389861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg"
      decimals="-3"
      id="Tc_KgXHs9dqs0iX6Sm-LHJfzw_13_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-10640000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw"
      decimals="INF"
      id="Tc_RaxKwwP44EGhWY9zgnVt5w_15_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">12560150</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw"
      decimals="-3"
      id="Tc_2sbJtUzWNUGqInOftPwzDw_15_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">13000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew"
      decimals="-3"
      id="Tc_HctF7tnFxUaf0BuKsZAsjg_15_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">23941000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_I25AzgMj0EqaYpax7lVU0A_15_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">23954000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw"
      decimals="INF"
      id="Tc_Qt9P5a1hwUCP0kq0ohFFuw_16_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">4691623</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw"
      decimals="-3"
      id="Tc_jDm-SVmY8kKxlNaptZ1jTg_16_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew"
      decimals="-3"
      id="Tc_7yFVthNarEaQ6J5gNTvg3Q_16_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">7778000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_lR29W7cfaUWr3CqoJrIr5w_16_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">7783000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew"
      decimals="-3"
      id="Tc_tnjvDQzGjkGm6NmGuY1ZUw_17_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1928000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_ctZRsSKrzkG_r0fh9h7LWg_17_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1928000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw"
      decimals="INF"
      id="Tc_gTVJD3YijEq3kJLePZySRA_18_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">1371362</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw"
      decimals="-3"
      id="Tc_GPJxCLrDMUCzJmiRw6L5hw_18_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew"
      decimals="-3"
      id="Tc_zB6Z2HYT8k2pT62AN_YVDg_18_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1519000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_5qg9l6XSpkyjq6zy9axHoQ_18_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1520000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_U7g1vhyh0kuYQOSuXAyEJw"
      decimals="INF"
      id="Tc_VVFY4k7Z3UyQPEM8uVixIA_19_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">538822</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fZzKyijbh0G3Bqr49--aew"
      decimals="-3"
      id="Tc_rHl2ge-rBUaAxSeKpYO5IQ_19_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_733kZL_vN0q5eAY-m1nR0g_19_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">712000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DsGA_yFdAkGbxa6Ly0IBzQ"
      decimals="-3"
      id="Tc_MWjoWNjC_kiWhXuS6TN4ZQ_20_11"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8312000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_P3PPswOACEi2lGvC-x4yQQ_20_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8312000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cPolotLkAUmM_tlTQRrk2Q"
      decimals="INF"
      id="Tc__LKvqMY1ikWXB_lChoFnPQ_21_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">72952124</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cPolotLkAUmM_tlTQRrk2Q"
      decimals="-3"
      id="Tc_bdOur1ixsEiAWfmyCHcC6A_21_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Bw-Z_-dW70-nqHUT020dcA"
      decimals="-3"
      id="Tc__koTryl_BkWpWnde84llMw_21_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">415045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_d0KQCrBldECa1kWPtwiqWA"
      decimals="-3"
      id="Tc_P0DxYTcdZE2-90xFRAxFAg_21_11"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-381549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_S2_BEx0LtEu044f3KReUSA_21_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">33569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_NcdWC0f2eUqpjFaF4c8VHg"
      decimals="-3"
      id="Tc_HywJyLadB0uFz7_D4sHNCg_23_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hOOB-4g72kSTGYF-6-8tow"
      decimals="-3"
      id="Tc_Yio4Zo4sw06W33geLwRewQ_23_11"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CoqAPYNvE0GJxaaTTSDOFw"
      decimals="-3"
      id="Tc_IwiOVs6cN0-54SkeECIAFA_23_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-169000</us-gaap:StockholdersEquity>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KwnYvQGzMUeyVPAkAtMuPg"
      decimals="INF"
      id="Tc_T__AfSlGSkyjQgL7FvXLgw_24_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">2216692</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KwnYvQGzMUeyVPAkAtMuPg"
      decimals="-3"
      id="Tc_7fFArYrpNUSsQH9PgrMOWw_24_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vWRZ9XKCTka09Mlcs7e8PQ"
      decimals="-3"
      id="Tc_BjJykerJ1Um8emUUpsVREg_24_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3624000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_0UfR15sDXEOOc4Uzl8ch6Q_24_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3626000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vWRZ9XKCTka09Mlcs7e8PQ"
      decimals="-3"
      id="Tc_is0DsEKGQESuioEEo1Pf6A_25_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1593000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_MlSpsOuixkO1BMFdYb0Q_w_25_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1593000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KwnYvQGzMUeyVPAkAtMuPg"
      decimals="INF"
      id="Tc_Igq2CQvO0UOipmBrSMA7eA_26_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">681459</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KwnYvQGzMUeyVPAkAtMuPg"
      decimals="-3"
      id="Tc_r2IT87G4U0CHmqIqsMspGQ_26_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vWRZ9XKCTka09Mlcs7e8PQ"
      decimals="-3"
      id="Tc_JWVibX_m80WGx8rmQD-HpA_26_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1659000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_Mu7d_7i3KU69khxI8tXM_Q_26_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1660000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fg1EWGDGnkyt0zoxUAK0Gw"
      decimals="-3"
      id="Tc_dgaPvpd4TEib3XeL-DQLXQ_27_11"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2932000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_A5D0xCMnn0euMSz9geXFPQ_27_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2932000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lgph02zA8EqaEK0ln7pqLw"
      decimals="INF"
      id="Tc_2drl4s5kn0uueohhx-67Iw_28_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">75850275</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lgph02zA8EqaEK0ln7pqLw"
      decimals="-3"
      id="Tc_jGyUXffCNU2izwca765xYg_28_5"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_s7t7THOam0ugmJppb04uiA"
      decimals="-3"
      id="Tc_KZo56igth0me6HgMfYfrRA_28_8"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">421528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zf_c8EYvN0-ChWXNMhtT7g"
      decimals="-3"
      id="Tc_ANXYqsYmdUCzPt36KGGw_g_28_11"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-378393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_JdNbP0Bz-Ei0n95IpIN5oA_28_14"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">43211000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_Yf-QvjJoBECQ_JfeeaGq6w_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-14927000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_6f-7Rlcm7kOPC-8qVjQEFg_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8312000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_XhC3W2mzq0uVWig3d8AHNA_4_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2932000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_nopp3CScrka6_FHSAIYoJg_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2085000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_6LndqmL6cUKSryFCZZrW1Q_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3448000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_STBROjtoRkCgHT1hXUoC9Q_6_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3253000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_RBEjEqYy30KWHv5Fecfv3A_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1086000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_sZzcA8UtO0yJ7aRr9tqyag_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1191000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_-S8gCznnukaRgAIQCIZWJw_7_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1304000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_zF_u3zLTkU2G9bMz9QkLDg_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">989000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_HDnI0jtDEEO6ekqJmngLjQ_8_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">446000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_285inWS9CE-0wTCAAmas4Q_8_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-310000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_gtSQF2dwi0KMT9YsQmUJGA_9_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-543000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_ePiOppWMNkOdg5zFUSVBAw_9_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_LpdCf89zBkqcvmba2cy01g_9_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-151000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_PiOrFN9ppESiGNKpHKhqbQ_10_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_GwZvcdaEk068cLJJZF4TEQ_10_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-3092000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_Mj6CzYsuH02cmHFu88rF0g_10_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">236000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_otPTPydIQEO3fSerkFVBdg_11_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-3000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_Rw1z4py9UkGEMi9fYPt6Gw_11_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">50000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_YNp95NYto0qFzjklW_kpyA_11_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">18000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_yQ9MqSsraUSW__eBMvF_mA_12_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_mJsJQyIEA0mBa_hZVY4jeA_12_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-9000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_oILfBfU_8Uy2YO_g6W_XFA_12_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <plx:GainLossOnDebtConversion
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_hPEd1uBNJ0GiFQDmFV926w_13_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</plx:GainLossOnDebtConversion>
    <plx:GainLossOnDebtConversion
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_a3e0ziqKokS1SVw9aMlL9g_13_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">421000</plx:GainLossOnDebtConversion>
    <plx:GainLossOnDebtConversion
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_W8N_QWCnfUu_-NqNC84kIA_13_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</plx:GainLossOnDebtConversion>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_XnGV6bL54ECWtoH5GwVwgQ_14_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">300000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_GyGO6UZpB0qG5U2X86iVTw_14_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">267000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_zFgy6BWYoEWPJy62iXunWA_14_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_cg43MBdSWkSCNEiC-syZuQ_16_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-7162000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_NA4kU7Bv9EG1nh_bOUm4_g_16_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-13178000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_x1HQZG6lNEuhKT6BlkaUMQ_16_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_BeC0KYG4EkaSyS7eIHDUtQ_17_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1194000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_Z2w6mvfDnEqlgu2OLvV18Q_17_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">428000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_F0lQ1N9v_0OmzWT8rQNeaA_17_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-2317000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_SPHHBuPDe0q17z3yYVsaeA_18_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc__ZgkjLRlQUikYjR4-Y_dBw_18_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-13000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_B1qqfccjk0K9MP8pky5siw_18_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_6-nUCWdsoUiMxGhW-Z-MKQ_19_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-1150000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_szvE47ExCUO_QP9vo3gz6Q_19_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2241000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_abOTaC-W5066nkhENoT7SQ_19_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2198000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_ItE4fasg6kSaDE_4uTphQQ_20_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-4804000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_llnCCHqBJkaBAC-uQRBLmg_20_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5295000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_BIpBAmmQkEG4MJlFrXaL3A_20_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">696000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_-XMsmSpozEy7AFODEEk36A_21_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-25000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_5akfTGsaxkaT5LZgj8CF1g_21_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-1318000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_-jn8SrhFKUGhk0TSl34RtQ_21_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8674000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_LW3FW08ikUG6DyzX3luy9w_24_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">16000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_NKqryKyq306sR__aA5DrDw_24_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20420000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_ve3ogmbcxkmHHI6Ls7a54g_24_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">15000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromWithdrawalOfShortTermDeposits
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_INS_1eo2nES6JIEEK3MPEg_25_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">11000000</plx:ProceedsFromWithdrawalOfShortTermDeposits>
    <plx:ProceedsFromWithdrawalOfShortTermDeposits
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_WBrHNEvD3kGD90WPkIB3Dw_25_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5000000</plx:ProceedsFromWithdrawalOfShortTermDeposits>
    <plx:ProceedsFromWithdrawalOfShortTermDeposits
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_-_d6gWKHw0Gas-Pttr5kKA_25_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20420000</plx:ProceedsFromWithdrawalOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_fwapVL5tW0ux7nBEsUX9cw_26_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">628000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_6XA5JDw4T0q06KpHL3MvXA_26_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1149000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_V4bhnsYrK0KUeuZKoZlFYQ_26_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1282000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_dbPjgjLF0UOTJBOqyyD6ww_27_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_fI-LOgErYEq_HIrctldLMw_27_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_rK4nkAHOuEywK4IzwHevgw_27_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_FsfCIIGOUE6cXkpqz-w4og_28_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-593000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_W-Y29NQNZkCciRV-VHvh6A_28_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">142000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_YiYlfpYp0k-WbMDr_027MA_28_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-80000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_T39tvwtjt02dvZwrXwymGA_29_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-5035000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_15EVq2048k68hKjfFYqORw_29_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-16711000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_BrOtUd3I7EKrMxNqxIQ5EA_29_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4221000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_q4JITGjdtkez5cZ6HqP93Q_32_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_C_TCCKpkhUawHpjDysg4Zw_32_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_ghW3tW7xXEm3FO9ROybVdw_32_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20420000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_qIA5DhkwdUeDPO9WFgRNxA_33_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8236000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_ZFpq86V2gE-efZ75dQlqfw_33_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">23954000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_ELUCxNWBqkSS76fENpVjRQ_33_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3626000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_F_IhESPiUkW4h9IKvXC8_g_34_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_b5zq48s0e0eN5WelMxLZqA_34_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">712000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_SFQueqICy0O1Yp6RZHsJmQ_34_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_Z1GRKLCdkk-qC3QKTEgAPQ_35_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8238000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_tBpTzEcHT02v7R5Fr171lg_35_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">24666000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_OGBiwkzbNECytn6IW8V8mw_35_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-16794000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_uXszRyW5EUGLQnvWxbfJoA_36_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-77000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_m-D6QFkSJ0S28Xd2eDwq2Q_36_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-114000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_k-vk8OOTXkmOApdUM_EdYg_36_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">25000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_I68mnB81KEuzDgCmTr6ZrA_37_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-21874000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_O1vdKw5IAk2VMtx8nnoWXw_37_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">6523000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_2awtuwzjMUKwWZ0gphR1ZA_37_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-3874000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_cq9GoAKDi0yCbmzEVhRxUA"
      decimals="-3"
      id="Tc_I1McGp8_FkCNMZpjflyUzg_38_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">38985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg"
      decimals="-3"
      id="Tc_ood_CGaphkOsIfAw-7aaMQ_38_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">17111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_3MXhuIuqV0eWnKpeQIMI2A_38_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">23634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg"
      decimals="-3"
      id="Tc_9TgdAHXEiEGDIfWnB-UbTQ_39_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">17111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_OOrE7BMC-kiJrOfc68BBJA_39_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">23634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_Rq5eaOukQU2ZCz7r0jKYiw_39_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19760000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_fFTpyfjAK0OBU5ygIBdJ7A_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">143000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_l53MplPmCEC4cBIbRZtp_g_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">614000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_EozSKGNOa0mcEi8PI111LA_4_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">254000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_QT2g8kFczEu7v9FcBz3CWw_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">794000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_naVBFWhZ90mWqv-aIyhB6A_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1567000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_xbsYH0nYPE62H76QohBndA_5_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">376000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_QLpxz-YNl0uqBiKflQmmGQ_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">7783000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_P6XeJG7k4USnnTKVbGhcRw_6_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <plx:PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_xk0DazYmnUKxsIXlQyYBow_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">882000</plx:PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds>
    <plx:PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_becTtTY9ykegzXdchn5E-w_7_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</plx:PartialSettlementOfLiabilityForEmployeeRightsUponRetirementThroughTransferOfRelatedFunds>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_Cv0hBZBEhEac3foQz6kzHQ_10_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">385000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_2paIcFA9ME-amLK3tRDVbg_11_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2198000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_cNwt46n2g0291z8pEgPv5Q_11_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2742000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_a_n6cEfnaEKKEWovmsFgoQ_11_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1532000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_kbIgOGBuQEC9ghrFw8AUxw_12_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">93000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_jy3vCI10uky23NtdqtqU9g_12_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">355000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_VhDlKnLBrEq4C-7JS6qPwQ_12_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1487000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_HmJjFwifJUaYvLe3P6FFQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;General&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix BV (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio (pegunigalsidase alfa), each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The situation could disrupt certain of the Company&#x2019;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of December&#160;31, 2024, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Functional currency&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#x2019;s revenues are derived in dollars. Most of the Company&#x2019;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#x2019;s financing has been provided in dollars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#x2013;&#160;exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#x2013;&#160;historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;Cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Accounts Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. As of December&#160;31, 2024 and 2023, the allowance was negligible.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;No write-off activity and recoveries for the periods presented were recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;g.&#160;&#160;&#160;&#160;Inventories&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#x201c;moving average&#x201d; basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#x201c;moving average&#x201d; basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;h.&#160;&#160;&#160;&#160;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;The Company&#x2019;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10-15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leasehold improvements are amortized by the straight-line method over the shorter of (i)&#160;the expected lease term and (ii)&#160;the estimated useful life of the improvements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;j.&#160;&#160;&#160;&#160;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Deferred income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Uncertainty in income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Tax benefits recognized in the financial statements are those that the Company&#x2019;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#x2019;s management deems more likely than not to be sustained. Liabilities relating to uncertain tax positions are classified as current in the consolidated balance sheets to the extent the Company anticipates making payments within one year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;k.&#160;&#160;&#160;&#160;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606, Revenue from Contracts with Customers, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with a Company&#x2019;s customer is based on either fixed amounts or variable amounts. Variable amounts are based on the average net selling price of the drug product in the applicable territory. The Company estimates the variable consideration and recognizes revenue only to the extent the variable consideration is probable and that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;) as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing. See also &lt;a href="#_k.__"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;revenue from selling products&lt;/span&gt;&lt;/a&gt; above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC&#160;606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely amount method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA in 2023, the Company received a milestone payment equal to $20.0&#160;million which was recognized as revenue from license and R&amp;amp;D services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;3.    Revenue from R&amp;amp;D services&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;l.&#160;&#160;&#160;&#160;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company&#x2019;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#x2019;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2023, the accounts receivables balance was composed of $0.7&#160;million from Chiesi and $4.6&#160;million from Pfizer and as of December&#160;31, 2024, the accounts receivables balance was composed of $1.7&#160;million from Fiocruz and $1.2&#160;million from Pfizer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;n.&#160;&#160;&#160;&#160;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. &lt;span style="background:#ffffff;"&gt;This option pricing model requires estimates as to the option&#x2019;s expected term and the price volatility of the underlying stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company measures compensation expense for &lt;/span&gt;restricted stock &lt;span style="background:#ffffff;"&gt;based on the market value of the underlying stock at the date of grant&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected to recognize compensation cost for awards to employees with only service conditions that has a graded vesting schedule using the accelerated method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elects to account for forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;o.&#160;&#160;&#160;&#160;Net earnings (loss) per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), outstanding during each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Diluted earnings per share is calculated by dividing (a)&#160;the net income that includes addition of financial expenses related to convertible notes by (b)&#160;the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options and non-vested restricted stock granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;p.&#160;&#160;&#160;&#160;Convertible notes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;). The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate.&#160;The Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Starting from January 1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost. See &lt;a href="#rNewaccountingpronouncements_158576"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Note 1(r)&lt;/span&gt;&lt;/a&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;q.&#160;&#160;&#160;&#160;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12&#160;months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;r.&#160;&#160;&#160;&#160;New accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Recently adopted accounting pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2020, the FASB issued&#160;ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&#x201d; (&#x201c;ASU 2020-06&#x201d;).&#160;ASU&#160;2020-06&#160;simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#x2014;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06&#160;using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital.&#160;The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods.&#160;Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability.&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;The impact to the Company&#x2019;s consolidated balance sheet as of January&#160;1, 2024 resulting from its adoption of ASU 2020-06 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Updated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 415,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 414,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d; This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (the &#x201c;CODM&#x201d;) and included within each reported measure of segment profit or loss and an amount and description of its composition for other segment items. The Company adopted this standard in the current period retrospectively to all prior periods presented in its consolidated financial statements. See &lt;/span&gt;&lt;a href="#_NOTE_13_"&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt;Note&#160;13&lt;/span&gt;&lt;/a&gt;&lt;span style="background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;In December 2023, the FASB issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In November 2024, the FASB issued ASU&#160;2024-03 &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures&lt;span style="font-family:'Palatino Linotype';"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_ccdDjEK3aEqPXWgrUalnCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;General&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix BV (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio (pegunigalsidase alfa), each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;), pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The situation could disrupt certain of the Company&#x2019;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of December&#160;31, 2024, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <plx:NumberOfGlobalLicensingAndSupplyAgreements
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_xAlGiaRfBk6pNPDaMGzZtA"
      unitRef="Unit_Standard_agreement_KD5G_ppkGEKfu9q5lyCQiQ">2</plx:NumberOfGlobalLicensingAndSupplyAgreements>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_E4Yge5ZBuUiAoIRfgSeqmw"
      decimals="2"
      id="Narr_qIxGXiai8EaJ9qbqdHksmA"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_EOLdRGNRr0a6F3aI4sObcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_RL4Pf9idlk-nCj0W4v9vBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Use of estimates in the preparation of financial statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_DgvsbXCqh0ikk3T1NFdzLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Functional currency&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The dollar is the currency of the primary economic environment in which the operations of the Company and its Subsidiaries are conducted. The Company&#x2019;s revenues are derived in dollars. Most of the Company&#x2019;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&#x2019;s financing has been provided in dollars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below) reflected in the statements of operations, the following exchange rates are used: (i)&#160;for transactions&#160;&#x2013;&#160;exchange rates at the transaction dates or average rates; and (ii)&#160;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.)&#160;&#x2013;&#160;historical exchange rates. Currency translation gains and losses are recorded as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_93LAkdlf4UicpY0hNoTcgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;Cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company considers all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three&#160;months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_GfYAOyPA9kCBQsROBHtDMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Accounts Receivables&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Accounts receivable have been reduced by an allowance for credit losses. The Company maintains the allowance for estimated losses resulting from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. As of December&#160;31, 2024 and 2023, the allowance was negligible.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;No write-off activity and recoveries for the periods presented were recognized.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-6"
      id="Narr_o7XKKk_SxE2ji_k7_T6hVA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-6"
      id="Narr_w8kLDkUoHEyzAUOUX-1wGA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_xKA4DAB5yUC79eh0GY3HUA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;g.&#160;&#160;&#160;&#160;Inventories&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost of raw and packaging materials and purchased products is determined using the &#x201c;moving average&#x201d; basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Cost of finished products is determined as follows: the value of the raw and packaging materials component is determined primarily using the &#x201c;moving average&#x201d; basis; the value of the labor and overhead component is determined on an average basis over the production period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Inventory is written down for estimated obsolescence based upon management assumptions about future demand and market conditions.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_-RZPs5sCtk-eRQbURcSkRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;h.&#160;&#160;&#160;&#160;Property and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Property and equipment are stated at cost, net of accumulated depreciation and amortization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;The Company&#x2019;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10-15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leasehold improvements are amortized by the straight-line method over the shorter of (i)&#160;the expected lease term and (ii)&#160;the estimated useful life of the improvements.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <plx:ScheduleOfUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_MFncE5vAE0iogOf_T014IA">The Company&#x2019;s assets are depreciated by the straight-line method on the basis of their estimated useful lives as follows:&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10-15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:87.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:ScheduleOfUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_h6xjOEjkiUm3MR0Og5Jvhg"
      id="Tc_0SzxdVNZC0CZfxZTnZCtsQ_2_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_vn410UpKkkGalJIGaHTUEg"
      id="Narr_zsn2zvKzykKkaCU8BNM6WQ">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_eCpUQmCcSESODwHxlLzo5w"
      id="Narr_mdIBmYHRf0687eZDaHF0pg">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_y8QfLO6YXkKf-_LOLQOaZQ"
      id="Tc_DsvrFyzlNkaPzQzF7qTKrQ_4_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_u8vbHMwcEE6iVSk_fzaZGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;i.&#160;&#160;&#160;&#160;Impairment in value of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company tests long-lived assets for impairment if an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the assets to their estimated fair values.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_P8aorFV4iE-OT2_gfWoyJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;j.&#160;&#160;&#160;&#160;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Deferred income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Deferred taxes are determined utilizing the assets and liabilities method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Uncertainty in income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Tax benefits recognized in the financial statements are those that the Company&#x2019;s management deems at least more likely than not to be sustained, based on technical merits. The amount of benefits recorded for these tax benefits is measured as the largest benefit the Company&#x2019;s management deems more likely than not to be sustained. Liabilities relating to uncertain tax positions are classified as current in the consolidated balance sheets to the extent the Company anticipates making payments within one year.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_y1mXLGj0qEOPzzS6UPaY0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;k.&#160;&#160;&#160;&#160;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606, Revenue from Contracts with Customers, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;Revenues from selling products&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price is the consideration to which the Company expects to be entitled from the customer. The consideration promised in a contract with a Company&#x2019;s customer is based on either fixed amounts or variable amounts. Variable amounts are based on the average net selling price of the drug product in the applicable territory. The Company estimates the variable consideration and recognizes revenue only to the extent the variable consideration is probable and that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;2.&#160;&#160;&#160;&#160;Revenues from Chiesi Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;) as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into a single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing was contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services. Following the regulatory approvals for Elfabrio received in May 2023, the Company started recognizing revenue from manufacturing. See also &lt;a href="#_k.__"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;revenue from selling products&lt;/span&gt;&lt;/a&gt; above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC&#160;606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely amount method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue. Following the approval of Elfabrio by the FDA in 2023, the Company received a milestone payment equal to $20.0&#160;million which was recognized as revenue from license and R&amp;amp;D services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi, is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;3.    Revenue from R&amp;amp;D services&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_2dRWMsEJ6EiuDNv182Eeiw"
      decimals="INF"
      id="Narr_gp9luNrf10WNKnMgIULUOA"
      unitRef="Unit_Standard_item_ZOMDUvl2U0qDBOvYPFWWmQ">2</plx:RevenuePerformanceObligationNumber>
    <plx:MilestonePaymentReceived
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_jaZy5wcLxkiCdAwjd5oXfQ"
      decimals="-5"
      id="Narr_ugHIYdw_GEKomj85UDjOKw"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20000000</plx:MilestonePaymentReceived>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_To-3M30_sUekn8gA-hBSnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;l.&#160;&#160;&#160;&#160;Research and development costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment and supplies for research and development activities. In connection with purchases of assets, amounts assigned to intangible assets to be used in a particular research and development project that have no alternative future use are charged to research and development costs at the purchase date. Costs incurred for performing research and development services are included in research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_Y_m4ycuS6E6j-JCZXzLzGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;m.&#160;&#160;&#160;&#160;Concentration of credit risks and trade receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits and account receivables - trade. The Company&#x2019;s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. The Company&#x2019;s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2023, the accounts receivables balance was composed of $0.7&#160;million from Chiesi and $4.6&#160;million from Pfizer and as of December&#160;31, 2024, the accounts receivables balance was composed of $1.7&#160;million from Fiocruz and $1.2&#160;million from Pfizer.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_VubLEAIky0aQAmEbs4Z7EA"
      decimals="-5"
      id="Narr_YYvMcJUSj0enPwO3QnvU3w"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_7kWtOAR1_USec_YP09u_Zg"
      decimals="-5"
      id="Narr_Ru_dfd3VU0uQslDjfowf4g"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_eMpI1Y46mEm3V5aABb_sXg"
      decimals="-5"
      id="Narr_upT5k1Y8TUyuzAbG6PMp7A"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_l6LgZROctkqAN5Bg47FtoA"
      decimals="-5"
      id="Narr_fQloYZQX3UKFpApYSz3SsA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_BtQzpxkQHkKV0xFEW6DIDQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;n.&#160;&#160;&#160;&#160;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for share-based payment awards classified as equity awards, including stock-based option awards and restricted stock, using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company calculates the fair value of stock-based option awards on the date of grant using the Black-Scholes option pricing model. &lt;span style="background:#ffffff;"&gt;This option pricing model requires estimates as to the option&#x2019;s expected term and the price volatility of the underlying stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company measures compensation expense for &lt;/span&gt;restricted stock &lt;span style="background:#ffffff;"&gt;based on the market value of the underlying stock at the date of grant&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected to recognize compensation cost for awards to employees with only service conditions that has a graded vesting schedule using the accelerated method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elects to account for forfeitures as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_TehcF3LbukSwyfq_3MRnhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;o.&#160;&#160;&#160;&#160;Net earnings (loss) per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic earnings (loss) per share is calculated by dividing the net income (loss) by the weighted average number of shares of common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), outstanding during each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Diluted earnings per share is calculated by dividing (a)&#160;the net income that includes addition of financial expenses related to convertible notes by (b)&#160;the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options and non-vested restricted stock granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_Zi7csbEQyESybyDv-RKYqw"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_Fu81K0QBwEWbaP31GJGdlA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;p.&#160;&#160;&#160;&#160;Convertible notes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;). The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company accounted for its outstanding convertible notes using the guidance set forth in the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 815 which required that the Company determine whether the embedded conversion option must be separated from the other features of the applicable note instrument and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate.&#160;The Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Starting from January 1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost. See &lt;a href="#rNewaccountingpronouncements_158576"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Note 1(r)&lt;/span&gt;&lt;/a&gt;.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_rldSNFnujkmNBG6adoOOkw"
      decimals="INF"
      id="Narr_rq9d5Iy06UKZCOQPmjbNKw"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_ZuMTJoji2k2hdLos7TjVWA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;q.&#160;&#160;&#160;&#160;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Leases are classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company determines if an arrangement is a lease at inception. Lease classification is governed by five criteria in ASC 842-10-25-2. If any of these five criteria is met, the Company classifies the lease as a finance lease. Otherwise, the Company classifies the lease as an operating lease. The Company does not have any finance leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of the lease payments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company elected the short-term lease recognition exemption for all leases with a term shorter than 12&#160;months. This means, for those leases, the Company does not recognize ROU assets or lease liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Lease terms include options to extend or terminate the lease when it is reasonably certain that the Company will either exercise or not exercise the option to renew or terminate the lease. The Company recognizes lease expenses over the lease term on a straight-line basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company applies the portfolio approach to account for the operating lease ROU assets and liabilities for certain car leases and incremental borrowing rates.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_1QWk71hQPkmPDXcBFXrenA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;r.&#160;&#160;&#160;&#160;New accounting pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt;Recently adopted accounting pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In August 2020, the FASB issued&#160;ASU 2020-06 &#x201c;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013; 40)&#x201d; (&#x201c;ASU 2020-06&#x201d;).&#160;ASU&#160;2020-06&#160;simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt&#x2014;Debt with Conversion and Other Options, for convertible instruments. ASU&#160;2020-06 updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. This will also result in the interest expense recognized for convertible debt instruments to be typically closer to the coupon interest rate when applying the guidance in Topic 835. On January&#160;1, 2024, the Company adopted ASU 2020-06&#160;using the modified retrospective method of adoption. Under this method, the Company applied the guidance to the 2024 Notes at the adoption date and was required to make an adjustment to January&#160;1, 2024, opening accumulated deficit balance and additional paid in capital.&#160;The prior period consolidated financial statements have not been retrospectively adjusted and continue to be reported under the accounting standards in effect for those periods.&#160;Under ASU 2020-06, the 2024 Notes (debt and conversion option) are accounted for as a liability.&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;The impact to the Company&#x2019;s consolidated balance sheet as of January&#160;1, 2024 resulting from its adoption of ASU 2020-06 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Updated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 415,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 414,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment Reporting: Improvements to Reportable Segment Disclosures.&#x201d; This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (the &#x201c;CODM&#x201d;) and included within each reported measure of segment profit or loss and an amount and description of its composition for other segment items. The Company adopted this standard in the current period retrospectively to all prior periods presented in its consolidated financial statements. See &lt;/span&gt;&lt;a href="#_NOTE_13_"&gt;&lt;span style="font-style:normal;font-weight:normal;background:#ffffff;"&gt;Note&#160;13&lt;/span&gt;&lt;/a&gt;&lt;span style="background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;In December 2023, the FASB issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In November 2024, the FASB issued ASU&#160;2024-03 &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures&lt;span style="font-family:'Palatino Linotype';"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_R1qrGHQXVkGXQOTJy5X44w">&lt;span style="background:#ffffff;"&gt;The impact to the Company&#x2019;s consolidated balance sheet as of January&#160;1, 2024 resulting from its adoption of ASU 2020-06 is as follows:&lt;/span&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As Reported&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Updated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Effect of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,251&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Additional paid in capital&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 415,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 414,652&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (393)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated deficit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 381,325&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 224&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_MPMo01U1DE2eTRxBhtkynA_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20251000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_Wf4l6EemkUiStX1y_Xvkzg"
      decimals="-3"
      id="Tc_G5_SPbkUX0--VLizuNEQeg_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20420000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CoqAPYNvE0GJxaaTTSDOFw"
      decimals="-3"
      id="Tc_ZsynfivCkkmPJYofBraJNQ_4_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">169000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_dQAzSMhus0mxSmrOhKnz4w_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">415045000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_Wf4l6EemkUiStX1y_Xvkzg"
      decimals="-3"
      id="Tc_j3lBfEOELEu1qoWE7RrzMw_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">414652000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CoqAPYNvE0GJxaaTTSDOFw"
      decimals="-3"
      id="Tc_0YhPvcJGokmujfA2AtJfeg_5_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-393000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_1dsKGwbXGkSrNUZcegdFHg_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-381549000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_Wf4l6EemkUiStX1y_Xvkzg"
      decimals="-3"
      id="Tc_ORO-krb7zEOTSN5LoosOkA_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-381325000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_CoqAPYNvE0GJxaaTTSDOFw"
      decimals="-3"
      id="Tc_kzagx2DzWUyGzHtiat8hGQ_6_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-224000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_znK-7iER70abBadA2TsRiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- COMMERCIALIZATION AGREEMENTS&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In October&#160;2015, the Company entered into the Amended Pfizer Agreement with Pfizer that amended and restated the Pfizer Agreement of November&#160;30, 2009. Pursuant to the amendment, the Company granted Pfizer an exclusive license in the entire world, including Israel but excluding Brazil. Pfizer acquired all the information, knowledge and permission to manufacture and sell Elelyso.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix Ltd. also agreed to provide Pfizer with:&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;1.&lt;/span&gt;Manufacturing and supply of the drug substance for its incorporation into the licensed product in consideration of an agreed price per unit.&lt;/div&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;2.&lt;/span&gt;Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.&lt;/div&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&lt;/b&gt;&#160;&#160;&#160;&#160;In October&#160;2017, Protalix&#160;Ltd. entered into the Chiesi Ex-U.S. Agreement with respect to the commercialization of pegunigalsidase alfa (hereafter&#160;&#x2013;&lt;span style="direction:rtl;"&gt;&#160;&lt;/span&gt;the drug) for the treatment of Fabry disease. Under the terms of the Chiesi Ex-U.S. Agreement, Protalix&#160;Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets outside of the United States. At the effective date, Protalix&#160;Ltd. had maintained the exclusive commercialization rights to the drug in the United States, which rights were subsequently granted to Chiesi in July&#160;2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix&#160;Ltd. is mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted and (ii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#x2019;s requests.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The consideration consists of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Upfront, non-refundable payment of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in development costs, capped at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$10.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million per&#160;year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments for additional studies, as may be approved from time to time by Chiesi.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Milestone payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$320.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi Ex-U.S.Agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;5.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments as consideration for the supply of the drug. The payment will vary from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;15%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;35%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of Chiesi&#x2019;s average selling price of the drug, depending on the amount of annual sales.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;6.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Protalix Ltd. will be the sole manufacturer of the drug.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Chiesi does not have sublicensing rights (except for certain territories).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In July 2018, Protalix Ltd. entered into the Chiesi US Agreement with respect to the commercialization of the drug for the treatment of Fabry disease. Under the terms of the Chiesi US Agreement, Protalix Ltd. granted to Chiesi exclusive licensing rights for the commercialization of the drug for all markets in the United States. Protalix Ltd. is mainly responsible for (i)&#160;continuing the development of the drug until a regulatory approval is granted, (ii)&#160;continuing certain clinical development efforts in relation to the drug after a regulatory approval is granted and (iii)&#160;manufacture and supply the drug to Chiesi, based on Chiesi&#x2019;s requests.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The consideration consists of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Upfront, non-refundable payment of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$25.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$20.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in development costs, capped at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$7.5&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million per&#160;year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Payments for additional studies, as may be approved from time to time by Chiesi.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Milestone payments of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$760.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million with respect to certain regulatory and commercial events as defined in the Chiesi US Agreement, which has been reduced to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$735.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;5.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Additional payments as consideration for the supply of the drug. The payment will vary from &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;15%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;40%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of Chiesi&#x2019;s average selling price of the drug, depending on the amount of annual sales.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;6.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Protalix will be the sole manufacturer of the drug.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Chiesi does not have sublicensing rights.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;c.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;On June&#160;18, 2013, Protalix Ltd. entered into the Brazil Agreement with Fiocruz for BioManguinhos. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_YOGpnjsFYUmoeJZPBCVsFQ"
      decimals="-5"
      id="Narr_Q5TmOfcpZUycl8GXPbXRBQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">25000000</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_YOGpnjsFYUmoeJZPBCVsFQ"
      decimals="-5"
      id="Narr_xn67yzgz-EaqFhF4sMmSkg"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">25000000</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_YOGpnjsFYUmoeJZPBCVsFQ"
      decimals="-5"
      id="Narr_bA40dRdewkCs7rgY1ZgCPQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">10000000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_YOGpnjsFYUmoeJZPBCVsFQ"
      decimals="-5"
      id="Narr__XUpFHVCq0e7Oiidj2ew2A"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">320000000</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_B46HhSBVz0yrsK0DY71Erw"
      decimals="2"
      id="Narr_CIWYor9Usk6Yx6bcRRxuVQ"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3WAGON0zpU6ERbyAHqCRzA"
      decimals="2"
      id="Narr_j45Y3q6wi02mXvF2Snc8Jg"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:UpfrontNonrefundableNoncreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA"
      decimals="-5"
      id="Narr_Rgk_rtDCSkSxCvEGA5-xfQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">25000000</plx:UpfrontNonrefundableNoncreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA"
      decimals="-5"
      id="Narr_QQAkk7mVmEG-8WcYuwXXgQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20000000</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA"
      decimals="-5"
      id="Narr_nvBCtDXQokWX2kbSRnOqhQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_AocDzl10TkytnnPZqwKMyA"
      decimals="-5"
      id="Narr_MfcYNAYKDkKeekFkDMxKFA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">760000000</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_12_31_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_t_yYq1YsV0acGDoyhAPn0w"
      decimals="-5"
      id="Narr_niiKtmPgpUKlz2fGC0-1Rg"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">735000000</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_S5aqBYd2ZEqjmaTVHLVYcA"
      decimals="2"
      id="Narr_olIWjFpvX0ynTbhfIAx7eA"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_rPFgBIuGN0iZ81CflTcjcA"
      decimals="2"
      id="Narr_5s0ne9b60kqTa4MR5aGH3w"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.40</plx:PaymentOnNetSalesPercentage>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_1yhOn8UZL0-dzpDBL0ZUBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Composition of property and equipment grouped by major classifications is as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,043&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,644&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,913&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less &#x2013; accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,688)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35,739)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,973&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&lt;/b&gt;Depreciation in respect of property and equipment totaled approximately $1.1&#160;million, $1.2&#160;million and $1.3&#160;million for the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_jYu1UV6NlEyRLtS4sXbpiA">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Composition of property and equipment grouped by major classifications is as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,043&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,084&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,644&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,913&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,661&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less &#x2013; accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,688)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35,739)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,973&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_ur7u-fiQ5k-UQkYO2y0uwQ"
      decimals="-3"
      id="Tc_s_jydl1iMECMuBD2e0zhnQ_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">18933000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_LaboratoryEquipmentMember_h6xjOEjkiUm3MR0Og5Jvhg"
      decimals="-3"
      id="Tc_OnecnT6630SrbkQa9Bh0fg_3_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19043000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_PjfN7L5Bbk2NLvVOBqJ8Lw"
      decimals="-3"
      id="Tc_fZiwQ_ZIA0WwYLUnU5RpUw_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3084000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_plx_FurnitureAndComputerEquipmentMember_S7h6B8zov0uIXGD5I22dew"
      decimals="-3"
      id="Tc_s991rNTfD0S0rKFxwxoYEw_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3374000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_EF4dwmnF_kWBNzMVSjLHhQ"
      decimals="-3"
      id="Tc_xzRQWWSmjkuk00XlTAaeag_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">17644000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_oNp3Hf3CWECKBYdKr9AjAg"
      decimals="-3"
      id="Tc_nlngp4BUD0e-mFIJdwXNXA_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">17913000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_ClXaIc16vES0jGvejYwskw_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">39661000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_PtpYqOF2WkWDAyj0iBF2sw_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">40330000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_y9Z198VhkUSV7WH_pDKQDw_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">34688000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_8AspLsP-gECHiV1HdxnRFw_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">35739000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_ErEgeq9jVUq6WTyYTWdiJA_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4973000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_-zp8wYU0fk2zyRKaVUFSTw_8_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4591000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-5"
      id="Narr_xdAL_xkm-EG1tAF0Wo7Orw"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-5"
      id="Narr_7L4cJmOUIkiwNTybKGymBA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-5"
      id="Narr_89-WfwbwXkO3HYM_IXMKow"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1300000</us-gaap:Depreciation>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_8mXBP0KLBkmVzF7yyvSySQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;4&#160;- INVENTORIES&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Inventories at December&#160;31, 2023 and 2024 consisted of the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,549&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,243&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&lt;/b&gt;During the&#160;years ended December&#160;31, 2022, 2023 and 2024, the Company recorded approximately $0.04&#160;million, $0.8&#160;million and $0.09&#160;million, respectively, for write-down of inventory under cost of goods sold.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_UPWnbWl5nUK3d5zYjdpwOw">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Inventories at December&#160;31, 2023 and 2024 consisted of the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,549&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,045&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,243&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_T9i6OxkGekexpv3culC6cg_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4176000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_OcAfHTiJ5EaIo8bxtOOjDg_3_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4549000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_U8Q04UusAU-1T8tsPs8-6A_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">9055000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_wtiXJ2SO3U2PD6BDnRs94A_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">11245000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_cJ8DJU4Pq0GhmYKS85OSew_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5814000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_zhGUFCndLUuyWoIYTiREtQ_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5449000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_W6Wm3wQfq0qz-SU2tnN7Ow_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19045000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_krGRdbS7VkOZSmbX-QxVWw_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">21243000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-4"
      id="Narr_IUMy0x3zCkCsjJSZtROnNA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">40000.00</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-5"
      id="Narr_JyhvshVZPUqt0vdvaBX4vA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">800000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-4"
      id="Narr_C5Sodu1TEk6mapDr7EiY4g"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">90000.00</us-gaap:InventoryWriteDown>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_qm4OPaXkaUOPXfgDht-rkQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;5&#160;- LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Israeli Subsidiary is required to make a severance payment upon dismissal of an employee or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest&#160;monthly salary&#160;- one&#160;month&#x2019;s salary for each&#160;year employed) is recorded on the Company&#x2019;s balance sheets under &#x201c;Liability for employee rights upon retirement.&#x201d; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Company&#x2019;s balance sheets under &#x201c;Funds in respect of employee rights upon retirement.&#x201d; These policies are the Company&#x2019;s assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December&#160;31, 2022, 2023 and 2024, the Company deposited approximately $96,000, $142,000 and $&lt;span style="direction:rtl;"&gt;32,000&lt;/span&gt;, respectively, with insurance companies in connection with its severance payment obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In accordance with the current employment agreements with certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#x2019;s rights upon retirement. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&#x2019;s balance sheets, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#x201c;Contribution Plans&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The amounts of severance pay expenses were approximately $945,000, $801,000 and $&lt;span style="direction:rtl;"&gt;820,000&lt;/span&gt; for each of the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively, of which approximately $800,000, $798,000 and $&lt;span style="direction:rtl;"&gt;859,000&lt;/span&gt; in the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively, were in respect of the Contribution Plans. Gain (loss) on amounts funded in respect of employee rights upon retirement totaled approximately $(3,000), $50,000 and $18,000 for the&#160;years ended December&#160;31, 2022, 2023 and 2024, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company expects to contribute approximately $&lt;span style="direction:rtl;"&gt;956,000 &lt;/span&gt;in the&lt;span style="direction:rtl;"&gt; &lt;/span&gt;year ending December&#160;31, 2025 to insurance companies in connection with its severance liabilities, approximately $&lt;span style="direction:rtl;"&gt;931,000 &lt;/span&gt;of which will be contributed to one or more Contribution Plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;During the five-year period following December&#160;31, 2024, the Company expects that up to 10 employees may retire upon normal retirement age.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <plx:EmployeeSeveranceObligationPayment
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="0"
      id="Narr_3Fzebx2YKU-LeC7_9DID7A"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">96000</plx:EmployeeSeveranceObligationPayment>
    <plx:EmployeeSeveranceObligationPayment
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="0"
      id="Narr_5l1EtSMv3EyVXUHHvgl-2w"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">142000</plx:EmployeeSeveranceObligationPayment>
    <plx:EmployeeSeveranceObligationPayment
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="0"
      id="Narr_fgf__r05OUmebgfY46Ye7A"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">32000</plx:EmployeeSeveranceObligationPayment>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="0"
      id="Narr_u4J8simrSUazBvwqJmHiTw"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">945000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="0"
      id="Narr_xKeITlOtCES8BMY0cb-NaQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">801000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="0"
      id="Narr_v84AgIjSAUupvNOGCQm7Jg"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">820000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="0"
      id="Narr_cZySKQnDM02_vBpnL21OHQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="0"
      id="Narr_QjVoEmRezkulTq_umk3Wiw"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">798000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="0"
      id="Narr_-YgMJ2sZbEG0njOxWj2N8g"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">859000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="0"
      id="Narr_zR57-cKTqEOGWphdkbafIA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-3000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="0"
      id="Narr_Hillohs8xE6Nyts2owvKCA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">50000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="0"
      id="Narr_YTU8n_4NKUCfa_r0Eco-UQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">18000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="As_Of_12_31_2024_us-gaap_RetirementPlanTypeAxis_us-gaap_DefinedBenefitPostretirementLifeInsuranceMember_wUeqT_M4AEqDZuDuEQf3xw"
      decimals="0"
      id="Narr_tx4n4ZUGC0qp3vjy86h0pA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">956000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="As_Of_12_31_2024_us-gaap_RetirementPlanTypeAxis_plx_ContributionPlansMember_Mp-0M08qeUKO7h9uqA1McQ"
      decimals="0"
      id="Narr_lmqdv4YhGUOZqUOG-W5zpQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">931000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <plx:NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears
      contextRef="As_Of_12_31_2024_srt_RangeAxis_srt_MaximumMember_iREdhYdsg0S_5qYZGs1pFw"
      decimals="INF"
      id="Narr_t--bRf6jDUiriL_ktEsyFA"
      unitRef="Unit_Standard_employee_ocaisUO_C0WWcRJExAkgCA">10</plx:NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_-o1La22ml0Sm7SP5Jp3zKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;6&#160;- COMMITMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;Royalty Commitments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is obligated to pay royalties to the National Authority for Technological Innovation (&#x201c;NATI&#x201d;) on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from NATI or its predecessor, the Office of the Israeli Innovation Authority (IIA). At the time the grants were received, successful development of the related projects was not assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In the case of failure of a project that was partly financed as described above, the Company is not obligated to pay any such royalties or repay funding received from NATI or the IIA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Under the terms of the applicable funding arrangements, royalties of 3% to 6% are payable on the sale of products developed from projects funded by NATI or the IIA, which payments shall not exceed, in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January&#160;1, 2001, interest at an annual rate based on SOFR. In addition, if the Company receives approval to manufacture products developed with government grants outside the State of Israel, it will, subject to certain exceptions, be required to pay an increased total amount of royalties, depending on the manufacturing volume that is performed outside the State of Israel, and, possibly, an increased royalty rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Royalty expenses to NATI or the IIA are included in the statement of operations as a component of the cost of revenues and were approximately $1.2&#160;million, $1.9&#160;million and $1.6&#160;million during the years ended December&#160;31, 2022, 2023 and 2024, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;At December&#160;31, 2023 and 2024, the maximum total royalty amount payable by the Company under these funding arrangements is approximately $35.5&#160;million and $33.9&#160;million, respectively (without interest, assuming 100% of the funds are payable).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Subcontracting Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has entered into sub-contracting agreements with several clinical providers and consultants in Israel, the United States and certain other countries in connection with its primary product development process. As of December&#160;31, 2024, total commitments under said agreements were approximately $1.5&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Fill/Finish Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:10pt;"&gt;On August&#160;29, 2022, the Company entered into a Fill/Finish Agreement (the &#x201c;F/F&#160;Agreement&#x201d;) and a Letter Agreement, in each case with Chiesi. The Company agreed to supply Chiesi with drug substance for pegunigalsidase alfa and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide the Company with commercial fill/finish services for pegunigalsidase alfa, including to support the global launch of pegunigalsidase alfa. The F/F&#160;Agreement did not change the terms and conditions of the Chiesi Agreements. Subsequently, in November 2024, the Company and Chiesi amended the F/F&#160;Agreement to provide that a different Chiesi facility may act as a secondary supplier of such services and that the F/F&#160;Agreement shall have an initial term of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;10&#160;years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement. Prior to expiration of the initial term, the term may be extended by mutual agreement for an additional period of &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;seven years&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; upon mutual written agreement prior to expiration of the initial term. Under the F/F&#160;Agreement, the Company is obligated to pay to Chiesi an amount equal to &lt;/span&gt;&#x20ac;2.5&#160;million in connection with the necessary technology &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10.5pt;margin:0pt 0pt 0pt 54pt;"&gt;transfer, QA tests and capital expenditures. &lt;span style="font-size:10pt;"&gt;Such amount is to be paid over the term of the F/F agreement based on the actual vials produced by Chiesi thereunder. Under the amendment, the Company and Chiesi agreed to share equally the costs of establishing the new facility as an alternative source for Fill/Finish. The Company&#x2019;s share of such costs amounting to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$400,000&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; shall be due and payable upon Chiesi&#x2019;s completion of the manufacture of the requisite validation batches and issuance of the process validation report.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <plx:RoyaltiesOnSaleOfProducts
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_qm_86HOq70OOencxym3GVg"
      decimals="2"
      id="Narr_i80oo-7dGkWyIL01lbD6rw"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.03</plx:RoyaltiesOnSaleOfProducts>
    <plx:RoyaltiesOnSaleOfProducts
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember__u8SZ_kTp0GNsmMYnwI58Q"
      decimals="2"
      id="Narr_QP0p-xdbWUucjJgpHQLRJQ"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.06</plx:RoyaltiesOnSaleOfProducts>
    <plx:PercentageOfRoyaltiesToGrantReceived
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_uwDD5nTakUC2KmTkoR6W8g"
      decimals="2"
      id="Narr_sr_LCsZ_J0mtliHwTB1P_Q"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">1</plx:PercentageOfRoyaltiesToGrantReceived>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_HeexSHIpsECzwXPmjXRSIg"
      decimals="-5"
      id="Narr_enXT7c3OPk-rkQ-rGqrlwQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_07Y7_KkIgE2gCqBzVKzHGA"
      decimals="-5"
      id="Narr_0KvkrO79FkiZDPgkXZa4Ew"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1900000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_0jCSqJ2VNUGntWiwLim66g"
      decimals="-5"
      id="Narr_xa2qY-M9CUuQkY_t-xjQuQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1600000</us-gaap:RoyaltyExpense>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2023_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_VUjg-GUWqkaM24vUWwpyKQ"
      decimals="-5"
      id="Narr_hFLFfQZN5UuIpRnTDhXVAw"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">35500000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2024_srt_CounterpartyNameAxis_plx_OfficeOfIsraeliInnovationAuthorityMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_RoyaltyAgreementTermsMember_uwDD5nTakUC2KmTkoR6W8g"
      decimals="-5"
      id="Narr_Bdb8Ap6lfki8nNdpqrLP3A"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">33900000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <plx:CommitmentAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_TypeOfArrangementAxis_us-gaap_NoncollaborativeArrangementTransactionsMember_7_J4-MrHIkS9N0JY0GZlRw"
      decimals="-5"
      id="Narr_lnP6hG5Qck6quVybigTICg"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1500000</plx:CommitmentAmount>
    <plx:InitialTermOfArrangement
      contextRef="Duration_11_1_2024_To_11_30_2024_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_7SbCZK859Uiaib6y5h0qfQ"
      id="Narr_fbNfXuWBIUGjYwcKSEvvNQ">P10Y</plx:InitialTermOfArrangement>
    <plx:ExtendedTermOfAgreement
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_HhtwKHGlsEOO6RfMSrfRww"
      id="Narr_e-TgyKLd_0evJOLD0r8F7g">P7Y</plx:ExtendedTermOfAgreement>
    <plx:ContractAmountUnderAgreementPayable
      contextRef="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_CtbP6sYsCUSsa4BOxiiwkw"
      decimals="-5"
      id="Narr_a_E8xAbbWUiA_Wuu0vER7g"
      unitRef="Unit_Standard_EUR_iTLnFIhgHUOHLxUiOlWFJw">2500000</plx:ContractAmountUnderAgreementPayable>
    <plx:ContractAmountUnderAgreementFacilityPayable
      contextRef="As_Of_9_30_2024_us-gaap_TypeOfArrangementAxis_plx_FillFinishAgreementMember_OUM-7GtNokqwYO6vx-ub9A"
      decimals="0"
      id="Narr_OHgZxFL9TEudOo8N9T9tnA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">400000</plx:ContractAmountUnderAgreementFacilityPayable>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_gqGhGvyjdkGl7WCRNh9dtQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE 7 - OPERATING LEASES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is a party to several lease agreements for its facilities, the latest of which has been extended until 2026. The Company has the option to extend certain of such agreements on one additional occasion for an additional five-year period. During the extended lease period, the aggregate&#160;monthly rental payments will increase by 7.5%-10% for the option. The Company expects to exercise the final option in future periods. As of December&#160;31, 2024, the Company provided bank guarantees of approximately $513,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company entered into several three-year leases for vehicles which are regularly amended as new vehicles are leased.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth data regarding the Company&#x2019;s operating leases for the years ended December&#160;31, 2022, 2023 and 2024:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.89%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,471&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,639&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,634&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth a maturity analysis of the Company&#x2019;s operating lease liabilities as of December&#160;31, 2024:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,040&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2029 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_K6MzxDGN10m12r_1KkFvgA">true</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="INF"
      id="Narr_zjA88L_6D0aMJDdRMgqmdw"
      unitRef="Unit_Standard_item_ZOMDUvl2U0qDBOvYPFWWmQ">1</plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      id="Narr_iQYqoQX9_kSsmEojUwu9kA">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_W3yUCAONf0SfAzEtMt6Mbw"
      decimals="3"
      id="Narr_52Xa8G1zq06KE-2ABApH-g"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.075</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
    <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_XGzd5dVqLk6U007ZQL4UiQ"
      decimals="2"
      id="Narr_MU-txTH8OEK1RvIxrpsB3Q"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.10</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="0"
      id="Narr_CiLNrRPdjUC03GXq3GTCxA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">513000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_pqIJYP9qBkuWs3kgYe1bCA"
      id="Narr_s2cGuVkrjEibEj76qwXlsg">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_WXyvaKUzo065fg3Whjv5Aw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth data regarding the Company&#x2019;s operating leases for the years ended December&#160;31, 2022, 2023 and 2024:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.89%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,471&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,639&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,634&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_jZ9WWCBugkqfxKS87irfOA_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1398000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_hQf_3964m0q0TDkpVo_9JQ_3_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1471000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_Z0Y4nFH8dE-iIcZztSG6Pg_3_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1639000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_qms7_W8_C0W7k1Cxk4iVUg_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1404000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_s-Jjj-eSekenNUimSGyzvQ_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1484000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_tLnOyzulz02xMwmYMMBaZw_4_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1634000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg"
      id="Tc_pJvHd3US6Ua3Tdxsroa_xg_5_3">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      id="Tc_ztlgWYPP30Sd6P-sByE0Sw_5_6">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      id="Tc_zr89N1p1d0WR0nDsGqp3DA_5_9">P6Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg"
      decimals="3"
      id="Tc__4qix_r5g0qshlvz3IGUpQ_6_3"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="3"
      id="Tc_VpuQ9YtMSk698m92OINakA_6_6"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="3"
      id="Tc_byluLK82QUKUErYoSHFZaA_6_9"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_0XhrUjwmyEiBfDrA3cY_qA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth a maturity analysis of the Company&#x2019;s operating lease liabilities as of December&#160;31, 2024:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,040&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2029 and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_g62jWwenpkahBlwTnZ0KfA_2_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_IIHuNPzok0eiRWF73WiaxA_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1241000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_eVghGPqv_kK_WeAF_u2khQ_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1085000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_kNPl5x9RBUGrhX8kzG3bsg_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1040000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_lGfXkWzHGkKGF4vcVac8Cg_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3003000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_UExjDXkN2UmltEnB9oxrhA_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">7869000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_BjE1km7rBEOvFhzfTod0Sg_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2343000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_NpJGroqSLEW0H7KIUxANBw_9_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">5526000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_tQhjd1HGh0WhBO71oqsZ3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;8&#160;- SHARE CAPITAL&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;a.&#160;&#160;&#160;&#160;Authorized Capital&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Under the Company&#x2019;s Certificate of Incorporation, as amended, the Company is authorized to issue 185,000,000 shares of Common Stock and 100,000,000 shares of preferred stock, par value $0.0001 per share. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:18pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;b.&lt;/b&gt;&lt;/span&gt;Rights of the Company&#x2019;s Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s Common Stock is listed on the NYSE American. The Company voluntarily delisted its Common Stock from the Tel Aviv Stock Exchange effective March&#160;22, 2023. Each share of Common Stock is entitled to one vote. The holders of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Stock based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On December&#160;14, 2006, the Board of Directors adopted the Protalix BioTherapeutics,&#160;Inc. 2006 Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). The Plan has since been amended to, among other things, increase the number of shares of Common Stock available under the Plan to 17,475,171 shares. The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Sections&#160;102 and 102A of the Israeli Income Tax Ordinance (the &#x201c;Ordinance&#x201d;). Each option grant made to an Israeli citizen is subject to the track chosen by the Company, either Section&#160;102 or Section&#160;102A of the Ordinance, and pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company&#x2019;s accounts, in respect of options granted to employees under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees, the share option plan is subject to Section&#160;3(i) of the Ordinance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2024, 4,139,412 shares of Common Stock remain available for grant under the Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The vesting period of the outstanding options and restricted shares is generally &lt;span style="-sec-ix-hidden:Hidden_HsTYEK9eRkCkgOq9_9rEew;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; or four years from the date of grant. The rights of common stock obtained from the exercise of options (once vested) and the restricted stock are identical to those of other common stock of the Company. The contractual term of these options is primarily for ten years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;For purposes of determining the fair value of restricted stock granted to employees and non-employees, the Company&#x2019;s management uses the fair value of the Common Stock. &lt;span style="background:#ffffff;"&gt;The fair value of options granted for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 54pt;"&gt;1.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Options and restricted stock granted to employees and directors:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A summary of share option plans, and related information, under all of the Company&#x2019;s equity incentive plans for the&#160;year ended December&#160;31, 2024, and the effect of share-based compensation on the statement of operations for the&#160;year ended December&#160;31, 2024, is as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Options granted to employees and directors:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,965,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,015,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Forfeited  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (326,969)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (252,062)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,402,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,247,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;b)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Restricted stock granted to employees:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;&lt;/b&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;  &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; of fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at grant date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; 1,173,670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; 704,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; (23,410)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; (992,313)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non vested at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; 862,816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;c)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;The following table summarizes information concerning outstanding and exercisable options as of December&#160;31, 2024:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;width:58.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;end&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$1.03-$2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,899,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,744,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$3.55-$3.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 994,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 994,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$4.69-$5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 435,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 435,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$17.20 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,402,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,247,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;&lt;span style="color:#231f20;"&gt;As of December&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;&#160;&lt;/span&gt;&lt;span style="color:#231f20;"&gt;31, 2024, the aggregate intrinsic value of all the outstanding options and exercisable&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.1pt;"&gt; &lt;/span&gt;&lt;span style="color:#231f20;"&gt;options&lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt; was approximately &lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;$&lt;/span&gt;1.0&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;&#160;million and &lt;/span&gt;&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;$&lt;/span&gt;0.5&lt;span style="color:#231f20;letter-spacing:0.05pt;"&gt;&#160;million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;d)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;The weighted average grants date fair value of restricted stock granted in 2022, 2023 and 2024 was $0.82, $1.99 and $1.24, respectively.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;e)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;The fair value of each option granted during 2022, 2023 and 2024 for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the options&#x2019; fair value on their grant date:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Weighted average grants date fair value (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Exercise price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;f)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;The total unrecognized compensation cost of employee stock options at December&#160;31, 2024 is approximately $1.3&#160;million. The unrecognized compensation cost of employee stock options is expected to be recognized over a weighted average period of 0.8&#160;years.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;"&gt;During the three years ended December&#160;31, 2024, there were no exercises of stock options, and the Company did not realize any tax benefit in connection with any exercises.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 89.85pt;"&gt;&lt;span style="background:#ffffff;"&gt;The total vesting-date value of equity classified restricted stock vested during &lt;/span&gt;the year ended December&#160;31, 2024&lt;span style="background:#ffffff;"&gt; was &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$&lt;/span&gt;1.2&lt;span style="background:#ffffff;"&gt;&#160;million. As of December&#160;31, 2024, the unrecognized compensation cost related to all unvested equity classified restricted stock of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$&lt;/span&gt;0.6&lt;span style="background:#ffffff;"&gt;&#160;million is expected to be recognized as an expense over a weighted-average period of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;0.7&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;years.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:72pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;g)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;The following table illustrates the effect of share-based compensation on the statement of operations:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 631&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 589&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,253&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Private and 144A Offerings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;During the year ended December&#160;31, 2022&lt;/span&gt;, the Company issued 1,000 shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $2,360 from such exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;During the year ended December&#160;31, 2023&lt;/span&gt;, the Company issued (i)&#160;301,810 shares of Common Stock in connection with the cash exercise of a warrant issued in 2020 and generated proceeds equal to $0.7&#160;million from such exercise and (ii)&#160;237,012 shares of Common Stock in connection with the cashless exercise of a &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;warrant to purchase 845,000 shares of Common Stock issued in 2020. The Company did not generate any proceeds from the cashless exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="background:#ffffff;"&gt;During the year ended December&#160;31, 2023&lt;/span&gt;, the Company issued, in the aggregate, 4,691,623 shares of Common Stock in connection with the conversions of 2024 Notes. In connection with such conversions, during &lt;span style="background:#ffffff;"&gt;the year ended December&#160;31, 2023&lt;/span&gt;, the Company paid to the converting holders $0.9&#160;million representing cash payments due to accrued but unpaid interest, make-whole interest payments and payments in lieu of fractional shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;At-the-Market (ATM) Offering&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July&#160;2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;) which was amended on May&#160;2, 2022. Pursuant to the terms of the 2021 Sales Agreement, the Company was able to sell from time to time through the Agent&lt;span style="background:#ffffff;"&gt;, shares of Common Stock having an aggregate offering price of up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$20.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million &lt;/span&gt;(the &#x201c;ATM Shares&#x201d;)&lt;span style="background:#ffffff;"&gt;. &lt;/span&gt;During the term of the 2021 Sales Agreement which ended during the quarter ended March&#160;31, 2023, the Company sold a total of 13,980,060 ATM Shares for total gross proceeds of approximately $20.0&#160;million, thereby completing the ATM program under said agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into an At The Market Offering Agreement (the &#x201c;2023 Sales Agreement&#x201d;) with the Agent. Pursuant to the terms of the 2023 Sales Agreement, the Company may sell, from time to time through the Agent, ATM Shares having an aggregate offering price of up to &lt;span style="background:#ffffff;"&gt;$20.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has no obligation to sell any shares of Common Stock under the 2023 Sales Agreement, and may at any time suspend sales under the 2023 Sales Agreement or terminate the 2023 Sales Agreement in accordance with its terms. The Agent is entitled to a commission of up to 3.0% of the aggregate gross proceeds from the shares of Common Stock sold under the 2023 Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the year ended December&#160;31, 2022, the Company sold, in the aggregate, 7,473,038 shares of Common Stock under the 2021 Sales Agreement. The Company generated gross proceeds equal to approximately $8.7&#160;million in connection with such sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the year ended December&#160;31, 2023, the Company sold, in the aggregate, 12,560,150 shares of Common Stock under the 2021 Sales Agreement and 2023 Sales Agreement. The Company generated gross proceeds equal to approximately $24.9&#160;million in connection with such sales. All such sales were completed during the quarters ended March&#160;31, 2023 and June&#160;30, 2023. No sales were completed during the six months ended December&#160;31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;During the year ended December&#160;31, 2024, the Company sold, in the aggregate 2,216,692 shares of Common Stock under the 2023 Sales Agreement. The Company generated gross proceeds equal to approximately $3.8&#160;million in connection with such sales (issuance cost was approximately $0.1&#160;million). All such sales were completed during the quarter ended December&#160;31, 2024. Subsequent to December&#160;31, 2024, the Company sold the remaining amount of shares of Common Stock available for sale under the 2023 Sales Agreement thereby completing the ATM program thereunder.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_JGtJnGZ6rU2mjh3fmPpqvQ"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_Z66lYzA43kuwQVHk-opYTA"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_9GKyRUnSHU-EGS8bZy3mZA"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <plx:CommonStockNumberOfVotingRights
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_zcanYFy2p0aKsj0vaDiO4Q"
      unitRef="Unit_Standard_Vote_0mlCI0gGfUK1x1wJKqfHQQ">1</plx:CommonStockNumberOfVotingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_tq949hURe0qn3llpv8mqpw"
      decimals="INF"
      id="Narr_mpvA1okKskq6xfelZaAamw"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">17475171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="INF"
      id="Narr_CICj4_5oDkmUkOYIsMfR-A"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">4139412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_ACAfcts15EeexRuNnjxxSA"
      id="Narr_5tAqo-KkgUKYceqrCpmEuw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_plx_OptionsAndRestrictedSharesMember_EUp6tTdW0UGDY4bhmHe7MA"
      id="Narr_GChgm0Nst0u-ZMoNk5VHiA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_JaEe-wVdPkeRXo0eICR-VQ">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:72pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Options granted to employees and directors:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,965,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,015,725&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Forfeited  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (326,969)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (252,062)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,402,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,247,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.49&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gk0_QwpkNUi8I2fbbRac5A"
      decimals="INF"
      id="Tc_WIBHsqJvj0eeZbQSQj-JyA_6_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">6965601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gk0_QwpkNUi8I2fbbRac5A"
      decimals="2"
      id="Tc_z67vqcZS-U2j8Oc3RS9HUw_6_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g"
      decimals="INF"
      id="Tc_ygZ_lLYjdkewtRpTD5dgKA_8_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">1015725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g"
      decimals="2"
      id="Tc_1Yym2ACU00OlzYO48hBZJA_8_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.1</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g"
      decimals="INF"
      id="Tc_7YQ_8bX-6EO2t0PO9_tNhQ_9_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">326969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g"
      decimals="2"
      id="Tc_hBzuH4tJDE2VeoIliBMfyw_9_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g"
      decimals="INF"
      id="Tc_3kSMN5eZ4EKF3ZsQEAW-YQ_10_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">252062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_cxOJIUIleU-8ZI39KIEO0g"
      decimals="2"
      id="Tc_pU_A4eF9HkOBfuzvGhhQVg_10_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">3.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_V7gvzO9fdE2ntwQ96Fp-5Q"
      decimals="INF"
      id="Tc_pZYTeIv5FUmENmanrySvBA_11_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">7402295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_V7gvzO9fdE2ntwQ96Fp-5Q"
      decimals="2"
      id="Tc_NtJ_QhmWCUyM3Lt6wVu02Q_11_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_V7gvzO9fdE2ntwQ96Fp-5Q"
      decimals="INF"
      id="Tc_BdUnDk8bDkmEIaluY_AVTg_12_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">4247896</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_V7gvzO9fdE2ntwQ96Fp-5Q"
      decimals="2"
      id="Tc_S83D6UoevEyfjSvE2CdBmQ_12_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">2.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_9TNZKzPMTE2kEdieYWA-eA">Restricted stock granted to employees:&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:69.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:46.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;&lt;/b&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;  &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; of fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at grant date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at beginning of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; 1,173,670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Changes during the year:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; 704,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; (23,410)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;  Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; (992,313)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non vested at end of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; 862,816&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_gI5UhphCH06Ect3eEtQGMg"
      decimals="INF"
      id="Tc_GjoU4GB7F0aTHl5Xgdo0VQ_6_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">1173670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_gI5UhphCH06Ect3eEtQGMg"
      decimals="2"
      id="Tc_5PwYJEJ6BUShCOSxqnEd3w_6_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ"
      decimals="INF"
      id="Tc_Z5QnOERk-06-nyPWu58wJw_8_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">704869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ"
      decimals="2"
      id="Tc_09P-NuZdB0KO1CSHRyzaLg_8_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ"
      decimals="INF"
      id="Tc_gGD7vQDKd0iJu9SUypAmng_9_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">23410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ"
      decimals="2"
      id="Tc_-CYilF36oU2dSrY2hK5S9A_9_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ"
      decimals="INF"
      id="Tc_MutQqKjn2Uujs5O1R5M5LQ_10_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">992313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_OslryCM450ufP6xjRZq-UQ"
      decimals="2"
      id="Tc_oGKXSeAl5UODK9MyQkJaRQ_10_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AzD7wSLn2kKSXb3VDmVzTQ"
      decimals="INF"
      id="Tc_trttbJNi9kGVot9_FF2QNQ_11_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">862816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_plx_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AzD7wSLn2kKSXb3VDmVzTQ"
      decimals="2"
      id="Tc_MJyjDqJkQ0e3L8Y2ZJX0Jw_11_5"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_OtdCdYXN80m4wQ0maiBgtA">The following table summarizes information concerning outstanding and exercisable options as of December&#160;31, 2024:&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;width:58.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;end&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$1.03-$2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,899,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,744,767&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$3.55-$3.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 994,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 994,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$4.69-$5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 435,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 435,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$17.20 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,950&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.21&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,402,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,247,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_ZwQZST8ycESPqOtaPxvgmg"
      decimals="2"
      id="Narr_8nG2C0LhNkGIYYRVXAMwGg"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.03</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_ZwQZST8ycESPqOtaPxvgmg"
      decimals="2"
      id="Narr_N6yG0Hjqs0qHEaLPBqkJtQ"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">2</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_Ggw7m_bIUEukSBW28yKxbA"
      decimals="INF"
      id="Tc_TkuSCz_D5UWmeiN9qEum6A_8_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">5899166</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_ZwQZST8ycESPqOtaPxvgmg"
      id="Tc_XDDhHOeKhkuMbmXnMHA-rQ_8_4">P7Y11M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_Ggw7m_bIUEukSBW28yKxbA"
      decimals="INF"
      id="Tc_THhTsODyGUyjeSvAcRlP2g_8_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">2744767</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice103To200Member_ZwQZST8ycESPqOtaPxvgmg"
      id="Tc_U9tmrecbDk2PdfKjcZtyKA_8_8">P6Y11M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_i8MSOPNUfk-c4_p410zsvA"
      decimals="2"
      id="Narr_HULJHnk2jEmHHhx7SToZow"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">3.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_i8MSOPNUfk-c4_p410zsvA"
      decimals="2"
      id="Narr_Hlwr1SA6sUqL-3Z8gKK-2A"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">3.73</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_CZ0iGJrw8kGgZlq0gK2Vkw"
      decimals="INF"
      id="Tc_iFnRMK2wsUa4lrpq-nkZwA_9_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">994679</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_i8MSOPNUfk-c4_p410zsvA"
      id="Tc_AO9Wkar4l0SOd3gz-AM8Pw_9_4">P4Y7M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_CZ0iGJrw8kGgZlq0gK2Vkw"
      decimals="INF"
      id="Tc_1-WYElFqy0OZFEYlC6ubWA_9_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">994679</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice355To373Member_i8MSOPNUfk-c4_p410zsvA"
      id="Tc_tCUVjih8g0WgkyfxmPhY_w_9_8">P4Y7M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_D7MJGpt1U0KbxRKh_zdQpA"
      decimals="2"
      id="Narr_Y4O6AcSHqkuZX6b6I0LjqQ"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">4.69</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_D7MJGpt1U0KbxRKh_zdQpA"
      decimals="2"
      id="Narr_Zo16E8zKfEWsuiL7UigaUg"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">5.6</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_c58oJTn8dU-QqeJQC9hc2g"
      decimals="INF"
      id="Tc_3AQX_yHQ502XDl9DVEdAqw_10_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">435500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_D7MJGpt1U0KbxRKh_zdQpA"
      id="Tc_z_-szT0C8EOZpLDRj7HqCA_10_4">P3Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_c58oJTn8dU-QqeJQC9hc2g"
      decimals="INF"
      id="Tc_-Uu4e-PF6kG4gZWDm4E8Xg_10_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">435500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice469To560Member_D7MJGpt1U0KbxRKh_zdQpA"
      id="Tc_0TFOQEBHPEuNlpq_RoyHsA_10_8">P3Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_6w7SOn5UPUu_KdKhVUxCsA"
      decimals="2"
      id="Narr_PWEseGJU5ESkzWVMFOKfFw"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">17.2</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_k1pPvAGNuUqJ8-G1h9Wyeg"
      decimals="INF"
      id="Tc_EkgKeugyzkSZAizyqezMYw_11_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">72950</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_6w7SOn5UPUu_KdKhVUxCsA"
      id="Tc_q6HgaPnwdkSjRZVGzuI3pw_11_4">P0Y2M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_k1pPvAGNuUqJ8-G1h9Wyeg"
      decimals="INF"
      id="Tc_yhJUVfK54ku8JWPjhFf5ig_11_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">72950</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_plx_ExercisePrice1720Member_6w7SOn5UPUu_KdKhVUxCsA"
      id="Tc_ZmZ_RsmjrUe5uK5Lauj0cA_11_8">P0Y2M15D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A"
      decimals="INF"
      id="Tc_FiIXqzjykkmpHoyY48xM-A_12_2"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">7402295</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A"
      decimals="INF"
      id="Tc_ON52nUH9Z02cN4HESjt2YQ_12_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">4247896</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A"
      decimals="-5"
      id="Narr_oHCd2Kapd06tQKQPdrcd1g"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A"
      decimals="-5"
      id="Narr_1cWRNEnThES9pd0ok4_Jdg"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_AqEdmyQF8UC1svkRrbF5pg"
      decimals="2"
      id="Narr_PJsCMR4mLECyhVXTxduLwQ"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_yX24jpZNrE2GFNvD-IrRLg"
      decimals="2"
      id="Narr_NSQUSpiDh0Ktif5joeqBTw"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qjP7y_S0VUuKi14nuJCCzA"
      decimals="2"
      id="Narr_iQjxVScGoketlfP7QfViRw"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_rE5BDku8q0yA28KOsyIf3w">The fair value of each option granted during 2022, 2023 and 2024 for both employees and directors is estimated at the date of grant using the Black-Scholes option-pricing model. The following weighted average assumptions were applied in determining the options&#x2019; fair value on their grant date:&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Weighted average grants date fair value (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Exercise price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Expected life (Years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PjbfOLibbE-CFhp_5N4qIg"
      decimals="2"
      id="Tc_UTanaOcdG0q9HnBmFHQItQ_3_2"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.03</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0w_5kQqvoEm_P4OrjYWqWA"
      decimals="2"
      id="Tc_haKMw4Vz7UqK6TsE7blWcQ_3_4"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.84</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A"
      decimals="2"
      id="Tc_P__2L4XAmke35m1yV9QyGA_3_6"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.1</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PjbfOLibbE-CFhp_5N4qIg"
      decimals="2"
      id="Tc_ITkZ0cjObkOiFGTivkQsFQ_4_2"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0w_5kQqvoEm_P4OrjYWqWA"
      decimals="2"
      id="Tc_pbJqh9NIrE-o1Y1nSv01IQ_4_4"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A"
      decimals="2"
      id="Tc_glNvgLjcgESqiRCeSZEXmw_4_6"
      unitRef="Unit_Divide_USD_shares_e5Wb33PppE-pL9-YjTr4pQ">1.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qzrqPtv4Nk2sivn3hBJl_A"
      decimals="4"
      id="Tc_GW2dDE6vJ0eeC6mxbdmWNw_5_2"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.0332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GiEgmTjqQECUzJqeHnRG3g"
      decimals="4"
      id="Tc_Kg6gVx2iVkSK64WOHtghOQ_5_4"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.0444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ"
      decimals="4"
      id="Tc_wHtrVQrF00Cm11h_98RWsg_5_6"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.0355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qzrqPtv4Nk2sivn3hBJl_A"
      decimals="4"
      id="Tc_WRdoiiU6fEyd3HmwEhZfNg_6_2"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.8594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GiEgmTjqQECUzJqeHnRG3g"
      decimals="4"
      id="Tc_Q1Y0W7gDpEqvV1nPCBxNiQ_6_4"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.7941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ"
      decimals="4"
      id="Tc_whroeIaIvUyoRFrkwvLafQ_6_6"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.7929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qzrqPtv4Nk2sivn3hBJl_A"
      decimals="2"
      id="Tc_lfa418aKvEuHtncbLfKlaw_7_2"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GiEgmTjqQECUzJqeHnRG3g"
      decimals="2"
      id="Tc_bH1RJrvuGkymMIjv6CMNYA_7_4"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ"
      decimals="2"
      id="Tc_iU5Grp_ZFkyA-_tJqVsKbw_7_6"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qzrqPtv4Nk2sivn3hBJl_A"
      id="Tc_tt5KRIyOpUa7wFYMqwQmlQ_8_2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GiEgmTjqQECUzJqeHnRG3g"
      id="Tc_MdQClQXVz0284HLlkkLMlQ_8_4">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ"
      id="Tc_wfIDam89JkquwEu7Kzkm1Q_8_6">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_0-8b35NWo0usu_tHd5DL_A"
      decimals="-5"
      id="Narr_UXUytBKUZ0yAsvW3YDS7UA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_oXSD_KBf0kSbrQC-j47kVQ"
      id="Narr_Ws0t7weCaUaRtxbP2OiJ7g">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZT00cGmYjUugrLQ9Ej7B2Q"
      decimals="INF"
      id="Narr_fLlwNGgWrUO5Nv--_R3cLQ"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qjP7y_S0VUuKi14nuJCCzA"
      decimals="-5"
      id="Narr_381-V-Z9e06lEFk05tsjGw"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_SDy9pRI4jka-vazM2Ar37Q"
      decimals="-5"
      id="Narr_I4rLJUE1WUmSySiUZfci-g"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_qjP7y_S0VUuKi14nuJCCzA"
      id="Narr_ygeBQkZGJUuvEIaXep2fnA">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_e2uJDec5RUGhD1EbsxbkoQ">The following table illustrates the effect of share-based compensation on the statement of operations:&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 135&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 596&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 631&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 589&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Selling, general and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,448&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,253&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9RS1hcr690mkdTePbZl2Pg"
      decimals="-3"
      id="Tc_4XxF5faTm0OkIW704HBpoQ_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_GkNNnx-5s06WAA30ohh8Nw"
      decimals="-3"
      id="Tc_E1MEix9yp0Cd-R4f01ekyA_3_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_A7nWnFTiPkOdLlt5xxqpEQ"
      decimals="-3"
      id="Tc_5dKkCsZADky2uFmv5rm58Q_3_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XRg9HSXWv0C3QWfvvFGWxA"
      decimals="-3"
      id="Tc_uSTy5cIS7EClT1gyAFWjqw_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">518000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0aTAUQn5Gkm5jNYX11QpwQ"
      decimals="-3"
      id="Tc_wLquSK6vGU-xgYYSs0GVWg_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">777000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6ZtY09PpU0m9d_EG_ZwvkQ"
      decimals="-3"
      id="Tc_NwTrizRvdEenddgWsMsWng_4_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">589000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_L8FMbjn4ykuUigKlaKNOwQ"
      decimals="-3"
      id="Tc_bbb_OIwF7UqGd8I32el7KQ_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1432000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_REAyJtvAFU2ys4pnWOJcXw"
      decimals="-3"
      id="Tc_nzm19bA-40m3I1nCsEMl7A_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2075000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_UuhJLwHi6Em0GrZfesGVyA"
      decimals="-3"
      id="Tc_jnPoonOatkOn9GYeyQEx3w_5_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2033000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_jlZl4VFTgEeLtyYeYO7s6Q_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_yFFa_3qBTU-K3iZoLkG3Bw_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_3xj5uzlRg0aRccYUBvY-mw_6_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3253000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_vxkDkBSQz068hELrseMSzA"
      decimals="INF"
      id="Narr_bjoPaNS6GUOaDlhQtEpu6g"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_vxkDkBSQz068hELrseMSzA"
      decimals="0"
      id="Narr_N7XgzSDnDUarLvKMDDhRLQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2360</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xZcFCwrL3kSsF04JdIujqg"
      decimals="INF"
      id="Narr_XjDnf_8cj0GgGfO-gsBg8w"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">301810</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xZcFCwrL3kSsF04JdIujqg"
      decimals="-5"
      id="Narr_cATZxbO0jkap8Ygp45jW6Q"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">700000</us-gaap:ProceedsFromWarrantExercises>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_xZcFCwrL3kSsF04JdIujqg"
      decimals="INF"
      id="Narr_UgxBeHdEdUGdR3_QGTni0A"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">237012</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_MOfdfIKjcUiCrIPtQO8BWA"
      decimals="INF"
      id="Narr_8Fb-jAhxiUyT_B9Lm8SYMg"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">845000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VM8wfhoeo0Cfc2e6wRsqqA"
      decimals="INF"
      id="Narr_VkuUgUKBSkOQs0opKIN5kg"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">4691623</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <plx:PaymentsToDebtHoldersOnConversion
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_Notes2024Member_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VM8wfhoeo0Cfc2e6wRsqqA"
      decimals="-5"
      id="Narr_4WKB1YdZj0-KwMFCtOwanA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">900000</plx:PaymentsToDebtHoldersOnConversion>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_Yo6i5FE6pU22Md7ma24KKg"
      decimals="-5"
      id="Narr_jGAE_UdRp0iYuGcCkDgf3Q"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20000000</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2021_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_pvpGc5YOlE--wrnCQNPHeg"
      decimals="INF"
      id="Narr_7yhZLVQ9FE6qaSGkSWCB4w"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">13980060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_1_2021_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_pvpGc5YOlE--wrnCQNPHeg"
      decimals="-5"
      id="Narr_hgkdVSuTQE6svvjrbB-BNA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="As_Of_2_27_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_wXBT2eXbL0O3AsKeYlYxOA"
      decimals="-5"
      id="Narr_lA_gf0RSG0CbiSeTrLonyg"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20000000</plx:SaleOfStockMaximumOfferingPrice>
    <plx:PercentageOfCommissionOnSaleOfShares
      contextRef="Duration_7_2_2021_To_7_2_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_NYbG0_upI0OqrbiUEof-HQ"
      decimals="3"
      id="Narr_BhDdbc_vXUWtM2zxcI3DDw"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.03</plx:PercentageOfCommissionOnSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_nxW7H0bxUUC9vT-aI9jhyA"
      decimals="INF"
      id="Narr_p5zQBpJud0WrA9y9zsvSqA"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">7473038</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2021Member_nxW7H0bxUUC9vT-aI9jhyA"
      decimals="-5"
      id="Narr_on0xqM07dEeBnleXZjvB2g"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_tIPYYN_ZtU-qDljU2Ir6gA"
      decimals="INF"
      id="Narr_8t56ValgEkOZK4T7jdhc_g"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">12560150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_tIPYYN_ZtU-qDljU2Ir6gA"
      decimals="-5"
      id="Narr__kUg29eQiEWdiY_0cMC6yQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">24900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2023_To_12_31_2023_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_cGsHWgE_gUuxZ-cHUDKhgw"
      decimals="INF"
      id="Narr_94ARtEAiz0WBypBdQvWdBg"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_F6fA0kenUkmkxMJFS7dV_w"
      decimals="INF"
      id="Narr_u_-oxcdAm0KbLLCVJ8p58A"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">2216692</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_F6fA0kenUkmkxMJFS7dV_w"
      decimals="-5"
      id="Narr_KdNPJw8QkEae324JTWR9_g"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_F6fA0kenUkmkxMJFS7dV_w"
      decimals="-5"
      id="Narr_3EVa5QL5HkunmaqIUV60tA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_ujyb91I_LEeULuLbTSFcBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE 9&#160;- CONVERTIBLE NOTES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;span style="color:#212529;"&gt;In September 2024, the Company repaid all of the &lt;/span&gt;&lt;span style="color:#212529;"&gt;$20.42&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;million outstanding principal and interest payable under the 2024 Notes. The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The 2024 Notes were issued pursuant to an indenture entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the 2024 Notes was payable semi-annually at a rate of 7.50% per annum. The outstanding 2024&#160;Notes matured three years after the issuance thereof and were guaranteed by the Company&#x2019;s subsidiaries. The 2024 Notes were secured by perfected liens on all of the assets of the Company and its subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth total interest expense recognized related to the 2024 Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024*&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contractual interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,534&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt issuance costs and debt discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,801&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;* See also Note&#160;1(r).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_2OeigBROdEaDOLaH-ucKEg"
      decimals="-4"
      id="Narr_wWIOAs7qekej1tEVxYdEgQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20420000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_PqNi2C8w-UiBnkc4Uh5lLw"
      decimals="INF"
      id="Narr_W4n31ahFTE67czrZFTCYHg"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_EYL9IKHmnkqnNQvhCDuZ0A"
      id="Narr_Q5t1ugfTV06Mxi8WQs8EKA">P3Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw"
      id="Tb_EU20KgN2JkiuDXrBA5vhaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table sets forth total interest expense recognized related to the 2024 Notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:41.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024*&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contractual interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,156&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,534&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization of debt issuance costs and debt discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,801&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;/span&gt;* See also Note&#160;1(r).&lt;/p&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kOxCb2VXAkiXIt-mPT3RhA"
      decimals="-3"
      id="Tc_VfXAMwJbZ0i0Fyw-pbjogA_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2156000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_nUbBkLnYekaez7e1Ka3ENg"
      decimals="-3"
      id="Tc_COHg1_ek7UObDtSu3-NoXw_3_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2534000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw"
      decimals="-3"
      id="Tc_SDQe1xxvhUyV0Hc66Nl10Q_3_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1022000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kOxCb2VXAkiXIt-mPT3RhA"
      decimals="-3"
      id="Tc_Cv4y4kQScUGXraoBSiDpcA_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">300000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_nUbBkLnYekaez7e1Ka3ENg"
      decimals="-3"
      id="Tc_VHi4Eqz6M0mStTwGhQrqfQ_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">267000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_kOxCb2VXAkiXIt-mPT3RhA"
      decimals="-3"
      id="Tc_3x6uhSbso0ePPniWxua_Ag_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2456000</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_nUbBkLnYekaez7e1Ka3ENg"
      decimals="-3"
      id="Tc_QtfB4bl4qkqMXEBQlBjH3g_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2801000</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gTpackCMAUGy6SSqlo-prw"
      decimals="-3"
      id="Tc_xGhFaeZ140WbXRySWy3czw_5_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1022000</us-gaap:InterestCostsIncurred>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_yGn3uiNfeUabNO3MFP_40w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;10&#160;- FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_3gbxNBhaD0WGOCsLYytYoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;11&#160;&#x2013; NET EARNINGS (LOSS) PER SHARE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:43.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,932&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,168)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,971&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,472,159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,512,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,530,698&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,335,430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,667,323&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of stock options and restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,576,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 859,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,472,159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82,424,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,057,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the year and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted loss per share do not include 34,097,716 shares of Common Stock underlying outstanding stock options, warrants and convertible notes of the Company for the year ended December&#160;31, 2022 because the effect would be anti-dilutive. In the year ended December&#160;31, 2023, the diluted earnings per share do not include 18,254,264 shares of Common Stock underlying outstanding warrants and stock options because the effect would be anti-dilutive. In the year ended December&#160;31, 2024, the diluted earnings per share do not include 16,661,907 shares of Common Stock underlying outstanding warrants and stock options because the effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_aFgRrT2IU0CD3L4jXJsadw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic and diluted net earnings (loss) per share attributable to common stockholders were calculated as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:43.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,932&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,168)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,144&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,971&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,472,159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 67,512,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72,530,698&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,335,430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,667,323&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of stock options and restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,576,059&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 859,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 48,472,159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82,424,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,057,176&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the year and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_Xk_NzAN9VE-aYdfOl7wCOQ_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-14927000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_T3XvFcOj1USeq4soI5yt2g_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8312000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_nawaQPq7G0e35F7eLFWKAA_4_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2932000</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_xR8Ax3EzOEalOhLPFO4yJw_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-1168000</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_PV9gq55EmUWO70eMz8ts-Q_6_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">39000</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_iFBG3BRNy02tnVyk7XuRtA_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-14927000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_d8pvx-unQk-pmGuVEhRU1w_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">7144000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_xUZh0jfcCEK_4vJqzXKz9A_7_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2971000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="0"
      id="Tc_mot7dQNIXUqb_SS1H40Mjw_9_3"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">48472159</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="0"
      id="Tc_JtbiVZcRDUihl3CnMQ4wsA_9_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">67512527</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="0"
      id="Tc_g5ioxJhl_0af5946AkoA7Q_9_9"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">72530698</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="INF"
      id="Tc_EZLBeu8AokCMENJlldTraA_10_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">13335430</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="INF"
      id="Tc_dRMlr4in2k-IkTG8yl1D4A_10_9"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">7667323</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="INF"
      id="Tc_ITIvYBOLQke0HWXvgBrE4g_11_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">1576059</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="INF"
      id="Tc_bmbpMpYL6UaTYe1HF4i9qA_11_9"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">859155</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="0"
      id="Tc_L7kaX1KkvU6tiXXtwxGY9w_12_3"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">48472159</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="0"
      id="Tc_hg-w098_tkKcfu7tDxx1Ww_12_6"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">82424016</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="0"
      id="Tc_6ctgjrxnMUKUjs1cW_OTeA_12_9"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">81057176</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsWarrantsAnd2024NotesMember_wHXsbG_dxEq9ZOpZb9KkbA"
      decimals="INF"
      id="Narr_2uibjN107Uy9RiAmPnPABQ"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">34097716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_0rzuJ4XtCE6Cs1WYUEVqEw"
      decimals="INF"
      id="Narr_gUXmgDYLvE2bZr_HYkex9g"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">18254264</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_iQmr4uFt5kqfTe94aSywZQ"
      decimals="INF"
      id="Narr_TQSF7pZEjECdYwWIkGIFDQ"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">16661907</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_CYyUChrcPEustD0TA50Yqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;12&#160;- TAXES ON INCOME&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;The Company&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics,&#160;Inc. is taxed according to U.S. tax laws. The Company&#x2019;s income is taxed in the United States at a rate of up to 21%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:37.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,092)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Following the regulatory approvals for Elfabrio in May 2023, the receipt of the $20.0&#160;million milestone payment and the launch of Elfabrio in the United States, the Company released the valuation allowance previously recorded on deferred tax assets in respect of its NOLs in the United States resulting in a net tax benefit of $3.1&#160;million. The Company concluded that, based upon the preponderance of positive evidence over negative evidence and the anticipated ability to use the deferred tax assets, it was more likely than not &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;that these deferred tax assets would be realizable due to forecasted profits. The Company considered the following: (i)&#160;cumulative profits for tax over the previous 12 quarters in its U.S. operations; (ii)&#160;the impact of Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act, which was enacted into law in December 2017 (the &#x201c;TCJA&#x201d;) which requires the Company to capitalize and amortize its research and development expenses over 15 years; and (iii) its forecasted profits in the United States following the regulatory approvals of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The TCJA represents fundamental and dramatic modifications to the U.S. tax system. It contains several key tax provisions that impacted the Company including the reduction of the maximum U.S. federal corporate income tax rate from 35% to 21%, effective January&#160;1, 2018. Other significant changes under the TCJA includes, among others, a one-time repatriation tax on accumulated foreign earnings, a limitation of NOL deduction to 80% of taxable income, and indefinite carryover of post-2017 NOLs. The TCJA also repealed the corporate alternative minimum tax for tax years beginning after December&#160;31, 2017. Losses generated prior to January&#160;1, 2018 will still be subject to the 20-year carryforward limitation and the alternative minimum tax. Other impacts due to the TCJA included the repeal of the domestic manufacturing deduction, modification of taxation of controlled foreign corporations, a base erosion anti-abuse tax, modification of interest expense limitation rules, modification of limitation on deductibility of excessive executive compensation, and taxation of global intangible low-taxed income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Modification of interest expense limitation rules under the TCJA provides generally that for taxable&#160;years 2019-2022 interest expense deduction shall be limited to 50% of the EBITDA and for taxable years 2022 onwards to 30% of EBIT. Disallowed interest deduction may be carried forward indefinitely. The Company believes that any potential impact (if applicable) of this limitation will be offset by utilization of available NOLs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Section&#160;174 of the TCJA requires taxpayers to capitalize and amortize research and development expenses for tax years beginning after December&#160;31, 2021. This rule became effective for the Company during the year ended December&#160;31, 2022, and resulted in the capitalization of research and development costs of approximately $28.5&#160;million, $14.4&#160;million and $11.9&#160;million in 2022, 2023 and 2024, respectively. The Company will amortize these costs for tax purposes over 15&#160;years for research and development performed outside the United States and over five years in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company believes that all future profits of its Subsidiaries will be indefinitely reinvested or that there is no expectation to distribute any taxable dividends from these Subsidiaries. The determination of the amount of the unrecognized deferred tax liability related to the undistributed earnings is estimated as an immaterial amount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;b.&#160;&#160;&#160;&#160;Protalix&#160;Ltd.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company as a &#x201c;foreign-investment company&#x201d; measures its results for tax purposes in dollar based on Income Tax Regulations (Bookkeeping Principles of Foreign Invested Companies and of Certain Partnerships and the Determination of Their Taxable Income), 1986. The Israeli Subsidiary is taxed according to Israeli tax laws:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Tax rates&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The income of the Israeli Subsidiary, other than income from &#x201c;Approved Enterprises,&#x201d; is taxed in Israel at the regular corporate tax rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The corporate tax rate was 23% for 2018 and thereafter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Capital gain on a sale of assets is subject to capital gain tax according to the corporate tax rate in effect in the&#160;year during which the assets are sold.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;The Law for the Encouragement of Capital Investments, 1959 (the &#x201c;Encouragement of Capital Investments Law&#x201d;)&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Under the Encouragement of Capital Investments Law, including Amendment No.&#160;60 to the Encouragement of Capital Investments Law as published in April&#160;2005, by virtue of the &#x201c;Approved Enterprise&#x201d; or &#x201c;Benefited Enterprise&#x201d; status the Israeli Subsidiary is entitled to various tax benefits as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;a.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Reduced tax rates&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;Income derived from the Approved Enterprise during a 10-year period commencing upon the&#160;year in which the enterprise first realizes taxable income is tax exempt, provided that the maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Israeli Subsidiary has an &#x201c;Approved Enterprise&#x201d; plan since 2004 and &#x201c;Benefited Enterprise&#x201d; plan since 2009. The period of benefits in respect of the main enterprise of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited Enterprise expired in 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;If the Israeli Subsidiary subsequently pays a dividend out of income derived from the &#x201c;Approved Enterprise&#x201d; or &#x201c;Benefited Enterprise&#x201d; during the tax exemption period, it will be subject to tax on the gross amount distributed (including the company tax on these amounts), at the rate which would have been applicable if such income not been exempted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;b.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Accelerated depreciation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Israeli Subsidiary is entitled to claim accelerated depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery and equipment used by the Approved Enterprise and the Benefited Enterprise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;c.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Conditions for entitlement to the benefits&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Israeli Subsidiary&#x2019;s entitlement to the benefits described above is subject to its fulfillment of conditions stipulated by the law, rules&#160;and regulations published thereunder, and the instruments of approval for the specific investment in an approved enterprise. Failure by the Israeli Subsidiary to comply with these conditions may result in the cancellation of the benefits, in whole or in part, and the Israeli Subsidiary may be required to refund the amount of the benefits with interest. The Israeli Subsidiary received a final implementation approval with respect to its &#x201c;Approved Enterprise&#x201d; from the Investment Center.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 10pt 72pt;"&gt;d.&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Amendment of the Law for the Encouragement of Capital Investments, 1959&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;In recent&#160;years, several amendments have been made to the Encouragement of Capital Investments Law which have enabled new alternative benefit tracks, subject to certain conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the&#160;years 2011-2012 (amendment 68 to the Encouragement of Capital Investments Law), which was passed by the Israeli Knesset on December&#160;29, 2010. The amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law. On December&#160;29, 2016, Amendment 73 to the Encouragement of Capital Investments Law was published. This amendment sets new benefit tracks, inter alia, &#x201c;Preferred Technological Enterprise&#x201d; and &#x201c;Special Preferred Technological Enterprise&#x201d; (the &#x201c;Capital Investments Law Amendment&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 90pt;"&gt;To date, the Company has elected not to have the Capital Investments Law Amendment apply to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;c.&#160;&#160;&#160;&#160;Tax losses carried forward to future&#160;years&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;As of December&#160;31, 2024 and 2023, the Company had aggregate NOL carry-forwards equal to approximately $227.2&#160;million and $234.8&#160;million, respectively, that are available to reduce future taxable income as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;The Company&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company&#x2019;s carry-forward NOLs, equal to approximately $24.4&#160;million and $22.2&#160;million as of December&#160;31, 2023 and 2024, respectively, may be restricted under Section&#160;382 of the Internal Revenue Code (&#x201c;IRC&#x201d;). IRC Section&#160;382 applies whenever a corporation with NOL experiences an ownership change. As a result of IRC Section&#160;382, the taxable income for any post change&#160;year that may be offset by a pre-change NOL may not exceed the general IRC Section&#160;382 limitation, which is the fair market value of the pre-change entity multiplied by the IRC long-term tax exempt rate.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Protalix&#160;Ltd.&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;At December&#160;31, 2023 and 2024, the Israeli Subsidiary had approximately $210.4&#160;million and $205.0&#160;million, respectively, of carry-forward NOLs that are available to reduce future taxable income with no limited period of use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible tax planning strategies. The Company reassesses its valuation allowance periodically and if future evidence allows for a partial or full release of the valuation allowance, a tax benefit will be recorded accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;d.&#160;&#160;&#160;&#160;Deferred income taxes:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The components of the Company&#x2019;s net deferred tax assets at December&#160;31, 2023 and 2024 were as follows: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In respect of:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other timing differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,387)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carry forwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,618)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,665)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,856&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;e.&#160;&#160;&#160;&#160;Reconciliation of the theoretical tax expense to actual tax expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A reconciliation of the statutory U.S. federal income tax rate of 21% in 2024, 2023 and 2022 to the effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:middle;white-space:nowrap;width:31.51%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax computed at the statutory U.S. income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,023)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Differences in tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,512&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (899)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (436)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutorily non-deductible expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in Valuation allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,970)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,932)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (953)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Utilization of carry-forward losses and other temporary items without deferred taxes recognition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Withholding tax &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;f.&#160;&#160;&#160;&#160;Valuation allowance roll-forward&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table presents the change in the Company&#x2019;s valuation allowance during the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,550)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Additions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (728)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reductions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Additions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reductions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 953&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,665)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;g.&#160;&#160;&#160;&#160;Uncertain tax position&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Provisions of ASC 740-10, Income Taxes, clarify whether to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase for tax position related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase for tax position related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;"&gt;h.&#160;&#160;&#160;&#160;Tax assessments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In accordance with the Income Tax Ordinance, as of December&#160;31, 2024, all of Protalix&#160;Ltd.&#x2019;s tax assessments through tax&#160;year 2019 are considered final.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A summary of open tax&#160;years by major jurisdiction is presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Jurisdiction:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Israel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;United States (*)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2021-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;(*)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_XGzd5dVqLk6U007ZQL4UiQ"
      decimals="2"
      id="Narr_09cSP1TWO0iJwY2_bTZc6Q"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_EXsRMfXWmES37A1FbFd1gA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:37.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 986&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,092)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_ZGOoWMWzcEqzXOmiIogDUA_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">530000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_IQK3Z-CSoEW5Q-Yu8wnpnA_3_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3346000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_egCA5VP2Rk2LAx4dlP_7Bg_3_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">986000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_h5zppj4B90KeS1K28pl0NQ_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-3092000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_mYUREfZ3QU6iiIQxlzuCMQ_4_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">236000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_PsOOBK8MvE-hWs13omU3pA_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">530000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_XqiNAVQtSkqKqhy9YrHmEg_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_UElFulPKEUOTULCHm1Viww_5_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1222000</us-gaap:IncomeTaxExpenseBenefit>
    <plx:MilestonePaymentReceived
      contextRef="Duration_5_1_2023_To_5_31_2023_NW-Pj9G-fkyAiLj-xYz3Gg"
      decimals="-5"
      id="Narr_NbaGTsfDjUmeFXEC0UGovA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">20000000</plx:MilestonePaymentReceived>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_5_1_2023_To_5_31_2023_NW-Pj9G-fkyAiLj-xYz3Gg"
      decimals="-5"
      id="Narr_5XJbcLNVH0GBLp7njevLVA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-3100000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg"
      decimals="-5"
      id="Narr_BVMjw3fZAkmc4Kv1OsFE4A"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">28500000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-5"
      id="Narr_nN_0Qg7yg0iZBC4wz1HkYA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">14400000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-5"
      id="Narr_o-HbeteBhkCSnvreizXqag"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">11900000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <plx:CapitalizedResearchAndDevelopmentCostAmortizationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_mOQcshjZ_06sDsFMHhwoDA">P15Y</plx:CapitalizedResearchAndDevelopmentCostAmortizationPeriod>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2018_To_12_31_2018_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_81bs3kgDHU6NRu_L1eP3yg"
      decimals="2"
      id="Narr_o66de2LBykuIZaDrUlCDYA"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_QXqL2IzWNEGo_hK_uR7-8Q"
      decimals="2"
      id="Narr_WfbCYoAVbUGWjdbKDhOHwQ"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_PrcXvhjZKk2qgA6qvhDFGQ"
      decimals="2"
      id="Narr_isOWDobrKUyvxPWte69F7Q"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_LmlSAoEiIUGYRz9pAOa8jA"
      decimals="2"
      id="Narr_pFE_OVEnEkCSpIs2orVaOg"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_Rre_qLcyTEWy4BikH0eDPA"
      decimals="2"
      id="Narr_d32IvPDHHkquxDtgZqwJGQ"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_vDFNTndzl0OM84fywfGerA"
      decimals="2"
      id="Narr_M-SkMUkwikufXnwEcsjxpg"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_us-gaap_IncomeTaxAuthorityAxis_plx_TaxYearThereafterMember_2uwOm7rxyEOlHzvvqCFFJg"
      decimals="2"
      id="Narr_JwXpTFXc_0uhKbsELogBrg"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-5"
      id="Narr_hNk55GnFoEqpBg5PMMN8oQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">227200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-5"
      id="Narr_-wVbzQws1EaH8Vnq1NMgKg"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">234800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_IFWTaYE7TEGUIFQbsRvpcA"
      decimals="-5"
      id="Narr_6ZkeAldg20qHg6-l7clFfw"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">24400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_ParentCompanyMember_7Kls7CQ7NUqv6IHxTOTP0g"
      decimals="-5"
      id="Narr_na-Fn4wCakaJsVHFE5WVtQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">22200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_hbAAdy1AFUuwPTqCDJatww"
      decimals="-5"
      id="Narr_acl2apoeO06DkNRncRG-5A"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">210400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_srt_ConsolidatedEntitiesAxis_srt_SubsidiariesMember_k_HBgOQfk0GnMVqO03JGnQ"
      decimals="-5"
      id="Narr_NTKOE0KCHEePFizm-U-CFQ"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">205000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_Pod1Y9IETEemo9P-2pHGGQ">The components of the Company&#x2019;s net deferred tax assets at December&#160;31, 2023 and 2024 were as follows:&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;In respect of:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other timing differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,387)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carry forwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51,472&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,618)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,665)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,856&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_kfKnfWS9LEquSWbc1usL4w_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4625000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_zEsCoyN5b0ST-2wH_CyIfg_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3055000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <plx:DeferredTaxAssetsOtherTimingDifferences
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_35KMSnGfmEmxYB-iE2qxXg_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-1387000</plx:DeferredTaxAssetsOtherTimingDifferences>
    <plx:DeferredTaxAssetsOtherTimingDifferences
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_ifRxxCsYZUegqbGzUvIxDA_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">452000</plx:DeferredTaxAssetsOtherTimingDifferences>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_7lyhncnHx0ajb2pV0mxybQ_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">51472000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_kO4vjh62DUSG9OEPpFz9iQ_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">50014000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_Z5jFzbz8iEWuFH5iw3OPFA_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">51618000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_3ensud_Y-EGIBck7HpRqeQ_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">50665000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_DEd1zlLJhk6UAxDkGKeXhQ_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3092000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_5IZUEqlE_0OaXG7bQ3MS-g_8_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2856000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_5lB7iSJ4vUmU19P0KKTLsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A reconciliation of the statutory U.S. federal income tax rate of 21% in 2024, 2023 and 2022 to the effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:middle;white-space:nowrap;width:31.51%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax computed at the statutory U.S. income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,023)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 872&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Differences in tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,512&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (899)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (436)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Statutorily non-deductible expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 506&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in Valuation allowances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,970)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,932)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (953)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Utilization of carry-forward losses and other temporary items without deferred taxes recognition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,233&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Withholding tax &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="2"
      id="Narr_ece485bhc0SMZvtcKCBgBQ"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="2"
      id="Narr_RKfFS4gC6kuluQZqwV1FPQ"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="2"
      id="Narr_Kd1wk5KA-0eO7q8FZxL5UQ"
      unitRef="Unit_Standard_pure_TAyZDnwQkkGHbb2g7mb0pQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_LcaSuUJjSU2aV4Av5RpDOw_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-3023000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_bPb7LP0TL0KUcyyam_qxIA_3_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1799000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_XKbJT6dDE0iAap58Lslw0w_3_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">872000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_UZ2pAunOTESOFbSP8O8RVg_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1512000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_6qzOcUr2sU-wllF73vntuw_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-899000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_luUcsu36b06jajLQDIIcUA_4_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-436000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_8ZqWKQvv0EiA-SmBdJwjxQ_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2979000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_VkBQR1iTCkiTM2viL8AlVw_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1684000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_xy9W1RjKMECCa1GoHXMbrA_5_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">506000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_ErJZZm91-UOb6MUhgivn1Q_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-2970000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_3zM2w5Lq7keuQrE7BKjVnQ_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-6932000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_A12EcJQWhEG1WNF_tEYpvA_6_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-953000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_toMOic1xKkGBVAiiX8GNFg_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2032000</plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition>
    <plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_ZqNEDqt3wUSSBppdEZSF0Q_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3602000</plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition>
    <plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_R8jY4Kw5wES1VMSn1H1teA_7_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1233000</plx:EffectiveIncomeTaxRateReconciliationUtilizationOfCarryForwardLossesAndOtherTemporaryItemsWithoutDeferredTaxesRecognition>
    <plx:EffectiveIncomeTaxRateReconciliationWithholdingTax
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_QHJLuhLu5UCTkT4PD27zlA_8_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-1000000</plx:EffectiveIncomeTaxRateReconciliationWithholdingTax>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_j7eFvlZkfUyVPZNT-TX06A_9_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">530000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_m02wndHK70yy2jwMd1izpA_9_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_Sk_K0X8n0E-o0UE_jXhNUg_9_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1222000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_hBZ6X-QhsE-HhLECKCe1wQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The following table presents the change in the Company&#x2019;s valuation allowance during the periods presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (58,550)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Additions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (728)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reductions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51,618)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Additions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Reductions to valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 953&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:85.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,665)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg"
      decimals="-3"
      id="Tc_Kfgp5ANjvUCihqVVuMQGpQ_2_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">58550000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <plx:DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_9dIJBvSSZ0etE8z_6kDFXw_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">728000</plx:DeferredTaxAssetsValuationAllowanceAdditionsDuringPeriod>
    <plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_ME4fE9twdkqSCQCdTINcvA_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">7660000</plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_Ir1-qULNA0G8blvA0GbOiA_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">51618000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_ABWpMu6iU02uBxBaMco0Xw_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">51618000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_Yt87BPYWnkSPQZcoB8kKdw_9_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">953000</plx:DeferredTaxAssetsValuationAllowanceReductionsDuringPeriod>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_R02ILVPgpUiDUT_Oq0EZJA_10_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">50665000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_0ewjuPm860CIvmv6LOOT8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Provisions of ASC 740-10, Income Taxes, clarify whether to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. A reconciliation of the beginning and ending amount of unrecognized tax benefits, is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase for tax position related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase for tax position related to current year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 805&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_XKquAogsW0Wv5y_ZWTJBrg"
      decimals="-3"
      id="Tc_q0mBUAmTvEi75h0ijLs0HQ_2_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">530000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_GhyD4cTcSEmf63V7An1rFQ_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">275000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_rqVmBbjxs0-4MvYjza-VTg_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">805000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_WI3blCcRp0mcuaxpK0e53A_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">805000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_vmQKNmUd60O6mnhREiOHEg_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_lmogYZ45lkCoN9_5HiCf9A_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">805000</us-gaap:UnrecognizedTaxBenefits>
    <plx:ScheduleOfOpenTaxYearsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_zbuBoXHEXkSInJx8tncIAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A summary of open tax&#160;years by major jurisdiction is presented below:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Jurisdiction:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Israel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2020-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;United States (*)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2021-2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;(*)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Includes federal, state and local (or similar provincial jurisdictions) tax positions.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</plx:ScheduleOfOpenTaxYearsTableTextBlock>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_CJv_84vfq0aMskjfjX9YfA"
      id="Narr_aq-d5RhV0UmchwIcFMB1Uw">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_plx_UsIsraelMember_MVIrjw2PD0mL89oHKVh0jg"
      id="Narr_cvWIhKnqqEKVsC1_g6US9g">2024</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_jt7xO17tI0q-J4gtN5A1ag"
      id="Narr_ihVMBg7GjUGMOTzPll4lWQ">2021</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_IncomeTaxAuthorityAxis_country_US_JlcwElfBZkmmA58XlgqPmw"
      id="Narr_HUqpDuV8lEG-EN5aU4N00A">2024</us-gaap:OpenTaxYear>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_zUJfKFBZl0W7USA-zpIC3A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;13&#160;&#x2013; SEGMENT INFORMATION&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company operates in Israel as a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_yJU9lqNC-UmtulHxkqsD_Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; operating segment. The Company&#x2019;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Segment information:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:middle;white-space:nowrap;width:34.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from customers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,638&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee salaries and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,388&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,780&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sub-contractors expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,682&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,529&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,180&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,062&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,146)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,286)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,299)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,191&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,304&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment expenses*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,716&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income before income taxes &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,397)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,154&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,932&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;"&gt;* Other expenses included in net income includes raw materials, rent and utilities and others.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.17%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Gaucher disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer (Ireland)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiocruz (Brazil)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10,401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;11,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fabry disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi (Italy)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,437&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;17,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;29,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;40,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;52,981&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;22,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25,076&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.7pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Long lived assets are located in Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_vkXoTUIRaEG1CVpjIMH0Cw">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Segment information:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:middle;white-space:nowrap;width:34.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from customers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,638&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 65,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee salaries and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,388&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,780&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sub-contractors expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,682&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,529&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,180&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,062&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,146)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,286)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,299)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,086&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,191&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,304&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment expenses*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,760&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,716&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income before income taxes &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,397)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,154&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:62.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,222&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:62.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,927)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,932&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;"&gt;* Other expenses included in net income includes raw materials, rent and utilities and others.&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_NzCV8iBzcEq4HJwGSislJQ_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">47638000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_jd-9F0YpAkmgKel_PUiOow_3_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">65494000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_7LN2Mj2QD0eayPMoyc68Ig_3_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">53399000</us-gaap:Revenues>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_dxNuHM6yAUSEWA1F1Yu09w_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19388000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_GCEroX-N-UmWKTsKuendWQ_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">24075000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_yU2yvXumEUO1VFYgOmhtxQ_5_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">21780000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_a61hRjpziE-YfzWgyyHVfw_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">24181000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_gtcQ3hY8Bkq6II1wFABYwA_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">14008000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_ocN7bEEfY0e_xSxl0D-iLg_6_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8682000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_ArjxFJOjdUyf1e7LeBJiOQ_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2529000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_ssEuGSIrmEaQqLZw-BHWnA_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3180000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_SVMhcpvdzkujhwY5MOiXNw_7_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1062000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc__4sQiPmO_k2ssLnKfKWwzw_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1146000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_WoWsukM_zE22TP8gEeiYlA_8_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1286000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_KbM6WjH4S0aDDQbES8ku8Q_8_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1299000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_fKruCLDBHE6Gpgte3mteyQ_9_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1086000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_aWqMiiclc06PdIV3nozVdQ_9_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1191000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_Hq3zJ1eitkmKrYVZkqHCKw_9_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1304000</us-gaap:Depreciation>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_lmLqM7Dfi0im9p84qncV_Q_10_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">15997000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_4Z43DfiuxEenVCJQ8dZKIA_10_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">15760000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_A5UoW_UPNEmT56TDrN0gvQ_10_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">17716000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_ftEwQD42_k6fpDFoXaKM0g_11_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-14397000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_D3i8Ti_As0ObZI57k66-Gw_11_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8566000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_j8h2e4kddUayLm3O6UJesQ_11_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4154000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_vd9edD0OJEyDspsxkKBL9A_12_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">530000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_tJOldF0A5E6wvBxeNvrExA_12_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_NEzhkrBCjkKiMHuh8tXceg_12_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1222000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      decimals="-3"
      id="Tc_PP9Etj9pUEuGGSSpYzyz-w_13_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">-14927000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      decimals="-3"
      id="Tc_Sw-e58SMSEm72XmzBp5cXQ_13_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">8312000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      decimals="-3"
      id="Tc_oyGKa3g52UCkxjWRLvu-LQ_13_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2932000</us-gaap:NetIncomeLoss>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2022_To_12_31_2022_EAVGqsCPpUqLQyaS4jHXfQ"
      id="Narr_v1Rmq85s7EWNb-y8WNRL4g">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2023_To_12_31_2023_QU5vt2vmrk-Jc73QAHoWBA"
      id="Narr_Sc_L_A8v6kmDDbxCu4Q7Dg">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Narr_JI28fZiqDEGaeeYlfIlzeA">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_L8chZpRBpU2FpPdMdP9EBQ">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.17%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:32.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Gaucher disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer (Ireland)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12,522&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiocruz (Brazil)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;10,401&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;11,031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fabry disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi (Italy)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,437&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;17,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;29,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;40,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;52,981&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;22,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25,076&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_E_xaP5k14k6Q6Z72Y_IfPA"
      decimals="-3"
      id="Tc_09bhS96EVEqKaOCYsJIYXQ_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">12403000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_gyzvZwhYWUOBEq112uDzLg"
      decimals="-3"
      id="Tc_imly_kP-MkOlDGfOAoKsdQ_4_7"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">12522000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_vAdZZrKJB0GA0kWl76_O5g"
      decimals="-3"
      id="Tc_dXIIynuJWEOCKuuA9AkxEQ_4_10"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">12617000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xaYAPIOiqEOStP3Kpoa1Bg"
      decimals="-3"
      id="Tc_1q-CrEUhAUGbhFAMVdxYkA_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">9452000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_QZxZBUTrMkaZV4V80woRlw"
      decimals="-3"
      id="Tc_xNNSXERQV0Gh_WYohCSpQg_5_7"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">10401000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_yxjzBIAj6UibHOxMuOXLmg"
      decimals="-3"
      id="Tc_TxjIMAkxbUqbsaXte-ktJA_5_10"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">11031000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_nzjGNNa5BUaHDbbP-O186A"
      decimals="-3"
      id="Tc_tXDwzvEsYEeZjNaFoKjRvA_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3437000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_cq0BPynITUyIX0XEGY5DFg"
      decimals="-3"
      id="Tc_9ibmk-ZAXkCUt7J8Zy-pKg_7_7"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">17495000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_e4DfQC6YoEqi8RVuaPKj1w"
      decimals="-3"
      id="Tc_KbKwG8_OoUa1GJQI39NwXQ_7_10"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">29333000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_PQ5mf5BQdkWUxiMCts1pFw"
      decimals="-3"
      id="Tc_NXP6oDpUhkiTLjWIV8ocNA_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">25292000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_ProductMember_aKTCTOwnPkytYKKR5g2_wA"
      decimals="-3"
      id="Tc_YfUj9VvzrE-7hXiXlHa4qw_8_7"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">40418000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_HHFZ61393UWe4ugtQPzFMg"
      decimals="-3"
      id="Tc_POMG1kHa3UWRU-cc9G9lrQ_8_10"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">52981000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_w4HPugC1VEGsdplZft_5fQ"
      decimals="-3"
      id="Tc_kozVDPQBVUKJYvO77BIrag_9_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">22346000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_n_xrcTEwnEeMZJ4ZcUw8eA"
      decimals="-3"
      id="Tc_S8TJgfBLL0eaeu_C6U5SWw_9_7"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">25076000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_kRf1Vl0L_E68nTZynfgMNw"
      decimals="-3"
      id="Tc_Sr0Z7x_eVkWeKfHgHnK5HA_9_10"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">418000</us-gaap:Revenues>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_0z5_AaWnAkS-s1XIpE2n6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;14&#160;- SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 49.5pt;"&gt;a.&#160;&#160;&#160;&#160;&#160;Balance sheets:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;a.&#160;&#160;&#160;&#160;&#160;Other assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sundry&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 110&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,096&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,437&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,811&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 637&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,080&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payable to customer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,056&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales reserves (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;"&gt;(1) The balance as of December&#160;31, 2024 is based on a final reconciliation that was performed with the customer.&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <plx:SupplementaryBalanceSheetsInformationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_gG-0oArouEO_vfbI5qyVfg">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;a.&#160;&#160;&#160;&#160;&#160;Other assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 482&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 486&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sundry&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 129&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 110&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,096&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;b.&#160;&#160;&#160;&#160;&#160;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,437&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 511&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,605&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,811&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 637&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,080&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payable to customer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,056&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales reserves (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 45pt;"&gt;(1) The balance as of December&#160;31, 2024 is based on a final reconciliation that was performed with the customer.&lt;/p&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
    <plx:OtherAssetsInstitutionsCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_BFLlVtrMd0el8siBbpCL4Q_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">482000</plx:OtherAssetsInstitutionsCurrent>
    <plx:OtherAssetsInstitutionsCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_5DwpTGx-FEqL8pdFBh2IKQ_5_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">486000</plx:OtherAssetsInstitutionsCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_tYMAMp_5FU-gi0o9-4wMpg_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">444000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_QxzxaKQOcEiJUaO9RxHCew_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">500000</us-gaap:PrepaidExpenseCurrent>
    <plx:OtherAssetsSundryCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_F-wV-Mr-u0259UrZcP9NGg_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">129000</plx:OtherAssetsSundryCurrent>
    <plx:OtherAssetsSundryCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_ryj2S4gDnE25pJ-ZIr1C-w_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">110000</plx:OtherAssetsSundryCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_t7nE-bndYE-ysFapVbV1vg_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1055000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_gR-GbgkzQkao5ncn3noAjQ_8_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1096000</us-gaap:OtherAssetsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_3ZWXDTHzXEC4P77CipuX5g_4_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1437000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_jZ_wYimxckSRDneJYn3HtQ_4_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1343000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_n_QAM4rBuEG3H_QWzYpuhw_5_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">511000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_w1ZxCuUCLkCZag9_5gtIWg_6_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1605000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_VkdGDuFleEqxvWtQzxgP0g_6_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1811000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_u_0R-v_f4kCFuqW8txnRFA_7_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">9009000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_koTxPi_XnkSqpfeeGZp_cA_7_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">9568000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_rTLjjO9Ypk-gRfu_dgQ9Kw_8_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">637000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_cxwh9Zd91UOl55dOxrzfzQ_8_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1080000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_h5Lf2v5__U6be8HqvfXRdw_9_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2876000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_cILrZsPF7UuPcoPuBNUXWg_9_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">3476000</us-gaap:TaxesPayableCurrent>
    <plx:PayableToCustomerCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_DVoZlrbetUWDphONoNd5ag_10_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2056000</plx:PayableToCustomerCurrent>
    <plx:ReserveForDeductionsFromRevenueCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_6xZYS55AN0GBJD4jOt3v8g_11_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2861000</plx:ReserveForDeductionsFromRevenueCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_vmGAoPVXKEevv8L8dKQizw_12_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">614000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_T9Wd-Wol_0aWnJ6wODsWUA_12_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">254000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_12_31_2023_7bP_5svpwkCVpCKnDvahDQ"
      decimals="-3"
      id="Tc_JEZd7BDa1U6ambckMDkhPQ_13_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19550000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_12_31_2024_ILGNC9HDI0-fEzqHLl_IRw"
      decimals="-3"
      id="Tc_SWb_ZDTWy0KnU98DUt41BQ_13_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">19588000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_2JJFW_zkG0yq2EZTsa4q2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;15&#160;- RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Non-Executive Director Compensation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation (including share-based compensation) to the non-executive directors&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 555&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In September 2023, with the consent of the Audit Committee of the Board of Directors, the Company engaged one of its non-executive directors to advise the Company regarding business development and licensing efforts on a consultancy basis. For the years ended December&#160;31, 2023 and 2024, we recorded an expense of a total of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$35,475&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1,350&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; for such consulting fees, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Group_iaGdkbJqOESiB8_A4V27uQ">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Non-Executive Director Compensation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:30.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands&lt;/i&gt;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation (including share-based compensation) to the non-executive directors&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 429&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 555&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_mW8C4Y6b6kywMvvRfs9dNA"
      decimals="-3"
      id="Tc_Td13I-7C1UqdYyw_5eb4eQ_3_3"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">368000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_pglWe4H_g0q1VCrHkTEK2Q"
      decimals="-3"
      id="Tc_I2kOIpbxSEKumW6TM7X8PA_3_6"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">429000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EoGEj4NR3k60cggFbmTsmg"
      decimals="-3"
      id="Tc_K15vEIFSOkqzUNxPgpF1zg_3_9"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">555000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_pglWe4H_g0q1VCrHkTEK2Q"
      decimals="0"
      id="Narr_8JDZSjsOw0GpYFZJFiuGUA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">35475</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_CounterpartyNameAxis_srt_DirectorMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_EoGEj4NR3k60cggFbmTsmg"
      decimals="0"
      id="Narr_IqNpF5YNT0mFWTWmHuPeBg"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">1350</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_Tb_Z7NFaik-yotmExnaodA"
      id="Tb_T0DwMebzKEabrAJUTHWRyw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE&#160;16&#160;- SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Since December&#160;31, 2024, the Company has collected approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$4.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from sales to Pfizer and approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.9&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from sales to Brazil.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Since December&#160;31, 2024, the Company sold, in the aggregate &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1,223,935&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock under the 2023 Sales Agreement. &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company generated &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;gross proceeds equal to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.5&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in connection with such sales. As a result of such sales, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares remain available for sale under the 2023&#160;Sales Agreement and the ATM program thereunder is now complete.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Since December&#160;31, 2024, the Company issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;908,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from such exercises. The warrants expired on March&#160;11, 2025. Accordingly, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;as of March&#160;12, 2025, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; warrants remain outstanding.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In January 2025, the Company deregistered Protalix BV in the Netherlands thereby ending its corporate existence.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_aERhFlXodEOqRgwjEGZTtA"
      decimals="-5"
      id="Narr_AwHL0URI-Eq8BZCyl25H5w"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">4000000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_LO7FCaAqo0anOZnr8urSlg"
      decimals="-5"
      id="Narr_i11hYyee_UK-r7_h1XAcdA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2900000</us-gaap:ProceedsFromCustomers>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_KFKHQh7CBUC1lg8cpMFN3Q"
      decimals="INF"
      id="Narr_AYj__Q37R0uzGSbKRgHZ1Q"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">1223935</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_KFKHQh7CBUC1lg8cpMFN3Q"
      decimals="-5"
      id="Narr_pxW6SFU9jEGXj6QvZ1qHPA"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreement2023Member_RWonuWiPxEq0TdRkIcpNIQ"
      decimals="-5"
      id="Narr_8jsqApboYEWysGmPTvQFIA"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_iDlflgLsKkiQFmx1cSBg5w"
      decimals="INF"
      id="Narr_L2eGYh8dt0e9PMRwPfc1Jw"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">908000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_3_16_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_iDlflgLsKkiQFmx1cSBg5w"
      decimals="-5"
      id="Narr_AbNQxtkuMU-A40X3C9r8Ng"
      unitRef="Unit_Standard_USD_3K_AmhBl-kusnLn6mcvgRg">2100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_12_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_PIfW3nBp4kCRd_d9eGzbYg"
      decimals="INF"
      id="Narr_ZaJhz8FjnkyGByoPnjwtyg"
      unitRef="Unit_Standard_shares_5ivCOq0YhkOLa6qFLYqTMQ">0</us-gaap:ClassOfWarrantOrRightOutstanding>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
